<SEC-DOCUMENT>0001558370-24-011079.txt : 20240806
<SEC-HEADER>0001558370-24-011079.hdr.sgml : 20240806
<ACCEPTANCE-DATETIME>20240806160549
ACCESSION NUMBER:		0001558370-24-011079
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240806
DATE AS OF CHANGE:		20240806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RIGEL PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001034842
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943248524
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29889
		FILM NUMBER:		241179126

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BOULEVARD, SUITE 900
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-624-1100

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BOULEVARD, SUITE 900
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rigl-20240630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 8/5/2024 11:54:47 PM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: ec29c16f-d210-49e0-9d88-a7cd945da31a -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:rigl="http://www.rigel.com/20240630" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" xs:nil="true" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_yDGzFrfcrEOmNGA7I9jCyg"/><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" xs:nil="true" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_2AI0OC10Y06diHgXqAS-1w"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" id="Hidden_tLN0a4X5JU2Cq3R9ffzyHQ">P24M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" sign="-" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_ctTfnEu_tkqhRm4vV9ngHQ">0.06</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" sign="-" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_5KELc9U4NUif45kVCZ-0dQ">0.38</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" sign="-" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_rflHIBSyUUetrL1tzhin1g">0.53</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" sign="-" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_nLgi9I2UlkyQbQfrdOSHrw">1.16</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_UoJdFgu_IkWu_Qxlk8o0YQ">17549000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_5JdjzeEPu0Wh6kWkPeDgvQ">17356000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_JO3IwUSKB0ip4_u39kEa-g">17534000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_QosfsYYINEKeFnE4rrZZNw">17365000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" xs:nil="true" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" name="rigl:NetSubleaseIncomeExpense" id="Hidden__uvDi--VAUGqtC3eWeIntA"/><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" xs:nil="true" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" name="rigl:NetSubleaseIncomeExpense" id="Hidden_RyRJdE2X_E-Mg-mp9DscQQ"/><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" xs:nil="true" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="rigl:NetSubleaseIncomeExpense" id="Hidden_lQtRnSPQoE-Il8zeJ8WGew"/><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" xs:nil="true" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" name="rigl:NetSubleaseIncomeExpense" id="Hidden_mnAsvI_5pkqF9r4khAkUlQ"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityRegistrantName" id="Hidden_fH6LEQzMaEGXhp8V1oGx4A">RIGEL PHARMACEUTICALS INC</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityFilerCategory" id="Hidden_XpVfPSs_-UGk-hUG348m0Q">Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:DocumentFiscalPeriodFocus" id="Tc_h8wadImYIU22G70HrsnAow_1_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityCentralIndexKey" id="Tc_wCIkaT3Ps0SxqNEqe6-_AQ_2_1">0001034842</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:CurrentFiscalYearEndDate" id="Tc_RVsgnlekekKF2seTzMl_RQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:AmendmentFlag" id="Tc_X6Zen7yAMkKWOaY61tE6Bg_4_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:DocumentPeriodEndDate" id="Tc_R-HBsYc660KNGNpFbwbQkw_5_1">2024-06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:SecurityExchangeName" id="Hidden_V62lT-Nc40uzkgz0WDXucA">NASDAQ</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_QvpswMek70eb5QDV4za2tQ" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Hidden_BSYq7x4JLEq-_Jg2cZgicA">P2Y1M24D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" id="Hidden_U2j5tAbzr0-MSQXB1Kv0GQ">P24M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_10_1_2022_To_12_31_2022_GWiAmU3NwEe-z4kehp2dcw" decimals="-5" name="rigl:CollaborativeArrangementRevenueRecognized" id="Hidden_HvqYF3vuKUK_Cbhmr3ItgA">20000000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_6_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_1Qsy0om_TUCfBSYK6lE0DQ" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Hidden_xfW9usukwk2f_jXEjoY-Ag">P0Y11M1D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="ecd:Rule10b51ArrAdoptedFlag" id="Hidden_8fNFwOpvSkS3Ae-chWCEig">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="ecd:Rule10b51ArrTrmntdFlag" id="Hidden_qBoUQQL0r0CNAQ63h7ll_w">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="ecd:NonRule10b51ArrAdoptedFlag" id="Hidden_tgDiYNPmjkeAMaI3ed0HFw">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="ecd:NonRule10b51ArrTrmntdFlag" id="Hidden_4jghMFuwh06SniMlhZ5R1A">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ" decimals="1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_cVzsh-nsgkmvDysnunKDMw">0.1</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ" decimals="1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_avsxiqC5EEGbi6wZ76xCjw">0.1</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ" decimals="1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_8Yk6g2alTk2siSqoGmM1-A">0.1</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ" decimals="1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_nJcNMH1G4kyCDx--KfxI4A">0.1</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_1_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BqxcFSw3c0GKMZqu-UgZLg" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" id="Hidden_zN5HkjsdLkqRRzBvM8xfWQ">P24M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rigl-20240630.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_cuHB688G_ked7r68OdX4FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_YseB19IaTUeq6LVKzfKj0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_tCX8H5e_0kK--61UsSImug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_XZhamrPP1kS0gkYOdPFL2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_uk1O_sp-Y0--KVAhhGNE-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_zCeB2BBtfU-Wb3oZ3EUjpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_YfpRiaWZxUqB5w9lvYJvVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pt2UPlNyCUWGebgWK5jSPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Ij2f4OxgUUCWtD_5lHA7pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_yxzYceuVAE2CBLGPEXWLcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_5kGrsJtJPUaXWHfMUTNnAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_6fGEzsR-EU2ukRaZfEQHTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_K66Fz-gvL0-4yU--dKixIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__q2T26iax0eiR5sdI86W6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_pvl3dQL-10KWQKcJlK7PhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_pwaobjInbUCU4wLXJWRgWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pxFiNodJ0UaXW8PVpDH_dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DeoG3uLWSE6eChBxTmVl_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ieLLpNjElUSlKRg-RIcl7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0jRDeqtQJE6s6Jso2tDR_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5haw8gzz_kCqIrKMQPuu3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m6FKz0lCzEavyGq5m7-dVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-27</xbrli:startDate><xbrli:endDate>2024-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6_5O45BUnkyJOAznzy2CsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k8Gu3743e0GwNZtJz5p2Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gsUfXJSf702qktCA38R1iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sIg7hAM9oUWSDXtYBBt_Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KlQgIhdaH0KRHwHHBqCVag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IA3yy1pN9UWx3KzvJPTixQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_rFOBOeyLMEiRCtDUqDQoow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rPjPB2Hmbk-fkqxrA8Qngw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_otHOXZ_Ey0WmO49o2jMv6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JKqbAPtAjkGccR66L8k_qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGqVrCjqIU2_N3yu6dMC8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tVwp1l-1kEuXU6ahtps2VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_izJ-lHsOY06-uJsEfZQQXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2hx_ymqnNEmbyAqqcCVWhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GnF2WrQG20ug_b0PbRql7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zBZ0CJwMEUaUNEdiy_40SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_RB2aD2voQkKnT5jqSouijg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P4KZWdg170yGNV_k_L91Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1lu-VK7_o0-Max8PseaIIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7oPrIr8cXkqlq5Yd3Q1yWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jynRgS2pl0CPMnlU_535aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ons628waiU-GMU91DELbBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBUO2o21ukOtCErji3SQCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c4Il3dY-Cka-Z7hPZIh3_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w10yELUyuUKFpRmpWRAlCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M9P7eTJN40GnRu7yAa6KCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkUV1BM-xU2eirtWLK871A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2024_To_5_31_2024_DjxYIP5b9kafOLRsY1Sj5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_31_2024_ljnvk8kzm0a4q-SYLyQozA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_viFreQeDZ0G9JJCWlMU9Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_ProductOrServiceAxis_rigl_OcadusertibMember_XRvY_5ZJrkuCeHrOO7K53A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_L2X2ODMWN02W75JbcgBOuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_YUs53Q9t60y3XCZGyv6pTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_66nF3F7T6EeO_T5ormWp2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_kgj2lfO1x06p8zrIfFzVjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_jsAPdtswwUqlYhdOCwaqtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxQfYCTi-EmntNNb3PEHNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_X2QX2SMv0UeS4dY9h3vreQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_HU2T--c6-k2PWST4x-p1iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rnk0gbYth0SBm1kX1fW23A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_dRwb9LpMMUGY_8SiQzA0vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_qF77QLopJkm7QArlC1YAAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_KLumYMF9xEy2B9eFN1r15g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember__ugQCo2hvkaHA8jhmfIr6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_vkZ_1rGsnkW09QyZQM9DaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_crGh4Gmf10KG35aVQN5FmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_0CKs5sN0Y06oyeNfimQy-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ktlf9P2M7UaLAIc_BeIB8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_aYmi2v0mz0e4c5dQ7lldvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_n6rbBTWKREaLGIeGb095og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_sXlfY9W4v0-bUvEUlAVg8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mtfju_YpJkGk_bnLaNb2Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:AchievementOfCertainNearTermRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_hZmC_MKxK0ib0qKh4OuwDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FZKSbfgCCUOxIEsBo793zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember__kWatA4PfkmKIM4_lvUSqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:CreditableAdvanceRoyaltyPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_XFzWo9hPBEqqowv7IqsqMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d_VNrgzWz0a3BkPN9MKEVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MyObbAmPakSYdCOgOM9oXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dWSzM4PiYkqhpk6Pu6GX4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H4solk7YuEifDSX0Yinypw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zmuW7qmKekWpcj688rHkvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_srt_RangeAxis_srt_MaximumMember_wXz-NhXK80mSJezdO35NGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_cDqO7iaeK0Go2Z-84kZ9jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:AmendedLillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_1Qsy0om_TUCfBSYK6lE0DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rigl:HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R1A7IWBmT0KvJy9Tq1LCYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nR9Unjlvxk-pD68DK4-gZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a0Js5EGrGk62uZjqtY72Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gvz4si6MdkS4fdUVQlbKOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_hDix6efDJEqhQT4ixJzEQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_DJRbQsRz1EqcG6iJ-_88Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_W7cIc5yiHEas_ePcVbSr0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_Pa4eaLZ_bkuPdtNWU8Iy2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_eYkavSct0kShqm_SrY7OiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_uZH0PMnJBEKSBgu31l8iYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_VuYcYAoXfUqSaPoOv41VZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_moMylpkG0EKqa1L_9E6qSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_2ZqFwePmoEW5EP2yf9fpUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_3NxUn5GogkWWrIfF-O4kPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SLvI2lqsxkmQG2QFPN79Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_N7Gpz1AcU0-D3M0pAjqqNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_bumoYf9sREKWHIIx5_Gz1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kR5PxZmiZEehJumbiChaaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6YzcAGW4m0ayhMSEkUdByA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BRYGoVu9R0e32mZYGbN33w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_LrJM0R9Q4EqCjEm9Lk2Smw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SCWsGh-x_EiHDPQEk17sgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_TowDf4q6oE-409UeTRDU9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_Ke66dznHTEab1HHdbbjp0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_tfFBS5hWFE6pF6skJ5FQLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_78B3hepUPkmvOj-N8djJNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_U7guuJSV4U6vqE5RJhmf9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_60P2wgsrD0awxLyja-p9nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zmcdanbJ0SDNc-vDFtkkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5l5sjSngpkO-FXuFuyQBGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bJS_m4Vp_0uGViKVve720w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_DMeCAgkRW0C78bbvGK_1ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lWODGT6XzEuM8DkFcLQ2LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_8_QPIix-oEu90IoZH6mxdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_RqBa2FWeTk6bS0CYoSM8OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_URKfF5ajyUiJLXquchdVgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FdaApprovalAndFirstCommercialSaleOfProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_E24Tg32FFUaoGudnG6SLlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_mp0URjlEF0yvPpfS-o63hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_QvpswMek70eb5QDV4za2tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aH2IYHCJPkuM5HXlyZvgaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_NSJW9_H2-Uyr8T7g60jFnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_eZ13M7o2S0y8eAY3w05FHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RgL4dFy2q0eUvIbUb8HPxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_YXCwufdL2kCunkEAIR-kOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_BiMbBxhh6Uq0yCW2lzj5vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_EBFPUJEfP0-IMk-f5UWHvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_Oloq2T-qkUSk0moW_WdUNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingFourthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_W4Ti807K5EGWOf1btN6_6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_w34DeP8NUkiGwpi5OQ3ysw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingFourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6ou1l9PZikOK2y-Wb2RGFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_xDqwa338u06zbkGihig_Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingFourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i1LjpfRajUeDxjso7nYoyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PbJR__bHUUymqE5jma_jhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Q7EkAAoHeUKJsjYoTZrhbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_zwK5QRRX6EqsKGahncDIOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jkelz1ePoUOQLw4bzruVCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eFVzoQltvEO4gINVqtxI-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7fwMtHOoHUm7LRR4eArbsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NhxdhXczxkO1of_nfPZIOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oLL4Ndsu6UyV_O0-24gTWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_9m5rS6MB3E-SUlgdlXlTSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LEnPZ15moEKAEm_18pTBow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_GgfOc-xLJ0CVzgWger3Arw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_ykyILY5HlkKht7OKVYHIvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_1A5iQpFj_USrbxcLaNA6XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_JbLXs-0VY0esSnNCYQq-kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_aYSlG3CFDEO3az0cwNa1cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_XVD5BbqpPk-9fwQojvfB5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ckfW59j6Okm6xRNuxxkwMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_hTn2f1VUkUCR_wGtI1n8ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_p4HneMQsy0Sje5M5K7gO5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_89x-n-BkT02zjUtAjZbcGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_I_VPJB4u6EaCQYJB-1nRzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_YesGsLryt0qGsoVabogaQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_LwXt8QqnrUCTiqADnWfuhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_kZWlKhsNBU6_AklsH7sLKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_QPE9o_N_LkOoOgf3_7ge7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_Som_sdy7kEqstJssH42W1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstCommercialSaleMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_HquhUMFeGkasyQJBoBZ3wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FirstCommercialSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstAnniversaryOfClosingDateMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_0IVrFL5NR0Kuz75nULfm_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FirstAnniversaryOfClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_SZRu02N1XEGrAyfYF5SwyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JastdyjIyEGJursVulIfKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RaKuxSzhSUupPD2oOUXYKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_XpXugziTxk2FFISdmEQLwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_FZjvdGbKikurAAd8fQxjGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q7YoKf7gyU2XWicwj8JbrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bYo6kwZv60OcoBnM9_riJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_MiyxZQLaX0CaycIWWGMjpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_P5Ej5A9ePUSqZtXcVBF9vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_w7P1z0EI5EueFIgNkc89sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_3xxTQ5sXyEG51cWWfHtXmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fv5v2douMUSk7zWe57p0FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bSe8WAEXkUG7k9-Nd_2uvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ieBTYFxiqUCvCIZyspbbWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xJyvi82Gwk2Tr-43Oekyrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2LCsKqr1LEqrGC4lXCGiqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v32Ol4crf0K8DOnTPxOuGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9NUp0OtJ9ku2HiQECijrIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aqTJrxACT0OLl53X_CyKsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EYUKQoEsRUCEo0sMj1Wymg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QJLTwjYbzkmfnUQQu3xMaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_KnTLXRz0jkWgF6jXhPXEDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_KKP0C9QqkUiTkWevYxJzTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8oQqRK0A4Eeyfv827MVcYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_OVx2OrQCKEaSY3aBoBA0Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_XjdV-Jp880KnhPP0PN-3mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_LS7cZ0Bs8U-InZ3368zHAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_vAVgV6NViE6ez_AdrA5iUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_gG5MuB9lWk-MYGQsRJNXbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_sBMx05ZL3UeBF780dfwknA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_YF4pFiaiVkGskNRvWduW9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_uiwrXRdPDki6YFyL0CW_EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_N2zaSMxsLEqGccjjlPSgFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_slyl5l3MBUW5I6J4gR0GNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_y28o3J_GDUGpZFQI6JGFgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_TsNN5CZDIEuTUPQMmSOPqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_cM6viZkjnk2XQ_C6vVZS3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_1_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BqxcFSw3c0GKMZqu-UgZLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_rBLR8Q6qY0qEWXFfKO_L3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_nO2J61EcMEKdr-tpRvz54A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_60j9a_IIDEa-xMryMMg8Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_yt0kuytHc0y7T2LLTRMBFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:AmendedLillyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jcLc51bfe0y7CaULox55yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_4FtiCBTyVkqS_xmhg_p41w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_-mlrFhf7yU-O2VqahK8vIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_oSHvi732xUWC_qqhrIXIIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_E2TAw1ebLEyqMCfIkUc_jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithMdaccMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_yedyexNn70m-Ww5Mtpn2GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_gz1pnQN6FE2qge7r5TPFfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithConnectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_yUFONy52JkaEdNe2JBvS1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithMdaccMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_CpgL9jNlMUCw-IA9e3o4uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_BbXVI_lx-kK6eTLL9cByJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_7B-bKGDqJkynpyyI5LI52A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_I9tiGJJzSUW1uADT_0QYGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedRegulatoryEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_7aOcJ_X2Jka6LsC0YG-yLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedProductLaunchEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_VqV4K0jYxU-ud5heUgA7Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedDevelopmentEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_4tLATJ2ucUu7Kj1hYljxvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_ErotTwxGbUGeaPCNLokv5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LP6c6fDybkun2r_aQWcizQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_VrqE9RWak0OFqmj1P2jvzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_mlAixP0Kq0KRgxnPySwCUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_1QwBIhoEuUGYpKJv6_D94Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_30_2021_pVVWDpbMUESUodMAWy20aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_6gKiuqunlUW1exXxbGX2YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_5HvpBOyAi0i27BmKK4fzHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_4TZ-_gslzUuCVFLIXWN05Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_DpExNDuvFEiRGecQztGf_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_82mZ1UCHkUeFIeF9NNLnDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_fiVixnDOc0CkJwTCK4-50w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_MfToFdRbjkuykAJfE2s1oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RFpgzqwWbUSTBMlmSIJ36w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_LGpOh5i-pkuYqfZStMMnVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LqSICzN8jECsv3g5VfvRtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_Ed6jJO0mDEC7vy2gXWKNvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_zrxVuGp9HUq29bG3-ZjB6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_Q7Q9_fXocUmGbwkegfzFlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_oyau3O4tJkKVZI8B-c9oEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_z6tFpSWYtUeOPKO1v5sshA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_r0ldwSj5VEOIFSa8XhrMcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_93VaWr0Vn0W3qhHJHD5l2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_maf7KtajvE6t_Jc1HPqseQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_SI850_iDiUWOa__58mOaXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AvQMdmjfrkKF0n7u_e-4ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8YAIxGaCJ0WOl3D_P-ZFyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_AIuTRpIOpUS1-j2v1hsfzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_GWiAmU3NwEe-z4kehp2dcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_N5mf8PGqUEGmxmbdkeM6pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:LicensedRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_dwtnlJ6pzU2O_-cHitWnLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:NonCentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_8_31_2023_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_5kULnBvdYEevZnx2IVnM6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_ZZ7iW4JQ8UGfKFajT3fUtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_4U40SB3W_kmm7wCJE8B4_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_Yi_QU2DWrk2zU3zLJ3F28w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithMdaccMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_6M9-yuHtNE6cG9tYWmjCqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithConnectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_bk4CtdQf3EaimZs7lkGnMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_vUvPo1jezUiyVDGej1nLMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_Gnk6YUapu02MxjednNsESw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2024_ZkEoN3QwO0iUKn5isedLVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001034842</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_XCinVrYiMEykKvzVM-r2og"><xbrli:measure>rigl:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_period_7S5qJ8_ryE2V-D21SVB1hA"><xbrli:measure>rigl:period</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_lkAE3fTQ8kCadM7_hQ6xtA"><xbrli:measure>rigl:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_position__77Wb-sxgEODSR6HmbQE7w"><xbrli:measure>rigl:position</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;min-height:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><a id="_21305650_9ef0_4231_acc9_206d03c6d7b2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:DocumentType" id="Narr_lReETCNoU0aeBz39TL0spg"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_5debbd54_8c85_418f_bfc4_8986b21547ae"></a><a id="Tc_RI74X6i88kiXHgXmZnrrKw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:92.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:DocumentQuarterlyReport" id="Tc_ZhR2QEOyHUS1HV3dTw8Mig_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:92.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED JUNE 30, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:DocumentFiscalYearFocus" id="Narr_ZHOi2RWqQ0WOYY6QbFojJQ"><b style="font-size:9pt;font-weight:bold;">2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_58eaec18_4de3_4071_a640_0759179aebf6"></a><a id="Tc_4EEQIc7PN0G6BTeTG2FGWw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:92.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:DocumentTransitionReport" id="Tc_S8XUA8iX5EOWxEuKoE2Vlg_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:92.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityFileNumber" id="Narr_XNXwtmMbR0iFD7RxIennEg"><b style="font-size:9pt;font-weight:bold;">0-29889</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:72pt;text-align:center;text-indent:-72pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_fH6LEQzMaEGXhp8V1oGx4A;"><b style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-style:normal;font-weight:bold;">Rigel Pharmaceuticals,&#160;Inc.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_c03b5a42_5e6e_4f2d_a6ec_8c739f409f68"></a><a id="Tc_GJ07JV5kfUK84Al9RFPtwA_4_0"></a><a id="Tc_t4VXekbrJ0-Hagg-S_YpqA_4_2"></a><a id="Tc_1ZTcK4hyH0ef3bI8PnPKUw_5_0"></a><a id="Tc_581qHgKAREScxC3LzAH-dQ_9_0"></a><a id="Tc_U0ygeg1wDk2TsgYcvjuSvg_10_0"></a><a id="Tc_ghXaYCPV4EyXbhK6eJUxCg_10_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityIncorporationStateCountryCode" id="Tc_DQ4ijrEdDEyyd12VlJ98jg_3_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityTaxIdentificationNumber" id="Tc_vqExNYZNiUmcfRrnL0S-Vw_3_2"><b style="font-size:9pt;font-weight:bold;">94-3248524</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">organization)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityAddressAddressLine1" id="Tc_JvU688dQN0KkRTmbyAgLIg_8_0"><b style="font-size:9pt;font-weight:bold;">611 Gateway Boulevard, Suite 900,</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityAddressCityOrTown" id="Narr_BipdUlPG2EWskiEJnNqRuQ"><b style="font-size:9pt;font-weight:bold;">South San Francisco</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityAddressStateOrProvince" id="Narr_2mZo2rpPzEybPboSbE5kIw"><b style="font-size:9pt;font-weight:bold;">CA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityAddressPostalZipCode" id="Tc_osqtv3txmUqovvIUre3Ggw_9_2"><b style="font-size:9pt;font-weight:bold;">94080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:CityAreaCode" id="Narr_Tz0roqazekG_PFK9mxqP7Q"><b style="font-size:9pt;font-weight:bold;">650</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:LocalPhoneNumber" id="Narr_7J5HINKj7kq9XdGqDJmyYg"><b style="font-size:9pt;font-weight:bold;">624-1100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_2528715e_2d4e_42b7_814d_3282a604a3cd"></a><a id="Tc_MBbM7OdotkSfixoa1ry_Gg_2_0"></a><a id="Tc_AjTGckkuJk6LzhaImPoInQ_2_2"></a><a id="Tc__FLlubS_ykmS41gf6r7jSw_2_4"></a><a id="Tc__MH_jhTlbkKc2AxW1jkNIA_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.09%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:30.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:33.1%;margin:0pt;padding:0pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.09%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:30.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:33.1%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:33.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class:</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:30.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></p></td></tr><tr><td style="vertical-align:top;width:33.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:Security12bTitle" id="Tc_Y1K82NcZfkidhf9EdVDgkQ_3_0"><span style="font-size:9pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:TradingSymbol" id="Tc_37HSumNmjkaPAuzbKnB9aQ_3_2"><span style="font-size:9pt;">RIGL</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">The </span><span style="-sec-ix-hidden:Hidden_V62lT-Nc40uzkgz0WDXucA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Nasdaq</span></span><span style="font-size:9pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk42160639"></a><a id="_Hlk42160722"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;</span><span style="font-size:9pt;white-space:pre-wrap;">days.  </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityCurrentReportingStatus" id="Narr_Bzz5UDdbYEq-MfCyBXscuw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;</span><span style="font-size:9pt;white-space:pre-wrap;">months (or for such shorter period that the registrant was required to submit such files).  </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityInteractiveDataCurrent" id="Narr_gu0lN9CMz0-fgUijH3IlFg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:18pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.02777481%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Large accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_XpVfPSs_-UGk-hUG348m0Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Accelerated filer</span></span><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p></td></tr><tr><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Non-accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntitySmallBusiness" id="Narr_etajvsjInUyxnZ9iaOBk9g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:26.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Emerging Growth Company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityEmergingGrowthCompany" id="Narr_dT7w1JhmukyQt7oECXbHJQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:18pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="dei:EntityShellCompany" id="Narr_NwksFjm1yEujlUWuaew_aA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">As of August 1, 2024, there were </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_8_1_2024_ZkEoN3QwO0iUKn5isedLVg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_eDgYLYC00EqpU4sVqz4Uvg">17,594,977</ix:nonFraction></span><span style="font-size:9pt;"> shares of the registrant&#8217;s Common Stock outstanding (after giving effect to the 1-for-10 reverse stock split effected on June 27, 2024)</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cfe07234_54ce_4e8a_abef_df1d3e26be45"></a><a id="Toc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;IN</b><b style="font-weight:bold;">C.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT ON FORM&#160;10-Q</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:81.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTIFINANCIALINFORMATION_587520"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTIFINANCIALINFORMATION_587520"><b style="font-style:normal;font-weight:bold;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1FinancialStatements_419379"><b style="font-style:normal;font-weight:bold;">Item 1.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1FinancialStatements_419379"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#BALANCESHEETS_710088"><span style="font-style:normal;font-weight:normal;">Condensed Balance Sheets &#8212; June 30, 2024 (Unaudited) and December 31, 2023</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#STATEMENTSOFOPERATIONS_342998"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Operations (Unaudited) &#8212; three and six months ended June 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#COMPREHENSIVE_LOSS"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Comprehensive Loss (Unaudited) &#8212; three and six months ended June 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">5</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#STOCKHOLDERSEQUITY"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Stockholders&#8217; Deficit (Unaudited) &#8212; three and six months ended June 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#STATEMENTSOFCASHFLOWS_16439"><span style="font-style:normal;font-weight:normal;">Condensed Statements of Cash Flows (Unaudited) &#8212; six months ended June 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">7</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#NotestoCondensedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">8</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2_ManagementsDiscussionAndAna_120616"><b style="font-style:normal;font-weight:bold;">Item 2.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2_ManagementsDiscussionAndAna_120616"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">24</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3_QuantitativeandQualitative_065227"><b style="font-style:normal;font-weight:bold;">Item 3.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3_QuantitativeandQualitative_065227"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">45</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4_ControlsandProcedures_065229"><b style="font-style:normal;font-weight:bold;">Item 4.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4_ControlsandProcedures_065229"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">45</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTII_OTHERINFORMATION_065230"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTII_OTHERINFORMATION_065230"><b style="font-style:normal;font-weight:bold;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">45</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1_LegalProceedings_065231"><b style="font-style:normal;font-weight:bold;">Item 1.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1_LegalProceedings_065231"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">45</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1A_RiskFactors_065233"><b style="font-style:normal;font-weight:bold;">Item 1A.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1A_RiskFactors_065233"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">46</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2UnregisteredSalesofEquitySecurities"><b style="font-style:normal;font-weight:bold;">Item 2.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">96</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3DefaultsUponSeniorSecurities"><b style="font-style:normal;font-weight:bold;">Item 3.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item3DefaultsUponSeniorSecurities"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">96</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4MineSafetyDisclosures"><b style="font-style:normal;font-weight:bold;">Item 4.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">96</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item5OtherInformation"><b style="font-style:normal;font-weight:bold;">Item 5.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item5OtherInformation"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">96</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item6_Exhibits_122646"><b style="font-style:normal;font-weight:bold;">Item 6.</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item6_Exhibits_122646"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">97</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Signatures_122812"><b style="font-style:normal;font-weight:bold;">Signatures</b></a></p></td><td style="vertical-align:top;width:81.12%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">98</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_b3a1b230_5269_4717_99ef_d18dab4e45c9"></a><a id="PARTIFINANCIALINFORMATION_587520"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PART&#160;I. FINANCIAL INFORMATIO</b><b style="font-weight:bold;">N</b></p><a id="Item1FinancialStatements_419379"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1.</b></span><b style="font-weight:bold;">Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS, INC.</b></p><a id="BALANCESHEETS_710088"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED BALANCE SHEET</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands) </b></p><a id="_6f1190be_dca3_4329_b200_46c7f37fa8c7"></a><a id="Tc_NrGM_6oLokiiMObILNHhwQ_1_2"></a><a id="Tc_tpsMl6J2mEK-1W7ZUzWG1A_2_2"></a><a id="Tc_cei-uDQsfUOAOhlVojY9Pg_2_5"></a><a id="Tc_VNBMTwb_602GW9XXNH-YuA_3_2"></a><a id="Tc_Js4Zil7pcEOBSzqFfgq6XQ_4_0"></a><a id="Tc_fNXQBv8OXEWAjY-scps4Lg_5_0"></a><a id="Tc_BDpLJ7AUWUWEABepxlYN_Q_6_0"></a><a id="Tc_i6XofVWAjUiJS5c-Y3pz9Q_6_2"></a><a id="Tc_jzdXe-4_KEiTsFDsHnX7lg_6_5"></a><a id="Tc_IRVv3Ygz6E2sgsbmf_jAkw_7_0"></a><a id="Tc_kvieA6CoREe-qxW1qDShYQ_8_0"></a><a id="Tc_wASmHinGa0K8-IH2qmhcbw_9_0"></a><a id="Tc_0Tbbx9Ff4U-3e_1_k6w-eA_10_0"></a><a id="Tc_tSFM27fQ3kuIAbjHX1Quzw_11_0"></a><a id="Tc_9Ec5Uf9lyEGKKPpHOyuZMw_12_0"></a><a id="Tc_Nq7jPXNmkUumc71sfosP4A_13_0"></a><a id="Tc_jkuKaZrp6ECHxRv43ErT8A_14_0"></a><a id="Tc_WB9ov35fZ0yVmURqiOk1Sw_15_0"></a><a id="Tc_Djjfwc1xrkyhGc4QyKegKw_16_0"></a><a id="Tc_4Eq-gJfhe0mb0aRiPhCvbA_16_2"></a><a id="Tc_nfaNn4wziUiFC6zkF16lLA_16_5"></a><a id="Tc_irDTKdKNlE2XD5YeR13txg_17_0"></a><a id="Tc_n-hr0juk-UWvO53zmRCt-g_18_0"></a><a id="Tc_wtDYGHw2MEKtFGfEjwPp2A_19_0"></a><a id="Tc_1jnRi2D8Okuo2Qs7M2mBJA_19_2"></a><a id="Tc_ZqW8wgYVZUSnfc4LeDhaGQ_19_5"></a><a id="Tc_WBYGd1bB40-ifhanTN4tNg_20_0"></a><a id="Tc_R3qwhNrpI0WncAvIrWzykg_21_0"></a><a id="Tc_hGuQW88zKEClx6pIcEPI-w_22_0"></a><a id="Tc_yKyqDyNclUOUBiSthFrgxQ_22_6"></a><a id="Tc_tr_eIjDP10iloFhNE2U-Bg_23_0"></a><a id="Tc_jGobhwLSIEqnmOwXhEzNsQ_24_0"></a><a id="Tc_TYXRUstaw0WJ_fc10KFoQg_24_3"></a><a id="Tc_DcGbpQwmvUSE_ZjvryZb2Q_25_0"></a><a id="Tc_2eW1G2ecGkm_KDyHlFZuOg_26_0"></a><a id="Tc_dWhWwPv8kU2yzNF5Dr7XLA_27_0"></a><a id="Tc_aEHo2C58m0qIghKJe-Ixbw_28_0"></a><a id="Tc_OBzgLt9J7UyKWWNrYqu9qQ_28_3"></a><a id="Tc_-hcw5Dvk-0iAU6J6nqkDQA_29_0"></a><a id="Tc_Q3VaNAn4e0SwDuC4jpeIhw_30_0"></a><a id="Tc_Mb7V6PvEqU-l7lS7iYI7NA_30_3"></a><a id="Tc_kb5DJc9xQkeix0UGAZMBlA_31_0"></a><a id="Tc_YRgFc6CpMEqy22WIsh3jjw_32_0"></a><a id="Tc_r-5IhuJy6Eunry46djEgnw_33_0"></a><a id="Tc_ppLZgdJOikuxB96TwS-AYQ_35_0"></a><a id="Tc_Ya-1T8hLPE-Kl2bKNmk4JA_37_0"></a><a id="Tc_5YLEAjJGs0K62-HENK2Wgw_38_0"></a><a id="Tc_8iJBf6ssRkK_V7t_Tm1jdg_39_0"></a><a id="Tc_XgsdVrm5PkOZd3ai51BtwA_40_0"></a><a id="Tc_lpK-LYVEfk6pztD4hqZixQ_41_0"></a><a id="Tc_iqy1DiXMXEib_I9vLRl9oA_42_0"></a><a id="Tc_niudUOea4kiJUTInj9dyVQ_43_0"></a><a id="Tc_dgSe__xKc0y9Nu-HmMoTeA_43_2"></a><a id="Tc_q-po0VCfTEmOpVsd471xaw_43_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.6587677%;padding-left:0pt;padding-right:0pt;width:103.31%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_tGxYN4fWJEaX6u5WwJIiJA_6_3">36,053</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_9nNS5k0J20uLDszoekCW2w_6_6">32,786</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_ZUBoBL2gnEK26lwXEscBvg_7_3">13,049</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_2z9NULN830OR0bmdMKobrw_7_6">24,147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_17wjKpuEGkakunyD7dcxiQ_8_3">28,904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_jbYWVC_GGEuSvyFwMQR1rA_8_6">30,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_jKCQePuZYkilBj8dNlysXw_9_3">8,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_rbZ6M15pl0K_RjiOFzK1Zw_9_6">5,522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_01WuhbTo6UmrpBCBxxoCzA_10_3">8,658</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_rgSpX4ir4kGEzYELUtHY8Q_10_6">6,261</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc__Q1jewbg7U6LjOo5TOF97A_11_3">94,723</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_cvmo9F3KYkiTHrEAwmZgFQ_11_6">99,266</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Rtr9epP6jkafozeogIUZqg_12_3">115</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_RYPkdAUd2Ua849R28Pk_Jw_12_6">165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc_Oza0iW15n0mDff7dOrjEqA_13_3">28,275</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc_bMR8zTMZzEC9mauz4Biuzg_13_6">13,878</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_iWVnE1Ff1UWDx2k-Yb8ZSw_14_3">560</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_l0rShuRX5UyBHocv2i2pWw_14_6">861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_2x73TY66D0-u6HjRQQpKKw_15_3">4,735</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_KBkBxVA6Q0G0FkONQrVkzw_15_6">3,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_jgPNltEmn0myFcKL2Uf89w_16_3">128,408</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_FbVQzIRK7UeO8CC0DCiniQ_16_6">117,225</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_GpIAy2BApEaU3vJy64rkRg_19_3">6,130</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Hv_cGeGdIku9VnDKuicHcQ_19_6">7,142</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued compensation</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_GjAnJ8rYV0CMWORHgRgY0w_20_3">6,373</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_azaOguUxeEGmrD72FPcviA_20_6">8,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued research and development</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="rigl:AccruedResearchAndDevelopmentLiabilityCurrent" scale="3" id="Tc_FyAyVFW7gU-nLaaCLq-Ceg_21_3">4,672</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="rigl:AccruedResearchAndDevelopmentLiabilityCurrent" scale="3" id="Tc_vS3FMfYLd0qxRhCaBtR9jg_21_6">3,513</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquisition-related liabilities</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" id="Tc_YD4Lxq8wDU6hD6lu-7Daow_22_3">15,000</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Revenue reserves and refund liability</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="Tc_GV3fqEjn3UyzBg5Z9lD53Q_23_3">18,547</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="Tc_RyuKr1XEaE6jgqUB00CfgQ_23_6">15,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loans payable, net, current portion</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="Tc_DfW5dic6EkKlzQXzwd_gBA_24_6">7,229</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_lGxF2seVJkeW2Toff_RsZg_25_3">5,933</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_hV-m1M9Ad0aoOV86QHRiEg_25_6">5,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Deferred revenue</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_KKNnndZlWUWNyOpMLfvCkw_26_3">1,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_kDT1mGRVGEqEJQD6T8ANbQ_26_6">1,355</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liabilities, current portion</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_StsLO34EjEuxhnmoe7HpnQ_27_3">639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_M-jyv_PNzkisIdyxC1kbhA_27_6">692</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other long-term liabilities, current portion</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_0oQLcjrmokKRCYcW45vw6w_28_6">3,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_9vmFhQ2JFkqQxcGd0PfT8g_29_3">58,649</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_RE9Uc8jh5Eu0IHqxR0yB9w_29_6">53,267</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of lease liabilities</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_e-Q1ayWYekKGPKr2aLXR0w_30_6">285</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of loans payable, net</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_QnMCa_gdBkadtZMjsl04dg_31_3">59,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_Pf0HHS-H_UOABQO381TX4Q_31_6">52,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_D-oxEfcgtE--2VlVaR7zTw_32_3">39,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_hoz8SztUpUWBsPUi47GNXA_32_6">39,944</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_NUY3jZv4VU-tXbzkc7ny7Q_33_3">158,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_lp79YbrMTEm6t571pYuHsQ_33_6">145,869</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_z-nzBVJH1k-wb43jIxM8sg_38_3">17</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_4f7W3UX8F0uA8Cf90hwqtw_38_6">17</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_bFleT3K4aE6ft581AxxLqA_39_3">1,386,905</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_zUth746V6Uuo_Fno-OeflA_39_6">1,378,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive (loss) income</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_476NNQZ-c02rVfwgCVsMmA_40_3">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_H7oC04_c30GlE3QIwwn3rw_40_6">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_H0OPGtKx6Uyfj-qhi2oiDA_41_3">1,416,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_o8VypU4dh0uoG73Ps5WO4A_41_6">1,407,550</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_09HmkWSDmUSreHiVgYROwg_42_3">29,914</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IHL5Q_F1k0OujO1whVhV0A_42_6">28,644</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_IWT4GVjORkuqyNSls-TRnQ_43_3">128,408</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_K9xCI_HO6Eiacmp-AVRSLw_43_6">117,225</ix:nonFraction> </p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"><a id="_4caea8af_7920_4589_a4ad_7ff3f8a7b746"></a><a id="_e5909fd6_dcf4_47b5_8886_23bec0eb441c"></a><a id="_1d9d7ba2_5ecd_4806_a78d_7ee0fb7fffc9"></a></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The balance sheet as of December 31, 2023 has been derived from the audited financial statements included in Rigel&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on March 5, 2024</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Common stock and additional paid-in capital have been restated to reflect the </span><span style="-sec-ix-hidden:Hidden_cVzsh-nsgkmvDysnunKDMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">1-for-10</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> reverse stock split effected on June 27, 2024 on a retroactive basis for the periods presented.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 36pt;">See Accompanying Notes to Condensed Financial Statements</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_8f09fff4_f5e7_4f15_a507_282c3f0dfc56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="STATEMENTSOFOPERATIONS_342998"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF OPERATION</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_9eb06f4e_9f95_4b56_9331_d7514de72237"></a><a id="Tc_1remgkhScEOQ2Cot51HhMg_1_2"></a><a id="Tc_xLM2YF1gtkiO8ghto3C2Dw_1_8"></a><a id="Tc_QnaOJuLb_EquBLA7m1MlVw_2_2"></a><a id="Tc_JvZoY5WR9ESM4F8c3pCKYA_2_5"></a><a id="Tc_eSs6Yt_8hUOwtfCtTwD6Fg_2_8"></a><a id="Tc_mdwqkyq3cUCy4zqAvHtpDA_2_11"></a><a id="Tc_Y1AgSvJLjk-tDA56aNJ9Yw_3_0"></a><a id="Tc_IuCY4k6aEEOKgcZ4718n_w_4_0"></a><a id="Tc_btZ4_mZv3ES5tpBkJ4lpbA_4_2"></a><a id="Tc_7qZ_NNuJE0SW2jP2jKh5xg_4_5"></a><a id="Tc_VuWG7KdWeUGoweffjQPthA_4_8"></a><a id="Tc_N7Lr8AQogEyN8EkcH1MMFw_5_0"></a><a id="Tc_0qOun9vHcUmkOS-gP8CAsw_6_0"></a><a id="Tc_s5wiBJp0C02RmoEKf6kWSg_6_3"></a><a id="Tc_84D0IK_hCEaMqq_6zVYNAw_6_9"></a><a id="Tc_3BmRRDQp70GiG1o2hZUiHA_7_0"></a><a id="Tc_b4yMiYLq6EOe9lGgV0FNiQ_8_0"></a><a id="Tc_9S6-n5d2YESBFmtBAf0Rkg_9_0"></a><a id="Tc_n6_ejeqaxEmumyCyMw-g_w_10_0"></a><a id="Tc_kAiGM4b0EkW4JGH0X7kStQ_11_0"></a><a id="Tc_zhV5Cj908EOCqp3KQ8V7Sg_12_0"></a><a id="Tc_dle-4NVTQ0WnnSS72KGdHQ_13_0"></a><a id="Tc_dAGwP52JDE2PRyIzQFS71A_14_0"></a><a id="Tc_xcQMZvC9MkSugewaopYc9A_15_0"></a><a id="Tc_x913t5Ym6022LelvqH7xYw_16_0"></a><a id="Tc_IEVDKkg08EmCMoyU9qsDzg_16_2"></a><a id="Tc__51_lC6sk0KuJv1I_lly-Q_16_5"></a><a id="Tc_DtLHKwrIKUeO83gyCCfI0Q_16_8"></a><a id="Tc_kO0h_hrwn0qm4pzKVf8LgQ_16_11"></a><a id="Tc_tYTS9G71HkKdT-ftHt7NXw_18_0"></a><a id="Tc_61T927llQkibHb4FdoWE1A_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.66%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product sales, net</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_L2X2ODMWN02W75JbcgBOuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_QXV-qH1RYkOVk2mkSgw1Mw_4_3">33,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_qF77QLopJkm7QArlC1YAAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_TpWkpzWjv06uCUm7mqxwQw_4_6">23,881</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxQfYCTi-EmntNNb3PEHNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_iC-oCc0QCkOIjvekv-yjJg_4_9">59,453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_0CKs5sN0Y06oyeNfimQy-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_-07UZTKkbUqO9cr7-RFb_w_4_12">47,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contract revenues from collaborations</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_jsAPdtswwUqlYhdOCwaqtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_WbPTomUUKEe_Z3tbFVzEyA_5_3">3,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_crGh4Gmf10KG35aVQN5FmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_swRBfStK3kWhblgc8CLfjw_5_6">2,005</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_dRwb9LpMMUGY_8SiQzA0vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_10p2PDAeNkqjxz1cUbyARw_5_9">6,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_sXlfY9W4v0-bUvEUlAVg8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ziO8HN1aNES4X7jMWQUQ9Q_5_12">4,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Government contracts</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ZyYnBP85eEG-NrrAMg1mgA_6_6">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_AaF4k0P3CE6c54kRd7xnvw_6_12">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_iw81z4ADE0O6EwrgoP0rkg_7_3">36,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_dEvZe28WtUupBcFNhi_OgA_7_6">26,886</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_fCcON0f2w0CCzcrU47ozwQ_7_9">66,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_UYPZmexhlUaYZPYnkXRigA_7_12">52,956</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of product sales</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_y2BbPXSoyUGtWUww68BpVQ_9_3">2,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_nYwbkjaTG0SpWflKnEeLIA_9_6">1,075</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_bdvgs5yMR0aaM8HDmn5StA_9_9">4,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_0Lm-DLAJSEqWPS_6Fi_Xsw_9_12">2,052</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_QsiBODQnTUiWzEtKWedjcg_10_3">5,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_-SQ_opl1vkeEGrOYdhKrmQ_10_6">4,772</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_KDAMM7-e-0mdHCkQ9iV5Ng_10_9">11,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_hfFy35qQnUyxYab-OVHcBA_10_12">14,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_XQp7k3VyDUGs6Q1jrL3IjQ_11_3">28,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_hi3jHLalxkmrkb95e07Miw_11_6">26,306</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_g8Cpjbo2PkyoPPqQdfS0NA_11_9">56,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_mOZcD1X3_0C_SuxLntDGTQ_11_12">54,035</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_4OqoZCReb0WHMaEqEb0Xzg_12_3">36,394</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_rEp01StVIkirk3FPiy2zNQ_12_6">32,153</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_91uKpCfZFUKQ2XGdm4lW7A_12_9">72,894</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_qv9hbYoWlkigL9daFh-ujg_12_12">70,948</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income (loss) from operations</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_nIk9fJU5M0eRPmCW1SBE7A_13_3">447</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_RxaUu1zOukuAceO9hRzr0g_13_6">5,267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_JXCm98A0WEOTjXQy-L0FSw_13_9">6,519</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_SYfEfg29Q0O8U9Bi9mIc9A_13_12">17,992</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_EBOmj-XzdE2wbdsDk2Jg-Q_14_3">552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_PCM6AK5HlUKT4VelYKvaHA_14_6">529</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_tZKg4SKyI0uV2B-3CfPURg_14_9">1,145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_0Z4ZR4W59EqfmuT9zCvAYQ_14_12">922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_JdrHIAmTqkSANOqvnWG0Fw_15_3">2,029</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_gaJG3BiZ5kmYVvhlz39TzQ_15_6">1,862</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_cGzJzHy6-UW_JCcL7Sx2gw_15_9">3,903</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_lXF9nfdGAkGAMm0kp9rRkg_15_12">3,066</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_b83wVSHgIkis8uSVi5M50A_16_3">1,030</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_nXcpwFl5dkiFwkW5MdLIkg_16_6">6,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EtIWKdruz0OMWI--aVDbRg_16_9">9,277</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GkdxtlFWpUORp87rFx0_5g_16_12">20,136</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ctTfnEu_tkqhRm4vV9ngHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ebN-OvkkdEClxKmtg-DaSg_18_3">0.06</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_5KELc9U4NUif45kVCZ-0dQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_h7-Jfx3ON0KM032sU8z5gg_18_6">0.38</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_rflHIBSyUUetrL1tzhin1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_3qToF9XoDUid-PCBACZWUw_18_9">0.53</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nLgi9I2UlkyQbQfrdOSHrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_t_DMaVrUxUWaW5m5McqvtQ_18_12">1.16</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing net loss per share, basic and diluted <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_D24eGdMSlESXBBAPv3VIjQ_19_3">17,549</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_GbezLLUmJkKsWO2XcAItWQ_19_6">17,356</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_-GB7SjdAbUeJv4l4fRjA4Q_19_9">17,534</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_jnN1mue86UuPQVn0dEdUmQ_19_12">17,365</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Share and per share amounts have been restated to reflect the </span><span style="-sec-ix-hidden:Hidden_avsxiqC5EEGbi6wZ76xCjw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">1-for-10</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> reverse stock split effected on June 27, 2024 on a retroactive basis for all periods presented. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_24ef69ce_4e2d_4563_b6fe_94b49c6afeb7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="COMPREHENSIVE_LOSS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF COMPREHENSIVE </b><b style="font-weight:bold;">LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_fdd9d852_5533_42f8_952d_7d81e44edbed"></a><a id="Tc_ANtHD7OEzUObACu4tc71OA_1_2"></a><a id="Tc_hePrske9skaEATRO9hiD8Q_1_8"></a><a id="Tc_tcbr5lZ-oUug0EMuVqyszQ_2_2"></a><a id="Tc_AuiErI91zUmhN23muOBSKA_2_5"></a><a id="Tc_QpWg50iN_kmMIsNqOpRL8g_2_8"></a><a id="Tc_80YxLDYJjUmhxCnNBtmq1w_2_11"></a><a id="Tc_oh90YO9tlUiQLf9tKH5gSg_3_0"></a><a id="Tc_36BylJefgkShxLAt9PAXmA_3_2"></a><a id="Tc_O_6ADpIIsEOInouYqexk2Q_3_5"></a><a id="Tc_rhpeUUfLZ0eam6zuEMXlIQ_3_8"></a><a id="Tc_hyDLYkED5kSoUy0wCV_o4w_4_0"></a><a id="Tc_-zodZi1d90-t2uAyPk1a0A_5_0"></a><a id="Tc_mD-mqOjtDkq-VN40izkN-w_6_0"></a><a id="Tc_Jk3-eWMmbUCOgid2m8-TfA_6_2"></a><a id="Tc_xgQgm5HkBUW1QccGmLpIWA_6_5"></a><a id="Tc_qT-wQFhjH0CpKV5pqjfP9A_6_8"></a><a id="Tc_JJyKIzB4WEW9d0i7VHIqbw_6_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.499691%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_pr9GuL5_WUmiWImdkiDSjw_3_3">1,030</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_U1_SpzJp1k67gw-krsBtHg_3_6">6,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_EBHdD3ypYE-JpFdxwY7jEg_3_9">9,277</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_WacVSneLaUuP4N6egCiVdA_3_12">20,136</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive (loss) gain:</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net unrealized (loss) gain on short-term investments</p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_c-48VIsBL0a0Z6BnpngCTA_5_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_Tr6L8TT5L0WthMZjJNJcvQ_5_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_qRcyRpivDk-Bxb4L_xzhcg_5_9">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_KSurRzD4zU2uxaaEPrMlAA_5_12">128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.76%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Ad6OVeEtzEyZawMVZvgSBQ_6_3">1,034</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_yqOmsUXfuE6dnHEBLZkJ6A_6_6">6,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.88%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_-THL36yb7UKR9oNGib14ug_6_9">9,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.2%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_w-mWWkT4nkiRPmmsxSZZOg_6_12">20,008</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_ce427b93_84fa_42ee_b60d_3a52b304fc2d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="STOCKHOLDERSEQUITY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF STOCK</b><b style="font-weight:bold;">HOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_2989ac1d_e6e9_4515_a895_5bce1796dd19"></a><a id="Tc_OV96RYCXFU6Rf279k6d8yw_2_7"></a><a id="Tc_oCEBO6Ooak6ff5Q4zJ1VuQ_2_10"></a><a id="Tc_xZEH3wUWmEiNyYHN0p6W8w_2_16"></a><a id="Tc_peIPM1Pyy06VUOAxZQEvLw_3_2"></a><a id="Tc_DF6B2z2ZcUWakI4UuNVfIg_3_7"></a><a id="Tc_pB0RXP58-EG8SD9-bF_uZw_3_10"></a><a id="Tc_RWb_aTXyd0igFmJIE9qJAw_3_13"></a><a id="Tc_AeLF9po40EOp-83iAWtLZA_3_16"></a><a id="Tc_GLHb2zFmQ063On295hPPyA_4_2"></a><a id="Tc_lspkr_csz0q14o70vDZLyg_4_4"></a><a id="Tc_FzZx4g037UuJLS_9nI7mbg_4_7"></a><a id="Tc_R4eWpjtLDUShJzjPHuVFHQ_4_10"></a><a id="Tc_buNSVCbZxkC4qwUBOMLFmg_4_13"></a><a id="Tc_sc6eavaehUek75Fe-691Ng_4_16"></a><a id="Tc_zOB2GmQVk0irGTFzMvRM1A_5_0"></a><a id="Tc_J8rcnk6Ueke_Az1ibZhREw_5_4"></a><a id="Tc_r-ow9XZWhE23tsUEWlCvYQ_5_7"></a><a id="Tc_C1O-z3-Q_k6kaUXH7PR8jQ_5_10"></a><a id="Tc_Sn4L_ivVvUuQqTc-BHhnhg_5_13"></a><a id="Tc_DdYFhjfHWEeksxZalcTRVQ_5_16"></a><a id="Tc_T3COeVPHxkaBKgkafnzKGg_6_0"></a><a id="Tc_Ex3FvbY-EE-rQbK0W4XUzg_6_2"></a><a id="Tc_jqthTOneNEGB8Sk68p7-8A_6_5"></a><a id="Tc_TKp5Q6Tk8E-XdqW531mhlw_6_8"></a><a id="Tc_lQVqX8rl5EeqJlnsNPDsoQ_6_11"></a><a id="Tc_9H4be2LXP0GVBADcfG156A_7_0"></a><a id="Tc_3ZRDU4MhW0ePRayvCLVsVw_7_2"></a><a id="Tc_X38eNlndTkGgO0jT-39reA_7_5"></a><a id="Tc_2en8h_6Bbk2xyIGf9ZoRFw_7_8"></a><a id="Tc_XUIiMadn7kmwHUhreHNxfA_7_14"></a><a id="Tc_8tcEShpKR0GzzDHRefgw0Q_8_0"></a><a id="Tc_Bpt01bsxVU6AQZlAK-OBHQ_8_5"></a><a id="Tc_Gif09M0lIUSK9OoLnralzA_8_11"></a><a id="Tc_-t5XE8KqHkeWedI0nv0fjQ_8_14"></a><a id="Tc_lFVDX5geT06t49v4aX7a5g_9_0"></a><a id="Tc_gBigcI3jvkKcwzP4JiZNCw_9_5"></a><a id="Tc_f9s-4B9Fa0CVSu2t8PSaQQ_9_8"></a><a id="Tc_Ans_ibZ1Rk-BB_dPS61HZg_9_11"></a><a id="Tc_v_nDlLd8ZUi_HWKZIM1k8g_9_14"></a><a id="Tc_E2n0lAxlJk-Xc8l2hPIZyg_9_17"></a><a id="Tc_zFRirdf8fEWQd6AOOOqHOw_10_0"></a><a id="Tc_xuTtCdlyS0mWfK8X5zyeEw_10_2"></a><a id="Tc_YA8rcMm4oE2gRlizEse9TA_10_5"></a><a id="Tc_s3UOq-NjqkiZBrDflw-opQ_10_11"></a><a id="Tc_covL5nyCqUqOUjY8CI5H6A_10_14"></a><a id="Tc_10oGeXPbN0q1ZJLtp5zdZQ_11_0"></a><a id="Tc_pYzq9CeRCUCT9M3L55X1eQ_12_0"></a><a id="Tc__TEpD7GXNUOTiwpndQ7iOg_12_2"></a><a id="Tc_H1Tp93Fc9UuGOAQJMe2ABA_12_5"></a><a id="Tc_OquTIniALUaXQst80ll1zg_12_8"></a><a id="Tc_Oryy0TlIj0i-l2QzWntAjw_12_11"></a><a id="Tc_FTjoon9OOE69w6G1CUtBQg_13_0"></a><a id="Tc_44sdhXEnn0-Ij5aFwMFvTA_13_2"></a><a id="Tc_IqQmh6bG30WTv826ddEJ5Q_13_5"></a><a id="Tc_t-b2KpVVIE6PuazcLv_u7Q_13_8"></a><a id="Tc_7p04wNTtRkCYB_KjvMDJoQ_13_14"></a><a id="Tc_XUEJQsV9DEawHDvMmRA-Yg_14_0"></a><a id="Tc_qTgyJZfbKEiynSN1BlTWYg_14_5"></a><a id="Tc_TfrPfmzi_ECWpuw9ArGgaA_14_11"></a><a id="Tc_jPTMyWd5x0G33FW2II9V6Q_14_14"></a><a id="Tc_6UBMHxzpLECPeMYlqxERPw_15_0"></a><a id="Tc_BNJe6QcNHEuuR8sElXg9xw_15_5"></a><a id="Tc_0vagcPBprkKw_O8c0D1xhA_15_8"></a><a id="Tc_aZnL0Iv8iUqsSbA00KVvBg_15_11"></a><a id="Tc_OhpAky5eZ0axIoqcbtY6Hg_15_14"></a><a id="Tc_iQSwkIswOEiUnu-Xz1KT3Q_15_17"></a><a id="Tc_OExqarFhsE6ME-G8kDwHlw_16_0"></a><a id="Tc_e19UXq0ATUOUTpN-h8alNw_16_2"></a><a id="Tc_gv4bhjbOKUOA3iUXMkQwGg_16_5"></a><a id="Tc_DZ3txPSO1EWATZhkVE2q3Q_16_11"></a><a id="Tc_mrNOfhTpR0murTopinBGLw_16_14"></a><a id="Tc_N49cc2s2OkmCtY3kkWAC5g_17_0"></a><a id="Tc_JWiOmtIovkOTRjqZygrgpQ_17_4"></a><a id="Tc_fwCAGcUY3kGqPriogMJBAA_17_7"></a><a id="Tc_qP9byZ02t0GIuo7B8CHKeg_17_10"></a><a id="Tc_OPbo6PMedkq7-3OZh5Srdg_17_13"></a><a id="Tc_21g6E4_PdU-iFbnfe83zpw_17_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-7.459305%;padding-left:0pt;padding-right:0pt;width:114.91%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Income </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBUO2o21ukOtCErji3SQCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_a_GiI3j-ME6ISkT5-upGrA_5_2">17,482,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBUO2o21ukOtCErji3SQCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_a70VsEJNAUyfRnSZ55WUpw_5_5">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_otHOXZ_Ey0WmO49o2jMv6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_WI0hd0nIHEWlJVT-9s2Rjw_5_8">1,378,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JKqbAPtAjkGccR66L8k_qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xJlnnLmjvUWFGzvABO5b3A_5_11">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rPjPB2Hmbk-fkqxrA8Qngw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_-bEFTS_TBkaX4F7JUDs2NQ_5_14">1,407,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_emou6AapN0-zizu5QjoGNQ_5_17">28,644</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nR9Unjlvxk-pD68DK4-gZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_UjXzfcEnN0SuSFow71QEeg_6_14">8,247</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_oaN1H2MbN0ah7jLBMSuznw_6_17">8,247</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net change in unrealized loss on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dWSzM4PiYkqhpk6Pu6GX4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_Zo6HUtwVlUqhuwwhqU74sw_7_11">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_3K0_YXOrLEWMOPr0KSvf7Q_7_17">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0jRDeqtQJE6s6Jso2tDR_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_qof7egqtmk6J0Cd4b8nDVw_8_2">9,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aqTJrxACT0OLl53X_CyKsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_0_xzoqSWNU69LdSmq_pynA_8_8">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_qtCL_OV8FkuBEdyy9CE1Jg_8_17">89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of restricted stock units (RSUs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0jRDeqtQJE6s6Jso2tDR_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_5KssmgWXakOPM7Hjxt0NPA_9_2">48,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aqTJrxACT0OLl53X_CyKsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_e50xNrYhPkq4076E9Q-WGQ_10_8">5,144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ihnrW_i9RkeUQihCk6ZmmQ_10_17">5,144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ons628waiU-GMU91DELbBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_qLiEOMtzz0uT0l3tRq8qfg_11_2">17,540,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ons628waiU-GMU91DELbBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_WIhivPvFxEGhSsgv3EeiaA_11_5">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KlQgIhdaH0KRHwHHBqCVag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Y69tWUC6g0yndlMMckEzMw_11_8">1,384,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IA3yy1pN9UWx3KzvJPTixQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_THsgQmn_aUayeuqBNHUqNg_11_11">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sIg7hAM9oUWSDXtYBBt_Lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_L7Oq_65EOkuEz5f3F4Khlw_11_14">1,415,797</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2024_rFOBOeyLMEiRCtDUqDQoow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_q0bfOg6UOUeeD_bih9_2Fg_11_17">31,671</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R1A7IWBmT0KvJy9Tq1LCYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_6rbp_GUyQ0ysa7kA8iDlPQ_12_14">1,030</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_lWbOSePSVEK-3aFc-xoVOA_12_17">1,030</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net change in unrealized loss on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MyObbAmPakSYdCOgOM9oXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_KAAMGH2voEudRpT5xi5EFg_13_11">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_HVFh4Q_9PkqZWaoGZW-xLw_13_17">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options and participation in Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ieLLpNjElUSlKRg-RIcl7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_JFiNDd_iN0mT-z5GdNb-Ug_14_2">36,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9NUp0OtJ9ku2HiQECijrIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_Tpr2dwF5oEWqwCiLswrNjA_14_8">252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_MK-H87N3SEiQRTKmpjAIPg_14_17">252</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ieLLpNjElUSlKRg-RIcl7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_75eqINDtl0G4NLe_zyjNwg_15_2">17,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9NUp0OtJ9ku2HiQECijrIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_s1VOifmWWEST5OHtIZoBEg_16_8">2,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BZwl7Qvw00-uSBNUY3N6gg_16_17">2,539</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jynRgS2pl0CPMnlU_535aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_NufGJptqLU-e1kULCaq3Tg_17_2">17,594,117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jynRgS2pl0CPMnlU_535aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2f-8VoypsUeYtXWaR5kyKg_17_5">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k8Gu3743e0GwNZtJz5p2Rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rYvrP688LEC0oRXaRFWFjw_17_8">1,386,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gsUfXJSf702qktCA38R1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4R3pZQmp5EK6qC6cU46S9Q_17_11">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6_5O45BUnkyJOAznzy2CsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_iy7BuizdhU--HkICV0CFxw_17_14">1,416,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_9u3QDZ5OqUquRfm7qsHFPg_17_17">29,914</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a8573618_07b1_4a35_ba2b_11c14d22ec67"></a><a id="Tc_AEypQHvlnUe4CM6B1FZyRw_2_7"></a><a id="Tc_gwtBNWKIuEqrDyriGKCi4g_2_10"></a><a id="Tc_XnDXMfDEoUCgpE3tItN-Vw_2_16"></a><a id="Tc_Afdm6HELsEKW7KgOfpqhlQ_3_2"></a><a id="Tc_pKSbgtHWHUWkXPuhkOtHPQ_3_7"></a><a id="Tc_FgpL1pWEekqVL8UzC8DSWw_3_10"></a><a id="Tc_nOz6ALVKYEOcTmPvesPPnQ_3_13"></a><a id="Tc_EqBLD0qSYEeiNbarQwFa_g_3_16"></a><a id="Tc_UwaSZsStJEKJHHOlOZmuCg_4_2"></a><a id="Tc_M4an0_u1ckmNjYzXEjTSiw_4_4"></a><a id="Tc_Vhf2pEhD7UKnJb49jKAHrA_4_7"></a><a id="Tc_TL6lk0HfLkyyw5URmxj8pw_4_10"></a><a id="Tc_2PARWH9Kz027zYK38TSuvA_4_13"></a><a id="Tc_PA1FNeSPWUOHVqqADtZqLQ_4_16"></a><a id="Tc_9HL2D7oUu0aDqmFrdkQ8_Q_5_0"></a><a id="Tc_cYBMwh--40agqU8ykUpD4g_5_4"></a><a id="Tc_zf9JEthv3Eub_YOMyBWe7w_5_7"></a><a id="Tc_spnJ3GS-y0OaIjqRpxvrRg_5_10"></a><a id="Tc_800VnQo_702ALDpuWnKgaw_5_13"></a><a id="Tc_IOkEpFZeaEq9eRm-kOocGw_5_16"></a><a id="Tc_k1ILlmuNq0aYO1bX9VGWTw_6_0"></a><a id="Tc_USWWMt-JvUmVsGFxs1DcNQ_6_2"></a><a id="Tc_y5aCPCELlE-DVfJhCVs3ew_6_5"></a><a id="Tc_WgdJSoLaa0yp2IrEN2D4cg_6_8"></a><a id="Tc_9wGQkRcaYkqTqscHeA6q_g_6_11"></a><a id="Tc_nsLnhE8JuEGp_qPD_zBNpQ_7_0"></a><a id="Tc_lOJYHiFW406R4wRH1hB2LQ_7_2"></a><a id="Tc_oxWmnM5uzkSyYZMmFJsAMg_7_5"></a><a id="Tc_CIgKgvMYIE6kiXvxsH47vQ_7_8"></a><a id="Tc_h1IG7JTKcku38OObuH5v-w_7_14"></a><a id="Tc_hLlPmfXuLU6l5MekDiijvQ_8_0"></a><a id="Tc_DZPO3dEyjU6KHCX93VjULg_8_5"></a><a id="Tc_oMuDD1CTYU-sS0wlbnGg9Q_8_11"></a><a id="Tc_2CVtvwByVkiYrGSC5_OIKw_8_14"></a><a id="Tc_eMaVne3--0GWzYa9VJ-XZA_9_0"></a><a id="Tc_yQptGbk7oU6DhMVtReL6Lg_9_5"></a><a id="Tc_7c-XLYah2UWkwHuW4gRDWw_9_8"></a><a id="Tc_X5eux1KceEqu7wZgQJU3rA_9_11"></a><a id="Tc_yAbV1lMoTkiQp_9vD_A_Lg_9_14"></a><a id="Tc_VGJJDqDinUOsN8b3xymBUw_9_17"></a><a id="Tc_zLevxWNvTkS8tPNyF8f46Q_10_0"></a><a id="Tc_aRlGGB97N0OWXMqu98qrhQ_10_2"></a><a id="Tc_Ios2PpHE6kGpmMiB8NjS-A_10_5"></a><a id="Tc_p0xZs0IgDkinzBAUMP6axw_10_11"></a><a id="Tc_OMfnzrmbT0iWpmV0IBqlCQ_10_14"></a><a id="Tc_YCMG3InN0UGH9rvWB3GYPQ_11_0"></a><a id="Tc_gYyNpU6X0ky5NIrP--gjVw_12_0"></a><a id="Tc_ZZY8Sr5BNUK1ch-RpgjPQw_12_2"></a><a id="Tc_-QEb3K9mnkqhWst2EH704A_12_5"></a><a id="Tc_IZcWk6R98USRHtlLCWOrYg_12_8"></a><a id="Tc_sjrT0vp7i0W5-hDAIR7UXg_12_11"></a><a id="Tc_nE1PKtBHDUStwoTtC3ICsw_13_0"></a><a id="Tc_IBH1gQp6Rk-21HBCWiTEUQ_13_2"></a><a id="Tc_saG7MzUm8UapNy9l8yyTrg_13_5"></a><a id="Tc_3-BPkoK1DEuxF9Irwc9OUA_13_8"></a><a id="Tc_UAd31j-FJUO16gtEXhhXgA_13_14"></a><a id="Tc_5U97MqMS_kyddZojnDYjnQ_14_0"></a><a id="Tc_LKeTQSMwZkmvmq4F7ilPow_14_5"></a><a id="Tc_AHjH3l_Lw0SzlggLVTj9WA_14_11"></a><a id="Tc__NxLm1N2XUyLCyKrrXvRjg_14_14"></a><a id="Tc_DWDl4cgZRUu9dgwNjEqnXA_15_0"></a><a id="Tc_PmEJ8vj3qUu-8WznRwcQuw_15_5"></a><a id="Tc_OBx2yQQgo0eaXcEIqyuvfQ_15_8"></a><a id="Tc_v0FEdiPI7UGUPVCQ8-JDsg_15_11"></a><a id="Tc_hbpTmO6u1U2uzm0KgkmnZQ_15_14"></a><a id="Tc_4w5a2avrDky4JyD4CEd4yA_15_17"></a><a id="Tc_k8cWOQwKAkmj9FMiImtL5g_16_0"></a><a id="Tc_VkgzVja8Zkm0L9ZNVdoKIw_16_2"></a><a id="Tc_EiMG-Qq2OEmW0WZ7kDNnEw_16_5"></a><a id="Tc_DJyUwihNJki1GKbNitp7Tg_16_11"></a><a id="Tc_A5C0RJkTzUmMsVaHgWqRPw_16_14"></a><a id="Tc_4NDVR1fpAUeBQCoKtv4rMQ_17_0"></a><a id="Tc_t7dVY2himkWBBnT3hVYYjA_17_4"></a><a id="Tc_bYpSN1GzHU2BIOonCH11wA_17_7"></a><a id="Tc_-Ltp4gapXkSWHVpc3hJCyw_17_10"></a><a id="Tc_BSg-kOCB60qXPxPWzrZEWA_17_13"></a><a id="Tc_vZMTHXXYaEeH0vnUFz3nyw_17_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-7.6189995%;padding-left:0pt;padding-right:0pt;width:115.23%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M9P7eTJN40GnRu7yAa6KCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_lOPvEQ6xW0WrNVTYEUA41Q_5_2">17,339,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M9P7eTJN40GnRu7yAa6KCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MlRgJa-zqUqGEYnBYWpckw_5_5">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1lu-VK7_o0-Max8PseaIIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1IOF5jwWpE2kcnleQlvu9Q_5_8">1,368,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7oPrIr8cXkqlq5Yd3Q1yWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_m0xRg9r0JUK-16V3SkdDBw_5_11">153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P4KZWdg170yGNV_k_L91Hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_awVoI3bb9kipyLyG6lAH4Q_5_14">1,382,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_RpnuVw-ewkGjar8zQJ76mw_5_17">13,616</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gvz4si6MdkS4fdUVQlbKOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_tpMM9XFza0SEwP7L6SoMug_6_14">13,536</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_BEBa5sGD00GXvgTV2G_L1A_6_17">13,536</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net change in unrealized gain on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zmuW7qmKekWpcj688rHkvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_prrZgNyv00uaJH0I-wbEvQ_7_11">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_Vs6jzzaPwkafO972WEdsfQ_7_17">126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m6FKz0lCzEavyGq5m7-dVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_b07xPl5Ypkil5-sewoaw9g_8_2">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QJLTwjYbzkmfnUQQu3xMaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_tGwHkAASuUawtxThJltURg_8_8">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_r7Cwx72vK0Su9oZeN8kBCQ_8_17">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m6FKz0lCzEavyGq5m7-dVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_RZbQ4BYAiUCz4oBRNv7EvQ_9_2">26,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QJLTwjYbzkmfnUQQu3xMaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_L0Ag_n15-EewlVcuBdhrgw_10_8">2,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_IzLO_hr1fEa0oUKyb0DX-A_10_17">2,768</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w10yELUyuUKFpRmpWRAlCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_xoZQCFqgk0qZsIFuT3_I3A_11_2">17,366,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w10yELUyuUKFpRmpWRAlCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_b0yMSyK7O0CeJTSMb-MBYQ_11_5">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GnF2WrQG20ug_b0PbRql7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yxKnlw-Y8Em20ixLO_T0HA_11_8">1,371,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zBZ0CJwMEUaUNEdiy_40SA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_MB0tF1dn4kqp78P7HTMtCg_11_11">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2hx_ymqnNEmbyAqqcCVWhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_d5LER-xc9UaR1w_v4DAQLA_11_14">1,395,995</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2023_RB2aD2voQkKnT5jqSouijg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_cq2Wo5IaZUSlNtq_rUHOIw_11_17">24,257</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a0Js5EGrGk62uZjqtY72Kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_zBD1TjdRIE2_7UecBGIqrA_12_14">6,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_I8mMeXqF7EioeOKbJ3HhuA_12_17">6,600</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net change in unrealized gain on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H4solk7YuEifDSX0Yinypw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_lG2CkAVxpkicNkBFQalLng_13_11">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_QC6kFWUdb0-DN_kiPvLoaA_13_17">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of options and participation in Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5haw8gzz_kCqIrKMQPuu3g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_bnesGKfdNEm7Rb7eOq1GdQ_14_2">52,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EYUKQoEsRUCEo0sMj1Wymg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_VPjB5q6aT0CYE_T478pEmQ_14_8">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_rcs2wmMU2EaXNZytuPbIEg_14_17">554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5haw8gzz_kCqIrKMQPuu3g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_9b-CtIDJfEa9P1EsCJ9c5A_15_2">16,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EYUKQoEsRUCEo0sMj1Wymg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_fXE5bJVrnkSlJCr8va7Kyw_16_8">2,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_rs9bK5wMxUmKFyBxS981mg_16_17">2,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:39.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c4Il3dY-Cka-Z7hPZIh3_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_2y67zNPYPUiY4bPmh4wZRA_17_2">17,435,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c4Il3dY-Cka-Z7hPZIh3_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BTEAdjckjUytf0U571afEQ_17_5">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tVwp1l-1kEuXU6ahtps2VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YL1u_TVSqk2cKxDKy7aMBg_17_8">1,374,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_izJ-lHsOY06-uJsEfZQQXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_bUTXdnayK0qlMpm8dbs0jA_17_11">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGqVrCjqIU2_N3yu6dMC8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_czVcxhHkIkq8Feck354TOw_17_14">1,402,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_p5HrI-IyUU2-OJ7pmUkvfQ_17_17">28,115</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the </span><span style="-sec-ix-hidden:Hidden_8Yk6g2alTk2siSqoGmM1-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">1-for-10</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> reverse stock split effected on June 27, 2024 on a retroactive basis for all periods presented. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_136a7f13_ccf6_4749_8758_1a509c0abc3d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGEL PHARMACEUTICALS,&#160;INC.</b></p><a id="STATEMENTSOFCASHFLOWS_16439"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED STATEMENTS OF CASH FLOW</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_2ea32c1a_3f39_42e8_ab9d_19c775316bc2"></a><a id="Tc_R3pxHzPxmkSK4XMcuTz3KA_1_2"></a><a id="Tc_XGomnVhuTkutdESo3WgOfQ_2_2"></a><a id="Tc_XOOHBn_tCkyCF6KVY6XhBA_2_5"></a><a id="Tc_uDUisfy4akGbwPV9tD_qmA_3_0"></a><a id="Tc__R2qcHkHB0O6kaqjVnddnA_4_0"></a><a id="Tc_Ngcd0Oxns020FbKR9ICbww_4_2"></a><a id="Tc_-FSi3LUykUKHABvM9ToLtg_4_5"></a><a id="Tc_blYDuq_c2Ums5CgTLGVO0g_5_0"></a><a id="Tc_vbbcgzs3B0maRinXzSt5QQ_6_0"></a><a id="Tc_7duXzuVJ6kCwVG1gEKMiyQ_7_0"></a><a id="Tc_lFnCxKSwRkGkdzAqRP81XA_7_3"></a><a id="Tc_SFyKpPwXhUydJWVqnFNgTA_8_0"></a><a id="Tc_WSTi7OKlp0658HA8QTyklg_9_0"></a><a id="Tc_fDxRz5i_0kKYZ6Hdur4zww_10_0"></a><a id="Tc_8ZsNpR4Jp0WUR9xdtQQWWw_11_0"></a><a id="Tc__re2k9rnwU63zleyoMa8OQ_12_0"></a><a id="Tc_m2N2nGg0JUCtdLfFesm__w_13_0"></a><a id="Tc_5rdt3sR4VESbWB_LYrPWyw_14_0"></a><a id="Tc_-qNHrtAz7kuJZjQbag6Zkw_15_0"></a><a id="Tc_Ho5QdUIhn0G2kfTWQxY10Q_16_0"></a><a id="Tc_YkG6proxpk67sr9PKki9pw_17_0"></a><a id="Tc_R9sWDwY5n0qeBsEZ_bmFSQ_18_0"></a><a id="Tc_zjPnn-SPA0Kjj35vjeQCJQ_19_0"></a><a id="Tc_6bvpQGksyUSi3gk4eTe8Rg_20_0"></a><a id="Tc_nbxZdWKCoE2mYqv8y945PQ_21_0"></a><a id="Tc_5eatIuFHeUG2kpNzokm-SQ_21_3"></a><a id="Tc_YJPP3Dk7dUKgwiCzy1gCBw_22_0"></a><a id="Tc_0hKHoYMtZ0ehtH3pB7Dpvw_22_3"></a><a id="Tc_T8A0kYYJx0Ck4Hzuj8tdQA_23_0"></a><a id="Tc_0b-PllikJEmW-IcbS091YA_24_0"></a><a id="Tc_qdZfa6d4cUe4BmMz1Pae5A_25_0"></a><a id="Tc_COLeyLLJdkyE9tOBKKXGDQ_26_0"></a><a id="Tc_X0-TVlmLl0q5Vt26c_Il7Q_27_0"></a><a id="Tc_736xiY25cUusxEe8JLFxew_28_0"></a><a id="Tc_8XMo6o2zmUyWl0ZRK-esXQ_28_3"></a><a id="Tc_6oMoaCNy6E2BOyBxfqGZJg_29_0"></a><a id="Tc_naCYppRSVUKO5KHbo3XNSw_30_0"></a><a id="Tc_FkM9VcdNHE2TxDpEQepxEQ_31_0"></a><a id="Tc_bmNW3xIux0WdlM2HNnWEig_31_3"></a><a id="Tc_USwwt26i1U6i76g0bHlWRA_32_0"></a><a id="Tc_-gv4TAnbqk6qHNEb4nVX3A_33_0"></a><a id="Tc_rMFa0OHblUSQbg0kobgwCg_34_0"></a><a id="Tc_FZxvItK54U2Vj339APJfmA_35_0"></a><a id="Tc_84bwAGk7vE2Y_ys-NBFXjA_36_0"></a><a id="Tc_XNQtVaHNt06L8oqjTyPcGg_37_0"></a><a id="Tc_y7oD6kQcFUWg-fdRCK8KCA_37_2"></a><a id="Tc_jxiqPShAgE-LZawqL6XJ_Q_37_5"></a><a id="Tc_XVX7IylUdE6Aub0Gz5LfZQ_38_0"></a><a id="Tc_nbKT4I2uikaXodcU0l0_PQ_39_0"></a><a id="Tc_Hl6px60NRU-03KNZ3PH2Qg_39_2"></a><a id="Tc_q1cIWO-jv0K3EM8OG_ey8g_39_5"></a><a id="Tc_b_CsR3qTT0eW_R_KJ0Disg_40_0"></a><a id="Tc_IkwWtL0nGUapxLaGlZ8N9w_40_2"></a><a id="Tc_aY7qWkpeHUObSrrGUSkttA_40_5"></a><a id="Tc_m0n4s8ShmESrax39SIBP6Q_40_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Zv4EwjatikeOUiZp2Vb0hg_4_3">9,277</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_XyVFDQYQ5EihBNFes7fS-g_4_6">20,136</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_r8gSHcqADUOQ_njv-llyjw_6_3">7,662</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_g10cepHtM0eTZloGRA3Ejg_6_6">4,930</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on sale and disposal of fixed assets</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" sign="-" scale="3" id="Tc_S1OGwdrTsEq-_KnSMaAbkw_7_6">398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_hNEBjS0BBEittBpf8vQQwQ_8_3">1,013</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_U-JEdsFXVEWd3DqkldkLCg_8_6">653</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net amortization of discount on short-term investments and term loans</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="Tc_eMoyspbgKU2s7Hk4HK7awQ_9_3">364</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="Tc_2mU4Tw_s50-yKdrP836nUw_9_6">114</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_CKnFhIl-8EeXVccHFH4EAg_11_3">1,646</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_fPbFB6Mkt0aU-ZKNHmpLUQ_11_6">19,501</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Inventories</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_GRTYxOSAF0-JyfTAktt2QQ_12_3">4,505</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_iIj8djfUGkK8zGuOyAXEGw_12_6">1,640</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaid and other current and non-current assets</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_xDH5-E-9Y0-iTiSVzoRfQw_13_3">2,088</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_0XJs5nuYSkqIDTsqRHidkA_13_6">3,391</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_kJsTu3f6lkCOVLuuK4U-_Q_14_3">301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_fbFb3t5KwUKu7V2yr59E2A_14_6">933</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_HzPdgnopW0WcF-nN0EBRLQ_15_3">1,012</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_rSu2eeXVD0qX6u2Wvi4frA_15_6">2,268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued compensation</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" sign="-" scale="3" id="Tc_P1fyWwiL_kmtB-iJN2-W-Q_16_3">2,303</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" sign="-" scale="3" id="Tc_12rTC7ScBEq2tYQpe-AHAg_16_6">2,127</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued research and development</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" scale="3" id="Tc_FlVl6Nb58kK61m-HfXZ6mA_17_3">1,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" sign="-" scale="3" id="Tc_f-GCgNqPzEW6znH-zS2bbQ_17_6">1,882</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Revenue reserves and refund liability</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="rigl:RevenueReservesAndRefundLiability" scale="3" id="Tc_99kq9O9Zq0eO8VnBETP8kQ_18_3">2,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="rigl:RevenueReservesAndRefundLiability" scale="3" id="Tc_HZYm2BCA6UCE_FZz6ZeMkw_18_6">1,539</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="Tc_pixl_I5pJk-OsU1ucOT5rQ_19_3">532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" sign="-" scale="3" id="Tc_o2CgZjEkQ0-jWW2nSonIMA_19_6">1,472</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Lease liability</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_1mXVad-bekyPoxO8pM1pBA_20_3">338</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_LxnCU9iaW0iGaU8dEya5Kw_20_6">1,011</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Deferred revenue</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_4QJYG7E7r0qAfrtyGQAGxA_21_6">14</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Other current and long-term liabilities</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_dbt0CR7m10alCQjVtMB_6Q_22_6">1,175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash (used in) provided by operating activities</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_PLxsMaHRHk2zL00wXwTS5Q_23_3">4,711</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_PZ6QOE6sckCkMIGsKTr3mA_23_6">1,856</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Maturities of short-term investments</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="Tc_Sm5RL0Vw0UGhXYtple4K9g_25_3">26,950</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" scale="3" id="Tc_3rkBCXfCWUSXytFMjTrYQg_25_6">27,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchases of short-term investments</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_jGI4yjb_lUKPXEDkE_OpoA_26_3">15,348</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_Nfr-K0_if0yAn9B46NEtag_26_6">8,780</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Payments for acquisition of intangible assets</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_qMJ6CwSZDkKlZc13Lhlv4Q_27_3">360</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_WFLbCgYjW0CrHlUIn48RTg_27_6">15,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from sale of property and equipment </p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_UeVHxaKNgUiC3hEPvHBoZQ_28_6">127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_siqbr8sWGEGY0bxKMXkIiQ_29_3">11,242</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_-zZCTLyGOUW_16hQw6yekg_29_6">3,747</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net proceeds from term loan financing</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="Tc_sicD5NHaPUiiatpu59VDcQ_31_6">19,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net proceeds from issuances of common stock upon exercise of options</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_5_vr4KeSHkmgixkuRXMe6A_32_3">341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_2jT9w4fE5ki671Kc5OnQGQ_32_6">554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost share payments to a collaboration partner</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="rigl:PaymentOfCostShareToCollaborationPartner" scale="3" id="Tc_tuQ6kci05EGE87oKFJOfWA_33_3">3,605</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="rigl:PaymentOfCostShareToCollaborationPartner" scale="3" id="Tc_IxqZcN0Hd0Gw1pYH3ZUlYw_33_6">1,754</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_RruNvL1WWE-FOFkBQoqCYQ_34_3">3,264</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_K2DOyuBY5kynwvAzUoyI6g_34_6">18,750</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_KmhyK6gbk0qeqM5vPsYCmA_35_3">3,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_P4B8jC6hK0KKYiCErfBHsA_35_6">24,353</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of period</p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Q3dZlDQle0C092l0zLpqTg_36_3">32,786</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_9KYq44rq7UODUowFGdmcQg_36_6">24,459</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at end of period</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ZI1hz9d7_UGHMMEPnLr2yw_37_3">36,053</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_W_42X6liF0qPG6Shh6m4EQ_37_6">48,812</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest paid</p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_AhIHkFVcqUyljkgryWioqw_39_3">3,457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_T4uXNHVPSUWbBGKt9BjISA_39_6">2,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets included within acquisition-related liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="rigl:IntangibleAssetsIncurredButNotYetPaid" scale="3" id="Tc_9xaj5hVYB0yDyhcMtXupxg_40_3">15,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See Accompanying Notes to Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_85d87bec_3ba0_4c8f_ab2c_75adeeea7af0"></a><a id="NotestoCondensedFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rigel Pharmaceuticals,&#160;In</b><b style="font-weight:bold;">c.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Condensed Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:9pt 0pt 9pt 0pt;">In this report, &#8220;Rigel,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Rigel Pharmaceuticals,&#160;Inc.</p><a id="_Hlk140826264"></a><a id="_Hlk172618604"></a><a id="_Hlk155775503"></a><a id="_Hlk156550326"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="Tb_I3Kxb_ycXE68YfawGg_VIQ" continuedAt="Tb_I3Kxb_ycXE68YfawGg_VIQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Organization and Summary of Significant Accounting Policies</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">TAVALISSE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (fostamatinib disodium hexahydrate) is our first product approved by the US Food and Drug Administration (FDA). TAVALISSE is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">REZLIDHIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;&#160;</sup><span style="color:#222222;background:#ffffff;">(olutasidenib) is o</span>ur second FDA-approved product. REZLIDHIA capsules are indicated <span style="color:#222222;background:#ffffff;">for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. W</span>e in-licensed REZLIDHIA<span style="color:#222222;background:#ffffff;"> </span>from Forma Therapeutics, Inc., now Novo Nordisk (Forma), with exclusive, worldwide rights for its development, manufacturing and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">GAVRETO</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;"> (pralsetinib) is our third FDA-approved product which we began commercializing on June 27, 2024. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild-type rearranged during transfection (RET) and oncogenic RET fusions. GAVRETO is approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. GAVRETO is also approved under accelerated approval based on overall response rate and duration response rate, for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). We acquired the rights to research, develop, manufacture and commercialize GAVRETO in the US from Blueprint Medicines Corporation (Blueprint) pursuant to an Asset Purchase Agreement entered in February 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">We continue to advance the development of R289, our interleukin receptor-associated kinases 1 and 4 (IRAK 1/4) </span><span style="font-size:10pt;">inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk </span><span style="color:#222222;font-size:10pt;background:#ffffff;">myelodysplastic syndrome (MDS)</span><span style="font-size:10pt;"> who are relapsed, refractory or resistant to prior therapies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">We have strategic development collaborations with the University of Texas MD Anderson Cancer Center (MDACC) to expand our evaluation of REZLIDHIA in AML and other hematologic cancers with IDH1 mutations, and with Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in combination with temozolomide in patients with high-grade glioma (HGG) harboring an IDH1 mutation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with our partner Eli Lilly and Company (Lilly). We also have product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).  </span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="rigl:StockholdersEquityReverseStockSplitPolicyPolicyTextBlock" id="Tb_m7I2PcevGEqNtVQElJ7DcQ" continuedAt="Tb_m7I2PcevGEqNtVQElJ7DcQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">We filed with the Secretary of State of the State of Delaware a certificate of amendment to our Amended and Restated Certificate of Incorporation, to effect a </span><span style="-sec-ix-hidden:Hidden_nJcNMH1G4kyCDx--KfxI4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-10</span></span><span style="font-size:10pt;"> reverse stock split, effective June 27, 2024. As a result of the reverse stock split, every ten issued and outstanding shares of our common stock were automatically combined into one issued and outstanding share of common stock. Accordingly, an amount equal to the par value of the decreased shares </span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk70506756"></a><ix:continuation id="Tb_I3Kxb_ycXE68YfawGg_VIQ_cont1" continuedAt="Tb_I3Kxb_ycXE68YfawGg_VIQ_cont2"><ix:continuation id="Tb_m7I2PcevGEqNtVQElJ7DcQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">resulting from the reverse stock split was reclassified from common stock to additional paid-in capital on the condensed balance sheet and statement of changes in stockholders&#8217; deficit. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock were entitled to receive the cash value </span><span style="font-size:10pt;background:#ffffff;">equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the common stock as reported by Nasdaq on the last trading day prior to the effective date of the split. </span><span style="font-size:10pt;">As a result of the reverse stock split, proportionate adjustments were made to the number of shares underlying (and as applicable, the exercise or conversion prices of) our outstanding equity awards and to the number of shares of common stock issuable under our equity incentive plans. The reverse stock split did not change the par value of our common stock, which remains </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4TL5BxVXXUqaOKRgB0MrZw">0.001</ix:nonFraction></span><span style="font-size:10pt;">, or the authorized number of shares of our common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_itGe_sr4E0yiHzjCjr0Daw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2023 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:UseOfEstimates" id="Tb_S5ZHIq2vakCQRPgee9MM9Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Our significant accounting policies are described in &#8220;Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Financial Statements&#8221;&#160;contained in Part II, Item&#160;8, &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to these accounting policies except for the accounting consideration related to the Asset Purchase Agreement with Blueprint as discussed below in &#8220;Note 5 &#8211; In-licensing and Acquisition.&#8221;</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="rigl:LiquidityAndCapitalResourcesPolicyPolicyTextBlock" id="Tb_iGx7YVHZc0aC8j6G2BYkBQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">As of June 30, 2024, we had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_Nfp2OpPoDUenIY5L8bqENw">49.1</ix:nonFraction> million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_P-6AXP-Nt0eN9xEmm10IQA" continuedAt="Tb_P-6AXP-Nt0eN9xEmm10IQA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2023, FASB issued ASU 2023-07,&#160;<i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&#160;</i>This update expands public entities&#8217; segment disclosures, among others, requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss; an amount and description of its composition for other segment items; and </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_I3Kxb_ycXE68YfawGg_VIQ_cont2"><ix:continuation id="Tb_P-6AXP-Nt0eN9xEmm10IQA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;background:#ffffff;margin:0pt;">interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under this update are also required for public entities with a single reportable segment. This update is effective for our Annual Report on Form 10-K for the fiscal year ending December 31, 2024, and interim periods thereafter. Early adoption is permitted. The update should be applied retrospectively to all periods presented in the financial statements. We are currently evaluating the impact of adopting this update on our financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">In December 2023, FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i>, which enhance the annual disclosure requirements regarding the tax rate reconciliation and incomes taxes paid information. This update is effective for our fiscal year ending December 31, 2025, and maybe adopted on a prospective or retrospective basis. Early adoption is permitted. We are currently assessing the impact of adopting this guidance but does not expect to have a significant impact to our financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">Other recently issued accounting guidance not discussed in this Quarterly Report on Form 10-Q are either not applicable or did not have, or are not expected to have, a material impact on us.</p></ix:continuation></ix:continuation><a id="_6c9496ef_45c3_4d75_8325_12e3b78e00cb"></a><a id="Tc_obYQQVEeAEKNlxZi_U1QrA_1_2"></a><a id="Tc_UHkb4bwCukCsfs42I3_NrQ_1_8"></a><a id="Tc_PhZxhGHDCEiMbRPyegUYEA_2_2"></a><a id="Tc_cCDsU2FjgkOJpiCFSGn6CA_2_5"></a><a id="Tc_43nVP1hLd0OXUpSu-xMHrQ_2_8"></a><a id="Tc_e85jElJ9kUKy2Mi53XKCiw_2_11"></a><a id="Tc_6TxQ4Gs8q0mcMMLjrKDQxQ_3_0"></a><a id="Tc_qM5Ftp8HeE2xMF3x7uWR2Q_4_0"></a><a id="Tc_UmOJEyLch0OtVH-zcmgOIw_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_XGGfe0N4J0K4ZPY7KOVR0A" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Net Loss Per Share</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period and the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Potentially dilutive securities include stock options, RSUs and shares issuable under our Employee Stock Purchase Plan (Purchase Plan). The dilutive effect of these potentially dilutive securities is reflected in diluted earnings per share using the treasury stock method. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The potential shares of common stock that were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive are as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_jxxHfO4tTUyJbMDnK5khww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RaKuxSzhSUupPD2oOUXYKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_MDFdhnSrnkWSj_W4FdyHYA_3_3">3,691</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bYo6kwZv60OcoBnM9_riJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc__Vww80aIs0KnlN44wZK0hg_3_6">3,524</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_FZjvdGbKikurAAd8fQxjGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_3B15ro6zekuQq-AV_pyz-w_3_9">3,691</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_P5Ej5A9ePUSqZtXcVBF9vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_gMM2mhbvBUCyt2mdmQ0aqw_3_12">3,524</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JastdyjIyEGJursVulIfKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Jbc49jFbHUis5Gt1n-PtyA_4_3">388</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q7YoKf7gyU2XWicwj8JbrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_D80EAUNhE0erm73tKvWPuw_4_6">196</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_XpXugziTxk2FFISdmEQLwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_ndPdOL31ZUexiznwchKwtQ_4_9">388</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_MiyxZQLaX0CaycIWWGMjpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_JP4awCPtfUOwnp4w-jtubg_4_12">196</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_d6d-X_sZ90-SH-XiCVdEfA_5_3">4,079</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_A-nZ0YaiTE6OjK2MxLscoA_5_6">3,720</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_MHeDWO1RUUGVLtHgyr3zBQ_5_9">4,079</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_XJQya9-5FEOeSQvo_0JSSA_5_12">3,720</ix:nonFraction> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_b3093cc7_dfbb_4366_83cb_e49cc7c97489"></a><a id="Tc_qD0cXdTfekmHBqnjer85YA_1_2"></a><a id="Tc_jGM0wi6w0Eq2jJCFvoKuHQ_1_8"></a><a id="Tc_qOXFEFISmUmPhN9EGkDCdg_2_2"></a><a id="Tc_WbfGqFcEIUyg_M3qY-vrVQ_2_5"></a><a id="Tc_KoMqDwT7kkiGHmZP-p6Xyw_2_8"></a><a id="Tc__ip6Kau8akK2h6-sM7eHxg_2_11"></a><a id="Tc_u8p1qt68a0mPSqUQ2SEiBQ_3_0"></a><a id="Tc_5N3b1eSemUu0Bg4gb4CssA_4_0"></a><a id="Tc_V-JiijBlXESZFVfnZNefMQ_4_2"></a><a id="Tc_dUjPxG5tOUeKT1aTLnRFYA_4_5"></a><a id="Tc_okMghRj2wk-rdrKcaVCHMQ_4_8"></a><a id="Tc_OxOz8Y60eUSxRSk6JMeQCQ_4_11"></a><a id="Tc_D6qajJZd6keBKe-0EGveWg_5_0"></a><a id="Tc_LBtZt2iaj06peOueC94_qg_6_0"></a><a id="Tc_CrZAtUZg7EWC86dPyfVYUw_7_0"></a><a id="Tc_sTMUame7DUid54Bm02-2iQ_8_0"></a><a id="Tc_HoXXK33DFkaSwXR9cfhOSw_9_0"></a><a id="Tc_z7FKFS9ne0qcrJbWKGM0Ug_10_0"></a><a id="Tc_AMzdgWMr_0et71PqDU-iAA_10_3"></a><a id="Tc_YBvLXyzXaUmIttrqC6lEkw_10_9"></a><a id="Tc_qGm8hksn_EOM7q6Odh-xtA_11_0"></a><a id="Tc_UCLYmp5J20yS2Mawp9YL_w_11_2"></a><a id="Tc_vD9-Vw8MpUGXqiE3fcsywA_11_5"></a><a id="Tc_M1ayvleeUkuX5SwkdJw45g_11_8"></a><a id="Tc__2dhZXONd0-SFE3GNNovkQ_11_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_qFLpX7h74UiBccn7L9DMEw" continuedAt="Tb_qFLpX7h74UiBccn7L9DMEw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Revenues</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_z97QIKY3d0yMovsAhm7WvA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:7pt 0pt 9pt 0pt;">Revenues disaggregated by category were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales:</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross product sales</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_66nF3F7T6EeO_T5ormWp2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ceegp5OiwkKebiF_zQhzLw_4_3">48,980</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember__ugQCo2hvkaHA8jhmfIr6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_bxhVDCF9fE-HRAVezNIz4A_4_6">33,456</ix:nonFraction> </p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_HU2T--c6-k2PWST4x-p1iw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_cZU4rvLPMUOqpgChcGkgUg_4_9">87,406</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_aYmi2v0mz0e4c5dQ7lldvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_RUUAgTF83UKTkHYs4T-8tg_4_12">66,654</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discounts and allowances</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_kgj2lfO1x06p8zrIfFzVjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_URvR-VokzUmeGFBLcl6rcg_5_3">15,530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_vkZ_1rGsnkW09QyZQM9DaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_T7pAXu6sJkC4dLJbG7VA9A_5_6">9,575</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rnk0gbYth0SBm1kX1fW23A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_lxXcqshTpE-VZ8PrwGgavg_5_9">27,953</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_n6rbBTWKREaLGIeGb095og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" sign="-" scale="3" id="Tc_VDrP-2MAA06D3PYqZEnhLg_5_12">19,028</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total product sales, net</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_L2X2ODMWN02W75JbcgBOuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_O1AOml0FwE2lEPCCwCVBow_6_3">33,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_qF77QLopJkm7QArlC1YAAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_i-5dhpszl0-o8vsHz-TDng_6_6">23,881</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxQfYCTi-EmntNNb3PEHNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ppKj2VRRYEe8I-S3wS_3aw_6_9">59,453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_0CKs5sN0Y06oyeNfimQy-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_1HdY0ATzpkaYnWF9zlyQCA_6_12">47,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from collaborations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Delivery of drug supplies, royalty and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_YUs53Q9t60y3XCZGyv6pTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_gLeIDjvSZEunbIgvi4i-jg_8_3">3,391</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_KLumYMF9xEy2B9eFN1r15g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_TGqM3XW7z0-IFBS152MuVg_8_6">2,005</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_X2QX2SMv0UeS4dY9h3vreQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ukfcsAfyMkSIKQEUc1UkBA_8_9">6,922</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ktlf9P2M7UaLAIc_BeIB8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_IYpoACRM_06PsFMWHC4HQg_8_12">4,330</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues from collaborations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_jsAPdtswwUqlYhdOCwaqtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_YcQq8MMvOU-tU0Sjbj_uDQ_9_3">3,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_crGh4Gmf10KG35aVQN5FmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_9iXouj5iB0W7fif5jPl3Zw_9_6">2,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_dRwb9LpMMUGY_8SiQzA0vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ClJog9Xlfk219iaBmW1Q-A_9_9">6,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_sXlfY9W4v0-bUvEUlAVg8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_1KmFUVb0_0mtaGjafVItmQ_9_12">4,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contracts</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Ou8JuAZKykOrkUJEyjh3zA_10_6">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_JR3UXrW0kk2-tjCd_KhqxA_10_12">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_850WWTqa00CjxKb74RoWCA_11_3">36,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_FeKjYtAbdUK7feKdW-oQVw_11_6">26,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_nHYn3W9hokikZw6HOik8-A_11_9">66,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_nw1Qo8Az40CgWJ5nywlqWw_11_12">52,956</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Revenue from product sales are related to sales of our commercial products to our specialty distributors. For detailed discussions of our revenues from collaborations and government contracts, see &#8220;Note 4 &#8211; Sponsored Research, License Agreements and Government Contracts.&#8221;</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk520203236"></a><a id="_1c87c8d6_1540_47df_bbdf_32fdaafb2e23"></a><a id="Tc_-wiDwWLvi0630jTEDVqfAA_1_2"></a><a id="Tc_83VFiL69OkOhxIy7RxMYSg_1_5"></a><a id="Tc_6n4LPC0Pik-YLPn2gXpm9A_2_2"></a><a id="Tc_w5TgCRGOYUuFx2G9V9ypOw_2_5"></a><a id="Tc_gvPqgsoNc0iJzHijRto1bQ_3_2"></a><a id="Tc_eluGJTVqnECc8KKYuW3eMQ_3_5"></a><a id="Tc_b808EgFrmkKEByyidDk-zw_3_8"></a><a id="Tc_0uee1pNgX0eUX0ntY0kU7Q_3_11"></a><a id="Tc_b2BiYzZSskaR3vAV0QExiA_4_0"></a><a id="Tc_1W2U0mk-JESpVDfDPqmeoQ_4_2"></a><a id="Tc_bnflXtu-kkaAlxBqYFt93Q_4_5"></a><a id="Tc_VAaav5axo02xZLIqNZxpCw_4_8"></a><a id="Tc_vO090PXXqES2ICGglnwHEg_4_11"></a><a id="Tc_3IotBK6jCkCV9DSZG4mAzg_5_0"></a><a id="Tc_YF3S-CVNDE23xw_H1YFRxg_6_0"></a><a id="Tc_0HmCvFMKFEemzFfCCXF8bQ_7_0"></a><a id="Tc_BX_hTM93XEmPh8MBoc6FYQ_7_2"></a><a id="Tc_ypRzuykIzUmpVBrTvfpUVA_7_5"></a><a id="Tc_fF077aodE0ygfj0lm6wpng_7_8"></a><a id="Tc_ESfzUhMaak65psPJKqHhyA_7_11"></a><a id="_1461d7d4_6c28_4ea2_b887_e1aadf9c5e3c"></a><a id="Tc_0tSUsEV6KEGfg_gV3Ks3zQ_1_2"></a><a id="Tc_y4wZjKxvrkeAdUo_YEROhQ_1_5"></a><a id="Tc_dcgFAB-uUEqvGe7Mzd5sHQ_2_2"></a><a id="Tc_hvaH1w9hSkqUtA3qLdrueg_2_5"></a><a id="Tc_XCJj78dl9USgWDtw2ub6VQ_3_2"></a><a id="Tc_jODLZgM2s0yojWJjZHUYSA_3_5"></a><a id="Tc_GgLk1-YzCUil80vZjNEjrQ_3_8"></a><a id="Tc_28QTwbVQ20e5zpkTL_BlGg_3_11"></a><a id="Tc_oKzwiysP0ESyB_-yvtzqNQ_4_0"></a><a id="Tc_WbYexpf4akK938yxkVla8g_4_2"></a><a id="Tc_m0Tt0vx31UKJFbJMRCwBkA_4_5"></a><a id="Tc_KYkb15KB2EGK8TUFg_SFAA_4_8"></a><a id="Tc_B1UZpkNwKkaUZOfzSLIULg_4_11"></a><a id="Tc_tS-SRJHL9E-2YFGTgM6b4w_5_0"></a><a id="Tc_uWEPg_P2B0qIl4EkFNySHw_6_0"></a><a id="Tc_H_VAcb_hxEWCO3Kb91FRqA_7_0"></a><a id="Tc_yYzGJ1qDg0SzTRtZraQltA_7_2"></a><a id="Tc_1olBXqcBP0axoECNGoYjOg_7_5"></a><a id="Tc_VSYpTBF8rkKvJQte6zKUeQ_7_8"></a><a id="Tc_nqME8RTIKU23FgMyJjE1rg_7_11"></a><a id="Tc_YE5waa4WKE-ttb-9l-od7w_1_2"></a><a id="Tc_082M8KWHrEKPf0zW23jHAQ_1_9"></a><a id="Tc_UWCj8VNEn0S6RgqfLKzXHg_2_2"></a><a id="Tc_BeVNsXjUH0GMUznAY6QHkA_2_5"></a><a id="Tc_mK-wBOJIX0WLu_7_6jOoKQ_2_9"></a><a id="Tc_RufPBR2op0q44k9J2OON1A_2_12"></a><a id="Tc_Hn4lfOUIU0y8AijJw45fIg_3_0"></a><a id="Tc_ZK908Ib-6k-E-Ul7aiWDUA_4_0"></a><a id="Tc_lmCmV0rUrUmtV6QUmS6IkQ_5_0"></a><ix:continuation id="Tb_qFLpX7h74UiBccn7L9DMEw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. Of the total discounts and allowances from gross product sales for the six months ended June 30, 2024 and 2023, $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_2FYjcsSdsUilgbO-pL5zaA">27.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_cBS_waCBj0Wk5CbwtW4Kxg">18.6</ix:nonFraction> million, respectively, was accounted for as additions to revenue reserves and refund liability, and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_rBLR8Q6qY0qEWXFfKO_L3A" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_OAOb-tTKnUO75ZGY0SoiNg">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_nO2J61EcMEKdr-tpRvz54A" decimals="-5" format="ixt:numdotdecimal" name="rigl:SalesDiscountsAndAllowances" scale="6" id="Narr_gDpCcZgqhUehmp1KvlLK2A">0.4</ix:nonFraction> million, respectively, as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet. The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="Tb_Q_HQfOUnykeLlt-MEbCtxg" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_6fGEzsR-EU2ukRaZfEQHTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_EsWZNq8isk6FY1QIqK-wbg_4_3">8,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_5kGrsJtJPUaXWHfMUTNnAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_ohOxl4fN4U6o8v0JNULhKA_4_6">3,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_yxzYceuVAE2CBLGPEXWLcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_w_eHA3VyQE6sWGbcJVZxuQ_4_9">3,931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_j9P8jZh0aEqOI7oxQemCZA_4_12">15,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_tCX8H5e_0kK--61UsSImug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_0bQhKm2MPUm7HKQbQniu0g_5_3">21,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_YseB19IaTUeq6LVKzfKj0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_NW5BNMuXGUGCSaEfnK1PBA_5_6">5,259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_cuHB688G_ked7r68OdX4FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_lda1T5-QlEKxt5sYSj3wUw_5_9">522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_WreKuXkGuEKpBbNTdQrRYA_5_12">27,551</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_tCX8H5e_0kK--61UsSImug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_HdcuX-NVWECJRY74jeEDQQ_6_3">20,165</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_YseB19IaTUeq6LVKzfKj0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_r4g8qHKV-UmXzYBukEXQhw_6_6">4,441</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_cuHB688G_ked7r68OdX4FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_TS-eHADv9UWA3tvNS1dnAQ_6_9">82</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_dBx7qeuUzUGjNFhIBAUFVA_6_12">24,688</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Ij2f4OxgUUCWtD_5lHA7pA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_cfv20zagMUqdAJDY0wi61Q_7_3">9,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pt2UPlNyCUWGebgWK5jSPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_0l1t1Zcj4U-wZ8J9R7oa4g_7_6">4,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_YfpRiaWZxUqB5w9lvYJvVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_fUqFMUWYmkykjTfIP2oaJQ_7_9">4,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_k5hUo4eS2kGXJuUh7DPpig_7_12">18,547</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DeoG3uLWSE6eChBxTmVl_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_qtPcQ-jfB0Ga-jnrWZTe3g_4_3">6,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pxFiNodJ0UaXW8PVpDH_dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_nnRtS7xlU0qSa3bUkOJZdg_4_6">2,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_pwaobjInbUCU4wLXJWRgWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_z2mT251zgE-0FyswBW8boA_4_9">3,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_nXN31m5QiUeBTBGPXEYUdg_4_12">12,145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_zCeB2BBtfU-Wb3oZ3EUjpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_Gxe0RH6OgECZxny0s7y8Lw_5_3">14,439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_uk1O_sp-Y0--KVAhhGNE-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_0q7JfMRYxUSVL2nrZx7ZeA_5_6">3,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_XZhamrPP1kS0gkYOdPFL2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_ydCzcXyD0kWOnWjkhQt1ZQ_5_9">395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="Tc_TlgZjzxeoU2gYT1TSps1EA_5_12">18,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_zCeB2BBtfU-Wb3oZ3EUjpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_4wlaio2aZUaNvLzRNbNRZw_6_3">13,139</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_uk1O_sp-Y0--KVAhhGNE-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_vRlkjZAXSUCTXWqvQbvjAg_6_6">3,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_XZhamrPP1kS0gkYOdPFL2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_AlfbZ2GQxEuFfTz-5G6rbQ_6_9">116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="Tc_WgCsdxvvAEy-DQWYp1Cieg_6_12">17,020</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_pvl3dQL-10KWQKcJlK7PhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_SLiW55mYakGtBORwfEQ4fA_7_3">7,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__q2T26iax0eiR5sdI86W6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_NKuZ4rcbTUCkYL3TKCwsfg_7_6">2,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_K66Fz-gvL0-4yU--dKixIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_QqQSaxqbxEmsC_I-2Y7DMA_7_9">3,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="Tc_EE_eiI3xVU6QHBBZBgzhNw_7_12">13,684</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="rigl:DisaggregationOfRevenueByCustomerTableTextBlock" id="Tb_ulTC8umCI0-roWxCHy-ISg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_zwK5QRRX6EqsKGahncDIOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc__g81dAm5vUaGJWts15ZugA_3_3">49</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_9m5rS6MB3E-SUlgdlXlTSQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_wN3kRZwmcUuwwba80X7I5Q_3_6">44</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i1LjpfRajUeDxjso7nYoyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_AFMCda_hnEKRHK0eIHmm1g_3_10">46</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7fwMtHOoHUm7LRR4eArbsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_HSXO9BPd8062la_5yrUjBQ_3_13">45</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eFVzoQltvEO4gINVqtxI-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_NmC39FwQjkiZZRWVA-yBBA_4_3">21</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_GgfOc-xLJ0CVzgWger3Arw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc__h3dN0qftUWdcekMeh04jA_4_6">28</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Q7EkAAoHeUKJsjYoTZrhbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_PNAc00XASEa4Fr_foTDeWA_4_10">22</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oLL4Ndsu6UyV_O0-24gTWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_IPxhsnTQbkKGlntg5J4TcA_4_13">26</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cencora Inc. (formerly ASD Healthcare)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jkelz1ePoUOQLw4bzruVCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_GueRg9tY-EGxmfDd36rlIg_5_3">20</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LEnPZ15moEKAEm_18pTBow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_ixUcjAS5C0-0syv-8YMbQw_5_6">19</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PbJR__bHUUymqE5jma_jhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_jnmQHs15HkmZAOlP9-CUmQ_5_10">21</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NhxdhXczxkO1of_nfPZIOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_v2CMrHZXe0e3aGVBLtbZxA_5_13">21</ix:nonFraction>%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk147304152"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_-2zpGxaN50-OxQpdarf6Zw" continuedAt="Tb_-2zpGxaN50-OxQpdarf6Zw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Sponsored Research, License Agreements and Government Contracts</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Research and License Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We conduct research and development programs independently and in connection with our corporate collaborators. As of June 30, 2024, we are a party to collaboration agreements with Lilly to develop and commercialize ocadusertib (previously R552), a RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases and collaboration aimed at developing additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases; with Grifols S.A. (Grifols) to commercialize fostamatinib for human diseases in all indications in Grifols territory which includes Europe, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States); with Kissei Pharmaceutical Co., Ltd. (Kissei) to develop and commercialize fostamatinib in Kissei territory which includes Japan, China, Taiwan and the Republic of Korea; with Medison Pharma Trading AG (Medison Canada) and Medison Pharma Ltd. (Medison Israel and, together with Medison Canada, Medison) to commercialize fostamatinib in all indications, in Medison territory which includes Canada and Israel; and with Knight Therapeutics International SA (Knight) to commercialize fostamatinib in all indications, in Knight territory which includes Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Further, we are also a party to collaboration agreements, but do not have ongoing performance obligations with BerGenBio for the development and commercialization of <span style="background:#ffffff;">AXL receptor tyrosine kinase (</span>AXL) inhibitors in oncology, and with Daiichi to pursue research related to <span style="background:#ffffff;">murine double minute 2&#160;(</span>MDM2) inhibitors, a novel class of drug targets called ligases. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk85058675"></a><a id="_Hlk147304120"></a><a id="_Hlk146618096"></a><a id="_Hlk85468656"></a><ix:continuation id="Tb_-2zpGxaN50-OxQpdarf6Zw_cont1" continuedAt="Tb_-2zpGxaN50-OxQpdarf6Zw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the above existing agreements that we entered into in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2024, total future contingent payments to us under all of the above existing agreements, excluding terminated agreements, could exceed $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-8" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="9" id="Narr_n68AZRO_8E2E015mHPm5zQ">1.3</ix:nonFraction> billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. Of this amount, $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_VqV4K0jYxU-ud5heUgA7Fw" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_zUnO4fGZQkC8vt1Fo3nfXg">279.5</ix:nonFraction>&#160;million relates to the achievement of development events, $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_I9tiGJJzSUW1uADT_0QYGQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_5RZtzcWSd0KJ29MmpiVCxQ">263.1</ix:nonFraction> million relates to the achievement of regulatory events and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_7aOcJ_X2Jka6LsC0YG-yLA" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_ipFLcWosdE68mbDiWZR4ww">796.0</ix:nonFraction>&#160;million relates to the achievement of certain commercial events. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#8217; future efforts and achievements of specified development, regulatory and/or commercial events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We account for the milestone payments when such milestones are considered probable of being achieved, and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, and recorded as part of contract revenues from collaborations during the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"><i style="font-style:italic;">Global Exclusive License Agreement with Lilly </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We have a global exclusive license agreement and strategic collaboration with Lilly (Lilly Agreement) entered in February 2021, which became effective in March 2021, upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, to develop and commercialize ocadusertib (previously R552) for the treatment of non-CNS diseases. In addition, the collaboration is aimed at developing additional RIPK1 inhibitors for the treatment of CNS diseases. Pursuant to the terms of the Lilly Agreement, we granted Lilly the exclusive rights to develop and commercialize ocadusertib and related RIPK1 inhibitors in all indications worldwide. The parties&#8217; collaboration is governed through a joint governance committee and appropriate subcommittees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">Under the terms of the Lilly Agreement, we were entitled to receive a non-refundable and non-creditable upfront cash payment amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2021_To_4_30_2021_pVVWDpbMUESUodMAWy20aA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_AAE5y4ZUC0ul9YC3N-D1IQ">125.0</ix:nonFraction> million, which we received in April 2021. We are also entitled to additional milestone payments for non-CNS disease products consisting of up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_4tLATJ2ucUu7Kj1hYljxvw" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_y9sKHD-PAE6SH6VRSm6imw">330.0</ix:nonFraction> million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_BbXVI_lx-kK6eTLL9cByJg" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_qMl5hJOKzk6uLaVzcklDBQ">100.0</ix:nonFraction> million in sales milestone payments on a product-by-product basis. In addition, depending on the extent of our co-funding of ocadusertib development activities, we would be entitled to receive tiered royalty payments on net sales of non-CNS disease products at percentages ranging from the mid-single digits to high-teens, subject to certain standard reductions and offsets. We are also eligible to receive milestone payments for CNS disease products consisting of up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_ErotTwxGbUGeaPCNLokv5w" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_e2daQwMVWEaVOcqSU-Jheg">255.0</ix:nonFraction> million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_7B-bKGDqJkynpyyI5LI52A" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_zYYxAnfsIECwx1qxxC5SRw">150.0</ix:nonFraction> million in sales milestone payments on a product-by-product basis. We would be entitled to receive tiered royalty payments on net sales of CNS disease products up to low-double digits, subject to certain standard reductions and offsets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 0pt 0pt;">Under the Lilly Agreement, we were responsible for performing and funding initial discovery and identification of CNS disease development candidates. Following candidate selection, Lilly is responsible for performing and funding all future development and commercialization of the CNS disease development candidates. Under the Lilly Agreement, we are responsible for <ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw" decimals="2" format="ixt:numdotdecimal" name="rigl:DevelopmentCostsCostSharingArrangementPercentage" scale="-2" id="Narr_ASjISeIAhkqj8ADrHo4sEw">20</ix:nonFraction>% of the development costs for ocadusertib in the US, Europe, and Japan, up to a specified cap, and Lilly is responsible for funding the remainder of all development activities for ocadusertib and other non-CNS disease development candidates. Pursuant to the terms of the Lilly Agreement, we have the right to opt-out of co-funding the ocadusertib development activities in the US, Europe and Japan at <ix:nonFraction unitRef="Unit_Standard_period_7S5qJ8_ryE2V-D21SVB1hA" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="INF" format="ixt-sec:numwordsen" name="rigl:RightToOptOutOfAgreementNumberOfPeriods" scale="0" id="Narr_UZ3m8XSoYEe1Y438KyyvxQ">two</ix:nonFraction> different specified times and as a result receive lesser royalties from sales. Prior to us providing our first opt-out notice as discussed below, under the Lilly Agreement, we were required to fund our share of the ocadusertib development activities up to a maximum funding </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk147304135"></a><ix:continuation id="Tb_-2zpGxaN50-OxQpdarf6Zw_cont2" continuedAt="Tb_-2zpGxaN50-OxQpdarf6Zw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">commitment of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_srt_RangeAxis_srt_MaximumMember_wXz-NhXK80mSJezdO35NGw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="Narr_psklkUf5KEilu_ruSN8Z8w">65.0</ix:nonFraction> million through April 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license rights over the non-CNS penetrant intellectual property (IP), and (b) granting of the license rights over the CNS penetrant IP which will be delivered to Lilly upon completion of the additional research and development efforts specified in the agreement. We concluded that each of these performance obligations is distinct. We based our assessment on the assumption that Lilly can benefit from each of the licenses on its own by developing and commercializing the underlying product using its own resources. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">At the inception of the Lilly Agreement, given our rights to opt-out from the development of ocadusertib, we believed at the minimum, we had a commitment to fund the development costs up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_srt_RangeAxis_srt_MaximumMember_wXz-NhXK80mSJezdO35NGw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="Narr_78LXxoywx0-0zPwNsKgJQw">65.0</ix:nonFraction> million as discussed above. We considered this commitment to fund the development costs as a significant financing component of the contract, which we accounted for as a reduction of the upfront fee to derive the transaction price. This financing component was recorded as a liability at its net present value of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProductLiabilityAccrualComponentAmount" scale="6" id="Narr_cjaDwA6p0UKnAkrQNEE23Q">57.9</ix:nonFraction> million using a <ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw" decimals="3" format="ixt:numdotdecimal" name="rigl:FinancingLiabilityInterestAccretionDiscountRate" scale="-2" id="Narr_QvGeJUe4LkyUu1yBjtwfVw">6.4</ix:nonFraction>% discount rate. Interest expense was accreted on such liability over the expected commitment period, adjusted for timing of expected cost share payments. <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_TsNN5CZDIEuTUPQMmSOPqA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccretionExpense" scale="6" id="Narr_QyQkxirhZUipFuGSJKN8rQ"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_y28o3J_GDUGpZFQI6JGFgA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccretionExpense" scale="6" id="Narr_dtTJrtZEw0qu6l6FbNEakQ"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccretionExpense" scale="6" id="Narr_A8Iqhu11v0eRAtCddlYPbQ"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_slyl5l3MBUW5I6J4gR0GNA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccretionExpense" scale="6" id="Narr_5v-yzZi1SUCcABtSoGbgrg">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> interest was accreted during the three and six months ended June 30, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At the inception, we allocated the net transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_31_2021_srt_ProductOrServiceAxis_rigl_OcadusertibMember_XRvY_5ZJrkuCeHrOO7K53A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_L7SCpBSUhEe5mN-gvQXO4w">67.1</ix:nonFraction>&#160;million to each performance obligation based on our best estimate of its relative standalone selling price using the adjusted market assessment approach. The transaction price allocated to the non-CNS penetrant IP of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_dwtnlJ6pzU2O_-cHitWnLA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_eeqKpdr0vUKJS0tsdG2KtQ">60.4</ix:nonFraction> million was recognized as revenue upon delivery of the non-CNS penetrant IP to Lilly during the first quarter of 2021. The transaction price allocated to the CNS penetrant IP of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2021_To_12_31_2021_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_N5mf8PGqUEGmxmbdkeM6pg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_-mSygPr2mUeF5qm1rXmtkA">6.7</ix:nonFraction> million was recognized as revenue from the effective date of the Lilly Agreement through the eventual acceptance by Lilly in June 2022 using the input method. There was <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredRevenue" scale="6" id="Narr_cfGqnQ3jR0KBh4hc-GDMkw"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_yedyexNn70m-Ww5Mtpn2GA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredRevenue" scale="6" id="Narr_opK84te3CkqA54nqDuttwA">no</ix:nonFraction></ix:nonFraction> outstanding deferred revenue related to Lilly Agreement as of June 30, 2024 and December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"><span style="font-size:10pt;">On September 28, 2023, we entered into an amendment to the Lilly Agreement which provides, among others that if we exercise our first opt-out right, we have the right to opt-in to the co-funding of ocadusertib development, upon us providing notice to Lilly within </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_yt0kuytHc0y7T2LLTRMBFg" format="ixt-sec:durwordsen" name="rigl:RightToOptBackInCoFundingTerm" id="Narr_VsNNWS4hcUufNafhUNY7Rw"><span style="font-size:10pt;">30 days</span></ix:nonNumeric><span style="font-size:10pt;"> of certain events as specified in the Lilly Agreement, and as a result receive greater royalties from sales. Following the amendment to the Lilly Agreement, on September 29, 2023, we provided the first opt-out notice to Lilly, and our share on the ocadusertib development cost was capped to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_cDqO7iaeK0Go2Z-84kZ9jQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="Narr_JMg54YipeEm1shyH3HBuLA">22.6</ix:nonFraction></span><span style="font-size:10pt;"> million through April 1, 2024. If we exercise our opt-in right, we will be required to continue to share in global development costs, and if we later exercise our second opt-out right (no later than April 1, 2025), our share in global development costs will be up to a specified cap through December 31, 2025, as provided for in the Lilly Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">Lilly billed us $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg" decimals="-5" format="ixt:numdotdecimal" name="rigl:DueToCollaborationPartner" scale="6" id="Narr_ImTWLYddvU6_ET2JE98E7g">21.4</ix:nonFraction> million for our share of development costs incurred through April 1, 2024, and the amount was fully paid as of June 30, 2024. The outstanding liability to Lilly reported within other long-term liabilities (current and non-current) in the condensed balance sheet as of June 30, 2024 and December 31, 2023 amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg" decimals="-5" format="ixt:numdotdecimal" name="rigl:FinancingLiabilityIncludingInterestExpenseAccretion" scale="6" id="Narr_Ixd2U1erbUe1k26HDYtkFQ">40.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_yedyexNn70m-Ww5Mtpn2GA" decimals="-5" format="ixt:numdotdecimal" name="rigl:FinancingLiabilityIncludingInterestExpenseAccretion" scale="6" id="Narr_F_-xV-uQ2kCzcR4-mHBHEg">43.6</ix:nonFraction> million, respectively. As discussed above, following the amendment to the Lilly Agreement, and us providing the first opt-out notice to Lilly, our cost share obligation for ocadusertib development ended on April 1, 2024. Although currently we are no longer obligated to pay Lilly for our share in the ocadusertib development cost incurred subsequent to April 1, 2024, the outstanding liability reported in our condensed balance sheet as of June 30, 2024 amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg" decimals="-5" format="ixt:numdotdecimal" name="rigl:FinancingLiabilityIncludingInterestExpenseAccretion" scale="6" id="Narr_Y26dgIT9KEyLimNdZoHd5A">40.0</ix:nonFraction> million has not been recognized as revenue because we cannot conclude that it is probable that a significant reversal of the amount of revenue, if recognized, will not occur until the likelihood of us exercising our opt-in right becomes remote, or when the opt-in right period lapses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Grifols License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We have an exclusive commercialization license agreement with Grifols entered in January 2019 with exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop fostamatinib in Grifols territory. Under the agreement, we received an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_5HvpBOyAi0i27BmKK4fzHg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_G7XnnFMvSUGSD14GBR4DCQ">30.0</ix:nonFraction> million, with the potential for $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_VrqE9RWak0OFqmj1P2jvzw" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_ZQsW9GPETUe0KgycHkSvQA">297.5</ix:nonFraction> million in total regulatory and commercial milestones. We are also entitled to receive stepped double-digit royalty payments based on tiered net sales which may reach <ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_60j9a_IIDEa-xMryMMg8Gg" decimals="2" format="ixt:numdotdecimal" name="rigl:RoyaltyPaymentAsPercentageOfNetSales" scale="-2" id="Narr_LG4ulclMpEuY-4igSrxVBQ">30</ix:nonFraction>% of net sales. In January 2020, the European Commission (EC) granted a centralized Marketing Authorization (MA) for fostamatinib valid throughout the European Union (EU) and in the UK after the departure of the UK from the EU for the treatment of chronic ITP in adult patients who are refractory to other treatments. With this approval, in February 2020, we received $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_XFzWo9hPBEqqowv7IqsqMw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="Narr_OM0NqbzIgUmgnVLd_n_fNg">20.0</ix:nonFraction> million non-refundable payment, composed of a $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LP6c6fDybkun2r_aQWcizQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_OfT6bwscWUKdUiSZy2NIVQ">17.5</ix:nonFraction> million payment due upon Marketing Authorization Application (MAA) approval by the European Medicines </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk6831824"></a><a id="_Hlk160551229"></a><a id="_Hlk1408655"></a><ix:continuation id="Tb_-2zpGxaN50-OxQpdarf6Zw_cont3" continuedAt="Tb_-2zpGxaN50-OxQpdarf6Zw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Agency (EMA) of fostamatinib for the first indication and a $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember__kWatA4PfkmKIM4_lvUSqA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="Narr_Oze_C38rlk2mHLgOxJJtNA">2.5</ix:nonFraction>&#160;million creditable advance royalty payment, based on the terms of our collaboration agreement with Grifols. The above milestone payment was allocated to the distinct performance obligations in the collaboration agreement with Grifols. We accounted for this agreement under ASC 606 and identified distinct performance obligations at inception of the agreement. We allocated the transaction price to the distinct performance obligations in our collaboration agreement based on our best estimate of the relative standalone selling price, and recognized the corresponding revenue in the periods we satisfied the performance obligations. There was <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_eZ13M7o2S0y8eAY3w05FHw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredRevenue" scale="6" id="Narr_A9rTtbVF-k25GKXsSMbLJg"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_BiMbBxhh6Uq0yCW2lzj5vw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredRevenue" scale="6" id="Narr_7nDGCWvwu0ekWxd1x9r56Q">no</ix:nonFraction></ix:nonFraction> outstanding deferred revenue related to the Grifols license agreement as of June 30, 2024 and December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We entered into a Commercial Supply Agreement with Grifols in October 2020 to supply and sell our drug product priced at a certain markup specified in the agreement, in quantities Grifols order from us pursuant to and in accordance with the agreement. Prior to the Commercial Supply Agreement, we had a Drug Product Purchase Agreement with Grifols entered in December 2019. There was <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_Q7Q9_fXocUmGbwkegfzFlw" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_uT5QWxSFFUi1e2TVdvKSzg"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_MfToFdRbjkuykAJfE2s1oA" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_K0Ppt_Eq3UWfW1pg3fBtWQ">no</ix:nonFraction></ix:nonFraction> revenue recognized related to the delivery of drug supply to Grifols for the three and six months ended June 30, 2024. For the three and six month ended June 30, 2023, we recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_SI850_iDiUWOa__58mOaXw" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_FTs7XRk1JES1DF_eC1Q_5A">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_AIuTRpIOpUS1-j2v1hsfzg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_cb2YVTG-20mHgck3ftwsMg">2.8</ix:nonFraction> million, respectively, from the delivery of drug supply to Grifols. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We recognize royalty revenue from Grifols included within contract revenues from collaboration. Royalty revenue recognized for the three months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_fiVixnDOc0CkJwTCK4-50w" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_kRuGdseCaUeH5sBP8DmFiw">1.1</ix:nonFraction></span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_maf7KtajvE6t_Jc1HPqseQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_jPVmMZiI4ESa-kZIzItPhA">0.8</ix:nonFraction></span><span style="background:#ffffff;"> million, respectively, and for the six months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_zrxVuGp9HUq29bG3-ZjB6w" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_NNIsK5dMOU2UN7VhIIe4NA">2.2</ix:nonFraction></span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8YAIxGaCJ0WOl3D_P-ZFyQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_2V9Bw5WSLU2G-cL7aHWfsg">1.5</ix:nonFraction></span><span style="background:#ffffff;"> million, respectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Kissei License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have an exclusive license and supply agreement with Kissei entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#8217;s territory. Kissei is responsible for performing and funding all development activities for fostamatinib in the above-mentioned territories. We received an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_4TZ-_gslzUuCVFLIXWN05Q" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_zoqDKHVCIU6ljbcmRjcsiA">33.0</ix:nonFraction>&#160;million, with the potential for up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_4TZ-_gslzUuCVFLIXWN05Q" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr__AIPuY9W30eUZwD0gdUh1Q">147.0</ix:nonFraction>&#160;million in development, regulatory and commercial milestone payments, and will receive mid- to upper twenty percent, tiered, escalated net sales-based payments for the supply of fostamatinib. Under the agreement, we granted Kissei the license rights to fostamatinib in Kissei&#8217;s territory and are obligated to supply Kissei with drug product for use in clinical trials and pre-commercialization activities. We are also responsible for the manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement. We accounted for this agreement under ASC 606 and identified the distinct performance obligations at inception of the agreement. We concluded that each of these performance obligations is distinct. We determined that the upfront fee represented the transaction price and was allocated to the performance obligations based on our best estimate of the relative standalone selling price and recognized the corresponding revenue in the period we satisfied the performance obligations. As of June 30, 2024 and December 31, 2023, the remaining deferred revenue <span style="background:#ffffff;">was related to the material right associated with discounted fostamatinib supply which amounted to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_NSJW9_H2-Uyr8T7g60jFnw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="Narr_DT9sfAtF_U248eKMTMdu5g"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_YXCwufdL2kCunkEAIR-kOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="Narr_wQ3ZfTq_0EOuBa8MnAzj9Q">1.4</ix:nonFraction></ix:nonFraction></span><span style="background:#ffffff;">&#160;million</span>. <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AvQMdmjfrkKF0n7u_e-4ng" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_NIKLVmgzPk-z8ehXcpxIuA"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_93VaWr0Vn0W3qhHJHD5l2g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_l_xFpvKVnES8r4Sg9vU-OA"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_Ed6jJO0mDEC7vy2gXWKNvA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_htqZzIXvqky0evyCT3L0PA"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_82mZ1UCHkUeFIeF9NNLnDQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_tw8HVWfrfE-m8Ed-tUZdDQ">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue was recognized during the three and six months ended June 30, 2024 and 2023 associated with the remaining performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">In April 2022, Kissei announced that an NDA was submitted to Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) for fostamatinib in chronic ITP. With this milestone event, we received&#160;</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FZKSbfgCCUOxIEsBo793zQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="Narr_VUeJGVYMo0iXLgpPvnVhow">5.0</ix:nonFraction></span><span style="font-size:10pt;">&#160;million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, and such amount was recognized as revenue in the second quarter of 2022. In December 2022, Kissei announced that Japan&#8217;s PMDA approved the NDA for fostamatinib in chronic ITP. With this milestone event, we were entitled to receive </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_cM6viZkjnk2XQ_C6vVZS3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_w2ijIyAng06PPZ2WE_JWOw">20.0</ix:nonFraction></span><span style="font-size:10pt;"> million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, which we recognized as revenue in the fourth quarter of </span><span style="-sec-ix-hidden:Hidden_HvqYF3vuKUK_Cbhmr3ItgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2022</span></span><span style="font-size:10pt;white-space:pre-wrap;">. The amount was subsequently collected in January 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">For the three and six months ended June 30, 2024, we recognized $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_82mZ1UCHkUeFIeF9NNLnDQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_6PtGm__Hg0K3VGlDCrDDnA">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_Ed6jJO0mDEC7vy2gXWKNvA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_6LWDS9ER8keXVMAX1JqdHg">4.5</ix:nonFraction> million, respectively, of revenue related to the delivery of drug supply to Kissei mainly for commercial use.&#160;<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AvQMdmjfrkKF0n7u_e-4ng" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_R-t3Lp05pEinAzZE1oDrmQ"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_93VaWr0Vn0W3qhHJHD5l2g" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_d9Xha_o2qEuU0ZfVXmihlg">No</ix:nonFraction></ix:nonFraction> such revenue was recognized during the three and six months ended June 30, 2023.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk149817647"></a><a id="_Hlk108704489"></a><a id="_Hlk140153230"></a><a id="_Hlk154322834"></a><ix:continuation id="Tb_-2zpGxaN50-OxQpdarf6Zw_cont4" continuedAt="Tb_-2zpGxaN50-OxQpdarf6Zw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Medison Commercial and License Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><span style="font-size:10pt;">We have </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_agreement_XCinVrYiMEykKvzVM-r2og" contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_6gKiuqunlUW1exXxbGX2YQ" decimals="INF" format="ixt-sec:numwordsen" name="rigl:NumberOfAgreements" scale="0" id="Narr_e2ejHqgqq02mgYNbMtoZhA">two</ix:nonFraction></span><span style="font-size:10pt;"> exclusive commercial and license agreements with Medison entered in October 2019 for the commercialization of fostamatinib for chronic ITP in Medison territory, pursuant to which, we received a </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_6gKiuqunlUW1exXxbGX2YQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_wAUyJcGC4EOtvSGXmd4gNw">5.0</ix:nonFraction></span><span style="font-size:10pt;"> million upfront payment with respect to the agreement in Canada. We accounted for this agreement under ASC 606 and identified the following combined performance obligations at inception of the agreement: (a) granting of the license and (b) obtaining regulatory approval in Canada of fostamatinib in ITP. However, under the agreement, we have the option to buy back all rights to the product in Canada within </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_Gnk6YUapu02MxjednNsESw" format="ixt-sec:durwordsen" name="rigl:AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" id="Narr_bLrh8PBGG0qB9fIIMImQLg"><span style="font-size:10pt;">six months</span></ix:nonNumeric><span style="font-size:10pt;"> from obtaining regulatory approval for the treatment of </span><span style="font-size:10pt;background:#ffffff;">auto immune hemolytic anemia</span><span style="font-size:10pt;"> in Canada. We determined that the non-refundable upfront fee represented the transaction price, however, due to the buyback provision, we accounted this upfront payment as financing arrangement under ASC 606. In 2022, management </span><span style="font-size:10pt;background:#ffffff;">concluded that the likelihood of exercising the buyback option right was remote considering the top-line results from our Phase 3 trial of fostamatinib in warm auto immune hemolytic anemia (wAIHA) which showed that the trial did not demonstrate statistical significance in the primary efficacy endpoint, and the guidance received from the FDA. As such, in accordance with ASC 606, we relieved the outstanding financing liability which included the upfront payment and accreted interest, and recognized such amount as revenue in 2022. </span><span style="font-size:10pt;">There was </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aH2IYHCJPkuM5HXlyZvgaw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredRevenue" scale="6" id="Narr_ipS2oobe60Co-2JVKksoTw"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RgL4dFy2q0eUvIbUb8HPxw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DeferredRevenue" scale="6" id="Narr_mEOIvxUYm0-I4Qj8uwCGbQ">no</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;"> outstanding deferred revenue related to Medison license agreement as of June 30, 2024 and December 31, 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">For the three and six months ended June 30, 2024, we recognized revenue from Medison of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_DpExNDuvFEiRGecQztGf_g" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_TxH2-_ISpEeVM6Sh2Z7pNQ">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LqSICzN8jECsv3g5VfvRtQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_Ye8M31hnukOJMuC_39P3eA">0.2</ix:nonFraction><span style="white-space:pre-wrap;"> million, respectively, related to the delivery of drug supply and earned royalties. There was no material revenue  recognized in the three and six months ended June 30, 2023 related to the delivery of drug supply and earned royalties. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Knight Commercial License and Supply Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We have commercial license and supply agreements with Knight entered in May 2022 for the commercialization of fostamatinib for approved indications in Knight territory. Pursuant to such commercial license agreement, we received a $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_1QwBIhoEuUGYpKJv6_D94Q" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontFeeReceived" scale="6" id="Narr_9wa1uCs2IE6OP26_lusJuQ">2.0</ix:nonFraction> million one-time, non-refundable, and non-creditable upfront payment, with potential for up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_CpgL9jNlMUCw-IA9e3o4uA" decimals="-5" format="ixt:numdotdecimal" name="rigl:ContingentPaymentsUnderAgreement" scale="6" id="Narr_sq4RX3W4fk-lYQzz7-gcOA">20.0</ix:nonFraction> million in regulatory and sales-based commercial milestone payments, and will receive twenty- to mid-thirty percent, tiered, escalated net-sales based royalty payments for products sold in the Knight territory. We accounted for this agreement under ASC 606 and identified that the upfront payment was a consideration for granting Knight the license to commercialize fostamatinib for approved indication in the Knight territory, and no further material deliverables associated to such upfront payment. As such, we recognized the upfront payment as revenue in 2022. We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Contracts </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">US Department of Defense (DOD)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Government contract revenue for the three and six months ended June 30, 2023 of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_XMqqydBJlUi_15vbwshl0Q"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_25oUsvkSz0yG-x8U2eWIHw">1.0</ix:nonFraction></ix:nonFraction> million was from an award we received from DOD to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19. <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_z6tFpSWYtUeOPKO1v5sshA" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_GUkqdhvnwEqWfkhJutta5w"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_LGpOh5i-pkuYqfZStMMnVQ" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_ujrihNmipkG3czVWTSe1Pw">No</ix:nonFraction></ix:nonFraction> revenue was recognized during the three and six months ended June 30, 2024 from this grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">Biomedical Advanced Research and Development (BARDA)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In August 2023, we were awarded up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_8_1_2023_To_8_31_2023_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_5kULnBvdYEevZnx2IVnM6g" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementPotentialPayments" scale="6" id="Narr_K6-wILDY9U2X7bixgB4IoQ">0.8</ix:nonFraction> million by BARDA, part of the Office of the Assistant Secretary for the Preparedness and Response at the US Department of Health and Human Services (DHHS), for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress. <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_oyau3O4tJkKVZI8B-c9oEQ" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_NqjyjO8I1kK_Nk41bXsJrw"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RFpgzqwWbUSTBMlmSIJ36w" decimals="-5" format="ixt-sec:numwordsen" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_zSvG0a8uzUSG2qJoMg6iJg">No</ix:nonFraction></ix:nonFraction> revenue was recognized during the three and six months ended June 30, 2024 from this grant. Through June 30, 2024, we have received $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_8_1_2023_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_r0ldwSj5VEOIFSa8XhrMcQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementRevenueRecognized" scale="6" id="Narr_5-j0Lz19Okar8jnbPYUamA">0.1</ix:nonFraction> million of the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Strategic Development Collaborations with MDACC and CONNECT</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In December 2023, we entered into a Strategic Collaboration Agreement with MDACC, a comprehensive cancer research, treatment, and prevention center. The collaboration will expand our evaluation of REZLIDHIA (olutasidenib) in AML and other hematologic cancers. Under the collaboration, we will provide MDACC the study materials and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_yUFONy52JkaEdNe2JBvS1Q" decimals="-5" format="ixt:numdotdecimal" name="rigl:DueToCollaborationPartner" scale="6" id="Narr_lSQ8sU8GF02gB6edEf-pUA">15.0</ix:nonFraction> million in time-based milestone payments as compensation for services to be provided for the </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-2zpGxaN50-OxQpdarf6Zw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">studies, over the </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_Yi_QU2DWrk2zU3zLJ3F28w" format="ixt-sec:durwordsen" name="rigl:CollaborationTerm" id="Narr_MuyvBoP3jEGA62zEDxNzYQ"><span style="font-size:10pt;">five-year</span></ix:nonNumeric><span style="font-size:10pt;"> collaboration term, unless terminated earlier as provided for in the agreement. Through June 30, 2024, we provided </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_12_1_2023_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_E2TAw1ebLEyqMCfIkUc_jg" decimals="-5" format="ixt:numdotdecimal" name="rigl:PaymentOfCostShareToCollaborationPartner" scale="6" id="Narr_q32m_aa7fk6WCo4jOTOg7g">2.0</ix:nonFraction></span><span style="font-size:10pt;"> million funding to MDACC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">In January 2024, we announced our collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in glioma. Under the collaboration, we will provide funding up to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_1_31_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_gz1pnQN6FE2qge7r5TPFfQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:DueToCollaborationPartner" scale="6" id="Narr_FxIeeF0ib0GMg_PWrNXnsA">3.0</ix:nonFraction></span><span style="font-size:10pt;"> million and study material over the </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_6M9-yuHtNE6cG9tYWmjCqQ" format="ixt-sec:durwordsen" name="rigl:CollaborationTerm" id="Narr_NnRHUaYRAECRl_ZFjzPR-Q"><span style="font-size:10pt;">four-year</span></ix:nonNumeric><span style="font-size:10pt;"> collaboration. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We account for the funding we provide under the above research collaboration agreements as prepaid research and development in the balance sheet to the extent the payment is made in advance of services being rendered, and recognize such amount as research and development expense within the statements of operations as the collaborative partners render the services under the respective agreement.<span style="font-size:12pt;"> </span></p></ix:continuation><a id="_163446af_8885_4ce1_9f08_488145e4b200"></a><a id="Tc_wb5m8-r26keWS_09Os1cLg_1_0"></a><a id="Tc_8H4KyaNqTUiy0wNPC9H0UA_1_2"></a><a id="Tc_xTCFpNQFakCvO-uCZglxbg_2_0"></a><a id="Tc_wAQ_8eGWTEObJqjwHPW9vw_3_0"></a><a id="Tc_SOvGpdKYPkqDjDPlzHfHew_3_2"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Tb_0CN_KJ0XQU2haPBHqDzcFg" continuedAt="Tb_0CN_KJ0XQU2haPBHqDzcFg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">In-licensing and Acquisition </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Asset Purchase Agreement with Blueprint</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February 22, 2024, we acquired the US rights to research, develop, manufacture and commercialize GAVRETO (pralsetinib) from Blueprint pursuant to an Asset Purchase Agreement. The acquired assets <span style="background:#ffffff;">include, among other things, applicable intellectual property related to pralsetinib in the US, including patents, copyrights and trademarks, as well as clinical regulatory and commercial data and records.</span> Pursuant to the Asset Purchase Agreement, we agreed to pay a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_SZRu02N1XEGrAyfYF5SwyQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" scale="6" id="Narr_AOF9-9KpvUeB_RiaLGdArQ">15.0</ix:nonFraction> million, of which, $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstCommercialSaleMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_HquhUMFeGkasyQJBoBZ3wQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" scale="6" id="Narr_r6opWJvqfEuyfZ_8-PeUzA">10.0</ix:nonFraction> million was payable upon our first commercial sale of GAVRETO and an additional $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstAnniversaryOfClosingDateMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_0IVrFL5NR0Kuz75nULfm_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" scale="6" id="Narr_zUhqpYWYH0O6s2u0y_1iSw">5.0</ix:nonFraction> million is payable on the first anniversary of the closing date of the agreement, subject to certain conditions. Blueprint is also eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_-mlrFhf7yU-O2VqahK8vIQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:PotentialMilestonePaymentObligations" scale="6" id="Narr_sqYf3odI4kC4zuSX_6Bn7g">97.5</ix:nonFraction> million in future commercial milestone payments and up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_oSHvi732xUWC_qqhrIXIIw" decimals="-5" format="ixt:numdotdecimal" name="rigl:PotentialMilestonePaymentObligations" scale="6" id="Narr_8HR-rYI0LEyxh_j307Wm3A">5.0</ix:nonFraction> million in future regulatory milestone payments. <span style="background:#ffffff;">The potential regulatory milestones include full regulatory approval of pralsetinib (or related compounds) for the treatment of adult RET-fusion positive thyroid cancer, and maintenance of the current regulatory approval of pralsetinib for the treatment of adult RET-fusion positive thyroid cancer during the period beginning on February 22, 2024 and ending on the third anniversary of the first commercial sale of pralsetinib subject to certain conditions.&#160;</span>Subject to the terms and conditions of the Asset Purchase Agreement, Blueprint would be entitled to tiered royalty payments on net sales of products containing pralsetinib (or related compounds) ranging from <ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jcLc51bfe0y7CaULox55yA" decimals="2" format="ixt:numdotdecimal" name="rigl:PotentialTieredRoyaltyPercentage" scale="-2" id="Narr_C97sYRKk-kyUryjUM_gaHQ">10</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_4FtiCBTyVkqS_xmhg_p41w" decimals="2" format="ixt:numdotdecimal" name="rigl:PotentialTieredRoyaltyPercentage" scale="-2" id="Narr_NVBZqqANuUGeNn6hgxNY2g">30</ix:nonFraction>%, subject to certain reductions and offsets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with ASC 805 <i style="font-style:italic;">Business Combinations </i>(ASC 805)<i style="font-style:italic;">, </i>the transaction was accounted for as an asset acquisition, because substantially all of the fair value of the gross assets acquired is concentrated in a single asset, which is the GAVRETO product rights. The GAVRETO product rights comprised <span style="background:#ffffff;">developed technology, customers, trademarks and trade name, and are considered a single asset as they are inextricably linked. ASC 805 provides for a screen test, wherein if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock" id="Tb_clWA1sNPe0Ks_fUyY7fdDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the total purchase consideration in connection with the asset acquisition (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing purchase price</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="Tc_pLmSwayRkkK-KwtU5jGxzw_1_3">15,000</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="3" id="Tc_eA7DM5JE9Eui4ydrZWucTQ_2_3">360</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="3" id="Tc_PEz4d1HerUuZO6B1p4qXtQ_3_3">15,360</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">The closing purchase price was recorded within acquisition-related liabilities in the condensed balance sheet and was outstanding as of June 30, 2024, of which, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_7_1_2024_To_7_31_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d_VNrgzWz0a3BkPN9MKEVA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="Narr_-3yaLOoZDkKDmljuQ9dF5w">10.0</ix:nonFraction></span><span style="font-size:10pt;"> million was paid in July 2024 following our first commercial sale of GAVRETO at the end of June 2024. The transaction costs have been paid in cash as of June 30, 2024. The contingent considerations relating to future commercial and regulatory milestones were not included in the total purchase price consideration, and will be accounted for when the contingency is resolved and the consideration becomes payable. Royalties will be recognized within cost of sales, as revenue from GAVRETO product sales is recognized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In an asset acquisition, the acquiring entity should recognize the assets acquired at cost to the acquiring entity which includes transaction costs and consideration given, allocated based on a relative fair value of the assets acquired measured at acquisition date. The fair value of the developed technology, customers, trademarks and trade name was </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk140154763"></a><ix:continuation id="Tb_0CN_KJ0XQU2haPBHqDzcFg_cont1" continuedAt="Tb_0CN_KJ0XQU2haPBHqDzcFg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;background:#ffffff;">estimated using a multi-period excess earnings income approach that discounts expected cash flows to present value by applying discount rate that represents the estimated rate that market participants would use to value such assets. The relative fair value are based on estimates that required judgement and certain assumptions, categorized as Level 3 in the fair value hierarchy. Since we acquired a single asset, the total purchase consideration was recorded as intangible assets. The related intangible </span><span style="font-size:10pt;">assets is being amortized on a straight-line basis over the estimated useful life of </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_KKP0C9QqkUiTkWevYxJzTw" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_Ogl5chOF90y0zwABV2juQA"><span style="font-size:10pt;">12 years</span></ix:nonNumeric><span style="font-size:10pt;">, and the related </span><span style="font-size:10pt;background:#ffffff;">amortization is recorded within cost of sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Simultaneously and in connection with entering into the Asset Purchase Agreement, we also entered into certain supporting agreements, including a customary transition agreement, pursuant to which, during the transition period, Blueprint will transition regulatory and distribution responsibility for GAVRETO to us. We also agreed to purchase certain drug product inventories from Blueprint under a Material Transfer Agreement, and received such inventories amounting to approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_vUvPo1jezUiyVDGej1nLMQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:AssetPurchaseAgreementDrugProductInventories" scale="6" id="Narr_adcDg1WlOkmxJ7AX4qku0g">6.5</ix:nonFraction></span><span style="font-size:10pt;"> million during the six months ended June 30, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License and Transition Services Agreement with Forma </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have a license and transition services agreement with Forma entered in July 2022, for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mutated IDH1 (mIDH1), for any uses worldwide, including for the treatment of AML and other malignancies. Forma became a wholly owned subsidiary of Novo Nordisk following the closing of its acquisition by Novo Nordisk in October 2022. Pursuant to the terms of the license and transition services agreement, we paid an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_mlAixP0Kq0KRgxnPySwCUQ" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementUpfrontPayment" scale="6" id="Narr_Z7uJjd4mtUKaUmw2U_n8Wg">2.0</ix:nonFraction> million, with the potential to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_4U40SB3W_kmm7wCJE8B4_g" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementPotentialPayments" scale="6" id="Narr_ddFOadpFjEqJTwP17RdHXQ">67.5</ix:nonFraction> million of additional payments upon achievement of specified development and regulatory milestones and up to $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_ZZ7iW4JQ8UGfKFajT3fUtA" decimals="-5" format="ixt:numdotdecimal" name="rigl:CollaborativeArrangementPotentialPayments" scale="6" id="Narr_Bbo5PSIox0uQp8wQpUubew">165.5</ix:nonFraction> million of additional payments upon achievement of certain commercial milestones. <span style="background:#ffffff;">In addition, subject to the terms and conditions of the license and transition services agreement, Forma would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portion of our sublicensing revenue, subject to certain standard reductions and offsets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The transaction was accounted for as an acquisition of asset under ASC 730, <i style="font-style:italic;">Research and Development</i>. In accordance with the guidance, in a transaction accounted for as an asset acquisition, any acquired IPR&amp;D that does not have alternative future use is charged to expense at the acquisition date. <span style="background:#ffffff;">At the acquisition date, the acquired license asset was accounted for as IPR&amp;D, and we anticipated no other economic benefit to be derived from such acquired licensed asset other than the primary indications. As such, we accounted for the upfront fee of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_hZmC_MKxK0ib0qKh4OuwDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_qfFegwUhEkKUgBDIMpbPug">2.0</ix:nonFraction></span><span style="background:#ffffff;"> million </span>as IPR&amp;D and recorded such cost within research and development expense in the statements of operations in 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under the accounting guidance, we account for contingent <span style="background:#ffffff;">payments when a </span>contingency is resolved, and the consideration becomes payable.<span style="background:#ffffff;">&#160;We account for m</span>ilestone payment obligations incurred at development stage and prior to a regulatory approval of an indication associated with the acquired licensed asset as research and development expense when the event requiring payment of the milestone occurs. Milestone payment obligations incurred upon and after a regulatory approval of an indication associated with the acquired licensed asset, and at the commercial stage, are recorded as intangible assets when the event requiring payment of the milestones occurs. Prior to the FDA approval of REZLIDHIA in December 2022, a certain regulatory milestone was met which entitled Forma to receive a $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mtfju_YpJkGk_bnLaNb2Gw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_8F6vy5sOK0O4aYbneIco9g">2.5</ix:nonFraction> million milestone payment. Because such milestone payment obligation was incurred prior to a regulatory approval of an indication associated with the acquired licensed asset, we recorded such amount as research and development expense in the fourth quarter of 2022. On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with susceptible IDH1 mutations as detected by an FDA-approved test. Following the FDA approval, we launched REZLIDHIA and made first shipments of the product to our customers in December 2022. With this FDA approval and first commercial sale of the product, Forma was entitled to receive a total of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_URKfF5ajyUiJLXquchdVgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="Narr_sj5i5LXKP0invWVg4zkhxQ">15.0</ix:nonFraction> million milestone payments. Since such milestone payment obligations were incurred upon and after regulatory approval of the product, we recorded such amount as intangible assets on our condensed balance sheet in the fourth quarter of 2022. No new milestone was met in 2023 and during the six months ended June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The amount recorded as intangible asset is being amortized on a straight-line basis over the estimated useful life of </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_KnTLXRz0jkWgF6jXhPXEDQ" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_qN5ohqce10qXFcdfFhL4oQ"><span style="font-size:10pt;">14 years</span></ix:nonNumeric><span style="font-size:10pt;">, and the related </span><span style="font-size:10pt;background:#ffffff;">amortization is recorded within cost of sales</span><span style="font-size:10pt;">. Royalties are recognized within cost of sales, as revenue from REZLIDHIA product sales is recognized. </span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0CN_KJ0XQU2haPBHqDzcFg_cont2"></ix:continuation><a id="_33a71a7e_7449_444e_a361_7c0368a38251"></a><a id="Tc_vO8DnPVj8kCt_rkPUo7Q-A_1_2"></a><a id="Tc_Eotm_hEPAEKWkuU8LYnWiw_1_8"></a><a id="Tc_4zPvprwZ4Em3lny4ZAXFPg_2_2"></a><a id="Tc_Nx2CENTc1EWF3sdI4G28Ng_2_5"></a><a id="Tc_QCgybwe3IkeEYREhdRWt0g_2_8"></a><a id="Tc_B2vCnq2uaUOvIxsSqjEZPg_2_11"></a><a id="Tc_FB1eiKiWqEeVFq8GhlwOLQ_3_0"></a><a id="Tc_76lVJlMipEKHlZV7Sglmvw_3_2"></a><a id="Tc_nTzyg1lS0kuM79j27Ys4bA_3_5"></a><a id="Tc_qFWRAjCwh0uOUV8fawqFHg_3_8"></a><a id="Tc_ZJrpfNh6wUKFQFabQuxNVQ_3_11"></a><a id="Tc_nD0cKu9rvUGfkM87MjGdnw_4_0"></a><a id="Tc_kgs03vrD8kGLceJLwOriTg_5_0"></a><a id="Tc_eKY_ibUpNEiJ-jTwOXNXnQ_5_2"></a><a id="Tc_5VHVHsWvl0OpmFChFCQM6g_5_5"></a><a id="Tc_PitZXsNloUuDHf-kgRSXdg_5_8"></a><a id="Tc_ArVf1cKdb0OnCQ0LfRW4mg_5_11"></a><a id="_Hlk77201288"></a><a id="Tc_tKhZu6pI10azs9cRmhVSzw_1_2"></a><a id="Tc_hM40_LySq06-Ifq3ThJpxQ_1_7"></a><a id="Tc_utGcFc5mukuqnQ6SgISdbw_2_2"></a><a id="Tc_Pt8w79tw60WOboYoykAGyA_2_4"></a><a id="Tc_XATUj5enn0iLPzCNuliO-g_2_7"></a><a id="Tc_atmrM9A8_EuC4HGUfAc8rA_2_9"></a><a id="Tc_vDbNkDPdp02ML1k-F1C_rQ_3_0"></a><a id="Tc_wWUaNkwcWEGuduPCM4j7Lw_3_3"></a><a id="Tc_Ykmym_Hg50W67pcJ1PsxpQ_3_5"></a><a id="Tc_BWVyo1hvK0O9wwisLOL9ww_3_8"></a><a id="Tc_XEj8Op9Bn027KB754i5m7g_3_10"></a><a id="Tc_JvvsUqCzq0izxMAODzWsbw_4_0"></a><a id="Tc_IlkLzFqg1kmnX0v7bnomQg_5_0"></a><a id="Tc_vI1CprHD6ESGqPJmskVZog_5_3"></a><a id="Tc_DaUCJIqjtkCEfR-EVwbdmw_5_5"></a><a id="Tc_arD0v0xKpUawiAb6uazDIQ_5_8"></a><a id="Tc_hd0PE880p06VoEMw-EfLMw_5_10"></a><a id="Tc_OalymYWSMEKAmUH0jAqSWA_6_0"></a><a id="Tc_JjAlTWLx_kC3P0w4zMaP4Q_6_3"></a><a id="Tc_mPREje0hfEC_bQfteFS9CA_6_5"></a><a id="Tc_BcQ25QRtqk6UyeLDRnTWTQ_6_8"></a><a id="Tc_bajKfbwtfkm72AUxTMRHuA_6_10"></a><a id="_Hlk77202049"></a><a id="_Hlk77202164"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_8prAQRojv0GwkvD5MPKGfg" continuedAt="Tb_8prAQRojv0GwkvD5MPKGfg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Stock-Based Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_IGTqLXscC0y4B4GoHQs9FQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation for the periods presented was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_w7P1z0EI5EueFIgNkc89sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_zH2GD5GgPECo5PjYc-_vFg_3_3">2,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ieBTYFxiqUCvCIZyspbbWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tvjdC2pBzUGW5HdgBSytvA_3_6">1,796</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fv5v2douMUSk7zWe57p0FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_qqbKxV37jUur0YS1xZ0HMQ_3_9">6,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2LCsKqr1LEqrGC4lXCGiqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ydpM9aXpzU2bNY13ptaHTQ_3_12">3,531</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_3xxTQ5sXyEG51cWWfHtXmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_7OebIbZn00e6Fic0jby55w_4_3">305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xJyvi82Gwk2Tr-43Oekyrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_VFx0J2pbQ0OiGdXIRgFulQ_4_6">376</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bSe8WAEXkUG7k9-Nd_2uvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_lkp-1kr5VE2Xn-EpdqLDHw_4_9">955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v32Ol4crf0K8DOnTPxOuGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6HrVRGGg6ECJ2dXbMU-EHg_4_12">1,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_pRSOLpt8YU2c1yx4upXlQw_5_3">2,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_gBag667zW0WY6yMvNP6vkw_5_6">2,172</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_bobHtZ88ZUG_18WeITVDMA_5_9">7,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ZKstY3IkYUCBnDCm4_VfWg_5_12">4,930</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">During the six months ended June 30, 2024, we granted stock options to purchase </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_0JMUJOnWZ0WSEiCGnHclEw">599,772</ix:nonFraction></span><span style="font-size:10pt;"> shares of common stock with weighted-average grant-date fair value of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_gs_fuu9HA0evWQrpEmocpw">9.64</ix:nonFraction></span><span style="font-size:10pt;"> per share, and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_NUCziGL2kk2L-_4TnyF2WA">9,294</ix:nonFraction></span><span style="font-size:10pt;"> stock options were exercised. </span><span style="font-size:10pt;">The stock options granted during the six months ended June 30, 2024 generally vest over </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_zDYPBy5gUEe3dXOsv151Yg"><span style="font-size:10pt;">3 years</span></ix:nonNumeric><span style="font-size:10pt;">. As of June 30, 2024, there were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkUV1BM-xU2eirtWLK871A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_rPB7eXJErkWr0PphEAldGw">3,691,139</ix:nonFraction></span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">stock options outstanding, of which, </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_E24Tg32FFUaoGudnG6SLlg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_9RlkLyAEjUG1tyThQDQ9AQ">132,250</ix:nonFraction></span><span style="font-size:10pt;"> are outstanding performance-based stock options wherein the achievement of the corresponding corporate-based milestones were assessed not probable as of June 30, 2024. Accordingly, none of the </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_E24Tg32FFUaoGudnG6SLlg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_a7rWeEzW0kmhiqxphEVcJQ">2.5</ix:nonFraction></span><span style="font-size:10pt;"> million grant date fair value for these awards has been recognized as stock-based compensation expense as of June 30, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. The following table summarizes the weighted-average assumptions relating to options granted pursuant to our Equity Incentive Plans (our 2018 Equity Incentive Plan and Inducement Plan, as amended) for the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_z1-K2Xeg40myQKxN5H8Nlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_jHOTsEJ0QUWnhCaHcaMBVA_3_2">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc__0NRjH7j_kKG8rm1ZGNeCw_3_4">3.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_5rczz7HuUkqsc7JN2EZ1Iw_3_7">4.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Y03zQy0_c0i_v7JBvwZHMg_3_9">3.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_beVR6OzVp0u63m8CBrijsg_4_2"><span style="font-size:10pt;">6.0</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Pt4IUjm7lkGWWiRhWEINTA_4_4"><span style="font-size:10pt;">6.7</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Nw3ogNKHvEmiREeqjfiExA_4_7"><span style="font-size:10pt;">6.2</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_nrn-QWBw2UmM6WBBy9KxkA_4_9"><span style="font-size:10pt;">7.0</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_DRc0R7C8-kmw_JSPSjgnmQ_5_2">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_3rbpYVHTOUyQkjZsxXZptA_5_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_mBKWLhlQoUC6cSndIXSmLQ_5_7">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_oFcTRovcbEOtragDpmzvjQ_5_9">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_YjSCG5wuEkWYmiRsRpYNmA_6_2">88.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_8c6QW8ukYUOiPnYVaNRCzw_6_4">86.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_5ie7iyTbCUCWWcPuyycnuw_6_7">87.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_tFeSJr6T-kav4XFqnbLvMQ_6_9">83.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">During the six months ended June 30, 2024, we granted </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_dMLlmGfiXECoRPvqyx0y9w">291,373</ix:nonFraction></span><span style="font-size:10pt;"> </span><span style="font-size:10pt;background:#ffffff;">RSUs </span><span style="font-size:10pt;">with a grant-date weighted-average fair value of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_OPDyRZ4Xt0W0phP44uIW4g">12.52</ix:nonFraction></span><span style="font-size:10pt;"> per share, and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_lRKL_42QMkCey2B8cjzsLQ">66,408</ix:nonFraction></span><span style="font-size:10pt;"> RSUs were released. The RSUs granted during the six months ended June 30, 2024 generally vest over </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_0MLM276bY0-jh-b5KruE3A"><span style="font-size:10pt;">3 years</span></ix:nonNumeric><span style="font-size:10pt;">. As of June 30, 2024, there were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_viFreQeDZ0G9JJCWlMU9Bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_yYu-qbIXHky-B5Bfm-bo2g">387,729</ix:nonFraction></span><span style="font-size:10pt;"> RSUs outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">As of June 30, 2024, there was approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_mp0URjlEF0yvPpfS-o63hg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_by_aBDtwyE--3ljVHjDGCQ">14.0</ix:nonFraction></span><span style="font-size:10pt;"> million </span><span style="font-size:10pt;">of unrecognized stock-based compensation cost which is expected to be recognized over a remaining weighted-average period of </span><span style="-sec-ix-hidden:Hidden_BSYq7x4JLEq-_Jg2cZgicA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.15</span></span><span style="font-size:10pt;"> years, related to time-based stock options, performance-based stock options wherein achievement of the corresponding corporate-based milestones was considered as probable, and RSUs. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In March 2024 and April 2024, our Board of Directors approved additional <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_3_1_2024_To_3_31_2024_ljnvk8kzm0a4q-SYLyQozA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_NoTP5HYLl02XfdI9ZxL3vA">78,232</ix:nonFraction> shares of common stock reserved for issuance under our Inducement Plan. In May 2024, our stockholders approved an amendment to our 2018 Plan, to, among other items, add an additional&#160;<ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_5_1_2024_To_5_31_2024_DjxYIP5b9kafOLRsY1Sj5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_TM6-3bKyh0S7Rl5kBrDvKw">650,000</ix:nonFraction>&#160;shares&#160;to the number of shares of common stock authorized for issuance under our 2018 Plan.&#160;As of June 30, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_aXwepT8G2kO-MmJUjpEvLg">1,412,669</ix:nonFraction> shares of common stock available for future grant under our Equity Incentive Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">Our Purchase Plan provides for a </span><span style="-sec-ix-hidden:Hidden_tLN0a4X5JU2Cq3R9ffzyHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period comprises </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_item_lkAE3fTQ8kCadM7_hQ6xtA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw" decimals="INF" format="ixt-sec:numwordsen" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" scale="0" id="Narr_YsdJjCR7VEWtutf3fyLeNw">four</ix:nonFraction></span><span style="font-size:10pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw" format="ixt-sec:durwordsen" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" id="Narr_mT_LhrFCy0e2-dIfb0crGw"><span style="font-size:10pt;">six-month</span></ix:nonNumeric><span style="font-size:10pt;"> purchase periods with a look-back option. A look-back option is a provision in our Purchase Plan under which eligible employees can purchase shares of our common stock at a price per share equal to the lesser of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_Jpozo7Vv80yLixxotDcTLg">85</ix:nonFraction>%</span><span style="font-size:10pt;"> of the fair market value on the first day of the offering period or </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw" decimals="2" format="ixt:numdotdecimal" name="rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" scale="-2" id="Narr_76zLH48mHUOCb6lwgCgJFQ">85</ix:nonFraction>%</span><span style="font-size:10pt;"> of the fair market value on the purchase date. </span><span style="font-size:10pt;">Our Purchase Plan also includes a feature that provides for a new offering period to begin when the fair market value of our common stock on any purchase date during an offering period falls below the fair market value of our common stock on the first day of such offering period. This feature is called a &#8220;reset.&#8221; Participants are automatically enrolled in the new offering period. </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_8prAQRojv0GwkvD5MPKGfg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">Our </span><span style="-sec-ix-hidden:Hidden_U2j5tAbzr0-MSQXB1Kv0GQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period under our Purchase Plan ended on June 30, 2024, and a new </span><span style="-sec-ix-hidden:Hidden_zN5HkjsdLkqRRzBvM8xfWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period started on July 1, 2024. </span><span style="font-size:10pt;">The fair value of awards under our Purchase Plan is estimated on the date of our new offering period using the Black-Scholes option pricing model, which is being amortized over the requisite service periods. </span><span style="font-size:10pt;">As of June 30, 2024, there was </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_ykyILY5HlkKht7OKVYHIvw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="Narr_31OA3umKLU2pWTaxcIs_6Q">no</ix:nonFraction></span><span style="font-size:10pt;"> unrecognized stock-based compensation cost related to our Purchase Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the six months ended June 30, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" id="Narr_APpuJTFYh0m4ck7qb3dAPw">35,902</ix:nonFraction> shares purchased under the Purchase Plan. As of June 30, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw" contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_ykyILY5HlkKht7OKVYHIvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_E1f_qj39zESk0y9vITAHdA">213,681</ix:nonFraction> shares reserved for future issuance under the Purchase Plan.</p></ix:continuation><a id="_28ae21c5_458a_4304_9602_02c0bdfc5534"></a><a id="Tc_0I2IhwTpsECkCd8Wf6im9w_2_2"></a><a id="Tc_w-sni44zl0mmK_zHV6EJdA_3_2"></a><a id="Tc_Q7hzva3SDkG6vNmLBNQDHg_3_5"></a><a id="Tc_L6FnyrBlhEehd4JrjzNF6g_4_0"></a><a id="Tc_LdVxxfArVEyHrSXpg0E84w_4_2"></a><a id="Tc_jedK8_DtX0Wf1BNvNySSvw_4_5"></a><a id="Tc_unYXl-J2YEqDTJS6x7Tm2Q_5_0"></a><a id="Tc_TCYGOoq7pkOgVEgReLDtBQ_6_0"></a><a id="Tc_Myx9ZvY8GEuRYZ0FpB9gMg_7_0"></a><a id="Tc_N3o9UdUL_kGKwGTZTlV0Rw_7_2"></a><a id="Tc_-YYVu4Yq3UyoyVJlnVrRKw_7_5"></a><a id="Tc_7qH0KMz0AU6jTDw0OgwUMg_8_0"></a><a id="Tc_yT_xazOT0ky0cVDp7W4oEg_9_0"></a><a id="Tc_x6D_IgCfk06vwKzpyIZWaQ_9_2"></a><a id="Tc_EK7eSH6XFEal_ncm4MncvA_9_5"></a><a id="Tc_bFgsco_O6EeUSlDwIXxFYA_10_0"></a><a id="Tc_sDLyQrRH_UKgO7XvjeLBaQ_11_0"></a><a id="Tc_H6QBq_VH8kO6NYSjevAgiA_11_2"></a><a id="Tc_k_qK10YJZEScLdTvT_hJdA_11_5"></a><a id="_Hlk147758768"></a><a id="_4a7f7fc0_b3f2_4793_bb3e_d03489ebbd27"></a><a id="Tc_QKpAOJ5bVUiE1cCZqiC3nQ_1_2"></a><a id="Tc_iqGWEgAmPkCJxglVtdxJ0g_2_2"></a><a id="Tc_RwGzZNiOikGopv84KDNm4g_2_5"></a><a id="Tc_cLR0agsl006jqDX1qR4XXg_3_0"></a><a id="Tc_soJNBPFNq0ezp6r-Z6XuQA_3_2"></a><a id="Tc_rrpOjwhFOkOhT09Rpi2UKg_3_5"></a><a id="Tc_Mw2ZzLOB_kO4vdN_Vim1GA_4_0"></a><a id="Tc_ZHwm7ZdXzEyqWudi7F6fiA_5_0"></a><a id="Tc_KPJ9c5swXUyVtVVoeNPTVQ_5_2"></a><a id="Tc_peXJ0f2OLkCbNpd5-lR09w_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_ILKO4zBphEC2f6NZHFp0lA" continuedAt="Tb_ILKO4zBphEC2f6NZHFp0lA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Other Balance Sheet Components</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_QF7B6dZBhkes-V1tsnKsPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Inventories for the periods presented consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.71%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_Vn6I9baq8kW6fZ74423dZg_4_3">2,145</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_oEuytnnzVEmIWop-vPig6A_4_6">4,609</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_Z41efP7ly0KDPGsXBHg2kw_5_3">6,006</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_-EWVj5uT50qHUmsLnbz7Hg_5_6">1,876</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_KV6-OUJ6CUe5i9_RFSrJOA_6_3">4,368</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_LsKCRveSXU2jZkrTEr8JEA_6_6">1,508</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="rigl:InventoryAndInventoryReportedAsOtherAssets" scale="3" id="Tc_UKUxlsnX1E2TeadLTj8Ahg_7_3">12,519</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="rigl:InventoryAndInventoryReportedAsOtherAssets" scale="3" id="Tc_qBh1JTBHGkq1hLpQp9xXWg_7_6">7,993</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_-i05lcq6V0aWO0IDP0LrnA_9_3">8,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_kk4PJQ-soUyGe2tTrwtXwg_9_6">5,522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="rigl:InventoryReportedAsOtherAssets" scale="3" id="Tc_ALnqoNI3rk-XX4OMmT9Pyg_10_3">4,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="rigl:InventoryReportedAsOtherAssets" scale="3" id="Tc_yFJkwR9NEE-ls8FFp473Wg_10_6">2,471</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="rigl:InventoryAndInventoryReportedAsOtherAssets" scale="3" id="Tc_fhDVuPGaa0-3oC1NY0ityA_11_3">12,519</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="rigl:InventoryAndInventoryReportedAsOtherAssets" scale="3" id="Tc_Ip6qw23WDUK_paGNTOU_qQ_11_6">7,993</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Inventories as of June 30, 2024 and December 31, 2023 include inventories acquired from Forma pursuant to the license and transition services agreement.</span><span style="font-size:10pt;"> Inventories as of June 30, 2024 also include inventories acquired from Blueprint pursuant to a Material Transfer Agreement as discussed in Note 5 &#8211; In-licensing and Acquisition. As of June 30, 2024, advance payments to the manufacturer of our raw materials were included within prepaid and other current assets in the condensed balance sheet</span><span style="font-size:10pt;"> amounted to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" id="Narr_JshpjXm2l0W0icld9FRAQw">2.2</ix:nonFraction></span><span style="font-size:10pt;"> million. </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AdvancesOnInventoryPurchases" scale="6" id="Narr_4oM0Jxuc_kqVmvY1qGqkcg">No</ix:nonFraction></span><span style="font-size:10pt;"> such advance payment was included within prepaid and other current assets as of December 31, 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Non-current inventories consist primarily of active pharmaceutical ingredients classified as raw materials which have multi-year shelf life, as well as certain work in process and finished goods inventories that are not expected to be consumed beyond our normal operating cycle. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_cfEJ3Y18-E2XTZFM3JLC8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Intangible assets consist of the following (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.62%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_cMxrJvDtYEqsJvWWtwmeeA_3_3">30,360</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_x2FTp8SerkiuumvjThOi6w_3_6">15,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_XFQKYqk65k-pxE3r6JqU0g_4_3">2,085</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_DVqNJQH9Ok29Uy8zAJKQBQ_4_6">1,122</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_BO2ays6JB0az3Fmzc9Q27w_5_3">28,275</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_oMAYE-fyXUajnRdd9NyrtQ_5_6">13,878</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">See &#8220;Note 5 &#8211; In-licensing and Acquisition&#8221; for related discussions of capitalized intangible assets. Amortization expense recorded within cost of sales in the statements of operations for the three months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_LzEsL98YbEa0cr-ZZttuWA">0.6</ix:nonFraction></span><span style="background:#ffffff;">&#160;million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_C4Lln4J32E6eAunvzJBKdg">0.3</ix:nonFraction></span><span style="background:#ffffff;">&#160;million, respectively, and for the six months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_u2JHG7xJD0yVR5ivWKrq-g">1.0</ix:nonFraction></span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_Z47IQ2Nrm0iQpIfvSgQL6A">0.5</ix:nonFraction></span><span style="background:#ffffff;"> million, respectively.</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_20fa33d8_a25e_4bf4_870c_a3e5d7078029"></a><a id="Tc_gsYnvloABUybUiC5PGC5kw_1_0"></a><a id="Tc_Ei0xEnFIX0GvvbD4o8d_NQ_1_2"></a><a id="Tc_ytR7654Om06o-c32S5dOzQ_2_0"></a><a id="Tc_WBX02OEt_EiflIQ37M7INg_3_0"></a><a id="Tc_1wzxPoP3iku_WK1neOWzXw_4_0"></a><a id="Tc_JmxMi9qOnEin6OwXf4I3XA_5_0"></a><a id="Tc_SRtEpNTD8UORLS2czJYBew_6_0"></a><a id="Tc_9C8yeyExXEeCgSFeF71o5w_7_2"></a><ix:continuation id="Tb_ILKO4zBphEC2f6NZHFp0lA_cont1"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_i-qFXqM_vkyKgu_heNCElg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The following table presents the estimated future amortization expense of intangible assets as of June 30, 2024 (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.69%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_Ot4PevaIEE-5CmduNfiH5Q_1_3">1,176</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_aAD-yC4CY0CdQMuebNPTSg_2_3">2,351</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_F0jwugOFoUStkIAdYVYzjw_3_3">2,351</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_9fwcAPgOxkuPbn5vM1-ndw_4_3">2,351</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_CqmtRFV5ZEKKmeJRm2x3SQ_5_3">2,351</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_fed-Odh8ZU6V4PsxufV66w_6_3">17,695</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_qOsMTkv0c0q66-Nhx21S-Q_7_3">28,275</ix:nonFraction> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><a id="_7d437357_134b_4c05_a4a8_8b008f4d3a2f"></a><a id="Tc_3Mn1xl55fEe9R8RGxDBcTQ_1_2"></a><a id="Tc_6IldVKuKMEGWwhuIFbk6wg_2_2"></a><a id="Tc_WlbntrpZgEC8N_VP9WmgTQ_2_5"></a><a id="Tc_wqVSt5VdSUm7QyTD_uVj7w_3_0"></a><a id="Tc_X8vl4FAYp0aMwo1wwstCyw_3_2"></a><a id="Tc_Uk2Iha33ZkW0isgNSLkWIA_3_5"></a><a id="Tc_J74Ve53xgUKD0WgpPYhi0w_4_0"></a><a id="Tc_GJyiyBXmHkSIXgcYQdao3w_5_0"></a><a id="Tc_w_u4cLMqZEqwIMwzvLE61Q_6_0"></a><a id="Tc_u93ld26bvUaWMzeZ3Wulkw_7_0"></a><a id="Tc_2ZXMH0DN40-8Fi57radB5A_8_2"></a><a id="Tc_ufU-O_-eQEuGHl-n-QbzCg_8_5"></a><a id="Tc_BCMjTYdyA0-h1le1-Ycsqg_9_0"></a><a id="Tc_QsKLZJsRikycKTQS3kv2LA_10_0"></a><a id="Tc_67suq2Qw_EC2E99STL2feQ_10_2"></a><a id="Tc_vrm4FC_MPkacTdldVNF_jg_10_5"></a><a id="Tc_dXPRfzyB60ePrlKUMfcB5w_11_0"></a><a id="Tc_n_h0z-7tJEO9INJHUZABvg_12_2"></a><a id="Tc_AqQRJjWhAUiPvi0-YEXxCQ_12_5"></a><a id="_25e74ed7_67c5_4a30_99d2_d478b1b91b89"></a><a id="Tc_5Vf7gy5jG06zrdwZ8IQLtA_1_5"></a><a id="Tc_EtO_U5QwE02o3DSP_lUu8g_1_8"></a><a id="Tc_vfbGu6AAlUKc64P9ZNsQyA_2_2"></a><a id="Tc_sLEeIJTVO0G1feY29Sv9Rg_2_5"></a><a id="Tc_WEUAmBaHF0WS6HllbR5LrQ_2_8"></a><a id="Tc_mnv63HDvXE68LNQXbC1umA_3_0"></a><a id="Tc_UzkZ4aQWdkmUCH68MCtf8g_3_2"></a><a id="Tc_3hNbNRDbeEeiDytgHZKvvw_3_5"></a><a id="Tc_NAfhmgBXMUSdYYmb3e9NHA_3_8"></a><a id="Tc_ibmh8Cos4EqDjgIclr1iIw_3_11"></a><a id="Tc_R3_XP4MByUmmAl1JqiZIrA_4_0"></a><a id="Tc_3fudVEYNrka86wxr1PTeyA_4_2"></a><a id="Tc_CVyf5e3T5EavCJSWhrr72A_4_5"></a><a id="Tc_k0WBPWuoO0eLCXNBmSpBYw_4_6"></a><a id="Tc_RzxXIAMchUi1HkfPekfW-g_4_8"></a><a id="Tc_Z6dKhRe-0EChoK7vnGHRMA_4_9"></a><a id="Tc_vjVWOruVb0aV7kFg-QrKoQ_4_11"></a><a id="Tc_CqyYGSrvQEqD4jaqzCUCNg_5_0"></a><a id="Tc_ZZvMjp00Wk-5WcHB5aq5iQ_5_6"></a><a id="Tc_WSrVUb0v6kyxXZ1ZZIgOpQ_6_0"></a><a id="Tc_zFIE4qG7AEiheXB4okQ7Lg_6_6"></a><a id="Tc_kD_qmxoo4EO6lpcSQClU5w_7_0"></a><a id="Tc_NIADpvH060WFOS6qcgyNXQ_7_2"></a><a id="Tc_w_mfOlBKhEGdZZpvm319Mg_7_5"></a><a id="Tc_VOhnwLS_IUOswM4FoxNFPw_7_6"></a><a id="Tc_rq6-xutEeUqJNUrXvi0_6A_7_8"></a><a id="Tc_IdrNflB0y0uguHGG0RbkQw_7_11"></a><a id="_876ddf36_b66a_45f2_84f5_bfe6af1f2cb7"></a><a id="Tc_7D-JxQ5v6UW_Tej2LqWWNg_1_5"></a><a id="Tc_GUpJd5ZrakmtaM_o42dYjw_1_8"></a><a id="Tc_fAu_8Sw6vUCm_1_YYE5Ghg_2_2"></a><a id="Tc_pmWazuIVXka8aPFWFoUoaA_2_5"></a><a id="Tc_S4POfA7n0EGatMzxtgkI9g_2_8"></a><a id="Tc_pWnF5LghlkuiQ9im8vGHZA_3_0"></a><a id="Tc_07ZZxvO_L0-eG0XrqWAECw_3_2"></a><a id="Tc_mX9HP0AmjEuS8KhP8l-NWg_3_5"></a><a id="Tc_f1uRP6fOrkSZsoVL0tjonA_3_8"></a><a id="Tc_Bw_6KsoUt0OD3Q40oMaK2w_3_11"></a><a id="Tc_FmlOTY0_hEqALo8_uSx6Wg_4_0"></a><a id="Tc_PgtyaSBFuUahWgBtNHis1w_4_2"></a><a id="Tc_2rAjseXl30emc4mfgIyDiQ_4_5"></a><a id="Tc_Bz6hkz3n7UK05UZX3i6etQ_4_8"></a><a id="Tc_oe1ICXQGs061-HY6vdcytA_4_9"></a><a id="Tc_WvlxhbzXkUeSlgZusSN2AA_4_11"></a><a id="Tc_Qa_x9_EHAk-IYwAahzDudA_5_0"></a><a id="Tc_7Pp6lGUQikCWp1XhQlxWxQ_6_0"></a><a id="Tc_v5VWfHv1GUWXFzPNxEYCZw_7_0"></a><a id="Tc_cjplhiFDsUiydPe-NWwAmg_7_2"></a><a id="Tc_bwIubVyN00mCsVoaxDWPdQ_7_5"></a><a id="Tc_1rXOgrVHaUOzjQN0spOaog_7_8"></a><a id="Tc_QY0WYEGnbEiU-WqHKsac3Q_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="Tb_g9l5i5tC70Kddk7jTuo8Ag" continuedAt="Tb_g9l5i5tC70Kddk7jTuo8Ag_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span><b style="font-weight:bold;">Cash, Cash Equivalents and Short-Term Investments</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="Tb_Dh2y09qDFke-TBnnky-1cQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_aYSlG3CFDEO3az0cwNa1cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_XkEZs3HKI0y7aQdK-d1w_A_3_3">6,126</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_p4HneMQsy0Sje5M5K7gO5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_cBmJlskmjECBfJmIXtE6vA_3_6">8,247</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_JbLXs-0VY0esSnNCYQq-kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_Z9MQAp-JVkyd4hKZP4xN0Q_4_3">13,805</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_hTn2f1VUkUCR_wGtI1n8ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_7TrVlc_BFkKpw2lXqnTFmg_4_6">9,685</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_1A5iQpFj_USrbxcLaNA6XA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_H2svNJmLtEaSrfIH7xWROA_5_3">4,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_XVD5BbqpPk-9fwQojvfB5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_IYclSLp7VUKeggM434P-MA_5_6">12,594</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_2UPYQbxtFk22_tFpBpiQjg_6_3">10,444</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ckfW59j6Okm6xRNuxxkwMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_b1mQR6skyUS6gdkmWb0bJg_6_6">11,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_YnVLc7JM60y_22qd_vwv6Q_7_3">13,764</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_89x-n-BkT02zjUtAjZbcGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_GkYtYwT7K0qdEYbG-DVmxQ_7_6">15,174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_u8C2NDqyzU-6CSTMrEkS6w_8_3">49,102</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_Owuy7GIlZ0SHegF88tmNEg_8_6">56,933</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_AEH1TyVMlEubRoMx4TUaCQ_10_3">36,053</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_WrJ1xG5oRkOT99507QnOAQ_10_6">32,786</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_RALlmcp2lUaEvxr3SfMB3g_11_3">13,049</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_-l3ykg4XfkuZmbA9wpSrdw_11_6">24,147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_pAgDGERU7EiRxvyO0PHSWA_12_3">49,102</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_v9nJ2DDsw0aFfBCNtuNuNg_12_6">56,933</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="Tb_7oG9BlP1lECEDqbnC5ekGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_I_VPJB4u6EaCQYJB-1nRzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_KB33WYLeaUi803PFpfxhbA_4_3">4,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_I_VPJB4u6EaCQYJB-1nRzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_yzA98qDHg0eAqPQiHRW1uA_4_12">4,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_YesGsLryt0qGsoVabogaQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_s5wknm51FUSHfTfNB7fQCw_5_3">10,446</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8oQqRK0A4Eeyfv827MVcYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_TZTxk4w9D0eiVlTQe5Dh0g_5_9">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_YesGsLryt0qGsoVabogaQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_n4QrQGJBTka6n3kgPghCjQ_5_12">10,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_LwXt8QqnrUCTiqADnWfuhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_0KldBGacQUe-DoNX3Pir3A_6_3">13,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_OVx2OrQCKEaSY3aBoBA0Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_8fb8d55ty0SOMwpgPlEWaw_6_9">7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_LwXt8QqnrUCTiqADnWfuhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_iD43firJC0uXgbGPGm8uEQ_6_12">13,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_FICV7gW2dk-JlC3rHlKcSA_7_3">29,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_XjdV-Jp880KnhPP0PN-3mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_4ti6kQN890e7HUGsExqmWA_7_9">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_0FhVDO4OzU-eA8CEYtSHFQ_7_12">29,171</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_kZWlKhsNBU6_AklsH7sLKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_BERRkQyeOEaaoiSguv9Fng_4_3">12,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_LS7cZ0Bs8U-InZ3368zHAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_7BV-m3jFfkGDeKnSQHLV6w_4_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_kZWlKhsNBU6_AklsH7sLKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_qBzQxAMrtEKfw7GSpfSyuA_4_12">12,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_QPE9o_N_LkOoOgf3_7ge7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_t4YhJTxOukGl77jmMO7b8Q_5_3">11,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_vAVgV6NViE6ez_AdrA5iUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_5MeQBquEdkGqln6jdhRFbQ_5_6">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_gG5MuB9lWk-MYGQsRJNXbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_IN0DOzZqo0O7dhqMy8t3hA_5_9">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_QPE9o_N_LkOoOgf3_7ge7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_YU0W2L6PEUClyLQlmD2aZg_5_12">11,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_Som_sdy7kEqstJssH42W1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_we_pdXQSZUqobYaeNYwFAg_6_3">15,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_sBMx05ZL3UeBF780dfwknA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_cGMbGwqRJk2MTxnTEMN9WQ_6_6">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_YF4pFiaiVkGskNRvWduW9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc__WPxP-E_3keshczDEGo3vQ_6_9">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_Som_sdy7kEqstJssH42W1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_zTxAsL90EkatR18wMUTFew_6_12">15,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_waJThiiLvkGKTK0-NmgaHg_7_3">38,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_uiwrXRdPDki6YFyL0CW_EQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="3" id="Tc_IIgzGtnweECh0P7YoXlVAQ_7_6">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_N2zaSMxsLEqGccjjlPSgFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" sign="-" scale="3" id="Tc_t05GpulPa06O56wQA6AqEw_7_9">7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_Qkm-2T9jG0K6f0vebbdIRg_7_12">39,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">As of June 30, 2024 and December 31, 2023, our cash equivalents and short-term investments had a weighted-average time to maturity of approximately </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" format="ixt-sec:durwordsen" name="rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" id="Narr_P0ueg2K1n0-ozSZXbRIMEg"><span style="font-size:10pt;">68 days</span></ix:nonNumeric><span style="font-size:10pt;"> and </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_bk4CtdQf3EaimZs7lkGnMA" format="ixt-sec:durwordsen" name="rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" id="Narr_q4H1IqBHnUOPDAxsHzDpYA"><span style="font-size:10pt;">82 days</span></ix:nonNumeric><span style="font-size:10pt;">, respectively. </span><span style="font-size:10pt;background:#ffffff;">Our short-term investments are classified as available-for-sale securities. Accordingly, we have classified these securities as short-term investments on our condensed balance sheets as they are available for use in the current operations. </span><span style="font-size:10pt;">As of </span><span style="font-size:10pt;">June 30, 2024, we had </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_position__77Wb-sxgEODSR6HmbQE7w" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="Narr_vxl7xK5WsUSRUx7q8iGLMw">no</ix:nonFraction></span><span style="font-size:10pt;"> investments that had been in a continuous unrealized loss position for more than 12 months. As of June 30, 2024, a total of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_position__77Wb-sxgEODSR6HmbQE7w" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="Narr_0loDrtwho0O4ooYNAcytqQ">26</ix:nonFraction></span><span style="font-size:10pt;"> individual securities had been in an unrealized loss position for 12 months or less, and the losses were determined to be temporary. No significant facts or circumstances have arisen to indicate that there has been any significant </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b0abda64_b2c5_4a90_8845_a7ad1462c837"></a><a id="Tc_dJJX9yt__0GPE7zxYZhAyg_1_0"></a><a id="Tc_M0cpyhO8s02i2PQqyQa3Dg_1_2"></a><a id="Tc_w48Kf4sR4E6NfHUihArqdQ_1_5"></a><a id="Tc_4YZ3dt1aD0e72OktVJkMyg_2_0"></a><a id="Tc_O4QjnzkQdUSpIIAOxyTN5w_2_2"></a><a id="Tc_B8w82HqTD0Obv0ty3aPkZQ_2_5"></a><a id="Tc_iR6GHWaFJkWv5DEwGZzjXQ_3_0"></a><a id="Tc_bwJyWCZRFEWJmqQ0CZurag_4_0"></a><a id="Tc_q9Xso4ywOU6-eNex343V1w_4_2"></a><a id="Tc_V0zrSeQj1kiVTWeK_rxhRA_4_5"></a><ix:continuation id="Tb_g9l5i5tC70Kddk7jTuo8Ag_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">deterioration in the creditworthiness of the issuers of the securities held by us. Based on our review of these securities, including the assessment of the duration and severity of the unrealized losses, we have </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-5" format="ixt-sec:numwordsen" name="rigl:InvestmentsCreditLossExpense" scale="6" id="Narr_6-uc10Qy_EewR3YC0QOYwQ"><ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-5" format="ixt-sec:numwordsen" name="rigl:InvestmentsCreditLossExpense" scale="6" id="Narr_5GK2zaDoVkmK4AQ7WrmFNA">no</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;">t recognized any credit losses on these securities as of June 30, 2024 and December 31, 2023.</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="Tb_sbo9isx2D0OBU3xo5USPXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_vnypFXwYBUC67hu65AieMA_2_3">9,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_WieO4erLOEed0Gj-b0i35Q_2_6">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_1YbkZCet7UW93J9W2Bwxpg_3_3">13,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_E6b_dV7TPUGhO7UbNDKqPg_3_6">7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="Tc_n047Sv6bvkeZMYghNLtrsA_4_3">22,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="Tc_zRKkA63DYEuofmu5B3GDwg_4_6">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_e1f831c8_b4b3_47e8_b27d_a32df83534b6"></a><a id="Tc_YkSIDhZ4KU6kwjYC9r3JFg_1_2"></a><a id="Tc_5WQ4JDKAxE2rOmXHQ7UHKg_2_2"></a><a id="Tc_zKVdZfujnEOzUtQoiT-5SQ_2_5"></a><a id="Tc_u6sM6t7qf025L01oAZLe2A_2_8"></a><a id="Tc_Z_Ybck0P80uxjgJ9S1oitA_2_11"></a><a id="Tc_Z-QWyPDlVE6zkx_7yP_WLg_3_0"></a><a id="Tc_g60K3EtnpEuCZcxn8SWiwQ_3_2"></a><a id="Tc_8Muc9YV5j0GsaN-n1F4CXA_3_5"></a><a id="Tc_gQP7_DugJkCVtCW7lbp_zA_3_6"></a><a id="Tc_AtThCFZAe0et4BZkF5gulw_3_8"></a><a id="Tc_RFF_pzLAH0maPuchNoT_FA_3_9"></a><a id="Tc_TahUKglwRUaAG1NBCnMNKA_3_11"></a><a id="Tc_HNhGAopjRkWjtctnOZGEww_4_0"></a><a id="Tc_-h9AuHZXgUKhpcYexaMpTQ_4_3"></a><a id="Tc_hnKySD6Ssk2OBxrkZDVC8Q_4_9"></a><a id="Tc_b_STACVOp0qiSAmcWbbVzQ_5_0"></a><a id="Tc_v3aSxgoSLk6rugQRB48M8A_5_3"></a><a id="Tc_0QN9svO3PUqc-G01FTAobw_5_9"></a><a id="Tc_MnPv3Fx6iU68YpHgKM34vA_6_0"></a><a id="Tc_mao8c-iXIU6PstM-1FgHkw_6_3"></a><a id="Tc_mHi9kd92ZEaPf9QyQRKc2A_6_9"></a><a id="Tc_36J3RKvWqkmmnmtJ-ZxFTg_7_0"></a><a id="Tc_XEDyy5_XnkCWANnz-fR-Gg_7_2"></a><a id="Tc_Yikdf_RXPkuigd15Y33glQ_7_5"></a><a id="Tc_CJJh9hh920OLsGWT9BKZEQ_7_8"></a><a id="Tc_8CNKK83w1U-D3GdvgGt6bw_7_9"></a><a id="Tc_8eiOijqasUGqzdK6uXliZA_7_11"></a><a id="_068722dd_d51c_4e3a_9cd4_8b0c2bc0d80a"></a><a id="Tc_eArPOcj68EiO1HJijBlr3A_1_2"></a><a id="Tc_botHWWuQLUalH4tpB8Lrhw_2_2"></a><a id="Tc_gPtZCFMWu0ODJsoiBTmTQw_2_5"></a><a id="Tc_JwNyFVcc_UaVhGzgcbIytg_2_8"></a><a id="Tc_DPOqKU06FUm6TuNgcxxuxA_2_11"></a><a id="Tc_YYKALHgPBku1AoKLLyAJJg_3_0"></a><a id="Tc_3HVWhSYxr0Gt7VZw7Z6vzQ_3_2"></a><a id="Tc_j6l4WY-fC0GsJCkSP3f7UQ_3_5"></a><a id="Tc_N2Q3GURGMEukQIAqpj5LvA_3_6"></a><a id="Tc_chrmnlyJjEaCV2WEGWWI2g_3_8"></a><a id="Tc_JL90YbKQQUG9MGDkFmYqdQ_3_9"></a><a id="Tc_EN9B4UzQskiocSgxyCmJLw_3_11"></a><a id="Tc_GMCq2nGaIUin159nVCqoZQ_4_0"></a><a id="Tc_KHZp2jr5HEeFjqmehIkThw_4_3"></a><a id="Tc_oQusYienNUe5tcmmxF17Jg_4_9"></a><a id="Tc_YSb1E2XwYEWUoWsbXzdq0A_5_0"></a><a id="Tc_ZT0YDRKb5EWpTTzbIuXq6g_5_3"></a><a id="Tc_xovh9JvL4UCdtXZDBtJn5A_5_9"></a><a id="Tc_Zv99LB3djEWkdtI5cyBHgg_6_0"></a><a id="Tc_v5a9_SWxB0a2WRf6s9Oo0g_6_3"></a><a id="Tc_yTiMDttm5k2PEyh7zxgnWg_6_9"></a><a id="Tc_eprACDbdNUm8JScRYJ4YIQ_7_0"></a><a id="Tc_ZJ3_p1uwS0SnZF_87RWD5g_7_2"></a><a id="Tc_io_9qyVdk0GdM7Wx--RZDQ_7_5"></a><a id="Tc_Qni91cZIH0SR5Medp-QMeQ_7_8"></a><a id="Tc_l_L-gMkaP0KUvajzBLxzHw_7_9"></a><a id="Tc_T8zqvWyRsk-TCOs9A8nvHA_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_rpfHin8oI06RiHMmwDqKcg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Fair Value</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_6Cc7tnwpt0W12k76uAeu7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_2ZqFwePmoEW5EP2yf9fpUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_4Aw_t8r5o0-32XG6y5AlXw_3_3">13,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_N7Gpz1AcU0-D3M0pAjqqNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_ITBXarSy-kmowiqHX2Ttqw_3_12">13,805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_uZH0PMnJBEKSBgu31l8iYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_jeCGY9FKeE2ae3kCoI2p3g_4_6">4,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_3NxUn5GogkWWrIfF-O4kPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_gtxqtTZT_k6h57_fu0NYnw_4_12">4,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_VuYcYAoXfUqSaPoOv41VZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_dq3WZ_iNZUmWSSgNzWHOSQ_5_6">10,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SLvI2lqsxkmQG2QFPN79Dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_6huAMHWOe0KUkqKrC6Otlw_5_12">10,444</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_moMylpkG0EKqa1L_9E6qSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_cv5qxwhSoUiC189uxSGihw_6_6">13,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_bumoYf9sREKWHIIx5_Gz1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_0A6G0r8ur02cJzg-nLUd4A_6_12">13,764</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6YzcAGW4m0ayhMSEkUdByA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_k8UMt1tj3Eiir0pRCkRFyQ_7_3">13,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kR5PxZmiZEehJumbiChaaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc__QVKmJKIokW3WNKeRu5Rpw_7_6">29,171</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BRYGoVu9R0e32mZYGbN33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_nmNaRBcWhUyzxzBiNpybvQ_7_12">42,976</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_Ke66dznHTEab1HHdbbjp0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_1cOqhgty_kuyhdBm0vlPsw_3_3">9,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_U7guuJSV4U6vqE5RJhmf9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_XVJOx-BeREWrNIazplvJ9g_3_12">9,685</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_LrJM0R9Q4EqCjEm9Lk2Smw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_FzBQ-2akQkGkutDTK0YJkw_4_6">12,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_tfFBS5hWFE6pF6skJ5FQLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_6NRYnEwc-UG4j5Y7kvSuhg_4_12">12,594</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SCWsGh-x_EiHDPQEk17sgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_psBTLQr63Uu6WQnxyZhMvA_5_6">11,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_78B3hepUPkmvOj-N8djJNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_mX2kwPkFkku2d2Nz3bHV4Q_5_12">11,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_TowDf4q6oE-409UeTRDU9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_WkLWtkgeX0yjQTKzZ0Gt3A_6_6">15,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_60P2wgsrD0awxLyja-p9nA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_5KRP0OWpBUevs4cchHH0Bg_6_12">15,174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5l5sjSngpkO-FXuFuyQBGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_nmAdIr0sUEykfxCJdT_IAg_7_3">9,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zmcdanbJ0SDNc-vDFtkkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_jVt0j_tc9EmVou-HP2RNGA_7_6">39,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bJS_m4Vp_0uGViKVve720w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_aF_S5UfCCkKGD3CzpfZOqw_7_12">48,686</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_88096228_0147_447f_896f_cc925704b56a"></a><a id="Tc_rBZRKnz_9EqvvAH4Y2-UYQ_1_2"></a><a id="Tc_zOrZTyzmrU-srLzQwrStUA_2_2"></a><a id="Tc_Y08MdTOBokuBCcBEpwZq7Q_2_5"></a><a id="Tc_dRMyvxRWEUW9wI-6q1sKEw_3_0"></a><a id="Tc_xEBCxAbJ702luE1SJTaWaA_3_2"></a><a id="Tc_qCHS0EHwPEirarofXllDVg_3_5"></a><a id="Tc_BiThHAF0p0WJI4oD2tNe3A_4_0"></a><a id="Tc_PVhKxAoHjEuduyy33U-XJg_5_0"></a><a id="Tc_HBBk45ghfUGBRyzgbwgL9g_5_2"></a><a id="Tc_VdwZYvHFZ0msTsYIXISGrA_5_5"></a><a id="Tc_jZ3zezm4o0i3EQ6J4yf7FA_7_0"></a><a id="Tc_fQ6fKozeqEaLj7c-B8OaKQ_8_0"></a><a id="Tc_o83i5WOo1kKBv93s12G8fA_8_2"></a><a id="Tc_TSk1sIKrP0OPaVSyVBeRsA_8_3"></a><a id="Tc_fFUnwlBcrkWw3VNvxcQjRQ_8_5"></a><a id="Tc_1-rG7IZZzkm7ZRH_ZvU89A_9_0"></a><a id="Tc_1x21juZiYUq6U3kZ2eS_FA_10_2"></a><a id="Tc_S13o7O0yWUu6PegwXhyIZA_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_Y051GmuqpUqt3LpguSY1pA" continuedAt="Tb_Y051GmuqpUqt3LpguSY1pA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span><b style="font-weight:bold;">Debt</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Tb_paaG8otW_ke8roT1-Opwqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">The following table summarizes loans payable, net (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_Ya-hVISjGE6h9pV97LgwHw_3_3">60,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_y18AJy-b20KSkSdgsBjrIw_3_6">60,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="Tc_TTCloBQNAEmV6Ovp-_1xBw_4_3">308</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="Tc_0epb5ulc6kiwZS_5oa6gCw_4_6">398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal outstanding, net of unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="rigl:DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" scale="3" id="Tc_Wd0UWaGGdEGmFFoF5c3qQg_5_3">59,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="rigl:DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" scale="3" id="Tc_S9C1DZev8k62_kKHEJEUjA_5_6">59,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans payable, net, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="Tc_NjUsFkMpvEuQLJkDpUiXlw_8_6">7,229</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term portion of loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_sCZdYxACMk2-C8I1TEVsaA_9_3">59,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_knBL9UTxlUilGu7a4K8U6g_9_6">52,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayable" scale="3" id="Tc_2FhTPYJtVk2xx9Wmd-y7oQ_10_3">59,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayable" scale="3" id="Tc_ZTJEXWJ86EG5Y1luU6mNIw_10_6">59,602</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The outstanding loans payable as of the periods presented was related to our Credit and Security Agreement (Credit Agreement) with MidCap Financial Trust (MidCap) entered into on September 27, 2019 (Closing Date) and amended on March 29, 2021 (First Amendment), February 11, 2022 (Second Amendment), July 27, 2022 (Third Amendment), and on April 11, 2024 (Fourth Amendment).</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ff4b3004_4239_4fed_a0c5_6c2acc4f0dac"></a><a id="Tc_qoTjz8mNEEuL6BO4qVeuGw_1_0"></a><a id="Tc_HbbjodSu_EqKhhCZBiIdIg_1_2"></a><a id="Tc_SFWudEcccESCIKMCwPaJsg_1_3"></a><a id="Tc_yKLHcvYdKkSI8PtRnKpKPA_2_0"></a><a id="Tc_dU1m-o-kF0GRgsamVdyLhg_3_0"></a><a id="Tc_hR9YMwLycUabG9sdTefjWQ_4_0"></a><a id="Tc_SaMD08faOkKATGKX23TdQQ_5_0"></a><a id="Tc_7JJs8BU1cU6EIdjTyAM9ZA_5_2"></a><ix:continuation id="Tb_Y051GmuqpUqt3LpguSY1pA_cont1" continuedAt="Tb_Y051GmuqpUqt3LpguSY1pA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Credit Agreement provides for a $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_XzmU_W-m3kOqduEhby64ug">60.0</ix:nonFraction>&#160;million term loan credit facility. At the Closing Date, $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_hDix6efDJEqhQT4ixJzEQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_kY1Q0dNzxE2YBbL0zotk7w">10.0</ix:nonFraction> million was funded (Tranche 1), in May 2020, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_eYkavSct0kShqm_SrY7OiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_AbyGeNbov0mcidHKX6xOow">10.0</ix:nonFraction> million was funded (Tranche 2), at the Second Amendment, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_W7cIc5yiHEas_ePcVbSr0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_GAibrG3sx0mtUY4_kFmHYw">10.0</ix:nonFraction> million was funded (Tranche 3), at the Third Amendment, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_Pa4eaLZ_bkuPdtNWU8Iy2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_WOQzPSuopUO_HkvXWKlwvQ">10.0</ix:nonFraction> million was funded (Tranche 4), and in March 2023, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_DJRbQsRz1EqcG6iJ-_88Iw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_hWmUOsemcEilZW1bswHQyQ">20.0</ix:nonFraction> million was funded (Tranche 5). As of June 30, 2024, the outstanding principal balance of the loan was $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="6" id="Narr_jQTVKbdiWE-OdKSySifHrQ">60.0</ix:nonFraction> million, and <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="Narr_h67u9mUyxkeHETN6d6hx8w">no</ix:nonFraction> remaining funds are available for draw under the term loan credit facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The First Amendment to the Credit Agreement extended the period through which Tranche 3 was available to us. The Second Amendment to the Credit Agreement, among other things, amended the applicable funding conditions, applicable commitments and certain other terms relating to available credit facilities (Tranches 3 and 4), added additional term loan credit facility (Tranche 5), and revised certain terms related to the financial covenants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Following the Third Amendment but prior to the Fourth Amendment to the Credit Agreement in April 2024 as discussed below, the term loans would mature on September 1, 2026, and the interest-only period was through October 1, 2024. The term loans bore interest equal to </span><span style="font-size:10pt;background:#ffffff;">the sum of one-month </span><span style="font-size:10pt;">Secured Overnight Financing Rate (SOFR)</span><span style="font-size:10pt;background:#ffffff;">, plus an adjustment of </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6ou1l9PZikOK2y-Wb2RGFQ" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate" id="Narr_0iAGwJxixky90Ukiui48DQ"><span style="font-size:10pt;background:#ffffff;">0.11448%</span></ix:nonNumeric><span style="font-size:10pt;background:#ffffff;">, subject to </span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_W4Ti807K5EGWOf1btN6_6g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_PsfLMf6hd0OSOWHu27-vqg">1.50</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;"> applicable floor, plus applicable margin of&#160;</span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6ou1l9PZikOK2y-Wb2RGFQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_Dg2HAyARh0KL171MyUFsPQ">5.65</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;">, and a</span><span style="font-size:10pt;"> final payment fee of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_EBFPUJEfP0-IMk-f5UWHvg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="Narr_qcFOv9XO0UuGxAHUBrCYyg">2.5</ix:nonFraction>%</span><span style="font-size:10pt;"> of principal due at maturity date. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;background:#ffffff;">Following the Fourth Amendment to the Credit Agreement in April 2024, </span><span style="font-size:10pt;">the term loans mature on September 1, 2027, and the interest-only period is through October 1, 2025. The term loans bear interest equal to the sum of one-month </span><span style="font-size:10pt;">SOFR</span><span style="font-size:10pt;background:#ffffff;"> plus an adjustment of </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_xDqwa338u06zbkGihig_Sw" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate" id="Narr_qrbhsstCiUut6S01JfXARA"><span style="font-size:10pt;background:#ffffff;">0.11448%</span></ix:nonNumeric><span style="font-size:10pt;background:#ffffff;">, subject to a </span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_w34DeP8NUkiGwpi5OQ3ysw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_uMpUWWSXF0-pXanT30-XKg">4.00</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;"> applicable floor, plus applicable margin of&#160;</span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_xDqwa338u06zbkGihig_Sw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_jfGFOdwoGEqIqx9ruIzzlw">6.50</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;">. A final payment fee of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_Oloq2T-qkUSk0moW_WdUNg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="Narr_i4G7ZE9PykuXnXucIhf1GQ">4.25</ix:nonFraction>%</span><span style="font-size:10pt;"> of principal is due at maturity date. The amendment was accounted for as debt modification in accordance with the standards. The unamortized debt issuance costs are continuously being amortized as interest expense through maturity using the effective interest rate method.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We </span>may make voluntary prepayments, in whole or in part, subject to certain prepayment premiums and additional interest payments. The Credit Agreement also contains certain provisions, such as event of default and change in control provisions, which, if triggered, would require us to make mandatory prepayments on the term loan, which are subject to certain prepayment premiums and additional interest payments. The obligations under the amended Credit Agreement are secured by a perfected security interest in all of our assets including our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Interest expense, including amortization of the debt discount and accretion of the final fees related to the Credit Agreement for the three months ended June 30, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_DMeCAgkRW0C78bbvGK_1ag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_CQdwNPifjEe5olVa9XvulQ">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_8_QPIix-oEu90IoZH6mxdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_vzKU1zj5IUO-2vXdkTmVLA">1.9</ix:nonFraction> million, respectively, and for the six months ended June 30, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lWODGT6XzEuM8DkFcLQ2LQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_qaR6LfUG8EGTAja_nDwbGw">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_RqBa2FWeTk6bS0CYoSM8OA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_bJd9WxENGUeY6d6PRNkg2A">3.1</ix:nonFraction> million, respectively. Accrued interest of $<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lWODGT6XzEuM8DkFcLQ2LQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" scale="6" id="Narr_cKmGaaiiA06eizGOQ24MAg">1.8</ix:nonFraction> million was included within other accrued liabilities in the condensed balance sheet as of June 30, 2024. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="Tb_5F0n5oBguk-8QCRtbsIpmw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_Fb_eJsG-Ok-wqjNFyXo3Uw_2_3">7,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_gKU2pDnMdkCNmET4IPu5_Q_3_3">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_8LzeWMBrDUC-bCMWsl8UNQ_4_3">22,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount (Tranches 1, 2, 3 and 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_FXtayv4nKk6klUnOZMUKCA_5_3">60,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amended Credit Agreement contains certain covenants which, among others, require us to deliver financial reports at designated times of the year and maintain minimum unrestricted cash and trailing net revenues. As of June 30, 2024, we were not in violation of any covenants.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Y051GmuqpUqt3LpguSY1pA_cont2"></ix:continuation><a id="_a0e07898_4ae6_4028_a635_da1caef30a6f"></a><a id="Tc_bRkxbm0Osk-oan7P6l-yGA_1_2"></a><a id="Tc_5_m-he8rrUmgw69WtaW8gw_1_8"></a><a id="Tc_LSd1hPnQKkaga05adVyBlA_2_2"></a><a id="Tc_XuGPTLUcMUmaHxezWUQEog_2_5"></a><a id="Tc_PJJe_gP1-0G3w8PnzXTNsQ_2_8"></a><a id="Tc_DNP2vZzwlE2iD3k37kFLPQ_2_11"></a><a id="Tc_eRNPJ3Ura0m0XO3SaC5gew_3_0"></a><a id="Tc_9mAhG2F0rECSbtmwoJSU_A_3_2"></a><a id="Tc_H4Sz3IFcOkyS9aBj79uo6Q_3_5"></a><a id="Tc_aEcp3FsvdEWJ6r8f-jQbqg_3_8"></a><a id="Tc_TJFrkaqm60W3dmP6_KTmEQ_4_0"></a><a id="Tc_AC1FLuRR9kSwKKzvef331g_5_0"></a><a id="Tc_ZMPX8dt6GUycjk7DIG8xFQ_5_2"></a><a id="Tc_eZqljtpyEUKzCpU0BmvRkg_5_5"></a><a id="Tc_Ke383WeNokaHo7EIzPGZZA_5_8"></a><a id="Tc_ylLYwBRVCUO90qR4I6mKnQ_5_11"></a><a id="_afba53c4_5509_4a91_943c_d8ed1b065c77"></a><a id="Tc_aCqtrFBtJE2jS7tBykkYNA_1_2"></a><a id="Tc_vge0p-vQvEGJHF0Tv6cHhA_1_8"></a><a id="Tc_21OJu0VCI02ZN994EMaKMw_2_2"></a><a id="Tc_-TRvJcsGmkCvu0LFndcrFQ_2_5"></a><a id="Tc_ZLQabK_iS0upnCZnDPe9cQ_2_8"></a><a id="Tc_Iu4wb5wNS06cWPP1G3aM9g_2_11"></a><a id="Tc_MNJrpQkHw0KwBT3PrGLhWg_3_0"></a><a id="Tc_hwuU2QoXdUCVWsC1hJgu2w_3_2"></a><a id="Tc_ZpQog9-Gl02qNjxn0KuG5A_3_5"></a><a id="Tc_w-HLZLS-Pk6PPdheBYX-4Q_3_8"></a><a id="_e447c6e4_4408_4e0f_9d60_ce142055cd14"></a><a id="Tc_2FPShEval0qZ82CM5OWa1w_1_2"></a><a id="Tc_TlFlbeGaKk2DLLGnuMcyeA_1_8"></a><a id="Tc_ShW3mRdrs02K0mDha04jSw_2_2"></a><a id="Tc_EPUQOm0nnkaYNh97xmOvKA_2_5"></a><a id="Tc_YPayJMT3nk-vAtgsUE_TXw_2_8"></a><a id="Tc_Q2k-owzdpUy_atnoxMcC2w_2_11"></a><a id="Tc_OxeySXgaGkiiQqdPoH3UMg_3_0"></a><a id="Tc_wCBUrSDcmUKlnQR5wa193w_3_2"></a><a id="Tc_CV0onxqefEeWuQQaCSRDnw_3_3"></a><a id="Tc_6kQhZRR1W0yCIlw3dsQ9eQ_3_5"></a><a id="Tc_Sr3KtkUjw0myXr9r9QrWMQ_3_6"></a><a id="Tc_2Zk0tIGCDkKzJd86667n4Q_3_8"></a><a id="Tc_w4D9VIh7-0WZ0dnAxicTaw_3_9"></a><a id="Tc_a-kmn0F12UmM1AXeyaBj2Q_4_0"></a><a id="Tc_5GHBosE0rkCyUQ6e7FtCSA_4_3"></a><a id="Tc_fIwQ-HmKFUef5Q6MAtr56A_4_6"></a><a id="Tc_qe4_TkSsbECKq7bJ8n0VeA_4_9"></a><a id="Tc_CrYCmDFqwUaBEZWeNPWtwQ_5_0"></a><a id="Tc_9Dp_BHVVAU-Z6WdcPg3tPA_5_3"></a><a id="Tc_e895GTi1bEKxkJAYPWVz8w_5_6"></a><a id="Tc_8uJNCg8i5kimxQMrnoNcoA_5_9"></a><a id="Tc_yELQNoZZX0G2SiNxdv_rmQ_6_0"></a><a id="Tc_pevN2F4SE0Kpx7dptQ6GKA_6_2"></a><a id="Tc_eyfeX3WsdUq16lUvGpVHvQ_6_5"></a><a id="Tc_VB7aQ45d5kqHMCkgc0xLGg_6_8"></a><a id="Tc_KjgGBcUVsE6U5lM3Akg9ww_6_11"></a><a id="_cbbcf87e_12aa_463d_b9fa_1cfdf5a2bf5e"></a><a id="Tc_8hoWI7pzlUW6pr679ee20A_1_0"></a><a id="Tc_nXm4Mxo4K02ov8OK2PdWHw_1_2"></a><a id="Tc_GBexuw2qgEyCXDPasW5ZVg_2_0"></a><a id="Tc_JfSckGXdG0yephK5pKalhw_3_0"></a><a id="Tc_tFa2a98Dj0y-c2j_EKpqhg_3_2"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="rigl:LeaseDisclosureTextBlock" id="Tb_N0ZZK3-EzUOfNq4UOaKTpw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;background:#ffffff;">We have a sublease agreement with Atara Biotherapeutics, Inc. (Atara) entered in October 2022 to sublease an office space located in South San Francisco, California. Subject to the terms of the sublease agreement, the lease term commenced in November 2022 and shall expire in May 2025. This leased facility is currently held as our new Headquarters following the expiration of our previously leased facility in January 2023. </span><span style="font-size:10pt;">The weighted average remaining term of our leases as of June 30, 2024 was </span><span style="-sec-ix-hidden:Hidden_xfW9usukwk2f_jXEjoY-Ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.92</span></span><span style="font-size:10pt;"> years. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We previously leased our prior headquarter space located in South San Francisco, California with Healthpeak Properties, Inc. (formerly known as HCP BTC, LLC), and had a sublease agreement with an unrelated third-party to sublet a portion of the leased facility. Both leases expired in January 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The components of our operating lease expense were as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_6_qSUlxmSUqzxpGPMbjKfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Q8vqJs6r_EGs_Ih0yigS2Q_3_3">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_jjREkWQDWUKkiqfkddLocQ_3_6">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_fF97NNVenUa_kht9YwEDbA_3_9">332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_oy9HGxycVkK4QH_g2SBuCA_3_12">778</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable operating lease expense (net credit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_vTfzKIGAYkW8012U_iqBnw_4_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableLeaseExpenseNetCredit" sign="-" scale="3" id="Tc_12ArSiH3jEKgwdRze4VqVg_4_6">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_QWRWUEzjG0y79Uk8Maxk0Q_4_9">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_t6E8KUFbVUe8mkhyp_b3sQ_4_12">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_BKSzFawNh0avb95babhrSQ_5_3">194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_sTTmKm75DkeZpcwC40b79g_5_6">124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_r16oca1jmUCLuQALwWBTZQ_5_9">388</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_6bpCKAelykmgTEqfyjarjA_5_12">808</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Supplemental information related to our operating lease were as follow (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock" id="Tb_vEreIKCRy0CvVnpjO_MsIg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments included in the measurement of operating lease liabilities</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_0IHv00lX5EOovdtqduKsTw_3_3">184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_ZN7qey1nHkiltvaREqQ1VQ_3_6">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_THpsoC5-FkKDjWsSzJP_Hw_3_9">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_p44CynB18UmOs_HyB0VWsw_3_12">1,174</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Supplemental information related to our operating sublease was as follow (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="Tb_uYbo_N2fD0uXfeZgJ3Mjlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="rigl:FixedSubleaseExpense" scale="3" id="Tc__qp-BV9kA0yqTDKx_i4g4g_3_12">365</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="rigl:VariableSubleaseExpense" scale="3" id="Tc_KnZ54_DsHE2hKWePy4lStw_4_12">77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_a6XBsAVXpEGLsVcXtjfIcA_5_12">442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__uvDi--VAUGqtC3eWeIntA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_RyRJdE2X_E-Mg-mp9DscQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lQtRnSPQoE-Il8zeJ8WGew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_mnAsvI_5pkqF9r4khAkUlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future lease payments as of June 30, 2024 (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_Oh3c96_lAkqgJPZYe1fNmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:56.56%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_9UgbUWy0mEeqNCHK7oAPeg_1_3">371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_2ziV3OntX0S1k9AjrKt3eg_2_3">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum payments required</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ" contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_jbL8eIzMbUaji_DDTV1Sew_3_3">672</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6e240971_1044_4412_9c25_53e9c722649e"></a><a id="Item2_ManagementsDiscussionAndAna_120616"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.</b></span><b style="font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">This discussion and analysis should be read in conjunction with our financial statements and the accompanying notes included in this report and the audited financial statements and accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024. Our financial results for the three and six months ended June 30, 2024 are not necessarily indicative of results that may occur in future interim periods or for the full fiscal year.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form&#160;10-Q contains statements indicating expectations about future performance and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act) and Section&#160;21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. </i><i style="font-style:italic;">We usually use words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;might,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;intend,&#8221; or the negative of these terms or similar expressions to identify these forward-looking statements.</i><i style="font-style:italic;"> These statements appear throughout this Quarterly Report on Form 10-Q and </i><i style="font-style:italic;">are statements regarding our current expectations, beliefs or intent, primarily with respect to our operations and related industry developments. Examples of these statements include, but are not limited to: </i><i style="font-style:italic;">our </i><i style="font-style:italic;">business and scientific strategies;</i><i style="font-style:italic;"> risks and uncertainties associated with the commercialization, distribution and marketing of our products in the US and outside the US; risks that the FDA, EMA, the Medicines and Health Products Regulatory Agency (MHRA) or other regulatory authorities may make adverse decisions regarding our products; </i><i style="font-style:italic;">the progress of our and our collaborators&#8217; product development programs, including clinical testing, and the timing of results thereof; our corporate collaborations and revenues that may be received from our collaborations and the timing of those potential payments; our expectations with respect to timing of recognizing product sales; our expectations with respect to regulatory submissions and approvals;&#160;our drug discovery technologies; our research and development expense; protection of our intellectual property and our intention to vigorously enforce our intellectual property rights; the availability and sufficiency of our cash and capital resources and the need for additional capital; our ability to successfully identify and acquire or in-license products or companies, and to successfully transition assets to operate acquisitions; our operations and legal risks; the effectiveness of our cybersecurity risk management process; and our acquisition of certain assets comprising rights to GAVRETO (pralsetinib) in the US. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including as a result of the risks and uncertainties discussed under the heading &#8220;Risk Factors&#8221; in Item 1A of Part&#160;II of this Quarterly Report on Form&#160;10-Q. Any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as required by applicable law. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><a id="_Hlk172619727"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">TAVALISSE (fostamatinib disodium hexahydrate) is our first product approved by the FDA. TAVALISSE is the only approved oral SYK inhibitor for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the UK (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">REZLIDHIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup><span style="color:#222222;background:#ffffff;">(olutasidenib) is o</span>ur second FDA-approved product. REZLIDHIA capsules are indicated <span style="color:#222222;background:#ffffff;">for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. W</span>e in-licensed <span style="color:#222222;background:#ffffff;">REZLIDHIA</span> from Forma with exclusive, worldwide rights for its development, manufacturing and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">GAVRETO (pralsetinib) is our third FDA-approved product which we began commercializing on June 27, 2024. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild-type RET and oncogenic RET fusions. GAVRETO is approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive NSCLC as detected by an FDA-approved test. GAVRETO is also approved under accelerated approval based on overall response rate and duration response rate, for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). We acquired the rights to research, develop, manufacture and commercialize GAVRETO in the US from Blueprint pursuant to an Asset Purchase Agreement entered in February 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We continue to advance the development of R289, our IRAK 1/4 inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk <span style="color:#222222;background:#ffffff;">MDS</span> who are relapsed, refractory or resistant to prior therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We have strategic development collaborations with MDACC to expand our evaluation of REZLIDHIA in AML and other hematologic cancers with IDH1 mutations, and with CONNECT to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in combination with temozolomide in patients with HGG harboring an IDH1 mutation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have a RIPK1 inhibitor program in clinical development with our partner Lilly. We also have product candidates in clinical development with partners BerGenBio and Daiichi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We filed with the Secretary of State of the State of Delaware a certificate of amendment to our Amended and Restated Certificate of Incorporation, to effect a 1-for-10 reverse stock split, effective June 27, 2024. As a result of the reverse stock split, every ten issued and outstanding shares of our common stock were automatically combined into one issued and outstanding share of common stock. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from common stock to additional paid-in capital on the condensed balance sheet and statement of changes in stockholders&#8217; deficit. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock were entitled to receive the cash value <span style="background:#ffffff;">equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the common stock as reported by Nasdaq on the last trading day prior to the effective date of the split. </span>As a result of the reverse stock split, proportionate adjustments were made to the number of shares underlying (and as applicable, the exercise or conversion prices of) our outstanding equity awards and to the number of shares of common stock issuable under our equity incentive plans. The reverse stock split did not change the par value of our common stock, which remains $0.001, or the authorized number of shares of our common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Updates </b></p><a id="_Hlk77251980"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">TAVALISSE IN ITP</span></p><a id="_Hlk94800903"></a><a id="_Hlk128487678"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">For the six months ended June 30, 2024, net product sales of TAVALISSE were $47.5 million, increased by $3.8 million or 9% compared to $43.6 million net product sales in the same period in 2023. The increase was primarily due to increased quantities sold, as well as increased price per bottle. This increase was partially offset by the increase in revenue reserves driven by higher government and private payor rebates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="color:#222222;font-style:italic;font-weight:bold;background:#ffffff;">REZLIDHIA</span><span style="font-style:italic;font-weight:bold;"> in R/R AML with mIDHI</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#222222;background:#ffffff;">For the six months ended June 30, 2024, net product sales of REZLIDHIA were $10.0 million, increased by $6.0 million or 150% compared to $4.0 million net product sales in the same period in 2023. The increase was primarily due to increased quantities sold </span><span style="background:#ffffff;">primarily driven by increased number of patients under therapy, partially offset by the increase in revenue reserves primarily due to higher government rebates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">GAVRETO in metastatic RET fusion-positive NSCLC and advanced thyroid cancers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We began our commercialization and started recognizing revenue from product sales of GAVRETO in June 2024. We recognized approximately $1.9 million of net product sales for the sale of GAVRETO to our distributors at the end of June 2024. We believe GAVRETO is highly synergistic with our current product portfolio, and we expect to continue to leverage our existing commercial infrastructure to ensure current and newly prescribed GAVRETO patients have continued access to this important treatment option. We distribute and market GAVRETO for approved indications in RET fusion-positive NSCLC and advanced thyroid cancers. We acquired GAVRETO from Blueprint pursuant to an Asset Purchase Agreement entered into on February 22, 2024. Pursuant to the Asset Purchase Agreement, we purchased certain assets comprising the right to research, develop, manufacture and commercialize GAVRETO in the US from Blueprint. Under the terms of the agreement, we agreed to pay Blueprint a purchase price of $15.0 million, of which, $10.0 million was paid in July 2024 following our first commercial sale of GAVRETO at the end of June 2024, and an additional $5.0 million is payable on the first anniversary of the closing date of the agreement, subject to certain conditions. Blueprint is also eligible to receive up to $97.5 million in future commercial milestone payments and up to $5.0 million in future regulatory milestone payments, in addition to tiered royalties ranging from 10% to 30%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Simultaneously and in conjunction with entering into the Asset Purchase Agreement, we also entered into certain supporting agreements, including a customary transition agreement, pursuant to which, during the transition period, Blueprint will transition regulatory and distribution responsibility for GAVRETO to us. We also agreed to purchase certain drug product inventories from Blueprint under a Material Transfer Agreement, and received such inventories amounting to approximately $6.5 million during the six months ended June 30, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk164947973"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;font-style:italic;font-weight:bold;">R289, an Oral IRAK1/4 Inhibitor for LR-MDS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk159416046"></a><a id="_Hlk147304362"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We advanced the development of our IRAK 1/4 inhibitor program, following further evaluation of single and multiple ascending doses of R289 in healthy subjects. The Phase 1b open-label, multicenter trial evaluates the safety, tolerability and preliminary efficacy of R289 in patients with R/R lower-risk MDS. This <span style="background:#ffffff;">Phase 1b trial is expected to enroll approximately 40 patients (up to 30 participants in the dose escalation phase, and up to 10 participants in the dose expansion phase). The primary objective of the trial is safety, with secondary and exploratory objectives to assess preliminary efficacy and characterize the pharmacokinetic and pharmacodynamic profile of R289. The safety </span><span style="color:#222222;background:#ffffff;">and efficacy data from this Phase 1b trial is intended to inform the recommended dose of R289 for further clinical evaluation in lower-risk MDS. To date, enrollment in the fourth dose level (250 mg twice daily) of the trial is underway. </span><span style="background:#ffffff;">Preliminary data are expected by the end of 2024.</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk158982281"></a><a id="_Hlk164943348"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#222222;font-style:italic;font-weight:bold;background:#ffffff;">REZLIDHIA in AML, Other Hematologic Cancers and HGG</span></p><a id="_Hlk158982248"></a><a id="_Hlk159849713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In December 2023, we entered into a Strategic Collaboration Agreement with MDACC, a comprehensive cancer research, treatment, and prevention center. The collaboration will expand our evaluation of REZLIDHIA in AML and other hematologic cancers with IDH1 mutations. Under the Strategic Collaboration Agreement, we will jointly lead the clinical development efforts with MDACC to evaluate the potential of olutasidenib to treat newly diagnosed and R/R patients with AML, higher-risk MDS, and advanced myeloproliferative neoplasms, in combination with other agents. The collaboration will also support the evaluation of olutasidenib as monotherapy in patients with IDH1 mutated clonal cytopenia of undermined significance and lower-risk MDS, as well as maintenance therapy following hematopoietic stem cell transplant. Under the Strategic Collaboration Agreement, we will provide MDACC the study materials and $15.0 million in time-based milestone payments as compensation for services to be provided for the studies, over the five-year collaboration term, unless terminated earlier as provided for in the agreement. Through June 30, 2024, we provided $2.0 million funding to MDACC. In early August 2024, MDACC, with our support, opened enrollment for a Phase 1b/2 trial of <span style="color:#222222;">decitabine and venetoclax in combination with olutasidenib in patients with IDH1-mutated AML. This is the first trial in our multi-year strategic development collaboration with MDACC. The Phase 1b part of the trial seeks to determine the safety and tolerability and recommended Phase 2 dose of decitabine and venetoclax in combination with olutasidenib. The primary objective of the Phase 2 part of the trial is to determine the complete remission rate in both newly diagnosed and R/R patients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In January 2024, we announced our collaboration with Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in combination with temozolomide in patients with HGG harboring an IDH1 mutation. Under the collaboration, CONNECT will include olutasidenib in CONNECT&#8217;s TarGet-D, a molecularly guided Phase 2 umbrella clinical trial for HGG. In our sponsored arm, adolescents and young adult patients (&lt;39 years old) with newly-diagnosed IDH1-mutation positive HGG will receive maintenance therapy with of olutasidenib in combination with temozolomide for the first year after radiotherapy, followed by olutasidenib monotherapy for the second year. Under the collaboration, we will provide CONNECT with a funding up to $3.0 million and study material over the four-year collaboration.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Global Strategic Partnership with Lilly</span></p><a id="_Hlk101965566"></a><a id="_Hlk132270242"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Lilly is continuing to advance ocadusertib (previously R552), an investigational, potent and selective RIPK1 inhibitor. Lilly has initiated the Phase 2a trial studying ocadusertib in adult patients with moderately to severely active rheumatoid arthritis. The Phase 2a enrollment of approximately 100 patients is advancing well, with preliminary analysis of the Phase 2a results anticipated in the first half of 2025. RIPK1 is implicated in a broad range of key inflammatory cellular processes and plays a key role in tumor necrosis factor signaling, especially in the induction of pro-inflammatory necroptosis. The program also includes RIPK1 compounds that cross the blood-brain barrier (CNS-penetrants) to address neurodegenerative diseases such as Alzheimer&#8217;s disease and amyotrophic lateral sclerosis. </p><a id="_Hlk147304336"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:11pt;text-indent:36pt;margin:11pt 0pt 0pt 0pt;">Under the Lilly Agreement, we are responsible for 20% of the development costs for ocadusertib in the US, Europe, and Japan, up to a specified cap, and Lilly is responsible for funding the remainder of all development activities for ocadusertib and other non-CNS disease development candidates. Under the Lilly Agreement, we have the right to opt-out of co-funding the ocadusertib development activities in the US, Europe and Japan at two different specified times and as a result receive lesser royalties from sales. In September 2023, we provided the first opt-out notice to Lilly and our funding commitment was capped at a specified amount <span style="background:#ffffff;">through April 1, 2024, as provided for in the Lilly Agreement, as amended in September 2023</span>. We provided $21.4 million funding to Lilly throughout the periods for our share for ocadusertib development costs incurred through April 1, 2024. Under the Lilly Agreement as amended, we have the right to opt-in to co-funding of ocadusertib development, upon us providing notice to Lilly within 30 days of certain events, as specified in the Lilly Agreement. If we decide to exercise our opt-in right, we will be required to continue to share in global development costs, and if we later exercise our second opt-out right (no later than April 1, 2025), our share in global development costs will be up to a specified cap through December 31, 2025, as provided for in the Lilly Agreement. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:242.18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patent Infringement Lawsuit</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In June 2022, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by Annora Pharma Private Limited (Annora) requesting approval to market a generic version of TAVALISSE. In July&#160;2022, we filed a lawsuit in the US District Court for the District of New Jersey against Annora and its subsidiaries for infringement of certain of our US patents. Litigation continues, and no trial date is currently set. For a more detailed discussion of this litigation matter, see Part II, Item 1, &#8220;Legal Proceedings&#8221; of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Our Product Portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span>The following&#160;table summarizes our portfolio: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="rigl-20240630x10q006.jpg" alt="Graphic" style="display:inline-block;height:242.18pt;width:458.29pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Commercial Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">TAVALISSE/Fostamatinib in ITP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Chronic ITP affects an estimated 81,300 adult patients in the US. In patients with ITP, the immune system attacks and destroys the body&#8217;s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts. Current therapies for ITP include steroids, blood platelet production boosters that imitate thrombopoietin (TPO) and splenectomy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Taken in tablet form, fostamatinib blocks the activation of SYK inside immune cells. ITP is typically characterized by the body producing antibodies that attach to healthy platelets in the blood stream. Immune cells recognize these antibodies and affix to them, which activates the SYK enzyme inside the immune cell, and triggers the destruction of the antibody and the attached platelet. When SYK is inhibited by fostamatinib, it interrupts this immune cell function and allows the platelets to escape destruction. The results of our Phase&#160;2 clinical trial, in which fostamatinib was orally administered to 16 adults with chronic ITP, published in <i style="font-style:italic;">Blood</i>, showed that fostamatinib significantly increased the platelet counts of certain ITP patients, including those who had failed other currently available agents.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk511203532"></a><a id="_cp_text_1_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Fostamatinib for Immune Thrombocytopenia (FIT) Phase 3 clinical program had a total of 150 ITP patients which were randomized into two identical multicenter, double-blind, placebo-controlled clinical trials. The patients were diagnosed with persistent or chronic ITP, and had blood platelet counts consistently below 30,000 per microliter of blood. Two-thirds of the subjects received fostamatinib orally at 100 mg twice daily (bid) and the other third received placebo on the same schedule. Subjects were expected to remain on treatment for up to 24 weeks. At week four of treatment, subjects who failed to meet certain platelet counts and met certain tolerability thresholds could have their dosage of fostamatinib (or corresponding placebo) increased to 150 mg bid. The primary efficacy endpoint of this program was a stable platelet response by week 24 with platelet counts at or above 50,000 per microliter of blood for at least four of the final six qualifying blood draws. In August 2016, we announced the results of the first FIT study, reporting that fostamatinib met the study&#8217;s primary efficacy endpoint. The study showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control. In October 2016, we announced the results of the second FIT study, reporting that the response rate (16% in the treatment group, versus 4% in the placebo group) was consistent with the first study, although the difference was not statistically significant. In the ITP double-blind studies, the most commonly reported adverse reactions occurring in at least 5% of patients treated with TAVALISSE were diarrhea, hypertension, nausea, dizziness, increased alanine aminotransferase, increased aspartate aminotransferase, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia. Serious adverse drug reactions occurring in at least 1% of patients treated with TAVALISSE in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis. A post-hoc analysis from our Phase 3 clinical program in adult patients with chronic ITP, highlighting the potential benefit of using TAVALISSE in earlier lines of therapy, was published in the British Journal of Haematology in July 2020. In addition, a report describing the long-term safety and durable efficacy of TAVALISSE with up to five years of treatment was published in Therapeutic Advances in Hematology in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA granted our request for orphan drug designation for fostamatinib for the treatment of ITP in August 2015. TAVALISSE was approved by the FDA in April 2018 for the treatment of ITP in adult patients who have had an insufficient response to a previous treatment, and successfully launched in the US in May 2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">Competitive landscape for TAVALISSE</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our industry is intensely competitive and subject to rapid and significant technological change. TAVALISSE is competing with other existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. For example, there are existing therapies and drug candidates in development for the treatment of ITP that may be alternative therapies to TAVALISSE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Currently, corticosteroids remain the most common first line therapy for ITP, occasionally in conjunction with intravenous immunoglobulin (IVIg) or anti-Rh(D) to help further augment platelet count recovery, particularly in emergency situations. However, it has been estimated that frontline agents lead to durable remissions in only a small percentage of newly diagnosed adults with ITP. Moreover, concerns with steroid-related side effects often restrict therapy to approximately four weeks. As such, many patients progress to persistent or chronic ITP, requiring other forms of therapeutic intervention. In long-term treatment of chronic ITP, patients are often cycled through several therapies over time in order to maintain a sufficient response to the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Other approaches to treat ITP are varied in their mechanism of action, and there is no consensus about the sequence of their use. Options include splenectomy, thrombopoietin receptor agonists (TPO-Ras) and various immunosuppressants (such as rituximab). The response rate criteria of the above-mentioned options vary, precluding a comparison of response rates for individual therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Even with the above treatment options, a significant number of patients remain severely thrombocytopenic for long durations and are subject to risk of spontaneous or trauma-induced hemorrhage. The addition of fostamatinib to the currently available treatment options could be beneficial because it has a different mechanism of action than any of the therapies that are currently available. Fostamatinib is a potent and relatively selective SYK inhibitor, and its inhibition of Fc receptors and B-cell receptors of signaling pathways make it a potentially broad immunomodulatory agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Other products in the US that are approved by the FDA to increase platelet production through binding to TPO receptors on megakaryocyte precursors include PROMACTA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Novartis International AG (Novartis)), Nplate<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Amgen, Inc.) and DOPTELET<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Swedish Orphan Biovitrum AB). In the longer term, we may eventually face competition from </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">potential manufacturers of generic versions of our marketed products, including the proposed generic version of TAVALISSE that is the subject of an ANDA submitted to the FDA by Annora, which, if approved and allowed to enter the market, it could result in significant decreases in the revenue derived from sale of TAVALISSE and thereby materially harm our business and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Commercial activities, including sales and marketing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our marketing and sales efforts are focused on hematologists and hematologist-oncologists in the US who manage chronic adult ITP patients.&#160;We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes our products in the US using customary pharmaceutical company practices. Our products are sold initially through third-party wholesale distribution and specialty pharmacy channels and group purchasing organizations before being ultimately prescribed to patients. To facilitate our commercial activities in the US, we also enter into arrangements with various third parties, including advertising agencies, market research firms and other sales-support-related services as needed. We believe that our commercial team and distribution practices are adequate to ensure that our marketing efforts reach relevant customers and deliver our products to patients in a timely and compliant fashion. Also, to help ensure that all eligible patients in the US have appropriate access to our products, we have established a reimbursement and patient support program called Rigel OneCare<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (ROC). Through ROC, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free product to uninsured or under-insured patients who meet certain established clinical and financial eligibility criteria. In addition, ROC is designed to provide reimbursement support, such as information related to prior authorizations, benefits investigations and appeals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have entered into various license and commercial agreements to commercialize fostamatinib globally as discussed below, but we retain the global rights to fostamatinib outside of the&#160;respective&#160;territories under such license and commercial agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">Fostamatinib in EU and in the UK</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have a commercialization license agreement with Grifols S.A. (Grifols) entered in January 2019, for exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop, fostamatinib in their territory. Grifols territory includes EU, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States). In January 2020, the European Commission (EC) granted a centralized MA for fostamatinib (TAVLESSE) valid throughout the Europe and in the UK, after the departure of the UK from the EU, for the treatment of chronic ITP in adult patients who are refractory to other treatments. Grifols has launched TAVLESSE in the UK and certain countries in EU including Germany, France, Italy and Spain, and continues a phased rollout across the rest of EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Fostamatinib in Asia </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">We have an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. (Kissei) entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#8217;s territory, which includes Japan, China, Taiwan and the Republic of Korea. Kissei is a&#160;Japan-based pharmaceutical company addressing patients&#8217; unmet medical needs through its research, development and commercialization efforts, as well as through collaborations with partners. Japan&#160;has the third highest prevalence of chronic ITP in the world behind the US and Europe. Kissei was granted orphan drug designation from the Japanese Ministry of Health, Labor and Welfare for R788 (fostamatinib) in chronic ITP in February 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Kissei initiated a Phase 3 trial in Japan of fostamatinib in adult Japanese patients with chronic ITP in September 2019, and reported positive top-line results meeting its primary end point in December 2021. The efficacy and safety of orally administered fostamatinib was assessed by comparing it with placebo in a randomized, double-blind study.&#160;The trial showed that patients receiving fostamatinib achieved a stable platelet response significantly higher than&#160;patients receiving a placebo control. Based on the positive Phase 3 results, Kissei submitted an NDA to Japan&#8217;s PMDA for fostamatinib in chronic ITP in April 2022. In December 2022, Japan&#8217;s PMDA approved TAVALISSE for the treatment of chronic ITP, and in April 2023, Kissei launched TAVALISSE for chronic ITP in Japan. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">&#160;<i style="font-style:italic;">Fostamatinib in Canada/Israel </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">We have two exclusive commercial and license agreements with Medison Pharma Trading AG (Medison Canada) and Medison Pharma Ltd. (Medison Israel, and together with Medison Canada, Medison) entered in October 2019,&#160;to commercialize fostamatinib in all potential indications in Canada and Israel. Pursuant to this exclusive commercialization license agreement, in August 2020, we entered into a commercial supply agreement with Medison. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2020, Health Canada approved the New Drug Submission for TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments. In August 2021, Medison Israel received the licenses for registrational approval from the Ministry of Health. Medison launched TAVALISSE in Canada and Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fostamatinib in Latin America</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have a commercial license agreement with <span style="background:#ffffff;">Knight Therapeutics International SA (</span>Knight) entered in May 2022, to commercialize fostamatinib for approved indications in Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory). We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under a Commercial and Supply Agreement.&#160;In August 2023, Knight submitted the MAA for regulatory approval in Mexico, Colombia and Brazil for fostamatinib for the treatment of adult patients with ITP who had insufficient response to a previous treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">REZLIDHIA in R/R AML with mIDH1</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">mIDH1 alterations are seen in AML, MDS, glioma, chondrosarcoma, and intrahepatic cholangiocarcinoma. It is estimated that there are approximately 1,000 adult patients, a well-identified patient population, with mIDH1 R/R AML, part of an AML market estimated to have an incidence of approximately 20,000 cases in the US and an estimated 120,000 cases globally. Despite having approved treatment options for R/R AML patients who are mIDH1 positive, an unmet need remains. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Olutasidenib, an oral, small molecule drug designed to selectively bind to and inhibit mIDH1, is a treatment option with durable remissions, reduced QTc potential, and a stable pharmacokinetics profile that enables a consistent drug exposure over time. This targeted agent has the potential to provide therapeutic benefit by reducing 2-hydroxyglutarate levels and restoring normal cellular differentiation. IDH1 is a natural enzyme that is part of the normal metabolism of all cells. When mutated, IDH1 activity can promote blood malignancies and solid tumors.<span style="background:#ffffff;"> Olutasidenib was designated by the FDA as an orphan drug for the treatment of AML, which provides orphan drug market exclusivity from the time of marketing approval on December 1, 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="color:#222222;background:#ffffff;">REZLIDHIA is designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells. REZLIDHIA is a novel, non-intensive monotherapy treatment in the R/R AML setting demonstrating a CR+CRh rate of 35% in patients with over 90% of those responders in complete remission.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="color:#222222;background:#ffffff;">W</span>e in-licensed <span style="color:#222222;background:#ffffff;">REZLIDHIA</span> from Forma pursuant to a license and transition services agreement entered in July 2022, with exclusive, worldwide rights for development, manufacturing and commercialization of REZLIDHIA for any uses, including for the treatment of AML and other malignancies. In accordance with the terms of the license and transition services agreement, we paid an upfront fee of $2.0 million, with the potential to pay up to $67.5 million additional payments upon achievement of specified development and regulatory milestones and up to $165.5 million additional payments upon achievement of certain commercial milestones. <span style="background:#ffffff;">In addition, subject to the terms and conditions of the license and transition services agreement, Forma would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portions of our sublicensing revenue, subject to certain standard reductions and offsets.</span> In 2022, certain milestones were met which entitled Forma to receive a $17.5 million milestone payments. No new milestone was met in 2023 and during the six months ended June 30, 2024.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk140159639"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In December 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with IDH1 mutation as detected by an FDA-approved test, and </span>we began the commercialization of REZLIDHIA and made it available to patients. <span style="color:#222222;background:#ffffff;">The recommended dosage of REZLIDHIA is 150 mg taken orally twice daily until disease progression or unacceptable toxicity. The FDA approval was based on the </span>NDA <span style="background:#ffffff;">for olutasidenib for the treatment of m1DH1 R/R AML submitted by </span><span style="background:#ffffff;">Forma</span><span style="background:#ffffff;">, that had a PDUFA action date for the application of February 15, 2023.</span> The NDA application was supported with a Phase 2 registrational trial for olutasidenib in mIDH1 R/R AML. Interim results from the Phase 2 registrational trial were reported at the American Society of Clinical Oncology (ASCO) annual meeting in June 2021. The interim results of this trial of 153 patients showed that olutasidenib demonstrated a favorable tolerability profile as a monotherapy in patients with R/R AML who have a susceptible mIDH1, and achieved a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 33.3% (30% CR and 3% CRh), the primary efficacy endpoint. While a median duration of CR/CRh was not yet reached, a sensitivity analysis (with a hematopoietic stem cell transplant, as the end of a response) indicated the median duration of CR/CRh was 13.8 months<b style="font-weight:bold;">.</b> The overall response rate, comprised CR, CRh, Cri, partial response, and morphologic leukemia-free state (MLFS), was 46% and the median duration of overall response rate (ORR) was 11.7 months. The median overall survival was 10.5 months. For patients with CR/CRh, the median overall survival was not reached, but the estimated 18-month survival was 87%. The most frequently reported treatment emergent adverse events were nausea, constipation, increased white blood cell count, decreased red blood cell count, pyrexia, febrile neutropenia, and fatigue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2022, we announced the presentation of five posters highlighting data from our commercial and clinical hematology-oncology portfolio at the 64<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition which was held in December 2022. An updated interim analysis from the Phase 2 registrational trial of olutasidenib in patients with R/R AML demonstrated robust efficacy and safety results. The registrational cohort of the Phase 2 trial enrolled 153 patients with mIDH1 R/R AML who received olutasidenib monotherapy 150 mg twice daily. The efficacy evaluable population was 147 patients who received their first dose at least six months prior to the interim analysis cutoff date of June 18, 2021. The primary endpoint was a CR/CRh defined as less than 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt;50,000/microliter and absolute neutrophil count &gt;500/microliter). The results from the updated interim analysis of patients with mIDH1 R/R AML demonstrated a 35% CR+CRh rate with a median duration of 25.9 months. The ORR a secondary end point, was 48%, and was defined as the rate of CR, CRh, CR with incomplete blood count recovery (Cri), partial remission (which required recovery of neutrophil and platelet counts consistent with a CR), or MLFS. Olutasidenib was effective in a broad range of patients including those with prior high-intensity chemotherapy and/or post-venetoclax. The abstract concluded that the observed activity is clinically meaningful and represents a therapeutic advance in the treatment of this patient population. In this pivotal cohort, olutasidenib was well tolerated with an adverse event profile largely characteristic of symptoms or conditions experienced by patients undergoing treatment for AML or of the underlying disease itself.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2022, we also announced the publication of data in <i style="font-style:italic;">The Lancet Haematology, </i>which summarizes the Phase 1 results of the Phase 1/2 trial of olutasidenib<span style="color:#222222;">. The objectives of the first phase of the multicenter, open-label Phase 1/2 trial were to assess the safety, pharmacokinetic and pharmacodynamic profile, and clinical activity of olutasidenib, both as monotherapy and in combination with azacitidine, in patients with treatment-na&#239;ve or R/R AML or MDS harboring IDH1 mutations. The published data suggest that olutasidenib, with or without azacitidine, was well-tolerated and was associated with improvements in clinical efficacy endpoints in patients with mIDH1 AML. This trial showed that olutasidenib has the potential to provide an additional treatment option for mIDH1 AML.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2023, we announced that REZLIDHIA has been added by the National Comprehensive Cancer Network (NCCN) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML. REZLIDHIA is now included as a recommended targeted therapy for adult patients with R/R AML with IDH1 mutation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In February 2023, we announced peer-reviewed publication data in <i style="font-style:italic;">Blood Advances</i>, which summarize clinical results from the Phase 2 registrational trial of REZLIDHIA in patients with mIDH1 R/R AML. The published data demonstrate that REZLIDHIA induced durable remissions and transfusion independence with a well-characterized safety profile. The observed efficacy is clinically meaningful and represents a therapeutic advance in this poor prognosis patient population with limited treatment options.&#160;REZLIDHIA demonstrated both a high rate of response and an extended median duration of complete response of 28.1 months, which is more than a year longer than what is reported with the standard of care. In June 2023, we announced the second REZLIDHIA publication in <i style="font-style:italic;">Blood Advances</i>, a review </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">article examining the preclinical and clinical development, and the positioning of REZLIDHIA in the mIDH1 AML treatment landscape. The review concluded that the approval of REZLIDHIA is a critical addition to the mIDH1 AML treatment landscape. Further, the available data support the use of REZLIDHIA as monotherapy in R/R AML patients who have failed intensive chemotherapy or venetoclax plus <span style="background:#ffffff;">hypomethylating agents</span> combination therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:13.5pt;text-indent:36pt;background:#ffffff;margin:1.5pt 0pt 0pt 0pt;"><span style="color:#222222;">In June 2023, we announced presentation of data from an analysis from the Phase 2 study of REZLIDHIA in patients with mIDH1 AML who were previously treated with venetoclax. Data was featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress. The data support REZLIDHIA induced durable remissions in patients with mIDH1 AML in this poor-prognosis patient population who were R/R to venetoclax-based treatment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:13.5pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="color:#222222;">In April 2024, we announced a peer-reviewed publication in </span><i style="color:#222222;font-style:italic;">Leukemia &amp; Lymphoma</i><span style="color:#222222;"> on data from an analysis of the Phase 2 study evaluating REZLIDHIA in patients with mIDH1 AML who are R/R to prior venetoclax-based regimens. The findings from these analyses suggest that REZLIDHIA alone or in combination with azacitidine demonstrated potential efficacy in patients with AML following failure of venetoclax combination therapy. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 13.5pt 0pt;"><span style="color:#222222;">In May 2024, we announced the presentation of the five-year results from the registrational Phase 2 trial of REZLIDHIA in R/R mIDH1 AML patients at the 2024 ASCO Annual Meeting and EHA 2024 Hybrid Congress. The data published reinforces REZLIDHIA&#8217;s efficacy in heavily pretreated patients with mIDH1 AML, including those R/R to prior venetoclax. The safety profile was consistent with what was previously reported. Further, REZLIDHIA was generally well tolerated in elderly patients with R/R mIDH1 AML and induced durable remissions. Despite the challenges of treating elderly patients who had already failed prior AML treatment, the results suggest that elderly patients can benefit from therapy with REZLIDHIA. REZLIDHIA was also effective in achieving remission in patients with mIDH1 R/R AML and served as a bridging strategy towards potentially curative allogeneic transplantation in a substantial subset of these previously ineligible patients. Additionally, REZLIDHIA was well tolerated in a subset of patients with post-myeloproliferative neoplasms (MPN) mlDH1 AML, a patient population often associated with poor responses to available therapies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Competitive landscape for REZLIDHIA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;background:#ffffff;margin:0pt 0pt 11.25pt 0pt;"><span style="font-weight:normal;">There is currently one other product approved in the US for patients with IDH1 mutation. The FDA granted approval to TIBSOVO</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-weight:normal;"> (ivosidenib), an oral targeted IDH1 mutation inhibitor, (i) in July 2018, for adult patients with R/R AML with a susceptible IDH1 mutation, (ii) in May 2019, for newly diagnosed AML with a susceptible IDH1 mutation who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy, (iii) in August 2021, for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test, (iv) in May 2022, </span><span style="font-weight:normal;">in combination with azacitidine (azacitidine for injection)&#160;for newly diagnosed AML with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, and (v) in October 2023, for adult patients with R/R MDS with a susceptible IDH1 mutation, as detected by an FDA-approved test. In addition, some clinicians may utilize non-targeted treatments for patients with mIDH1 R/R AML, including use of venetoclax combinations, hypomethylating agents, other chemotherapy regimens, or investigational agents that may be available to them.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Commercial activities, including sales and marketing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#222222;background:#ffffff;">We believe REZLIDHIA</span><span style="background:#ffffff;"> is highly synergistic with our existing hematology-oncology focused commercial and medical affairs infrastructure. </span><span style="background:#ffffff;">Our commercial effort focuses on growing awareness of REZLIDHIA within key institutions, and among targeted </span><span style="background:#ffffff;">HCPs</span> who manage <span style="background:#ffffff;">patients with R/R AML with mIDH1.</span> We plan to enter collaborations with third parties to commercialize REZLIDHIA outside of US.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">GAVRETO</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-style:italic;font-weight:bold;">in metastatic RET fusion-positive NSCLC and advanced thyroid cancers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;">RET is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET can be activated by mutation or when a portion of the RET gene that encodes the kinase domain is joined to part of another gene creating a fusion gene that encodes an aberrantly activated RET fusion protein. RET </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">alterations, such as fusions or mutations, drive the growth of multiple tumor types. It is estimated that over 230,000 adult patients in the US will be diagnosed with lung cancer in 2024. NSCLC is the most common type of lung cancer in the US accounting for 80-85% of all lung cancer diagnoses. RET activating fusions are key disease drivers in NSCLC. RET fusions are implicated in approximately 1-2% of patients with NSCLC. </p><a id="_Hlk159848980"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We acquired the rights to research, develop, manufacture and commercialize GAVRETO from Blueprint, pursuant to an Asset Purchase Agreement entered in February 2024. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild-type RET and oncogenic RET fusions. Currently, GAVRETO is one of only two approved RET inhibitors on the market for patients. GAVRETO is approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive NSCLC as detected by an FDA-approved test. GAVRETO is also approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication was approved by the FDA under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial. Discussions with the FDA regarding confirmatory requirements are ongoing.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">On June 24, 2024, we announced the completion of the transfer to us of the NDA for GAVRETO, and GAVRETO is commercially available from us in the US by prescription beginning June 27, 2024. GAVRETO was co-marketed by Blueprint and Genentech, a member of Roche Group (Roche), to patients in the US since September 2020 pursuant to a collaboration agreement between Blueprint and Roche, which was terminated effective in February 2024. </span></p><a id="_Hlk159861311"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;">The patent portfolio covering pralsetinib contains patents and patent applications directed to compositions of matter for pralsetinib, including solid forms, formulations, and methods of use and manufacture. Pralsetinib is covered as a composition of matter in a US issued patent that has an expiration date in November 2036 and subject to potential extensions.<span style="font-size:12pt;"> </span>Patents that have been issued or are expected to be issued covering pralsetinib will have statutory expiration dates between 2036 and 2041. The FDA granted GAVRETO new chemical entity exclusivity until September 2025 and orphan drug exclusivity until September 2027 with respect to the approval for treatment of adult patients with metastatic RET fusion-positive NSCLC as detected by an FDA-approved test. The FDA also granted GAVRETO two orphan drug exclusivities until December 2027 with respect to FDA approval for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), and for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid carcinoma who require systemic therapy.<span style="font-size:12pt;"> </span></p><a id="_Hlk160006248"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-top:9pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">Competitive landscape for GAVRETO</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">GAVRETO faces competition for RET fusion-positive NSCLC and advanced thyroid cancers from Lilly&#8217;s selpercatinib.</span> In addition, other commercially available therapies used to treat RET fusion-positive NSCLC include cabozantanib and platinum-based chemotherapy regimens with or without pembrolizumab, atezolizumab, nivolumab/ipilumumab, cemiplimab or tremelimumab-durvalumab. Pralsetinib may also face competition from other drug candidates in development for RET-altered cancers, as well as multi-kinase inhibitors with RET activity being evaluated in clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Commercial activities, including sales and marketing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">We began our commercialization and started recognizing revenue from product sales of GAVRETO in June 2024. We believe GAVRETO is highly synergistic with our current product portfolio, and we expect to continue to leverage our existing commercial infrastructure to ensure current and newly prescribed GAVRETO patients have continued access to this important treatment option. We distribute and market GAVRETO for approved indications in RET fusion-positive NSCLC and advanced thyroid cancers. </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical Stage Programs</b></p><a id="_Hlk94686962"></a><a id="_Hlk165044579"></a><a id="_Hlk164943264"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">R289, an Oral IRAK 1/4 Inhibitor for Hematology-Oncology, Autoimmune, and Inflammatory Diseases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the second quarter of 2018, we selected R835, a proprietary molecule from our IRAK 1/4 inhibitor program, for human clinical trials. This investigational candidate is an orally administered, potent and selective inhibitor of IRAK1 and IRAK4 that blocks inflammatory cytokine production in response to toll-like receptor (TLR) and the interleukin-1 receptor (IL-1R) family signaling. TLRs and IL-1Rs play a critical role in the innate immune response and dysregulation of these pathways can lead to a variety of inflammatory conditions. R835 prevents cytokine release in response to TLR and IL-1R activation in vitro, and is active in multiple rodent models of inflammatory disease including psoriasis, arthritis, lupus, multiple sclerosis and gout. Preclinical studies show that R835 inhibits both the IRAK1 and IRAK4 signaling pathways, which play a key role in inflammation and immune responses to tissue damage. Dual inhibition of IRAK1 and IRAK4 allows for more complete suppression of pro-inflammatory cytokine release than inhibition of either one individually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In October 2019, we announced results from a Phase 1 randomized, placebo-controlled, double-blind clinical trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of R835 in 91 healthy adult subjects. The Phase 1 trial showed that R835 had a favorable safety, tolerability and PK profile and established proof-of-mechanism by demonstrating the inhibition of inflammatory cytokine production in response to a lipopolysaccharide (LPS) challenge.<span style="font-size:12pt;"> </span></p><a id="_Hlk164946341"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We advanced the development of our IRAK 1/4 inhibitor program, following further evaluation of single and multiple ascending doses of R289, a new pro-drug formulation of R835 in healthy subjects. In January 2022, we received clearance from the FDA to initiate a Phase 1b open-label, multicenter trial to evaluate the safety, tolerability and preliminary efficacy of R289 in patients with R/R lower-risk MDS. In December 2022, we announced the dosing of the first patient. This <span style="background:#ffffff;">Phase 1b trial is expected to enroll approximately 40 patients (up to 30 participants in the dose escalation phase, and up to 10 participants in the dose expansion phase). The primary objective of the trial is safety, with secondary and exploratory objectives to assess preliminary efficacy and characterize the pharmacokinetic and pharmacodynamic profile of R289. The safety </span><span style="color:#222222;background:#ffffff;">and efficacy data from this Phase 1b trial is intended to inform the recommended dose of R289 for further clinical evaluation in lower-risk MDS. </span><span style="color:#222222;background:#ffffff;">To date, enrollment in the fourth dose level (250 mg twice daily) of the trial is underway. </span><span style="background:#ffffff;">Preliminary data are expected by the end of 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#222222;font-size:10pt;visibility:hidden;background:#c0c0c0;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Partnered Clinical Programs </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:9pt 0pt 9pt 36pt;"><span style="font-style:italic;font-weight:bold;">Ocadusertib &#8211; Lilly </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:12pt 0pt 12pt 0pt;">Lilly is continuing to advance ocadusertib (previously R552) and has initiated the Phase 2a trial studying ocadusertib in adult patients with moderately to severely active rheumatoid arthritis. The Phase 2a enrollment of approximately 100 patients is advancing well, with preliminary analysis of the Phase 2a results anticipated in the first half of 2025. RIPK1 is implicated in a broad range of key inflammatory cellular processes and plays a key role in tumor necrosis factor signaling, especially in the induction of pro-inflammatory necroptosis. The program also includes RIPK1 compounds that cross the blood-brain barrier (CNS-penetrants) to address neurodegenerative diseases such as Alzheimer&#8217;s disease and amyotrophic lateral sclerosis. </p><a id="_Hlk159339944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:9pt 0pt 9pt 36pt;"><span style="font-style:italic;font-weight:bold;">Bemcentinib &#8211; BerGenBio </span></p><a id="_Hlk159338438"></a><a id="_Hlk116633571"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have an exclusive, worldwide research, development and commercialization agreement with BerGenBio for our investigational AXL receptor tyrosine kinase inhibitor, R428 (now referred to as bemcentinib (BGB324)). In February 2023, BerGenBio announced positive data from the Phase 2 trial of bemcentinib in combination with pembrolizumab in patients with second-line NSCLC. The treatment with bemcentinib in combination with pembrolizumab demonstrated long survival benefit and sustained disease control, particularly in patients with AXL TPS &gt; 5, substantiating the relevance of AXL as a target and bemcentinib&#8217;s selective inhibition capabilities in NSCLC. Also in March 2023, BerGenBio announced its first patient dosed in a Phase 1b/2a trial evaluating bemcentinib in first-line NSCLC patients harboring STK11 mutations<i style="font-style:italic;">.</i> In March 2024, BerGenBio announced initiation of the Phase 2a portion of the study following a positive decision by the Data and Safety Monitoring Board following review of the Phase 1b safety data. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 9pt 36pt;"><span style="font-style:italic;font-weight:bold;">Milademetan &#8211; Daiichi</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">DS-3032 is an investigational oral selective inhibitor of the MDM2 protein investigated by Daiichi in three Phase 1 clinical trials for solid and hematological malignancies including AML, acute lymphocytic leukemia, chronic myeloid leukemia in blast phase, lymphoma and MDS. Preliminary safety and efficacy data from a Phase 1 trial of DS-3032 suggests that DS-3032 may be a promising treatment for hematological malignancies including R/R AML and high-risk MDS. In September 2020, worldwide rights to DS-3032 (milademetan) were out-licensed from Daiichi to Rain Oncology Inc., formerly Rain Therapeutics Inc. (Rain). In January 2024, Pathos Al, Inc. (Pathos) completed the acquisition of Rain. Pathos indicated that it has continued interest in further developing milademetan for cancer patients using its propriety PathOS Platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research, Preclinical and Clinical Development Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have retained selected experts in drug discovery and preclinical development to leverage our existing proprietary collection of inhibitors, small-molecule compound libraries and large database of associated phenotypic and biochemical assay results of therapeutic interest. We maintain leading expertise on specific areas of operation such as inhibition of SYK, IRAK 1/4, RIPK1 and mIDH1 kinases to assist clinical development and commercial affairs, as well as to expand and explore additional opportunities for such inhibitors in the clinical space. Our preclinical operations involve collaborations with clinical research organizations, leading investigators from universities and research organizations around the world, and strategic collaborations with other pharmaceutical companies. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have experts in drug development to design and implement clinical trials and to analyze the data derived from these trials. The clinical development group possesses expertise in project management and regulatory affairs. We work with external clinical research organizations with expertise in managing clinical trials, drug formulation, and the manufacture of clinical trial supplies to support our drug development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We also have strategic development collaborations with MDACC and CONNECT to conduct evaluation of REZLIDHIA (olutasidenib) in AML, other hematologic cancers and glioma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Commercialization and Sponsored Research and License Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">See &#8220;Note 4 &#8211; Sponsored Research, License Agreements and Government Contracts&#8221; and &#8220;Note 5 &#8211; In-licensing and Acquisition&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q for related discussions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_26183957_7570_4b92_937c_ad23d7b87842"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenues</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="19" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:35.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:63.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales, net</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,450</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,881</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,569</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,453</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,626</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,827</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract revenues from collaborations</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,391</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,005</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,386</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,922</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,330</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,592</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contracts</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,000)</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,841</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,886</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,955</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52,956</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,419</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.45%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">45%</p></td></tr><tr><td style="vertical-align:bottom;width:36.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cencora Inc. (formerly ASD Healthcare)</p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Revenue from product sales is related to our sale of our products in the US, net of chargebacks, discounts and fees, government and other rebates and returns. <span style="background:#ffffff;">Typically, our first quarter net sales are impacted by the first quarter reimbursement issues such as the resetting of co-pays and the Medicare donut hole.</span><span style="display:inline-block;width:26.48pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> TAVALISSE net product sales for the three and six months ended June 30, 2024 were $26.4 million and $47.5 million, respectively, increased by 24% and 9%, respectively, compared to $21.3 million and $43.6 million net product sales for the three and six months ended June 30, 2023, respectively. The increase was primarily due to increased quantities sold, as well as increased price per bottle. This increase was partially offset by the increase in revenue reserves driven by higher government and private payor rebates. REZLIDHIA net product sales in the three and six months ended June 30, 2024 were $5.2 million and $10.0 million, respectively, increased by 102% and 150% compared to $2.6 million and $4.0 million net product sales for the three and six months ended June 30, 2023, respectively. </span><span style="color:#222222;background:#ffffff;">The increase was primarily due to increased quantities sold </span><span style="background:#ffffff;">primarily driven by increased number of patients under therapy, partially offset by the increase in revenue reserves primarily due to higher government rebates. Following the commercialization of </span>GAVRETO on June 27, 2024, we started recognizing revenue from shipments to our distributors. During the three and six months ended June 30, 2024, we recognized $1.9 million of GAVRETO net product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Contract revenues from collaborations in the three and six months ended June 30, 2024 consisted primarily of revenue from Kissei of $2.2 million and $4.5 million, respectively, related to the delivery of drug supplies, and revenue from Grifols of $1.1 million and $2.2 million, respectively, related to earned royalty. <span style="background:#ffffff;">Contract revenues from collaborations in the three and six months ended June 30, 2023 consisted primarily of revenue from Grifols of $2.0 million and $4.3 million, respectively, related to earned royalty and delivery of drug supplies.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Government contract revenue in the three and six months ended June 30, 2023 was related to the income we recognized upon achievement of certain milestones from the award granted to us by the DOD. No government contract revenue was recognized during the three and six months ended June 30, 2024.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">We expect that our future revenues to include product sales of our existing commercial products and product sales from new commercial products we may have in the future. Our net product sales may be impacted by the demand from our customers, changes to government and private payor rebate programs, chargeback and discount programs, co-payment assistance programs, and any other rebate and discount programs we may enter in the future. In addition, our future revenues may include payments from our existing and new collaboration partners <span style="background:#ffffff;">and </span>government grants. As of June 30, 2024, we had $1.4 million of deferred revenue relating to our collaboration agreement with Kissei which we will recognize as revenue upon satisfaction of our remaining performance obligations. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cost of Product Sales</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="19" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:34.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:63.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of product sales</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,807</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,075</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,732</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,832</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,052</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,780</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The cost of product sales includes the cost of inventories sold to specialty distributors and to our collaborative partners. Inventories sold for the periods presented include inventory quantities acquired or produced prior to the FDA approval of the product, and do not reflect the full cost of the inventories sold, since such costs incurred prior to FDA approval were previously expensed and charged to research and development expense. In particular, we still utilize active pharmaceutical ingredients with zero cost for our TAVALISSE inventories, which we expect to make use of for the next 2 to 3 years. As such, we recognize lower cost of product sales in the periods where we sell inventory quantities acquired or produced prior to the FDA approval of the product. As we acquire or produce more FDA approved inventory quantities in the future, our inventory cost in the balance sheet and cost of product sales will reflect the full cost of acquiring or producing such products. Cost of product sales may also include <span style="background:#ffffff;">reserves for potential excess, dated or obsolete inventories, estimated based upon assumptions about future demand and market conditions as well as product shelf lives. </span>We recognize amortization of intangible assets acquired from in-licensing or acquisition of commercialized products as well as royalty expense within cost of sales.</p><a id="_Hlk140161225"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The increase in cost of product sales in the three and six months ended June 30, 2024 compared to the same periods in 2023 was partly due to increased royalty expense and amortization of intangible assets of approximately $0.9 million and $1.5 million, respectively. Further, the increase in cost of product sales was also partly due to increased product sales, and increased delivery of drug supplies pursuant to our supply agreements with our collaborative partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and Development Expense</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.81%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="19" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:33.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,540</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,772</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 768</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,861</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,295)</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense included in research and development expense</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 305</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 376</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (71)</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 955</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,399</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (444)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The increase in research and development expense in the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to increased various research and development expenses of $1.6 million due to progress of trial activities of R289, our IRAK 1/4 inhibitor program and other clinical activities. The increase was partly offset by decreased clinical trial costs of $0.8 million due to reduced trial activities of our completed <span style="background:#ffffff;">Phase 3 clinical trials of fostamatinib in patients with COVID-19 and wAIHA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The decrease in research and development expense in six months ended June 30, 2024 compared to the same period in 2023 was partly due to </span><span style="background:#ffffff;">decreased clinical trial activities of $1.8 million</span> due to reduced <span style="background:#ffffff;">trial activities of our completed Phase 3 clinical trials of fostamatinib in patients with COVID-19 and wAIHA, as well as </span>$1.2 million decreased clinical trial related expenses <span style="background:#ffffff;">due to progress of trial activities of R289,</span> our IRAK 1/4 inhibitor program<span style="background:#ffffff;">. Other research and development expense including allocated facilities and laboratory costs also decreased by $0.3 million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Our research and development expenditures include costs related to preclinical and clinical trials, scientific personnel, supplies, equipment, consultants, sponsored research, stock-based compensation, and allocated facility costs. W<span style="background:#ffffff;">e expect to continue to incur significant research and development expense as we continue our activities in our clinical studies including R289, our IRAK 1/4 inhibitor program; our collaborative partnerships with </span>MDACC<span style="background:#ffffff;"> and CONNECT to evaluate REZLIDIHIA (olutasidenib) in </span>AML, other hematologic cancers and glioma; <span style="background:#ffffff;">and any other clinical programs we may pursue in the future.</span> </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We do not track fully burdened research and development costs separately for each of our drug candidates. We review our research and development expense by focusing on three categories: research, development, and other. Our research team is focused on identifying and evaluating product candidates in our focused range of therapeutic indications that can be developed into small molecule therapeutics in our own proprietary programs or with potential collaborative partners. &#8220;Research&#8221; expenses relate primarily to personnel expenses, lab supplies, fees to third-party research consultants and compounds. Our development group leads the implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds may be studied in clinical trials. &#8220;Development&#8221; expenses relate primarily to clinical trials, personnel expenses, costs related to our regulatory filings, lab supplies and fees to third-party research consultants. &#8220;Other&#8221; expenses primarily consist of allocated facilities costs and allocated stock-based compensation expense relating to personnel in research and development groups. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition to reviewing the three categories of research and development expense described in the preceding paragraph, we principally consider qualitative factors in making decisions regarding our research and development programs, which include enrollment in clinical trials and the results thereof, the clinical and commercial potential for our drug candidates and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy, which includes the evaluation of potential collaborations for the development of our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Preclinical testing and clinical development are long, expensive and uncertain processes, and we cannot reliably predict the timing of such clinical trial activities. In general, biopharmaceutical development involves a series of steps, beginning with identification of a potential target and including, among others, proof of concept in animals and Phase 1, 2 and 3 clinical trials in humans. Significant delays in clinical testing could materially impact our product development costs and timing of completion of the clinical trials. We do not know whether planned clinical trials will begin on time, will need to be halted or revamped or will be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a trial, delays from scale up, delays in reaching agreement on acceptable clinical trial agreement terms with prospective clinical sites, delays in obtaining institutional review board approval to conduct a clinical trial at a prospective clinical site or delays in recruiting subjects to participate in a clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We currently do not have reliable estimates of total costs for a particular drug candidate to reach the market. Our potential products are subject to a lengthy and uncertain regulatory process that may involve unanticipated additional clinical trials and may not result in receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our potential products may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The following table presents our total research and development expense by category (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.52%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:22.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">From&#160;January&#160;1,&#160;2007*</b></p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">to June 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Categories:</b></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 454</span></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 861</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 957</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 269,917</span></p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,664</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,823</span></p></td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,467</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,763</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 571,942</span></p></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 470</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 495</span></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,238</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,141</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 278,488</span></p></td></tr><tr><td style="vertical-align:bottom;width:32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,540</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,772</span></p></td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,861</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,120,347</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>We started tracking research and development expense by category on January&#160;1, 2007.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">&#8220;Other&#8221; expenses in the three months ended June 30, 2024 and 2023 consisted of allocated facilities costs of $0.2 million and $0.1 million, respectively, and <span style="background:#ffffff;">allocated stock-based compensation expense of $0.3 million and $0.4 million, respectively. For the six months ended June 30, 2024 and 2023, allocated facilities costs was $0.3 million and $0.8 million, respectively, and allocated stock-based compensation expense was $1.0 million and $1.4 million, respectively. The major portion of our total research and development expense in the three and six months ended June 30, 2024 and 2023 was associated with R289, our IRAK 1/4 inhibitor program. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Selling, General and Administrative Expense</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="19" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:63.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative expense</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,047</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,306</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,741</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,496</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,035</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,461</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense included in selling, general and administrative expense</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,223</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,796</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 427</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,707</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,531</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,176</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk70346410"></a><a id="_Hlk96511060"></a><a id="_Hlk528599932"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The increase in selling, general and administrative expense in the three months ended June 30, 2024 compared to the same period in 2023 was primarily due to the increase in personnel-related costs of $1.1 million, increase in stock-based compensation expense of $0.4 million, and increase in other various sales, general and administrative costs of $0.2 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#c0c0c0;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The increase in selling, general and administrative expense in the six months ended June 30, 2024 compared to the same period in 2023 was primarily due to the increase of $3.2 million in stock-based compensation expense primarily from our performance-based stock awards, and increase in personnel-related costs of $1.3 million. This was partially offset by the decrease of $2.0 million in other various sales, general and administrative costs primarily due to lower facilities cost. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_Hlk140162226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We expect to incur significant selling, general and administrative expenses, as we expect our commercial related expenses to increase as we continue to expand our commercial activities for TAVALISSE, REZLIDHIA, and our recently commercialized product, GAVRETO. </span><span style="background:#ffffff;">We continue to deploy resources to enable our field-based employees to engage with healthcare providers. </span>These engagements have enabled our field team to cover existing prescribers, as well as develop relationships with new prescribers to identify appropriate patients for our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interest Income and Interest Expense</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="19" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:35.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:62.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 552</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 529</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,145</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 922</span></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 223</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,029)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,862)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (167)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,903)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,066)</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (837)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Interest income is related to our interest-bearing cash and investment balances. The increase interest income in the three and six months ended June 30, 2024 compared to the same periods in 2023 was primarily driven by higher interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Interest expense comprised primarily of interest on the outstanding term loan with MidCap. Increased interest expense in the three and six months ended June 30, 2024 compared to the same periods in 2023 was primarily due to higher interest on our term loan with Midcap. Also contributing to higher interest expense for the six months ended June 30, 2024 compared to the same period in 2023 was the higher outstanding principal balance of the term loan throughout the respective periods as the Tranche 5 ($20.0 million) term loan was funded in March 2023. </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with US GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our critical accounting estimates and significant accounting policies are described in &#8220;Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Financial Statements&#8221;&#160;contained in Part II, Item&#160;8, &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to these accounting policies except for the accounting consideration related to the Asset Purchase Agreement with Blueprint as discussed in &#8220;Note 5 &#8211; In-licensing and Acquisition&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q.</p><a id="_Hlk70506876"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">See related discussions of recently issued accounting standards in &#8220;Note 1 &#8211; Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q. We continue to evaluate accounting standards that were recently issued but not yet adopted, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">As of June 30, 2024 and December 31, 2023, we had approximately $49.1 million and $56.9 million, respectively, in cash, cash equivalents and short-term investments. We continue to maintain investment portfolios primarily in money market funds, US treasury bills, government-sponsored enterprise securities, corporate bonds and commercial paper. Cash in excess of immediate requirements is invested with regard to liquidity and capital preservation. <span style="background:#ffffff;">We view our investments portfolio as available-for-sale and are available for use in current operations.&#160;</span>Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. We continue to monitor the impact of the changes in the conditions of the credit and financial markets to our investment portfolio and assess if future changes in our investment strategy are necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Following summarizes our cash flow activity for the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.3%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:33.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating activities</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,711)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,856</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investing activities</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,242</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,747</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing activities</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,264)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,750</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,267</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,353</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Net cash used in operating activities for the six months ended June 30, 2024 was primarily due to payments of our operating expenses, partially offset by <span style="background:#ffffff;">proceeds received from sales of our existing commercial products, and cash received from our collaboration partners. Net cash provided by operating activities for the six months ended June 30, 2023 was primarily due&#160;the proceeds from sales of our products, cash received from our collaboration partners including the $20.0 million regulatory milestone payment from Kissei received in January 2023, as well as cash received from government grants, partially offset by the&#160;payments of our&#160;operating expenses.&#160;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by investing activities for the six months ended June 30, 2024 comprised net maturities of short-term investments of $11.6 million, partially offset by payments for acquisition of intangible assets of $0.4 million. <span style="background:#ffffff;">Net cash provided by investing activities for the six months ended June 30, 2023 comprised net maturities of short-term investments of $18.6 million and proceeds from sale of property and equipment of $0.1 million, partially offset by the payment of milestone obligations to Forma recorded as intangible assets of $15.0 million.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Net cash used in financing activities for the six months ended June 30, 2024 comprised cost share payments to a collaboration partner of $3.6 million, partially offset by the net proceeds from issuance of common stock upon exercise of stock options and participation in the Purchase Plan of $0.3 million. <span style="background:#ffffff;">Net cash provided by financing activities for the six months ended June 30, 2023 was primarily due to the net cash proceeds from term loan financing of $20.0 million (Tranche 5) and proceeds from exercise of stock options and participation in the Purchase Plan of $0.6 million,&#160;partially offset by our cost share payments to collaboration partner of $1.8 million.&#160;</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We believe that our existing capital resources will be sufficient to support our current and projected funding requirements, including the continued commercialization of our products, through at least the next 12 months from the Form 10-Q filing date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with commercializing a product, the development of our product candidates and other research and development activities, we are unable to estimate with certainty our future product revenues, our revenues from our current and future collaborative partners, the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials and other research and development activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Since inception, we have financed our operations primarily through sales of equity securities, debt financing, from sales of our products, and contract payments under our collaboration agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Under our existing collaboration agreements that we entered in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2024, total future contingent payments to us under our existing agreements could exceed $1.3 billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#8217; future efforts and achievements of specified development, regulatory and/or commercial events. See further discussion in &#8220;Note 4 &#8211; Sponsored Research, License Agreements and Government Contracts&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q.</p><a id="_Hlk132271680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">We have an Open Market Sale Agreement with Jefferies LLC (Jefferies), as a sole agent, entered on August 4, 2020, and amended and restated on August 2, 2024. Pursuant to such Open Market Sale Agreement, we may sell from time to time, through Jefferies, shares of our common stock in sales deemed to be &#8220;at-the-market offerings&#8221; as defined in Rule 415 under the Securities Act, subject to conditions specified in the Open Market Sale Agreement, including maintaining an effective registration statement covering the sale of shares under the Open Market Sale Agreement. We have a shelf registration statement (the Prior Registration Statement) filed with the SEC that includes </span>a base prospectus registering the offering, issuance, and sale by us of up to $250.0 million in the aggregate of the securities identified from time to time in one or more offerings, which include the $100.0 million of shares of our common stock that may be offered, issued and sold under the Open Market Sale Agreement.<span style="white-space:pre-wrap;background:#ffffff;"> As of June 30, 2024, we have not sold any shares of common stock under such Open Market Sale Agreement. The Prior Registration Statement was set to expire on August 3, 2024. On August 2, 2024, we filed a new shelf registration statement (the New Registration Statement) with the SEC to replace the Prior Registration Statement. The New Registration Statement includes a base prospectus to register the offering, issuance and sale by us of up to $250.0 million in the aggregate of securities identified from time to time in one or more offerings, including up to $100.0 million of shares of our common stock that may be offered, issued and sold under the Open Market Sale Agreement. Under Rule 415(a)(5) under the Securities Act, we may offer and sell any unsold securities under the Prior Registration Statement until the SEC declares the New Registration Statement effective. Once the New Registration Statement is declared effective, all offerings under the Prior Registration Statement will be terminated.  </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We have a Credit Agreement with MidCap that provides for $60.0 million term&#160;loan&#160;credit facility, which was fully funded as of June 30, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Our operations will require significant additional funding in the foreseeable future. Unless and until we can generate sufficient cash from our operating activities, we may choose to raise additional funds through public and/or private offerings of equity securities, debt financings, or from other sources. However, certain external factors such as global pandemics, the global tensions arising from the Russia-Ukraine war and Hamas-Israel war, political and economic legislations, and other factors may continue to rapidly evolve which could significantly disrupt the global financial markets. Our ability to raise additional funds may be adversely impacted by potential worsening of global economic conditions and volatility in the credit and financial markets in the US and worldwide. We could experience an inability to access additional funds, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make important, opportunistic investments.<span style="background:#ffffff;"> To the extent that we raise additional funds through the sale of equity, our shareholders&#8217; ownership interest may experience substantial dilution</span>. Our current credit facility with MidCap and any debt financing that we can obtain in the future may involve operating covenants that may restrict our business. To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required to relinquish some of our rights to our technologies or product candidates or grant licenses on terms that are not favorable to us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">Our future funding requirements will depend upon many factors, including, but not limited to:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ongoing costs to commercialize our products, or any other future product candidates, if any such candidate receives regulatory approval for commercial sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate expected revenue from our commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to secure and maintain our patent protection and regulatory rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to meet operating covenants under our current and future credit facilities, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into partnering opportunities across our pipeline within and outside the US;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of regulatory filings and approvals by us and our collaborators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of research and development programs carried out by us and our collaborative partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes in the breadth of our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to achieve the events identified in our collaborative agreements that may trigger payments to us from our collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to acquire or license other technologies or compounds that we may seek to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manage our growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of obtaining, enforcing and defending our patent and other intellectual property rights, including regulatory rights such as regulatory data exclusivities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with any unforeseen litigation, including any arbitration and securities class action lawsuits.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Insufficient funds may require us to delay, scale back or eliminate some or all of our commercial efforts and/or research or development programs, to lose rights under existing licenses or to relinquish greater or all rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose or may adversely affect our ability to operate as a going concern. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Material Cash Requirements </span></p><a id="_Hlk70404843"></a><a id="_Hlk97202121"></a><a id="_Hlk147304450"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We conduct our commercial activities and research and development programs internally and through third parties that include, among others, arrangements with vendors, consultants, contract research organizations (CROs) and universities. We have contractual arrangements with these parties, however our contracts with them are cancelable generally on reasonable notice within one year and our obligations under these contracts are primarily based on services performed. We do not have any purchase commitments under any collaboration arrangements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">We have agreements with certain clinical research organizations to conduct our clinical trials including our  strategic development collaborations with MDACC and CONNECT, as well as with third parties relative to our commercialization of our products. The timing of payments for any amounts owed under the respective agreements will depend on various factors including, but not limited to, patient enrollment and other progress of the clinical trials, and various activities related to commercialization. We expect that we will continue to enter into contracts in the normal course of business with various third parties who support our clinical trials, support our preclinical research studies, and provide other services related to our operating purposes as well as our commercialization of our products. We can terminate these agreements at any time, and if terminated, we would not be liable for the full amount of the respective agreements. Instead, we will be liable for services provided through the termination date plus certain cancellation charges, if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be subjected to amendments as a result of any change orders executed by the parties. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As discussed in detail in &#8220;Note 4 &#8211; Sponsored Research, License Agreements and Government Contracts&#8221; of our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, pursuant to the amended Lilly Agreement, and us providing the first opt-out notice to Lilly on September 29, 2023, we were responsible for funding the development costs for ocadusertib (previously R552) in the US, Europe, and Japan, through April 1, 2024, capped at a specified amount. Lilly billed us $21.4 million of the funding development costs incurred through April 1, 2024 and the amount was fully paid as of June 30, 2024. Although currently we are no longer obligated to pay Lilly for our share in the ocadusertib development cost incurred subsequent to April 1, 2024, under the Lilly Agreement, we have the right to opt-in to co-funding the ocadusertib development, upon us providing notice to Lilly within 30 days of certain events, as specified in the Lilly Agreement. If we decide to exercise our opt-in right, we will be required to continue to share in global development costs, and if we later exercise our second opt-out right (no later than April 1, 2025), our share in global development costs will be up to a specified cap through December 31, 2025, as provided for in the Lilly Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">As discussed in detail in &#8220;Note 5 &#8211; In-licensing and Acquisition&#8221; of our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, </span><span style="font-size:10pt;">pursuant to an Asset Purchase Agreement with Blueprint entered in February 2024, we agreed to pay Blueprint a purchase price of $15.0 million, of which, $10.0 million was paid in July 2024 following our first commercial sale of GAVRETO at end of June 2024, and an additional $5.0 million is payable on the first anniversary of the closing date of the agreement, subject to certain conditions. Blueprint is also eligible to receive up to $97.5 million in future commercial milestone payments and up to $5.0 million in future regulatory milestone payments, in addition to tiered royalties ranging from 10% to 30%. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, as discussed in detail in &#8220;Note 5 &#8211; In-licensing and Acquisition&#8221; of our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, pursuant to our license and transition services agreement, Forma is entitled to potential development and regulatory milestone payments of up to $67.5 million, commercial milestone payments of up to $165.5 million, and tiered royalty payments. In 2022, certain milestones were met which entitled Forma to receive $17.5 million milestone payments, of which, $2.5 million was paid in the fourth quarter of 2022 and $15.0 million was paid in the first quarter of 2023. No new milestone was met in 2023 and during the six months ended June 30, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of June 30, 2024, we have a contractual commitment related to our leased facilities of $0.7 million and the amount is payable within 12 months. See &#8220;Note 11 &#8211; Leases&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q for further discussions of our leases. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed above, we have a contractual commitment with respect to our credit facility with MidCap, and as of June 30, 2024, the outstanding principal amount of the loan was $60.0 million. As discussed in detail in &#8220;Note 10 &#8211; Debt&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, the term loans mature on September 1, 2027, and the interest-only period is through October 1, 2025. The term loans bear interest equal to the sum of one-month SOFR<span style="background:#ffffff;"> plus an adjustment of 0.11448%, subject to a 4.00% applicable floor, plus applicable margin of&#160;6.50%. A final payment fee of </span>4.25% of principal is due at maturity date. As of June 30, 2024, no principal payments are due within 12 months. As of June 30, 2024, future interest calculated using the base interest rate as per the amended Credit Agreement, and the final fee payments associated with the credit facility amounted to $17.6 million, of which, approximately $6.6 million is payable within 12 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">We are also subject to claims related to the patent protection of certain of our technologies, as well as purported securities class action lawsuit, other litigations, and other contractual agreements. We are required to assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual matter. We do not have other material contractual commitments with respect to matters discussed above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_077a6fb9_2bbd_4505_8989_c88eadce1eac"></a><a id="Item3_QuantitativeandQualitative_065227"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:34.65pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 3.</b></span><b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities related to our investments and borrowings.&#160;There were no material changes to our quantitative and qualitative disclosures about market risks during the six months ended June 30, 2024 as disclosed in &#8220;Item 7A. Quantitative and Qualitative Disclosures About Market Risks&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2023. </p><a id="_3cfa3659_0263_4aef_9e78_e31d920dbbf3"></a><a id="Item4_ControlsandProcedures_065229"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:34.65pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 4.</b></span><b style="font-weight:bold;">Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Evaluation of Disclosure Controls and Procedures. </i>Based on the evaluation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act), our chief executive officer (who serves as our principal executive officer) and our chief financial officer (who serves as our principal financial officer) have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective.</p><a id="_Hlk511985372"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Changes in Internal Controls. </i>There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2024 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">Limitations on the Effectiveness of Controls. </i>A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the controls are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our chief executive officer and chief financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were sufficiently effective to provide reasonable assurance that the objectives of our disclosure control system were met.</p><a id="_63005913_c334_44e3_86c7_c79a47fee6f3"></a><a id="PARTII_OTHERINFORMATION_065230"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">PART&#160;II. OTHER INFORMATION</b></p><a id="Item1_LegalProceedings_065231"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Item 1. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">From time to time, we may be a party or subject to legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings that we may be involved in the future, are claims that are subject to substantial uncertainties and unascertainable damages or other remedies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our threshold for disclosing material environmental legal proceedings involving a government authority where potential monetary sanctions are involved is $1.0 million.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In June 2022, we received a notice letter regarding an ANDA submitted to the FDA by Annora Pharma Private Limited (Annora), requesting approval to market a generic version of TAVALISSE. The notice letter included a Paragraph IV certification with respect to our US Patent Nos. 7,449,458; 8,263,122; 8,652,492; 8,771,648 and 8,951,504, which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (referred to as the &#8220;Orange Book&#8221;). The notice letter asserts that these patents will not be infringed by Annora&#8217;s proposed product, are invalid and/or are unenforceable. Annora&#8217;s notice letter does not provide a Paragraph IV certification against our other patents listed in the Orange Book. On July 25, 2022, we filed a lawsuit in the US District Court for the District of New Jersey against Annora and its affiliates, Hetero Labs Ltd., and Hetero USA, Inc., for infringement of our US patents identified in Annora&#8217;s Paragraph IV certification. On September 21, 2022, Annora and its affiliates answered and counterclaimed for declaratory judgment of non-infringement and invalidity of the &#8217;458, &#8217;122, &#8217;492, &#8217;648, and &#8217;504 patents. We served an answer to Annora&#8217;s counterclaims in October 2022. Annora served invalidity and non-infringement contentions in December 2022. We served an answer to Annora&#8217;s invalidity and non-infringement contentions in March 2023. Litigation continues, and no trial date is currently set. <span style="white-space:pre-wrap;">We intend to vigorously enforce and defend our intellectual property related to TAVALISSE.  </span></p><a id="_9ebca11f_5225_42f2_b4ad_f2d674a56158"></a><a id="Item1A_RiskFactors_065233"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;1A.</b></span><b style="font-weight:bold;">Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">In evaluating our business, you should carefully consider the following risks, as well as the other information contained in this Quarterly Report on Form&#160;10-Q. These risk factors could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form&#160;10-Q and those we may make from time to time. If any of the following risks actually occurs, our business, financial condition and operating results could be harmed. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><i style="font-style:italic;">We have marked with an asterisk (*) those risk factors below that reflect a substantive change from the risk factors included in our Annual Report on Form&#160;10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024, if any.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Risk Factor Summary</b></p><div style="margin-top:9pt;"><a id="_Hlk159858553"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our prospects are highly dependent on our existing commercial products, TAVALISSE (fostamatinib disodium hexahydrate), REZLIDHIA (olutasidenib), and GAVRETO (pralsetinib). To the extent that the commercial success of our products in the US and respective territories outside of the US is diminished or halted, our business, financial condition and results of operations may be adversely affected, and the price of our common stock may decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to successfully develop or commercialize our product candidates if problems arise in the clinical testing and/or approval process. There is a high risk that drug discovery and development efforts might not generate successful product candidates. If the results of our clinical trials do not meet the primary efficacy endpoints, or if the top-line data from the results of our clinical trials may not ultimately meet the requirements for an NDA approval by the FDA and other regulatory authorities, the commercial prospects of our business may be harmed, and our ability to generate product revenues may be delayed or eliminated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our strategy to expand our hematology and oncology pipeline on our own, or through acquisitions or in-licensing of early or late-stage products or companies, or through partnerships with pharmaceutical and biotechnology companies, as well as academic institutions and government organizations, may not be successful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we, or any of our collaborative partners, are able to continue to commercialize our products or any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, unfavorable </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">health technology assessments (HTA)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, third-party payor reimbursement practices or labeling restrictions, all of which may vary from country to country and any of which could harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to successfully market and distribute our products and retain experienced commercial personnel, our business will be substantially harmed.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to stringent and evolving healthcare regulatory, privacy and information security laws, regulations, rules, policies and contractual obligations, and changes in such laws, regulations, rules, policies, contractual obligations and our actual or perceived failure to comply with such requirements could subject us to significant investigations, audits, fines, penalties, and claims, any of which may have a material adverse effect on our business, financial condition, results of operations or prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unforeseen safety issues could emerge with our products that could require us to change the prescribing information to add warnings, limit use of the product, and/or result in litigation. Any of these events could have a negative impact on our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely and may continue to rely on third-party distribution facilities for the sale of our products and potential sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be interrupted or otherwise adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We lack the capability to manufacture compounds for clinical development and we intend to rely on third parties for commercial supply, manufacturing and distribution, if any, of our product candidates which receive regulatory approval and we may be unable to obtain required material or product in a timely manner, at an acceptable cost or at a quality level required to receive regulatory approval. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, EMA, MHRA and other comparable regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we may be unable to generate revenue from the sale of such products, our potential for generating positive cash flow may be diminished, and the capital necessary to fund our operations will be increased. Additionally, approval of a drug under the accelerated drug approval program may be withdrawn or the labeled indication of the drug changed if trials fail to verify clinical benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our corporate collaborations or license agreements are unsuccessful, or if we fail to form new corporate collaborations or license agreements, our research and development efforts could be delayed.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 31.5pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our success is dependent on securing intellectual property rights and data exclusivity and other regulatory rights (such as orphan exclusivity, pediatric extensions and supplementary protection certificate) held by us and third parties, and our interest in such rights is complex and uncertain.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 13.5pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If a dispute arises regarding the infringement or misappropriation of the proprietary rights of others, such dispute could be costly and result in delays in our research and development activities, partnering and commercialization activities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 31.5pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our competitors develop technologies that are more effective than ours, our commercial opportunity will be reduced or eliminated.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Risks Related to Our Business and Our Industry</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:9pt 0pt 9pt 0pt;">Certain of the diseases that our products and our other product candidates being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for our products and our other product candidates may be smaller than what we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to continue to increase the size of our organization and we may encounter difficulties with managing our growth, which could adversely affect our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:9pt 0pt 9pt 0pt;">While we have substantially increased the size of our organization particularly in our sales force in 2021, we also implemented reductions in workforce particularly in our research and development group in 2021 and 2022. We may need to add additional qualified personnel and resources to support our commercial activities and expected growth. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including commercialization of our products and development of our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:6pt 0pt 6pt 0pt;">Our future financial performance and our ability to sustain successful commercialization of our products and our ability to commercialize other product candidates that may receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In particular, as we continue to commercialize our products, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manage our development efforts effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">integrate additional management, administrative and manufacturing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further develop our marketing and sales organization; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain sufficient administrative, accounting and management information systems and controls.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:27.8pt;margin:9pt 0pt 0pt 0pt;">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development, and commercialization goals. Our failure to accomplish any of these goals, including as a result of business or other interruptions resulting from a potential pandemic or global economic slowdown, could adversely affect our business and operations.</p><a id="_Hlk158890105"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our strategy to expand our hematology and oncology pipeline on our own, or through acquisitions or in-licensing of early or late-stage products or companies, or through partnerships with pharmaceutical and biotechnology companies, as well as academic institutions and government organizations, may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-top:3pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Our business is focused on the development and commercialization of novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. In this regard, we continue to pursue internal drug discovery efforts or partnerships with pharmaceutical and biotech companies, as well as academic institutions and government organizations, with the goal of identifying new product candidates to advance into clinical trials. Our discovery efforts to identify new product candidates require substantial technical, financial and human resources. These discovery efforts may initially show promise in identifying potential product candidates, yet ultimately fail to yield product candidates for clinical development for a number of reasons. For example, potential product candidates may, on later stage clinical trial, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Apart from our discovery efforts, we continue to seek to broaden and diversify our product portfolio through acquisition or in-licensing of a product. This strategy is dependent on our ability to successfully identify and acquire or in-license relevant product candidates. In July 2022, we entered into a license and transition services agreement with Forma for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mIDH1, for any uses worldwide, including for the treatment of AML and other malignancies. <span style="background:#ffffff;">On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with a susceptible IDH1 mutations as detected by an FDA-approved test. REZLIDHIA is our second commercial product and we believe is highly synergistic with our existing hematology-oncology focused commercial and medical affairs infrastructure. Further, in February 2024, we entered into an Asset Purchase Agreement with Blueprint to </span>purchase certain assets comprising the right to research, develop, manufacture and commercialize GAVRETO, Blueprint&#8217;s proprietary RET inhibitor of tyrosine kinase for the treatment of metastatic RET fusion-positive NSCLC and advanced thyroid cancer, in the US. Simultaneously and in connection with entering into the Asset Purchase Agreement, we also entered into certain supporting agreements with Blueprint, including a customary transition agreement, pursuant to which, during a transition period, Blueprint will transition regulatory and distribution responsibility for pralsetinib to us. On June 24, 2024, we announced the completion of the transfer of GAVRETO NDA to us, and GAVRETO became commercially available from us in the US by prescription beginning on June 27, 2024.<span style="background:#ffffff;"> </span>The in-licensing and acquisition of a product is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more well-established and diverse revenue streams may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. <span style="background:#ffffff;">The success of this strategy depends partly upon our ability to identify, select and acquire or&#160;in-license&#160;promising product candidates and technologies. The process of proposing, negotiating and implementing a license or acquisition of a product candidate is lengthy and complex, and we may be unable to&#160;in-license&#160;or acquire the rights to any such products, product candidates or technologies from third parties for several reasons. </span>We may also be unable to in-license or acquire additional relevant product candidates on acceptable terms. <span style="background:#ffffff;">Further, even if we identify acquisition or&#160;in-licensing&#160;targets, we may not be able to complete the transactions or we may determine after due diligence investigation not to pursue identified targets. </span>Even if we succeed in our efforts to obtain rights to suitable product candidates, the success of our investments in these areas, our investment strategy will remain subject to the inherent risks associated with the development and commercialization of the product, and with the competitive business environment in which we operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, acquisitions and in-licensing may entail numerous operational, financial and legal risks, including:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential failure of the due diligence process to identify significant problems, liabilities or other shortcomings or challenges of an acquired or licensed product candidate or technology, including problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, partner disputes or issues and other legal and financial contingencies and known and unknown liabilities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to integrate the target company or in-licensed asset successfully into our existing business, inability to maintain the key business relationships of the target,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in an in-licensing or an asset acquisition of a product that is commercially available in the market, we may not be able to successfully transition the existing patients who are dependent to the acquired or in-licensed product, or successfully enter into a reimbursement coverage contracts that the existing patients were previously dependent into, or successfully enter into a contract with contract manufacturers to continue the production of the in-licensed or acquired product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumption of unknown or contingent liabilities or incurrence of unanticipated expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to known and unknown liabilities, including possible intellectual property infringement claims, violations of laws, tax liabilities and commercial disputes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than expected acquisition and integration costs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to maintain uniform standards, controls, procedures and policies;</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is a high risk that drug discovery and development efforts might not generate successful product candidates.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We currently have product candidates in the clinical testing stage and may further pursue to expand our clinical testing efforts. In our industry, it is statistically unlikely that the limited number of compounds that we have identified as potential product candidates will actually lead to successful product development efforts. We have invested a significant portion of our efforts and financial resources into clinical development. Our ability to generate product revenue, which will not occur until after regulatory approval, if ever, will depend on the successful development, regulatory approval and eventual commercialization of our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our compounds in clinical trials and our future leads for potential drug compounds are subject to the risks and failures inherent in the development of pharmaceutical products. These risks include, but are not limited to, the inherent difficulty in selecting the right drug and drug target and avoiding unwanted side effects, as well as unanticipated problems relating to product development, testing, enrollment, obtaining regulatory approvals, obtaining and maintaining reimbursement in national markets and positive recommendation from HTA bodies, maintaining regulatory compliance, manufacturing, competition and costs and expenses that may exceed current estimates. In future clinical trials, we or our partners may discover additional side effects and/or a higher frequency of side effects than those observed in previously completed clinical trials. The results of preliminary and mid-stage clinical trials do not necessarily predict clinical or commercial success, and larger later-stage clinical trials may fail to confirm the results observed in the previous clinical trials. Similarly, a clinical trial may show that a product candidate is safe and effective for certain patient populations in a particular indication, but other clinical trials may fail to confirm those results in a subset of that population or in a different patient population, which may limit the potential market for that product candidate. With respect to our own compounds in development, we have established anticipated timelines with respect to the initiation of clinical trials based on existing knowledge of the compounds. However, we cannot provide assurance that we will meet any of these timelines for clinical development. Additionally, the initial results of a completed earlier clinical trial of a product candidate do not necessarily predict final results and the results may not be repeated in later clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because of the uncertainty of whether the accumulated preclinical evidence (PK, pharmacodynamic, safety and/or other factors) or early clinical results will be observed in later clinical trials, we can make no assurances regarding the likely results from our future clinical trials or the impact of those results on our business. For example, we conducted a <span style="color:#222222;background:#ffffff;">Phase 3 pivotal trial of fostamatinib in patients with wAIHA initiated</span> in March 2019 and completed in April 2022. In June 2022, we announced top-line efficacy and safety data results of the trial, and the <span style="color:#222222;background:#ffffff;">results did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population</span>. <span style="color:#222222;white-space:pre-wrap;background:#ffffff;">We conducted an in-depth analysis of these data to better understand differences in patient characteristics and outcomes and submitted these findings to the FDA. In October 2022, we announced that we received guidance from the FDA&#8217;s review of these findings. Based on the result of the trial and the guidance from the FDA, we did not file an sNDA for this indication. Further, we may experience errors in the analysis of our clinical trial results.  For example, we conducted our Phase 3 clinical trial to evaluate safety and efficacy of fostamatinib in hospitalized COVID-19 patients launched in November 2020 and completed enrollment in July 2022. </span><span style="background:#ffffff;">We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint. Upon further analysis, we discovered an error by the biostatistical CRO in the application of a statistical stratification factor. After correcting for this statistical error, the primary endpoint of the study was met. However, given the end of the federal COVID-19 PHE in May 2023, and based on feedback from the FDA, DOD and other advisors regarding the program&#8217;s regulatory requirements, costs, timeline and potential for success, we decided not to submit an EUA or sNDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Foreign regulatory requirements governing clinical trials may diverge and impose additional regulatory burdens, which may result in delays. For instance, the new EU Clinical Trials Regulation (EU) No 536/2014 (CTR) has amended the system of approval for clinical trials in the EU and has established a new clinical trials portal and database for application for authorizations, called the Clinical Trials Information System (CTIS). All ongoing clinical trials in the EU will be subject to the provisions of the CTR as of January 31, 2025. In addition, on June 18, 2024, new CTIS transparency rules came into effect, requiring scheduled publication of certain key clinical trial information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the results of our clinical trials fail to meet the primary efficacy endpoints, or otherwise do not ultimately meet the requirements for an NDA approval by the FDA, the commercial prospects of our business may be harmed, our ability to generate product revenues may be delayed or eliminated or we may be forced to undertake other strategic alternatives that are in our shareholders&#8217; best interests, including cost reduction measures. If we are unable to obtain adequate financing or engage in a strategic transaction on commercially reasonable terms or at all, we may be required to implement further cost reduction strategies which could significantly impact activities related to our commercial efforts and/or research and development of our future product candidates, and could significantly harm our business, financial condition and results of operations. In addition, these cost reduction strategies could cause us to further curtail our operations or take other actions that would adversely impact our shareholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to comply with such laws could result in substantial penalties. Our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable federal, state and foreign fraud and abuse and other healthcare laws and regulations including anti-kickback and false claims laws, data privacy and security laws, and transparency reporting laws. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws and regulations intended to prevent fraud, misconduct, bribery kickbacks, self-dealing and other abusive or inappropriate practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, including promoting off-label uses of our products, certain commission compensation, certain customer incentive programs, certain patient support offerings, and other business arrangements generally. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of patient recruitment for clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. </span><span style="font-size:10pt;background:#ffffff;">See &#8220;Business &#8211; Government Regulation &#8211;&#160;Healthcare and Privacy Law and Regulation and Healthcare Reform&#8221; contained in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2023, for more information on the healthcare laws and regulations that may affect our ability to operate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are also exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the US and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">We are also subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. Efforts to ensure that our business arrangements will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 9pt 0pt;"><span style="font-size:10pt;">affect our ability to operate our business and our results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to stringent and evolving privacy and information security laws, regulations, rules, policies, and contractual obligations, and changes in such laws, regulations, rules, policies, contractual obligations and our actual or perceived failure to comply with such requirements could subject us to significant investigations, fines, penalties and claims, any of which may have a material adverse effect on our business, financial condition, results of operations or prospects.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are subject to, or affected by, various federal, state and foreign laws, rules, directives, and regulations, as well as regulatory guidance, policies and contractual obligations relating to privacy and information security, governing the acquisition, collection, access, use, disclosure, processing, modification, retention, storage, transfer, destruction, protection, and security (collectively, &#8220;processing&#8221;) of personal information and other sensitive information about individuals. The global privacy and information security landscape is evolving rapidly, and implementation standards and enforcement practices are likely to continue to develop for the foreseeable future and may result in conflicting or inconsistent compliance obligations. Legislators and regulators are increasingly adopting or amending privacy and information security laws, rules, directives, and regulations that may create uncertainty in our business, affect our or our collaborators&#8217;, service providers&#8217; and contractors&#8217; ability to operate in certain jurisdictions or to process personal information, transfer data internationally, necessitate the acceptance of more onerous obligations in our contracts, result in enforcement actions, litigation or other liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us or our collaborators, service providers and contractors to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing the processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions, litigation, and other consequences for noncompliance with privacy and information security laws and regulations are rising. Compliance with applicable privacy and information security laws and regulations, as well as regulatory guidance, policies and contractual obligations, is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms to ensure compliance with the new privacy and information security requirements. If we fail to comply with any such obligations, we may face significant investigations, fines, penalties and claims that could materially and adversely affect our business, financial condition, results of operations, ability to process personal information and income from certain business initiatives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In the US, these obligations include various federal, state, and local statutes, rules, and regulations relating to privacy and data security. The Federal Trade Commission (FTC) has authority under Section 5 of the FTC Act to regulate unfair or deceptive or practices, and has used this authority to initiate enforcement actions against companies that implement inadequate controls around privacy and information security in violation of their externally facing policies. The FTC has recently brought several cases alleging violations of Section 5 of the FTC Act with respect to health information, and has proposed rulemaking on privacy and data security, including with respect to the Health Breach Notification Rule. Additionally, the FTC published an advance notice of proposed rulemaking in 2022 on commercial surveillance and data security, and may propose regulation concerning the ways in which companies collect, aggregate, protect, use, analyze, and retain consumer data, as well as transfer, share, sell, or otherwise monetize that data in the coming years. Additionally, the US federal government has also enacted statutes to address privacy and information security issues impacting particular industries or activities, including the following laws and regulations: the Electronic Communications Privacy Act, the Computer Fraud and Abuse Act, the Health Insurance Portability and Accountability Act (HIPPA), the Health Information Technology for Economic and Clinical Health Act, the Telephone Consumer Protection Act, the CAN-SPAM Act, and other laws and regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">In addition, state legislatures have enacted statutes to address privacy and information security issues, including the California Consumer Privacy Act of 2018 (the CCPA). For example, the CCPA, as amended by the California Privacy Rights Act (CPRA) in 2020, establishes a privacy framework applicable to for-profit entities that are doing business in California, including an expansive definition of personal information and data privacy rights for California residents, and authorizes potentially severe statutory damages and creates a private right of action for certain data security breaches. The CCPA also requires businesses subject to the law to provide disclosures to California residents and to provide them with rights with respect to their personal information, including the right to opt out of the sale of such information. Moreover, the CPRA, among other things, impose new requirements relating to data minimization and correction, and gives California residents additional rights over their personal information, including the right to opt-out of the use of their personal information in online behavioral advertising and to opt-out of certain types of consumer </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">profiling. The CPRA also provides for penalties for CPRA violations concerning California residents under the age of 16, and establishes a new California Privacy Protection Agency to implement and enforce the law. Although there are limited exemptions for clinical trial and other research-related data under the CCPA, the CCPA and other similar laws could impact our business depending on how it will be interpreted by the new California Privacy Protection Agency. As we expand our operations, the CCPA may increase our compliance costs and potential liability. Multiple other states have followed California and enacted comprehensive privacy laws. Additionally, multiple states have enacted or are considering similar legislation which will go into effect in the coming years, and Congress continues to consider federal privacy legislation. While these proposals and new laws generally include exemptions for HIPAA-covered and clinical trial data, they add layers of complexity to compliance in the US market, and could increase our compliance costs and adversely affect our business. Moreover, compliance with state laws related to health privacy may cause additional compliance costs such as the Washington My Health My Data Act and Nevada&#8217;s Consumer Health Data Privacy Law. Many states also have in place data security laws requiring companies to maintain certain safeguards with respect to the processing of personal information, and all states require companies to notify individuals or government regulators in the event of a data breach impacting such information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Laws and regulations relating to privacy, data protection, consumer protection and information security are evolving and subject to potentially differing interpretations. These requirements may be interpreted and applied in a manner that varies from one jurisdiction to another and/or may conflict with other laws or regulations. New laws and regulations add additional complexity, requirements, restrictions and potential legal risk. Accordingly, compliance programs may require additional investment in resources, and could impact availability of previously useful data. </p><a id="EUGDPR"></a><a id="GDPR"></a><a id="EEA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Internationally, our operations abroad may also be subject to increased scrutiny or attention from foreign data protection authorities. For example, our clinical trial programs and research collaborations outside the US may implicate foreign data protection laws, including those in the European Economic Area, Switzerland, and/or the UK (collectively, Europe). Many jurisdictions have established or are in the process of establishing privacy and data security legal frameworks with which we, our collaborators, service providers, including our CROs, and contractors must comply. For example, in the EU, the collection, use, disclosure, transfer and other processing of personal data (i.e., data which identifies an individual or from which an individual is identifiable) is governed by the EU General Data Protection Regulation 2016/679 (the EU GDPR), which came into direct effect in all EU Member States on and from May 25, 2018. The UK has implemented the EU GDPR as the UK GDPR which sits alongside the UK Data Protection Act 2018 (the UK GDPR, together with the EU GDPR, the GDPR). The GDPR has direct effect where an entity is established in the European Economic Area (EEA) or the UK (as applicable) and has extraterritorial effect, including where an entity established outside of the EEA or the UK processes personal data in relation to offering goods or services to individuals in the EEA and/or the UK or monitoring their behavior.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The GDPR imposes obligations on controllers, including, among others: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accountability and transparency requirements, requiring controllers to demonstrate and record compliance with the GDPR and to provide more detailed information to data subjects regarding processing of their personal data; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to process personal data lawfully including specific requirements for obtaining valid consent where consent is the lawful basis for processing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obligations to consider data protection when any new products or services are developed and designed (including e.g., to limit the amount of personal data processed);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obligations to comply with data protection rights of data subjects including a right: (i) of access to, erasure of, or rectification of personal data, (ii) to restriction of processing or to withdraw consent to processing, and (iii) to object to processing or to ask for a copy of personal data to be provided to a third party; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an obligation to report personal data breaches to: (i) the data supervisory authority without undue delay (and no later than 72 hours after discovering the personal data breach, where feasible), unless the personal data breach is unlikely to result in a risk to the data subjects&#8217; rights and freedoms; and (ii) to affected data subjects, where the personal data breach is likely to result in a high risk to their rights and freedoms. </span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the EU GDPR prohibits the international transfer of personal data from the EEA to jurisdictions that the European Commission does not recognize as having &#8216;adequate&#8217; data protection laws unless a data transfer mechanism has been put in place or a derogation under the EU GDPR can be relied on. In July 2020, the Court of Justice of the EU (CJEU) in its Schrems II judgement limited how organizations could lawfully transfer personal data from the EEA to the US by invalidating the EU-US Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (EU SCCs), including a requirement for companies to carry out a transfer privacy impact assessment (TIAs). A TIA, among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under EU SCCs will need to be implemented to ensure an &#8216;essentially equivalent&#8217; level of data protection to that afforded in the EEA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On October 7, 2022, US President Biden introduced an Executive Order to facilitate a new Trans-Atlantic Data Privacy Framework (DPF) and on July 10, 2023, the European Commission adopted its Final Implementing Decision granting the US adequacy (Adequacy Decision) for EU-US transfers of personal data for entities self-certified to the DPF. Entities relying on EU SCCs for transfers to the US. are also able to rely on the analysis in the Adequacy Decision as support for their TIA regarding the equivalence of US national security safeguards and redress. This may have implications for our cross-border data flows and has and may in the future result in increased compliance costs.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The UK GDPR also imposes similar restrictions on transfers of personal data from the UK to jurisdictions that the UK Government does not consider adequate, including the US. The UK Government has published its own form of the EU SCCs, known as the International Data Transfer Agreement and an International Data Transfer Addendum to the new EU SCCs. The UK Information Commissioner&#8217;s Office has also published its version of the TIA and guidance on international transfers, although entities may choose to adopt either the EU or UK style TIA. Further, on September 21, 2023, the UK Secretary of State for Science, Innovation and Technology established a UK-US data bridge (i.e., a UK adequacy decision) and adopted UK regulations to implement the UK-US data bridge (UK Adequacy Regulations). The UK Adequacy Regulations have now been passed in the UK Parliament, and personal data may be transferred from the UK under the UK-US data bridge through the UK extension to the DPF, from October 12, 2023, to organizations self-certified under the DPF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The GDPR imposes fines for serious breaches of up to the higher of 4% of the organization&#8217;s annual worldwide turnover or &#8364;20 million (under the EU GDPR) or &#163;17.5 million (under the UK GDPR). The GDPR identifies a list of points to consider when determining the level of fines for data supervisory authorities to impose (including the nature, gravity and duration of the infringement). Data subjects also have a right to compensation, as a result of an organization&#8217;s breach of the GDPR which has affected them, for financial or non-financial losses (e.g., distress). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Privacy and data protection compliance has and may in the future require substantial amendments to our procedures and policies and the changes could adversely impact our business by increasing operational and compliance costs or impact business practices. Further, there is a risk that the amended policies and procedures will not be implemented correctly or that individuals within the business will not be fully compliant with the new procedures. If there are breaches of these measures, we could face significant litigation, government investigations, administrative and monetary sanctions as well as reputational damage which may have a material adverse effect on our operations, financial condition and prospects. There is a risk that we could be impacted by a cybersecurity incident that results in loss or unauthorized disclosure of personal data, potentially resulting in us facing harms similar to those described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, with strict requirements and limitations for processing personal information, which could increase the cost and complexity of delivering our services and operating our business. For example, Brazil enacted the General Data Protection Law, New Zealand enacted the New Zealand Privacy Act, China released its Personal Information Protection Law, which went into effect November 1, 2021, and Canada introduced the Digital Charter Implementation Act. As with the EU GDPR, these laws are broad and may increase our compliance burdens, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain, and process personal information about them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">policies and other documentation, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees, collaborators, contractors, service providers or vendors fail to act in accordance with our published policies and documentation. Such failures can subject us to potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, trial participants or research subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information or exercise their right to do so under applicable privacy legislation. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy policies and documentation, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to data privacy requirements, cybersecurity requirements are laid down in various laws in the EU and the UK, the key ones being: (i) the GDPR (as discussed in detail above), which requires controllers and processors to implement appropriate technical and organizational measures to safeguard personal data to a level of security appropriate to the data protection risk; and (ii) the UK Network and Information Systems Regulation 2018 (NIS Regulations), and the EU Network and Information Systems Security 1 Directive (NISD1) as implemented into EU Member State law (and as updated by the EU Network and Information Systems Security 2 Directive (NISD2)).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The GDPR does not provide for a specific set of cybersecurity requirements or measures to be implemented, but rather requires a controller or processor to implement appropriate cyber and data security measures in accordance with the then-current risk, the state of the art, the costs of implementation and the nature, scope, context and purposes of the processing. The GDPR however does explicitly require that controllers notify personal data breaches, within the meaning of the GDPR, without undue delay and in any event within 72 hours after becoming aware of it, to the relevant data protection supervisory authority, unless the breach is unlikely to result in a risk to the rights and freedoms of individuals. In addition, controllers are required to notify the individuals concerned of any personal data breach, without undue delay, when the personal data breach is likely to result in a high risk to the rights and freedoms of individuals. Processors are required to notify the controller without undue delay after becoming aware of a personal data breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In the UK, the NIS Regulations apply to &#8216;operators of essential services&#8217; (OES) and &#8216;relevant digital service providers&#8217; (RDSP) and it was announced in January 2022, that the NIS Regulations will be updated to also cover &#8216;managed service providers&#8217; (MSP) and potentially other digital service providers. The NIS Regulations require that appropriate and proportionate technical and organizational measures are implemented to manage the risk of network and information systems, and impose requirements related to incident handling and notification in relation to incidents with significant disruptive effect. Under the NIS Regulations, the UK&#8217;s data protection supervisory authority, the Information Commissioner&#8217;s Office, may issue fines of up to &#163;17 million and take other action following non-compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EU, the NISD1 applies to &#8216;operators of essential services&#8217; (OES) and &#8216;digital service providers&#8217; (DSP) and an updated version of NISD1 has been adopted and entered into force on January 17, 2023, called NISD2. The NISD2 will take full effect following implementation into national EU Member State law (i.e., by October 17, 2024). Under the NISD1, OESs and DSPs are required to implement appropriate and proportionate technical and organizational measures to manage the risk of network and information systems, and adhere to incident handling and notification requirements regarding incidents with significant disruptive effect. Importantly, under the NISD2, more stringent cybersecurity and incident reporting requirements are imposed on &#8216;essential&#8217; and &#8216;important&#8217; entities, which include ICT managed service providers (MSP), cloud service providers as well as entities carrying out research and development activities of medicinal products, and certain specific medical device manufacturers. Our entities may be in scope of the NISD2 where they qualify as a MSP, cloud provider, R&amp;D entity and/or medical device manufacturer within the meaning of NISD2 and offer those services in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The NISD2 empowers the EU Member States to define all rules regarding penalties applicable to infringements, provided that they are effective, proportionate, and dissuasive. NISD2 states that any maximum fine which national implementing law provides for should at least be set at &#8364;10 million or 2% of total worldwide turnover, whichever is higher, where essential entities are concerned. Other sanctions may include (i) a temporary suspension to provide services in the EU (by suspending relevant authorizations/certifications); (ii) an order to make public certain elements of the infringement and/or inform customers; and (iii) injunctions to immediately cease infringing conduct. Importantly, NISD2 also provides that senior members of staff can be held personally liable, and face administrative fines or be temporarily suspended from exercising managerial functions at the legal representative or chief executive officer level.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk154147291"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the EU Critical Entities Resilience Directive (CER) entered into force on January 17, 2023 and will take full effect following implementation into national EU Member State law (i.e., by October 17, 2024 &#8211; coinciding with the NISD2). The CER is aimed at strengthening the resilience of &#8216;critical infrastructure&#8217; against specific threats including cyber incidents, natural hazards, terrorist attacks, insider threats, and sabotage. The scope of CER includes entities designated as &#8216;critical&#8217; under CER and includes (among other things) the health sector and the manufacturers of medical devices as &#8216;essential services.&#8217; The CER imposes cybersecurity and resilience requirements in particular in relation to incidents with so-called &#8216;significant disruptive effects&#8217; &#8211; which are incidents that are able to significantly impact the continuation of the critical infrastructure service offering in the EU. Requirements include to: (i) identify relevant risks that may significantly disrupt the provision of essential services (i.e., pursuant to a risk assessment); (ii) take appropriate and proportionate technical, security and organizational measures to ensure resilience (i.e., based on the outcome of the risk assessment); and (iii) notify disruptive incidents to the competent authorities within 24 hours after becoming aware of an incident. The CER is enforceable on a national EU Member State level by the competent authorities, and allows EU Member States to set penalties as long as they are effective, proportionate, and dissuasive. Our entities may be in scope of the CER where they qualify as critical entities within the meaning of CER.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk154146125"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In the EU, a number of new laws related to digital data and AI have also recently entered into force, are expected to enter into force in the foreseeable future, or have been proposed and are being considered. We are still assessing the scope of application, impact, and risk of these recent EU laws on our business, and will continue to assess this moving forward, including for example: (i) the EU&#8217;s Data Act&#8211; came into force as of December 13, 2023 which seeks to, among other things regulate the use of, and access to, data generated through connected (or Internet-of-Things) devices and introduces a new means for public sector bodies to access, use and re-use private sector data; and (ii) the proposed European Health Data Space Regulation (EHDS) &#8211; expected to be agreed by end of 2024 &#8211; which seeks to , among other things, provide individuals with more control over their electronic health data (EHD), enable cross-border sharing of EHD between national EU healthcare systems and facilitate the sharing of EHD for secondary research purposes.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The EU has also developed a standalone law to govern the offering and use of AI systems in the EU (the AI Act) which was published in the Official Journal of the European Union on July 12, 2024. The AI Act imposes regulatory requirements onto AI system providers, importers, distributors, and users of AI systems, in accordance with the level of risk involved with the AI system (&#8220;unacceptable&#8221;, &#8220;high&#8221;, &#8220;limited&#8221;, and &#8220;minimal&#8221; risk). Unacceptable-risk AI systems are banned from being offered and used in the EU, and high-risk AI systems (which include AI used as part of medical devices in certain instances) are subject to a set of regulatory requirements under the AI Act including to establish quality and post-marketing monitoring and risk assessment systems, requirements related to the training of AI systems and training data, and requirements related to human oversight. Limited-risk AI systems are subject mainly to transparency requirements only and minimal-risk AI systems are not subject to obligations under the AI Act. In the most recent iteration of the AI Act&#8217;s text, general-purpose AI systems have also been made subject to a number of requirements &#8211; mostly akin to the requirements that apply to high-risk AI systems under the AI Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Currently, the AI Act is expected to enter into application (i.e., be enforceable) in a gradual manner &#8211; depending on the regulatory requirement in question, and ranging anywhere from 6 to 36 months following adoption and entry into force of the AI Act (i.e., from 20 days after July 12, 2024). Non-compliance with the AI Act may be subject to regulatory fines of up to 7% of annual worldwide turnover. In parallel, the EU has proposed revisions to the EU Product Liability Directive and has introduced a new EU AI Liability Directive to facilitate claims for damages brought by EU users of AI systems. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The UK had adopted a &#8220;soft law&#8221; approach to AI regulation meaning that until now it has not adopted formal legislation to regulate AI but has adopted soft law guidelines in the form of a White Paper. However, following the UK General Election in July 2024, the new UK Government has announced it intends to introduce an AI Bill to the UK Parliament.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Further, many jurisdictions impose mandatory clinical trial information obligations on sponsors. In the EU, such obligations arise under the Transparency Regulation No 1049/ 2001, EMA Policy 0043, EMA Policy 0070 and the Clinical Trials Regulation No 536/2014 (which the UK has not implemented, as the law entered into force following the UK&#8217;s exist from the EU), all of which impose on sponsors the obligation to make publicly available certain information </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">stemming from clinical studies. In the EU, the transparency framework provides EU-based parties the right to submit an access to documents request to the EMA for information included in the MAA dossier for approved medicinal products. Only very limited information is exempted from disclosure, i.e., commercially confidential information (which is construed increasingly narrowly) and protected personal data. It is possible for competitors to access and use this data in their own research and development programs anywhere in the world, once this data is in the public domain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Enhanced governmental and public scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To help patients afford our products, we have a manufacturer-sponsored patient assistance program that helps financially needy patients in the US access our therapies. This type of program has become the subject of enforcement scrutiny in recent years. For example, some pharmaceutical manufacturers have been named in lawsuits challenging the legality of their patient assistance programs under a variety of federal and state laws. In addition, certain state and federal enforcement authorities have pursued investigations and settlements and members of Congress have initiated inquiries about manufacturer-sponsored patient support programs, including, for example, manufacturer-sponsored patient assistance programs, co-payment assistance programs, and manufacturer contributions to independent charitable patient assistance programs. Moreover, the DHHS, Office of the Inspector General continues to publish advisory opinions and other agency guidance on the topic of patient assistance, which reflects the government&#8217;s continued scrutiny of manufacturer sponsored or supported patient assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing litigation, enforcement activities and settlements related to their patient support programs and certain of these organizations have entered into, or have otherwise agreed to, significant civil settlements with applicable enforcement authorities. It is possible that future legislation may be proposed that would establish requirements or restrictions with respect to these programs and/or support that would affect pharmaceutical manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our patient assistance program could become the target of similar inquiries, litigation, enforcement, and/or legislative proposals. If we are deemed not to have complied with laws or regulations in the operation of, or our interactions with, these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate the laws or regulations of the jurisdictions in which we operate. A government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the ANDA applicant undertaking the clinical testing necessary to obtain approval to market a new drug. Generally, in place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product has the same active ingredient(s), strength, dosage form and route of administration&#160;and that it is bioequivalent to the branded product. In September 2019, the FDA published product-specific bioequivalence guidance on fostamatinib disodium to let potential ANDA applicants understand the data FDA would expect to see for approval of a generic version of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The FDCA requires that an applicant for approval of a generic form of a branded drug certify either that its generic product does not infringe any of the patents listed by the owner of the branded drug in the <span style="background:#ffffff;">FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (referred to as the &#8220;Orange Book&#8221;)</span> or that those patents are not enforceable. This process is known as a paragraph&#160;IV challenge. Upon notice of a paragraph&#160;IV challenge, a patent owner has 45&#160;days to bring a patent infringement suit in federal district court against the company seeking ANDA approval of a product covered by one of the owner&#8217;s patents. If this type of suit is commenced, the FDCA provides a 30-month stay on the FDA&#8217;s approval of the competitor&#8217;s application. If the litigation is resolved in favor of the ANDA applicant or the challenged patent expires during the 30-month stay period, the stay is lifted, and the FDA may thereafter approve the application based on the standards for approval of ANDAs. Once an ANDA is approved by the FDA, the generic manufacturer may market and sell the generic form of the branded drug in competition with the branded medicine.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The ANDA process can result in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner&#8217;s patents. If this were to occur with respect to our products or products with which it competes, our business would be harmed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In June 2022, we received a notice letter regarding an ANDA submitted to the FDA by Annora, requesting approval to market a generic version of TAVALISSE. The notice letter included a Paragraph IV certification with respect to our US Patent Nos. 7,449,458; 8,263,122; 8,652,492; 8,771,648 and 8,951,504, which are listed in the Orange Book. The notice letter asserts that these patents will not be infringed by Annora&#8217;s proposed product, are invalid and/or are unenforceable. Annora&#8217;s notice letter does not provide a Paragraph IV certification against our other patents listed in the Orange Book. On <span style="background:#ffffff;">July 25, 2022, we filed a lawsuit in the US District Court for the District of New Jersey against Annora and its affiliates, Hetero Labs Ltd., and Hetero USA, Inc., for infringement of our US patents identified in Annora&#8217;s Paragraph IV certification. On September 21, 2022, Annora and its affiliates answered and counterclaimed for declaratory judgment of non-infringement and invalidity of the &#8217;458, &#8217;122, &#8217;492, &#8217;648, and &#8217;504 patents. We filed an answer to Annora&#8217;s counterclaims on October 12, 2022. Annora served invalidity and non-infringement contentions on December 31, 2022. We filed an answer to Annora&#8217;s invalidity and non-infringement contentions in March 2023. Litigation continues, and no trial date is currently set. </span>We intend to vigorously enforce and defend our intellectual property related to TAVALISSE. We cannot be assured that such lawsuit will prevent the introduction of a generic version of TAVALISSE for any particular length of time, or at all. If an ANDA from Annora or any other generic manufacturer is approved, and a generic version of TAVALISSE is introduced, whether following the expiration of our patents, the invalidation of our patents as a result of any litigation, or the determination that the proposed generic product does not infringe on our patents, our sales of TAVALISSE would be adversely affected. In addition, we cannot predict what additional ANDAs could be filed by Annora or other potential generic competitors requesting approval to market generic forms of our products, which would require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby materially harm our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unforeseen safety issues could emerge with our products that could require us to change the prescribing information to add warnings, limit use of the product, and/or result in litigation. Any of these events could have a negative impact on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Discovery of unforeseen safety problems or increased focus on a known problem could impact our ability to commercialize our products and could result in restrictions on its permissible uses, including withdrawal of the medicine from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If we or others identify additional undesirable side effects caused by our products after approval:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, specific warnings, contraindications, or field alerts to physicians and pharmacies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the product and require us to take our approved drugs off the market or suspend their commercialization until the identified issues have been satisfactorily addressed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way the product is administered, conduct additional clinical trials, change the labeling of the product, or implement a Risk Evaluation and Mitigation Strategy (REMS);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have additional limitations on how we promote our drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party payors may limit coverage or reimbursement for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our products may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to litigation or product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:9pt;"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of our products and could substantially increase our operating costs and expenses, which in turn could delay or prevent us from generating significant revenue from sale of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Side effects and toxicities associated with our products, as well as the warnings, precautions and requirements listed in the prescribing information for our products, could affect the willingness of physicians to prescribe, and patients to utilize, our products and thus harm commercial sales of our products. For example, for REZLIDHIA, the FDA-approved label contains a boxed warning describing the risk of differentiation syndrome, which can be fatal, in patients receiving the drug.&#160;This and other restrictions could limit the commercial success of the product.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If a safety issue emerges post-approval, we may become subject to costly product liability litigation by our customers, their patients or payors. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. If we cannot successfully defend ourselves against claims that our products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of patients from clinical studies or cancellation of studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We currently hold $10.0&#160;million in product liability insurance coverage, which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to obtain insurance coverage at a reasonable cost or in amounts adequate to satisfy any liability or associated costs that may arise in the future. These events could harm our business and results of operations and cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;padding-bottom:9pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business could be materially and adversely affected by pandemics as a result of their potential impacts on our sales force and commercialization efforts, supply chain, regulatory, clinical development and corporate development activities and other business operations, in addition to the impact of a global economic slowdown.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;padding-top:5pt;text-indent:36pt;background:#ffffff;margin:0pt;">Pandemics may result in extended travel and other restrictions in order to reduce the spread of diseases. Government measures taken in response to pandemics could have a significant impact, both direct and indirect, on our business and commerce, as significant reductions in business related activities may occur, supply chains may be disrupted, and manufacturing and clinical development activities may be curtailed or suspended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">For example, during the COVID-19 pandemic, we observed reduced patient-doctor interactions and our representatives had fewer visits with health care providers, which negatively affected our product sales. Physicians with practices severely impacted by the COVID-19 pandemic, or a pandemic occurring in the future, and who currently prescribe our products, may eventually decide to close their independent practices and join a larger medical organization with a practice that does not prescribe our products. Additionally, a pandemic, including COVID-19 or any resurgence thereof, may impact commercial-related activities, such as our marketing programs, speaker bureaus, and market access initiatives which may be required to be conducted virtually, delayed or cancelled, all of which occurred as a result of the COVID-19 pandemic. During the COVID-19 pandemic, w</span><span style="background:#ffffff;">e had to deploy resources&#160;to enable our field-based employees to continue to engage with&#160;health care providers in hybrid virtual and in-person interactions, which may be required in the event a pandemic occurs in the future.&#160; </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">With respect to clinical development, in response to the COVID-19 pandemic, we took measures to implement remote and virtual approaches, including remote patient monitoring where possible and working with our investigators for appropriate care of these patients in a safe manner. Due to the effects of COVID-19 pandemic, we experienced a number of our clinical trial investigators either paused, postponed or delayed new patient enrollment and restricted site visits of existing patients enrolled. In the event that a global pandemic, or a resurgence of the COVID-19 pandemic, occurs in the future, we may need to make decisions&#160;on a country-by-country&#160;basis to minimize risk to the patients and clinical trial sites. We may also rely heavily on our clinical trial investigators to inform us of the best course of action with respect to resuming enrollment/screening, considering the ability of sites to ensure patient safety or data integrity. We experienced slower than anticipated enrollment in some of our clinical trials due to adverse effects of COVID-19 pandemic, and in the future, we may experience adverse impacts of a global pandemic on our clinical trials, including the timing thereof, or our ability to continue to treat patients enrolled in our trials, enroll and assess new patients, supply study drugs and obtain complete data points in accordance with study protocol. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Pandemics may cause significant disruption in the supply chain for our commercial products. We rely on third parties to, among other things, manufacture and ship our commercial product, raw materials and product supply for our clinical trials, perform quality testing and supply other goods and services to help manage our commercial activities, our clinical trials and our operations in the ordinary course of business. While we have engaged actively with various elements of our supply chain and distribution channel, including our customers, contract manufacturers, and logistics and transportation provider to meet demand for our products and to remain informed of any challenges within our supply chain, we may face disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our products. Such supply disruptions would adversely impact our ability to generate sales of and revenues from our products and our business, financial condition, results of operations and growth prospects could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Pandemics may affect</span> our collaboration and licensing partners for the commercialization of our products globally, as well as our ability to advance our various clinical stage programs. We cannot predict the impact of s<span style="background:#ffffff;">uch disruptions on our partners&#8217; ability to advance commercialization of our products in the market and the timing of enrollment and completion of various clinical trials being conducted by our collaboration partners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Health regulatory agencies globally may experience prolonged disruptions in their operations as a result of pandemics.&#160;For example, in response to the COVID-19 pandemic, the FDA delayed inspections and evaluations of certain drug manufacturing facilities and clinical research sites We cannot predict whether, and when, health regulatory agencies will decide to pause or resume inspections due to pandemics. Any&#160;de-prioritization&#160;of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the completion of our clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In addition, as seen in the COVID-19 pandemic, pandemics could result in a significant disruption of global financial markets. We could experience an inability to access</span> additional capital or <span style="background:#ffffff;">an impact on liquidity, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments,</span> or <span style="background:#ffffff;">we may not be able to meet the requirements under our Credit and Security Agreement (Credit Agreement) with MidCap Financial Trust (MidCap). While we expect </span>pandemics to <span style="background:#ffffff;">adversely affect</span> our <span style="background:#ffffff;">business, financial condition, results of operations and growth prospects in the future periods, the extent of the impact on our ability to generate sales of and revenues from our approved products, our ability to continue to secure new collaborations and support existing collaboration efforts with our partners, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our common stock,</span> will depend on future circumstances<span style="background:#ffffff;"> that are highly uncertain and</span> cannot be predicted <span style="background:#ffffff;">with confidence at this time, such as the ultimate duration and severity of pandemics, travel restrictions, quarantines, social distancing and business closure requirements in the US and other countries, and the effectiveness of actions taken globally to contain and treat diseases. </span>To the extent pandemics adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the US, we could be subject to additional rebate or discount requirements, fines, sanctions and exposure under other laws which could have an adverse effect on our business, results of operations and financial condition.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We participate in the Medicaid Drug Rebate Program, as administered by CMS, the 340B Drug Pricing Program, as administered by the Health Resources and Services Administration, and other federal and state government drug pricing programs in the US, and we may participate in additional government pricing programs in the future. These programs generally require us to pay rebates or otherwise provide discounts to government payors and/or required covered entities in connection with drugs that are dispensed to beneficiaries/recipients of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the rebates are based on pricing metrics that we report on a monthly and quarterly basis to the government agencies that administer the programs. Pricing requirements and rebate/discount calculations are complex, vary among products and programs, and are often subject to interpretation by governmental or regulatory agencies and the courts. The requirements of these programs, including, by way of example, their respective terms and scope, change frequently. Responding to current and future changes may increase our costs, and the complexity of compliance will be time consuming. Invoicing for rebates is provided in arrears, and there is frequently a time lag of up to several months between the sales to which rebate notices relate and our receipt of those notices, which further complicates our ability to accurately estimate and accrue for rebates related to the Medicaid program as implemented by individual states. Thus, there can be no assurance that we will be able to identify all factors that may cause our discount and rebate payment obligations to vary from period to period, and our actual results may differ significantly from our estimated allowances for discounts and rebates. Changes in estimates and assumptions may have an adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, the DHHS, Office of Inspector General and other governmental enforcement and administrative bodies have increased their focus on pricing requirements for products, including, but not limited to the methodologies used by manufacturers to calculate average manufacturer price and best price for compliance with reporting requirements under the Medicaid Drug Rebate Program. We are liable for errors associated with our submission of pricing data and for any overcharging of government payors. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the federal False Claims Act and other laws and regulations. Any required refunds to the US government or response to a government investigation or enforcement action would be expensive and time consuming and could have an adverse effect on our business, results of operations and financial condition. In addition, in the event that CMS were to terminate our rebate agreement, no federal payments would be available under Medicaid for our covered outpatient drugs or under Medicare Part B for any of our products that may be reimbursed under Part B.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Finally, we may be affected by developments relating to the 340B Drug Pricing Program (340B Program). Recently, multiple manufacturers have implemented policies to reduce diversion and inappropriate claims for discounts and rebates by in-house and contract pharmacies affiliated with 340B-eligible entities. The DHHS has sent several of these manufacturers&#8217; letters claiming that the policies violate the 340B statute and referring the manufacturers for potential enforcement action. Manufacturers have challenged these letters in federal court, and the US Court of Appeals for the Third Circuit and the District of Columbia Circuit have ruled in favor of several manufacturers. Multiple states have recently enacted laws that require manufacturers to ship 340B drugs to certain contract pharmacies and impose penalties on manufacturers that do not comply. These laws have been challenged in federal court and many of the cases are pending. In March 2024, the US Court of Appeals for the Eight Circuit upheld the Arkansas law prohibiting drug makers for restricting 340B drug discounts for providers using contract pharmacies. DHHS also issued a final rule on procedures for the 340B program&#8217;s administrative dispute resolution process in April 2024. It is unclear how the other pending litigation, recent and proposed legislation, or future administrative action relating to the 340B program will impact our business.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even for those product candidates that have or may receive regulatory approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">For our product candidates that have or may receive regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians, hospital administrators, patients, third-party payors and others in the medical community. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including the following: </p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to change their current treatment practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any additional support that may be required to administer the treatment to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of hospitals and hospital systems to include our product candidates as treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of efficacy and safety in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer product candidates for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price we charge for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of such coverage and adequate reimbursement.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Efforts to educate the physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates are approved, but do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable on a sustained basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need additional capital in the future to sufficiently fund our operations and research.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have consumed substantial amounts of capital to date as we continue our research and development activities, including preclinical studies and clinical trials and for the commercialization of our products. We may seek another collaborator or licensee in the future for further clinical development and commercialization of our products, as well as our other clinical programs, which we may not be able to obtain on commercially reasonable terms or at all. We believe that our existing capital resources will be sufficient to support our current and projected funding requirements, including the continued commercialization of our products through at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with commercial launch, the development of our product candidates and other research and development activities, we are unable to estimate with certainty our future product revenues, our revenues from our current and future collaborative partners, the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials and other research and development activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We will continue to need additional capital and the amount of future capital needed will depend largely on the success of our commercialization of our products, and the success of our internally developed programs as they proceed in later and more expensive clinical trials, including any additional clinical trials that we may decide to conduct with respect to our products. While we intend to opportunistically seek access to additional funds through public or private equity offerings or debt financings, we do not know whether additional financing will be available when needed, or that, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">if available, we will obtain financing on reasonable terms. Our ability to raise additional capital, including our ability to secure new collaborations and continue to support existing collaboration efforts with our partners, may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the US and worldwide resulting from a global pandemic and the global tensions arising from the Russia-Ukraine war and the Hamas-Israel war. Unless and until we are able to generate a sufficient amount of product, royalty or milestone revenue, which may never occur, we expect to finance future cash needs through public and/or private offerings of equity securities, debt financings or collaboration and licensing arrangements, as well as through proceeds from the exercise of stock options and interest income earned on the investment of our cash balances and short-term investments. To the extent we raise additional capital by issuing equity securities in the future, our stockholders could at that time experience substantial dilution. In addition, we have a significant number of stock options outstanding. To the extent that outstanding stock options have been or may be exercised or other shares issued, our stockholders may experience further dilution. Further, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Our credit facility with MidCap includes certain covenants that may restrict our business, and any other debt financing that we are able to obtain in the future may involve operating covenants that restrict our business. To the extent that we raise additional funds through any new collaboration and licensing arrangements, we may be required to refund certain payments made to us, relinquish some rights to our technologies or product candidates or grant licenses on terms that are not favorable to us.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have indebtedness in the form of a term loan pursuant to the Credit Agreement with MidCap, which could adversely affect our financial condition and our ability to respond to changes in our business. Further, if we are unable to satisfy certain conditions of the Credit Agreement, we will be unable to draw down the remainder of the facility.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We entered into a Credit Agreement with MidCap on September 27, 2019, amended on March 29, 2021, February 11, 2022, July 27, 2022, and April 11, 2024. The Credit Agreement provides for a $60.0&#160;<span style="white-space:pre-wrap;">million term loan credit facility. As of June 30, 2024, the outstanding principal balance of the loan was $60.0 million, and no remaining funds were available under the term loan credit facility. Under the Credit Agreement, we are required to repay amounts due when there is an event of default for the term loans that results in the principal, premium, if any, and interest, if any, becoming due prior to the maturity date for the term loans. The Credit Agreement also contains a number of other affirmative and restrictive covenants.  </span><span style="background:#ffffff;">See &#8220;Note 10 &#8211; Debt&#8221; to our&#160;&#8220;Notes to Condensed Financial Statements&#8221;&#160;contained in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q for additional details of the Credit Agreement.</span> These and other terms in the Credit Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. Our business may not generate cash flow from operations in the future sufficient to service our debt and support our growth strategies. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as restructuring our debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our current debt obligations. In addition, we cannot be sure that additional financing will be available when required or, if available, will be on terms satisfactory to us. Further, even if we are able to obtain additional financing, we may be required to use such proceeds to repay a portion of our debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our indebtedness may have other adverse effects, such as:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our vulnerability to adverse general economic conditions and heightened competitive pressures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dedication of a portion of our cash flow from operations to interest payments, limiting the availability of cash for other operational purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limited flexibility in planning for, or reacting to, changes in our business and industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to obtain additional financing in the future.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our Credit Agreement with MidCap contains a mandatory prepayment provision that gives MidCap and/or its agent the right to demand payment of the outstanding principal and additional interest and fees in the event of default. We may not have enough available cash or be able to obtain financing at the time we are required to repay the term loan </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">with additional interest and fees prior to maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely and may continue to rely on two distribution facilities for the sale of our products and potential sale of any of our product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our distribution operations for the sale of our products are currently concentrated in two distribution centers owned by a third-party logistics provider. Additionally, our distribution operations, if and when we launch any of our product candidates in the future, may also be concentrated in such distribution centers owned by a third-party logistics provider. Any errors in inventory level management and unforeseen inventory shortage could adversely affect our business. In addition, any significant disruption in the operation of the facility due to natural disaster or severe weather, or events such as fire, accidents, power outages, system failures, or other unforeseen causes, could devalue or damage a significant portion of our inventories and could adversely affect our product distribution and sales until such time as we could secure an alternative facility. <span style="background:#ffffff;">Further, climate change may increase both the frequency and severity of extreme weather conditions and natural disasters, which may affect our business operations.</span> If we encounter difficulties with any of our distribution facilities, whether due to the potential future impacts of a global pandemic (including as a result of disruptions of global shipping and the transport of products) or otherwise, or other problems or disasters arise, we cannot ensure that critical systems and operations will be restored in a timely manner or at all, and this would have an adverse effect on our business. In addition, growth could require us to further expand our current facility, which could affect us adversely in ways that we cannot predict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Forecasting potential sales for any of our product candidates will be difficult, and if our projections are inaccurate, our business may be harmed, and our stock price may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;">Our business planning requires us to&#160;forecast&#160;or make assumptions regarding product demand and revenues for any of our product candidates if they are approved despite numerous uncertainties. These uncertainties may be increased if we rely on our collaborators or other third parties to conduct commercial activities in certain geographies and provide us with accurate and timely information. Actual results may differ materially from projected results for various reasons, including the following, as well as risks identified in other risk factors:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety of any of our product candidates, including as relative to marketed products and product candidates in development by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing (including discounting or other promotions), reimbursement, product returns or recalls, competition, labeling, adverse events and other items that impact commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of adoption in the particular market, including fluctuations in demand for various reasons;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future impacts, if any, including a global pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of patient and physician familiarity with the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of patient use and physician prescribing history;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of commercialization experience with the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual sales to patients may significantly differ from expectations based on sales to wholesalers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainty relating to when the drug may become commercially available to patients and rate of adoption in other territories.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 0pt 0pt;">We expect that our revenues from sales of any of our products will continue to be based in part on estimates, judgment and accounting policies. Any incorrect estimates or disagreements with regulators or others regarding such estimates or accounting policies may result in changes to our guidance, projections or previously reported results. We make estimates for provisions for sales discounts, returns and allowances. Our estimates are based on available customer and payor data received from the specialty pharmacies and distributors, as well as third party market research data. In part, our estimates are dependent on our distribution channel and payor mix.<span style="background:#ffffff;"> If actual results in the future vary from our estimates, we adjust these estimates, which would affect our net product revenue and earnings in the period such variances become known. </span>Expected and actual product sales and quarterly and other results may greatly fluctuate, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">including in the near-term, and such fluctuations can adversely affect the price of our common stock, perceptions of our ability to&#160;forecast&#160;demand and revenues, and our ability to maintain and fund our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not and will not have access to all information regarding fostamatinib and product&#160;candidates we licensed to Lilly, Kissei, Grifols, Medison and Knight.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:9pt 0pt 9pt 0pt;">We do not and will not have access to all information regarding fostamatinib and other product candidates, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by Lilly, Kissei, Grifols, Medison and Knight. In addition, we have confidentiality obligations under our respective agreements with Lilly, Kissei, Grifols, Medison and Knight. Thus, our ability to keep our shareholders informed about the status of fostamatinib and other product candidates will be limited by the degree to which Lilly, Kissei, Grifols, Medison and/or Knight keep us informed and allows us to disclose such information to the public. If Lilly, Kissei, Grifols, Medison and/or Knight fail to keep us informed about commercialization efforts related to fostamatinib, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to them, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may adversely affect our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future funding requirements will depend on many uncertain factors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our future funding requirements will depend upon many factors, many of which are beyond our control, including, but not limited to:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs to commercialize our products in the US, or any other future product candidates, if any such candidate receives regulatory approval for commercial sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to secure patent and regulatory protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to secure a favorable price or a positive HTA assessment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future impacts, if any, of a global pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of regulatory filings and approvals by us and our collaborators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of research and development programs carried out by us and our collaborative partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes in the breadth of our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to achieve the events identified in our collaborative agreements that may trigger payments to us from our collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to acquire or license other technologies or compounds that we may seek to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manage our growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of obtaining, enforcing and defending our patent and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with any unforeseen litigation, including any arbitration and securities class action lawsuits.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Insufficient funds may require us to delay, scale back or eliminate some or all of our commercial efforts and/or research and development programs, to reduce personnel and operating expenses, to lose rights under existing licenses or to relinquish greater or all rights to product candidates at an earlier stage of development or on less favorable terms than </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">we would otherwise choose or may adversely affect our ability to operate as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success as a company is uncertain due to our history of operating losses and the uncertainty of any future profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">For the six months ended June 30, 2024, we recognized loss from operations of $6.5 million primarily due to higher operating and non-operating expenses, partly offset by our net product sales and collaboration revenues. We have historically incurred losses from operations each year since we were incorporated in June&#160;1996 other than in fiscal year 2010, due in large part to the significant research and development expenditures required to identify and validate new product candidates and pursue our development efforts, and the costs of our ongoing commercial efforts for our products. We expect to continue to incur losses from operations, at least in the next 12 months, and there can be no assurance that we will generate annual operating income in the foreseeable future. Currently, our potential sources of revenues are our sales of our products, upfront payments, research and development contingent payments and royalty payments pursuant to our collaboration arrangements, which may never materialize if our collaborators do not achieve certain events or generate net sales to which these contingent payments are dependent on. If our future drug candidates fail or do not gain regulatory approval, or if our drugs do not achieve sustainable market acceptance, we may not be profitable. As of June 30, 2024, we had an accumulated deficit of approximately $1.4&#160;billion. The extent of our future losses or profitability, if any, is highly uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our corporate collaborations or license agreements are unsuccessful, or if we fail to form new corporate collaborations or license agreements, our research and development efforts could be delayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our strategy depends upon the formation and sustainability of multiple collaborative arrangements and license agreements with third parties now and in the future. We rely on these arrangements for not only financial resources, but also for expertise we need now and in the future relating to clinical trials, manufacturing, sales and marketing, and for licenses to technology rights. To date, we have entered into several such arrangements with corporate collaborators; however, we do not know if these collaborations or additional collaborations with third parties, if any, will dedicate sufficient resources or if any development or commercialization efforts by third parties will be successful. In addition, our corporate collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate or development program. Should a collaborative partner fail to develop or commercialize a compound or product to which it has rights from us for any reason, including corporate restructuring, such failure might delay our ongoing research and development efforts, because we might not receive any future payments, and we would not receive any royalties associated with such compound or product. We may seek another collaborator or licensee in the future for clinical development and commercialization of our products, as well as our other clinical programs, which we may not be able to obtain on commercially reasonable terms or at all. If we are unable to form new collaborations or enter into new license agreements, our research and development efforts could be delayed. In addition, the continuation of some of our partnered drug discovery and development programs may be dependent on the periodic renewal of our corporate collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">&#160;Each of our collaborations could be terminated by the other party at any time, and we may not be able to renew these collaborations on acceptable terms, if at all, or negotiate additional corporate collaborations on acceptable terms, if at all. If these collaborations terminate or are not renewed, any resultant loss of revenues from these collaborations or loss of the resources and expertise of our collaborative partners could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">Conflicts also might arise with collaborative partners concerning proprietary rights to particular compounds. While our existing collaborative agreements typically provide that we retain milestone payments, royalty rights and/or revenue sharing with respect to drugs developed from certain compounds or derivative compounds, any such payments or royalty rights may be at reduced rates, and disputes may arise over the application of payment provisions or derivative payment provisions to such drugs, and we may not be successful in such disputes.  For example, in September 2018, BerGenBio served us with a notice of arbitration seeking declaratory relief related to the interpretation of provisions under our June 2011 license agreement, particularly as they relate to the rights and obligations of the parties in the event of the license or sale of a product in the program by BerGenBio and/or the sale of BerGenBio to a third party.&#160;The arbitration panel dismissed four of the six declarations sought by BerGenBio, and we thereafter consented to one of the remaining declarations requested by BerGenBio.&#160;On February 27, 2019, the arbitration panel issued a determination granting the declaration sought by BerGenBio on the remaining issue, and held that in the event of a sale of shares by BerGenBio&#8217;s shareholders where there is no monetary benefit to BerGenBio, we would not be entitled to a portion of the proceeds from such a sale.&#160; In this circumstance where the revenue share provision is not triggered, the milestone and </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">royalty payment provisions remain in effect.&#160; While we do not believe that the determination will have an adverse effect on our operations, cash flows or financial condition, we can make no assurance regarding any such impact. Additionally, the management teams of our collaborators may change for various reasons including due to being acquired. Different management teams or an acquiring company of our collaborators may have different priorities which may have adverse results on the collaboration with us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are also a party to various license agreements that give us rights to use specified technologies in our research and development processes. The agreements pursuant to which we have in-licensed technology permit our licensors to terminate the agreements under certain circumstances. If we are not able to continue to license these and future technologies on commercially reasonable terms, our product development and research may be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If conflicts arise between our collaborators or advisors and us, any of them may act in their self-interest, which may be adverse to our stockholders&#8217; interests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If conflicts arise between us and our corporate collaborators or scientific advisors, the other party may act in its self-interest and not in the interest of our stockholders. Some of our corporate collaborators are conducting multiple product development efforts within each disease area that is the subject of the collaboration with us or may be acquired or merged with a company having a competing program. In some of our collaborations, we have agreed not to conduct, independently or with any third party, any research that is competitive with the research conducted under our collaborations. Our collaborators, however, may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by our collaborators or to which our collaborators have rights, may result in their withdrawal of support for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If any of our corporate collaborators were to breach or terminate its agreement with us or otherwise fail to conduct the collaborative activities successfully and in a timely manner, the preclinical or clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated. We generally do not control the amount and timing of resources that our corporate collaborators devote to our programs or potential products. We do not know whether current or future collaborative partners, if any, might pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including our competitors, as a means for developing treatments for the diseases targeted by collaborative arrangements with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success is dependent on intellectual property rights held by us and third parties, and our interest in such rights is complex and uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our success will depend to a large part on our own, our licensees&#8217; and our licensors&#8217; ability to obtain and defend patents for each party&#8217;s respective technologies and the compounds and other products, if any, resulting from the application of such technologies. For example, fostamatinib is covered as a composition of matter in a US issued patent that has expiration date of September 2031, o<span style="background:#ffffff;">lutasidenib is covered as a composition of matter in a US issued patent that has an expected expiration date of December 2036, after taking into account patent term extension rules, and pralsetinib </span>is covered as a composition of matter in a US issued patent that has an expiration date in November 2036 and subject to extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In the future, our patent position might be highly uncertain and involve complex legal and factual questions<span style="background:#ffffff;">, and the cost to defend </span>may also be significant. For example, we may be involved in post-grant proceedings before the US Patent and Trademark Office. Post-grant proceedings are complex and expensive legal proceedings and there is no assurance we will be successful in any such proceedings. A post-grant proceeding could result in our losing our patent rights and/or our freedom to operate and/or require us to pay significant royalties. Additionally, third parties may challenge the validity, enforceability or scope of our issued patents, which may result in such patents being narrowed, invalidated or held unenforceable through interference, opposition or invalidity proceedings before the US Patent and Trademark Office or non-US patent offices. Any successful opposition to our patents could deprive us of exclusive rights necessary for the successful commercialization of our products or our other product candidates. Oppositions could also be filed to complementary patents, such as formulations, methods of manufacture and methods of use, that are intended to extend the patent life of the overall portfolio beyond the patent life covering the composition of matter. A successful opposition to any such complementary patent could impact our ability to extend the life of the overall portfolio beyond that of the related composition of matter patent.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. For example, in June 2022, we received a notice letter from Annora advising that it has filed an ANDA with the FDA for a generic version of TAVALISSE and asserting that certain patents related to TAVALISSE that are listed in the Orange Book will not be infringed by Annora&#8217;s proposed product, are invalid and/or are unenforceable. In July 2022, we filed a lawsuit in the US District Court for the District of New Jersey against Annora and its subsidiaries for infringement of those US patents. In September 2022, Annora and its subsidiaries answered and counterclaimed for declaratory judgment of non-infringement and invalidity of those patents. We filed an answer to Annora&#8217;s counterclaims on October 12, 2022. <span style="background:#ffffff;">Annora served invalidity and non-infringement contentions on December 31, 2022.</span> <span style="background:#ffffff;">We filed an answer to Annora&#8217;s invalidity and non-infringement contentions in March 2023. Litigation continues, and no trial date is currently set. </span>We intend to vigorously enforce and defend our intellectual property rights related to TAVALISSE. Should Annora or any other third parties receive FDA approval of an ANDA for a generic version of fostamatinib or a 505(b)(2) NDA with respect to fostamatinib, and if our patents covering fostamatinib were held to be invalid (or if such competing generic versions of fostamatinib were found to not infringe our patents), then they could introduce generic versions of fostamatinib or other such 505(b)(2) products before our patents expire, and the resulting competition would negatively affect our business, financial condition and results of operations. Please also see the risk factor entitled, &#8220;If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed.&#8221; In the future, there might be other <span style="background:#ffffff;">claims that are subject to substantial uncertainties and unascertainable damages or other remedies, and the cost to defend </span>may also be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Additional uncertainty may result because no consistent policy regarding the breadth of legal claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in our or other companies&#8217; patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Because the degree of future protection for our proprietary rights is uncertain, we cannot assure that:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we were the first to make the inventions covered by each of our pending patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we were the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of our pending patent applications will result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patents issued to us or our collaborators will provide a basis for commercially viable products or will provide us with any competitive advantages or will not be challenged by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will develop additional proprietary technologies that are patentable; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will obtain a supplementary protection certificate that will extend the protection afforded by the patent to the product with a marketing authorization; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others will not have a negative effect on our ability to do business.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable; however, trade secrets are difficult to protect. While we require employees, collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are a party to certain in-license agreements that are important to our business, and we generally do not control the prosecution of in-licensed technology. Accordingly, we are unable to exercise the same degree of control over this intellectual property as we exercise over our internally developed technology. Moreover, some of our academic institution licensors, research collaborators and scientific advisors have rights to publish data and information in which we have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations, our ability to receive patent protection or protect our proprietary information may otherwise be impaired. In addition, some of the technology we have licensed relies on patented inventions developed using US government resources.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The US government retains certain rights, as defined by law, in such patents, and may choose to exercise such rights. Certain of our in-licenses may be terminated if we fail to meet specified obligations. If we fail to meet such obligations and any of our licensors exercise their termination rights, we could lose our rights under those agreements. If we lose any of our rights, it may adversely affect the way we conduct our business. In addition, because certain of our licenses are sublicenses, the actions of our licensors may affect our rights under those licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If a dispute arises regarding the infringement or misappropriation of the proprietary rights of others, such dispute could be costly and result in delays in our research and development activities, partnering and commercialization activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our success will depend, in part, on our ability to operate without infringing or misappropriating the proprietary rights of others. There are many issued patents and patent applications filed by third parties relating to products or processes that are similar or identical to our licensors or ours, and others may be filed in the future. There may also be copyrights or trademarks that third parties hold. There can be no assurance that our activities, or those of our licensors, will not violate intellectual property rights of others. We believe that there may be significant litigation in the industry regarding patent and other intellectual property rights, and we do not know if our collaborators or we would be successful in any such litigation. Any legal action against our collaborators or us claiming damages or seeking to enjoin commercial activities relating to the affected products, our methods or processes could:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require our collaborators or us to obtain a license to continue to use, manufacture or market the affected products, methods or processes, which may not be available on commercially reasonable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent us from using the subject matter claimed in the patents held by others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject us to potential liability for damages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consume a substantial portion of our managerial and financial resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">result in litigation or administrative proceedings that may be costly, whether we win or lose.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are subject to taxation in numerous US states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the newly enacted federal income tax law, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating losses (NOLs) and certain other tax attributes is uncertain and may be limited.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Our ability to use our federal and state NOLs to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income before the expiration dates of the NOLs, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs. Federal NOLs generated prior to 2018 will continue to be governed by the NOL carryforward rules as they existed prior to the adoption of the Tax Cuts and Jobs Act (Tax Act), which means that generally they will expire 20 years after they were generated if not used prior thereto. Many states have similar laws. Accordingly, our federal and state NOLs could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Act as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), federal NOLs incurred in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding such loss, and NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning after January 1, 2021. Under Assembly Bill 85, our California NOL carryforwards are suspended for tax years 2020, 2021, and 2022, but </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the period to use these carryovers was extended. In June 2024, California Senate Bill 167 was signed into law which suspends NOL deductions for tax years beginning on or after January 1, 2024 and before January 1, 2027 for taxpayers with net business income or modified adjusted gross income of at least $1.0 million for the tax year. The legislation also limits the aggregate use of otherwise allowable business credits to $5.0 million for each tax year beginning on or after January 1, 2024 but before January 1, 2027 (except for certain credits not subject to the limitation). Further, the Tax Act requires the taxpayers to capitalize Research and Experimental (R&amp;E) expenditures under Section 174 of the Internal Revenue Code, as amended (Code), effective for taxable years beginning after December 31, 2021, which will reduce our NOLs beginning in 2022. R&amp;E expenditures attributable to US-based research must be amortized over a period of 5 years and R&amp;E expenditures attributable to research conducted outside of the US must be amortized over a period of 15 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">In addition, utilization of NOLs to offset potential future taxable income and related income taxes that would otherwise be due is subject to annual limitations under the &#8220;ownership change&#8221; provisions of Sections 382 and 383 of the Code and similar state provisions, which may result in the expiration of NOLs before future utilization. In general, under the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development credit carryforwards) to offset its post-change taxable income or taxes may be limited. Our equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change. Although we have completed studies to provide reasonable assurance that an ownership change limitation would not apply, we cannot be certain that a taxing authority would reach the same conclusion. If, after a review or audit, an ownership change limitation were to apply, utilization of our domestic NOLs and tax credit carryforwards could be limited in future periods and a portion of the carryforwards could expire before being available to reduce future income tax liabilities. Moreover, our ability to utilize our NOLs is conditioned upon us achieving profitability and generating US federal taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Because we expect to be dependent upon collaborative and license agreements, we might not meet our strategic objectives. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our ability to generate revenue in the near term depends on the timing of recognition of certain upfront payments, achievement of certain payment triggering events with our existing collaboration agreements and our ability to enter into additional collaborative agreements with third parties. Our ability to enter into new collaborations and the revenue, if any, that may be recognized under these collaborations is highly uncertain. If we are unable to enter into one or more new collaborations, our business prospects could be harmed, which could have an immediate adverse effect on our ability to continue to develop our compounds and on the trading price of our stock. Our ability to enter into a collaboration may be dependent on many factors, such as the results of our clinical trials, competitive factors and the fit of one of our programs with another company&#8217;s risk tolerance, including toward regulatory issues, patent portfolio, clinical pipeline, the stage of the available data, particularly if it is early, overall corporate goals and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To date, a portion of our revenues have been related to the research or transition phase of each of our collaborative agreements. Such revenues are for specified periods, and the impact of such revenues on our results of operations is at least partially offset by corresponding research costs. Following the completion of the research or transition phase of each collaborative agreement, additional revenues may come only from payments triggered by milestones and/or the achievement of other contingent events, and royalties, which may not be paid, if at all, until certain conditions are met. This risk is heightened due to the fact that unsuccessful research efforts may preclude us from receiving any contingent payments under these agreements. Our receipt of revenues from collaborative arrangements is also significantly affected by the timing of efforts expended by us and our collaborators and the timing of lead compound identification. We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi. Under several agreements, future payments may not be earned until the collaborator has advanced product candidates into clinical testing, which may never occur or may not occur until sometime well into the future. If we are not able to generate revenue under our collaborations when and in accordance with our expectations or the expectations of industry analysts, this failure could harm our business and have an immediate adverse effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business requires us to generate meaningful revenue from royalties and licensing agreements. To date, we have not recognized material amount of revenue from royalties for the commercial sale of drugs, and we do not know </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">when we will be able to generate such meaningful revenue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Securities class action lawsuits or other litigation could result in substantial damages and may divert management&#8217;s time and attention from our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We have been subject to class action lawsuits in the past and we may be subject to lawsuits in the future, such as those that might occur if there was to be a change in our corporate strategy. These and other lawsuits are subject to inherent uncertainties, and the actual costs to be incurred relating to the lawsuit will depend upon many unknown factors. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of such suits, and we may not prevail. Monitoring and defending against legal actions is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, we may incur substantial legal fees and costs in connection with any such litigation. We have not established any reserves for any potential liability relating to any such potential lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on any such actions could result in the payment of substantial damages, or possibly fines, and could have an adverse effect on our cash flow, results of operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our competitors develop technologies that are more effective than ours, our commercial opportunity will be reduced or eliminated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Many of the drugs that we are attempting to discover will be competing with existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. For example, the commercialization of new pharmaceutical products is highly competitive, and we face substantial competition with respect to our products in which there are existing therapies and drug candidates in development for the treatment of <span style="color:#222222;background:#ffffff;">hematologic disorders and cancer</span> that may be alternative therapies to our products. Many of our competitors, including a number of large pharmaceutical companies that compete directly with us, have significantly greater financial resources and expertise commercializing approved products than we do. Also, many of our competitors are large pharmaceutical companies that will have a greater ability to reduce prices for their competing drugs in an effort to gain market share and undermine the value proposition that we might otherwise be able to offer to payors. We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as from academic and research institutions and government agencies, both in the US and abroad. Some of these competitors are pursuing the development of pharmaceuticals that target the same diseases and conditions as our research programs. Our competitors including fully integrated pharmaceutical companies have extensive drug discovery efforts and are developing novel small-molecule pharmaceuticals. We also face significant competition from organizations that are pursuing the same or similar technologies, including the discovery of targets that are useful in compound screening, as the technologies used by us in our drug discovery efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Competition may also arise from:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new or better methods of target identification or validation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generic versions of our products or of products with which we compete;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other drug development technologies and methods of preventing or reducing the incidence of disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new small molecules; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other classes of therapeutic agents.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our competitors or their collaborative partners may utilize discovery technologies and techniques or partner with collaborators in order to develop products more rapidly or successfully than we or our collaborators are able to do. Many of our competitors, particularly large pharmaceutical companies, have substantially greater financial, technical and human resources and larger research and development staffs than we do. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies and may establish exclusive collaborative or licensing relationships with our competitors.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We believe that our ability to compete is dependent, in part, upon our ability to create, maintain and license scientifically-advanced technology and upon our and our collaborators&#8217; ability to develop and commercialize pharmaceutical products based on this technology, as well as our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary technology or processes, secure effective market access by ensuring competitive pricing and reimbursement in territories of interest, and secure sufficient capital resources for the expected substantial time period between technological conception and commercial sales of products based upon our technology. The failure by any of our collaborators or us in any of those areas may prevent the successful commercialization of our potential drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Many of our competitors, either alone or together with their collaborative partners, have significantly greater experience than we do in:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying and validating targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">screening compounds against targets; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">undertaking preclinical testing and clinical trials.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Accordingly, our competitors may succeed in obtaining patent protection, identifying or validating new targets or developing new drug compounds before we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our competitors might develop technologies and drugs that are more effective or less costly than any that are being developed by us or that would render our technology and product candidates obsolete and noncompetitive. In addition, our competitors may succeed in obtaining the approval of the FDA or other regulatory agencies for product candidates more rapidly. Companies that complete clinical trials, obtain required regulatory agency approvals and commence commercial sale of their drugs before us may achieve a significant competitive advantage, including certain patent and FDA marketing exclusivity rights that would delay or prevent our ability to market certain products. Any drugs resulting from our research and development efforts, or from our joint efforts with our existing or future collaborative partners, might not be able to compete successfully with competitors&#8217; existing or future products or obtain regulatory approval in the US or elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We face and will continue to face intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions and for licenses to additional technologies. These competitors, either alone or with their collaborative partners, may succeed in developing technologies or products that are more effective than ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our ability to compete successfully will depend, in part, on our ability to:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identify and validate targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discover candidate drug compounds that interact with the targets we identify in a safe and efficacious way;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract and retain scientific and product development personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruit subjects into our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain required regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain patent or other proprietary protection for our new drug compounds and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain access to manufacturing resources of the sufficient standard and scale; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter commercialization agreements for our new drug compounds; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain appropriate reimbursement price and positive recommendations by HTA bodies.</span></td></tr></table><div style="margin-top:9pt;"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our stock price may be volatile, and our stockholders&#8217; investment in our common stock could decline in value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The market prices for our common stock and the securities of other biotechnology companies have been highly volatile and may continue to be highly volatile in the future. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and success of our clinical trials and preclinical activities (including studies and manufacture of materials) of our product candidates conducted by us;</span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue to sell our products in the US;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into partnering opportunities across our pipeline;</span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt or failure to receive the additional funding necessary to conduct our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selling of our common stock by large stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">presentations of detailed clinical trial data at medical and scientific conferences and investor perception thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of technological innovations or new commercial products by our competitors or us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the announcement of regulatory applications, such as Annora&#8217;s ANDA, seeking approval of generic versions of our marketed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning proprietary rights, including patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning our collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity regarding actual or potential medical results relating to products under development by our competitors or us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the US and foreign countries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation or arbitration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic and other external factors or other disaster or crisis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in financial results.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We completed a reverse stock split of our shares of common stock, which may reduce and may limit the market trading liquidity of the shares due to the reduced number of shares outstanding and may potentially have an anti-takeover effect.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">We completed a reverse stock split of our common stock by a ratio of 1-for-10 effective June 27, 2024. The primary objective of the reverse stock split was to attempt to raise the per share trading price of our common stock. We believe that a low per share market price of our common stock impairs our marketability to, and acceptance by, institutional investors and other members of the investing public and creates a negative impression of us. Among other benefits, the effectuation of the reverse stock split seeks to help us maintain compliance with the minimum bid continued listing requirement of $1.00 per share required to maintain continued listing on The Nasdaq Global Select Market (the Bid Price Requirement). Prior to us effecting a reverse stock split, the closing bid price of our common stock at certain periods fell below $1.00 per share for 30 consecutive trading days. We received deficiency letters from the Listing Qualifications Department of Nasdaq on November 22, 2022 and November 27, 2023, notifying us that, for 30 consecutive business days, the bid price for our common stock had closed below the Bid Price Requirement. We received notification from the Listing Department of Nasdaq on January 5, 2023 and December 12, 2023 that we had  regained our compliance with the Bid Price Requirement because the closing price of our common stock closed at $1.00 </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="white-space:pre-wrap;">or more for over 10 consecutive days. </span><span style="background:#ffffff;">Although we regained compliance with the Nasdaq Bid Price Requirement, in the future, Nasdaq may initiate a delisting process with a notification letter if we were to again fall out of compliance. If we were to receive such a notification, we would be afforded a grace period of 180 calendar days to regain compliance with the Bid Price Requirement. In order to regain compliance, shares of our common stock would need to maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Additionally, we may be unable to meet other applicable Nasdaq listing requirements, including maintaining minimum levels of stockholders&#8217; equity or market values of our common stock in which case, our common stock could be delisted. If our common stock were to be delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Reducing the number of outstanding shares of our common stock through the reverse stock split increased the per share trading price of our common stock. However, there is no assurance that: </p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 9pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 9pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market price per share of our common stock after the reverse stock split will rise in proportion to the reduction in the number of shares outstanding before the reverse stock split;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 9pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 9pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reverse stock split will result in a per-share price that would attract brokers and investors who do not trade in lower-priced stocks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 9pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 9pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reverse stock split will result in a per-share price that will increase our ability to attract and retain employees and other service providers; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reverse stock split will promote greater liquidity for our stockholders with respect to their shares.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">In addition, the reverse stock split reduced the number of outstanding shares of our common stock without reducing the authorized number of shares of our common stock. Therefore, the number of shares of our common stock that are authorized and unissued has increased relative to the number of issued and outstanding shares of our common stock following the reverse stock split. Our Board of Directors may authorize the issuance of the remaining authorized and unissued shares without further stockholder action for a variety of purposes, except as such stockholder approval may be required in particular cases by our Amended and Restated Certificate of Incorporation, applicable law or the rules of any stock exchange on which our securities may then be listed. The issuance of additional shares would be dilutive to our existing stockholders and may cause a decline in the trading price of our common stock. The issuance of authorized but unissued shares of common stock could be used to deter a potential takeover of us that may otherwise be beneficial to stockholders by diluting the shares held by a potential suitor or issuing shares to a stockholder that will vote in accordance with the our Board of Director&#8217;s desires. A takeover may be beneficial to independent stockholders because, among other reasons, a potential suitor may offer such stockholders a premium for their shares of stock compared to the then-existing market price. We do not have any plans or proposals to adopt provisions or enter into agreements that may have material anti-takeover consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The market price of our common stock is based on our performance and other factors, some of which are unrelated to the number of shares outstanding. If the market price of our common stock declines, the percentage decline as an absolute number and as a percentage of our overall market capitalization may be greater than would occur in the absence of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The withdrawal of the UK from the EU may adversely impact our ability to obtain regulatory approvals of our product candidates in the UK, result in restrictions or imposition of taxes and duties for importing our product candidates into the UK, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the UK.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Following the result of a referendum in 2016, the UK left the<span style="white-space:pre-wrap;"> EU on January 31, 2020, commonly referred to as Brexit.  Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. A trade and cooperation agreement (Trade Agreement) that outlines the future trading relationship between the UK and the EU was agreed to in December 2020 and has been approved by each EU member state and the UK.</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Since a significant proportion of the regulatory framework in the UK applicable to our business and our product candidates is derived from EU directives and regulations, Brexit has had, and will continue to have, a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the UK or the EU. Great Britain (made up of England, Scotland, and Wales) is no longer covered by the EEA&#8217;s procedures for the grant of marketing authorizations (Northern Ireland will be covered by such procedures). The UK Government and the EU recently adopted a new agreement, the &#8220;Windsor Framework&#8221; which will replace the Northern Ireland Protocol. According to the Windsor Framework, medicinal products intended for the UK market including Northern Ireland will be authorized by the MHRA, and will bear a &#8220;UK only&#8221; label. This means that Medicinal products placed on the market in Northern Ireland will no longer need to be compliant with EU law. These new measures will be implemented from January 1, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">A separate marketing authorization will be required to market drugs in Great Britain. The MHRA has launched the Innovative Licensing and Access Pathway, or ILAP, a new accelerated assessment procedure for marketing authorization applications facilitating the interaction with pricing authorities and HTA bodies and aiming to enable companies to enter the UK market faster. On January 1, 2024, the MHRA launched a new International Recognition Procedure for Great Britain (England, Scotland and Wales) marketing authorization applications whereby the MHRA will, when considering such applications, recognize the approval of medicines by trusted reference regulators in Australia, Canada, Switzerland, Singapore, Japan, United States and EU following its own abbreviated assessment. Any delay in obtaining, or an inability to obtain, any marketing approvals would delay or prevent us from commercializing our product candidates in the UK or the EU and restrict our ability to generate revenue and achieve and sustain profitability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">While the Trade Agreement provides for the tariff-free trade of medicinal products between the UK and the EU, there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period.  Further, should the UK diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future.  We could therefore, both now and in the future, face significant additional expenses (when compared to the position prior to the end of the Transition Period) </span>to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Orphan designation in Great Britain following Brexit is granted on an essentially identical basis as in the EU but is based on the prevalence of the condition in Great Britain.&#160;It is therefore possible that conditions that are currently designated as orphan conditions in Great Britain will no longer be, and conditions that are not currently designated as orphan conditions in the EU will be designated as such in Great Britain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In April 2023, the European Commission adopted a wide ranging proposal for a new Directive and a new Regulation. If made into law, this proposal will revise and replace the existing general pharmaceutical legislation. This change will likely result in significant changes to the pharmaceutical industry. In particular, it is expected that the new Directive and Regulations will, if made into law, affect the duration of the period of regulatory protection afforded to medicinal products including regulatory data protection (also called &#8220;data exclusivity&#8221;), marketing exclusivity afforded to orphan medicinal products, as well as the conditions of eligibility to the orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The testing and marketing of medical products and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. We carry product liability insurance that is limited in scope and amount and may not be adequate to fully protect us against product liability claims. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">terms or in adequate amounts. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop, alone or with corporate collaborators. We, or our corporate collaborators, might not be able to obtain insurance at a reasonable cost, if at all. While under various circumstances we are entitled to be indemnified against losses by our corporate collaborators, indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on various scientific consultants and advisors for the success and continuation of our research and development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We work extensively with various scientific consultants and advisors. The potential success of our drug discovery and development programs depends, in part, on continued collaborations with certain of these consultants and advisors. We, and various members of our management and research staff, rely on certain of these consultants and advisors for expertise in our research, regulatory and clinical efforts. Our scientific advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We do not know if we will be able to maintain such consulting agreements or that such scientific advisors will not enter into consulting arrangements with competing pharmaceutical or biotechnology companies, any of which may have a detrimental impact on our research objectives and could have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">While we have a strong compliance process in place to ensure we are complying with all requirements of law, our consulting or advisory contracts with our scientific consultants and advisors may be scrutinized under the Anti-Kickback Statute, the UK Bribery Act 2010, and other similar national and state-level legislation, which prohibit, among other things, companies from offering or paying anything of value as remuneration for ordering, purchasing, or recommending the ordering or purchasing of pharmaceutical and biological products that may be paid for, in whole or in part, by Medicare, Medicaid, or another federal healthcare program. Although there are several statutory exceptions and regulatory safe harbors that may protect these arrangements from prosecution or regulatory sanctions, our consulting and advising contracts may be subject to scrutiny if they do not fit squarely within an available exception or safe harbor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages, penalties or fines.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, animals, and various radioactive compounds. We cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling or disposal of these animals and materials. In the event of contamination or injury, we could be held liable for damages that result or for penalties or fines that may be imposed, and such liability could exceed our resources. We are also subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with, or any potential violation of, these laws and regulations could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer other breakdowns, cyber-attacks, or information security breaches.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We are dependent upon information technology systems, infrastructure, and data to operate our business. While we believe our cybersecurity measures are adequate, our cybersecurity risk management, strategy and governance may be found to be inadequate that could harm our business. We rely on third-party vendors and their information technology systems. Despite the implementation of security measures, our recovery systems, security protocols, network protection mechanisms and other security measures and those of our CROs and other contractors and consultants are vulnerable to compromise from natural disasters; terrorism; war; telecommunication and electric failures; traditional computer hackers; malicious code (such as computer viruses or worms); employee error, theft or misuse; denial-of-service attacks; cyber-attacks by sophisticated nation-state and nation-state supported actors including ransomware; or other system disruptions. We receive, generate and store significant and increasing volumes of personal (including health), confidential and proprietary information. There can be no assurance that we, or our collaborators, CROs, third-party vendors, contractors and consultants will be successful in efforts to detect, prevent, protect against or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches. Any breakdown, cyber-attack or information security breach could result in a disruption of our drug development programs or other aspects of our business. For example, the loss of clinical trial data from completed or ongoing clinical trials for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, incur significant remediation or litigation costs, result in product development delays, disrupt key business operations, cause loss of revenue and divert attention of management and key information technology resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:14pt 0pt 9pt 0pt;">Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks, including on companies within the healthcare industry. As the cyber-threat landscape evolves, these threats are likely growing in frequency, sophistication and intensity and are increasingly difficult to detect. The costs of maintaining or upgrading our cyber-security systems at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing. Cyber threats may be generic, or they may be targeted against our information systems. Our network and storage applications and those of our contract manufacturing organizations, collaborators, contractors, CROs or vendors may be subject to unauthorized access or processing by hackers or breached due to operator or other human error, theft, malfeasance or other system disruptions. We may be unable to anticipate or immediately detect information security incidents and the damage caused by such incidents. These data breaches and any unauthorized access, processing or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information. Such attacks, such as in the case of a ransomware attack, also may interfere with our ability to continue to operate and may result in delays and shortcomings due to an attack that may encrypt our or our service providers&#8217; or partners&#8217; systems unusable. Additionally, because our services involve the processing of personal information and other sensitive information about individuals, we are subject to various laws, regulations, industry standards, and contractual requirements related to such processing. Any event that leads to unauthorized access, processing or disclosure of personal information, including personal information regarding our clinical trial participants or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to investigations and mandatory corrective action, and otherwise subject us to liability under laws, regulations or contracts that protect the privacy and security of personal information, which could disrupt our business, damage our reputation with our stakeholders, result in increased costs or loss of revenue, lead to negative publicity or result in significant financial exposure. The CCPA, in particular, includes a private right of action for California consumers whose personal information is impacted by a data security incident resulting from a company&#8217;s failure to maintain reasonable security procedures, and hence may result in civil litigation in the event of a security breach impacting such information. In addition, legislators and regulators in the US have enacted and are proposing new and more robust privacy and cybersecurity laws and regulations in response to increasing broad-based cyberattacks, including the CCPA and New York SHIELD Act. Notably, on July 26, 2023, the SEC adopted a final rule on cybersecurity risk management, strategy, governance and incident disclosure (SEC Cyber Rule). The SEC Cyber Rule requires public companies to make current disclosures about material cybersecurity incidents as well as annual disclosures of material information about their cybersecurity risk management, strategy and governance. The SEC Cyber Rule became effective on September 5, 2023. New data security laws add additional complexity, requirements, restrictions and potential legal risk, and compliance programs may require additional investment in resources, and could impact strategies and availability of previously useful data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The costs to respond to a security breach and/or to mitigate any identified security vulnerabilities could be significant, our efforts to address these issues may not be successful, and these issues could result in interruptions, delays, negative publicity, loss of customer trust, and other harms to our business and competitive position. Remediation of any potential security breach may involve significant time, resources, and expenses. We could be required to fundamentally change our business activities and practices in response to a security breach and our systems or networks may be perceived as less desirable, which could negatively affect our business and damage our reputation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">A security breach may cause us to breach our contracts with third parties. Our agreements with relevant stakeholders such as collaborators may require us to use legally required, industry-standard or reasonable measures to safeguard personal information. A security breach could lead to claims by relevant stakeholders that we have failed to comply with such contractual obligations, or require us to cooperate with these stakeholders in their own compliance efforts related to the security breach. In addition, any non-compliance with our data privacy obligations in our contracts or our inability to flow down such obligations from relevant stakeholders to our vendors may cause us to breach our contracts. As a result, we could be subject to legal action or the relevant stakeholders could end their relationships with us. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We may not have adequate insurance coverage for security incidents or breaches. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future equity issuances or a sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.*</span></p><a id="_Hlk172208566"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because we will continue to need additional capital in the future to continue to expand our business and our research and development activities, among other things, we may conduct additional equity offerings. We have an <span style="background:#ffffff;">Open Market Sale Agreement with Jefferies entered on August 4, 2020, and amended and restated on August 2, 2024. Pursuant to which, we may sell from time to time, through Jefferies, shares of our common stock in sales deemed to be &#8220;at-the-market offerings&#8221; as defined in Rule 415 under the Securities Act, subject to conditions specified in the Open Market Sale Agreement, including maintaining an effective registration statement covering the sale of shares under the Open Market Sale Agreement. We have a shelf registration statement (the Prior Registration Statement) filed with the SEC that includes </span>a base prospectus registering the offering, issuance, and sale by us of up to $250.0 million in the aggregate of the securities identified from time to time in one or more offerings, which include the $100.0 million of shares of our common stock that may be offered, issued and sold under the Open Market Sale Agreement.<span style="white-space:pre-wrap;background:#ffffff;"> As of June 30, 2024, we have not sold any shares of common stock under such Open Market Sale Agreement. The Prior Registration Statement was set to expire on August 3, 2024.  </span><span style="white-space:pre-wrap;background:#ffffff;">On August 2, 2024, we filed a new shelf registration statement (the New Registration Statement) with the SEC to replace the Prior Registration Statement. The New Registration Statement includes a base prospectus to register the offering, issuance and sale by us of up to $250.0 million in the aggregate of securities identified from time to time in one or more offerings, including up to $100.0 million of shares of our common stock that may be offered, issued and sold under the Open Market Sale Agreement. Under Rule 415(a)(5) under the Securities Act, we may offer and sell any unsold securities under the Prior Registration Statement until the SEC declares the New Registration Statement effective.  Once the New Registration Statement is declared effective, all offerings under the Prior Registration Statement will be terminated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We may also in the future enter into underwriting or sales agreements with financial institutions for the offer and sale of any combination of common stock, preferred stock, debt securities and warrants in one or more offerings.  If we or our stockholders sell, or if it is perceived that we or they will sell, substantial amounts of our common stock in the public market, the market price of our common stock could fall. A decline in the market price of our common stock could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate. In addition, future sales by us of our common stock may be dilutive to existing stockholders. Furthermore, if we obtain funds through a credit facility or through the issuance of debt or preferred securities, these securities would likely have rights senior to the rights of our common stockholders, which could impair the value of our common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges.* </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">On June 28, 2024, the US Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure Act &#8220;must exercise their independent judgment&#8221; and &#8220;may not defer to an agency interpretation of the law simply because a statute is ambiguous.&#8221; The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations of law, including those by the FDA and other agencies with significant oversight of the biopharmaceutical industry. The new framework is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government previously prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation judicial scrutiny. Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict.</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Risks Related to Clinical Development and Regulatory Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Enacted or future legislation, and/or potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of our product candidates and/or commercialize our products or our product candidates, once approved, and affect the prices we may set or obtain.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the US and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell our products, or any product candidates for which we obtain regulatory approval in the future. In particular, in March 2010, the Affordable Care Act was enacted, which substantially changed the way health care is financed by both governmental and private insurers, and continues to significantly impact the US pharmaceutical industry. On June 17, 2021, the US Supreme Court dismissed the legal challenge to the Affordable Care Act brought by several states (which argued that, without the individual mandate, the entire Affordable Care Act was unconstitutional) without specifically ruling on the constitutionality of the law. It is unclear how future actions before the Supreme Court, other such litigation, and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce the costs of healthcare and/or impose price controls may adversely affect, for example:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for our products, or our product candidates, if we obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to set a price that we believe is fair for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenue and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that we are required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In the US, the EU and other potentially significant markets for our current and future products, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. In the US, there have been several Congressional inquiries and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer-sponsored patient assistance programs, and reform government program reimbursement methodologies for drugs<span style="background:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which, among other changes, eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacture price, for single source and innovator multiple source drugs, effective January 1, 2024. The American Rescue Plan Act also temporarily increased premium tax credit assistance for individuals eligible for subsidies under the Affordable Care Act for 2021 and 2022 and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. The Inflation Reduction Act (IRA) extended this increased tax credit assistance and removal of the 400% federal poverty limit through 2025. Additionally, beginning in April 2013, the Budget Control Act of 2011 created an automatic reduction of Medicare payments to providers of up to 2%. As a result of the COVID-19 pandemic, this reduction was temporarily suspended from May 1, 2020 through March 31, 2022, with subsequent reductions to 1% from April 1, 2022 through June 30, 2022. The 2% reduction was then reinstated and has been in effect since July 1, 2022, and will remain in effect through the first eight months in which the fiscal year 2032 sequestration order is in effect, unless additional Congressional action is taken. Moreover, on June 16, 2022, the Federal Trade Commission issued a policy statement stating its intent to increase enforcement scrutiny of &#8220;exclusionary rebates&#8221; </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">to PBMs and other intermediaries that &#8220;foreclose competition.&#8221; On August 16, 2022, President Biden signed into law the IRA, which, among other reforms, allows Medicare to: beginning in 2026, establish a &#8220;maximum fair price&#8221; for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation with CMS; beginning in 2023, penalize drug companies that raise prices for products covered under Medicare Parts B and D faster than inflation; and beginning in 2025, impose new discount obligations on pharmaceutical and biological manufacturers for products covered under Medicare Part D. CMS continues to take steps to implement the IRA. For example, on June 30, 2023, CMS issued guidance detailing the requirements and parameters of the first round of price negotiations for products subject to the &#8220;maximum fair price&#8221; provision. On August 29, 2023, CMS released the initial list of ten drugs covered under Medicare Part D subject to price negotiations. This negotiation process will occur during 2023 and 2024 and result in maximum prices that will be effective beginning in 2026. None of our products were listed among the first ten products slated for the program as announced on August 29, 2023. On March 26, 2024, CMS released a list of 41 Medicare Part B products that had an adjusted coinsurance rate based on the inflationary rebate provisions of the IRA for the time period of April 1, 2024 to June 30, 2024. Most recently, on June 26, 2024, CMS released a list of 64 Medicare Part B products that will have an adjusted coinsurance rate based on the inflationary rebate provisions of the IRA for the time period of July 1, 2024 to September 30, 2024. While it remains to be seen how the drug pricing provisions imposed by the IRA will affect the broader pharmaceutical industry, several pharmaceutical manufacturers and other industry stakeholders have challenged the law, including through lawsuits brought against the DHHS, the Secretary of the DHHS, CMS, and the CMS Administrator challenging the constitutionality and administrative implementation of the IRA&#8217;s drug price negotiation provisions<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The</span> Biden administration has also taken executive action to address drug pricing and other healthcare policy changes<span style="background:#ffffff;">. </span>For example, on September 12, 2022, President Biden issued an Executive Order to promote biotechnology and biomanufacturing innovation that included several methods through which the Biden Administration would support the advancement of biotechnology and biomanufacturing in healthcare. <span style="background:#ffffff;">On October 14, 2022, President Biden issued an Executive Order on Lowering Prescription Drug Costs for Americans which instructed the Secretary of the DHHS to consider whether to select for testing by the CMS Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. </span><span style="white-space:pre-wrap;">On February 14, 2023, the DHHS issued a report in response to the October 14, 2022, Executive Order, which, among other things, selects three potential drug affordability and accessibility models to be tested by the CMS Innovation Center.  Specifically, the report addresses: (1) a model that would allow Part D Sponsors to establish a &#8220;high-value drug list&#8221; setting the maximum out-of-pocket costs for certain common generic drugs at $2 per month per drug; (2) a Medicaid-focused model that would establish a partnership between CMS, manufacturers, and state Medicaid agencies that would result in multi-state outcomes-based agreements for certain cell and gene therapy drugs; and (3) a model that would adjust Medicare Part B payment amounts for Accelerated Approval Program drugs to advance the developments of novel treatments. Additionally, consistent with President Biden&#8217;s previous announcements in connection with the Cancer Moonshot initiative, on June 27, 2023, the Center for Medicare Innovation at CMS announced a new model, the Enhancing Oncology Model, that is designed to make high-quality cancer care more affordable to both patients and Medicare.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Other proposed administrative actions may affect our government pricing responsibilities. For example, CMS has issued proposals to amend the existing Medicaid Drug Rebate Program regulations. In addition, there are pending legal and legislative developments relating to the 340B Drug Pricing Program, including ongoing litigation challenging federal enforcement actions against manufacturers and recently introduced and enacted state legislation. It remains to be seen how these drug pricing initiatives will affect the broader pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. Specifically, several US states and localities have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports, and/or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including the provision of gifts, meals or other items to certain healthcare providers, and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. Several state laws require disclosures related to state agencies and/or commercial purchasers with respect to price increases and new product launches that exceed certain thresholds as identified in the relevant statutes. Another emerging trend at the state level is the establishment of prescription drug affordability boards, some of which will prospectively permit certain states to establish upper payment limits for drugs that the state has determined to be </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;high-cost.&#8221; Some of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Furthermore, the increased emphasis on managed healthcare in the US and on country and regional pricing and reimbursement controls in the EU and the UK will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid, healthcare reform, pharmaceutical reimbursement policies and pricing in general. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise from future legislation or administrative action. However, we expect these initiatives to increase pressure on drug pricing. Further, certain broader legislation that is not targeted to the health care industry may nonetheless adversely affect our profitability.  If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="background:#ffffff;">See &#8220;Business &#8211; Government Regulation &#8211; Healthcare Reform&#8221; contained in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2023, for additional information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory approval for any approved product is limited by the FDA, the EC and other regulators to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and we may incur significant liability if it is determined that we are promoting the &#8220;off-label&#8221; use of our products or any of our future product candidates if approved.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Any regulatory approval is limited to those specific diseases, indications and patient populations for which a product is deemed to be safe and effective by the FDA, the EC and other regulators. For example, the FDA-approved label for TAVALISSE is only approved for use in adults with ITP who have had an insufficient response to other treatments and for REZLIDHIA is only approved for use in adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. Further, GAVRETO is approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive NSCLC and has a conditional approval for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.<span style="font-size:12pt;"> </span>In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products and product candidates, or if we are not able to maintain a conditional approval or transition a conditional approval to full approval,<span style="color:#ff0000;font-size:12pt;"> </span>our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote the products is limited to those indications and patient populations that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. We have implemented compliance and monitoring policies and procedures, including a process for internal review of promotional materials, to deter the promotion of our products for off-label uses. We cannot guarantee that these compliance activities will prevent or timely detect off-label promotion by sales representatives or other personnel in their communications with health care professionals, patients and others, particularly if these activities are concealed from us. Regulatory authorities in the US generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If our promotional activities fail to comply with the FDA&#8217;s or other competent national authority&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these regulatory authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters, suspend or withdraw an approved product from the market, require a recall or institute fines, which could result in the disgorgement of money, operating restrictions, injunctions or civil or criminal </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">enforcement, and other consequences, any of which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading and non-promotional scientific exchange concerning their products. We engage in medical education activities and communicate with investigators and potential investigators regarding our clinical trials. If the FDA or other regulatory or enforcement authorities determine that our communications regarding our marketed product are not in compliance with the relevant regulatory requirements and that we have improperly promoted off-label uses, or that our communications regarding our investigational products are not in compliance with the relevant regulatory requirements and that we have improperly engaged in pre-approval promotion, we may be subject to significant liability, including civil and administrative remedies as well as criminal sanctions.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in clinical testing could result in increased costs to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We may not be able to initiate or continue clinical studies or trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these clinical trials as required by the FDA or other regulatory authorities, whether due to the impacts of a global pandemic, global tensions arising from the Russian-Ukrainian war and Hamas-Israel war or otherwise. Even if we are able to enroll a sufficient number of patients in our clinical trials, if the pace of enrollment is slower than we expect, the development costs for our product candidates may increase and the completion of our clinical trials may be delayed, or our clinical trials could become too expensive to complete. Significant delays in clinical testing could negatively impact our product development costs and timing. Our estimates regarding timing are based on a number of assumptions, including assumptions based on past experience with our other clinical programs. If we are unable to enroll the patients in these trials at the projected rate, the completion of the clinical program could be delayed and the costs of conducting the program could increase, either of which could harm our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a study, delays from scaling up of a study, delays in reaching agreement on acceptable clinical trial agreement terms with prospective clinical sites, delays in obtaining institutional review board approval to conduct a study at a prospective clinical site or delays in recruiting subjects to participate in a study. In addition, we typically rely on third-party clinical investigators to conduct our clinical trials and other third-party organizations to oversee the operations of such trials and to perform data collection and analysis. The clinical investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. Failure of the third-party organizations to meet their obligations, whether due to the potential future impacts of a global pandemic, the global tensions arising from the Russian-Ukrainian war and Hamas-Israel war or otherwise, could adversely affect clinical development of our products. As a result, we may face additional delaying factors outside our control if these parties do not perform their obligations in a timely fashion. For example, any number of those issues could arise with our clinical trials causing a delay. Delays of this sort could occur for the reasons identified above or other reasons. If we have delays in conducting the clinical trials or obtaining regulatory approvals, our product development costs will increase. For example, we may need to make additional payments to third-party investigators and organizations to retain their services or we may need to pay recruitment incentives. If the delays are significant, our financial results and the commercial prospects for our product candidates will be harmed, and our ability to become profitable will be delayed. Moreover, these third-party investigators and organizations may also have relationships with other commercial entities, some of which may compete with us. If these third-party investigators and organizations assist our competitors at our expense, it could harm our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">Due to the effects of the COVID-19 pandemic, for several of our development programs, we experienced disruption or delay in our ability to enroll and assess patients, maintain patient enrollment, supply study drugs, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in employee resources or otherwise.  In addition, in the event that a global pandemic occurs in the future, some patients in our clinical trial may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services.  Similarly, our ability to recruit and retain patients and principal investigators and site staff may be adversely affected if a global pandemic continues and persists for an extended period of time, and we may experience significant disruptions to our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects in the future.</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We have conducted in the past and are currently conducting or may conduct in the future clinical trials in the US and outside the US including Ukraine, Russia and Israel. Recent actions taken by the Russian Federation in Ukraine and surrounding areas have destabilized the region and caused the adoption of comprehensive sanctions by, among others, the EU, the US and the UK, which restrict a wide range of trade and financial dealings with Russia and Russian persons, as well as certain regions in Ukraine. Also, the recent global tensions arising from the Hamas-Israel war may result in disruptions in the broader global economic environment. Further, some patients may not be able to comply with clinical trial protocols if the conflict impedes patient movement or interrupts healthcare services. In addition, clinical trial site initiation and patient enrollment may be delayed, and we may not be able to access sites for initiation and monitoring in regions affected by the Russian-Ukrainian war or the Hamas-Israel war including due to the prioritization of hospital resources away from clinical trials or as a result of warfare, violence, government-imposed curfews, or events or other governmental actions that restrict movement. We could also experience disruptions in our supply chain or limits our ability to obtain sufficient materials for our drug products in certain regions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public perception of the risk-benefit balance for our product candidates may be affected by adverse events in clinical trials involving our product candidate or other treatments.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop, or of other products similar to products we are developing, could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. If and when they are used in clinical trials, our developmental candidates and investigational medicines could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by US, state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We lack the capability to manufacture compounds for clinical development, and we rely on and intend to continue relying on third parties for commercial supply, manufacturing and distribution if any of our product candidates which receive regulatory approval and we may be unable to obtain required material or product in a timely manner, at an acceptable cost or at a quality level required to receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We currently do not have the manufacturing capabilities or experience necessary to produce our products or any product candidates for clinical trials. We currently use one active pharmaceutical ingredient manufacturer and one finished goods manufacturer for each of our products. We do not currently have, nor do we plan to acquire the infrastructure or capability to supply, manufacture or distribute preclinical, clinical or commercial quantities of drug substances or products. For each clinical trial of our unpartnered product candidates, we rely on third-party manufacturers for the active pharmaceutical ingredients, as well as various manufacturers to manufacture starting components, excipients and formulated drug products. Our ability to develop our product candidates, and our ability to commercially supply our products will depend, in part, on our ability to successfully obtain the active pharmaceutical ingredients and other substances and materials used in our product candidates from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply relationships with these third parties, we may be unable to continue to develop or commercialize our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We rely and will continue to rely on certain third parties, including those located outside the US, as our limited source of the materials they supply or the finished products they manufacture. The drug substances and other materials used in our product candidates are currently available only from one or a limited number of suppliers or manufacturers and certain of our finished product candidates are manufactured by one or a limited number of contract manufacturers. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Any of these existing suppliers or manufacturers may:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail to supply us with product on a timely basis or in the requested amount due to unexpected damage to or destruction of facilities or equipment or otherwise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fail to increase manufacturing capacity and produce drug product and components in larger quantities and at higher yields in a timely or cost-effective manner, or at all, to sufficiently meet our commercial needs;</span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be unable to meet our production demands due to issues related to their reliance on sole-source suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply us with product that fails to meet regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">become unavailable through business interruption or financial insolvency;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lose regulatory status as an approved source;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be unable or unwilling to renew current supply agreements when such agreements expire on a timely basis, on acceptable terms or at all; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discontinue production or manufacturing of necessary drug substances or products.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our current and anticipated future dependence upon these third-party manufacturers may adversely affect our ability to develop and commercialize product candidates on a timely and competitive basis, which could have an adverse effect on sales, results of operations and financial condition. If we were required to transfer manufacturing processes to other third-party manufacturers and we were able to identify an alternative manufacturer, we would still need to satisfy various regulatory requirements. Satisfaction of these requirements could cause us to experience significant delays in receiving an adequate supply of our products and products in development and could be costly. Moreover, we may not be able to transfer processes that are proprietary to the manufacturer, if any. These manufacturers may not be able to produce material on a timely basis or manufacture material at the quality level or in the quantity required to meet our development timelines and applicable regulatory requirements and may also experience a shortage in qualified personnel. Our third-party manufacturers import certain materials from China to produce our products. The tensions between the US and China have led to a series of tariffs and sanctions being imposed by the US on imports from China mainland, as well as other business restrictions. Such tensions could adversely impact us and our third-party manufacturers.<span style="background:#ffffff;"> </span>We may not be able to maintain or renew our existing third-party manufacturing arrangements, or enter into new arrangements, on acceptable terms, or at all. Our third-party manufacturers could terminate or decline to renew our manufacturing arrangements based on their own business priorities, at a time that is costly or inconvenient for us. If we are unable to contract for the production of materials in sufficient quantity and of sufficient quality on acceptable terms, our planned clinical trials may be significantly delayed. Manufacturing delays could postpone the filing of our investigational new drug (IND) applications and/or the initiation or completion of clinical trials that we have currently planned or may plan in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration, the EMA, national competent authorities in the EU and UK and other federal and state government and regulatory agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards and they may not be able to comply. Switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all. Additionally, if we are required to enter into new supply arrangements, we may not be able to obtain approval from the FDA of any alternate supplier in a timely manner, or at all, which could delay or prevent the clinical development and commercialization of any related product candidates. Failure of our third-party manufacturers or us to comply with applicable regulations, whether due to the impacts of a global pandemic or otherwise, could result in sanctions being imposed on us, including fines, civil penalties, delays in or failure to grant marketing approval of our product candidates, injunctions, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products and compounds, operating restrictions and criminal prosecutions, warning or similar letters or civil, criminal or administrative sanctions against us, any of which could adversely affect our business.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, EMA, MHRA and other comparable regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we may be unable to generate revenue from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We commercialize our products in the US and we have entered into commercialization agreements with third parties to commercialize fostamatinib outside the US. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EMA and other comparable international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians, import and export requirements and recordkeeping. If we or our suppliers encounter manufacturing, quality or compliance difficulties with respect to our products or any of our product candidates, when and if approved, whether due to the impacts of a global pandemic (including as a result of disruptions of global shipping and the transport of products) or otherwise, we may be unable to obtain or maintain regulatory approval or meet commercial demand for such products, which could adversely affect our business, financial conditions, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, the FDA often requires post-marketing testing and surveillance to monitor the effects of products. The FDA, the EMA and other comparable international regulatory agencies may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient. Additionally, the FDA may require REMS to help ensure that the benefits of the drug outweigh its risks. A REMS may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug&#8217;s risks, limitations on who may prescribe or dispense the drug, requirements that patients enroll in a registry or undergo certain health evaluations or other measures that the FDA deems necessary to ensure the safe use of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">untitled or warning letters or other adverse publicity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to allow us to enter into supply contracts, including government contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If such regulatory actions are taken, the value of our company and our operating results will be adversely affected. Additionally, if the FDA, the EMA or any other comparable international regulatory agency withdraws its approval of a product that is or may be approved, we will be unable to generate revenue from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, the marketing and sales of our products could be delayed and we may be subject to enforcement action, which could decrease our revenues.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Conducting our business requires us to manage relationships with third-party contractors. As a result, our success depends partially on the success of these third parties in performing their responsibilities to comply with FDA rules and regulations. Although we pre-qualify our contractors and we believe that they are fully capable of performing their contractual obligations, we cannot directly control the adequacy and timeliness of the resources and expertise that they apply to these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">If any of our partners or contractors fail to perform their obligations in an adequate and timely manner, or fail to comply with the FDA&#8217;s rules and regulations, then the marketing and sales of our products could be delayed. The FDA may also take enforcement actions against us based on compliance issues identified with our contractors. If any of these events occur, we may incur significant liabilities, which could decrease our revenues.  For example, sales and medical science liaison or MSL personnel, including contractors, must comply with FDA requirements for the advertisement and promotion of products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain regulatory approval to market products in the US and foreign jurisdictions, we will not be permitted to commercialize products we or our collaborative partners may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We cannot predict whether regulatory clearance will be obtained for any product that we, or our collaborative partners, hope to develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. Of particular significance to us are the requirements relating to research and development and testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Before commencing clinical trials in humans in the US, we, or our collaborative partners, will need to submit and receive approval from the FDA of an IND application. Clinical trials are subject to oversight by institutional review boards and the FDA and:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">must be conducted in conformance with the FDA&#8217;s good clinical practices and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">must meet requirements for institutional review board oversight;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">must meet requirements for informed consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are subject to continuing FDA and regulatory oversight;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may require large numbers of test subjects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may be suspended by us, our collaborators or the FDA at any time if it is believed that the subjects </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">participating in these trials are being exposed to unacceptable health risks or if the FDA finds deficiencies in the IND or the conduct of these trials.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">While we have stated that we intend to file additional INDs for future product candidates, this is only a statement of intent, and we may not be able to do so because we may not be able to identify potential product candidates. In addition, the FDA may not approve any IND we or our collaborative partners may submit in a timely manner, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Before receiving FDA approval to market a product, we must demonstrate with substantial clinical evidence that the product is safe and effective in the patient population and the indication that will be treated. Data obtained from preclinical and clinical activities are susceptible to varying interpretations that could delay, limit or prevent regulatory approvals. In addition, delays or rejections may be encountered based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. Failure to comply with applicable FDA or other applicable regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products, total or partial suspension of production or injunction, adverse publicity, as well as other regulatory action against our potential products or us. Additionally, we have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If regulatory approval of a product is granted, this approval will be limited to those indications or disease states and conditions for which the product is demonstrated through clinical trials to be safe and efficacious. We cannot assure that any compound developed by us, alone or with others, will prove to be safe and efficacious in clinical trials and will meet all of the applicable regulatory requirements needed to receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;">Outside the US, our ability, or that of our collaborative partners, to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. This foreign regulatory approval process typically includes all of the risks and costs associated with FDA approval described above and may also include additional risks and costs, such as the risk that such foreign regulatory authorities, which often have different regulatory and clinical trial requirements, interpretations and guidance from the FDA, may require additional clinical trials or results for approval of a product candidate, any of which could result in delays, significant additional costs or failure to obtain such regulatory approval. There can be no assurance, however, that we or our collaborative partners will not have to provide additional information or analysis, or conduct additional clinical trials, before receiving approval to market product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;margin:9pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have orphan drug designations from the FDA but we may not be able to obtain additional orphan drug designations in the future, or maintain the orphan drug designations or exclusivity for the approved drugs for the treatment of respective indications, or we may be unable to maintain the benefits associated with orphan drug designations, including the potential for market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;">We have an orphan drug designation in the US for fostamatinib for the treatment of ITP and wAIHA, and for olutasidenib for the treatment of AML. Also, pralsetinib has an orphan drug designation in the US for the treatment of adult patients with metastatic RET fusion-positive NSCLC, for the treatment of advanced or metastatic RET fusion-positive thyroid cancer, and for the treatment of advanced or metastatic RET-mutant medullary thyroid carcinoma. We may seek orphan drug designation for other product candidates in the future. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the US, or a patient population greater than 200,000 in the US where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the US. In the US, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. At this time, we do not have nor will we seek to apply for orphan drug designation in the EU or the UK in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:9pt;text-indent:36pt;margin:0pt;">We cannot assure that any future application for orphan drug designation with respect to any other product candidate will be granted. If we are unable to obtain orphan drug designation with respect to other product candidates in </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">the US, we will not be eligible to obtain the period of market exclusivity that could result from orphan drug designation or be afforded the financial incentives associated with orphan drug designation. Even though we have received orphan drug designation for fostamatinib for the treatment of ITP and wAIHA in the US, we may not be the first to obtain marketing approval for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products or we might not maintain our orphan drug designation. In addition, exclusive marketing rights in the US for fostamatinib for the treatment of ITP, wAIHA or any future product candidate may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, Congress is considering updates to the orphan drug provisions of the FDCA in response to a recent 11th Circuit decision. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Risks Related to Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our prospects are highly dependent on our commercial products. To the extent that the commercial success of our products in the US is diminished or is not commercially successful, our business, financial condition and results of operations may be adversely affected, and the price of our common stock may decline. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;">We are focusing a significant portion of our activities and resources on our products, and we believe our prospects are highly dependent on, and a significant portion of the value of our company relates to, our ability to sustain successful commercialization of our products in the US. We have also entered into exclusive commercialization agreements with third parties to commercialize fostamatinib outside the US, and we plan to further enter partnership with existing or other third parties to commercialize our products outside the US in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Sustained successful commercialization of our products is subject to many risks and uncertainties, including the impact of a global pandemic on the successful commercialization in the US, as well as the successful commercialization efforts for our products through our collaborative partners. There are numerous examples of unsuccessful product launches and failures to meet high expectations of market potential, including by pharmaceutical companies with more experience and resources than us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;">There are many factors that could cause the commercialization of our products to be unsuccessful, including a number of factors that are outside our control. The commercial success of our products depends on the extent to which patients and physicians accept and adopt our products to treat the related diseases. We also do not know how physicians, patients and payors will respond to our future price increases of our products. Physicians may not prescribe our products and patients may be unwilling to use our products if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost. Our products compete, and may in the future compete, with currently existing therapies, including generic drugs, and products currently under development. Our competitors, particularly large pharmaceutical companies, may deploy more resources to market, sell and distribute their products. If our efforts are not appropriately resourced to adequately promote our products, the commercial potential of our sales may be diminished. Additionally, any negative development for our products in clinical development in additional indications may adversely impact the commercialization and potential of fostamatinib. Thus, significant uncertainty remains regarding the commercial potential of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Market acceptance of our products will depend on a number of factors, including: </p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of the product as well as competitive products; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product is approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians, the medical community and patients of the product as a safe and effective treatment; </span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future impacts, if any, due to the effects of a global pandemic and the global tensions arising from the Russian-Ukrainian war and Hamas-Israel war;</span></td></tr></table><div style="margin-top:9pt;"></div><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to distinguish safety and efficacy from existing, less expensive generic alternative therapies, if any; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience of prescribing, administrating and initiating patients on the product and the length of time the patient is on the product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived value and advantages of the product over alternative treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments, including any similar generic treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing and the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a positive HTA concluding that the product is cost-effective and the HTA bodies issuing a positive recommendation for the use of the product as a first or second line of treatment for the granted therapeutic indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse side effects; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.25;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of sales and marketing efforts. </span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">If we are unable to sustain anticipated level of sales growth from our products, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a negative impact on our business, financial condition and results of operations. For example, during 2021, we experienced lower than anticipated sales of our products due to continuing impacts of <span style="background:#ffffff;">physician and patient access issues created by the COVID-19 pandemic.</span> From time to time, our net product sales are negatively impacted by the decrease in level of inventories remaining at our distribution channels. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We also may not be successful entering into arrangements with third parties to sell and market one or more of our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, including Kissei&#8217;s development and commercialization of fostamatinib in all indications in Japan, China, Taiwan, and the Republic of Korea, Grifols&#8217; commercialization of fostamatinib in Europe and Turkey, Medison for future commercialization of fostamatinib in Canada and Israel, and Knight for commercialization of fostamatinib in Latin America. As a consequence of our license agreements with Kissei, Grifols, Medison and Knight, we rely heavily upon their regulatory, commercial, medical affairs, market access and other expertise and resources for commercialization of fostamatinib in their respective territories outside of the US. We cannot control the amount of resources that our partners dedicate to the commercialization of fostamatinib, and our ability to generate revenues from the commercialization of fostamatinib by our partners depends on their ability to achieve market acceptance of fostamatinib in its approved indications in their respective territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 0pt 0pt;">Furthermore, foreign sales of fostamatinib by our partners could be adversely affected by the imposition of governmental controls, political and economic instability, outbreaks of pandemic diseases, such as the COVID-19 pandemic, trade restrictions or barriers and changes in tariffs and escalating global trade and political tensions. For example, the COVID-19 pandemic has resulted in increased travel restrictions and extended shutdowns of certain businesses in the US and around the world. If our collaborators are unable to successfully complete clinical trials, delay commercialization of fostamatinib or do not invest the resources necessary to successfully commercialize fostamatinib in international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these license agreements, resulting in harm to our business and operations. If we do not establish and maintain sales and marketing </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we, or any of our collaborative partners, are able to continue to commercialize our products or any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or labeling restrictions, all of which may vary from country to country and any of which could harm our business.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;">The commercial success of any product for which we have obtained regulatory approval, or for which we may obtain regulatory approval in the future will depend substantially on the extent to which the costs of our product or product candidates are or will be paid by third-party payors, including government health care programs and private health insurers. There is a significant trend in the health care industry by public and private payors to contain or reduce their costs, including by taking the following steps, among others: decreasing the portion of costs payors will cover, ceasing to provide full payment for certain products depending on outcomes, and/or not covering certain products at all. If payors implement any of the foregoing with respect to our products, it would have an adverse impact on our revenue and results of operations. If coverage is not available, or reimbursement is limited, we, or any of our collaborative partners, may not be able to successfully commercialize our products or any of our product candidates in some jurisdictions. Even if coverage is provided, the approved reimbursement amount may not be at a rate that covers our costs, including research, development, manufacture, sale and distribution. In the US, no uniform policy of coverage and reimbursement for products exists among third-party payors; therefore, coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific, clinical or other support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed, which could delay market entry (or, if pricing is not approved, we may be unable to sell at all in a country where we have received regulatory approval for a product. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some countries, the proposed pricing for a drug must be approved before it may be lawfully marketed). In addition, authorities in some countries impose additional obligations, such as HTAs, which assess the performance of a drug in comparison with its cost. The outcome of HTA assessments is judged on a national basis and some payors may not reimburse the use of our products or may reduce the rate of reimbursement for our products and as a result, revenue from such products may decrease. </p><a id="_Hlk172187875"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;">On January 1, 2025, the new HTA Regulation, Regulation No 2021/2282 on Health Technology Assessment (HTA Regulation) will start applying to certain products, and will impose a new procedure for the assessment of the pricing and reimbursement of medicinal products. The HTA Regulation intends to foster cooperation among EU member states in assessing health technologies and provide a procedure for joint clinical assessments of medicinal products at a centralized level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">  In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any of our collaborative partners, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. In particular, we cannot predict to what extent the effects of a global pandemic, depending on its scale and duration, may disrupt global healthcare systems and access to our products or result in a widespread loss of individual health insurance coverage due to unemployment, a shift from commercial payor coverage to government payor coverage, or an increase in demand for patient assistance and/or free drug programs, any of which would adversely affect access to and demand for our products and our net sales. Adverse pricing limitations may also hinder our ability or the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval. Further, even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborative partners receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.4pt;margin:0pt 0pt 9pt 0pt;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any of our collaborative partners, to successfully commercialize our products or any of our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:32.05pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">Additionally, the labeling ultimately approved for any of our product candidates for which we have or may obtain regulatory approval may include restrictions on their uses and may be subject to ongoing FDA or international regulatory authority requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. If we or any of our collaborative partners do not timely obtain or comply with the labeling approval by the FDA or international regulatory authorities on any of our product candidates, it may delay or inhibit our ability to successfully commercialize our products and generate revenues.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to successfully market and distribute our products and retain experienced commercial personnel, our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We continuously expend significant time and resources to maintain a sales force that is credible and compliant with applicable laws in marketing our products. In addition, we must continually train our sales force to ensure that an appropriate and compliant message about our products is being delivered. If we are unable to effectively train our sales force and equip them with compliant and effective materials, including medical and sales literature to help them appropriately inform and educate health care providers regarding the potential benefits and proper administration of our products, our efforts to successfully commercialize our products could be put in jeopardy, which would negatively impact our ability to generate product revenues. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have established our distribution, sales, marketing and market access capabilities, all of which will be necessary to successfully commercialize our products. As a result, we will be required to expend significant time and resources to market, sell, and distribute our products to hematologists and hematologist-oncologists. There is no guarantee that the marketing strategies we have developed, or the distribution, sales, marketing and market access capabilities that we have developed will be successful. Particularly, we are dependent on third-party logistics, specialty pharmacies and distribution partners in the distribution of our products. If they are unable to perform effectively or if they do not provide efficient distribution of the medicine to patients, our business may be harmed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with managing our commercial team, including our potential inability to successfully train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are also competing for talent with numerous commercial and pre-commercial-stage oncology-focused biotechnology companies seeking to build out their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. If we cannot maintain effective sales, marketing, market access and product distribution capabilities, we may be unable to realize the commercial potential of our products. Also, to the extent that the commercial opportunities for our products grow over time, we may not properly judge the requisite size and experience of our current commercialization teams or the level of distribution necessary to market and sell our products, which could have an adverse impact on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to successfully develop or commercialize our product candidates if problems arise in the clinical testing and approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The activities associated with the research, development and commercialization of our products and other product candidates in our pipeline must undergo extensive clinical trials, which can take many years and require substantial expenditures, subject to extensive regulation by the FDA and other regulatory agencies in the US and by comparable authorities in other countries. The process of obtaining regulatory approvals in the US and other foreign jurisdictions is expensive, and lengthy, if approval is obtained at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Our clinical trials may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">activities are susceptible to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA and decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. Varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of our products for any individual, additional indications. For example, in June 2022, we announced that the top-line results from our Phase 3 trial in wAIHA did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population. While we conducted an in-depth analysis of these data to better understand differences in patient characteristics and outcomes and submitted these findings to the FDA, in October 2022, we announced that we received guidance from the FDA of these findings. <span style="color:#222222;background:#ffffff;">Based on the result of the trial and the guidance from the FDA</span>, we did not file an sNDA for wAIHA.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">It is also possible that we could experience delays in the timing of our interactions with regulatory authorities due to absenteeism by governmental employees or the diversion of regulatory authority efforts and attention to approval of other therapeutics, or other public health emergencies including a global pandemic, which could delay or limit our ability to make planned regulatory submissions or develop and commercialize our product candidates on anticipated timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for our products or for our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Commercialization of our product candidates depends upon successful completion of extensive preclinical studies and clinical trials to demonstrate their safety and efficacy for humans. Preclinical testing and clinical development are long, expensive and uncertain processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In connection with clinical trials of our product candidates, we may face the following risks among others:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product candidate may not prove to be effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product candidate may cause harmful side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical results may not replicate the results of earlier, smaller trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or third parties with whom we collaborate, may be significantly impacted by force majeure events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or the FDA or similar foreign regulatory authorities, may delay, terminate or suspend the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our results may not be statistically significant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient recruitment and enrollment may be slower than expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients may drop out of the trials or otherwise not enroll; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and clinical trial requirements, interpretations or guidance may change.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We do not know whether we will be permitted to undertake clinical trials of potential products beyond the trials already concluded and the trials currently in process. It will take us or our collaborative partners several years to complete any such testing, and failure can occur at any stage of testing. Interim results of trials do not necessarily predict final results, and acceptable results in early trials may not be repeated in later trials. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after achieving promising results in earlier trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><span style="background:#ffffff;">Further, evolving FDA standards may cause additional setbacks. In 2023, FDA published guidance documents and a final rule which all concern clinical trial requirements. </span><span style="white-space:pre-wrap;">In June 2023, FDA published a draft guidance, E6(R3) Good Clinical Practice, which seeks to unify standards for clinical trial data for the International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use member countries and regions.  In August 2023, FDA published a guidance document, Informed Consent, Guidance for IRBs, Clinical Investigators, and Sponsors, which supersedes past guidance and finalizes draft guidance on informed consent. Further, in December 2023, FDA published a final rule, Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical </span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">Investigations, which allows exceptions from informed consent requirements when a clinical investigation poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of human subjects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">Alterations to clinical trial requirements, including due to judicial challenges, may affect recruitment and retention of patients and may hinder or delay a clinical trial.  Further, changes to data requirements may cause FDA or comparable foreign regulatory authorities to disagree with data from preclinical studies or clinical trials, and may require further studies.  Changes to trial requirements or trial data may increase costs and delay product development. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Global economic conditions could adversely impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deterioration in the macroeconomic economy could lead to losses or defaults by our customers or suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. <span style="background:#ffffff;">The global financial markets and economy are currently, and have from time to time experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Any significant deterioration in the US economy would likely affect the operation of our business and ability to raise capital. In addition, US debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the US. Although US lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the US. The impact of this or any further downgrades to the US government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the US and global financial markets and economic conditions. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The global financial markets and economy may also be adversely affected by the current or anticipated impact of military conflict, including the ongoing Russian-Ukrainian war, and the Hamas-Israel war, terrorism or other geopolitical events. Sanctions imposed by the US and other countries in response to such conflicts, including the Russian-Ukrainian war and the Hamas-Israel war, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The US government has indicated its intent to alter its approach to international trade policy and in some cases to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries. In addition, the US government has initiated or is considering imposing tariffs on certain foreign goods. Related to this action, certain foreign governments, including China, have instituted or are considering imposing tariffs on certain US goods. It remains unclear what the US Administration or foreign governments will or will not do with respect to tariffs or other international trade agreements and policies. A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt our research activities, affect our suppliers and/or the US or global economy or certain sectors thereof and, thus, could adversely impact our businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bank failures or other events affecting financial institutions could adversely impact our liquidity and other business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><span style="background:#ffffff;">Financial institutions have recently experienced, and may experience in the future, industry instability and failures which have led to disruptions in access to bank deposits or lending commitments. </span>In 2023, the closures of Silicon Valley Bank (SVB) and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation (FDIC), as well as the FDIC&#8217;s seizure and sale of First Republic Bank, created bank-specific and broader financial institution liquidity risk and concerns. On March 12, 2023, federal regulators announced that the FDIC would complete its resolution of SVB in a manner that fully protects all depositors. On March 27, 2023, First Citizens Bank (FCB) announced that it has entered into an agreement with FDIC to purchase all of the asset and liabilities of SVB. Customers of SVB automatically become customers of FCB following the acquisition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">We maintain a depository relationship with SVB/FCB and other banking institutions. All of our cash deposits are accessible to us, and <span style="background:#ffffff;">we do not anticipate any losses with respect to such funds. </span>Since the March 2023 financial institution failure, there has been a heightened risk and greater focus on the potential failures of other banks in the future. If these banks fail in the future, we may not be able to immediately (or ever) recover our cash in excess of the FDIC insured limits which would adversely impact our operating liquidity and could negatively impact our operations, results of operations and financial performance. Although we believe our exposure is limited, if in the future any of the financial institutions that we maintain depository or lending relationships were to be placed into receivership, we may be unable to access such funds to meet our working capital requirements. In addition, if any of our customers, suppliers or other parties with whom we conduct business are unable to access funds, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impacted by factors that affect us, the financial institutions with which we have credit agreement or arrangements directly, or the financial services industry or economy in general. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shareholder activism and private securities-related litigation could cause material disruption to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Publicly traded companies have increasingly become subject to campaigns by our stakeholders, including investors, and more recently regulatory organizations advocating corporate actions such as actions related to Environmental Social Governance (ESG) matters, impacts of climate change, financial restructuring, increased borrowing, dividends, share repurchases and even sales of assets or the entire company. Responding to proxy contests and other actions by such activist investors or others in the future could be costly and time-consuming, disrupt our operations and divert the attention of our Board of Directors and senior management from the pursuit of our business strategies, which could adversely affect our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">There is a growing emphasis from select investors, regulators, and other stakeholders on corporate responsibility, particularly regarding ESG factors. Some investors and advocacy groups utilize these factors to shape investment strategies, potentially opting out of investing in our company if they perceive our corporate responsibility policies as insufficient. Third-party providers offering corporate responsibility ratings and reports have surged to meet rising investor demand, with numerous organizations evaluating companies on ESG matters, and these evaluations receive widespread attention. A low ESG or sustainability rating from such providers could lead certain investors to overlook our common stock in favor of competitors. Institutional investors, in particular, use these ratings to compare companies, and any perceived lag in our ESG efforts might prompt voting decisions or other actions to hold our board accountable. Furthermore, evolving assessment criteria for corporate responsibility practices may raise expectations, compelling us to undertake costly initiatives to meet new standards. Failure to meet these evolving criteria could reinforce the perception of inadequate corporate responsibility policies. Non-compliance could also lead to reputational damage if our procedures or standards fall short of stakeholder expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Securities-related class action lawsuits and/or derivative lawsuits have often been brought against companies, including biotechnology and biopharmaceutical companies, that experience volatility in the market price of their securities. It is possible that such lawsuit will be filed, or allegations from stockholders with this matter. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of the pending lawsuits and any additional lawsuits, and we may not prevail. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Provisions of our Amended and Restated Certificate of Incorporation and our bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions:</p><div style="margin-top:9pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish that members of the board of directors may be removed only for cause upon the affirmative vote of stockholders owning a majority of our capital stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our board of directors to </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase the number of outstanding shares and thwart a takeover attempt;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit who may call a special meeting of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide for a board of directors with staggered terms; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by a resolution of our board of directors.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">In addition, Section&#160;203 of the Delaware General Corporation Law (DGCL), which imposes certain restrictions relating to transactions with major stockholders, may discourage, delay or prevent a third party from acquiring us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our bylaws designate a state or federal court located within the State of Delaware as the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our current or former directors, officers, stockholders, or other employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of us under Delaware law, (ii) any action asserting a claim of breach of a fiduciary duty by any current or former director, officer, or other employee of ours that is owed to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, or other employees arising pursuant to any provision of the DGCL or our Amended and Restated Certificate of Incorporation and our bylaws (as either may be amended from time to time), (iv) any action asserting a claim against us governed by the internal affairs doctrine, or (v) any other action asserting an &#8220;internal corporate claim,&#8221; as defined under Section 115 of the DGCL. The forgoing provisions do not apply to any claims arising under the Securities Act and, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our current or former directors, officers, or other employees, which may discourage lawsuits with respect to such claims. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find the choice of forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and may harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable laws, regulations and national and EU codes of conduct, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, sharing of publications in unintended audiences in other jurisdictions, or any inadvertent promotional activity or disclosure of material, nonpublic information through these means, may cause us to be found in violation of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to attract and retain key employees and relationships.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="background:#ffffff;">We are highly dependent on the commercial, research and development, clinical, business development, financial and legal expertise of our executive officers, as well as the other principal members of our management.</span> We expect to continue hiring and retaining qualified personnel which is critical to our success. R<span style="background:#ffffff;">eplacing key employees and executive officers may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. </span>In particular, our research programs depend on our ability to attract and retain highly skilled chemists, other scientists, and development, regulatory and clinical personnel. If we lose the services of any of our key personnel, our research and development efforts could be seriously and adversely affected. Our employees can terminate their employment with us at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our facilities are located near known earthquake fault zones, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fires, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired, and our research could be lost or destroyed. In addition, the unique nature of our research activities and of much of our equipment could make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions.</p><a id="_cp_text_1_73"></a><a id="_13b41e5e_c5c5_4334_80b9_4c783794158f"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.</b></span><b style="font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">None.</p><a id="_cp_text_1_75"></a><a id="_f60223f1_99f6_4f9e_a7cd_8b9758a3a02a"></a><a id="Item3DefaultsUponSeniorSecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 3.</b></span><b style="font-weight:bold;">Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">None.</p><a id="_cp_text_1_77"></a><a id="_5439a133_088e_4b87_8cd9_4a6705cb536e"></a><a id="Item4MineSafetyDisclosures"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 4.</b></span><b style="font-weight:bold;">Mine Safety Disclosures</b></p><a id="_cp_text_1_78"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Not applicable.</p><a id="_cp_text_1_79"></a><a id="_717777f0_2d99_4c6b_9b8e_fa377d52814e"></a><a id="Item5OtherInformation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 5.</b></span><b style="font-weight:bold;">Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Securities Trading Plans of Directors and Executive Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">During the three months ended June 30, 2024,&#160;none&#160;of our directors or executive officers </span><span style="-sec-ix-hidden:Hidden_8fNFwOpvSkS3Ae-chWCEig;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adopted</span></span><span style="font-size:10pt;"> or </span><span style="-sec-ix-hidden:Hidden_qBoUQQL0r0CNAQ63h7ll_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminated</span></span><span style="font-size:10pt;"> </span><span style="-sec-ix-hidden:Hidden_tgDiYNPmjkeAMaI3ed0HFw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span></span><span style="font-size:10pt;"> </span><span style="-sec-ix-hidden:Hidden_4jghMFuwh06SniMlhZ5R1A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contract</span></span><span style="font-size:10pt;">, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:6.9pt;"><a id="_Hlk77948760"></a><a id="_6ed4838c_8f5e_44b5_acf1_ab6793cee558"></a><a id="Item6_Exhibits_122646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 6.</b></span><b style="font-weight:bold;">Exhibits</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The exhibits listed on the accompanying index to exhibits are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:86.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Document</b></p></td></tr><tr style="height:4.55pt;"><td style="vertical-align:top;width:9.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:40.6pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465924085422/tm2420634d2_ex1-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Amended and Restated Open Market Sale Agreement</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;letter-spacing:0.15pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">, dated August&#160;2, 2024, by and between Rigel Pharmaceuticals,&#160;Inc. and Jefferies LLC</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (filed as an exhibit to Rigel&#8217;s Registration Statement on Form S-3, dated August 2, 2024 and incorporated herein by reference).</span></a></p></td></tr><tr style="height:27.55pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465912040165/a12-13153_1ex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation (filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K, dated June 24, 2003 and incorporated herein by reference).</span></a></p></td></tr><tr style="height:27.1pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/tm2229578d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws (filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K, dated November 3, 2022 and incorporated herein by reference).</span></a></p></td></tr><tr style="height:26.65pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465912040165/a12-13153_1ex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K, dated May 29, 2012 and incorporated herein by reference).</span></a></p></td></tr><tr style="height:26.65pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/a18-13825_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K, dated May 18, 2018 and incorporated herein by reference).</span></a></p></td></tr><tr style="height:27.1pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465924075697/tm2417992d2_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (filed as an exhibit to Rigel&#8217;s Current Report on Form 8-K, dated June 27, 2024 and incorporated herein by reference).</span></a></p></td></tr><tr style="height:36.1pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000091205700041537/a2025040zex-4_3.txt"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Form of warrant to purchase shares of common stock (filed as an exhibit to Rigel&#8217;s Registration Statement on Form&#160;S-1, filed on September 15, 2000, as amended and incorporated herein by reference).</span></a></p></td></tr><tr style="height:27.1pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1034842/000110465903012978/j2357_ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Specimen Common Stock Certificate (filed as an exhibit to Rigel&#8217;s Current Report on Form&#160;8-K dated June&#160;24, 2003 and incorporated herein by reference).</span></a></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1#+</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="rigl-20240630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended</span></a>.</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2#+</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="rigl-20240630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Rigel Pharmaceuticals, Inc. Inducement Plan, as amended</span></a>.</p></td></tr><tr style="height:17.65pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1#</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20240630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.</span></a></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2#</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20240630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.</span></a></p></td></tr><tr style="height:26.65pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1#*</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="rigl-20240630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification required by Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350).</span></a></p></td></tr><tr style="height:27.1pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr style="height:13.6pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr style="height:13.6pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p></td></tr><tr style="height:13.6pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr><tr style="height:13.6pt;"><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;"><span style="font-size:10pt;">#</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;"><span style="font-size:10pt;">Filed herewith.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;"><span style="font-size:10pt;">+</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:6pt;"><span style="font-size:10pt;">Indicates a management contract or compensatory plan or arrangement.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;">*     The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the registrant for purposes of Section&#160;18 of the Exchange Act.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;">&#160;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a9a12e8b_545d_461b_a760_0e11cb2904bc"></a><a id="Signatures_122812"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIGEL PHARMACEUTICALS, INC.</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ RAUL R. RODRIGUEZ</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raul R. Rodriguez</p></td></tr><tr style="height:27.55pt;"><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 6, 2024</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ DEAN L. SCHORNO</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dean L. Schorno</p></td></tr><tr style="height:27.55pt;"><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 6, 2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:22.5pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>rigl-20240630xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/5/2024 11:54:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Rigel Pharmaceuticals,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">2018 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Adopted by the Board of Directors: February&#160;1, 2018</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May&#160;16, 2018</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended January 23,2019</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended January 31, 2019</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 22, 2019</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended February 3, 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 14, 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended January 28, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended March 9, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 18, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 19, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 25, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Approved by the Stockholders: May 24, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">General.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Successor to and Continuation of Prior Plans.</b><font style="white-space:pre-wrap;">  The Plan is intended as the successor to and continuation of the Rigel Pharmaceuticals,&#160;Inc. 2011 Equity Incentive Plan (the &#8220;</font><font style="font-style:italic;font-weight:bold;">2011 Plan</font>&#8221;), the Rigel Pharmaceuticals,&#160;Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;<font style="font-style:italic;font-weight:bold;">2000 Plan</font>&#8221;), and the Rigel Pharmaceuticals,&#160;Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">2000 Non-Employee Directors&#8217; Plan</font>&#8221;, and together with the 2011 Plan, and the 2000 Plan, the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans</font>&#8221;). Following the Effective Date, no additional stock awards may be granted under the Prior Plans. Any unallocated shares remaining available for grant under the Prior Plans as of 12:01&#160;a.m., Pacific Time on the Effective Date (the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans&#8217; Available Reserve</font>&#8221;) will cease to be available under such Prior Plans at such time and will be added to the Share Reserve (as further described in Section&#160;3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan. In addition, from and after 12:01&#160;a.m., Pacific Time on the Effective Date, all outstanding stock awards granted under the Prior Plans will remain subject to the terms of such Prior Plans, as applicable; <i style="font-style:italic;">provided, however</i>, that any shares subject to outstanding stock awards granted under the Prior Plans that (i)&#160;expire or terminate for any reason prior to exercise or settlement, (ii)&#160;are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii)&#160;other than with respect to outstanding options and stock appreciation rights granted under the Prior Plans, with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans&#8217; Appreciation Awards</font>&#8221;), are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award(collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Prior Plans&#8217; Returning Shares</font>&#8221;) will immediately be added to the Share Reserve (as further described in Section&#160;3(a) below) as and when such shares become Prior Plans&#8217; Returning Shares and become available for issuance pursuant to Awards granted hereunder. All Stock Awards granted on or after 12:01&#160;a.m., Pacific Time on the Effective Date will be subject to the terms of this Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Eligible Award Recipients.</b><font style="white-space:pre-wrap;">  Employees, Directors and Consultants are eligible to receive Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Available Stock Awards.</b><font style="white-space:pre-wrap;">  The Plan provides for the grant of the following types of Stock Awards: (i)&#160;Incentive Stock Options, (ii)&#160;Nonstatutory Stock Options, (iii)&#160;Stock Appreciation Rights, (iv)&#160;Restricted Stock Awards, (v)&#160;Restricted Stock Unit Awards, (vi)&#160;Performance Stock Awards, and (vii)&#160;Other Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Purpose.</b><font style="white-space:pre-wrap;">  The Plan, through the granting of Stock Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">1</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Administration.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Administration by Board.</b><font style="white-space:pre-wrap;">  The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section&#160;2(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Powers of Board.</b><font style="white-space:pre-wrap;">  The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>To determine (A)&#160;who will be granted Stock Awards; (B)&#160;when and how each Stock Award will be granted; (C)&#160;what type of Stock Award will be granted; (D)&#160;the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award; (E)&#160;the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F)&#160;the Fair Market Value applicable to a Stock Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>To settle all controversies regarding the Plan and Stock Awards granted under it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Stock Award without his or her written consent except as provided in subsection&#160;(viii) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vi)</b></font>To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&#160;409A of the Code and/or to make the Plan or Stock Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section&#160;409A of the Code, subject to the limitations, if any, of applicable law. However, if required by applicable law or listing requirements, and except as provided in Section&#160;10(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D)&#160;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (E)&#160;materially expands the types of Stock Awards available for issuance under the Plan. Except as provided in the Plan (including Section&#160;2(b)(viii)) or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Stock Award without the Participant&#8217;s written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vii)</b></font>To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&#160;Section&#160;422 of the Code regarding incentive stock options or (B)&#160;Rule&#160;16b-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(viii)</b></font>To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <i style="font-style:italic;">provided, however,</i> that a Participant&#8217;s rights under any Stock Award will not be impaired by any such amendment unless (A)&#160;the Company requests the consent of the affected Participant, and (B)&#160;such Participant consents in writing. Notwithstanding the foregoing, (1)&#160;a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2)&#160;subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Stock Award as an Incentive Stock Option under Section&#160;422 of the Code; (B)&#160;to change the terms of an Incentive Stock Option, if such change results in impairment of the Stock Award solely because it impairs the qualified status of the Stock Award as an Incentive Stock Option under Section&#160;422 of the Code; (C)&#160;to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section&#160;409A of the Code; or (D)&#160;to comply with other applicable laws or listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ix)</b></font>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(x)</b></font>To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Delegation to Committee.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">General.</b><font style="white-space:pre-wrap;">  The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Rule&#160;16b-3 Compliance.</b><font style="white-space:pre-wrap;">  The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule&#160;16b-3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Delegation to an Officer.</b><font style="white-space:pre-wrap;">  The Board may delegate to one or more Officers the authority to do one or both of the following (i)&#160;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Stock Awards, and (ii)&#160;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; </font><i style="font-style:italic;">provided, however</i>, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section&#160;13(u)(iii) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(e)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Effect of Board&#8217;s Decision.</b><font style="white-space:pre-wrap;">  All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Repricing; Cancellation and Re-Grant of Stock Awards.</b><font style="white-space:pre-wrap;">  Neither the Board nor any Committee will have the authority to (i)&#160;reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii)&#160;cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within 12&#160;months prior to such an event.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(g)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Dividends and Dividend Equivalents.</b><font style="white-space:pre-wrap;">  Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Stock Award (other than an Option or SAR), as determined by the Board and contained in the applicable Stock Award Agreement; </font><i style="font-style:italic;">provided, however</i>, that (i)&#160;no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Stock Award Agreement, (ii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Stock Award Agreement (including, but not limited to, any vesting conditions), and (iii)&#160;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Stock Award Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Shares Subject to the Plan.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Share Reserve.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>Subject to Section&#160;10(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed (A) 3,815,713 shares (which number is the sum of (i) the number of shares (1,003,213) subject to the Prior Plans&#8217; Available Reserve and (ii) an additional 500,000 new shares, plus 400,000 shares of Common Stock approved by the Board in January&#160;2019, and subsequently approved by the Company&#8217;s stockholders, plus 280,000 shares of Common Stock approved by the Board in February&#160;2020, and subsequently approved by the Company&#8217;s stockholders, plus 82,500 shares of Common Stock approved by the Board in January&#160;2021, and subsequently approved by the Company&#8217;s stockholders, plus 500,000 shares of Common Stock approved by the Board in March&#160;2022, and subsequently approved by the Company&#8217;s stockholders, plus 400,000 shares of Common Stock approved by the Board in February&#160;2023, and subsequently approved by the Company&#8217;s stockholders, plus 650,000 shares of Common Stock approved by the Board in February&#160;2024, and subsequently approved by the Company&#8217;s stockholders&#160;and&#160;(B) the Prior Plans&#8217; Returning Shares, if any, which become available for grant under this Plan from time to time (such aggregate number of shares described in (A) and (B) above, the &#8220;<font style="font-style:italic;font-weight:bold;">Share Reserve</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>For clarity, the Share Reserve in this Section&#160;3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section&#160;3(a) does not limit the granting of Stock Awards except as provided in Section&#160;8(a). Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule&#160;5635(c) or, if applicable, NYSE Listed Company Manual Section&#160;303A.08, AMEX Company Guide Section&#160;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>Subject to Section&#160;3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A)&#160;one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant; and (B)&#160;one and forty four hundredths (1.44) shares for each share of Common Stock issued pursuant to a Full Value Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Reversion of Shares to the Share Reserve.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Shares Available For Subsequent Issuance.</b><font style="white-space:pre-wrap;">  If (A)&#160;any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (</font><i style="font-style:italic;">i.e.</i>, the Participant receives cash rather than stock), (B)&#160;any shares of Common Stock issued pursuant to a </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C)&#160;with respect to a Full Value Award, any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">2018 Plan Returning Shares</font>&#8221;). For each (1)&#160;2018 Plan Returning Share subject to a Full Value Award or (2)&#160;Prior Plans&#8217; Returning Share subject to a stock award other than a Prior Plans&#8217; Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by one and forty-four hundredths (1.44) shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Shares Not Available For Subsequent Issuance.</b><font style="white-space:pre-wrap;">  Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of a Stock Award will no longer be available for issuance under the Plan, including any shares subject to a Stock Award that are not delivered to a Participant because such Stock Award is exercised through a reduction of shares subject to such Stock Award (</font><i style="font-style:italic;">i.e</i>., &#8220;net exercised&#8221;). In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award will no longer be available for issuance under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Incentive Stock Option Limit.</b><font style="white-space:pre-wrap;">  Subject to the Share Reserve and Section&#160;10(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 3,907,040 shares of Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Source of Shares.</b><font style="white-space:pre-wrap;">  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Eligibility.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Eligibility for Specific Stock Awards.</b><font style="white-space:pre-wrap;">  Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections&#160;424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule&#160;405, unless (i)&#160;the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii)&#160;the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section&#160;409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Ten Percent Stockholders.</b><font style="white-space:pre-wrap;">  A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Non-Employee Directors Compensation Limits</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Employee Director Compensation Limit</b>. The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any period commencing on the date of the Company&#8217;s Annual Meeting of Stockholders for a particular year and ending on the day immediately prior to the date of the Company&#8217;s Annual Meeting of Stockholders for the next subsequent year (the &#8220;Annual Period&#8221;), including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed (i) $1,000,000 in total value or (ii) in the event such Non-Employee Director is first appointed or elected to the Board during such Annual Period, $1,500,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. The limitations in this Section 5 shall apply commencing on the date of the 2021 Annual Meeting of Stockholders.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Provisions Relating to Options and Stock Appreciation Rights.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; <i style="font-style:italic;">provided, however</i>, that each Stock Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Term.</b><font style="white-space:pre-wrap;">  Subject to the provisions of Section&#160;4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of its grant, or such shorter period specified in the Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Exercise Price.</b><font style="white-space:pre-wrap;">  Subject to the provisions of Section&#160;4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section&#160;409A of the Code and, if applicable, Section&#160;424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Purchase Price for Options.</b><font style="white-space:pre-wrap;">  The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>by cash, check, bank draft or money order payable to the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>pursuant to a program developed under Regulation&#160;T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>if an Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <i style="font-style:italic;">provided, however</i>, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A)&#160;shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B)&#160;shares are delivered to the Participant as a result of such exercise, and (C)&#160;shares are withheld to satisfy tax withholding obligations; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font>in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Stock Award Agreement.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Exercise and Payment of a SAR.</b><font style="white-space:pre-wrap;">  To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Award Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B)&#160;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(e)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Transferability of Options and SARs.</b><font style="white-space:pre-wrap;">  The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section&#160;6(e) on the transferability of Options and SARs will apply. Notwithstanding the foregoing or anything in the Plan or a Stock Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Restrictions on Transfer.</b><font style="white-space:pre-wrap;">  An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections&#160;6(e)(ii) and 6(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant. Subject to the foregoing paragraph, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Domestic Relations Orders.</b><font style="white-space:pre-wrap;">  Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section&#160;1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Beneficiary Designation.</b><font style="white-space:pre-wrap;">  Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(f)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Vesting Generally.</b><font style="white-space:pre-wrap;">  The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(g)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination of Continuous Service.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&#160;the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(h)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Extension of Termination Date.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i)&#160;the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii)&#160;the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. In addition, unless otherwise provided in a Participant&#8217;s Stock Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i)&#160;the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii)&#160;the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Disability of Participant.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&#160;the date 12&#160;months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(j)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Death of Participant.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i)&#160;a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii)&#160;the Participant dies within the period (if any) specified in the Stock Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i)&#160;the date 18&#160;months following the date of death (or such longer or shorter period specified in the Stock Award Agreement), and (ii)&#160;the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(k)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination for Cause.</b><font style="white-space:pre-wrap;">  Except as explicitly provided otherwise in a Participant&#8217;s Stock Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(l)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Non-Exempt Employees.</b><font style="white-space:pre-wrap;">  If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&#160;if such non-exempt employee dies or suffers a Disability, (ii)&#160;upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii)&#160;upon a Change in Control, or (iv)&#160;upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Stock Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section&#160;6(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Provisions of Stock Awards Other than Options and SARs.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Restricted Stock Awards.</b><font style="white-space:pre-wrap;">  Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i)&#160;held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Consideration.</b><font style="white-space:pre-wrap;">  A Restricted Stock Award may be awarded in consideration for (A)&#160;cash, check, bank draft or money order payable to the Company, (B)&#160;past services to the Company or an Affiliate, or (C)&#160;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Vesting.</b><font style="white-space:pre-wrap;">  Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service.</b><font style="white-space:pre-wrap;">  If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(iv)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Transferability.</b><font style="white-space:pre-wrap;">  Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Restricted Stock Unit Awards.</b><font style="white-space:pre-wrap;">  Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Consideration.</b><font style="white-space:pre-wrap;">  At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Vesting.</b><font style="white-space:pre-wrap;">  At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Payment.</b><font style="white-space:pre-wrap;">  A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(iv)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Additional Restrictions.</b><font style="white-space:pre-wrap;">  At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(v)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Performance Stock Awards.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Performance Stock Awards.</b><font style="white-space:pre-wrap;">  A Performance Stock Award is a Stock Award that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Board, in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Stock Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Discretion.</b><font style="white-space:pre-wrap;">  The Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Other Stock Awards.</b><font style="white-space:pre-wrap;">  Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><i style="font-style:italic;">e.g</i>., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards granted under Section&#160;6 and this Section&#160;7. Subject to the provisions of the Plan (including, but not limited to, Section&#160;2(g)), the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Covenants of the Company.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Availability of Shares.</b><font style="white-space:pre-wrap;">  The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Securities Law Compliance.</b><font style="white-space:pre-wrap;">  The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><i style="font-style:italic;">provided, however</i>, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">No Obligation to Notify or Minimize Taxes.</b><font style="white-space:pre-wrap;">  The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Miscellaneous.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Use of Proceeds from Sales of Common Stock.</b><font style="white-space:pre-wrap;">  Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Corporate Action Constituting Grant of Stock Awards.</b><font style="white-space:pre-wrap;">  Corporate action constituting a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (</font><i style="font-style:italic;">e.g</i>., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (<i style="font-style:italic;">e.g</i>., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the preparation of the Stock Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Stock Award Agreement or related grant documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stockholder Rights.</b><font style="white-space:pre-wrap;">  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i)&#160;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii)&#160;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">No Employment or Other Service Rights.</b><font style="white-space:pre-wrap;">  Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&#160;the employment of an Employee with or without notice and with or without cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii)&#160;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(e)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Change in Time Commitment.</b><font style="white-space:pre-wrap;">  In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole discretion to (x)&#160;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y)&#160;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(f)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Incentive Stock Option Limitations.</b><font style="white-space:pre-wrap;">  To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(g)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Investment Assurances.</b><font style="white-space:pre-wrap;">  The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i)&#160;to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><font style="white-space:pre-wrap;">business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii)&#160;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&#160;the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B)&#160;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(h)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Withholding Obligations.</b><font style="white-space:pre-wrap;">  Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; </font><i style="font-style:italic;">provided, however,</i> that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii)&#160;withholding cash from a Stock Award settled in cash; (iv)&#160;withholding payment from any amounts otherwise payable to the Participant; or (v)&#160;by such other method as may be set forth in the Stock Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Electronic Delivery.</b><font style="white-space:pre-wrap;">  Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(j)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Deferrals.</b><font style="white-space:pre-wrap;">  To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section&#160;409A of the Code. Consistent with Section&#160;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(k)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Compliance with Section&#160;409A of the Code.</b><font style="white-space:pre-wrap;">  Unless otherwise expressly provided for in a Stock Award Agreement, the Plan and Stock Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Stock Awards granted hereunder exempt from Section&#160;409A of the Code, and, to the extent not so exempt, in compliance with Section&#160;409A of the Code. To the extent that the Board determines that any Stock Award granted hereunder is not exempt from and is therefore subject to Section&#160;409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&#160;409A(a)(1) of the Code, and, to the extent applicable, the Plan and Stock Award Agreements will be interpreted in accordance with the requirements of Section&#160;409A of the Code. Notwithstanding anything to the contrary in this Plan (and unless the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding a Stock Award that constitutes &#8220;deferred compensation&#8221; under Section&#160;409A of the Code is a &#8220;specified employee&#8221; for purposes of Section&#160;409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section&#160;409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">(l)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Clawback/Recovery.</b><font style="white-space:pre-wrap;">  All Stock Awards granted under the Plan will be subject to recoupment in accordance with the clawback policy adopted by the Compensation Committee in January 2019 and then ratified by the Board of Directors, or any successor to such policy.  This clawback policy complies with the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Plan Administrator may impose such other clawback, recovery or recoupment provisions in a Stock Award Agreement as the Plan Administrator determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Adjustments upon Changes in Common Stock; Other Corporate Events.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Capitalization Adjustments.</b><font style="white-space:pre-wrap;">  In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the Plan pursuant to Section&#160;3(a), (ii)&#160;the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&#160;3(c), and (iii)&#160; the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Dissolution or Liquidation.</b><font style="white-space:pre-wrap;">  Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, </font><i style="font-style:italic;">provided, however</i>, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(c)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Corporate Transaction.</b><font style="white-space:pre-wrap;">  The provisions of this Section&#160;10(c) will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(i)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stock Awards May Be Assumed.</b><font style="white-space:pre-wrap;">  In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">(ii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stock Awards Held by Current Participants.</b><font style="white-space:pre-wrap;">  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;Current Participants&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;"><font style="white-space:pre-wrap;">Corporate Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iii)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Stock Awards Held by Persons other than Current Participants.</b><font style="white-space:pre-wrap;">  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">(iv)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Payment for Stock Awards in Lieu of Exercise.</b><font style="white-space:pre-wrap;">  Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction (including, at the discretion of the Board, any unvested portion of such Stock Award), over (B)&#160;any exercise price payable by such holder in connection with such exercise. For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">Change in Control.</b><font style="white-space:pre-wrap;">  A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur. Notwithstanding the foregoing, upon a Change in Control, all Stock Awards held by each Director who is not an Employee and whose Continuous Service has not terminated immediately prior to the Change in Control shall become fully vested and exercisable immediately prior to the effectiveness of such Change in Control.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Termination or Suspension of the Plan.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The Board may suspend or terminate the Plan at any time. No Incentive Stock Option will be granted after the tenth anniversary of the earlier of (i)&#160;the date the Plan is adopted by the Board, or (ii)&#160;the date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b><i style="font-style:italic;white-space:pre-wrap;">  </i><b style="font-weight:bold;">No Impairment of Rights.</b><font style="white-space:pre-wrap;">  Suspension or termination of the Plan will not materially impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Effective Date of Plan.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Plan will become effective on the Effective Date.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Choice of Law.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-variant:small-caps;font-weight:bold;">Definitions.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Affiliate</font>&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule&#160;405. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Annual Meeting</font>&#8221; means the annual meeting of the stockholders of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Board</font>&#8221; means the Board of Directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Capitalization Adjustment</font>&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Cause</font>&#8221; will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events: (i)&#160;such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii)&#160;such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii)&#160;such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv)&#160;such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate. The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Change in Control</font>&#8221; will be deemed to have occurred upon the first to occur of an event set forth in any one of the following paragraphs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>the acquisition (other than from the Company, by any person (as such term is defined in Section&#160;13(c) or 14(d) of the Exchange Act) of beneficial ownership (within the meaning of Rule&#160;13d 3 promulgated under the Exchange Act) of fifty percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding voting securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>the individuals who, as of the effective date of the Plan, are members of the Board (the &#8220;<font style="font-style:italic;font-weight:bold;">Incumbent Board</font>&#8221;), cease for any reason to constitute at least a majority of the Board, unless the election, or nomination for election by the Company&#8217;s stockholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, and such new director shall, for purposes of this Plan, be considered as a member of the Incumbent Board; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>the closing of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">(1)</b><font style="display:inline-block;width:24.34pt;"></font>a merger or consolidation involving the Company if the stockholders of the Company, immediately before such merger or consolidation, do not, as a result of such merger or </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">15</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 72pt;">consolidation, own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the corporation resulting from such merger or consolidation in substantially the same proportion as their ownership of the combined voting power of the voting securities of the Company outstanding immediately before such merger or consolidation; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 72pt;"><b style="font-weight:bold;">(2)</b><font style="display:inline-block;width:24.34pt;"></font>a complete liquidation or dissolution of the Company or an agreement for the sale or other disposition of all or substantially all of the assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because fifty percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding securities is acquired by (i)&#160;a trustee or other fiduciary holding securities under one or more employee benefit plans maintained by the Company or any of its subsidiaries or (ii)&#160;any corporation which, immediately prior to such acquisition, is owned directly or indirectly by the stockholders of the Company in the same proportion as their ownership of stock in the Company immediately prior to such acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing or any other provision of this Plan, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(h)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Committee</font>&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section&#160;2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221; means the common stock of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(j)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Company</font>&#8221; means Rigel Pharmaceuticals,&#160;Inc., a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(k)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Consultant</font>&#8221; means any person, including an advisor, who is (i)&#160;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&#160;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form&#160;S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(l)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Continuous Service</font>&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; <i style="font-style:italic;">provided, however,</i> that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&#160;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">16</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">other personal leave, or (ii)&#160;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(m)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Corporate Transaction</font>&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>a sale, lease or other disposition of all or substantially all of the assets of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iv)</b></font>a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Corporate Transaction will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(n)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Director</font>&#8221; means a member of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(o)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Disability</font>&#8221; means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12&#160;months, as provided in Sections&#160;22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(p)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Effective Date</font>&#8221; means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2018, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(q)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Employee</font>&#8221; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(r)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Entity</font>&#8221; means a corporation, partnership, limited liability company or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(s)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(t)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Fair Market Value</font>&#8221; means, as of any date, the value of the Common Stock determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(i)</b></font>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">17</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font>Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(iii)</b></font>In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections&#160;409A and 422 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(u)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Full Value Award</font>&#8221; means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(v)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Incentive Stock Option</font>&#8221; means an option granted pursuant to Section&#160;6 that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(w)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Non-Employee Director</font>&#8221; means a Director who either (i)&#160;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item&#160;404(a) of Regulation&#160;S-K promulgated pursuant to the Securities Act (&#8220;<font style="font-style:italic;font-weight:bold;">Regulation&#160;S-K</font>&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item&#160;404(a) of Regulation&#160;S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation&#160;S-K; or (ii)&#160;is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule&#160;16b-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(x)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font>&#8221; means any option granted pursuant to Section&#160;6 that does not qualify as an Incentive Stock Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(y)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Officer</font>&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(z)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Option</font>&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(aa)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Option Agreement</font>&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(bb)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Optionholder</font>&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(cc)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Other Stock Award</font>&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&#160;7(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(dd)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Other Stock Award Agreement</font>&#8221; means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ee)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Own,</font>&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Owned,</font>&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Owner,</font>&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">Ownership</font>&#8221; A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ff)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Participant</font>&#8221; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">18</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(gg)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Criteria</font>&#8221; means the one or more criteria that the Board shall select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to establish such Performance Goals may be based on any one of, or combination of, the following: (i)&#160;earnings per share; (ii)&#160;earnings before interest, taxes and depreciation; (iii)&#160;earnings before interest, taxes, depreciation and amortization (EBITDA); (iv)&#160;net earnings; (v)&#160;total stockholder return; (vi)&#160;return on equity; (vii)&#160;return on assets, investment, or capital employed; (viii)&#160;operating margin; (ix)&#160;gross margin; (x)&#160;operating income; (xi)&#160;net income (before or after taxes); (xii)&#160;net operating income; (xiii)&#160;net operating income after tax; (xiv)&#160;pre- and after-tax income; (xv)&#160;pre-tax profit; (xvi)&#160;operating cash flow; (xvii)&#160;sales or revenue targets; (xviii)&#160;increases in revenue or product revenue; (xix)&#160;expenses and cost reduction goals; (xx)&#160;improvement in or attainment of expense levels; (xxi)&#160;improvement in or attainment of working capital levels; (xxii)&#160;economic value added (or an equivalent metric); (xxiii)&#160;market share; (xxiv)&#160;cash flow; (xxv)&#160;cash flow per share; (xxvi)&#160;share price performance; (xxvii)&#160;debt reduction; (xxviii)&#160;implementation or completion of projects or processes; (xxix)&#160;customer satisfaction; (xxx)&#160;total stockholder return; (xxxi)&#160;stockholders&#8217; equity; and (xxxii)&#160;other measures of performance selected by the Board. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement. The Board shall, in its sole discretion, define the manner of calculating the Performance Criteria it selects to use for such Performance Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(hh)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Goals</font>&#8221; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The Board is authorized at any time in its sole discretion, to adjust or modify the calculation of a Performance Goal for such Performance Period in order to prevent the dilution or enlargement of the rights of Participants, (a)&#160;in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development; (b)&#160;in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Company, or the financial statements of the Company in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business conditions; or (c)&#160;in view of the Board&#8217;s assessment of the business strategy of the Company, performance of comparable organizations, economic and business conditions, and any other circumstances deemed relevant. Specifically, the Board is authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (ii)&#160;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; and (iii)&#160;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends. In addition, the Board is authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i)&#160;to exclude restructuring and/or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated net sales growth and operating earnings; (iii)&#160;to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv)&#160;to exclude the effects of any items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (v)&#160;to exclude the effects to any statutory adjustments to corporate tax rates; and (vi)&#160;to make other appropriate adjustments selected by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ii)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Period</font>&#8221; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Performance Stock Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(jj)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Performance Stock Award</font>&#8221; means a Stock Award granted under the terms and conditions of Section&#160;7(c)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(kk)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Plan</font>&#8221; means this Rigel Pharmaceuticals,&#160;Inc. 2018 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ll)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Award</font>&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;7(a).</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">19</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(mm)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font>&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(nn)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font>&#8221; means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;7(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(oo)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font>&#8221; means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(pp)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Rule&#160;16b-3</font>&#8221; means Rule&#160;16b-3 promulgated under the Exchange Act or any successor to Rule&#160;16b-3, as in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(qq)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Rule&#160;405</font>&#8221; means Rule&#160;405 promulgated under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(rr)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ss)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Appreciation Right</font>&#8221; or &#8220;<font style="font-style:italic;font-weight:bold;">SAR</font>&#8221; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&#160;6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(tt)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font>&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(uu)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Award</font>&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(vv)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Stock Award Agreement</font>&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(ww)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Subsidiary</font>&#8221; means, with respect to the Company, (i)&#160;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&#160;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(xx)</b></font><b style="font-weight:bold;">&#8220;</b><font style="font-style:italic;font-weight:bold;">Ten Percent Stockholder</font>&#8221; means a person who Owns (or is deemed to Own pursuant to Section&#160;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">20</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>rigl-20240630xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/5/2024 11:54:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><a name="OLE_LINK4"></a><a name="OLE_LINK3"></a></font><b style="font-variant:small-caps;font-weight:bold;">Rigel Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Inducement Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Adopted by the Compensation Committee: October 10, 2016</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: January 3, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: August 16, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: November 7, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: December 23, 2017</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: January 24, 2018</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: August 19, 2020 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: September 30, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: January 4, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">April 4, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">December 8, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">April 4, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">June 29, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: October 3</b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">December 26, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">March 26, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">April 4, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended by the Compensation Committee: </b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">July 8, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:10pt;font-variant:small-caps;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447064"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">General.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_DV_M7"></a><a name="_Ref98825084"></a><a name="_Ref92447068"></a><b style="font-weight:bold;">Eligible Stock Award Recipients.</b> The only persons eligible to receive grants of Stock Awards under this Plan are individuals who satisfy the standards for inducement grants under NASDAQ Marketplace Rule 5635(c)(4) and the related guidance under NASDAQ IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Stock Awards under the Plan, other than following a <i style="font-style:italic;">bona fide</i> period of non-employment. Persons eligible to receive grants of Stock Awards under this Plan are referred to in this Plan as &#8220;<font style="font-style:italic;font-weight:bold;">Eligible Employees</font>&#8221;. These Stock Awards must be approved by either a majority of the Company&#39;s &#8220;<font style="font-style:italic;font-weight:bold;">Independent Directors</font>&#8221; (as such term is defined in NASDAQ Listing Rule 5605(a)(2)) or the Company&#8217;s compensation committee, provided such committee is comprised solely of Independent Directors (the &#8220;<font style="font-style:italic;font-weight:bold;">Independent Compensation Committee</font>&#8221;) in order to comply with the exemption from the stockholder approval requirement for &#8220;inducement grants&#8221; provided under Rule 5635(c)(4) of the NASDAQ Listing Rules. NASDAQ Marketplace Rule 5635(c)(4) and the related guidance under NASDAQ IM 5635-1 are referred to in this Plan as the &#8220;<font style="font-style:italic;font-weight:bold;">Inducement Award Rules</font>&#8221;.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Available Awards.</b> The Plan provides for the grant of Options and&#160;Restricted Stock Unit Awards<a name="_DV_M8"></a>. All Options will be Nonstatutory Stock Options. Awards intended to qualify as stockholder-approved performance based compensation for purposes of Section 162(m) of the Code may not be granted under this Plan. </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">1</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Purpose.</b> This Plan, through the granting of Stock Awards, is intended to provide (i) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, (ii) incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and (iii) a means by which Eligible Employees may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Stock Awards.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447603"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Administration.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Administration by Board.</b> The Board will administer the Plan, provided, however, that Stock Awards may only be granted by either (i) a majority of the Company&#39;s Independent Directors or (ii) the Independent Compensation Committee. Subject to those constraints and the other constraints of the Inducement Award Rules, the Board may delegate some of its powers of administration of the Plan to a Committee, as provided in Section 2(c). </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Powers of Board.</b> The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan and the Inducement Award Rules:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>To determine: (A)&#160;who will be granted Stock Awards; (B)&#160;when and how each Stock Award will be granted; (C)&#160;what type of Stock Award will be granted; (D)&#160;the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award; (E)&#160;the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award; provided, however, that Stock Awards may only be granted by either (i) a majority of the Company&#39;s Independent Directors or (ii) the Independent Compensation Committee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>To settle all controversies regarding the Plan and Stock Awards granted under it.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or at which cash or shares of Common Stock may be issued). </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Stock Award without his or her written consent except as provided in subsection (viii) below.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vi)</font>To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, adopting amendments relating to nonqualified deferred compensation under Section 409A of the Code and/or making the Plan or Stock Awards granted under the Plan exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D)&#160;materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E)&#160;materially extends the term of the Plan, or (F)&#160;materially expands the types of Stock Awards available for issuance under the Plan. Except as otherwise provided in the Plan (including subsection (viii) below) or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Stock Award without the Participant&#8217;s written consent. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vii)</font>To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Rule 16b-3 of Exchange Act or any successor rule.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(viii)</font>To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more outstanding Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion. A Participant&#8217;s rights under any Stock Award will not be impaired by any such amendment unless the Company requests the consent of the affected Participant, and the Participant consents in writing. However, a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights. In addition, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant&#8217;s consent (A)&#160;to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section 409A of the Code, or (B)&#160;to comply with other applicable laws or listing requirements.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ix)</font>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan and/or Stock Award Agreements.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(x)</font>To adopt such procedures and sub-plans as are necessary or appropriate (A) to permit participation in the Plan by individuals who are foreign nationals or employed outside the United States or (B) allow Stock Awards to qualify for special tax treatment in a foreign jurisdiction; <i style="font-style:italic;">provided</i> that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_Ref92447106"></a><b style="font-weight:bold;">Delegation to Committee.</b> </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">General. </b>The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><b style="font-weight:bold;">Rule 16b-3 Compliance.</b> The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3 of the Exchange Act.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><a name="_DV_M77"></a><a name="_DV_M78"></a><a name="_DV_M79"></a><a name="_DV_M80"></a><b style="font-weight:bold;">Effect of Board&#8217;s Decision.</b> All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-weight:bold;">Cancellation and Re-Grant of Stock Awards</b>. &#160;Neither the Board nor any Committee will have the authority to: (i) reduce the exercise, purchase or strike price of any outstanding Option, or (ii) cancel any outstanding Option that has an exercise price or strike price greater than the current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within twelve (12) months prior to such an event.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Shares Subject to the Plan.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Ref126996582"></a><a name="_Ref38179407"></a><b style="font-weight:bold;">Share Reserve</b>. <a name="OLE_LINK7"></a><a name="OLE_LINK8"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards will not exceed 702,892 shares (the &#8220;<font style="font-style:italic;font-weight:bold;">Share Reserve</font>&#8221;). &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Shares may be issued under the terms of this Plan in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><a name="_Ref134435282"></a><a name="_Ref126997548"></a><b style="font-weight:bold;">Reversion of Shares to the Share Reserve</b>. &#160;If a Stock Award or any portion of a Stock Award (i)&#160;expires or otherwise terminates without all of the shares covered by the Stock Award having been issued or (ii)&#160;is settled in cash (<i style="font-style:italic;">i.e.</i>, the Participant receives cash rather than stock), such expiration, termination or settlement will nevertheless reduce (or otherwise offset) the number of shares of Common Stock that are available for issuance under the Plan. If any shares of Common Stock issued under a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will not revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will not again become available for issuance under the Plan. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Source of Shares.</b> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Eligibility.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Eligibility for Specific Stock Awards.</b> Stock Awards may only be granted to persons who are Eligible Employees described in Section 1(a) of the Plan, where the Stock Award is an inducement material to the individual&#8217;s entering into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, <i style="font-style:italic;">provided however</i>, that Stock Awards may not be granted to Eligible Employees who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule&#160;405 of the Securities Act, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or comply with the distribution requirements of Section 409A of the Code. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><a name="_DV_M89"></a><a name="_Ref92447500"></a><b style="font-weight:bold;">Approval Requirements.</b> All Stock Awards must be granted either by a majority of the Company&#8217;s independent directors or the Independent Compensation Committee. </div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447517"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Provisions Relating to Options.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Option will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be Nonstatutory Stock Options. The provisions of separate Options need not be identical; <i style="font-style:italic;">provided, however</i>, that each Option Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Option Agreement or otherwise) the substance of each of the following provisions:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Term.</b> No Option will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Option Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Exercise Price.</b> The exercise or strike price of each Option will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">foregoing, an Option may be granted with an exercise price lower than 100% of the Fair Market Value of the Common Stock subject to the Option if such Option is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_Ref92447428"></a><b style="font-weight:bold;">Purchase Price for Options.</b> The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>by cash, check, bank draft or money order payable to the Company;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <i style="font-style:italic;">provided, however</i>, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Option Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Transferability of Options.</b> The Board may, in its sole discretion, impose such limitations on the transferability of Options as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options will apply:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Restrictions on Transfer.</b> An Option will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, an Option may not be transferred for consideration. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><b style="font-weight:bold;">Domestic Relations Orders.</b> Subject to the approval of the Board or a duly authorized Officer, an Option may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement <a name="_DV_C240"></a>or other divorce or separation instrument. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><b style="font-weight:bold;">Beneficiary Designation.</b> Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to exercise the Option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><a name="_Ref92447444"></a><b style="font-weight:bold;">Vesting Generally.</b> The total number of shares of Common Stock subject to an Option may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. The provisions of this Section 5(e) are subject to any Option provisions governing the minimum number of shares of Common Stock as to which an Option may be exercised.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-weight:bold;">Termination of Continuous Service.</b> Except as otherwise provided in the applicable Option Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date which occurs 3 months following the termination of the Participant&#8217;s Continuous Service<a name="_DV_C248"></a>, and (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option within the applicable time frame, the Option will terminate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><a name="_DV_M102"></a><b style="font-weight:bold;">Extension of Termination Date.</b> Except as otherwise provided in the applicable Stock Award Agreement, if the exercise of an Option following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option as set forth in the applicable Option Agreement.<a name="OLE_LINK5"></a><a name="OLE_LINK6"></a> In addition, unless otherwise provided in a Participant&#8217;s Option Agreement, if the sale of any Common Stock received upon exercise of an Option following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option will terminate on the earlier of (i) the expiration of a period of days or months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option as set forth in the applicable Option Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><a name="_DV_M103"></a><b style="font-weight:bold;">Disability of Participant.</b> Except as otherwise provided in the applicable Option Agreement or other agreement between the Participant and the Company, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such te<a name="_DV_C268"></a>rmination of Continuous Service<font style="color:#ff0000;"> </font>and (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option within the applicable time frame, the Option will terminate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_DV_M104"></a><b style="font-weight:bold;">Death of Participant.</b><a name="_DV_M105"></a> Except as otherwise provided in the applicable Option Agreement or other agreement between the Participant and the Company, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Option Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service for a reason other than death, then the Option may be exercised (to the extent the Participant was entitled to exercise such Option as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Participant&#8217;s death, but only within the period ending on the earlier of (i) the date 18 months following the date of death<a name="_DV_C274"></a><font style="color:#ff0000;">,</font> and (ii) the expiration of the term of such Option as set forth in the Option Agreement. If, after the Participant&#8217;s death, the Option is not exercised within the applicable time frame, the Option will terminate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><a name="_DV_M106"></a><a name="_DV_M107"></a><b style="font-weight:bold;">Termination for Cause. </b>Except as explicitly provided otherwise in a Participant&#8217;s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Participant&#8217;s Continuous Service is terminated for Cause, the Option will terminate upon the date on which the event giving rise to the termination for Cause first occurred, and the Participant will be prohibited from exercising his or her Option from and after the date on which the event giving rise to the termination for Cause first occurred (or, if required by applicable law, the date of termination of Continuous Service). If a Participant&#8217;s Continuous Service is suspended pending an investigation of the existence of Cause, all of the Participant&#8217;s rights under the Option will also be suspended during the investigation period, except to the extent prohibited by applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><b style="font-weight:bold;">Non-Exempt Employees</b>. If an Option is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option will not be first exercisable for any shares of Common Stock until at least 6 months following the date of grant of the Option (although the Option may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option is not assumed, continued, or substituted, or (iii) upon the non-exempt Employee&#8217;s retirement (as such term may be defined in the non-exempt Employee&#8217;s Option Agreement in another agreement between the non-exempt Employee and the Company, or, if no such definition, in accordance with the Company&#39;s then current employment policies and guidelines), the vested portion of any Options may be exercised earlier than 6 months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt Employee in connection with the exercise, vesting or issuance of any shares under any other Option will be exempt from such Employee&#8217;s regular rate of pay, the provisions of this paragraph will apply to all Options and are hereby incorporated by reference into such Option Agreements.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Provisions Relating to Restricted Stock Unit Awards.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><a name="_DV_M115"></a><a name="_Ref92447212"></a>Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_DV_M116"></a><b style="font-weight:bold;">Consideration.</b> At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><a name="_DV_M117"></a><a name="_Ref168993349"></a><b style="font-weight:bold;">Vesting. </b>At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><a name="_DV_M118"></a><b style="font-weight:bold;">Payment</b>. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><a name="_DV_M119"></a><b style="font-weight:bold;">Additional Restrictions. </b>At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><a name="_DV_M120"></a><b style="font-weight:bold;">Dividend Equivalents. </b>Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><a name="_DV_M121"></a><b style="font-weight:bold;">Termination of Participant&#8217;s Continuous Service. </b>Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.<b style="font-weight:bold;"> </b></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M128"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Covenants of the Company.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Ref147744725"></a><b style="font-weight:bold;">Availability of Shares.</b> The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Securities Law Compliance.</b> The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; <i style="font-style:italic;">provided, however,</i> that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">No Obligation to Notify or Minimize Taxes. </b>The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Miscellaneous.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Use of Proceeds from Sales of Common Stock. </b>Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will constitute general funds of the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Corporate Action Constituting Grant of Stock Awards.</b> Corporate action constituting a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (<i style="font-style:italic;">e.g.</i>, Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (<i style="font-style:italic;">e.g.</i>, exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement as a result of a clerical error in the papering of the Stock Award Agreement, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Stockholder Rights.</b> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i)&#160;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii)&#160;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">No Employment or Other Service Rights.</b> Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&#160;the employment of an Employee with or without notice and with or without cause, including, but not limited to, Cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii)&#160;the service </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-weight:bold;">Change in Time Commitment</b>. In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole discretion to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-weight:bold;">Investment Assurances.</b> The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i)&#160;to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award, and (ii)&#160;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (i)&#160;the issuance of the shares upon the exercise of a Stock Award or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (ii)&#160;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><a name="_Ref147744804"></a><b style="font-weight:bold;">Withholding Obligations.</b> Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local, foreign or other tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; <i style="font-style:italic;">provided, however</i>, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such other amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii)&#160;withholding cash from a Stock Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant, including proceeds from the sale of shares of Common Stock issued pursuant to a Stock Award; or (v)&#160;by such other method as may be set forth in the Stock Award Agreement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><b style="font-weight:bold;">Electronic Delivery</b>. Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto), or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Deferrals.</b> To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code (to the extent applicable to a Participant). Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><b style="font-weight:bold;">Compliance with Section 409A. </b>Unless otherwise expressly provided for in a Stock Award Agreement and the Plan will be interpreted to the greatest extent possible in a manner that makes the Plan and the Stock Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Stock Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent a Stock Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Stock Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a Stock Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section 409A of the Code) will be issued or paid before the date that is six (6) months following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six (6) month period elapses, with the balance paid thereafter on the original schedule.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font><b style="font-weight:bold;">Clawback/Recovery.</b> All Stock Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in a Stock Award Agreement as the Board determines necessary or appropriate, including, but not limited to, a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Adjustments upon Changes in Common Stock; Other Corporate Events.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><a name="_Ref92447089"></a><b style="font-weight:bold;">Capitalization Adjustments</b>. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the Plan pursuant to Section&#160;3(a) and (ii)&#160;the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Dissolution or Liquidation.</b>&#160; In the event of a dissolution or liquidation of the Company, then all outstanding Stock Awards shall terminate immediately prior to such event.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Corporate Transaction.</b>&#160; In the event of (i)&#160;a sale, lease or other disposition of all or substantially all of the securities or assets of the Company, (ii)&#160;a merger or consolidation in which the Company is not the surviving corporation or (iii)&#160;a reverse merger in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise (a &#8220;<font style="font-style:italic;font-weight:bold;">Corporate Transaction</font>&#8221;), then any surviving corporation or acquiring corporation may assume any Stock Awards outstanding under the Plan or may substitute similar stock awards (including an award to acquire the same consideration paid to the stockholders in such Corporate Transaction) for those outstanding under the Plan. In the event any surviving corporation or acquiring corporation does not assume such Stock Awards or substitute similar stock awards for those outstanding under the Plan, then with respect to Stock Awards held by Participants whose Continuous Service has not terminated, the vesting of such Stock Awards (and, if applicable, the time during which such Stock Awards may be exercised) shall be accelerated in full, and the Stock Awards shall terminate if not exercised (if applicable) at or prior to such event. With respect to any other Stock Awards outstanding under the Plan, such Stock Awards shall terminate if not exercised (if applicable) prior to such event.<sup style="font-size:7.5pt;font-variant:small-caps;font-weight:bold;vertical-align:top;"> </sup></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">10.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447246"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Termination or Suspension of the Plan.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;width:36pt;"></font>The Board may suspend or terminate the Plan at any time. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">11.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref92447127"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Effective Date of Plan; Timing of First Grant or Exercise.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Plan will come into existence on the Effective Date. No Stock Award may be granted prior to the Effective Date.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">12.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Choice of Law.</b></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The laws of the</font><b style="color:#0070c0;font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">13.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Definitions. &#160;</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#8220;Affiliate&#8221; </b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company, as such terms are defined in Rule&#160;405 of the Securities Act. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board of Directors of the Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or any Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of any felony or any crime involving moral turpitude or dishonesty, (ii) such Participant&#8217;s participation in a fraud or act of dishonesty against the Company, (iii) such Participant&#8217;s conduct that, based upon a good faith and reasonable factual investigation and determination by the Board, demonstrates the Participant&#8217;s gross unfitness to serve, or (iv) such Participant&#8217;s intentional, material violation of any contract between the Company and the Participant or any statutory duty that the Participant has to the Company that the Participant does not correct within 30 days after written notice to the Participant thereof. The determination as to whether a Participant is being terminated for Cause will be made in good faith by the Company and will be final and binding on the Participant. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company, any Affiliate or such Participant for any other purpose. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(f)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a committee of one (1) or more Independent Directors to whom authority has been delegated by the Board in accordance with Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2(c)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(g)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock of the Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(h)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Rigel Pharmaceuticals, Inc., a Delaware corporation.</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any person, including an advisor, who is (i)&#160;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&#160;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(j)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. If the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&#160;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&#160;transfers between the Company, an Affiliate, or their successors. In addition, if required for exemption from or compliance with Section 409A of the Code, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under Treasury Regulation Section 1.409A-1(h). A leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(k)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a member of the Board. Directors are not eligible to receive Stock Awards under the Plan with respect to their service in such capacity.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(l)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the permanent and total disability of a person within the meaning of Section&#160;22(e)(3)&#160;of the Code. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(m)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means October 10, 2016.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(n)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(o)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(p)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Ref147744671"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(q)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means, as of any date, the value of the Common Stock determined as follows:</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the last market trading day prior to the date of determination, as reported in a source the Board deems reliable.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.<a name="_Ref92447285"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman Bold';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Section 409A of the Code.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(r)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#8220;Independent Director&#8221;</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> has the meaning set forth in Section 1(a) above.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(s)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a Director who either (i)&#160;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii)&#160;is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3 of the Exchange Act.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(t)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any option granted pursuant to Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Plan that does not qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(u)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(v)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(w)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(x)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(y)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(z)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means this</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rigel Pharmaceuticals, Inc. Inducement Plan, as it may be amended.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(aa)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&#160;6(b).</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M55"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(bb)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(cc)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Rule 16b-3</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(dd)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Act of 1933, as amended.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M64"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ee)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Stock Award&#8221; </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means any right to receive Common Stock granted under the Plan, including an Option or a Restricted Stock Unit Award. </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ff)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_DV_M65"></a></font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>rigl-20240630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/5/2024 11:54:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Raul R. Rodriguez, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this quarterly report on Form 10-Q of Rigel Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: August 6, 2024</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ RAUL R. RODRIGUEZ</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Raul R. Rodriguez</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>rigl-20240630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/5/2024 11:54:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Dean L. Schorno, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Rigel Pharmaceuticals, Inc.;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: August 6, 2024</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ DEAN L. SCHORNO</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Dean L. Schorno</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>rigl-20240630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/5/2024 11:55:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Raul R. Rodriguez, Chief Executive Officer of Rigel Pharmaceuticals, Inc. (the &#8220;Company&#8221;), and Dean L. Schorno, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:34.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">In Witness Whereof, the undersigned have set their hands hereto as of August 6, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:47.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ RAUL R. RODRIGUEZ</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ DEAN L. SCHORNO</p></td></tr><tr><td style="vertical-align:top;width:47.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Raul R. Rodriguez</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Dean L. Schorno</p></td></tr><tr><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Rigel Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>rigl-20240630x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rigl-20240630x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'F Y@# 2(  A$! Q$!_\0
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M_%+_ **5XO\ _!]=?_'*/^&@_BE_T4KQ?_X/KK_XY7 44>QI?RK[@YY=SO\
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M(E(+_0$4G2I)7Y5]PU.;TN=1_P -!_%+_HI7B_\ \'UU_P#'*/\ AH/XI?\
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M_%+_ **5XO\ _!]=?_'*/^&@_BE_T4KQ?_X/KK_XY7 44>QI?RK[@YY=SO\
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M]H=322Z,B3Q!1MN]T:,-@)^\ <97/YWT5/\ 95.[DI:^B\_\P^MRLE;^M/\
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M6OMD_P#SU;\Z/MD__/5OSKPYOVTO@BFGS7I^(NDF&&<6[*/,,NX@G(C";V7
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M33P__P" HKV*BCZUB/\ GX_O8>RI_P J^X\=_P"&//@I_P!$T\/_ /@**/\
MACSX*?\ 1-/#_P#X"BO8J*/K6(_Y^/[V'LJ?\J^X\=_X8\^"G_1-/#__ ("B
MC_ACSX*?]$T\/_\ @**]BHH^M8C_ )^/[V'LJ?\ *ON/&Q^QS\$Q(S_\*UT#
M) &/LW'Y9Q3O^&//@I_T33P__P" HKV*BCZUB/\ GX_O8>RI_P J^X\=_P"&
M//@I_P!$T\/_ /@**/\ ACSX*?\ 1-/#_P#X"BO8J*/K6(_Y^/[V'LJ?\J^X
M\=_X8\^"G_1-/#__ ("BC_ACSX*?]$T\/_\ @**]BHH^M8C_ )^/[V'LJ?\
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M?\,>?!3_ *)IX?\ _ 45[%11]:Q'_/Q_>P]E3_E7W'CO_#'GP4_Z)IX?_P#
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MW'CO_#'GP4_Z)IX?_P# 44?\,>?!3_HFGA__ ,!17L5%'UK$?\_'][#V5/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=-\(Z3;A[VXA'SF65O*MT7_MHX8_[*-TZA/EBKM&D/:5)**?XG*_\+%\6?\
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M $U_[\O_ (4 6Z*J?VI;_P#37_OR_P#A1_:EO_TU_P"_+_X4 6Z*J?VI;_\
M37_OR_\ A1_:EO\ ]-?^_+_X4 6Z*J?VI;_]-?\ OR_^%']J6_\ TU_[\O\
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M -^7_P * +=%5/[4M_\ IK_WY?\ PH_M2W_Z:_\ ?E_\* +=%5/[4M_^FO\
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M_5XW +C'W#N^7R"BCV:#ZQ/^NE] HHHK4Y0HHHH ^JO^":__ "<>?^P-=?\
MH4=?JM7Y3?\ !-V98/VC"[YV_P!C70^523]Z/L*_4[^U+?\ Z:_]^7_PKPL9
M_%^1^@9'_NGS?Z%NBJG]J6__ $U_[\O_ (4?VI;_ /37_OR_^%<)] 6Z*J?V
MI;_]-?\ OR_^%']J6_\ TU_[\O\ X4 6Z*J?VI;_ /37_OR_^%']J6__ $U_
M[\O_ (4 6Z*J?VI;_P#37_OR_P#A1_:EO_TU_P"_+_X4 6Z*J?VI;_\ 37_O
MR_\ A1_:EO\ ]-?^_+_X4 6Z*J?VI;_]-?\ OR_^%']J6_\ TU_[\O\ X4 6
MZ*J?VI;_ /37_OR_^%']J6__ $U_[\O_ (4 6Z*J?VI;_P#37_OR_P#A1_:E
MO_TU_P"_+_X4 6Z*K1ZA#*X1?,W'@9B8?J110!9HHKY_^/WC"#PK\6?!!U4:
MU<>'VTG4Y+JUTB^:V4.)K)(YI2)HE")YC LS84.2<#) !] 45\[ZE;^(M/O_
M  +8:K;:[?6M]JVIR0Z18ZN%NA:>0S01RS^>BR%/O<R-@$#+8K>^)&FB#X;+
M#I^GZYHGB+4+G^R])@O]9F:2.XG(42L8;EPZH TF-QP(VX'- 'M5%>7^#+:Y
MT#XN7WAW^T[Z_L=/\):5L^V7#REY/M-ZCRMN)R[!%W-U.!Z"N"MKJ\\0^-M*
MTR^U/4GL9O&FM6[Q0W\T.Z*.W9HX\HX.U2,A<X'I0!]&T5X3\3KB^^&_]L:9
MI6J:FVFZEX8U2ZCCGNY)Y+*Y@"LLD<KDNH82D$%B 53&.<V_$?CC79]$\ QG
M0->T87&LZ7'-?SW5KLE1F&Y6\JX=R&]"O/>@#VNJ6LZU8>'M-FO]2NXK*SBQ
MOFF;:H). /<DD  <DD <FO%?^%F3^$/@%=:I<:LJ:U>ZOJ.EZ=<ZA-G$[ZC<
M11$LQ^[&@W<G 2(]A5#PG'=?$;X:ZEX2L_$5IXJUGPI>M:C4+BY$PU"W>)Q!
M+)(N09/+D(W=/,B.>Y ![AX?\5Z5XICN&TR\6X:W<1SQ%6CDB8@$!T8!ER""
M,CD'(K6KRGX&?"RZ^&UC);RVUKI]E#$;:TM+<AF"&625BY "_>D; 'N3R34%
MWXZ7PYXR^)?B?5+F\FTCP]:V.FP:?#(2K2E3*Y6/.TR2-/"@8_W0,@9H ]=H
MKS#Q+\0M?\/6EO!XBT*#2H=7CEM;6\T[4#<FWN?(DD1)08T*Y$; ,I8;@ 2,
M@UF_LZ?$:Z\5>#=(TF]BEFN]+\+:%>S:C/<&62[>YM"[%LC.08SDDDL6SQW
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MX\_]@:Z_]"CK]5J_*G_@FO\ \G'G_L#77_H4=?JM7A8S^+\C] R/_=/F_P!
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MJ26<A=#M/7=PI'HHQ78:)::A969CU+4%U.XWDB9;<0@+@8&T$^_/O4_VB?\
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M/ X=V4C#,S%0,= HZ98T >ET444 %%%% !1110 4444 %%%% !1110 4444
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MJW_#7^9X?1116ARA1110!]5?\$U_^3CS_P!@:Z_]"CK]5J_*G_@FO_R<>?\
ML#77_H4=?JM7A8S^+\C] R/_ '3YO] HHHKA/H HHHH **** "BBB@ HHHH
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MYQCJ:UE\&2O\0-/\53WZ//;Z/+I4EO' 561I)8I#("7)4 Q8V\_>^]QSU-%
M!1110 4444 ?G!_P5/\ ^1]\#?\ 8,G_ /1HKX>K[A_X*G_\C[X&_P"P9/\
M^C17P]7T.&_@Q/S3-?\ ?*GR_)!11174>4%=CJ'Q&D;P!H?A72K632;>RN)[
MZ]N$N2SWUS)M4.<*-BI&BJJ9/\1SEJXZBDTGN5&3C>W4]U\%?%C2]<\/Z\GB
MJRBN[NR\'MHYFFOA#+J4:ZA:/#&A*Y$L<8< _/E8P2ORG*?!OXFZ!I/CCPGI
M-EIL>@>'(M0>_P!0GUG4%G>YE$,J())=D2K&JNRA0HY=B2<C'A=%9^S6J.E8
MF:<7V.^?Q]H.C:7KMOX=\.7&G7^KP&SGNKO4A<QPP,ZLZ01B%"N2H&69R%R.
M<DUH:M\9H/$7B7QO<ZKH)N="\4WGVZ;3H[S9-:S*S-')%.8R R[W4DQD%688
M&<CS&BJY$9>VGW_!>?\ F>@W?Q;ETV?P@/"EC)X?MO"]R]]9>=<BYG>YD:,R
M222!$#9\F,;0H&!CG)SM7W[0M[??$G6_$?\ 9,=OH^JZ<=%?08+ADCM[$A,0
MPOC]V59%D!"XW9)!R<^244N2/8?MZBV?]+3\CTS2OC!:>$=7T74?#>A3Q7.G
MW#3RS:UJ;WSW*,C1M"0J1(L91V'";LD_-VJ?1OBMX6\*Z+XPL]#\%W5O<^(]
M,DTQKF\UGSQ:(TD<G[M1 N1F,##$MT^8<[O+**.2(*O46S_!>@4445H8!111
M0!]5?\$U_P#DX\_]@:Z_]"CK]5J_*G_@FO\ \G'G_L#77_H4=?JM7A8S^+\C
M] R/_=/F_P! HHHKA/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L74"?MDG/I_(5M5\Z_M ?%+Q1:_%'PI\+O TMKIGB/Q+!/>3ZY>P^<FFV
MD2C=)'$>))2<A0WRC'(.:UI4I59<L?Z2U9$YJ"NSVC)]31D^IKYB^*%Q\:?@
ME\(_B!K=U\0]/\56UEI3W=AJMQH\-MJ-K<@H OEQKY#Q8W'YEW9/4C&*.B_M
M7P^ KGQMJ'CG5M4UC3-/N?#]E';66D0J;*2]LEE9E9'WS*S$LV5#*>$4C KK
M6"J3BY4VI>E]=O+S6YBZ\8NTE;^G_D?5>3ZFC)]37RI\1?VO;36?AYXAE\/R
M>(OA_P")]"UC3;.^L]9T2"2\CBN)4VD0O*4V2*Q&[=N R=HRI/H/BC]JKPYX
M;\3ZAHEGX>\5^+/[(:./6-2\.:3]JM-,D;JDS;PQ95^8K&KD#CKQ4O!5TE[O
M]:?+6ZL5[>GW_K^D>U9/J:,GU->->//VIO"_@CQ(VA0:/XD\5:C;V2:CJ,7A
M[3?M!TRW< H]R&9"F5.[;@MCD@9&>$\#_M-7?Q:^/'PXC\-W-Y9>!?$7AN_U
M"33-0M8%F::&=X@[,N]E^X>%?!&,C-*.#K2BYM65KZ^E_P!- =:"?+?4^H,G
MU-&3ZFOEKXPZQ\3]+_:B^'WA71/B=<:/X;\7M=R&P71+*;[$MK:F4HLCQEW\
MQHSDDY7?QT%8_BC]MG3?'.C6+^")?$GAPVWB/3].O=1N]$MYX9O-G:-K8;IL
M98)DLN2JD8P3@:1P%6:C*#335^NEVUKIW3VN2\1&+:>EOQ/KW)]31D^IKYZ\
M;?MM^"O!ESXB== \6:_HOAZ5K74M?T;3%ET^WN0.8#*TBG?DJN<;<L/FQDCC
MX?VO1X*^)/Q6N?%5W?W_ (4TU="30M'LK.$W7FWB2$HI^7<3@$^9)@;3@\@&
M8X'$25^7_@ZI?JOD-XBFG:_]:_Y'UKD^IHR?4USW@/QG;_$#PI8:[;:?J6E1
MW:EOL6KVK6US"0<%70]P1U4E3V)%=!7%*+BW%[HW335T+D^IHR?4TE%2,7)]
M31D^II** %R?4T9/J:2B@!<GU-&3ZFDHH 7)]31D^II** %R?4T9/J:2B@!<
MGU-&3ZFDHH 7)]31D^II** %R?4T9/J:2B@!<GU-&3ZFDHH 7)]31D^II**
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MCG_YY-^5 $-%3?8Y_P#GDWY4?8Y_^>3?E0!#14WV.?\ YY-^5'V.?_GDWY4
M0T5-]CG_ .>3?E1]CG_YY-^5 $-%3?8Y_P#GDWY4?8Y_^>3?E0!#14WV.?\
MYY-^5'V.?_GDWY4 0T5-]CG_ .>3?E1]CG_YY-^5 $-%3?8Y_P#GDWY4?8Y_
M^>3?E0!#14WV.?\ YY-^5'V.?_GDWY4 0T5-]CG_ .>3?E1]CG_YY-^5 $-%
M3?8Y_P#GDWY4?8Y_^>3?E0!#14WV.?\ YY-^5'V.?_GDWY4 0T5-]CG_ .>3
M?E1]CG_YY-^5 $-%3?8Y_P#GDWY4?8Y_^>3?E0!#14WV.?\ YY-^5'V.?_GD
MWY4 0T5-]CG_ .>3?E1]CG_YY-^5 $-%3?8Y_P#GDWY4?8Y_^>3?E0!#14WV
M.?\ YY-^5'V.?_GDWY4 0T5-]CG_ .>3?E1]CG_YY-^5 $-%3?8Y_P#GDWY4
M?8Y_^>3?E0!#14WV.?\ YY-^5'V.?_GDWY4 0T5-]CG_ .>3?E1]CG_YY-^5
M $-%3?8Y_P#GDWY4?8Y_^>3?E0!#14WV.?\ YY-^5'V.?_GDWY4 0T5-]CG_
M .>3?E1]CG_YY-^5 $-%3?8Y_P#GDWY4?8Y_^>3?E0!#167KWBC2?"\T46K:
MA!I\DJED6=]I8#@D5E_\+1\)?]#!8_\ ?T5P5,PP=&;IU*T8R71R2?YG7#!X
MFI%3A3DT^J3.HHKE_P#A:/A+_H8+'_OZ*/\ A:/A+_H8+'_OZ*R_M3 ?]!$/
M_ H_YE_4,7_SYE_X"_\ (ZBBN7_X6CX2_P"A@L?^_HH_X6CX2_Z&"Q_[^BC^
MU,!_T$0_\"C_ )A]0Q?_ #YE_P" O_(ZBBN7_P"%H^$O^A@L?^_HH_X6CX2_
MZ&"Q_P"_HH_M3 ?]!$/_  */^8?4,7_SYE_X"_\ (ZBBN7_X6CX2_P"A@L?^
M_HH_X6CX2_Z&"Q_[^BC^U,!_T$0_\"C_ )A]0Q?_ #YE_P" O_(ZBBN7_P"%
MH^$O^A@L?^_HH_X6CX2_Z&"Q_P"_HH_M3 ?]!$/_  */^8?4,7_SYE_X"_\
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MQ2\'7>LZ+>>(-%BT?4Y;FRM!$P3$MH!,XED1-J;CEB?E#$],D 'OU%>3^'O
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ME"Y:6RO45MJWT);ERW 9CAANPX)"D^KT %%%% !1110 4444 %%%% !1110
M4444 %%%> _&2^N87^*"HT\RQZ=H)2"*3!.Z[G#*N2 "P&#D@'N<4 >_45X_
M\*KR'6O$%[XAT?0[CP?X:M[66RO+"^EA626[27EFABDD6,QJ&!9B&;S!QM53
M7+?#[XG7NH?$Z+Q!/?71\.^+9Y-/MM/N('1+18L_8YU8J%_?J)2>>3)$.<4
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M#_=?\A_C1_:T/]U_R'^- %VBJ7]K0_W7_(?XT?VM#_=?\A_C0!=HJE_:T/\
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M&OEW",)%^0 $[N<<YKU3^R8_[[4?V3'_ 'VH>(K-\SF[^H>S@E:R/(I?V=O
M5S\/9?!5UH\E[H,ER;TK=WL\TXN"Q;SUG=S(LF23O# \GU-.^'/[/G@KX5^)
M]2\1:!97JZWJ-NMK=WU]J5Q>2S1J00&:9V)(P.>N !TKUO\ LF/^^U']DQ_W
MVH=>JTXN;L]]=P]G"Z=MCAM.^'.@Z5X]UCQE;6;1^(=6M8;.\NC,Y$D46?+7
M83M&,GD $]ZK:9\)_"VDZOXPU*'2U>X\6[/[:$\C2QW86,QA2C$J!L8@@  Y
MYKT+^R8_[[4?V3'_ 'VJ/:3[OM\EL5RQ['C7@?\ 9L\!_#;6H]9\/Z3)%JUK
M;O;6$^H7EQ>I81L#E($ED(B0YP5CVY'%?.<W[%7B?Q'X@T"TO](\->&M&T[7
M4U>XO-"U>_>"14DWE+;392T5LS]"P=L<^N*^\?[)C_OM1_9,?]]JZZ>.KTVY
M*5V^]_ZZF,J%.22L>5:=\!/ VF>!==\'1Z&DWAS6[J:\O[*YE>42S2D%VRS$
MKRH(P1@CC%<]HG[)7PUT"_O;ZWTJ_GO;S29]#FN;W5[NYD:SE4*\6Z21B!@8
M&/N]L5[M_9,?]]J/[)C_ +[5@L165[3>N^II[.#M[JT/,(?@AX/@U'P/?)IC
MBY\%VALM$?[3+_HT1C6,J1NP_P J*,OD\5@:M^RQ\.]8M+VVFTV_@CO=2N]6
MN/LFKW=N99[E46?<4D&5=8U!3[O'3DU[=_9,?]]J/[)C_OM26(K1=U-_?_7<
M'3@]TCG="T.P\,Z)8:1I=K'9:;80);6UM$,+%&BA54>P  J]6I_9,?\ ?:C^
MR8_[[5BVV[LTV,NBM3^R8_[[4?V3'_?:D!ET5J?V3'_?:C^R8_[[4 9=%:G]
MDQ_WVH_LF/\ OM0!ET5J?V3'_?:C^R8_[[4 9=%:G]DQ_P!]J/[)C_OM0!ET
M5J?V3'_?:C^R8_[[4 9=%:G]DQ_WVH_LF/\ OM0!ET5J?V3'_?:C^R8_[[4
M9=%:G]DQ_P!]J/[)C_OM0!ET5J?V3'_?:C^R8_[[4 9=%:G]DQ_WVH_LF/\
MOM0!ET5J?V3'_?:C^R8_[[4 9=%:G]DQ_P!]J/[)C_OM0!ET5J?V3'_?:C^R
M8_[[4 9=%:G]DQ_WVH_LF/\ OM0!ET5J?V3'_?:C^R8_[[4 9=%:G]DQ_P!]
MJ/[)C_OM0!ET5J?V3'_?:C^R8_[[4 9=%:G]DQ_WVH_LF/\ OM0!ET5J?V3'
M_?:C^R8_[[4 9=%:G]DQ_P!]J/[)C_OM0!ET5J?V3'_?:C^R8_[[4 9=%:G]
MDQ_WVH_LF/\ OM0!ET5J?V3'_?:C^R8_[[4 9=%:G]DQ_P!]J/[)C_OM0!ET
M5J?V3'_?:C^R8_[[4 9=%:G]DQ_WVH_LF/\ OM0!ET5J?V3'_?:C^R8_[[4
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MVJ_] ZS_ /'_ /&C_A>VJ_\ 0.L__'_\: /;**\3_P"%[:K_ - ZS_\ '_\
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M^9OS'^% %FBJWV1O^?F;\Q_A1]D;_GYF_,?X4 6:*K?9&_Y^9OS'^%'V1O\
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MT:34SLL+^SO/M5G/-AB;<NR1NDNU2P!3:PZ,6RHZ*;Q3HMOK,>D2ZO81ZM(
M4L'N4$[ C(Q'G<> >U><>*[F?XP:AX;T[1M-U6RTW3=7MM6O=4U739[$)Y#&
M1(HXYT1Y&9U0$A=H4M\V>*YOPM;6&C_#L^#O$_@;7-8\2S3-)J(M]-FD34KH
MR%C=B_ $2EB ZLTJLF%4 %0* /;-3\4:-HM[;6>H:M8V%W<G$$%S<I')+SCY
M58@MSQQ3;SQ7HFG:5%J=WK%A:Z;*0([R:Z1(7)Z8<G!S@]^U>2VD5KX7U3Q[
M9^*?"FJZY?:]>RO%=VFE2WT>HV;(JPVYE166$(,ILE**"68?>)KD_@SHU[X
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M(UL&TUI+@18RJ925CP-NUMV"I  /I*^\7:%IDUE%>:UI]I+>@&U2>ZC1IP<
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M;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\
M/4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D
M:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4
M 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[
M1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^
M>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(
MT?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC
M;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\
M/4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D
M:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4
M 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[
M1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^>H_(T?VC;?\ /4?D:LT4 5O[1MO^
M>H_(T?VC;?\ /4?D:LT4 > _M%3QSZQHYC;<! ^?^^J\BKV#]H__ )#6C?\
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M1M:W!/$EL\84FW)W!6;S-P"_,K!@9/&_P)M/%'Q-\/>--/U*?0M1L6N/MIM
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M'CKX"^*?B-H^I#6-<TP:S?\ @74?"4]Q!"XB>>X>,K<[3RJXCR4YP6P"0,T
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ML@C):16MK$DZ2D#9RBAL GG<<8_"O-:T]9ULZQK\^IF$1&642>4&SCIQG\*
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MF_(?XT?:V_Y]IOR'^-6** *_VMO^?:;\A_C1]K;_ )]IOR'^-6** *_VMO\
MGVF_(?XT?:V_Y]IOR'^-6** *_VMO^?:;\A_C1]K;_GVF_(?XU8HH K_ &MO
M^?:;\A_C1]K;_GVF_(?XU8HH K_:V_Y]IOR'^-'VMO\ GVF_(?XU8HH K_:V
M_P"?:;\A_C1]K;_GVF_(?XU8HH K_:V_Y]IOR'^-'VMO^?:;\A_C5BB@"O\
M:V_Y]IOR'^-'VMO^?:;\A_C5BB@"O]K;_GVF_(?XT?:V_P"?:;\A_C5BB@"O
M]K;_ )]IOR'^-'VMO^?:;\A_C5BB@"O]K;_GVF_(?XT?:V_Y]IOR'^-6** *
M_P!K;_GVF_(?XT?:V_Y]IOR'^-6** *_VMO^?:;\A_C1]K;_ )]IOR'^-6**
M *_VMO\ GVF_(?XT?:V_Y]IOR'^-6** *_VMO^?:;\A_C1]K;_GVF_(?XU8H
MH K_ &MO^?:;\A_C1]K;_GVF_(?XU8HH K_:V_Y]IOR'^-'VMO\ GVF_(?XU
M8HH K_:V_P"?:;\A_C1]K;_GVF_(?XU8HH K_:V_Y]IOR'^-'VMO^?:;\A_C
M5BB@"O\ :V_Y]IOR'^-'VMO^?:;\A_C5BB@#R7XP> M:\<:CI\^F6JE((F1_
M.D5#DG/'->??\**\6_\ /I!_X$+_ (U]-T4 ?,G_  HKQ;_SZ0?^!"_XT?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445B^)M,FU$:4T",SVU_#.2K[=JC(8]1GY6/'O0!M45YA\3=-NM:
M\=>&K&#3K/5D>QOG:UO[V2UBR&@ ?<D;DL,G' ZGD5RD_B3Q-\-KBYTV$3^)
M]99='TSS,QL [1W!:0++-$I)\L*-TBEB5R2>" >]45X_H7Q0\3ZS#IFGW=E9
M^']3O=5N=/6[O_*EC*PQJ_$4%Q(OF,2Z;/.R/+<^@JC'\6?$T&KFWN+WP_<:
M=9:Q)I]]J5G"[!%'V<1YC\[<N7F='<;PC; 1@E@ >W45XIH?QA\6:IXNLHG\
M.%-#O=7FTN-W>T0HL98%P_VPRNP\MF*?9U.#[9/7>)/&FKZ'X^LK I;+H4\2
M*DB1>=-+<D2L86Q(#$2J*4)1E;#@LIV@@'>T5X-X<^.?B^XL%U/4O"<GV&YT
M>YU6%5>T0CRU#*J[+R5Y <A"3&F"1D#D#I/AK\1O%/B'Q-#IFNZ*+2"XTS^T
M4N-UHA W*%*K#>7!=&W'#D+]WOG@ ]5HKP3QI<^)(O'FN1V>JVXSK.AI;121
M2*D0=GSNQ)\PQU "[N.E;&M_%#Q9I5R-&M--CUO6/[8DT[S[&WC12BVB7&1%
M/=1KN^?&/-Z*QP<8H ]CHKC/A_K=U\0_!#3:_I26DLDT]K-;^9$ZR*DC)N_=
M2R*,[>5#M@@C)ZUY?H=Q=V_P*\+:-HMEJ5[J?B%2;K^RYHEN_(4C[1(CS2QJ
M&*[(PQ<;2X(R0 0#Z#HKQ[2_%%_'X?T/Q%JT=SH^I^'9SI>OV5[(F1 X4>:^
MQF3/_'O,&#$!2XSR:BUK5M8F\ LVFV6I7NM>,;MIEM;62..ZMK%@ S)YLB(C
MK J8RXQ(X//0@'LU%>)>&/%&JZCXA^'NG:M;7FE:O875_97UG=2H9)%6U+0R
M/Y;NC%XRCG#, Q8 G&:S=?=Y]1\3W4\BZM;Z9J][//HDEX\$LMLMM:[Y(&##
M#Q$Y .!\YY4G- 'O]%>(:AJEA%XMO=4$AU*UU1);?3]0MKV036%PEEEK6>+=
MRK*CR X(#$[@"58]%\"M'NK/P;HE[<Z-IU@UUI5JYO+6_DN)K@F-23(K1(%)
MSDX9N3^- 'IM%?/_ (#U/4?#7ANX\22:9I@CD\27=G+K%Q?2O/Y#ZS)"V^,Q
MA454R ?,( 1>,9 9\:_&VHS>*Y='@G$%KIK2X>V9E<O)HVI2,KD'!QLB8# Q
MD'TH ^@Z*\Q^)L%SJ&G>!K:"U@U%KC4HU>UN[EX(I1]EF.'=4<]0#]T\@5CK
MKOBOX=1W.G,;"\L]'T6XUF:U19)II"UQ,8[>*5F4!$0*NYES\O0=@#V:BO#-
M.^*_Q NTO;3_ (1VW&H'3X+VV:XDLH]Q>9$VK''?R[]R%RA9XPS(!GG(Z/1?
M'VL>+)U@TW5=)LD@TJ+4);R\L9,7&]Y%.V,RJ8U3RL,2S8+8[9(!ZA17A7B;
MQ1K>N7\IO)M-ETFUU1K.T^Q"=)=XT]YS-YBRA67)P%*D8Y/.,5+WQ[K>C?"[
MPX]Y>Z1X@L]<T>6)8+(31S)LL9)?-\U9<R*#&%=AL(+@@@\4 ?0%%>*Z;\0_
M$NF:!/JQ.EC0M-U&PTI;!8)FN)(Y3;QLYF:4X93/D95L[.3DY%N3XE^(CH.F
M>(EOM"ALK_68=-72I8',\8:X$3)YOF@&8 ,Q79Q@]=N2 >OT5XM\5_&&N>%/
MB-8_V&]L;N[L[*R2._#M;J9]2BA+E58'(5S@TSQ=JWB#5?$.D>'[V_L7-GXC
MLXYI8;-T2YC>UEE"E/..,,A[D'Y3CC! /;**\CMOB?KQT_2-7E.FFUU=[N*/
M2U@<7-J8HIG!=_,P^TQ!7&U<%N#QSD_\+(\>6?A[6M5NKG0)!I'AR'Q!-#%8
M3#SBZS2&!29OE&V'&\@\G.WM0![E17CVN?%+Q'X5G>TU!=+GFN;;3YX9UBDB
MALC<7)@<S$NV]$^4[AMR>#C.12\8^)/%,]WK.@MK>D-/IU]H$T=S9V<BNHN+
MPJR2IYQ_YYH1AN5)'?( /;J*\@\.>(]5^TQZ/I<VGZ7/=7FK7,UY?)-<(WD7
M)CVHC3 @G(8X;:H4X4 \5]#^)GB_QBFH7&FG1]-M+#18M0<W%M+.9Y6>Y0&,
MB1!Y3BWWJW7:PX.> #V>BLSPSK'_  D/AO2=5\OR?MUI%=>7G.W>@;&?;-:=
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8K8U[X6:WXI_M#4K[[%::C/J%I>KIMAJ=S#"P@1D :ZC1) [;\[E3C8@P<4
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MP0,V[ )VMC/7:?2K?B?Q7;>&;"UF:*6^N+V9;:RM+;!DN96!8*I) ^ZK,22
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M,\$_"SQ3\/K.VFL[;PYJU\^GM8SV]Q-+;PV_[^:5?)<1.=C"8!HRH^XOS<4
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M]DNI;/(*^<X58Y9?FS^[$* LPRNU<=!6OJI^'VMZ"^MZC)X<O=%><3MJ5Q)
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M.]U*+04T79I*6RSM/)*\=Y-+!'/B)U *1A)$ D*,2=PVC;R <'K_ ,!-9NO
MVD:19V>DO/ E^;J&=RL,[SWUO.-Y"Y8,D3!CC/05UFN> ]=\5:F=1;3K+1#'
M;6MHMM%<>9YPCO(IR6(4 !%C<(,?\M&Z=^.^)GCGQ->>%_$.I&X&DI9MK]EI
MPTN[EB=OL]I<A99FS@MNB!4 ?*1NR3P.C\>^-?$&@>'CIVM-;B35=+FN+:YT
M.>2*6VDB\LLID))8%7XE7;R,;1N% #K/X2:CI'P\\.Z3;K#:7FGF_ENI+$C?
MOF@N%WQ]-SEI4/)'3KQ6)X0O/^$M\??#@6&CZ=;Q^';&X%U+:2[I+6-K<1+$
MZ[%\G+D?NGP_RD[<(Q'6VGQ+UZ&Y-_J-KI\>AMK]SHD<-N)&N2L;R(DQ8G;D
MM'@IC@'.[^&DM_B)XH7_ (0K4;FTTC^R/$]ZMNL$;R"XM$>*26,[B=LK%8_F
MP%VGIN'( )IOAG=7GQ._M^Z@M+BPCU8:C")#N=,:>ENK $<,'4X]!S6%:_!O
M7&N=8B-Y#I]O=V7B"TMYK=R6M_MM['- 0H P JL2 1@\#UI^M^-O$FE_&+5=
M&T80WK7S:9;10ZC.XM[16AO9)955>^(02HQNV@9'44=9\:ZWJ_B_P[:WEVMI
M!I&JZC'J,>FM/&MY]GMEF0@+*IP4D'[MRZ[ASN % %GQ9\*M7\::2EH=!TC0
MX;?3X-.^RP3^9'<1K<P2&/A!B)%B?:#DDR'A><[6M?";^U+CQ*6L;"2+5-?T
MW4%6100UO;PVJ,K#'4>5( O3!]ZIWOQ8\1:7X0BU^XL-,F34M"NM8L+2%W#0
M-' )HXY7R1(&4X+J%"D8 ;<#3+[XD^-M(BUV>XL-#NET5K*.6WA:9&NI+@(2
MJ.2?+"&11N*MNY^5: +EU\/M:L_%%YKEO:66I)'X@?5+?3YIM@:-[*" R!MI
M"RJZ2L,CD,>0347AWX<:Q;:K]OETW3-(67Q0=;>TL92RK&;)X6).T R-(VYL
M#!))R>\TGQ.UZTU^7PM-:Z;+X@?4+>S@NU+QVHCDMGG9V0DL6412@(&&\A>4
MR=N=K?BOQC=7;:;+=:7876F^(K&T>>R65ENH90KC*^8"A(;#(2P/KS0!3T;X
M3>(= \-WFG-8Z=K,NJ:';:5(]S<%5LC&C*5'RG?&2_F8&#NS[&MVY^%E]'IO
MBH6RVQU/4M3T^\AO&.)'6V6V&YVQD,#%(1]>V:S_  MXVUZ2QETK1_)N)].M
M+C4;BYURXDF:93=W$<<2N""/]0^7.0@V *>R7WQEUW^R?$7B2TTZPC\-:)96
MNH-'<%S=W*20),Z#!"QLJMP2&R3C QD@'=^)=/U3Q;X"U[3WLX["^O(+BV@B
M><.,'<J,S 8&X8.!G&:Y:R^%U[9:7>)%%:17ESXJAUN25#R\2S1DDG'W_+0K
MC\,UZG10!Y/!X%UE/!G_  BT^@:5>+;QWGD:M-<#(ED67;.B&,E96,IW'(^\
M_)Z&K)\-O$1T:_\ #OV>T-AJ5U8W4NH_:3F 1+ )%\O;\Q_<?*<X^<9QBO8J
M* /&=3^&^OOX>_X1V+1-)O%&O)JW]M3W&UV'VD3&4IL+>?LS%G=C'\6/EJIX
M+^".H:)H7B^*^M]/DU'5M"&E02AM_'^DED8E>$)E0GUQR.!7N-% 'S'XJ@N=
M+\.>._!L^FVFIZUK4T7E-?R[)[EFBB6/RTVL9DC9<*RG"[?F";2:]?\ BIX.
MN?%<F@O#IXU2VL[B9[BU^VM:%T>!X\!UYQEAD=QFN]HH \FM? 7B#1[>*2?3
M]-\3W-QH:Z1+%>3>7'  S$IRAWQL&56P 3Y2G!SQ%HWPKUW1=2T*_-Q;W4NC
MZ?;:3C<5DNP(C')>._:10Y"+V7S06)D&SUZB@#P_P[\%]8MUTRRF<Z9_9=A>
M6D6K1ZC+-)YDT9C\R&,;1'N)$K!B?F"]2 XV-!\#ZW#KO@#SO#^D:79>&(9X
M'N+2XW%@UN8P(4V JC-AB&.>!UZUZQ10!P.O^!K[5OB5INI#[.WAYK<-J,$A
M)>6:(2"!0O0J?/=CGO$G'-<YX=^$&KV'@ZX\/7EZICU35"VHW<$I$O\ 9\4:
MQ01*W7<T<$*-Z!Y,<XS[#10!Y'XB^#]Y>&\TJSN[E]$U"\M+^>X?4)$NH)8V
M"R&-Q\P+1A""",%/?A^B?".?[+H6G:Q:6EU96:7\%]-YK,]_YHC"W#9Y\QMN
M6R<@C@]*]9HH \(UCX*>*+FSUVV;4[?5FN9+X6MU<'RY3%+IK6L(EP""X8J&
M88R!NP"<5J:Q\#)[S7_#MQ9WBVFE!;C^V+ $X::2PFMO/A[*Q,@W#HV W4'/
ML=% 'E]_H7CO5_#EIH<LL>GW\*" ^(M.OFC4C 4S>1MR7QR(R2N[J2*]/ P
M.3CUI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNX=1(0IV]0<$ 'L4EAX9&DQ7#&Q33EO#?QS^<!&+AG9C(&SC<69CUZFO(O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>rigl-20240630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2024 11:55:05 PM-->
<!--Modified on: 8/5/2024 11:55:05 PM-->
<xsd:schema xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsd="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.rigel.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:rigl="http://www.rigel.com/20240630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" id="StatementCondensedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" id="StatementCondensedStatementsOfComprehensiveLoss">
        <link:definition>995200300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" id="StatementCondensedStatementsOfCashFlows">
        <link:definition>995200500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" id="DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails">
        <link:definition>99940502 - Disclosure - IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInventoriesAlternateCalculationDetails" id="DisclosureInventoriesAlternateCalculationDetails">
        <link:definition>40602 - Disclosure - INVENTORIES - Alternate Calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails" id="DisclosureOtherBalanceSheetComponentsInventoriesDetails">
        <link:definition>99940701 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails" id="DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails">
        <link:definition>99940702 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" id="DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails">
        <link:definition>99940703 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails">
        <link:definition>99940801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails" id="DisclosureDebtSummaryOfLoansPayableDetails">
        <link:definition>99941001 - Disclosure - DEBT (Summary of Loans Payable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" id="DisclosureDebtFutureMinimumPaymentsDetails">
        <link:definition>99941003 - Disclosure - DEBT - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" id="DisclosureLeasesLeaseExpenseDetails">
        <link:definition>99941102 - Disclosure - LEASES - Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" id="DisclosureLeasesSubleaseInformationDetails">
        <link:definition>99941104 - Disclosure - LEASES - Sublease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails" id="DisclosureLeasesFutureLeasePaymentsDetails">
        <link:definition>99941105 - Disclosure - LEASES - Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit" id="StatementCondensedStatementsOfStockholdersDeficit">
        <link:definition>995200400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995210101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995210201 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>995210301 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" id="DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract">
        <link:definition>995210401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995210601 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponents" id="DisclosureOtherBalanceSheetComponents">
        <link:definition>995210701 - Disclosure - OTHER BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" id="DisclosureCashCashEquivalentsAndShortTermInvestments">
        <link:definition>995210801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureFairValue" id="DisclosureFairValue">
        <link:definition>995210901 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>995211001 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995211101 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99930203 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>99930303 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99930603 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables" id="DisclosureOtherBalanceSheetComponentsTables">
        <link:definition>99930703 - Disclosure - OTHER BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsTables">
        <link:definition>99930803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureFairValueTables" id="DisclosureFairValueTables">
        <link:definition>99930903 - Disclosure - FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>99931003 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>99931103 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails">
        <link:definition>99940101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>99940201 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" id="DisclosureRevenuesDisaggregatedDetails">
        <link:definition>99940301 - Disclosure - REVENUES - Disaggregated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" id="DisclosureRevenuesActivityDetails">
        <link:definition>99940302 - Disclosure - REVENUES - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" id="DisclosureRevenuesPercentageByCustomerDetails">
        <link:definition>99940303 - Disclosure - REVENUES - Percentage by Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" id="DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails">
        <link:definition>99940401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails" id="DisclosureInLicensingAndAcquisitionNarrativeDetails">
        <link:definition>99940501 - Disclosure - IN-LICENSING AND ACQUISITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>99940601 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" id="DisclosureStockBasedCompensationOptionsAndRsusDetails">
        <link:definition>99940602 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>99940603 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails" id="DisclosureStockBasedCompensationPlansDetails">
        <link:definition>99940604 - Disclosure - STOCK-BASED COMPENSATION - Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails">
        <link:definition>99940802 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" id="DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails">
        <link:definition>99940803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureFairValueDetails" id="DisclosureFairValueDetails">
        <link:definition>99940901 - Disclosure - FAIR VALUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureDebtNarrativeDetails" id="DisclosureDebtNarrativeDetails">
        <link:definition>99941002 - Disclosure - DEBT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>99941101 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails" id="DisclosureLeasesCashFlowInformationDetails">
        <link:definition>99941103 - Disclosure - LEASES - Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperationsParenthetical" id="StatementCondensedStatementsOfOperationsParenthetical">
        <link:definition>995200205 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitParenthetical" id="StatementCondensedStatementsOfStockholdersDeficitParenthetical">
        <link:definition>995200405 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisition" id="DisclosureInLicensingAndAcquisition">
        <link:definition>995210501 - Disclosure - IN-LICENSING AND ACQUISITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionTables" id="DisclosureInLicensingAndAcquisitionTables">
        <link:definition>99930503 - Disclosure - IN-LICENSING AND ACQUISITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rigl-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element id="rigl_SpecifiedProductLaunchEventsMember" name="SpecifiedProductLaunchEventsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" id="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AchievementOfMilestoneAxis" id="rigl_AchievementOfMilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AchievementOfMilestoneDomain" id="rigl_AchievementOfMilestoneDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementUpfrontFeeReceived" id="rigl_CollaborativeArrangementUpfrontFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="rigl_CollaborativeArrangementRevenueRecognized" name="CollaborativeArrangementRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="CorporateBondSecuritiesAndCommercialPaperMember" id="rigl_CorporateBondSecuritiesAndCommercialPaperMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" name="CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" id="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" name="CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CashEquivalentsAndAvailableForSaleSecuritiesAbstract" id="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SpecifiedDevelopmentEventsMember" name="SpecifiedDevelopmentEventsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SpecifiedRegulatoryEventsMember" name="SpecifiedRegulatoryEventsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentLiabilityCurrent" id="rigl_AccruedResearchAndDevelopmentLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" id="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="rigl_ContingentPaymentsUnderAgreement" name="ContingentPaymentsUnderAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_SubleaseAgreementAbstract" name="SubleaseAgreementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CorporateCollaborationsDisclosureAbstract" name="CorporateCollaborationsDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_ChargebacksDiscountsAndFeesMember" name="ChargebacksDiscountsAndFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_GovernmentAndOtherRebatesMember" name="GovernmentAndOtherRebatesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_ContractRevenuesFromCollaborationsMember" name="ContractRevenuesFromCollaborationsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_MckessonSpecialtyCareDistributionCorporationMember" name="MckessonSpecialtyCareDistributionCorporationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_GrossProductMember" name="GrossProductMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DiscountsAndAllowancesMember" name="DiscountsAndAllowancesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_GrifolsS.a.Member" name="GrifolsS.a.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_FostamatinibMember" name="FostamatinibMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_RoyaltyPaymentAsPercentageOfNetSales" name="RoyaltyPaymentAsPercentageOfNetSales" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_KisseiPharmaceuticalCo.Ltd.Member" name="KisseiPharmaceuticalCo.Ltd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SpecifiedCommercialMilestonesMember" name="SpecifiedCommercialMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" name="EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" name="AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" name="CashFlowInformationRelatedToOperatingLeaseTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_FixedSubleaseExpense" name="FixedSubleaseExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_VariableSubleaseExpense" name="VariableSubleaseExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_NetSubleaseIncomeExpense" name="NetSubleaseIncomeExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="rigl_DisaggregationOfRevenueByCustomerTableTextBlock" name="DisaggregationOfRevenueByCustomerTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" name="AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheOneMember" name="CreditAgreementTrancheOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheTwoMember" name="CreditAgreementTrancheTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheThreeMember" name="CreditAgreementTrancheThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditAgreementTrancheFourMember" name="CreditAgreementTrancheFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_SalesDiscountsAndAllowances" name="SalesDiscountsAndAllowances" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_MedisonPharmaLtd.Member" name="MedisonPharmaLtd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CreditableAdvanceRoyaltyPaymentMember" name="CreditableAdvanceRoyaltyPaymentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_NumberOfAgreements" name="NumberOfAgreements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_CommercialAndLicenseAgreementMember" name="CommercialAndLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_LicensedRightsMember" name="LicensedRightsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" name="OneTimeDeliveryOfDrugSupplyForCommercializationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DevelopmentCostsCostSharingArrangementPercentage" name="DevelopmentCostsCostSharingArrangementPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_IncreaseDecreaseRightOfUseAssets" name="IncreaseDecreaseRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" name="DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" name="DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_MilestonePaymentsOnProductByProductBasisMember" name="MilestonePaymentsOnProductByProductBasisMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" name="NonCentralNervousSystemPenetrantIntellectualPropertyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" name="CentralNervousSystemPenetrantIntellectualPropertyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_ShareBasedCompensationOptionsAndRsusMember" name="ShareBasedCompensationOptionsAndRsusMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" name="FinancingLiabilityIncludingInterestExpenseAccretion" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="rigl_FinancingLiabilityInterestAccretionDiscountRate" name="FinancingLiabilityInterestAccretionDiscountRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rigl_PaymentOfCostShareToCollaborationPartner" name="PaymentOfCostShareToCollaborationPartner" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" abstract="false" />
  <xsd:element name="CreditAgreementTrancheFiveMember" id="rigl_CreditAgreementTrancheFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LiquidityAndCapitalResourcesPolicyPolicyTextBlock" id="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DueToCollaborationPartner" id="rigl_DueToCollaborationPartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="KnightTherapeuticsInternationalSaMember" id="rigl_KnightTherapeuticsInternationalSaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DevelopmentAndRegulatoryMilestonesMember" id="rigl_DevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FormaTherapeuticsHoldingsIncMember" id="rigl_FormaTherapeuticsHoldingsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborativeArrangementUpfrontPayment" id="rigl_CollaborativeArrangementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborativeArrangementPotentialPayments" id="rigl_CollaborativeArrangementPotentialPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FollowingThirdAmendmentMember" id="rigl_FollowingThirdAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueReservesAndRefundLiability" id="rigl_RevenueReservesAndRefundLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RezlidhiaMember" id="rigl_RezlidhiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" id="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IntangibleAssetsIncurredButNotYetPaid" id="rigl_IntangibleAssetsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AchievementOfCertainNearTermRegulatoryMilestoneMember" id="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FdaApprovalAndFirstCommercialSaleOfProductMember" id="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RoyaltyDeliveryOfDrugSuppliesAndOthersMember" id="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VariableLeaseExpenseNetCredit" id="rigl_VariableLeaseExpenseNetCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RightToOptOutOfAgreementNumberOfPeriods" id="rigl_RightToOptOutOfAgreementNumberOfPeriods" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmendedLillyAgreementMember" id="rigl_AmendedLillyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoryAndInventoryReportedAsOtherAssets" id="rigl_InventoryAndInventoryReportedAsOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InventoryReportedAsOtherAssets" id="rigl_InventoryReportedAsOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InventoryAndInventoryReportedAsOtherAssetsAbstract" id="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RightToOptBackInCoFundingTerm" id="rigl_RightToOptBackInCoFundingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" id="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" id="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StrategicCollaborationAgreementWithConnectMember" id="rigl_StrategicCollaborationAgreementWithConnectMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationTerm" id="rigl_CollaborationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GavretoMember" id="rigl_GavretoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FirstCommercialSaleMember" id="rigl_FirstCommercialSaleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FirstAnniversaryOfClosingDateMember" id="rigl_FirstAnniversaryOfClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BlueprintMedicinesCorporationMember" id="rigl_BlueprintMedicinesCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PotentialMilestonePaymentObligations" id="rigl_PotentialMilestonePaymentObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PotentialTieredRoyaltyPercentage" id="rigl_PotentialTieredRoyaltyPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RegulatoryMilestonesMember" id="rigl_RegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FollowingFourthAmendmentMember" id="rigl_FollowingFourthAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" id="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AssetPurchaseAgreementDrugProductInventories" id="rigl_AssetPurchaseAgreementDrugProductInventories" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InvestmentsCreditLossExpense" id="rigl_InvestmentsCreditLossExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StrategicCollaborationAgreementWithMdaccMember" id="rigl_StrategicCollaborationAgreementWithMdaccMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockholdersEquityReverseStockSplitPolicyPolicyTextBlock" id="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CardinalHealthIncMember" id="rigl_CardinalHealthIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CencoraIncMember" id="rigl_CencoraIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OcadusertibMember" id="rigl_OcadusertibMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>rigl-20240630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2024 11:55:05 PM-->
<!--Modified on: 8/5/2024 11:55:05 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedBalanceSheets" roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfComprehensiveLoss" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInventoriesAlternateCalculationDetails" roleURI="http://www.rigel.com/role/DisclosureInventoriesAlternateCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponentsInventoriesDetails" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebtSummaryOfLoansPayableDetails" roleURI="http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebtFutureMinimumPaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesLeaseExpenseDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesSubleaseInformationDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesFutureLeasePaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638584989021030896" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638584989021030896" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989021030896" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638584989021030896" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989021030896" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638584989021030896" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638584989021030896" xlink:to="us-gaap_ShortTermInvestments_638584989021030896" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638584989021030896" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638584989021030896" xlink:to="us-gaap_AccountsReceivableNetCurrent_638584989021030896" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638584989021040855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638584989021030896" xlink:to="us-gaap_InventoryNet_638584989021040855" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638584989021040855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638584989021030896" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638584989021040855" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638584989021040855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638584989021040855" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989021040855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989021040855" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638584989021040855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638584989021040855" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638584989021040855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638584989021040855" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638584989021050887" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638584989021050887" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638584989021050887" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638584989021050887" xlink:to="us-gaap_LiabilitiesCurrent_638584989021050887" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638584989021050887" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_AccountsPayableCurrent_638584989021050887" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638584989021050887" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638584989021050887" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638584989021050887" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638584989021050887" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_638584989021050887" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_638584989021050887" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638584989021050887" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638584989021050887" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638584989021060793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638584989021060793" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638584989021060793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638584989021060793" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638584989021060793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638584989021060793" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_638584989021060793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_LoansPayableCurrent_638584989021060793" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638584989021060793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638584989021050887" xlink:to="us-gaap_OtherLiabilitiesCurrent_638584989021060793" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638584989021060793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638584989021050887" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638584989021060793" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_638584989021070797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638584989021050887" xlink:to="us-gaap_LongTermLoansPayable_638584989021070797" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638584989021070797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638584989021050887" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638584989021070797" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638584989021070797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638584989021070797" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638584989021070797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638584989021070797" xlink:to="us-gaap_CommonStockValue_638584989021070797" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638584989021070797" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638584989021070797" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638584989021070797" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638584989021080809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638584989021070797" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638584989021080809" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638584989021080809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638584989021070797" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638584989021080809" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638584989021080809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense_638584989021080809" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638584989021080809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_638584989021080809" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638584989021090793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638584989021090793" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638584989021090793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638584989021090793" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638584989021090793" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638584989021090793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638584989021090793" xlink:to="us-gaap_CostsAndExpenses_638584989021090793" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638584989021090793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638584989021090793" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638584989021090793" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638584989021090793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638584989021090793" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638584989021090793" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638584989021090793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638584989021090793" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638584989021090793" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638584989021100789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638584989021100789" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638584989021100789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638584989021100789" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638584989021100789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_ProfitLoss_638584989021100789" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638584989021100789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638584989021100789" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638584989021100789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638584989021100789" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638584989021100789" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638584989021100789" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInInventories_638584989021110785" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_ShareBasedCompensation_638584989021110785" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638584989021110785" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638584989021110785" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IncreaseDecreaseRightOfUseAssets" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="rigl_IncreaseDecreaseRightOfUseAssets_638584989021110785" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638584989021110785" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638584989021110785" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638584989021110785" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638584989021110785" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RevenueReservesAndRefundLiability" xlink:label="rigl_RevenueReservesAndRefundLiability_638584989021121024" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="rigl_RevenueReservesAndRefundLiability_638584989021121024" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638584989021121024" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638584989021121024" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638584989021121024" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638584989021121024" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638584989021121024" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638584989021121024" order="16" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638584989021121024" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989021100789" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638584989021121024" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989021121024" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989021121024" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638584989021130891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989021121024" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638584989021130891" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638584989021130891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989021121024" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638584989021130891" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638584989021130891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989021121024" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638584989021130891" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638584989021130891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989021121024" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638584989021130891" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638584989021130891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638584989021130891" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_638584989021130891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638584989021130891" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_638584989021130891" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638584989021140777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638584989021130891" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638584989021140777" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638584989021140777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638584989021130891" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638584989021140777" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638584989021140777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638584989021140777" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638584989021140777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638584989021140777" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureInventoriesAlternateCalculationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - INVENTORIES - Alternate Calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssets_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638584989021150778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssets_1" xlink:to="us-gaap_InventoryNet_638584989021150778" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryReportedAsOtherAssets" xlink:label="rigl_InventoryReportedAsOtherAssets_638584989021150778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssets_1" xlink:to="rigl_InventoryReportedAsOtherAssets_638584989021150778" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638584989021150778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:to="us-gaap_InventoryRawMaterials_638584989021150778" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638584989021150778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:to="us-gaap_InventoryWorkInProcess_638584989021150778" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638584989021150778" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:to="us-gaap_InventoryFinishedGoods_638584989021150778" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638584989021160768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638584989021160768" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638584989021160768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638584989021160768" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638584989021160768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638584989021160768" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638584989021160768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638584989021160768" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638584989021160768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638584989021160768" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638584989021160768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638584989021160768" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638584989021170763" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638584989021170763" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638584989021170763" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638584989021170763" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989021170763" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989021170763" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638584989021170763" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_638584989021170763" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - DEBT (Summary of Loans Payable) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" xlink:label="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638584989021180793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638584989021180793" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638584989021180793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" xlink:to="us-gaap_DeferredFinanceCostsNet_638584989021180793" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_638584989021180793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayableCurrent_638584989021180793" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_638584989021180793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LongTermLoansPayable_638584989021180793" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - DEBT - Future Minimum Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638584989021180793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638584989021180793" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638584989021180793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638584989021180793" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638584989021190782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638584989021190782" order="3" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - LEASES - Lease Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638584989021190782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638584989021190782" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638584989021190782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638584989021190782" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_VariableLeaseExpenseNetCredit" xlink:label="rigl_VariableLeaseExpenseNetCredit_638584989021190782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="rigl_VariableLeaseExpenseNetCredit_638584989021190782" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - LEASES - Sublease Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NetSubleaseIncomeExpense" xlink:label="rigl_NetSubleaseIncomeExpense" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FixedSubleaseExpense" xlink:label="rigl_FixedSubleaseExpense_638584989021190782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="rigl_FixedSubleaseExpense_638584989021190782" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_VariableSubleaseExpense" xlink:label="rigl_VariableSubleaseExpense_638584989021190782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="rigl_VariableSubleaseExpense_638584989021190782" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_638584989021190782" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="us-gaap_SubleaseIncome_638584989021190782" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - LEASES - Future Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638584989021200768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638584989021200768" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638584989021200768" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638584989021200768" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>rigl-20240630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2024 11:55:05 PM-->
<!--Modified on: 8/5/2024 11:55:05 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfStockholdersDeficit" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenuesDisaggregatedDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenuesActivityDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenuesPercentageByCustomerDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInLicensingAndAcquisitionNarrativeDetails" roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationOptionsAndRsusDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationPlansDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureFairValueDetails" roleURI="http://www.rigel.com/role/DisclosureFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.rigel.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.rigel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="rigl-20240630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://www.rigel.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_1" xlink:title="us-gaap_ValuationAllowancesAndReservesTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_1" xlink:title="us-gaap_ValuationAllowancesAndReservesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis_1" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ValuationAllowancesAndReservesTypeAxis_1 To us-gaap_ValuationAllowancesAndReservesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis_1" xlink:title="rigl_AchievementOfMilestoneAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain_1" xlink:title="rigl_AchievementOfMilestoneDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rigl_AchievementOfMilestoneAxis_1" xlink:to="rigl_AchievementOfMilestoneDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rigl_AchievementOfMilestoneAxis_1 To rigl_AchievementOfMilestoneDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_1" xlink:title="us-gaap_InvestmentTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_1" xlink:title="us-gaap_InvestmentTypeCategorizationMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_InvestmentTypeAxis_1" xlink:to="us-gaap_InvestmentTypeCategorizationMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_InvestmentTypeAxis_1 To us-gaap_InvestmentTypeCategorizationMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_ContractRevenuesFromCollaborationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GovernmentContractMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99930603 - Disclosure - STOCK-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - REVENUES - Disaggregated (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GrossProductMember" xlink:label="rigl_GrossProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_GrossProductMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DiscountsAndAllowancesMember" xlink:label="rigl_DiscountsAndAllowancesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_DiscountsAndAllowancesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_ContractRevenuesFromCollaborationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GovernmentContractMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - REVENUES - Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ChargebacksDiscountsAndFeesMember" xlink:label="rigl_ChargebacksDiscountsAndFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="rigl_ChargebacksDiscountsAndFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GovernmentAndOtherRebatesMember" xlink:label="rigl_GovernmentAndOtherRebatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="rigl_GovernmentAndOtherRebatesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_SalesReturnsAndAllowancesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SalesDiscountsAndAllowances" xlink:label="rigl_SalesDiscountsAndAllowances" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="rigl_SalesDiscountsAndAllowances" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xlink:type="extended" xlink:title="99940303 - Disclosure - REVENUES - Percentage by Customer (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rigl_MckessonSpecialtyCareDistributionCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CardinalHealthIncMember" xlink:label="rigl_CardinalHealthIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rigl_CardinalHealthIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CencoraIncMember" xlink:label="rigl_CencoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="rigl_CencoraIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FostamatinibMember" xlink:label="rigl_FostamatinibMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_FostamatinibMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_OcadusertibMember" xlink:label="rigl_OcadusertibMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_OcadusertibMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_RezlidhiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GovernmentContractMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GrifolsS.a.Member" xlink:label="rigl_GrifolsS.a.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="rigl_GrifolsS.a.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MedisonPharmaLtd.Member" xlink:label="rigl_MedisonPharmaLtd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_EntityDomain" xlink:to="rigl_MedisonPharmaLtd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_KnightTherapeuticsInternationalSaMember" xlink:label="rigl_KnightTherapeuticsInternationalSaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_EntityDomain" xlink:to="rigl_KnightTherapeuticsInternationalSaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_EntityDomain" xlink:to="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_EntityDomain" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="rigl_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="rigl_AchievementOfMilestoneAxis" xlink:to="rigl_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedDevelopmentEventsMember" xlink:label="rigl_SpecifiedDevelopmentEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedDevelopmentEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedRegulatoryEventsMember" xlink:label="rigl_SpecifiedRegulatoryEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedRegulatoryEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedProductLaunchEventsMember" xlink:label="rigl_SpecifiedProductLaunchEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedProductLaunchEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_LicensedRightsMember" xlink:label="rigl_LicensedRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_LicensedRightsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedCommercialMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_CreditableAdvanceRoyaltyPaymentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StrategicCollaborationAgreementWithMdaccMember" xlink:label="rigl_StrategicCollaborationAgreementWithMdaccMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rigl_StrategicCollaborationAgreementWithMdaccMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StrategicCollaborationAgreementWithConnectMember" xlink:label="rigl_StrategicCollaborationAgreementWithConnectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rigl_StrategicCollaborationAgreementWithConnectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AmendedLillyAgreementMember" xlink:label="rigl_AmendedLillyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rigl_AmendedLillyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CommercialAndLicenseAgreementMember" xlink:label="rigl_CommercialAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rigl_CommercialAndLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="rigl_MilestonePaymentsOnProductByProductBasisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContingentPaymentsUnderAgreement" xlink:label="rigl_ContingentPaymentsUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_ContingentPaymentsUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_DevelopmentCostsCostSharingArrangementPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_RightToOptOutOfAgreementNumberOfPeriods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RightToOptBackInCoFundingTerm" xlink:label="rigl_RightToOptBackInCoFundingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_RightToOptBackInCoFundingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborativeArrangementUpfrontFeeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualComponentAmount" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProductLiabilityAccrualComponentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_FinancingLiabilityInterestAccretionDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccretionExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DueToCollaborationPartner" xlink:label="rigl_DueToCollaborationPartner" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_DueToCollaborationPartner" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementRevenueRecognized" xlink:label="rigl_CollaborativeArrangementRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborativeArrangementRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" xlink:label="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborationTerm" xlink:label="rigl_CollaborationTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborationTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_RoyaltyPaymentAsPercentageOfNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NumberOfAgreements" xlink:label="rigl_NumberOfAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_NumberOfAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rigl_CollaborativeArrangementPotentialPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - IN-LICENSING AND ACQUISITION - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BlueprintMedicinesCorporationMember" xlink:label="rigl_BlueprintMedicinesCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="rigl_BlueprintMedicinesCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GavretoMember" xlink:label="rigl_GavretoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_GavretoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rigl_RezlidhiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="rigl_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="rigl_AchievementOfMilestoneAxis" xlink:to="rigl_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FirstCommercialSaleMember" xlink:label="rigl_FirstCommercialSaleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_FirstCommercialSaleMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FirstAnniversaryOfClosingDateMember" xlink:label="rigl_FirstAnniversaryOfClosingDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_FirstAnniversaryOfClosingDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_SpecifiedCommercialMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RegulatoryMilestonesMember" xlink:label="rigl_RegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_RegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PotentialMilestonePaymentObligations" xlink:label="rigl_PotentialMilestonePaymentObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="rigl_PotentialMilestonePaymentObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PotentialTieredRoyaltyPercentage" xlink:label="rigl_PotentialTieredRoyaltyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="rigl_PotentialTieredRoyaltyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AssetPurchaseAgreementDrugProductInventories" xlink:label="rigl_AssetPurchaseAgreementDrugProductInventories" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="rigl_AssetPurchaseAgreementDrugProductInventories" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementUpfrontPayment" xlink:label="rigl_CollaborativeArrangementUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="rigl_CollaborativeArrangementUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="rigl_CollaborativeArrangementPotentialPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BlueprintMedicinesCorporationMember" xlink:label="rigl_BlueprintMedicinesCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="rigl_BlueprintMedicinesCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - STOCK-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rigl_ShareBasedCompensationOptionsAndRsusMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - STOCK-BASED COMPENSATION - Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InvestmentsCreditLossExpense" xlink:label="rigl_InvestmentsCreditLossExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="rigl_InvestmentsCreditLossExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureFairValueDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - FAIR VALUE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - DEBT (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LineOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheOneMember" xlink:label="rigl_CreditAgreementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheTwoMember" xlink:label="rigl_CreditAgreementTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheThreeMember" xlink:label="rigl_CreditAgreementTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheFourMember" xlink:label="rigl_CreditAgreementTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheFiveMember" xlink:label="rigl_CreditAgreementTrancheFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rigl_CreditAgreementTrancheFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FollowingThirdAmendmentMember" xlink:label="rigl_FollowingThirdAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="rigl_FollowingThirdAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FollowingFourthAmendmentMember" xlink:label="rigl_FollowingFourthAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="rigl_FollowingFourthAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.rigel.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BuildingMember" xlink:to="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rigl_SubleaseAgreementAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="rigl_SubleaseAgreementAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>rigl-20240630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2024 11:55:05 PM-->
<!--Modified on: 8/5/2024 11:55:05 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DOCUMENT AND ENTITY INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Including Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:to="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Contingent Consideration, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-related liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Refund Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue reserves and refund liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable, net, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of loans payable, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of loans payable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split, conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product sales, net</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ContractRevenuesFromCollaborationsMember" xlink:to="rigl_ContractRevenuesFromCollaborationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents contract revenues from collaborations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues from collaborations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractMember" xlink:to="us-gaap_GovernmentContractMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentContractMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government contracts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of product sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (loss) from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing net loss per share, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares outstanding and common stock equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing net loss per share, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss) gain:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net unrealized (loss) gain on short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in unrealized gain (loss) on short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units (RSUs)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on sale and disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Net, Amortization of Discount and Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net amortization of discount on short-term investments and term loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current and non-current assets</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IncreaseDecreaseRightOfUseAssets" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_IncreaseDecreaseRightOfUseAssets" xlink:to="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase or decrease in right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:to="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Research and Development Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RevenueReservesAndRefundLiability" xlink:label="rigl_RevenueReservesAndRefundLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RevenueReservesAndRefundLiability" xlink:to="rigl_RevenueReservesAndRefundLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RevenueReservesAndRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RevenueReservesAndRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Reserves And Refund Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_RevenueReservesAndRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue reserves and refund liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current and long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for acquisition of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Long-term Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from term loan financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuances of common stock upon exercise of options</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_PaymentOfCostShareToCollaborationPartner" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of cost share to collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Cost Share To Collaboration Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost share payments to a collaboration partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of cost share to collaboration partner</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IntangibleAssetsIncurredButNotYetPaid" xlink:label="rigl_IntangibleAssetsIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_IntangibleAssetsIncurredButNotYetPaid" xlink:to="rigl_IntangibleAssetsIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_IntangibleAssetsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future cash outflow to pay for purchases of intangible assets that have occurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_IntangibleAssetsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets Incurred But Not Yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_IntangibleAssetsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets included within acquisition-related liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVENUES</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateCollaborationsDisclosureAbstract" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CorporateCollaborationsDisclosureAbstract" xlink:to="rigl_CorporateCollaborationsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Collaborations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IN-LICENSING AND ACQUISITION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IN-LICENSING AND ACQUISITION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER BALANCE SHEET COMPONENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER BALANCE SHEET COMPONENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DEBT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DEBT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEASES</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_LeaseDisclosureTextBlock" xlink:label="rigl_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_LeaseDisclosureTextBlock" xlink:to="rigl_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rigl_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEASES</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock" xlink:label="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock" xlink:to="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for reverse stock split arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Reverse Stock Split Policy Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Stock Split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xlink:to="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for liquidity and capital resources.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity And Capital Resources Policy Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenues disaggregated by category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of product revenue allowance and reserve categories</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xlink:to="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of disaggregation of revenue by customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation Of Revenue By Customer [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenues from product sales disaggregated by customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Contingent Consideration [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of total purchase consideration in connection with asset acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of weighted-average assumptions relating to options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated future amortization expense of intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash, cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain (Loss) on Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value and gross unrealized losses of investments in unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of loans payable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Line of Credit Facilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of operating lease expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of supplemental cash flow information related to operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow Information Related To Operating Lease [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of supplemental information related to operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Lease Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of operating sublease information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GrossProductMember" xlink:label="rigl_GrossProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GrossProductMember" xlink:to="rigl_GrossProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GrossProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents gross product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GrossProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross product sales</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DiscountsAndAllowancesMember" xlink:label="rigl_DiscountsAndAllowancesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DiscountsAndAllowancesMember" xlink:to="rigl_DiscountsAndAllowancesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DiscountsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents discounts and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DiscountsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discounts and allowances</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:to="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents royalty, delivery of drug supplies and others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Delivery of drug supplies, royalty and others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ChargebacksDiscountsAndFeesMember" xlink:label="rigl_ChargebacksDiscountsAndFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ChargebacksDiscountsAndFeesMember" xlink:to="rigl_ChargebacksDiscountsAndFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ChargebacksDiscountsAndFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents chargebacks, discounts and fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ChargebacksDiscountsAndFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chargebacks, Discounts and Fees</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GovernmentAndOtherRebatesMember" xlink:label="rigl_GovernmentAndOtherRebatesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GovernmentAndOtherRebatesMember" xlink:to="rigl_GovernmentAndOtherRebatesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GovernmentAndOtherRebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents government and other rebates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GovernmentAndOtherRebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government and Other Rebates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesReturnsAndAllowancesMember" xlink:to="us-gaap_SalesReturnsAndAllowancesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Returns</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:to="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing accounts receivable and prepaid and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable and prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Additions for Charges to Cost and Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision related to current period sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit or payments made during the period</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SalesDiscountsAndAllowances" xlink:label="rigl_SalesDiscountsAndAllowances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SalesDiscountsAndAllowances" xlink:to="rigl_SalesDiscountsAndAllowances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SalesDiscountsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of sales discounts and allowances during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SalesDiscountsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Discounts And Allowances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_SalesDiscountsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discounts and allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesMember" xlink:to="us-gaap_SalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name Of Major Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:to="rigl_MckessonSpecialtyCareDistributionCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents McKesson Specialty Care Distribution Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">McKesson Specialty Care Distribution Corporation</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CardinalHealthIncMember" xlink:label="rigl_CardinalHealthIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CardinalHealthIncMember" xlink:to="rigl_CardinalHealthIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CardinalHealthIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Cardinal Health Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CardinalHealthIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cardinal Health Inc.</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CencoraIncMember" xlink:label="rigl_CencoraIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CencoraIncMember" xlink:to="rigl_CencoraIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CencoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Cencora Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CencoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cencora Inc. (formerly ASD Healthcare)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FostamatinibMember" xlink:label="rigl_FostamatinibMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FostamatinibMember" xlink:to="rigl_FostamatinibMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FostamatinibMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents fostamatinib.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FostamatinibMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">fostamatinib</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_OcadusertibMember" xlink:label="rigl_OcadusertibMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_OcadusertibMember" xlink:to="rigl_OcadusertibMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_OcadusertibMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RIPK1 inhibitor for the treatment of non-central nervous system (non-CNS) diseases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_OcadusertibMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ocadusertib</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:to="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents non-central nervous system penetrant intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-CNS penetrant IP</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:to="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents central nervous system penetrant intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CNS penetrant IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RezlidhiaMember" xlink:to="rigl_RezlidhiaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RezlidhiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents REZLIDHIA product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RezlidhiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REZLIDHIA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GrifolsS.a.Member" xlink:label="rigl_GrifolsS.a.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GrifolsS.a.Member" xlink:to="rigl_GrifolsS.a.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GrifolsS.a.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Grifols, S.A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GrifolsS.a.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grifols</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Kissei Pharmaceutical Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kissei</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MedisonPharmaLtd.Member" xlink:label="rigl_MedisonPharmaLtd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_MedisonPharmaLtd.Member" xlink:to="rigl_MedisonPharmaLtd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_MedisonPharmaLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Medison Pharma Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_MedisonPharmaLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medison</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_KnightTherapeuticsInternationalSaMember" xlink:label="rigl_KnightTherapeuticsInternationalSaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_KnightTherapeuticsInternationalSaMember" xlink:to="rigl_KnightTherapeuticsInternationalSaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_KnightTherapeuticsInternationalSaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Knight Therapeutics International SA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_KnightTherapeuticsInternationalSaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Knight</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Biomedical Advanced Research and Development Authority [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BARDA</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FormaTherapeuticsHoldingsIncMember" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Forma Therapeutics Holdings, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forma</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AchievementOfMilestoneAxis" xlink:to="rigl_AchievementOfMilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by categories of milestones achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AchievementOfMilestoneDomain" xlink:to="rigl_AchievementOfMilestoneDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Different categories of achievement of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of Milestone [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedDevelopmentEventsMember" xlink:label="rigl_SpecifiedDevelopmentEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedDevelopmentEventsMember" xlink:to="rigl_SpecifiedDevelopmentEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedDevelopmentEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified development events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedDevelopmentEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specified Development Events</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedRegulatoryEventsMember" xlink:label="rigl_SpecifiedRegulatoryEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedRegulatoryEventsMember" xlink:to="rigl_SpecifiedRegulatoryEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedRegulatoryEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified regulatory events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedRegulatoryEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specified Regulatory Events</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedProductLaunchEventsMember" xlink:label="rigl_SpecifiedProductLaunchEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedProductLaunchEventsMember" xlink:to="rigl_SpecifiedProductLaunchEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedProductLaunchEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified product launch events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedProductLaunchEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specified Product Launch Events</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_LicensedRightsMember" xlink:label="rigl_LicensedRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_LicensedRightsMember" xlink:to="rigl_LicensedRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_LicensedRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents licensed rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_LicensedRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensed Rights</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development and regulatory milestones by non-central nervous system disease products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestones by non-CNS disease products</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development and regulatory milestones by central nervous system disease products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestones by CNS disease products</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:to="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a one-time delivery of drug supply for commercialization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Delivery of drug supply for commercialization</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SpecifiedCommercialMilestonesMember" xlink:to="rigl_SpecifiedCommercialMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SpecifiedCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents specified commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SpecifiedCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial milestones</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:to="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents European Medicines Agency approval of fostamatinib for treatment of chronic immune thrombocytopenic purpura.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon EMA approval of fostamatinib for treatment of chronic ITP</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:to="rigl_CreditableAdvanceRoyaltyPaymentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents creditable advance royalty payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Creditable advance royalty payment</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development and regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents FDA approval and first commercial sale of the product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA approval and first commercial sale of product</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StrategicCollaborationAgreementWithMdaccMember" xlink:label="rigl_StrategicCollaborationAgreementWithMdaccMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_StrategicCollaborationAgreementWithMdaccMember" xlink:to="rigl_StrategicCollaborationAgreementWithMdaccMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_StrategicCollaborationAgreementWithMdaccMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents strategic collaboration agreement with MDACC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_StrategicCollaborationAgreementWithMdaccMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strategic collaboration agreement with MDACC</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StrategicCollaborationAgreementWithConnectMember" xlink:label="rigl_StrategicCollaborationAgreementWithConnectMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_StrategicCollaborationAgreementWithConnectMember" xlink:to="rigl_StrategicCollaborationAgreementWithConnectMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_StrategicCollaborationAgreementWithConnectMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents strategic collaboration agreement with CONNECT, an international collaborative network of pediatric cancer centers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_StrategicCollaborationAgreementWithConnectMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strategic collaboration agreement with CONNECT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AmendedLillyAgreementMember" xlink:label="rigl_AmendedLillyAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AmendedLillyAgreementMember" xlink:to="rigl_AmendedLillyAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AmendedLillyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amended Lilly Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AmendedLillyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Lilly Agreement</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CommercialAndLicenseAgreementMember" xlink:label="rigl_CommercialAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CommercialAndLicenseAgreementMember" xlink:to="rigl_CommercialAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CommercialAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents commercial and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CommercialAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial and license agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:to="rigl_MilestonePaymentsOnProductByProductBasisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents milestone payments made on a product-by-product basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments on a product-by-product basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborations</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContingentPaymentsUnderAgreement" xlink:label="rigl_ContingentPaymentsUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ContingentPaymentsUnderAgreement" xlink:to="rigl_ContingentPaymentsUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ContingentPaymentsUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents additional contingent payments by entities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ContingentPaymentsUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ContingentPaymentsUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent payments</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:to="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of development costs in cost sharing arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Costs Cost Sharing Arrangement Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company's percentage of development costs</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:to="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of periods with right to opt out of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right To Opt Out Of Agreement Number Of Periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to opt out of agreement, different specified times</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funding commitment</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RightToOptBackInCoFundingTerm" xlink:label="rigl_RightToOptBackInCoFundingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RightToOptBackInCoFundingTerm" xlink:to="rigl_RightToOptBackInCoFundingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RightToOptBackInCoFundingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period of time of right to opt-back-in co-funding, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RightToOptBackInCoFundingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right To Opt Back In Co Funding Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_RightToOptBackInCoFundingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to opt-back-in co-funding of R552 development, term</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:to="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Upfront Fee Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualComponentAmount" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityAccrualComponentAmount" xlink:to="us-gaap_ProductLiabilityAccrualComponentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Liability Accrual, Component Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing component liability</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:to="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate applied to the undiscounted amount of financing liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Liability Interest Accretion Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing liability interest accretion discount rate</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:to="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of financing liability including interest expense accretion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Liability Including Interest Expense Accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing liability with accreted interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DueToCollaborationPartner" xlink:label="rigl_DueToCollaborationPartner" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DueToCollaborationPartner" xlink:to="rigl_DueToCollaborationPartner_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DueToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount due to collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DueToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due To Collaboration Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_DueToCollaborationPartner_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development costs due to collaboration partner</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Remaining Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, remaining performance obligation</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementRevenueRecognized" xlink:label="rigl_CollaborativeArrangementRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementRevenueRecognized" xlink:to="rigl_CollaborativeArrangementRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the revenue recognized during the period under the terms of sponsored research and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized associated with remaining performance obligation</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" xlink:label="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" xlink:to="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option under agreement to buy back product rights within number of months from regulatory approval, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Option To Buy Back Product Rights Within Number Of Months From Regulatory Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to buy back product rights within number of months from regulatory approval</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborationTerm" xlink:label="rigl_CollaborationTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborationTerm" xlink:to="rigl_CollaborationTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time of collaboration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Collaborators</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative payment received</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:to="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents royalty payment as a percentage of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Payment As Percentage Of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment as a percentage of net sales</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NumberOfAgreements" xlink:label="rigl_NumberOfAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_NumberOfAgreements" xlink:to="rigl_NumberOfAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_NumberOfAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_NumberOfAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_NumberOfAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of agreements</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementPotentialPayments" xlink:to="rigl_CollaborativeArrangementPotentialPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of contingent payments under collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Potential Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BlueprintMedicinesCorporationMember" xlink:label="rigl_BlueprintMedicinesCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_BlueprintMedicinesCorporationMember" xlink:to="rigl_BlueprintMedicinesCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_BlueprintMedicinesCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Blueprint Medicines Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_BlueprintMedicinesCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Blueprint</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GavretoMember" xlink:label="rigl_GavretoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_GavretoMember" xlink:to="rigl_GavretoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_GavretoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents GAVRETO (pralsetinib) product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_GavretoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GAVRETO (pralsetinib)</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FirstCommercialSaleMember" xlink:label="rigl_FirstCommercialSaleMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FirstCommercialSaleMember" xlink:to="rigl_FirstCommercialSaleMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FirstCommercialSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents first commercial sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FirstCommercialSaleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First commercial sale</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FirstAnniversaryOfClosingDateMember" xlink:label="rigl_FirstAnniversaryOfClosingDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FirstAnniversaryOfClosingDateMember" xlink:to="rigl_FirstAnniversaryOfClosingDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FirstAnniversaryOfClosingDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the first anniversary of the closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FirstAnniversaryOfClosingDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First anniversary of the closing date</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RegulatoryMilestonesMember" xlink:label="rigl_RegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_RegulatoryMilestonesMember" xlink:to="rigl_RegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_RegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_RegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:to="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents achievement of a certain near-term regulatory milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of certain near-term regulatory milestone</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Price of Acquisition, Expected</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset acquisition, expected price</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PotentialMilestonePaymentObligations" xlink:label="rigl_PotentialMilestonePaymentObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_PotentialMilestonePaymentObligations" xlink:to="rigl_PotentialMilestonePaymentObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_PotentialMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of potential milestone payment obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_PotentialMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential Milestone Payment Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_PotentialMilestonePaymentObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PotentialTieredRoyaltyPercentage" xlink:label="rigl_PotentialTieredRoyaltyPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_PotentialTieredRoyaltyPercentage" xlink:to="rigl_PotentialTieredRoyaltyPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_PotentialTieredRoyaltyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of potential tiered royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_PotentialTieredRoyaltyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential Tiered Royalty Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_PotentialTieredRoyaltyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential tiered royalties (as a percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Businesses, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, estimated useful life</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AssetPurchaseAgreementDrugProductInventories" xlink:label="rigl_AssetPurchaseAgreementDrugProductInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AssetPurchaseAgreementDrugProductInventories" xlink:to="rigl_AssetPurchaseAgreementDrugProductInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AssetPurchaseAgreementDrugProductInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of agreement for purchase of drug product inventories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AssetPurchaseAgreementDrugProductInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Purchase Agreement Drug Product Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_AssetPurchaseAgreementDrugProductInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset purchase agreement, drug product inventories</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementUpfrontPayment" xlink:label="rigl_CollaborativeArrangementUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CollaborativeArrangementUpfrontPayment" xlink:to="rigl_CollaborativeArrangementUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of collaborative arrangement upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing purchase price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total purchase consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense related to stock-based awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:to="rigl_ShareBasedCompensationOptionsAndRsusMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents share based compensation options and RSUs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock options and Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting upon achievement of corporate performance-based milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised during the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant-date weighted-average fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost related to performance-based stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average recognition period of unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions relating to Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the offering period for awards under the equity-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Award Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award offering period</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the purchase price expressed as a percentage of the fair market value of common stock on the first day of the offering period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Purchase Price of Common Stock Percentage on First Day of Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price expressed as a percentage of fair market value of common stock on the first day of the offering period</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of purchase periods per award offering period under the equity-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods Per Award Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of purchase periods per award offering period</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the purchase period for awards under the equity-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Award Purchase Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award purchase period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price expressed as a percentage of fair market value of common stock on the purchase date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional shares approved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock available for grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw Materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract" xlink:to="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory And Inventory Reported As Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory And Inventory Reported As Other Assets Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reported as:</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryReportedAsOtherAssets" xlink:label="rigl_InventoryReportedAsOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_InventoryReportedAsOtherAssets" xlink:to="rigl_InventoryReportedAsOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_InventoryReportedAsOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of inventory reported as other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_InventoryReportedAsOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Reported As Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_InventoryReportedAsOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:to="rigl_InventoryAndInventoryReportedAsOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of inventory and inventory reported as other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory And Inventory Reported As Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advances on Inventory Purchases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance payments for raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder of 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash and cash equivalent balances, excluding any restricted cash balances, and available-for-sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type Categorization [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US treasury bills</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government-sponsored enterprise securities</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate bonds and commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalent and short term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents and Available For Sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents and Available For Sale Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents and available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Including Portion Attributable to Noncontrolling Interest, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains (Losses)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents and Available For Sale Securities, Weighted Average Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average time to maturity of cash equivalents and available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investments in continuous unrealized loss position for more than 12 months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of individual securities in unrealized loss position for 12 months or less</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InvestmentsCreditLossExpense" xlink:label="rigl_InvestmentsCreditLossExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_InvestmentsCreditLossExpense" xlink:to="rigl_InvestmentsCreditLossExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_InvestmentsCreditLossExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for expected credit loss on investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_InvestmentsCreditLossExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Credit Loss Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_InvestmentsCreditLossExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit losses recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Continuous Unrealized Loss Position Less than 12 Months Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate Of Fair Value Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" xlink:label="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" xlink:to="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, after deduction of unamortized debt issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Principal Outstanding, Net Of Unamortized Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal outstanding, net of unamortized debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Current and Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reported as:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility with MidCap</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheOneMember" xlink:label="rigl_CreditAgreementTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheOneMember" xlink:to="rigl_CreditAgreementTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche one representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 1</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheTwoMember" xlink:label="rigl_CreditAgreementTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheTwoMember" xlink:to="rigl_CreditAgreementTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche two representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 2</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheThreeMember" xlink:label="rigl_CreditAgreementTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheThreeMember" xlink:to="rigl_CreditAgreementTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche three representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 3</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheFourMember" xlink:label="rigl_CreditAgreementTrancheFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheFourMember" xlink:to="rigl_CreditAgreementTrancheFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche four representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 4</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheFiveMember" xlink:label="rigl_CreditAgreementTrancheFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_CreditAgreementTrancheFiveMember" xlink:to="rigl_CreditAgreementTrancheFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_CreditAgreementTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche five representing borrowing capacity under terms of the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_CreditAgreementTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche 5</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SOFR</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FollowingThirdAmendmentMember" xlink:label="rigl_FollowingThirdAmendmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FollowingThirdAmendmentMember" xlink:to="rigl_FollowingThirdAmendmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FollowingThirdAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time following third amendment of credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FollowingThirdAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Following Third Amendment</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FollowingFourthAmendmentMember" xlink:label="rigl_FollowingFourthAmendmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FollowingFourthAmendmentMember" xlink:to="rigl_FollowingFourthAmendmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FollowingFourthAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time following fourth amendment of credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FollowingFourthAmendmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Following Fourth Amendment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Basis for Effective Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis spread on variable rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Floor rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment fee, percentage of principal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Increase, Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of Long-term Debt [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount (Tranches 1, 2, 3 and 4)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Building</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:to="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Headquarters office space sublease in South San Francisco, California.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Headquarters office space sublease, South San Francisco, California</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_SubleaseAgreementAbstract" xlink:to="rigl_SubleaseAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Agreement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rigl_SubleaseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating sublease information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable operating lease expense (net credit)</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_VariableLeaseExpenseNetCredit" xlink:label="rigl_VariableLeaseExpenseNetCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_VariableLeaseExpenseNetCredit" xlink:to="rigl_VariableLeaseExpenseNetCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_VariableLeaseExpenseNetCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of variable lease expense (net credit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_VariableLeaseExpenseNetCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease Expense Net Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_VariableLeaseExpenseNetCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable operating lease expense (net credit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments included in the measurement of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FixedSubleaseExpense" xlink:label="rigl_FixedSubleaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_FixedSubleaseExpense" xlink:to="rigl_FixedSubleaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_FixedSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fixed sublease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_FixedSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Sublease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_FixedSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed sublease expense</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_VariableSubleaseExpense" xlink:label="rigl_VariableSubleaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_VariableSubleaseExpense" xlink:to="rigl_VariableSubleaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_VariableSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of variable sublease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_VariableSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Sublease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rigl_VariableSubleaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable sublease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease income</label>
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NetSubleaseIncomeExpense" xlink:label="rigl_NetSubleaseIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rigl_NetSubleaseIncomeExpense" xlink:to="rigl_NetSubleaseIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rigl_NetSubleaseIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sublease income (expense).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rigl_NetSubleaseIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sublease Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="rigl_NetSubleaseIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder of 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum payments required</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>rigl-20240630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2024 11:55:05 PM-->
<!--Modified on: 8/5/2024 11:55:05 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.rigel.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedBalanceSheets" roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedBalanceSheetsParenthetical" roleURI="http://www.rigel.com/role/StatementCondensedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfOperationsParenthetical" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfOperationsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfComprehensiveLoss" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfStockholdersDeficit" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfStockholdersDeficitParenthetical" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureNetLossPerShare" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenues" roleURI="http://www.rigel.com/role/DisclosureRevenues" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInLicensingAndAcquisition" roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensation" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponents" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestments" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureFairValue" roleURI="http://www.rigel.com/role/DisclosureFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebt" roleURI="http://www.rigel.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeases" roleURI="http://www.rigel.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenuesTables" roleURI="http://www.rigel.com/role/DisclosureRevenuesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInLicensingAndAcquisitionTables" roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponentsTables" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureFairValueTables" roleURI="http://www.rigel.com/role/DisclosureFairValueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebtTables" roleURI="http://www.rigel.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesTables" roleURI="http://www.rigel.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" roleURI="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenuesDisaggregatedDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenuesActivityDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureRevenuesPercentageByCustomerDetails" roleURI="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" roleURI="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInLicensingAndAcquisitionNarrativeDetails" roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" roleURI="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationOptionsAndRsusDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureStockBasedCompensationPlansDetails" roleURI="http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponentsInventoriesDetails" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" roleURI="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" roleURI="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureFairValueDetails" roleURI="http://www.rigel.com/role/DisclosureFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebtSummaryOfLoansPayableDetails" roleURI="http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.rigel.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureDebtFutureMinimumPaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesLeaseExpenseDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesCashFlowInformationDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesSubleaseInformationDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rigl-20240630.xsd#DisclosureLeasesFutureLeasePaymentsDetails" roleURI="http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.rigel.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - DOCUMENT AND ENTITY INFORMATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638584989022240811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638584989022240811" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638584989022240811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638584989022240811" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638584989022250802" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638584989022250802" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638584989022250802" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638584989022250802" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638584989022250802" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638584989022250802" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638584989022250802" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638584989022250802" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638584989022250802" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638584989022250802" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638584989022250802" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638584989022250802" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638584989022250802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638584989022250802" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638584989022261082" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638584989022261082" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638584989022261082" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638584989022261082" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638584989022261082" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638584989022261082" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638584989022261082" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638584989022261082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638584989022261082" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638584989022270820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638584989022270820" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638584989022270820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638584989022270820" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638584989022270820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638584989022270820" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638584989022270820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638584989022270820" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638584989022270820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638584989022270820" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638584989022270820" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638584989022270820" order="29" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638584989022280908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638584989022280908" xlink:to="us-gaap_AssetsCurrentAbstract_638584989022280908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638584989022280908" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989022280908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638584989022280908" xlink:to="us-gaap_ShortTermInvestments_638584989022280908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638584989022280908" xlink:to="us-gaap_AccountsReceivableNetCurrent_638584989022280908" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638584989022280908" xlink:to="us-gaap_InventoryNet_638584989022280908" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638584989022280908" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638584989022280908" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638584989022280908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638584989022280908" xlink:to="us-gaap_AssetsCurrent_638584989022280908" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638584989022280908" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638584989022290833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638584989022280908" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989022290833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638584989022280908" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638584989022290833" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638584989022280908" xlink:to="us-gaap_OtherAssetsNoncurrent_638584989022290833" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638584989022280908" xlink:to="us-gaap_Assets_638584989022290833" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_AccountsPayableCurrent_638584989022290833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638584989022290833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638584989022290833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccruedResearchAndDevelopmentLiabilityCurrent" xlink:label="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="rigl_AccruedResearchAndDevelopmentLiabilityCurrent_638584989022300844" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_638584989022300844" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent_638584989022300844" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_LoansPayableCurrent_638584989022300844" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638584989022300844" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638584989022300844" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638584989022300844" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638584989022300844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_OtherLiabilitiesCurrent_638584989022300844" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638584989022310830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638584989022290833" xlink:to="us-gaap_LiabilitiesCurrent_638584989022310830" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638584989022310830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638584989022310830" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_638584989022310830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_LongTermLoansPayable_638584989022310830" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638584989022310830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638584989022310830" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638584989022310830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_Liabilities_638584989022310830" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638584989022310830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_CommitmentsAndContingencies_638584989022310830" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638584989022310830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_StockholdersEquityAbstract_638584989022310830" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638584989022320857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638584989022310830" xlink:to="us-gaap_CommonStockValue_638584989022320857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638584989022320857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638584989022310830" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638584989022320857" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638584989022320857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638584989022310830" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638584989022320857" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638584989022320857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638584989022310830" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638584989022320857" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638584989022320857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638584989022310830" xlink:to="us-gaap_StockholdersEquity_638584989022320857" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638584989022320857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638584989022290833" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638584989022320857" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022330812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022330812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638584989022330812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_638584989022330812" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638584989022330812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638584989022330812" xlink:to="srt_ProductOrServiceAxis_638584989022330812" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638584989022330812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638584989022330812" xlink:to="srt_ProductsAndServicesDomain_638584989022330812" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638584989022330812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022330812" xlink:to="us-gaap_ProductMember_638584989022330812" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022330812" xlink:to="rigl_ContractRevenuesFromCollaborationsMember_638584989022340804" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022330812" xlink:to="us-gaap_GovernmentContractMember_638584989022340804" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638584989022330812" xlink:to="us-gaap_StatementLineItems_638584989022340804" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638584989022340804" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_CostsAndExpensesAbstract_638584989022340804" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638584989022340804" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638584989022340804" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638584989022340804" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638584989022340804" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638584989022340804" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638584989022340804" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638584989022340804" xlink:to="us-gaap_CostsAndExpenses_638584989022340804" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638584989022340804" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_OperatingIncomeLoss_638584989022340804" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638584989022351161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_InvestmentIncomeInterest_638584989022351161" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638584989022351161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_InterestExpense_638584989022351161" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638584989022351161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_NetIncomeLoss_638584989022351161" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638584989022351161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_EarningsPerShareBasic_638584989022351161" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638584989022351161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_EarningsPerShareDiluted_638584989022351161" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638584989022351161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638584989022351161" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638584989022351161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022340804" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638584989022351161" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="995200205 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022360928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022360928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638584989022360928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638584989022360928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_638584989022360928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_638584989022360928" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638584989022360928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_638584989022360928" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638584989022360928" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638584989022360928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638584989022360928" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638584989022370922" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638584989022370922" xlink:to="us-gaap_StatementEquityComponentsAxis_638584989022370922" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638584989022370922" xlink:to="us-gaap_CommonStockMember_638584989022370922" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638584989022370922" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638584989022370922" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638584989022370922" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638584989022370922" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638584989022370922" xlink:to="us-gaap_RetainedEarningsMember_638584989022370922" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638584989022370922" xlink:to="us-gaap_EquityComponentDomain_638584989022370922" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638584989022370922" xlink:to="us-gaap_StatementLineItems_638584989022370922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638584989022370922" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_StockholdersEquity_638584989022370922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638584989022370922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_SharesIssued_638584989022370922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638584989022381084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_638584989022381084" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638584989022381084" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638584989022381084" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638584989022381084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638584989022381084" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638584989022381084" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638584989022381084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638584989022381084" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638584989022381084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_StockholdersEquity_638584989022381084" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638584989022390837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638584989022370922" xlink:to="us-gaap_SharesIssued_638584989022390837" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitParenthetical" xlink:type="extended" xlink:title="995200405 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022390837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022390837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638584989022390837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638584989022390837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638584989022390837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638584989022390837" xlink:to="us-gaap_ProfitLoss_638584989022390837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638584989022390837" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638584989022400898" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638584989022400898" xlink:to="us-gaap_ShareBasedCompensation_638584989022400898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638584989022400898" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638584989022400898" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638584989022400898" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638584989022400898" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638584989022400898" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_638584989022400898" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638584989022400898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInInventories_638584989022400898" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638584989022400898" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IncreaseDecreaseRightOfUseAssets" xlink:label="rigl_IncreaseDecreaseRightOfUseAssets_638584989022400898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="rigl_IncreaseDecreaseRightOfUseAssets_638584989022400898" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638584989022410785" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638584989022410785" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability" xlink:label="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability_638584989022410785" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RevenueReservesAndRefundLiability" xlink:label="rigl_RevenueReservesAndRefundLiability_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="rigl_RevenueReservesAndRefundLiability_638584989022410785" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_638584989022410785" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638584989022410785" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638584989022410785" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638584989022410785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638584989022400898" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638584989022410785" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989022421400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638584989022390837" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638584989022421400" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638584989022421400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638584989022421400" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638584989022421400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638584989022421400" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_638584989022421400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_638584989022421400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638584989022421400" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_638584989022421400" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638584989022421400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638584989022421400" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638584989022421400" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638584989022421400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638584989022421400" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638584989022421400" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989022421400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638584989022421400" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638584989022421400" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638584989022430892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638584989022430892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638584989022430892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638584989022430892" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638584989022430892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638584989022430892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638584989022430892" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638584989022430892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_638584989022430892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638584989022430892" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_638584989022430892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638584989022430892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638584989022430892" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638584989022430892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638584989022430892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638584989022430892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638584989022441245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638584989022441245" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6385849890224412451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6385849890224412451" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638584989022441245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638584989022441245" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638584989022441245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638584989022441245" xlink:to="us-gaap_InterestPaidNet_638584989022441245" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_IntangibleAssetsIncurredButNotYetPaid" xlink:label="rigl_IntangibleAssetsIncurredButNotYetPaid_638584989022441245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638584989022441245" xlink:to="rigl_IntangibleAssetsIncurredButNotYetPaid_638584989022441245" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_638584989022450802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_638584989022450802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995210201 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638584989022450802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638584989022450802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="995210301 - Disclosure - REVENUES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638584989022450802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638584989022450802" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract" xlink:type="extended" xlink:title="995210401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateCollaborationsDisclosureAbstract" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638584989022460868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CorporateCollaborationsDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638584989022460868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureInLicensingAndAcquisition" xlink:type="extended" xlink:title="995210501 - Disclosure - IN-LICENSING AND ACQUISITION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_638584989022460868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_638584989022460868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995210601 - Disclosure - STOCK-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638584989022460868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638584989022460868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponents" xlink:type="extended" xlink:title="995210701 - Disclosure - OTHER BALANCE SHEET COMPONENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638584989022460868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638584989022460868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments" xlink:type="extended" xlink:title="995210801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_638584989022471042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_638584989022471042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureFairValue" xlink:type="extended" xlink:title="995210901 - Disclosure - FAIR VALUE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638584989022471042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638584989022471042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebt" xlink:type="extended" xlink:title="995211001 - Disclosure - DEBT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638584989022471042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638584989022471042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995211101 - Disclosure - LEASES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_LeaseDisclosureTextBlock" xlink:label="rigl_LeaseDisclosureTextBlock_638584989022471042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rigl_LeaseDisclosureTextBlock_638584989022471042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock" xlink:label="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock_638584989022481191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock_638584989022481191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638584989022481191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638584989022481191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638584989022481191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638584989022481191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock" xlink:label="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_638584989022481191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock_638584989022481191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638584989022481191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638584989022481191" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99930203 - Disclosure - NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638584989022481191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638584989022481191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="99930303 - Disclosure - REVENUES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638584989022481191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638584989022481191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_638584989022490844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_638584989022490844" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DisaggregationOfRevenueByCustomerTableTextBlock" xlink:label="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_638584989022490844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="rigl_DisaggregationOfRevenueByCustomerTableTextBlock_638584989022490844" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionTables" xlink:type="extended" xlink:title="99930503 - Disclosure - IN-LICENSING AND ACQUISITION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_638584989022490844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_638584989022490844" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99930603 - Disclosure - STOCK-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022490844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022490844" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638584989022490844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022490844" xlink:to="us-gaap_AwardTypeAxis_638584989022490844" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638584989022490844" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022500811" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022500811" xlink:to="us-gaap_EmployeeStockOptionMember_638584989022500811" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022490844" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022500811" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022500811" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638584989022500811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022500811" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638584989022500811" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables" xlink:type="extended" xlink:title="99930703 - Disclosure - OTHER BALANCE SHEET COMPONENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_637489040313675745" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_637489040313675745" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638584989022500811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_637489040313675745" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638584989022500811" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638584989022500811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_637489040313675745" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638584989022500811" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" xlink:title="99930803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638584989022510806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638584989022510806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638584989022510806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_638584989022510806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_638584989022510806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_638584989022510806" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureFairValueTables" xlink:type="extended" xlink:title="99930903 - Disclosure - FAIR VALUE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638584989022510806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638584989022510806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="99931003 - Disclosure - DEBT (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637067339432329346" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_638584989022510806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637067339432329346" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_638584989022510806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_638584989022510806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637067339432329346" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_638584989022510806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="99931103 - Disclosure - LEASES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636915213672463198" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="us-gaap_LeaseCostTableTextBlock_638584989022521099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock_638584989022521099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_638584989022521099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915213672463198" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638584989022521099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638584989022521099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638584989022521099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638584989022521099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638584989022521099" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638584989022521099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638584989022521099" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638584989022521099" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638584989022521099" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638584989022531117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638584989022531117" xlink:to="us-gaap_EmployeeStockOptionMember_638584989022531117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638584989022531117" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638584989022531117" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638584989022521099" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638584989022531117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638584989022531117" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638584989022531117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - REVENUES - Disaggregated (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638584989022531117" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638584989022531117" xlink:to="srt_ProductOrServiceAxis_638584989022531117" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638584989022531117" xlink:to="srt_ProductsAndServicesDomain_638584989022531117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GrossProductMember" xlink:label="rigl_GrossProductMember_638584989022531117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022531117" xlink:to="rigl_GrossProductMember_638584989022531117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DiscountsAndAllowancesMember" xlink:label="rigl_DiscountsAndAllowancesMember_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022531117" xlink:to="rigl_DiscountsAndAllowancesMember_638584989022541207" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022531117" xlink:to="us-gaap_ProductMember_638584989022541207" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember" xlink:label="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022531117" xlink:to="rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_638584989022541207" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContractRevenuesFromCollaborationsMember" xlink:label="rigl_ContractRevenuesFromCollaborationsMember_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022531117" xlink:to="rigl_ContractRevenuesFromCollaborationsMember_638584989022541207" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022531117" xlink:to="us-gaap_GovernmentContractMember_638584989022541207" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638584989022531117" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638584989022541207" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638584989022541207" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638584989022541207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesActivityDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - REVENUES - Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_638584989022541207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_638584989022541207" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638584989022541207" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_638584989022551103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis_638584989022551103" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_638584989022551103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ChargebacksDiscountsAndFeesMember" xlink:label="rigl_ChargebacksDiscountsAndFeesMember_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_638584989022551103" xlink:to="rigl_ChargebacksDiscountsAndFeesMember_638584989022551103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GovernmentAndOtherRebatesMember" xlink:label="rigl_GovernmentAndOtherRebatesMember_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_638584989022551103" xlink:to="rigl_GovernmentAndOtherRebatesMember_638584989022551103" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain_638584989022551103" xlink:to="us-gaap_SalesReturnsAndAllowancesMember_638584989022551103" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638584989022541207" xlink:to="us-gaap_BalanceSheetLocationAxis_638584989022551103" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638584989022551103" xlink:to="us-gaap_BalanceSheetLocationDomain_638584989022551103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember" xlink:label="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638584989022551103" xlink:to="rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_638584989022551103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable_638584989022541207" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_638584989022551103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_638584989022551103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_638584989022551103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_638584989022551103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_638584989022561145" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SalesDiscountsAndAllowances" xlink:label="rigl_SalesDiscountsAndAllowances_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" xlink:to="rigl_SalesDiscountsAndAllowances_638584989022561145" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems_638584989022551103" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638584989022561145" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails" xlink:type="extended" xlink:title="99940303 - Disclosure - REVENUES - Percentage by Customer (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638584989022561145" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638584989022561145" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638584989022561145" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638584989022561145" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638584989022561145" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638584989022561145" xlink:to="us-gaap_SalesMember_638584989022561145" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638584989022561145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638584989022561145" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638584989022561145" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638584989022561145" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638584989022570861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638584989022570861" xlink:to="us-gaap_CustomerConcentrationRiskMember_638584989022570861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638584989022561145" xlink:to="srt_MajorCustomersAxis_638584989022570861" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638584989022570861" xlink:to="srt_NameOfMajorCustomerDomain_638584989022570861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MckessonSpecialtyCareDistributionCorporationMember" xlink:label="rigl_MckessonSpecialtyCareDistributionCorporationMember_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638584989022570861" xlink:to="rigl_MckessonSpecialtyCareDistributionCorporationMember_638584989022570861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CardinalHealthIncMember" xlink:label="rigl_CardinalHealthIncMember_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638584989022570861" xlink:to="rigl_CardinalHealthIncMember_638584989022570861" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CencoraIncMember" xlink:label="rigl_CencoraIncMember_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638584989022570861" xlink:to="rigl_CencoraIncMember_638584989022570861" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638584989022561145" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638584989022570861" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638584989022570861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638584989022570861" xlink:to="us-gaap_ConcentrationRiskPercentage1_638584989022570861" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateCollaborationsDisclosureAbstract" xlink:label="rigl_CorporateCollaborationsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CorporateCollaborationsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" xlink:to="srt_ProductOrServiceAxis_638584989022580837" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638584989022580837" xlink:to="srt_ProductsAndServicesDomain_638584989022580837" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FostamatinibMember" xlink:label="rigl_FostamatinibMember_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022580837" xlink:to="rigl_FostamatinibMember_638584989022580837" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_OcadusertibMember" xlink:label="rigl_OcadusertibMember_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022580837" xlink:to="rigl_OcadusertibMember_638584989022580837" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022580837" xlink:to="rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_638584989022580837" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CentralNervousSystemPenetrantIntellectualPropertyMember" xlink:label="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022580837" xlink:to="rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_638584989022580837" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022580837" xlink:to="us-gaap_RoyaltyMember_638584989022580837" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022580837" xlink:to="rigl_RezlidhiaMember_638584989022580837" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractMember" xlink:label="us-gaap_GovernmentContractMember_638584989022580837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022580837" xlink:to="us-gaap_GovernmentContractMember_638584989022580837" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" xlink:to="dei_LegalEntityAxis_638584989022591151" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638584989022591151" xlink:to="dei_EntityDomain_638584989022591151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GrifolsS.a.Member" xlink:label="rigl_GrifolsS.a.Member_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638584989022591151" xlink:to="rigl_GrifolsS.a.Member_638584989022591151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_KisseiPharmaceuticalCo.Ltd.Member" xlink:label="rigl_KisseiPharmaceuticalCo.Ltd.Member_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638584989022591151" xlink:to="rigl_KisseiPharmaceuticalCo.Ltd.Member_638584989022591151" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MedisonPharmaLtd.Member" xlink:label="rigl_MedisonPharmaLtd.Member_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638584989022591151" xlink:to="rigl_MedisonPharmaLtd.Member_638584989022591151" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_KnightTherapeuticsInternationalSaMember" xlink:label="rigl_KnightTherapeuticsInternationalSaMember_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638584989022591151" xlink:to="rigl_KnightTherapeuticsInternationalSaMember_638584989022591151" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638584989022591151" xlink:to="rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_638584989022591151" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember_638584989022591151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638584989022591151" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember_638584989022591151" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638584989022601144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" xlink:to="srt_RangeAxis_638584989022601144" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638584989022601144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638584989022601144" xlink:to="srt_RangeMember_638584989022601144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638584989022601144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638584989022601144" xlink:to="srt_MaximumMember_638584989022601144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis_638584989022601144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" xlink:to="rigl_AchievementOfMilestoneAxis_638584989022601144" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain_638584989022601144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneAxis_638584989022601144" xlink:to="rigl_AchievementOfMilestoneDomain_638584989022601144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedDevelopmentEventsMember" xlink:label="rigl_SpecifiedDevelopmentEventsMember_638584989022601144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_SpecifiedDevelopmentEventsMember_638584989022601144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedRegulatoryEventsMember" xlink:label="rigl_SpecifiedRegulatoryEventsMember_638584989022601144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_SpecifiedRegulatoryEventsMember_638584989022601144" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedProductLaunchEventsMember" xlink:label="rigl_SpecifiedProductLaunchEventsMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_SpecifiedProductLaunchEventsMember_638584989022610896" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_LicensedRightsMember" xlink:label="rigl_LicensedRightsMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_LicensedRightsMember_638584989022610896" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_638584989022610896" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_638584989022610896" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember" xlink:label="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_638584989022610896" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_SpecifiedCommercialMilestonesMember_638584989022610896" order="8" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember" xlink:label="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_638584989022610896" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditableAdvanceRoyaltyPaymentMember" xlink:label="rigl_CreditableAdvanceRoyaltyPaymentMember_638584989022610896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_CreditableAdvanceRoyaltyPaymentMember_638584989022610896" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember_638584989022621383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember_638584989022621383" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_638584989022621383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022601144" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_638584989022621383" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638584989022621383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" xlink:to="us-gaap_TypeOfArrangementAxis_638584989022621383" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638584989022621383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638584989022621383" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638584989022621383" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StrategicCollaborationAgreementWithMdaccMember" xlink:label="rigl_StrategicCollaborationAgreementWithMdaccMember_638584989022621383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638584989022621383" xlink:to="rigl_StrategicCollaborationAgreementWithMdaccMember_638584989022621383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_StrategicCollaborationAgreementWithConnectMember" xlink:label="rigl_StrategicCollaborationAgreementWithConnectMember_638584989022630807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638584989022621383" xlink:to="rigl_StrategicCollaborationAgreementWithConnectMember_638584989022630807" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_638584989022630807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638584989022621383" xlink:to="us-gaap_CollaborativeArrangementMember_638584989022630807" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AmendedLillyAgreementMember" xlink:label="rigl_AmendedLillyAgreementMember_638584989022630807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638584989022630807" xlink:to="rigl_AmendedLillyAgreementMember_638584989022630807" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CommercialAndLicenseAgreementMember" xlink:label="rigl_CommercialAndLicenseAgreementMember_638584989022630807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638584989022621383" xlink:to="rigl_CommercialAndLicenseAgreementMember_638584989022630807" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638584989022630807" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" xlink:to="srt_StatementScenarioAxis_638584989022630807" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638584989022640833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638584989022630807" xlink:to="srt_ScenarioUnspecifiedDomain_638584989022640833" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_MilestonePaymentsOnProductByProductBasisMember" xlink:label="rigl_MilestonePaymentsOnProductByProductBasisMember_638584989022640833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638584989022640833" xlink:to="rigl_MilestonePaymentsOnProductByProductBasisMember_638584989022640833" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638584989022580837" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ContingentPaymentsUnderAgreement" xlink:label="rigl_ContingentPaymentsUnderAgreement_638584989022640833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_ContingentPaymentsUnderAgreement_638584989022640833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentCostsCostSharingArrangementPercentage" xlink:label="rigl_DevelopmentCostsCostSharingArrangementPercentage_638584989022640833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_DevelopmentCostsCostSharingArrangementPercentage_638584989022640833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RightToOptOutOfAgreementNumberOfPeriods" xlink:label="rigl_RightToOptOutOfAgreementNumberOfPeriods_638584989022650821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_RightToOptOutOfAgreementNumberOfPeriods_638584989022650821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment_638584989022650821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_OtherCommitment_638584989022650821" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RightToOptBackInCoFundingTerm" xlink:label="rigl_RightToOptBackInCoFundingTerm_638584989022650821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_RightToOptBackInCoFundingTerm_638584989022650821" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementUpfrontFeeReceived" xlink:label="rigl_CollaborativeArrangementUpfrontFeeReceived_638584989022701129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_CollaborativeArrangementUpfrontFeeReceived_638584989022701129" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityAccrualComponentAmount" xlink:label="us-gaap_ProductLiabilityAccrualComponentAmount_638584989022701129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_ProductLiabilityAccrualComponentAmount_638584989022701129" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FinancingLiabilityInterestAccretionDiscountRate" xlink:label="rigl_FinancingLiabilityInterestAccretionDiscountRate_638584989022710877" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_FinancingLiabilityInterestAccretionDiscountRate_638584989022710877" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FinancingLiabilityIncludingInterestExpenseAccretion" xlink:label="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_638584989022710877" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_FinancingLiabilityIncludingInterestExpenseAccretion_638584989022710877" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense_638584989022710877" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_AccretionExpense_638584989022710877" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DueToCollaborationPartner" xlink:label="rigl_DueToCollaborationPartner_638584989022710877" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_DueToCollaborationPartner_638584989022710877" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PaymentOfCostShareToCollaborationPartner" xlink:label="rigl_PaymentOfCostShareToCollaborationPartner_638584989022710877" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_PaymentOfCostShareToCollaborationPartner_638584989022710877" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_638584989022721208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_638584989022721208" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementRevenueRecognized" xlink:label="rigl_CollaborativeArrangementRevenueRecognized_638584989022721208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_CollaborativeArrangementRevenueRecognized_638584989022721208" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_638584989022721208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_DeferredRevenue_638584989022721208" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638584989022721208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638584989022721208" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval" xlink:label="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval_638584989022721208" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval_638584989022721208" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborationTerm" xlink:label="rigl_CollaborationTerm_638584989022731115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_CollaborationTerm_638584989022731115" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators_638584989022731115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_ProceedsFromCollaborators_638584989022731115" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RoyaltyPaymentAsPercentageOfNetSales" xlink:label="rigl_RoyaltyPaymentAsPercentageOfNetSales_638584989022731115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_RoyaltyPaymentAsPercentageOfNetSales_638584989022731115" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638584989022731115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_AccountsReceivableNetCurrent_638584989022731115" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NumberOfAgreements" xlink:label="rigl_NumberOfAgreements_638584989022741123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_NumberOfAgreements_638584989022741123" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments_638584989022741123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="rigl_CollaborativeArrangementPotentialPayments_638584989022741123" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989022741123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989022741123" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638584989022741123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_AccountsPayableCurrent_638584989022741123" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638584989022741123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638584989022640833" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638584989022741123" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - IN-LICENSING AND ACQUISITION - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638584989022751123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2" xlink:to="us-gaap_AssetAcquisitionTable_638584989022751123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638584989022751123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022751123" xlink:to="us-gaap_AssetAcquisitionAxis_638584989022751123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638584989022751123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638584989022751123" xlink:to="us-gaap_AssetAcquisitionDomain_638584989022751123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BlueprintMedicinesCorporationMember" xlink:label="rigl_BlueprintMedicinesCorporationMember_638584989022751123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638584989022751123" xlink:to="rigl_BlueprintMedicinesCorporationMember_638584989022751123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638584989022751123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022751123" xlink:to="srt_ProductOrServiceAxis_638584989022751123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638584989022751123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638584989022751123" xlink:to="srt_ProductsAndServicesDomain_638584989022751123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_GavretoMember" xlink:label="rigl_GavretoMember_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022751123" xlink:to="rigl_GavretoMember_638584989022761112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RezlidhiaMember" xlink:label="rigl_RezlidhiaMember_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638584989022751123" xlink:to="rigl_RezlidhiaMember_638584989022761112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022751123" xlink:to="dei_LegalEntityAxis_638584989022761112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638584989022761112" xlink:to="dei_EntityDomain_638584989022761112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FormaTherapeuticsHoldingsIncMember" xlink:label="rigl_FormaTherapeuticsHoldingsIncMember_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638584989022761112" xlink:to="rigl_FormaTherapeuticsHoldingsIncMember_638584989022761112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneAxis" xlink:label="rigl_AchievementOfMilestoneAxis_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022751123" xlink:to="rigl_AchievementOfMilestoneAxis_638584989022761112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfMilestoneDomain" xlink:label="rigl_AchievementOfMilestoneDomain_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneAxis_638584989022761112" xlink:to="rigl_AchievementOfMilestoneDomain_638584989022761112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FirstCommercialSaleMember" xlink:label="rigl_FirstCommercialSaleMember_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022761112" xlink:to="rigl_FirstCommercialSaleMember_638584989022761112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FirstAnniversaryOfClosingDateMember" xlink:label="rigl_FirstAnniversaryOfClosingDateMember_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022761112" xlink:to="rigl_FirstAnniversaryOfClosingDateMember_638584989022761112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SpecifiedCommercialMilestonesMember" xlink:label="rigl_SpecifiedCommercialMilestonesMember_638584989022761112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022761112" xlink:to="rigl_SpecifiedCommercialMilestonesMember_638584989022761112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_RegulatoryMilestonesMember" xlink:label="rigl_RegulatoryMilestonesMember_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022761112" xlink:to="rigl_RegulatoryMilestonesMember_638584989022771511" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DevelopmentAndRegulatoryMilestonesMember" xlink:label="rigl_DevelopmentAndRegulatoryMilestonesMember_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022761112" xlink:to="rigl_DevelopmentAndRegulatoryMilestonesMember_638584989022771511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember" xlink:label="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022761112" xlink:to="rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_638584989022771511" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FdaApprovalAndFirstCommercialSaleOfProductMember" xlink:label="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_AchievementOfMilestoneDomain_638584989022761112" xlink:to="rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_638584989022771511" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022751123" xlink:to="srt_RangeAxis_638584989022771511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638584989022771511" xlink:to="srt_RangeMember_638584989022771511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638584989022771511" xlink:to="srt_MinimumMember_638584989022771511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638584989022771511" xlink:to="srt_MaximumMember_638584989022771511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638584989022771511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022751123" xlink:to="us-gaap_SubsequentEventTypeAxis_638584989022771511" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638584989022771511" xlink:to="us-gaap_SubsequentEventTypeDomain_638584989022781113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638584989022781113" xlink:to="us-gaap_SubsequentEventMember_638584989022781113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022751123" xlink:to="us-gaap_AssetAcquisitionLineItems_638584989022781113" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_638584989022781113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PotentialMilestonePaymentObligations" xlink:label="rigl_PotentialMilestonePaymentObligations_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="rigl_PotentialMilestonePaymentObligations_638584989022781113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_PotentialTieredRoyaltyPercentage" xlink:label="rigl_PotentialTieredRoyaltyPercentage_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="rigl_PotentialTieredRoyaltyPercentage_638584989022781113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_638584989022781113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638584989022781113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638584989022781113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AssetPurchaseAgreementDrugProductInventories" xlink:label="rigl_AssetPurchaseAgreementDrugProductInventories_638584989022791116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="rigl_AssetPurchaseAgreementDrugProductInventories_638584989022791116" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementUpfrontPayment" xlink:label="rigl_CollaborativeArrangementUpfrontPayment_638584989022791116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="rigl_CollaborativeArrangementUpfrontPayment_638584989022791116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CollaborativeArrangementPotentialPayments" xlink:label="rigl_CollaborativeArrangementPotentialPayments_638584989022791116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="rigl_CollaborativeArrangementPotentialPayments_638584989022791116" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638584989022791116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638584989022791116" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989022791116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022781113" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638584989022791116" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3" xlink:to="us-gaap_AssetAcquisitionTable_638584989022801233" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022801233" xlink:to="us-gaap_AssetAcquisitionAxis_638584989022801233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638584989022801233" xlink:to="us-gaap_AssetAcquisitionDomain_638584989022801233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_BlueprintMedicinesCorporationMember" xlink:label="rigl_BlueprintMedicinesCorporationMember_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638584989022801233" xlink:to="rigl_BlueprintMedicinesCorporationMember_638584989022801233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638584989022801233" xlink:to="us-gaap_AssetAcquisitionLineItems_638584989022801233" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022801233" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638584989022801233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022801233" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638584989022801233" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638584989022801233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638584989022801233" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638584989022801233" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - STOCK-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638584989022811247" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638584989022811247" xlink:to="us-gaap_IncomeStatementLocationAxis_638584989022811247" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638584989022811247" xlink:to="us-gaap_IncomeStatementLocationDomain_638584989022811247" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638584989022811247" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638584989022811247" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638584989022811247" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638584989022811247" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638584989022811247" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638584989022811247" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638584989022811247" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638584989022811247" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635972700703720791" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022811247" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635972700703720791" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022811247" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022811247" xlink:to="us-gaap_AwardTypeAxis_638584989022821395" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022821395" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationOptionsAndRsusMember" xlink:label="rigl_ShareBasedCompensationOptionsAndRsusMember_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022821395" xlink:to="rigl_ShareBasedCompensationOptionsAndRsusMember_638584989022821395" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022821395" xlink:to="us-gaap_EmployeeStockOptionMember_638584989022821395" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022821395" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638584989022821395" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022811247" xlink:to="us-gaap_VestingAxis_638584989022821395" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638584989022821395" xlink:to="us-gaap_VestingDomain_638584989022821395" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638584989022821395" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022811247" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022821395" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638584989022821395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638584989022821395" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638584989022821395" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638584989022821395" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638584989022821395" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638584989022821395" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638584989022831125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638584989022831125" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638584989022831125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638584989022831125" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638584989022831125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638584989022831125" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638584989022831125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638584989022831125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638584989022831125" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638584989022831125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022821395" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022831125" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638584989022831125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022831125" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638584989022831125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638584989022841279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022831125" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638584989022841279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638584989022841279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022831125" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638584989022841279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638584989022841279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022831125" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638584989022841279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637779241883707043" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022841279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637779241883707043" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022841279" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638584989022841279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022841279" xlink:to="us-gaap_AwardTypeAxis_638584989022841279" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022841279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638584989022841279" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022841279" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638584989022841279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022841279" xlink:to="us-gaap_EmployeeStockOptionMember_638584989022841279" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022841279" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022851119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022851119" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022851119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022851119" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638584989022851119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022851119" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638584989022851119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022851119" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638584989022851119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022851119" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638584989022851119" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022851119" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022851119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638584989022851119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022851119" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638584989022851119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - STOCK-BASED COMPENSATION - Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022861142" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022861142" xlink:to="us-gaap_AwardTypeAxis_638584989022861142" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638584989022861142" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022861142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638584989022861142" xlink:to="us-gaap_EmployeeStockMember_638584989022861142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022861142" xlink:to="us-gaap_SubsequentEventTypeAxis_638584989022861142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638584989022861142" xlink:to="us-gaap_SubsequentEventTypeDomain_638584989022861142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638584989022861142" xlink:to="us-gaap_SubsequentEventMember_638584989022861142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638584989022861142" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022861142" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022861142" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod_638584989022861142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod_638584989022861142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_638584989022861142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod_638584989022861142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod" xlink:label="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod_638584989022871117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638584989022871117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638584989022871117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638584989022871117" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638584989022871117" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638584989022871117" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638584989022871117" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638584989022861142" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638584989022871117" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022871117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638584989022861142" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022871117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638584989022881221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022871117" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638584989022881221" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638584989022881221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022871117" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638584989022881221" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638584989022881221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022871117" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638584989022881221" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638584989022881221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638584989022871117" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638584989022881221" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638584989022881221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_InventoryRawMaterials_638584989022881221" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638584989022881221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_InventoryWorkInProcess_638584989022881221" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_InventoryFinishedGoods_638584989022891104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_638584989022891104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_638584989022891104" xlink:to="us-gaap_InventoryNet_638584989022891104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryReportedAsOtherAssets" xlink:label="rigl_InventoryReportedAsOtherAssets_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract_638584989022891104" xlink:to="rigl_InventoryReportedAsOtherAssets_638584989022891104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InventoryAndInventoryReportedAsOtherAssets" xlink:label="rigl_InventoryAndInventoryReportedAsOtherAssets_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="rigl_InventoryAndInventoryReportedAsOtherAssets_638584989022891104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AdvancesOnInventoryPurchases_638584989022891104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638584989022891104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638584989022891104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638584989022891104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638584989022891104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638584989022900800" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638584989022900800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638584989022900800" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638584989022900800" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638584989022900800" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638584989022900800" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638584989022900800" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638584989022900800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638584989022900800" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022911196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022911196" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638584989022911196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638584989022911196" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638584989022911196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638584989022911196" xlink:to="us-gaap_CashMember_638584989022911196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022911196" xlink:to="us-gaap_InvestmentTypeAxis_638584989022911196" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_638584989022911196" xlink:to="us-gaap_InvestmentTypeCategorizationMember_638584989022911196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022911196" xlink:to="us-gaap_MoneyMarketFundsMember_638584989022911196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022911196" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_638584989022911196" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022911196" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022911196" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022911196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022911196" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022911196" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638584989022921097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022911196" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638584989022921097" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989022921097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638584989022921097" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638584989022921097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_638584989022921097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638584989022921097" xlink:to="us-gaap_ShortTermInvestments_638584989022921097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638584989022921097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638584989022921097" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638584989022921097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495982422198217" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022921097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495982422198217" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022921097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638584989022921097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022921097" xlink:to="us-gaap_FinancialInstrumentAxis_638584989022921097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638584989022921097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638584989022921097" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638584989022921097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638584989022921097" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_638584989022931095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638584989022921097" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022931095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638584989022921097" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022931095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022921097" xlink:to="us-gaap_StatementEquityComponentsAxis_638584989022931095" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638584989022931095" xlink:to="us-gaap_EquityComponentDomain_638584989022931095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638584989022931095" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_638584989022931095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638584989022931095" xlink:to="rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_638584989022931095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022921097" xlink:to="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638584989022931095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638584989022931095" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638584989022931095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638584989022931095" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638584989022931095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638584989022931095" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_638584989022931095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638584989022931095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract_638584989022931095" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638584989022931095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495973119372251" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_635495973119372251" xlink:to="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022941124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022941124" xlink:to="us-gaap_InvestmentTypeAxis_638584989022941124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_638584989022941124" xlink:to="us-gaap_InvestmentTypeCategorizationMember_638584989022941124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022941124" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022941124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022941124" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022941124" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable_638584989022941124" xlink:to="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638584989022941124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems_638584989022941124" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod" xlink:label="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" xlink:to="rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod_638584989022941124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_638584989022941124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_638584989022941124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_InvestmentsCreditLossExpense" xlink:label="rigl_InvestmentsCreditLossExpense_638584989022941124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" xlink:to="rigl_InvestmentsCreditLossExpense_638584989022941124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_638584989022951112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_638584989022941124" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_638584989022951112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureFairValueDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - FAIR VALUE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638584989022951112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638584989022951112" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638584989022951112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638584989022951112" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638584989022951112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638584989022951112" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638584989022951112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638584989022951112" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638584989022951112" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638584989022951112" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638584989022951112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638584989022951112" xlink:to="us-gaap_FairValueInputsLevel1Member_638584989022951112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638584989022951112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638584989022951112" xlink:to="us-gaap_FairValueInputsLevel2Member_638584989022951112" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638584989022951112" xlink:to="us-gaap_InvestmentTypeAxis_638584989022961080" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_638584989022961080" xlink:to="us-gaap_InvestmentTypeCategorizationMember_638584989022961080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022961080" xlink:to="us-gaap_MoneyMarketFundsMember_638584989022961080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022961080" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_638584989022961080" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022961080" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638584989022961080" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CorporateBondSecuritiesAndCommercialPaperMember" xlink:label="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_638584989022961080" xlink:to="rigl_CorporateBondSecuritiesAndCommercialPaperMember_638584989022961080" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638584989022951112" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638584989022961080" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638584989022961080" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638584989022961080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638584989022961080" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638584989022961080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638584989022951112" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638584989022961080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638584989022961080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638584989022961080" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638584989022961080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - DEBT (Summary of Loans Payable) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638584989022971120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638584989022971120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638584989022971120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DeferredFinanceCostsNet_638584989022971120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts" xlink:label="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts_638584989022971120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts_638584989022971120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_638584989022971120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_638584989022971120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_638584989022971120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_638584989022971120" xlink:to="us-gaap_LoansPayableCurrent_638584989022971120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_638584989022971120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_638584989022971120" xlink:to="us-gaap_LongTermLoansPayable_638584989022971120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable_638584989022971120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract_638584989022971120" xlink:to="us-gaap_LoansPayable_638584989022971120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - DEBT (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637067369541427086" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637067369541427086" xlink:to="us-gaap_DebtInstrumentTable_638584989022981022" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638584989022981022" xlink:to="us-gaap_CreditFacilityAxis_638584989022981022" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638584989022981022" xlink:to="us-gaap_CreditFacilityDomain_638584989022981022" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638584989022981022" xlink:to="us-gaap_LineOfCreditMember_638584989022981022" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638584989022981022" xlink:to="us-gaap_DebtInstrumentAxis_638584989022981022" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638584989022981022" xlink:to="us-gaap_DebtInstrumentNameDomain_638584989022981022" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheOneMember" xlink:label="rigl_CreditAgreementTrancheOneMember_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638584989022981022" xlink:to="rigl_CreditAgreementTrancheOneMember_638584989022981022" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheTwoMember" xlink:label="rigl_CreditAgreementTrancheTwoMember_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638584989022981022" xlink:to="rigl_CreditAgreementTrancheTwoMember_638584989022981022" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheThreeMember" xlink:label="rigl_CreditAgreementTrancheThreeMember_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638584989022981022" xlink:to="rigl_CreditAgreementTrancheThreeMember_638584989022981022" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheFourMember" xlink:label="rigl_CreditAgreementTrancheFourMember_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638584989022981022" xlink:to="rigl_CreditAgreementTrancheFourMember_638584989022981022" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_CreditAgreementTrancheFiveMember" xlink:label="rigl_CreditAgreementTrancheFiveMember_638584989022981022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638584989022981022" xlink:to="rigl_CreditAgreementTrancheFiveMember_638584989022981022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638584989022990912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638584989022981022" xlink:to="us-gaap_VariableRateAxis_638584989022990912" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638584989022990912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638584989022990912" xlink:to="us-gaap_VariableRateDomain_638584989022990912" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638584989022990912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638584989022990912" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638584989022990912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638584989022990912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638584989022981022" xlink:to="srt_StatementScenarioAxis_638584989022990912" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638584989022990912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638584989022990912" xlink:to="srt_ScenarioUnspecifiedDomain_638584989022990912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FollowingThirdAmendmentMember" xlink:label="rigl_FollowingThirdAmendmentMember_638584989022990912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638584989022990912" xlink:to="rigl_FollowingThirdAmendmentMember_638584989022990912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FollowingFourthAmendmentMember" xlink:label="rigl_FollowingFourthAmendmentMember_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638584989022990912" xlink:to="rigl_FollowingFourthAmendmentMember_638584989023000855" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638584989022981022" xlink:to="us-gaap_DebtInstrumentLineItems_638584989023000855" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638584989023000855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638584989023000855" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_638584989023000855" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638584989023000855" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638584989023000855" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_638584989023000855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_638584989023000855" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_638584989023010957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_638584989023010957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638584989023010957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_InterestExpense_638584989023010957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_638584989023010957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638584989023000855" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_638584989023010957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - DEBT - Future Minimum Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637069051856462272" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_638584989023010957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637069051856462272" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_638584989023010957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638584989023010957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638584989023010957" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638584989023010957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638584989023010957" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638584989023020800" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638584989023010957" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638584989023020800" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract_638584989023010957" xlink:to="us-gaap_LongTermDebt_638584989023020800" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - LEASES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638584989023020800" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638584989023020800" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638584989023020800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638584989023020800" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638584989023020800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638584989023020800" xlink:to="us-gaap_BuildingMember_638584989023020800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember" xlink:label="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_638584989023020800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BuildingMember_638584989023020800" xlink:to="rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_638584989023020800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638584989023030845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638584989023020800" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638584989023030845" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract_638584989023030845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638584989023030845" xlink:to="rigl_SubleaseAgreementAbstract_638584989023030845" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638584989023030845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638584989023030845" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638584989023030845" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - LEASES - Lease Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636915211722771774" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638584989023030845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915211722771774" xlink:to="us-gaap_OperatingLeaseCost_638584989023030845" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638584989023030845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915211722771774" xlink:to="us-gaap_VariableLeaseCost_638584989023030845" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_VariableLeaseExpenseNetCredit" xlink:label="rigl_VariableLeaseExpenseNetCredit_638584989023030845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915211722771774" xlink:to="rigl_VariableLeaseExpenseNetCredit_638584989023030845" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638584989023030845" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915211722771774" xlink:to="us-gaap_LeaseCost_638584989023030845" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - LEASES - Cash Flow Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636915251773897105" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638584989023040926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636915251773897105" xlink:to="us-gaap_OperatingLeasePayments_638584989023040926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - LEASES - Sublease Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637073416785770995" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_SubleaseAgreementAbstract" xlink:label="rigl_SubleaseAgreementAbstract_638584989023040926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637073416785770995" xlink:to="rigl_SubleaseAgreementAbstract_638584989023040926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_FixedSubleaseExpense" xlink:label="rigl_FixedSubleaseExpense_638584989023040926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638584989023040926" xlink:to="rigl_FixedSubleaseExpense_638584989023040926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_VariableSubleaseExpense" xlink:label="rigl_VariableSubleaseExpense_638584989023040926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638584989023040926" xlink:to="rigl_VariableSubleaseExpense_638584989023040926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_638584989023040926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638584989023040926" xlink:to="us-gaap_SubleaseIncome_638584989023040926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rigl-20240630.xsd#rigl_NetSubleaseIncomeExpense" xlink:label="rigl_NetSubleaseIncomeExpense_638584989023040926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rigl_SubleaseAgreementAbstract_638584989023040926" xlink:to="rigl_NetSubleaseIncomeExpense_638584989023040926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - LEASES - Future Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637073417401946655" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638584989023050796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637073417401946655" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638584989023050796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638584989023050796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638584989023050796" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638584989023050796" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638584989023050796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638584989023050796" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638584989023050796" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638584989023050796" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638584989023050796" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638584989023050796" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699743779792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>DOCUMENT AND ENTITY INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-29889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RIGEL PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3248524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Boulevard, Suite 900,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">624-1100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RIGL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001034842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,594,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699738043600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,053<span></span>
</td>
<td class="nump">$ 32,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">13,049<span></span>
</td>
<td class="nump">24,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">28,904<span></span>
</td>
<td class="nump">30,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,059<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">8,658<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">94,723<span></span>
</td>
<td class="nump">99,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">28,275<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,735<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">128,408<span></span>
</td>
<td class="nump">117,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,373<span></span>
</td>
<td class="nump">8,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AccruedResearchAndDevelopmentLiabilityCurrent', window );">Accrued research and development</a></td>
<td class="nump">4,672<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Acquisition-related liabilities</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Revenue reserves and refund liability</a></td>
<td class="nump">18,547<span></span>
</td>
<td class="nump">15,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, net, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">5,933<span></span>
</td>
<td class="nump">5,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other long-term liabilities, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,642<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">58,649<span></span>
</td>
<td class="nump">53,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Long-term portion of loans payable, net</a></td>
<td class="nump">59,692<span></span>
</td>
<td class="nump">52,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">39,981<span></span>
</td>
<td class="nump">39,944<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">158,322<span></span>
</td>
<td class="nump">145,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,386,905<span></span>
</td>
<td class="nump">1,378,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,416,827)<span></span>
</td>
<td class="num">(1,407,550)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(29,914)<span></span>
</td>
<td class="num">(28,644)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 128,408<span></span>
</td>
<td class="nump">$ 117,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AccruedResearchAndDevelopmentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AccruedResearchAndDevelopmentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828771920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical)<br></strong></div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699736384224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 36,841<span></span>
</td>
<td class="nump">$ 26,886<span></span>
</td>
<td class="nump">$ 66,375<span></span>
</td>
<td class="nump">$ 52,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">2,807<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">5,540<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">11,566<span></span>
</td>
<td class="nump">14,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">28,047<span></span>
</td>
<td class="nump">26,306<span></span>
</td>
<td class="nump">56,496<span></span>
</td>
<td class="nump">54,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">36,394<span></span>
</td>
<td class="nump">32,153<span></span>
</td>
<td class="nump">72,894<span></span>
</td>
<td class="nump">70,948<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">447<span></span>
</td>
<td class="num">(5,267)<span></span>
</td>
<td class="num">(6,519)<span></span>
</td>
<td class="num">(17,992)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,029)<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="num">(3,066)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,030)<span></span>
</td>
<td class="num">$ (6,600)<span></span>
</td>
<td class="num">$ (9,277)<span></span>
</td>
<td class="num">$ (20,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">17,549<span></span>
</td>
<td class="nump">17,356<span></span>
</td>
<td class="nump">17,534<span></span>
</td>
<td class="nump">17,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">17,549<span></span>
</td>
<td class="nump">17,356<span></span>
</td>
<td class="nump">17,534<span></span>
</td>
<td class="nump">17,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 33,450<span></span>
</td>
<td class="nump">$ 23,881<span></span>
</td>
<td class="nump">$ 59,453<span></span>
</td>
<td class="nump">$ 47,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember', window );">Revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,391<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">$ 6,922<span></span>
</td>
<td class="nump">4,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828771920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)<br></strong></div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED STATEMENTS OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699736307440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (1,030)<span></span>
</td>
<td class="num">$ (6,600)<span></span>
</td>
<td class="num">$ (9,277)<span></span>
</td>
<td class="num">$ (20,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized (loss) gain on short-term investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (1,034)<span></span>
</td>
<td class="num">$ (6,598)<span></span>
</td>
<td class="num">$ (9,294)<span></span>
</td>
<td class="num">$ (20,008)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699739446032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 1,368,979<span></span>
</td>
<td class="num">$ (153)<span></span>
</td>
<td class="num">$ (1,382,459)<span></span>
</td>
<td class="num">$ (13,616)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">17,339,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,536)<span></span>
</td>
<td class="num">(13,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net change in unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">26,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,371,748<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(1,395,995)<span></span>
</td>
<td class="num">(24,257)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">17,366,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,368,979<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(1,382,459)<span></span>
</td>
<td class="num">(13,616)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">17,339,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net change in unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,374,488<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(1,402,595)<span></span>
</td>
<td class="num">(28,115)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">17,435,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,371,748<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(1,395,995)<span></span>
</td>
<td class="num">(24,257)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">17,366,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,600)<span></span>
</td>
<td class="num">(6,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net change in unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">52,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">16,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,374,488<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(1,402,595)<span></span>
</td>
<td class="num">(28,115)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">17,435,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,378,881<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(1,407,550)<span></span>
</td>
<td class="num">(28,644)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">17,482,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,247)<span></span>
</td>
<td class="num">(8,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net change in unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">9,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">48,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,144<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,384,114<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1,415,797)<span></span>
</td>
<td class="num">(31,671)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">17,540,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,378,881<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(1,407,550)<span></span>
</td>
<td class="num">(28,644)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">17,482,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net change in unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,386,905<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(1,416,827)<span></span>
</td>
<td class="num">(29,914)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">17,594,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">1,384,114<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1,415,797)<span></span>
</td>
<td class="num">(31,671)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">17,540,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net change in unrealized gain (loss) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">36,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 1,386,905<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (1,416,827)<span></span>
</td>
<td class="num">$ (29,914)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">17,594,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735862816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)<br></strong></div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699739647520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (9,277)<span></span>
</td>
<td class="num">$ (20,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,662<span></span>
</td>
<td class="nump">4,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale and disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization of discount on short-term investments and term loans</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">1,646<span></span>
</td>
<td class="nump">19,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(4,505)<span></span>
</td>
<td class="num">(1,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current and non-current assets</a></td>
<td class="num">(2,088)<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_IncreaseDecreaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,012)<span></span>
</td>
<td class="num">(2,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(2,303)<span></span>
</td>
<td class="num">(2,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability', window );">Accrued research and development</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="num">(1,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_RevenueReservesAndRefundLiability', window );">Revenue reserves and refund liability</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">532<span></span>
</td>
<td class="num">(1,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(4,711)<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">26,950<span></span>
</td>
<td class="nump">27,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(15,348)<span></span>
</td>
<td class="num">(8,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for acquisition of intangible assets</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">11,242<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Net proceeds from term loan financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from issuances of common stock upon exercise of options</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PaymentOfCostShareToCollaborationPartner', window );">Cost share payments to a collaboration partner</a></td>
<td class="num">(3,605)<span></span>
</td>
<td class="num">(1,754)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(3,264)<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">3,267<span></span>
</td>
<td class="nump">24,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">32,786<span></span>
</td>
<td class="nump">24,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">36,053<span></span>
</td>
<td class="nump">48,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">3,457<span></span>
</td>
<td class="nump">$ 2,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_IntangibleAssetsIncurredButNotYetPaid', window );">Intangible assets included within acquisition-related liabilities</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_IncreaseDecreaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase or decrease in right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_IncreaseDecreaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_IntangibleAssetsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of intangible assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_IntangibleAssetsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_PaymentOfCostShareToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of cost share to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_PaymentOfCostShareToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_RevenueReservesAndRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_RevenueReservesAndRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735135136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Organization and Summary of Significant Accounting Policies</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">TAVALISSE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (fostamatinib disodium hexahydrate) is our first product approved by the US Food and Drug Administration (FDA). TAVALISSE is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">REZLIDHIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;&#160;</sup><span style="color:#222222;background:#ffffff;">(olutasidenib) is o</span>ur second FDA-approved product. REZLIDHIA capsules are indicated <span style="color:#222222;background:#ffffff;">for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. W</span>e in-licensed REZLIDHIA<span style="color:#222222;background:#ffffff;"> </span>from Forma Therapeutics, Inc., now Novo Nordisk (Forma), with exclusive, worldwide rights for its development, manufacturing and commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">GAVRETO</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;"> (pralsetinib) is our third FDA-approved product which we began commercializing on June 27, 2024. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild-type rearranged during transfection (RET) and oncogenic RET fusions. GAVRETO is approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. GAVRETO is also approved under accelerated approval based on overall response rate and duration response rate, for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). We acquired the rights to research, develop, manufacture and commercialize GAVRETO in the US from Blueprint Medicines Corporation (Blueprint) pursuant to an Asset Purchase Agreement entered in February 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">We continue to advance the development of R289, our interleukin receptor-associated kinases 1 and 4 (IRAK 1/4) </span><span style="font-size:10pt;">inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk </span><span style="color:#222222;font-size:10pt;background:#ffffff;">myelodysplastic syndrome (MDS)</span><span style="font-size:10pt;"> who are relapsed, refractory or resistant to prior therapies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">We have strategic development collaborations with the University of Texas MD Anderson Cancer Center (MDACC) to expand our evaluation of REZLIDHIA in AML and other hematologic cancers with IDH1 mutations, and with Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in combination with temozolomide in patients with high-grade glioma (HGG) harboring an IDH1 mutation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with our partner Eli Lilly and Company (Lilly). We also have product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">We filed with the Secretary of State of the State of Delaware a certificate of amendment to our Amended and Restated Certificate of Incorporation, to effect a </span><span style="-sec-ix-hidden:Hidden_nJcNMH1G4kyCDx--KfxI4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-10</span></span><span style="font-size:10pt;"> reverse stock split, effective June 27, 2024. As a result of the reverse stock split, every ten issued and outstanding shares of our common stock were automatically combined into one issued and outstanding share of common stock. Accordingly, an amount equal to the par value of the decreased shares </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">resulting from the reverse stock split was reclassified from common stock to additional paid-in capital on the condensed balance sheet and statement of changes in stockholders&#8217; deficit. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock were entitled to receive the cash value </span><span style="font-size:10pt;background:#ffffff;">equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the common stock as reported by Nasdaq on the last trading day prior to the effective date of the split. </span><span style="font-size:10pt;">As a result of the reverse stock split, proportionate adjustments were made to the number of shares underlying (and as applicable, the exercise or conversion prices of) our outstanding equity awards and to the number of shares of common stock issuable under our equity incentive plans. The reverse stock split did not change the par value of our common stock, which remains </span><span style="font-size:10pt;">$0.001</span><span style="font-size:10pt;">, or the authorized number of shares of our common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2023 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Our significant accounting policies are described in &#8220;Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Financial Statements&#8221;&#160;contained in Part II, Item&#160;8, &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to these accounting policies except for the accounting consideration related to the Asset Purchase Agreement with Blueprint as discussed below in &#8220;Note 5 &#8211; In-licensing and Acquisition.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">As of June 30, 2024, we had approximately $49.1 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2023, FASB issued ASU 2023-07,&#160;<i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&#160;</i>This update expands public entities&#8217; segment disclosures, among others, requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss; an amount and description of its composition for other segment items; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;background:#ffffff;margin:0pt;">interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under this update are also required for public entities with a single reportable segment. This update is effective for our Annual Report on Form 10-K for the fiscal year ending December 31, 2024, and interim periods thereafter. Early adoption is permitted. The update should be applied retrospectively to all periods presented in the financial statements. We are currently evaluating the impact of adopting this update on our financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">In December 2023, FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i>, which enhance the annual disclosure requirements regarding the tax rate reconciliation and incomes taxes paid information. This update is effective for our fiscal year ending December 31, 2025, and maybe adopted on a prospective or retrospective basis. Early adoption is permitted. We are currently assessing the impact of adopting this guidance but does not expect to have a significant impact to our financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">Other recently issued accounting guidance not discussed in this Quarterly Report on Form 10-Q are either not applicable or did not have, or are not expected to have, a material impact on us.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699736033376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Net Loss Per Share</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period and the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Potentially dilutive securities include stock options, RSUs and shares issuable under our Employee Stock Purchase Plan (Purchase Plan). The dilutive effect of these potentially dilutive securities is reflected in diluted earnings per share using the treasury stock method. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The potential shares of common stock that were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,691 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,524 </p></td><td style="vertical-align:bottom;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,691 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,524 </p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">388 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">196 </p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">388 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">196 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,079 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,720 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,079 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,720 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735901824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Revenues</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:7pt 0pt 9pt 0pt;">Revenues disaggregated by category were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales:</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross product sales</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">48,980 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">33,456 </p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">87,406 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">66,654 </p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discounts and allowances</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(15,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,575)</p></td><td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27,953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(19,028)</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total product sales, net</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,881</p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,626</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from collaborations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Delivery of drug supplies, royalty and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,391 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,005 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,922 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,330 </p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues from collaborations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,330</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contracts</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,956</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Revenue from product sales are related to sales of our commercial products to our specialty distributors. For detailed discussions of our revenues from collaborations and government contracts, see &#8220;Note 4 &#8211; Sponsored Research, License Agreements and Government Contracts.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. Of the total discounts and allowances from gross product sales for the six months ended June 30, 2024 and 2023, $27.6 million and $18.6 million, respectively, was accounted for as additions to revenue reserves and refund liability, and $0.4 million and $0.4 million, respectively, as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet. The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,684</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,551</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,165)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,688)</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,547</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,145</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,559</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,020)</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,684</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">45%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cencora Inc. (formerly ASD Healthcare)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735140496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CorporateCollaborationsDisclosureAbstract', window );"><strong>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Sponsored Research, License Agreements and Government Contracts</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Research and License Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We conduct research and development programs independently and in connection with our corporate collaborators. As of June 30, 2024, we are a party to collaboration agreements with Lilly to develop and commercialize ocadusertib (previously R552), a RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases and collaboration aimed at developing additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases; with Grifols S.A. (Grifols) to commercialize fostamatinib for human diseases in all indications in Grifols territory which includes Europe, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States); with Kissei Pharmaceutical Co., Ltd. (Kissei) to develop and commercialize fostamatinib in Kissei territory which includes Japan, China, Taiwan and the Republic of Korea; with Medison Pharma Trading AG (Medison Canada) and Medison Pharma Ltd. (Medison Israel and, together with Medison Canada, Medison) to commercialize fostamatinib in all indications, in Medison territory which includes Canada and Israel; and with Knight Therapeutics International SA (Knight) to commercialize fostamatinib in all indications, in Knight territory which includes Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Further, we are also a party to collaboration agreements, but do not have ongoing performance obligations with BerGenBio for the development and commercialization of <span style="background:#ffffff;">AXL receptor tyrosine kinase (</span>AXL) inhibitors in oncology, and with Daiichi to pursue research related to <span style="background:#ffffff;">murine double minute 2&#160;(</span>MDM2) inhibitors, a novel class of drug targets called ligases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the above existing agreements that we entered into in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2024, total future contingent payments to us under all of the above existing agreements, excluding terminated agreements, could exceed $1.3 billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. Of this amount, $279.5&#160;million relates to the achievement of development events, $263.1 million relates to the achievement of regulatory events and $796.0&#160;million relates to the achievement of certain commercial events. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#8217; future efforts and achievements of specified development, regulatory and/or commercial events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We account for the milestone payments when such milestones are considered probable of being achieved, and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, and recorded as part of contract revenues from collaborations during the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"><i style="font-style:italic;">Global Exclusive License Agreement with Lilly </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We have a global exclusive license agreement and strategic collaboration with Lilly (Lilly Agreement) entered in February 2021, which became effective in March 2021, upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, to develop and commercialize ocadusertib (previously R552) for the treatment of non-CNS diseases. In addition, the collaboration is aimed at developing additional RIPK1 inhibitors for the treatment of CNS diseases. Pursuant to the terms of the Lilly Agreement, we granted Lilly the exclusive rights to develop and commercialize ocadusertib and related RIPK1 inhibitors in all indications worldwide. The parties&#8217; collaboration is governed through a joint governance committee and appropriate subcommittees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">Under the terms of the Lilly Agreement, we were entitled to receive a non-refundable and non-creditable upfront cash payment amounting to $125.0 million, which we received in April 2021. We are also entitled to additional milestone payments for non-CNS disease products consisting of up to $330.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $100.0 million in sales milestone payments on a product-by-product basis. In addition, depending on the extent of our co-funding of ocadusertib development activities, we would be entitled to receive tiered royalty payments on net sales of non-CNS disease products at percentages ranging from the mid-single digits to high-teens, subject to certain standard reductions and offsets. We are also eligible to receive milestone payments for CNS disease products consisting of up to $255.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $150.0 million in sales milestone payments on a product-by-product basis. We would be entitled to receive tiered royalty payments on net sales of CNS disease products up to low-double digits, subject to certain standard reductions and offsets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 0pt 0pt;">Under the Lilly Agreement, we were responsible for performing and funding initial discovery and identification of CNS disease development candidates. Following candidate selection, Lilly is responsible for performing and funding all future development and commercialization of the CNS disease development candidates. Under the Lilly Agreement, we are responsible for 20% of the development costs for ocadusertib in the US, Europe, and Japan, up to a specified cap, and Lilly is responsible for funding the remainder of all development activities for ocadusertib and other non-CNS disease development candidates. Pursuant to the terms of the Lilly Agreement, we have the right to opt-out of co-funding the ocadusertib development activities in the US, Europe and Japan at two different specified times and as a result receive lesser royalties from sales. Prior to us providing our first opt-out notice as discussed below, under the Lilly Agreement, we were required to fund our share of the ocadusertib development activities up to a maximum funding </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">commitment of $65.0 million through April 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license rights over the non-CNS penetrant intellectual property (IP), and (b) granting of the license rights over the CNS penetrant IP which will be delivered to Lilly upon completion of the additional research and development efforts specified in the agreement. We concluded that each of these performance obligations is distinct. We based our assessment on the assumption that Lilly can benefit from each of the licenses on its own by developing and commercializing the underlying product using its own resources. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">At the inception of the Lilly Agreement, given our rights to opt-out from the development of ocadusertib, we believed at the minimum, we had a commitment to fund the development costs up to $65.0 million as discussed above. We considered this commitment to fund the development costs as a significant financing component of the contract, which we accounted for as a reduction of the upfront fee to derive the transaction price. This financing component was recorded as a liability at its net present value of approximately $57.9 million using a 6.4% discount rate. Interest expense was accreted on such liability over the expected commitment period, adjusted for timing of expected cost share payments. No interest was accreted during the three and six months ended June 30, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At the inception, we allocated the net transaction price of $67.1&#160;million to each performance obligation based on our best estimate of its relative standalone selling price using the adjusted market assessment approach. The transaction price allocated to the non-CNS penetrant IP of $60.4 million was recognized as revenue upon delivery of the non-CNS penetrant IP to Lilly during the first quarter of 2021. The transaction price allocated to the CNS penetrant IP of $6.7 million was recognized as revenue from the effective date of the Lilly Agreement through the eventual acceptance by Lilly in June 2022 using the input method. There was no outstanding deferred revenue related to Lilly Agreement as of June 30, 2024 and December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"><span style="font-size:10pt;">On September 28, 2023, we entered into an amendment to the Lilly Agreement which provides, among others that if we exercise our first opt-out right, we have the right to opt-in to the co-funding of ocadusertib development, upon us providing notice to Lilly within </span><span style="font-size:10pt;">30 days</span><span style="font-size:10pt;"> of certain events as specified in the Lilly Agreement, and as a result receive greater royalties from sales. Following the amendment to the Lilly Agreement, on September 29, 2023, we provided the first opt-out notice to Lilly, and our share on the ocadusertib development cost was capped to </span><span style="font-size:10pt;">$22.6</span><span style="font-size:10pt;"> million through April 1, 2024. If we exercise our opt-in right, we will be required to continue to share in global development costs, and if we later exercise our second opt-out right (no later than April 1, 2025), our share in global development costs will be up to a specified cap through December 31, 2025, as provided for in the Lilly Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;">Lilly billed us $21.4 million for our share of development costs incurred through April 1, 2024, and the amount was fully paid as of June 30, 2024. The outstanding liability to Lilly reported within other long-term liabilities (current and non-current) in the condensed balance sheet as of June 30, 2024 and December 31, 2023 amounted to $40.0 million and $43.6 million, respectively. As discussed above, following the amendment to the Lilly Agreement, and us providing the first opt-out notice to Lilly, our cost share obligation for ocadusertib development ended on April 1, 2024. Although currently we are no longer obligated to pay Lilly for our share in the ocadusertib development cost incurred subsequent to April 1, 2024, the outstanding liability reported in our condensed balance sheet as of June 30, 2024 amounting to $40.0 million has not been recognized as revenue because we cannot conclude that it is probable that a significant reversal of the amount of revenue, if recognized, will not occur until the likelihood of us exercising our opt-in right becomes remote, or when the opt-in right period lapses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Grifols License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">We have an exclusive commercialization license agreement with Grifols entered in January 2019 with exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop fostamatinib in Grifols territory. Under the agreement, we received an upfront payment of $30.0 million, with the potential for $297.5 million in total regulatory and commercial milestones. We are also entitled to receive stepped double-digit royalty payments based on tiered net sales which may reach 30% of net sales. In January 2020, the European Commission (EC) granted a centralized Marketing Authorization (MA) for fostamatinib valid throughout the European Union (EU) and in the UK after the departure of the UK from the EU for the treatment of chronic ITP in adult patients who are refractory to other treatments. With this approval, in February 2020, we received $20.0 million non-refundable payment, composed of a $17.5 million payment due upon Marketing Authorization Application (MAA) approval by the European Medicines </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Agency (EMA) of fostamatinib for the first indication and a $2.5&#160;million creditable advance royalty payment, based on the terms of our collaboration agreement with Grifols. The above milestone payment was allocated to the distinct performance obligations in the collaboration agreement with Grifols. We accounted for this agreement under ASC 606 and identified distinct performance obligations at inception of the agreement. We allocated the transaction price to the distinct performance obligations in our collaboration agreement based on our best estimate of the relative standalone selling price, and recognized the corresponding revenue in the periods we satisfied the performance obligations. There was no outstanding deferred revenue related to the Grifols license agreement as of June 30, 2024 and December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We entered into a Commercial Supply Agreement with Grifols in October 2020 to supply and sell our drug product priced at a certain markup specified in the agreement, in quantities Grifols order from us pursuant to and in accordance with the agreement. Prior to the Commercial Supply Agreement, we had a Drug Product Purchase Agreement with Grifols entered in December 2019. There was no revenue recognized related to the delivery of drug supply to Grifols for the three and six months ended June 30, 2024. For the three and six month ended June 30, 2023, we recognized revenue of $1.2 million and $2.8 million, respectively, from the delivery of drug supply to Grifols. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We recognize royalty revenue from Grifols included within contract revenues from collaboration. Royalty revenue recognized for the three months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$1.1</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$0.8</span><span style="background:#ffffff;"> million, respectively, and for the six months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$2.2</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$1.5</span><span style="background:#ffffff;"> million, respectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Kissei License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have an exclusive license and supply agreement with Kissei entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#8217;s territory. Kissei is responsible for performing and funding all development activities for fostamatinib in the above-mentioned territories. We received an upfront cash payment of $33.0&#160;million, with the potential for up to an additional $147.0&#160;million in development, regulatory and commercial milestone payments, and will receive mid- to upper twenty percent, tiered, escalated net sales-based payments for the supply of fostamatinib. Under the agreement, we granted Kissei the license rights to fostamatinib in Kissei&#8217;s territory and are obligated to supply Kissei with drug product for use in clinical trials and pre-commercialization activities. We are also responsible for the manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement. We accounted for this agreement under ASC 606 and identified the distinct performance obligations at inception of the agreement. We concluded that each of these performance obligations is distinct. We determined that the upfront fee represented the transaction price and was allocated to the performance obligations based on our best estimate of the relative standalone selling price and recognized the corresponding revenue in the period we satisfied the performance obligations. As of June 30, 2024 and December 31, 2023, the remaining deferred revenue <span style="background:#ffffff;">was related to the material right associated with discounted fostamatinib supply which amounted to </span><span style="background:#ffffff;">$1.4</span><span style="background:#ffffff;">&#160;million</span>. No revenue was recognized during the three and six months ended June 30, 2024 and 2023 associated with the remaining performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">In April 2022, Kissei announced that an NDA was submitted to Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) for fostamatinib in chronic ITP. With this milestone event, we received&#160;</span><span style="font-size:10pt;">$5.0</span><span style="font-size:10pt;">&#160;million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, and such amount was recognized as revenue in the second quarter of 2022. In December 2022, Kissei announced that Japan&#8217;s PMDA approved the NDA for fostamatinib in chronic ITP. With this milestone event, we were entitled to receive </span><span style="font-size:10pt;">$20.0</span><span style="font-size:10pt;"> million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, which we recognized as revenue in the fourth quarter of </span><span style="-sec-ix-hidden:Hidden_HvqYF3vuKUK_Cbhmr3ItgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2022</span></span><span style="font-size:10pt;white-space:pre-wrap;">. The amount was subsequently collected in January 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">For the three and six months ended June 30, 2024, we recognized $2.2 million and $4.5 million, respectively, of revenue related to the delivery of drug supply to Kissei mainly for commercial use.&#160;No such revenue was recognized during the three and six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Medison Commercial and License Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"><span style="font-size:10pt;">We have </span><span style="font-size:10pt;">two</span><span style="font-size:10pt;"> exclusive commercial and license agreements with Medison entered in October 2019 for the commercialization of fostamatinib for chronic ITP in Medison territory, pursuant to which, we received a </span><span style="font-size:10pt;">$5.0</span><span style="font-size:10pt;"> million upfront payment with respect to the agreement in Canada. We accounted for this agreement under ASC 606 and identified the following combined performance obligations at inception of the agreement: (a) granting of the license and (b) obtaining regulatory approval in Canada of fostamatinib in ITP. However, under the agreement, we have the option to buy back all rights to the product in Canada within </span><span style="font-size:10pt;">six months</span><span style="font-size:10pt;"> from obtaining regulatory approval for the treatment of </span><span style="font-size:10pt;background:#ffffff;">auto immune hemolytic anemia</span><span style="font-size:10pt;"> in Canada. We determined that the non-refundable upfront fee represented the transaction price, however, due to the buyback provision, we accounted this upfront payment as financing arrangement under ASC 606. In 2022, management </span><span style="font-size:10pt;background:#ffffff;">concluded that the likelihood of exercising the buyback option right was remote considering the top-line results from our Phase 3 trial of fostamatinib in warm auto immune hemolytic anemia (wAIHA) which showed that the trial did not demonstrate statistical significance in the primary efficacy endpoint, and the guidance received from the FDA. As such, in accordance with ASC 606, we relieved the outstanding financing liability which included the upfront payment and accreted interest, and recognized such amount as revenue in 2022. </span><span style="font-size:10pt;">There was </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> outstanding deferred revenue related to Medison license agreement as of June 30, 2024 and December 31, 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">For the three and six months ended June 30, 2024, we recognized revenue from Medison of $0.1 million and $0.2<span style="white-space:pre-wrap;"> million, respectively, related to the delivery of drug supply and earned royalties. There was no material revenue  recognized in the three and six months ended June 30, 2023 related to the delivery of drug supply and earned royalties. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">Knight Commercial License and Supply Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We have commercial license and supply agreements with Knight entered in May 2022 for the commercialization of fostamatinib for approved indications in Knight territory. Pursuant to such commercial license agreement, we received a $2.0 million one-time, non-refundable, and non-creditable upfront payment, with potential for up to an additional $20.0 million in regulatory and sales-based commercial milestone payments, and will receive twenty- to mid-thirty percent, tiered, escalated net-sales based royalty payments for products sold in the Knight territory. We accounted for this agreement under ASC 606 and identified that the upfront payment was a consideration for granting Knight the license to commercialize fostamatinib for approved indication in the Knight territory, and no further material deliverables associated to such upfront payment. As such, we recognized the upfront payment as revenue in 2022. We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Contracts </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">US Department of Defense (DOD)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Government contract revenue for the three and six months ended June 30, 2023 of $1.0 million was from an award we received from DOD to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19. No revenue was recognized during the three and six months ended June 30, 2024 from this grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-size:10pt;font-style:italic;">Biomedical Advanced Research and Development (BARDA)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">In August 2023, we were awarded up to $0.8 million by BARDA, part of the Office of the Assistant Secretary for the Preparedness and Response at the US Department of Health and Human Services (DHHS), for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress. No revenue was recognized during the three and six months ended June 30, 2024 from this grant. Through June 30, 2024, we have received $0.1 million of the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Strategic Development Collaborations with MDACC and CONNECT</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In December 2023, we entered into a Strategic Collaboration Agreement with MDACC, a comprehensive cancer research, treatment, and prevention center. The collaboration will expand our evaluation of REZLIDHIA (olutasidenib) in AML and other hematologic cancers. Under the collaboration, we will provide MDACC the study materials and $15.0 million in time-based milestone payments as compensation for services to be provided for the </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">studies, over the </span><span style="font-size:10pt;">five-year</span><span style="font-size:10pt;"> collaboration term, unless terminated earlier as provided for in the agreement. Through June 30, 2024, we provided </span><span style="font-size:10pt;">$2.0</span><span style="font-size:10pt;"> million funding to MDACC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">In January 2024, we announced our collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in glioma. Under the collaboration, we will provide funding up to </span><span style="font-size:10pt;">$3.0</span><span style="font-size:10pt;"> million and study material over the </span><span style="font-size:10pt;">four-year</span><span style="font-size:10pt;"> collaboration. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We account for the funding we provide under the above research collaboration agreements as prepaid research and development in the balance sheet to the extent the payment is made in advance of services being rendered, and recognize such amount as research and development expense within the statements of operations as the collaborative partners render the services under the respective agreement.<span style="font-size:12pt;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CorporateCollaborationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Collaborations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CorporateCollaborationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828707424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-LICENSING AND ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>IN-LICENSING AND ACQUISITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">IN-LICENSING AND ACQUISITION</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">In-licensing and Acquisition </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Asset Purchase Agreement with Blueprint</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February 22, 2024, we acquired the US rights to research, develop, manufacture and commercialize GAVRETO (pralsetinib) from Blueprint pursuant to an Asset Purchase Agreement. The acquired assets <span style="background:#ffffff;">include, among other things, applicable intellectual property related to pralsetinib in the US, including patents, copyrights and trademarks, as well as clinical regulatory and commercial data and records.</span> Pursuant to the Asset Purchase Agreement, we agreed to pay a purchase price of $15.0 million, of which, $10.0 million was payable upon our first commercial sale of GAVRETO and an additional $5.0 million is payable on the first anniversary of the closing date of the agreement, subject to certain conditions. Blueprint is also eligible to receive up to $97.5 million in future commercial milestone payments and up to $5.0 million in future regulatory milestone payments. <span style="background:#ffffff;">The potential regulatory milestones include full regulatory approval of pralsetinib (or related compounds) for the treatment of adult RET-fusion positive thyroid cancer, and maintenance of the current regulatory approval of pralsetinib for the treatment of adult RET-fusion positive thyroid cancer during the period beginning on February 22, 2024 and ending on the third anniversary of the first commercial sale of pralsetinib subject to certain conditions.&#160;</span>Subject to the terms and conditions of the Asset Purchase Agreement, Blueprint would be entitled to tiered royalty payments on net sales of products containing pralsetinib (or related compounds) ranging from 10% to 30%, subject to certain reductions and offsets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with ASC 805 <i style="font-style:italic;">Business Combinations </i>(ASC 805)<i style="font-style:italic;">, </i>the transaction was accounted for as an asset acquisition, because substantially all of the fair value of the gross assets acquired is concentrated in a single asset, which is the GAVRETO product rights. The GAVRETO product rights comprised <span style="background:#ffffff;">developed technology, customers, trademarks and trade name, and are considered a single asset as they are inextricably linked. ASC 805 provides for a screen test, wherein if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the total purchase consideration in connection with the asset acquisition (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing purchase price</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000 </p></td></tr><tr><td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">360 </p></td></tr><tr><td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,360 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">The closing purchase price was recorded within acquisition-related liabilities in the condensed balance sheet and was outstanding as of June 30, 2024, of which, </span><span style="font-size:10pt;">$10.0</span><span style="font-size:10pt;"> million was paid in July 2024 following our first commercial sale of GAVRETO at the end of June 2024. The transaction costs have been paid in cash as of June 30, 2024. The contingent considerations relating to future commercial and regulatory milestones were not included in the total purchase price consideration, and will be accounted for when the contingency is resolved and the consideration becomes payable. Royalties will be recognized within cost of sales, as revenue from GAVRETO product sales is recognized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In an asset acquisition, the acquiring entity should recognize the assets acquired at cost to the acquiring entity which includes transaction costs and consideration given, allocated based on a relative fair value of the assets acquired measured at acquisition date. The fair value of the developed technology, customers, trademarks and trade name was </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;background:#ffffff;">estimated using a multi-period excess earnings income approach that discounts expected cash flows to present value by applying discount rate that represents the estimated rate that market participants would use to value such assets. The relative fair value are based on estimates that required judgement and certain assumptions, categorized as Level 3 in the fair value hierarchy. Since we acquired a single asset, the total purchase consideration was recorded as intangible assets. The related intangible </span><span style="font-size:10pt;">assets is being amortized on a straight-line basis over the estimated useful life of </span><span style="font-size:10pt;">12 years</span><span style="font-size:10pt;">, and the related </span><span style="font-size:10pt;background:#ffffff;">amortization is recorded within cost of sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Simultaneously and in connection with entering into the Asset Purchase Agreement, we also entered into certain supporting agreements, including a customary transition agreement, pursuant to which, during the transition period, Blueprint will transition regulatory and distribution responsibility for GAVRETO to us. We also agreed to purchase certain drug product inventories from Blueprint under a Material Transfer Agreement, and received such inventories amounting to approximately </span><span style="font-size:10pt;">$6.5</span><span style="font-size:10pt;"> million during the six months ended June 30, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License and Transition Services Agreement with Forma </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have a license and transition services agreement with Forma entered in July 2022, for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mutated IDH1 (mIDH1), for any uses worldwide, including for the treatment of AML and other malignancies. Forma became a wholly owned subsidiary of Novo Nordisk following the closing of its acquisition by Novo Nordisk in October 2022. Pursuant to the terms of the license and transition services agreement, we paid an upfront fee of $2.0 million, with the potential to pay up to $67.5 million of additional payments upon achievement of specified development and regulatory milestones and up to $165.5 million of additional payments upon achievement of certain commercial milestones. <span style="background:#ffffff;">In addition, subject to the terms and conditions of the license and transition services agreement, Forma would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portion of our sublicensing revenue, subject to certain standard reductions and offsets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The transaction was accounted for as an acquisition of asset under ASC 730, <i style="font-style:italic;">Research and Development</i>. In accordance with the guidance, in a transaction accounted for as an asset acquisition, any acquired IPR&amp;D that does not have alternative future use is charged to expense at the acquisition date. <span style="background:#ffffff;">At the acquisition date, the acquired license asset was accounted for as IPR&amp;D, and we anticipated no other economic benefit to be derived from such acquired licensed asset other than the primary indications. As such, we accounted for the upfront fee of </span><span style="background:#ffffff;">$2.0</span><span style="background:#ffffff;"> million </span>as IPR&amp;D and recorded such cost within research and development expense in the statements of operations in 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under the accounting guidance, we account for contingent <span style="background:#ffffff;">payments when a </span>contingency is resolved, and the consideration becomes payable.<span style="background:#ffffff;">&#160;We account for m</span>ilestone payment obligations incurred at development stage and prior to a regulatory approval of an indication associated with the acquired licensed asset as research and development expense when the event requiring payment of the milestone occurs. Milestone payment obligations incurred upon and after a regulatory approval of an indication associated with the acquired licensed asset, and at the commercial stage, are recorded as intangible assets when the event requiring payment of the milestones occurs. Prior to the FDA approval of REZLIDHIA in December 2022, a certain regulatory milestone was met which entitled Forma to receive a $2.5 million milestone payment. Because such milestone payment obligation was incurred prior to a regulatory approval of an indication associated with the acquired licensed asset, we recorded such amount as research and development expense in the fourth quarter of 2022. On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with susceptible IDH1 mutations as detected by an FDA-approved test. Following the FDA approval, we launched REZLIDHIA and made first shipments of the product to our customers in December 2022. With this FDA approval and first commercial sale of the product, Forma was entitled to receive a total of $15.0 million milestone payments. Since such milestone payment obligations were incurred upon and after regulatory approval of the product, we recorded such amount as intangible assets on our condensed balance sheet in the fourth quarter of 2022. No new milestone was met in 2023 and during the six months ended June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The amount recorded as intangible asset is being amortized on a straight-line basis over the estimated useful life of </span><span style="font-size:10pt;">14 years</span><span style="font-size:10pt;">, and the related </span><span style="font-size:10pt;background:#ffffff;">amortization is recorded within cost of sales</span><span style="font-size:10pt;">. Royalties are recognized within cost of sales, as revenue from REZLIDHIA product sales is recognized. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828764896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:10pt;font-weight:bold;">Stock-Based Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation for the periods presented was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,531</p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,172</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,930</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">During the six months ended June 30, 2024, we granted stock options to purchase </span><span style="font-size:10pt;">599,772</span><span style="font-size:10pt;"> shares of common stock with weighted-average grant-date fair value of </span><span style="font-size:10pt;">$9.64</span><span style="font-size:10pt;"> per share, and </span><span style="font-size:10pt;">9,294</span><span style="font-size:10pt;"> stock options were exercised. </span><span style="font-size:10pt;">The stock options granted during the six months ended June 30, 2024 generally vest over </span><span style="font-size:10pt;">3 years</span><span style="font-size:10pt;">. As of June 30, 2024, there were </span><span style="font-size:10pt;">3,691,139</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">stock options outstanding, of which, </span><span style="font-size:10pt;">132,250</span><span style="font-size:10pt;"> are outstanding performance-based stock options wherein the achievement of the corresponding corporate-based milestones were assessed not probable as of June 30, 2024. Accordingly, none of the </span><span style="font-size:10pt;">$2.5</span><span style="font-size:10pt;"> million grant date fair value for these awards has been recognized as stock-based compensation expense as of June 30, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. The following table summarizes the weighted-average assumptions relating to options granted pursuant to our Equity Incentive Plans (our 2018 Equity Incentive Plan and Inducement Plan, as amended) for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">6.0</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">6.7</span></p></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">6.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">7.0</span></p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">88.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">87.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">During the six months ended June 30, 2024, we granted </span><span style="font-size:10pt;">291,373</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;background:#ffffff;">RSUs </span><span style="font-size:10pt;">with a grant-date weighted-average fair value of </span><span style="font-size:10pt;">$12.52</span><span style="font-size:10pt;"> per share, and </span><span style="font-size:10pt;">66,408</span><span style="font-size:10pt;"> RSUs were released. The RSUs granted during the six months ended June 30, 2024 generally vest over </span><span style="font-size:10pt;">3 years</span><span style="font-size:10pt;">. As of June 30, 2024, there were </span><span style="font-size:10pt;">387,729</span><span style="font-size:10pt;"> RSUs outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">As of June 30, 2024, there was approximately </span><span style="font-size:10pt;">$14.0</span><span style="font-size:10pt;"> million </span><span style="font-size:10pt;">of unrecognized stock-based compensation cost which is expected to be recognized over a remaining weighted-average period of </span><span style="-sec-ix-hidden:Hidden_BSYq7x4JLEq-_Jg2cZgicA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.15</span></span><span style="font-size:10pt;"> years, related to time-based stock options, performance-based stock options wherein achievement of the corresponding corporate-based milestones was considered as probable, and RSUs. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In March 2024 and April 2024, our Board of Directors approved additional 78,232 shares of common stock reserved for issuance under our Inducement Plan. In May 2024, our stockholders approved an amendment to our 2018 Plan, to, among other items, add an additional&#160;650,000&#160;shares&#160;to the number of shares of common stock authorized for issuance under our 2018 Plan.&#160;As of June 30, 2024, there were 1,412,669 shares of common stock available for future grant under our Equity Incentive Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">Our Purchase Plan provides for a </span><span style="-sec-ix-hidden:Hidden_tLN0a4X5JU2Cq3R9ffzyHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period comprises </span><span style="font-size:10pt;">four</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">six-month</span><span style="font-size:10pt;"> purchase periods with a look-back option. A look-back option is a provision in our Purchase Plan under which eligible employees can purchase shares of our common stock at a price per share equal to the lesser of </span><span style="font-size:10pt;">85%</span><span style="font-size:10pt;"> of the fair market value on the first day of the offering period or </span><span style="font-size:10pt;">85%</span><span style="font-size:10pt;"> of the fair market value on the purchase date. </span><span style="font-size:10pt;">Our Purchase Plan also includes a feature that provides for a new offering period to begin when the fair market value of our common stock on any purchase date during an offering period falls below the fair market value of our common stock on the first day of such offering period. This feature is called a &#8220;reset.&#8221; Participants are automatically enrolled in the new offering period. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">Our </span><span style="-sec-ix-hidden:Hidden_U2j5tAbzr0-MSQXB1Kv0GQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period under our Purchase Plan ended on June 30, 2024, and a new </span><span style="-sec-ix-hidden:Hidden_zN5HkjsdLkqRRzBvM8xfWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24</span></span><span style="font-size:10pt;">-month offering period started on July 1, 2024. </span><span style="font-size:10pt;">The fair value of awards under our Purchase Plan is estimated on the date of our new offering period using the Black-Scholes option pricing model, which is being amortized over the requisite service periods. </span><span style="font-size:10pt;">As of June 30, 2024, there was </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> unrecognized stock-based compensation cost related to our Purchase Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the six months ended June 30, 2024, there were 35,902 shares purchased under the Purchase Plan. As of June 30, 2024, there were 213,681 shares reserved for future issuance under the Purchase Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828765632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>OTHER BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">OTHER BALANCE SHEET COMPONENTS</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Other Balance Sheet Components</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Inventories for the periods presented consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.71%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,145 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,609 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,006 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,876 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,368 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,508 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,519 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,993 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,522</p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,471</p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,519 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,993 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Inventories as of June 30, 2024 and December 31, 2023 include inventories acquired from Forma pursuant to the license and transition services agreement.</span><span style="font-size:10pt;"> Inventories as of June 30, 2024 also include inventories acquired from Blueprint pursuant to a Material Transfer Agreement as discussed in Note 5 &#8211; In-licensing and Acquisition. As of June 30, 2024, advance payments to the manufacturer of our raw materials were included within prepaid and other current assets in the condensed balance sheet</span><span style="font-size:10pt;"> amounted to </span><span style="font-size:10pt;">$2.2</span><span style="font-size:10pt;"> million. </span><span style="font-size:10pt;">No</span><span style="font-size:10pt;"> such advance payment was included within prepaid and other current assets as of December 31, 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Non-current inventories consist primarily of active pharmaceutical ingredients classified as raw materials which have multi-year shelf life, as well as certain work in process and finished goods inventories that are not expected to be consumed beyond our normal operating cycle. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Intangible assets consist of the following (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.62%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,360 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000</p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,085)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,122)</p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,275 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,878</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">See &#8220;Note 5 &#8211; In-licensing and Acquisition&#8221; for related discussions of capitalized intangible assets. Amortization expense recorded within cost of sales in the statements of operations for the three months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$0.6</span><span style="background:#ffffff;">&#160;million and </span><span style="background:#ffffff;">$0.3</span><span style="background:#ffffff;">&#160;million, respectively, and for the six months ended June 30, 2024 and 2023 was </span><span style="background:#ffffff;">$1.0</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$0.5</span><span style="background:#ffffff;"> million, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The following table presents the estimated future amortization expense of intangible assets as of June 30, 2024 (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.69%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,176 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,695 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,275 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735862560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span><b style="font-weight:bold;">Cash, Cash Equivalents and Short-Term Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,126 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,247</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,805 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,444 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,764 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49,102 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,933</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,053 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,786</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,049 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,147</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49,102 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">56,933 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:10pt;">As of June 30, 2024 and December 31, 2023, our cash equivalents and short-term investments had a weighted-average time to maturity of approximately </span><span style="font-size:10pt;">68 days</span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">82 days</span><span style="font-size:10pt;">, respectively. </span><span style="font-size:10pt;background:#ffffff;">Our short-term investments are classified as available-for-sale securities. Accordingly, we have classified these securities as short-term investments on our condensed balance sheets as they are available for use in the current operations. </span><span style="font-size:10pt;">As of </span><span style="font-size:10pt;">June 30, 2024, we had </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> investments that had been in a continuous unrealized loss position for more than 12 months. As of June 30, 2024, a total of </span><span style="font-size:10pt;">26</span><span style="font-size:10pt;"> individual securities had been in an unrealized loss position for 12 months or less, and the losses were determined to be temporary. No significant facts or circumstances have arisen to indicate that there has been any significant </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">deterioration in the creditworthiness of the issuers of the securities held by us. Based on our review of these securities, including the assessment of the duration and severity of the unrealized losses, we have </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;">t recognized any credit losses on these securities as of June 30, 2024 and December 31, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699745174080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"><b style="font-size:10pt;font-weight:bold;">Fair Value</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,805</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,444</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,764</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,976</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,686</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828780128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span><b style="font-weight:bold;">Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">The following table summarizes loans payable, net (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (308)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (398)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal outstanding, net of unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,602</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans payable, net, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,229</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term portion of loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,373</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,602</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The outstanding loans payable as of the periods presented was related to our Credit and Security Agreement (Credit Agreement) with MidCap Financial Trust (MidCap) entered into on September 27, 2019 (Closing Date) and amended on March 29, 2021 (First Amendment), February 11, 2022 (Second Amendment), July 27, 2022 (Third Amendment), and on April 11, 2024 (Fourth Amendment).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Credit Agreement provides for a $60.0&#160;million term loan credit facility. At the Closing Date, $10.0 million was funded (Tranche 1), in May 2020, an additional $10.0 million was funded (Tranche 2), at the Second Amendment, an additional $10.0 million was funded (Tranche 3), at the Third Amendment, an additional $10.0 million was funded (Tranche 4), and in March 2023, an additional $20.0 million was funded (Tranche 5). As of June 30, 2024, the outstanding principal balance of the loan was $60.0 million, and no remaining funds are available for draw under the term loan credit facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The First Amendment to the Credit Agreement extended the period through which Tranche 3 was available to us. The Second Amendment to the Credit Agreement, among other things, amended the applicable funding conditions, applicable commitments and certain other terms relating to available credit facilities (Tranches 3 and 4), added additional term loan credit facility (Tranche 5), and revised certain terms related to the financial covenants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Following the Third Amendment but prior to the Fourth Amendment to the Credit Agreement in April 2024 as discussed below, the term loans would mature on September 1, 2026, and the interest-only period was through October 1, 2024. The term loans bore interest equal to </span><span style="font-size:10pt;background:#ffffff;">the sum of one-month </span><span style="font-size:10pt;">Secured Overnight Financing Rate (SOFR)</span><span style="font-size:10pt;background:#ffffff;">, plus an adjustment of </span><span style="font-size:10pt;background:#ffffff;">0.11448%</span><span style="font-size:10pt;background:#ffffff;">, subject to </span><span style="font-size:10pt;background:#ffffff;">1.50%</span><span style="font-size:10pt;background:#ffffff;"> applicable floor, plus applicable margin of&#160;</span><span style="font-size:10pt;background:#ffffff;">5.65%</span><span style="font-size:10pt;background:#ffffff;">, and a</span><span style="font-size:10pt;"> final payment fee of </span><span style="font-size:10pt;">2.5%</span><span style="font-size:10pt;"> of principal due at maturity date. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;background:#ffffff;">Following the Fourth Amendment to the Credit Agreement in April 2024, </span><span style="font-size:10pt;">the term loans mature on September 1, 2027, and the interest-only period is through October 1, 2025. The term loans bear interest equal to the sum of one-month </span><span style="font-size:10pt;">SOFR</span><span style="font-size:10pt;background:#ffffff;"> plus an adjustment of </span><span style="font-size:10pt;background:#ffffff;">0.11448%</span><span style="font-size:10pt;background:#ffffff;">, subject to a </span><span style="font-size:10pt;background:#ffffff;">4.00%</span><span style="font-size:10pt;background:#ffffff;"> applicable floor, plus applicable margin of&#160;</span><span style="font-size:10pt;background:#ffffff;">6.50%</span><span style="font-size:10pt;background:#ffffff;">. A final payment fee of </span><span style="font-size:10pt;">4.25%</span><span style="font-size:10pt;"> of principal is due at maturity date. The amendment was accounted for as debt modification in accordance with the standards. The unamortized debt issuance costs are continuously being amortized as interest expense through maturity using the effective interest rate method.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We </span>may make voluntary prepayments, in whole or in part, subject to certain prepayment premiums and additional interest payments. The Credit Agreement also contains certain provisions, such as event of default and change in control provisions, which, if triggered, would require us to make mandatory prepayments on the term loan, which are subject to certain prepayment premiums and additional interest payments. The obligations under the amended Credit Agreement are secured by a perfected security interest in all of our assets including our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Interest expense, including amortization of the debt discount and accretion of the final fees related to the Credit Agreement for the three months ended June 30, 2024 and 2023 was $2.0 million and $1.9 million, respectively, and for the six months ended June 30, 2024 and 2023 was $3.9 million and $3.1 million, respectively. Accrued interest of $1.8 million was included within other accrued liabilities in the condensed balance sheet as of June 30, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount (Tranches 1, 2, 3 and 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amended Credit Agreement contains certain covenants which, among others, require us to deliver financial reports at designated times of the year and maintain minimum unrestricted cash and trailing net revenues. As of June 30, 2024, we were not in violation of any covenants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735723056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_LeaseDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:10pt;background:#ffffff;">We have a sublease agreement with Atara Biotherapeutics, Inc. (Atara) entered in October 2022 to sublease an office space located in South San Francisco, California. Subject to the terms of the sublease agreement, the lease term commenced in November 2022 and shall expire in May 2025. This leased facility is currently held as our new Headquarters following the expiration of our previously leased facility in January 2023. </span><span style="font-size:10pt;">The weighted average remaining term of our leases as of June 30, 2024 was </span><span style="-sec-ix-hidden:Hidden_xfW9usukwk2f_jXEjoY-Ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.92</span></span><span style="font-size:10pt;"> years. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We previously leased our prior headquarter space located in South San Francisco, California with Healthpeak Properties, Inc. (formerly known as HCP BTC, LLC), and had a sublease agreement with an unrelated third-party to sublet a portion of the leased facility. Both leases expired in January 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The components of our operating lease expense were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 778</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable operating lease expense (net credit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Supplemental information related to our operating lease were as follow (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments included in the measurement of operating lease liabilities</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,174</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Supplemental information related to our operating sublease was as follow (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 365</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (442)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__uvDi--VAUGqtC3eWeIntA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_RyRJdE2X_E-Mg-mp9DscQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lQtRnSPQoE-Il8zeJ8WGew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_mnAsvI_5pkqF9r4khAkUlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future lease payments as of June 30, 2024 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:56.56%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum payments required</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828623280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,030)<span></span>
</td>
<td class="num">$ (6,600)<span></span>
</td>
<td class="num">$ (9,277)<span></span>
</td>
<td class="num">$ (20,136)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828658816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735910592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">We filed with the Secretary of State of the State of Delaware a certificate of amendment to our Amended and Restated Certificate of Incorporation, to effect a </span><span style="-sec-ix-hidden:Hidden_nJcNMH1G4kyCDx--KfxI4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-10</span></span><span style="font-size:10pt;"> reverse stock split, effective June 27, 2024. As a result of the reverse stock split, every ten issued and outstanding shares of our common stock were automatically combined into one issued and outstanding share of common stock. Accordingly, an amount equal to the par value of the decreased shares </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;">resulting from the reverse stock split was reclassified from common stock to additional paid-in capital on the condensed balance sheet and statement of changes in stockholders&#8217; deficit. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock were entitled to receive the cash value </span><span style="font-size:10pt;background:#ffffff;">equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the common stock as reported by Nasdaq on the last trading day prior to the effective date of the split. </span><span style="font-size:10pt;">As a result of the reverse stock split, proportionate adjustments were made to the number of shares underlying (and as applicable, the exercise or conversion prices of) our outstanding equity awards and to the number of shares of common stock issuable under our equity incentive plans. The reverse stock split did not change the par value of our common stock, which remains </span><span style="font-size:10pt;">$0.001</span><span style="font-size:10pt;">, or the authorized number of shares of our common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2023 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">As of June 30, 2024, we had approximately $49.1 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2023, FASB issued ASU 2023-07,&#160;<i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&#160;</i>This update expands public entities&#8217; segment disclosures, among others, requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss; an amount and description of its composition for other segment items; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;background:#ffffff;margin:0pt;">interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under this update are also required for public entities with a single reportable segment. This update is effective for our Annual Report on Form 10-K for the fiscal year ending December 31, 2024, and interim periods thereafter. Early adoption is permitted. The update should be applied retrospectively to all periods presented in the financial statements. We are currently evaluating the impact of adopting this update on our financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;">In December 2023, FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures</i>, which enhance the annual disclosure requirements regarding the tax rate reconciliation and incomes taxes paid information. This update is effective for our fiscal year ending December 31, 2025, and maybe adopted on a prospective or retrospective basis. Early adoption is permitted. We are currently assessing the impact of adopting this guidance but does not expect to have a significant impact to our financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;">Other recently issued accounting guidance not discussed in this Quarterly Report on Form 10-Q are either not applicable or did not have, or are not expected to have, a material impact on us.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity and capital resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reverse stock split arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735794768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,691 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,524 </p></td><td style="vertical-align:bottom;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,691 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,524 </p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">388 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">196 </p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">388 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">196 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,079 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,720 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,079 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,720 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828586736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of revenues disaggregated by category</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:7pt 0pt 9pt 0pt;">Revenues disaggregated by category were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product sales:</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross product sales</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">48,980 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">33,456 </p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">87,406 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">66,654 </p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Discounts and allowances</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(15,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9,575)</p></td><td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27,953)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(19,028)</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total product sales, net</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,881</p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,626</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from collaborations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Delivery of drug supplies, royalty and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,391 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,005 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,922 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,330 </p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total revenues from collaborations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,330</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government contracts</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,956</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule of product revenue allowance and reserve categories</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,684</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,551</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,165)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,688)</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,547</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,145</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Provision related to current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,559</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Credit or payments made during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,020)</p></td></tr><tr><td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,684</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DisaggregationOfRevenueByCustomerTableTextBlock', window );">Schedule of revenues from product sales disaggregated by customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">45%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cencora Inc. (formerly ASD Healthcare)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_DisaggregationOfRevenueByCustomerTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue by customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_DisaggregationOfRevenueByCustomerTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699831363280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-LICENSING AND ACQUISITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>IN-LICENSING AND ACQUISITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock', window );">Summary of total purchase consideration in connection with asset acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the total purchase consideration in connection with the asset acquisition (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing purchase price</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000 </p></td></tr><tr><td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">360 </p></td></tr><tr><td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total purchase consideration</p></td><td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,360 </p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735861296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation for the periods presented was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,531</p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,172</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,930</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of weighted-average assumptions relating to options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">6.0</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">6.7</span></p></td><td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">6.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">7.0</span></p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">88.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">87.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828599952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>OTHER BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Inventories for the periods presented consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.71%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,145 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,609 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,006 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,876 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,368 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,508 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,519 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,993 </p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,522</p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,471</p></td></tr><tr><td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,519 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,993 </p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Intangible assets consist of the following (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.62%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,360 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000</p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,085)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,122)</p></td></tr><tr><td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,275 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,878</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated future amortization expense of intangible asset</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The following table presents the estimated future amortization expense of intangible assets as of June 30, 2024 (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.69%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,176 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,351 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,695 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,275 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828787968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and short-term investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,126 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,247</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,805 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,444 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,764 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49,102 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,933</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,053 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,786</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments</p></td><td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,049 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,147</p></td></tr><tr><td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49,102 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">56,933 </p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of fair value and gross unrealized losses of investments in unrealized loss position</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699831363280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial assets measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,805</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,444</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,764</p></td></tr><tr><td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,976</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US treasury bills</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,594</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Government-sponsored enterprise securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,233</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds and commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,174</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,686</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735851776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of loans payable, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;">The following table summarizes loans payable, net (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (308)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (398)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal outstanding, net of unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,602</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reported as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans payable, net, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,229</p></td></tr><tr><td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term portion of loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,373</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,602</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of future minimum payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal amount (Tranches 1, 2, 3 and 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699737403040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of operating lease expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 778</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable operating lease expense (net credit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 808</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock', window );">Schedule of supplemental information related to operating lease</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments included in the measurement of operating lease liabilities</p></td><td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,174</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of operating sublease information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 365</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable sublease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (442)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden__uvDi--VAUGqtC3eWeIntA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_RyRJdE2X_E-Mg-mp9DscQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_lQtRnSPQoE-Il8zeJ8WGew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_mnAsvI_5pkqF9r4khAkUlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:56.56%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum payments required</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699853399952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,102<span></span>
</td>
<td class="nump">$ 56,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735959616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from the computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,079<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
<td class="nump">4,079<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from the computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,691<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">3,691<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from the computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699736860112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Disaggregated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 36,841<span></span>
</td>
<td class="nump">$ 26,886<span></span>
</td>
<td class="nump">$ 66,375<span></span>
</td>
<td class="nump">$ 52,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_GrossProductMember', window );">Gross product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">48,980<span></span>
</td>
<td class="nump">33,456<span></span>
</td>
<td class="nump">87,406<span></span>
</td>
<td class="nump">66,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_DiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(15,530)<span></span>
</td>
<td class="num">(9,575)<span></span>
</td>
<td class="num">(27,953)<span></span>
</td>
<td class="num">(19,028)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,450<span></span>
</td>
<td class="nump">23,881<span></span>
</td>
<td class="nump">59,453<span></span>
</td>
<td class="nump">47,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember', window );">Delivery of drug supplies, royalty and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,391<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">6,922<span></span>
</td>
<td class="nump">4,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember', window );">Revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,391<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">$ 6,922<span></span>
</td>
<td class="nump">4,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_GrossProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_GrossProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_DiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_DiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_ContractRevenuesFromCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699738470144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 15,684<span></span>
</td>
<td class="nump">$ 12,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">27,551<span></span>
</td>
<td class="nump">18,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(24,688)<span></span>
</td>
<td class="num">(17,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">18,547<span></span>
</td>
<td class="nump">13,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SalesDiscountsAndAllowances', window );">Discounts and allowances</a></td>
<td class="nump">27,600<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">5,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember', window );">Accounts receivable and prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SalesDiscountsAndAllowances', window );">Discounts and allowances</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_ChargebacksDiscountsAndFeesMember', window );">Chargebacks, Discounts and Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">6,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">21,770<span></span>
</td>
<td class="nump">14,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(20,165)<span></span>
</td>
<td class="num">(13,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">9,841<span></span>
</td>
<td class="nump">7,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_GovernmentAndOtherRebatesMember', window );">Government and Other Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">3,517<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">5,259<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(4,441)<span></span>
</td>
<td class="num">(3,765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">4,335<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">3,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credit or payments made during the period</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="nump">$ 4,371<span></span>
</td>
<td class="nump">$ 3,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_SalesDiscountsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales discounts and allowances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_SalesDiscountsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(1)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(2)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_ChargebacksDiscountsAndFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_ChargebacksDiscountsAndFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_GovernmentAndOtherRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=rigl_GovernmentAndOtherRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699737222848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Percentage by Customer (Details) - Sales - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">McKesson Specialty Care Distribution Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Cardinal Health Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Cencora Inc. (formerly ASD Healthcare)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rigl_MckessonSpecialtyCareDistributionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rigl_MckessonSpecialtyCareDistributionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rigl_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rigl_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=rigl_CencoraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=rigl_CencoraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699723207104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>period</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_RightToOptOutOfAgreementNumberOfPeriods', window );">Right to opt out of agreement, different specified times | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PaymentOfCostShareToCollaborationPartner', window );">Payment of cost share to collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,904<span></span>
</td>
<td class="nump">$ 28,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,130<span></span>
</td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember', window );">Specified Development Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember', window );">Specified Regulatory Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember', window );">Specified Product Launch Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by non-CNS disease products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by CNS disease products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember', window );">Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member', window );">Grifols</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member', window );">Grifols | Delivery of drug supply for commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member', window );">Grifols | Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member', window );">Kissei</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember', window );">Knight | Commercial and license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember', window );">Knight | Maximum | Commercial milestones | Commercial and license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementPotentialPayments', window );">Potential payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementPotentialPayments', window );">Potential payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Collaborative payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ContingentPaymentsUnderAgreement', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols | Creditable advance royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Collaborative payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Grifols | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_RoyaltyPaymentAsPercentageOfNetSales', window );">Royalty payment as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Kissei</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized associated with remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Collaborative payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Medison</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | Medison | Commercial and license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval', window );">Option to buy back product rights within number of months from regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember', window );">fostamatinib | BARDA | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementPotentialPayments', window );">Potential payments</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_OcadusertibMember', window );">ocadusertib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DevelopmentCostsCostSharingArrangementPercentage', window );">Company's percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityAccrualComponentAmount', window );">Financing component liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,900<span></span>
</td>
<td class="nump">57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_FinancingLiabilityInterestAccretionDiscountRate', window );">Financing liability interest accretion discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_FinancingLiabilityIncludingInterestExpenseAccretion', window );">Financing liability with accreted interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DueToCollaborationPartner', window );">Development costs due to collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400<span></span>
</td>
<td class="nump">21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_OcadusertibMember', window );">ocadusertib | Amended Lilly Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_RightToOptBackInCoFundingTerm', window );">Right to opt-back-in co-funding of R552 development, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_OcadusertibMember', window );">ocadusertib | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember', window );">Non-CNS penetrant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember', window );">CNS penetrant IP | Licensed Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty | Grifols</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember', window );">REZLIDHIA | Strategic collaboration agreement with MDACC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DueToCollaborationPartner', window );">Development costs due to collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PaymentOfCostShareToCollaborationPartner', window );">Payment of cost share to collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborationTerm', window );">Collaboration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember', window );">REZLIDHIA | Strategic collaboration agreement with CONNECT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DueToCollaborationPartner', window );">Development costs due to collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborationTerm', window );">Collaboration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember', window );">REZLIDHIA | Forma | FDA approval and first commercial sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option under agreement to buy back product rights within number of months from regulatory approval, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time of collaboration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementPotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of contingent payments under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementPotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the revenue recognized during the period under the terms of sponsored research and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementUpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementUpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ContingentPaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents additional contingent payments by entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ContingentPaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_DevelopmentCostsCostSharingArrangementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs in cost sharing arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_DevelopmentCostsCostSharingArrangementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_DueToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_DueToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_FinancingLiabilityIncludingInterestExpenseAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financing liability including interest expense accretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_FinancingLiabilityIncludingInterestExpenseAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_FinancingLiabilityInterestAccretionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate applied to the undiscounted amount of financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_FinancingLiabilityInterestAccretionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_PaymentOfCostShareToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of cost share to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_PaymentOfCostShareToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_RightToOptBackInCoFundingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of time of right to opt-back-in co-funding, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_RightToOptBackInCoFundingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_RightToOptOutOfAgreementNumberOfPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of periods with right to opt out of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_RightToOptOutOfAgreementNumberOfPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_RoyaltyPaymentAsPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents royalty payment as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_RoyaltyPaymentAsPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481639/420-10-35-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityAccrualComponentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recorded amount of the accrual for a material component of a product liability contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityAccrualComponentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=rigl_MilestonePaymentsOnProductByProductBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=rigl_MilestonePaymentsOnProductByProductBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_GrifolsS.a.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_GrifolsS.a.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rigl_CommercialAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rigl_CommercialAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_FostamatinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_FostamatinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_CreditableAdvanceRoyaltyPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_CreditableAdvanceRoyaltyPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_MedisonPharmaLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_MedisonPharmaLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_OcadusertibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_OcadusertibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rigl_AmendedLillyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rigl_AmendedLillyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_LicensedRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_LicensedRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_RezlidhiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rigl_StrategicCollaborationAgreementWithMdaccMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rigl_StrategicCollaborationAgreementWithMdaccMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rigl_StrategicCollaborationAgreementWithConnectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rigl_StrategicCollaborationAgreementWithConnectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699737122544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,540<span></span>
</td>
<td class="nump">$ 4,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,566<span></span>
</td>
<td class="nump">$ 14,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementUpfrontPayment', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementPotentialPayments', window );">Potential payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CollaborativeArrangementPotentialPayments', window );">Potential payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember', window );">Forma | Achievement of certain near-term regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_GavretoMember', window );">GAVRETO (pralsetinib)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember', window );">REZLIDHIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember', window );">REZLIDHIA | Forma | FDA approval and first commercial sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_AssetPurchaseAgreementDrugProductInventories', window );">Asset purchase agreement, drug product inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Asset acquisition, expected price</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib) | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquisition payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PotentialTieredRoyaltyPercentage', window );">Potential tiered royalties (as a percentage)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PotentialTieredRoyaltyPercentage', window );">Potential tiered royalties (as a percentage)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib) | First commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Asset acquisition, expected price</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib) | First anniversary of the closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Asset acquisition, expected price</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib) | Commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PotentialMilestonePaymentObligations', window );">Potential milestone payments</a></td>
<td class="nump">97,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember', window );">Blueprint | GAVRETO (pralsetinib) | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_PotentialMilestonePaymentObligations', window );">Potential milestone payments</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AssetPurchaseAgreementDrugProductInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of agreement for purchase of drug product inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AssetPurchaseAgreementDrugProductInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementPotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of contingent payments under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementPotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of collaborative arrangement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_PotentialMilestonePaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of potential milestone payment obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_PotentialMilestonePaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_PotentialTieredRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of potential tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_PotentialTieredRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionPriceOfAcquisitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_GavretoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_GavretoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rigl_RezlidhiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rigl_RezlidhiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_FirstCommercialSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_FirstCommercialSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_FirstAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_FirstAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_AchievementOfMilestoneAxis=rigl_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_AchievementOfMilestoneAxis=rigl_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699737403040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>IN-LICENSING AND ACQUISITION - Purchase Consideration (Details) - Blueprint<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 22, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Closing purchase price</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="nump">$ 15,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699738381312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense related to stock-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,528<span></span>
</td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 7,662<span></span>
</td>
<td class="nump">$ 4,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense related to stock-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">6,707<span></span>
</td>
<td class="nump">3,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense related to stock-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
<td class="nump">$ 1,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735036928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Options and RSUs (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rigl_ShareBasedCompensationOptionsAndRsusMember', window );">Employee stock options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs | $</a></td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period of unrecognized compensation cost</a></td>
<td class="text">2 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">599,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised during the period (in shares)</a></td>
<td class="nump">9,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">3,691,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Vesting upon achievement of corporate performance-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">132,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs | $</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">291,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">66,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">387,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant-date weighted-average fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rigl_ShareBasedCompensationOptionsAndRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rigl_ShareBasedCompensationOptionsAndRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699738780272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions (Details) - Employee Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">88.10%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
<td class="nump">83.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699723047952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Plans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th">
<div>May 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares approved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="nump">78,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod', window );">Award offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod', window );">Purchase price expressed as a percentage of fair market value of common stock on the first day of the offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod', window );">Number of purchase periods per award offering period | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod', window );">Award purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price expressed as a percentage of fair market value of common stock on the purchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to purchase plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Purchase Plan | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod', window );">Award offering period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the offering period for awards under the equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase period for awards under the equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purchase periods per award offering period under the equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price expressed as a percentage of the fair market value of common stock on the first day of the offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699741237232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER BALANCE SHEET COMPONENTS - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>OTHER BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw Materials</a></td>
<td class="nump">$ 2,145<span></span>
</td>
<td class="nump">$ 4,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">6,006<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,059<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_InventoryReportedAsOtherAssets', window );">Other assets</a></td>
<td class="nump">4,460<span></span>
</td>
<td class="nump">2,471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_InventoryAndInventoryReportedAsOtherAssets', window );">Total</a></td>
<td class="nump">12,519<span></span>
</td>
<td class="nump">7,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advance payments for raw materials</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_InventoryAndInventoryReportedAsOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory and inventory reported as other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_InventoryAndInventoryReportedAsOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory And Inventory Reported As Other Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_InventoryReportedAsOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reported as other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_InventoryReportedAsOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699852055648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>OTHER BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible asset cost</a></td>
<td class="nump">$ 30,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(2,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,122)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="nump">28,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735306432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>OTHER BALANCE SHEET COMPONENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Remainder of 2024</a></td>
<td class="nump">$ 1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">2,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">2,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">2,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">2,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">17,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="nump">$ 28,275<span></span>
</td>
<td class="nump">$ 13,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699723189648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,053<span></span>
</td>
<td class="nump">$ 32,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">13,049<span></span>
</td>
<td class="nump">24,147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">49,102<span></span>
</td>
<td class="nump">56,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">13,805<span></span>
</td>
<td class="nump">9,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">12,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="nump">11,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">13,764<span></span>
</td>
<td class="nump">15,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, cash equivalent and short term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 6,126<span></span>
</td>
<td class="nump">$ 8,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699738392800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 29,180<span></span>
</td>
<td class="nump">$ 38,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">29,171<span></span>
</td>
<td class="nump">39,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">12,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">12,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills | Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,446<span></span>
</td>
<td class="nump">11,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="nump">11,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities | Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities | Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,771<span></span>
</td>
<td class="nump">15,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">13,764<span></span>
</td>
<td class="nump">15,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper | Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper | Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash equivalents and available-for-sale securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Gross Unrealized Gains (Losses)</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699736948928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod', window );">Weighted-average time to maturity of cash equivalents and available-for-sale securities</a></td>
<td class="text">68 days<span></span>
</td>
<td class="text">82 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of investments in continuous unrealized loss position for more than 12 months | position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of individual securities in unrealized loss position for 12 months or less | position</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_InvestmentsCreditLossExpense', window );">Credit losses recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">22,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">9,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember', window );">Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair value and gross unrealized losses of investments in individual securities in unrealized loss position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="nump">13,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_InvestmentsCreditLossExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for expected credit loss on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_InvestmentsCreditLossExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699737220704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">$ 29,171<span></span>
</td>
<td class="nump">$ 39,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">42,976<span></span>
</td>
<td class="nump">48,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Money market funds | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">13,805<span></span>
</td>
<td class="nump">9,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | US treasury bills | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">12,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Government-sponsored enterprise securities | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="nump">11,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Corporate bonds and commercial paper | Estimate Of Fair Value Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">13,764<span></span>
</td>
<td class="nump">15,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">13,805<span></span>
</td>
<td class="nump">9,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">13,805<span></span>
</td>
<td class="nump">9,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">29,171<span></span>
</td>
<td class="nump">39,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2 | US treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">12,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2 | Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="nump">11,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring | Level 2 | Corporate bonds and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments at fair value</a></td>
<td class="nump">$ 13,764<span></span>
</td>
<td class="nump">$ 15,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=rigl_CorporateBondSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699738379520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Summary of Loans Payable) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(308)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts', window );">Principal outstanding, net of unamortized debt issuance costs</a></td>
<td class="nump">59,692<span></span>
</td>
<td class="nump">59,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, net, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Long-term portion of loans payable, net</a></td>
<td class="nump">59,692<span></span>
</td>
<td class="nump">52,373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Total</a></td>
<td class="nump">$ 59,692<span></span>
</td>
<td class="nump">$ 59,602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699743704512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 28, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 2,029<span></span>
</td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="nump">$ 3,903<span></span>
</td>
<td class="nump">$ 3,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=rigl_FollowingFourthAmendmentMember', window );">Following Fourth Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Final payment fee, percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR | Following Fourth Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Rate adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.11448%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Floor rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Following Third Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Final payment fee, percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | SOFR | Following Third Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Rate adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.11448%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Floor rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Credit Facility with MidCap | Tranche 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the credit facility for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=rigl_FollowingFourthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=rigl_FollowingFourthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=rigl_FollowingThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=rigl_FollowingThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rigl_CreditAgreementTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699837969584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Future Minimum Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Future minimum payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount (Tranches 1, 2, 3 and 4)</a></td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735350704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember', window );">Headquarters office space sublease, South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SubleaseAgreementAbstract', window );"><strong>Sublease Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">11 months 1 day<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_SubleaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_SubleaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699738056240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease expense</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">$ 778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease expense (net credit)</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_VariableLeaseExpenseNetCredit', window );">Variable operating lease expense (net credit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease expense</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_VariableLeaseExpenseNetCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease expense (net credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_VariableLeaseExpenseNetCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699828594240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735371824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Sublease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_SubleaseAgreementAbstract', window );"><strong>Operating sublease information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_FixedSubleaseExpense', window );">Fixed sublease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_VariableSubleaseExpense', window );">Variable sublease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(442)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rigl_NetSubleaseIncomeExpense', window );">Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_FixedSubleaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed sublease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_FixedSubleaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_NetSubleaseIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sublease income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_NetSubleaseIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_SubleaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_SubleaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rigl_VariableSubleaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable sublease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rigl_VariableSubleaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rigl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139699735801216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Future Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2024</a></td>
<td class="nump">$ 371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments required</a></td>
<td class="nump">$ 672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8I6=NF8)+=?IP>6+U%H&Z>U*<%>HY 7X?R&E/B22#^1GWX/_ %!+ P04
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M:#"YI<2T#=@&J.MPZ!N-KH7"L'1W%HQ/<.L[K?$<^#[J_P+97U!+ P04
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M$Y02-$WHBD<DYCU=P$&DG#ZKC%Z71JTWC-IH2(E(. I(C&,%WS_,=P_P=0A
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M&Y1+L/=[*<TE<(YK_Q?)7U!+ P04    " "T@ 99)X^C\J$'  "_(0  &
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M8 B20JE7LN[RVP8&5Z"5A#HD17>:;:BMJ EUCZ9YN&XH*GHPWJH-TZ;*TRS
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M*WX9 +1"0_R"X#ZF_L/M$+8L9G1$%Q>G /O@+F9LRJU0;A@=G?@%5)1(Y 9
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M]84W)?_$9VZ\-SG_N0+Q5I86X/G"H /&"Q+0_.;KP[\!4$L#!!0    ( +2
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M<%N&(($/RSH,5D'HLF@[86AJT\357TRB<44?(GKF>K9/J?]HY\[D*YV+OZO
M%!_:@T9^7SCQ)_ QE-Z!OZ DB&^@VI7">5W@?&JJNJY+7*5ZJ@RI*Q9_(#=9
M7_(FW_0G-J 8C'L"L'YHV&4B<HV:5,[EHI:;E%A>C^[5JAB:/%2#67_LJ-Y[
M@8>Y<8>YJ<QD+KN36#VX(G >@45+YK5X@YJU)!V7I8B=CL_PL]\K!(LMBX>8
MSZ^]H^>&XZ0Q5U@K)2*,H\&PF:P,!R_Z<Y4DKKT_=BC2SFB4T;GA1NFK5D;7
M$'')W#;#=P-QVUHR.E^3H5M484F<P(JC)BL.U[.".MQNFRU+O;S)L,WOHSJ
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MPG! #=@.T1Q-2,Z(?[!6%3(64Q%G.%%24P6#W"^YD,=PD( QGC,_J6-1ELP
ML<5 *L<V(R87&B!82"GF-+K$G6)&C"3:+.*HO2'V[HY;)'24I<:2'4QN7$['
M@B06A#RBD'5:0W&:=&IRW%S.*RR==*%RHQ36PL-&V!FZPQAQ&;-L-H0Q&>AB
M6-8+)*B8.9J\SJXX><G";31,Z4HBIZBXG+>H[JBB(VZ<5&)2YR4Y_SA;P'(1
M"1ALB]BBGVNJ)WY+/T?GL2@X4KA-^D][SK>T5+R26R/@QXZ-.GNHE*/6.3Q&
MS\SDA2KEAZG+#T2_49TN,0R=@JKE[@ZW<Y:D -OO=NA@HY&&$:?V :VQXLW(
M(48*T]3+MHE5]94SY0KR(IW^1(8[H#ZPE"0/*C7;LW)5J?(*.NW-U%A*-!O5
M6.#UVKTRB-Y&'MUVF=$HW4XAJ)&[@S,(,9,VOZ@J9HMKOLO\=FNU/+\CO.5Z
M1!5* D,D]>LG[1K3^;U;/K!JXNZZ!LI:E;K/,? 8-"W _T.E[')  HK+SXM_
M %!+ P04    " "T@ 99T,ZR9($#  #'"@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6S%5FUOVS80_BL'=2@V0(U>[=B);<!)FZY%"P1)DWVFI;-%
M1")5DK*;_?H>*5EUBT19VF'[8K[</0_OR.?DF^VDNM,%HH$O52GTW"N,J4^"
M0&<%5DP?R1H%6=925<S04FT"72MDN0-591"'X3BH&!?>8N;V+M5B)AM3<H&7
M"G1354S=GV$I=W,O\O8;5WQ3&+L1+&8UV^ UFIOZ4M$JZ%ER7J'07 I0N)Y[
MR^CD++7^SN&6XTX?S,%FLI+RSB[>Y7,OM %AB9FQ#(R&+9YC65HB"N-SQ^GU
M1UK@X7S/?N%RIUQ63..Y+/_BN2GFWL2#'->L*<V5W/V)73XCRY?)4KM?V+6^
M4>)!UF@CJPY,$51<M"/[TMW# 6 2/@*(.T#LXFX/<E&^9H8M9DKN0%EO8K,3
MEZI#4W!<V$>Y-HJLG'!F<;%\=P6WRP\W;V:!(3Z[&V0=]JS%QH]@Q_!1"E-H
M>"-RS+_'!Q1''TR\#^8L'B1\WX@C2$(?XC!.!_B2/KG$\24_E5R+31_&VF(X
MT37+<.Z1VC6J+7J+ER^B<7@Z$%G:1Y8.L3\1V3!V>@07C"NX966#\*E ,&Q5
M(JQLA775Q?]&#89,:^NY=9YR#;)1D#%= 'YN..VB,!J8R$$74IE7!E4%7&Q1
MF\J9*F2Z49@#,]\Q435116:-4EQL;%5P[3L>II .,+B1-H3<%4P.34T(&PT%
M2-Q0XA9+&X_F&\'7/&/"T+EU8\!(YVC/8;9L-?S.+58VFOCU'R?P\L4D#I/3
M_WQ<:HWVMLSA[3-MTR#=8J_;'O#!91EU8]R-"7R2AI6V=/">*EG=T9=WW5!N
M/? WB!)_$HX.-NPLBD\'=SK0S348Y=[M'E:\+/6#&1U"]V/J3\?),[W?RBTJ
M8=7R2M,K:VG50BM4M>(:05N5<,-1/TH8A7Z:ID^9SZ6JI2)IP4K:R[)JRV15
MH<HX76?-:E2/<R3^\7C@B-;</LS *\13/SJ.!A\AC?WI\?A_$^D_$.MKS+!:
MT64ED1/LMQ?_!<%._?'DN7IM,3\OURCV1]/TN>[_AF C/TZ2I\R_)M@1*6U
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M.Z9HYT5K*%[;AGC'E6ZO=EGH$0O"!.C])>=J:QB!?F@G?P%02P,$%     @
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M(=B2?\[1E"I'"_!\:M&EI LZH/WL=?9?4$L#!!0    ( +2 !EDB_C]D=0(
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MZQY9&UH4KB^MA#9=SDTS\ZR M "SOA9"'PR[0?-01;\ 4$L#!!0    ( +2
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MQ"/- IA?"J&;@5'0OL_-_@-02P,$%     @ M( &63/M:;&* @  #08  !D
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MWA"YIEP!P]1 @]/S,P]D/7SJC1:%,_Q*:#,^W#(S\QJE33#GJ1!ZL[$%VB]
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M:@+5)*HI5(M1+:$TL]R:D(AOO]+'7PH]^KLW4&DYZWQEG_K@4D(#(*@6H9I
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M-WE=Z)L?5A/<Y\4?ZY=Y\3]02P,$%     @ M( &60E 7BY> @  204  !D
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MS\[/T.G5Q?7YY>SX]NO5)3I 5ZFNFT T"=#-[$Z@_3.0-(S$)[2'7"26E(-
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MVGM:[1<%"[>RH)=5I4M>;?BY\IJ$^29A@2'8B0>7C0>7AA+ZI4DS3,)\D[#
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M;7:^-@-!TWSS:$:%H'%^N@0R!Z8"Y/T%I>)]H/:CROW'X?]02P,$%     @
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MOODL9;,BV2+]LF/"I&11NCBG9$9Y8J#V/S(FGU>2CT7RCX.&_P-02P,$%
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MUJ6?:D^?3QB9.IT\N4+3&Z>,%!JRC(><6B)7:#K5SDJ>RZ4\=-+ P11V?."
ME*=!PY?SE)Y/&3T823J=)[E"TUNFO!4:LJB'G%HG5V@Z566=D,.%O0:KN]YL
MFB68P@RS!+_S?H1\.>4FH<]9R4".5R(O.!N+SM#]^Q[['4ZJ^I6))\(Y*>K-
M-4Z6F,H <7Y%"'_=D6]AM&_=+/X%4$L#!!0    ( +2 !EF!Z.D%Z0(  '<)
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;*U686_:,!#]*U963:W4
M-B&!0!A$6LNF;=HD5-KMLPD'6'7LS#;0[M?OG$ $Q4U;J7P@=G+O^;VSS_9@
M(]6]7@(8\I!SH8?>TIBB[_LZ6T).]:4L0."7N50Y-=A5"U\7"NBL!.7<#X,@
M]G/*A)<.RG=CE0[DRG F8*R(7N4Y58]7P.5FZ+6\W8L;ME@:^\)/!P5=P 3,
M73%6V/-KEAG+06@F!5$P'WJ?6_WKQ,:7 ;\9;/1>FU@G4RGO;>?[;.@%5A!P
MR(QEH/A8PS5P;HE0QM\MIU</:8'[[1W[U]([>IE2#=>2_V$SLQQZ/8_,8$Y7
MW-S(S3?8^NE8ODQR7?Z3314;=SV2K;21^1:,"G(FJB=]V.9A#]!J/P,(MX#P
MM8!H"XA*HY6RTM:(&IH.E-P09:.1S3;*W)1H=,.$G<6)4?B5(<ZDHR]7M^1T
M4LTAD7/R4U*AR9@^TBF',W(Z D,9UV?D@MQ-1N3TY(R<$";([5*N-!4S/? -
MZK!L?K8=\ZH:,WQFS!\K<4FBX)R$0=AVP*^;X2/($-XJX=$AW$?W=0K".@5A
MR1<UI,!EHD*UW2A;77U=T R&'I:/!K4&+_WXH14'GUR6WHGLP&!4&XR:V-.Q
M8B)C!>4$RU@;G#0F%B['%4U<TMCR7Z=Q@+^!O]ZW\E+4@<9VK;'=J/%.T%PJ
MP_[!#*MP:@C3>D5%!B23VC@76478V=-Q$06])V)=04G/K;53:^V\/9_G1.">
MBP6T>KN3SI'(3A(GX1,KSJ@@='N):R]QX^*_@0+%HE2J^RYI\7L6P3N1'1CM
MUD:[C9-6[6M%M:^5DW6.^ZM2( RQ*< SQ>6_D?2M_KM',]@-P\0]@;W:5^\%
M7V)Q84#E.Q=V#?(CLRYOO5<M.T=4&'4CM^JD5ITTJKZ5AG*7IN1H<W%I<D8=
ME8*_=RS:*\DOJA8,\\)ACKC@LHNF5'7,5QTCB_*DG$J#YV[97.+-")0-P.]S
M*<VN8P_?^JZ5_@=02P,$%     @ M( &6>.&YD:+"   )&8  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3,N>&ULM9UK;]LV%(;_"N%=T )=;%WL.%EBH(YX
MZ;!L1=IM'X9]8&PFUB9+GD0G+; ?/]UBF;;"2.N[?F@LF><Y8OA&ASJ'DBX>
MD_2O;*64)I_649Q=#E9:;\Z'PVRQ4FN9G20;%>??W"7I6NI\,[T?9IM4R65I
MM(Z&[F@T&:YE& ]F%^6^]^GL(MGJ*(S5^Y1DV_5:II_G*DH>+P?.X&G'37B_
MTL6.X>QB(^_5!Z5_V;Q/\ZWACK(,URK.PB0FJ;J['+QUSH7O%@9EBU]#]9CM
M?29%5VZ3Y*]BX]WR<C JCDA%:J$+A,Q_/*@K%44%*3^.OVOH8.>S,-S__$1G
M9>?SSMS*3%TET6_A4J\N!],!6:H[N8WT3?(H5-VA<<%;)%%6_D\>J[83;T 6
MVTPGZ]HX/X)U&%<_Y:?Z%[%GD'/:#=S:P#TT\)\Q\&H#KZL'OS;PNWH8UP;C
MK@:3VF!R:/#<;^FT-CCM:C"M#:;EZ%;#48YE(+6<7:3)(TF+UCFM^% *HK3.
MAS","^U^T&G^;9C;Z5E YQ_)JY]DFLI"1*_)JT!I&4;9:_(=^>5#0%Y]_9I\
M3<*8?%PEVTS&R^QBJ'/'A?EP43N95T[<9YQXY#J)]2HC-%ZJ98M]8+>?6.R'
M>8=WO7:?>CUWK< ?MO$)\49OB#MR_9;CN>IN[K5UY\N\TR_SSNSFUS(](>[T
M67/^DOEGXCFEM=MB+3I;CRSCZ.W4ZY4X[SGUJEM-WL693K?Y^523WW_,&Y!W
M6JVS/]ID6M'\=EH1)LZSC5RHRT$>!S*5/JC![-NOG,GH^S:-(&$!$D:1,(:$
M<21,@&"&\OR=\GP;??8NUBJG:J(^Y=.(3+6IK2),2D(QAWB8Y;(_NQ@^[*OH
MN)$SG;AFH^"XD7<V\LQ&M*71:#(Q&S%KK_J.)A(F0#!C-,>[T1Q;1Y,E43Z)
M"^-[PI)MJE?D;7XZ61:GE+9QM;+ZGD60L  )HT@80\(X$B9 ,$-WDYWN)M#X
M-4$J#PD+D#"*A#$DC"-A @0SE'>Z4]ZI_8P7QC(B&_FYU-V=4F_(1J6+?"._
M8B7)'=FD8;P(-S)JTZ&5W5>'2%A0P1QG+PJ.3D:^.SX(EDBG# GC2)@ P0R)
M37<2FUHE]N%G=D/^(?UBJQ795UE(6("$422,(6$<"1,@F"&_LYW\SJ"Q]0RI
M/"0L0,(H$L:0,(Z$"1#,4)XS:I)J(^NI[T9J1>3RSVVFGSO1V0E]]0:E!2_T
M;G3B.+X__:9-7M #85 :A]($BF9*;"]OZU@'82ZS,"-5P8(D,7F0:2AO(T72
M7'NM@K/R>@L.20MJVN&T;7(X:X-Z95 :A]($BF:JRVW4Y=HO#Z(D29^74F5<
M_ 48L^R#U);=1V^-=')*H4X9E,:A-(&BF1)I4N^.-;\ZNTK5,M2$R448A?HS
M>0SSN?UUN+R2FU;-0'/O4%H I5$HC4%I'$H3*)JIP"8%[_C0&;Z#S%=?06D!
ME$:A- :E<2A-H&BF!)NZ@6,O'%S+3^%ZNR:W29I628Z%S-WEY\-6 8Z/2C23
M4?[O,&Y":P+=G%*H4P:E<2A-H&BF9)J4OV/-Z\YN5+&DJ)!*1]%4N/'^M.=0
M,-!4_LL.*=0A@](XE"90-%,L39;>L:?I?][J3,MX6<I%1C)>M$_(3X^&K/7$
M DVU=W-*H4X9E,:A-(&BF5IITNV./=_>94E"C3#7)!SKY+B5<W;8*JA;[8^_
M=]2*MK \Y[ 5LW>M][!"D]@HFCFL31K;L>8J9V\7BW2KEB2LA[=U6*'):R@M
MJ&GF"I=CF4#STE :A]($BF8N?&Q2TZX]>6NY;#>*=1]78;JTU^KLGOJJ#DH+
MH#0*I3$HC4-I D4SU=EDM5T'>DGO0I/:4%H I5$HC4%I'$H3*)HIP2;U[;Z0
M^OZBE3%V>&]!0C/H->VPRG*T-@;JE4%I'$H3*)HIM2:%[O[G%'H>BX_6SW0)
MR= L.Y060&D42F-0&H?2!(IFBK3)LKO8++L+S;)#:0&41J$T!J5Q*$V@:*8$
MFRR[:\^R=UA.8R?T5ATT _]"[VS+:: 'PJ T#J4)%,V46).5=^U9^=[+:>R\
MWH*#9O!KVN%$;WRTG@;JED%I'$H3*)HIKR:/[[ZPW-ZZGL9M7[7N' S7E=U)
M;Y5T\TJA7AF4QJ$T@:*9(FD2^*X]@6^_'/B8RGBQ4L1I51!TW3R4%D!I%$IC
M4!J'T@2*9JJQJ3NXV/7S+K0& :4%4!J%TAB4QJ$T@:*9-_<WM0K/7JOH6/VN
M*4:%J:7Z;7?65U+=G%*H4P:E<2A-H&BF5IK*@6=?#]\M>+8]LF)N)_<]<T%I
M 91&H30&I7$H3:!HIAJ;(H+G0H.G!RT;0&D!E$:A- :E<2A-H&BF!/<>C6,O
M+G0-GMAGXF ?BH-]*@[VL3C8Y^)@'XSCO3 W,275E (\:YZW8XQM>ZC4W$[N
M+3-H50!*HU :@](XE"90-%.-357 &V-C++1$ *4%4!J%TAB4QJ$T@:*9$FRJ
M!IZ]:M UQD)K!5!: *51*(U!:;RFO7#%+E!.34DUE0+/7BGH%F/;'ALYMY-[
MRPQ:;(#2*)3&H#0.I0D4S51C4Y+PIM@8"ZU#0&D!E$:A- :E<2A-H&BF!)LZ
MA&>__Z%KC(66'Z"T $JC4!J#TKC7<K-'6XS]/^H*?E-7\+_D'HBG&#MNDYF=
MW%=F4%H I5$HC4%I'$H3*)JIQJ9RX6/O>?"AY0HH+8#2*)3&H#0.I0D4S91@
M4Z[P[?<\=(RQ=DIOY4&K%% :A=)833N\Z_8@*G*H4X&B59(:[KUB8JW2^_)U
M(QE9)-M85\_KW^W=O=+D;?DBCX/]<^?\RFG9'SCGM'IA28.OWI]R+=/[,,Y(
MI.YR5Z.3T_& I-4K2:H-G6S*%US<)EHGZ_+C2LFE2HL&^?=W2:*?-@H'NQ?#
MS/X%4$L#!!0    ( +2 !EF2H-VZ1@(  'L%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;(546V_:,!3^*T=9-16I(R&0,+$0:915W:1*J+3;LQL.
MQ*HOF>U ^^]G.VG$U$!?B(_M[V9\G!VD>M8EHH$7SH2>!Z4QU2P,=5$B)WHH
M*Q1V92L5)\:6:A?J2B'9>!!G81Q%:<@)%4&>^;F5RC-9&T8%KA3HFG.B7A?(
MY&$>C(*WB7NZ*XV;"/.L(CM<HWFL5LI68<>RH1R%IE* PNT\^#Z:+5*WWV_X
M3?&@C\;@DCQ)^>R*GYMY$#E#R+ PCH'8SQZOD3%'9&W\;3F#3M(!C\=O[#<^
MN\WR1#1>2_:';DPY#[X&L,$MJ9FYEX=;;/,DCJ^03/M?.#1[DS2 HM9&\A9L
M'7 JFB]Y:<_A"!#')P!Q"XB][T;(NUP20_),R0,HM]NRN8&/ZM'6'!7N3UD;
M95>IQ9E\^6/Q %_@IC:U0KBC@O*:PXJ\VH,W&BZ7: AE>@ 70 4\E++61&QT
M%AHK[BC"HA5:-$+Q":%?M1C".+J".(HG\+A>PN7%X'^:T'KO L1=@-CSCD_P
MMLYYZ[QJG?<9;(@F_43N]L]T10J<!_9Z:U1[#/+/GT9I].V,S7%G<WR./;>I
MDSY/#2KU*-= ^WR:1%$6[GNT)IW6Y".MM$^K025'6N,H.B66=&+)1V+3/K'D
MG5@<GTR6=F+I6;&5HJ*@%6% N*R%@<L'181]J#2,[,VZ@C'8VPF309^C]-U1
MISWQPZ-><L_2'5$[*C0PW%I<-)S:2*II]:8PLO+M]22-;58_+.WKB,IML.M;
M*<U;X3JV>V_S?U!+ P04    " "T@ 99DRW8!"4"  #K!   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6RU5.]OFS 0_5<L)DV;5(4?2;,I Z0D;=5-
MFQ05;?WLP %6C4UM$]K_?F=#4"8E^;8OX+/OWKV'WQ'W4KWH&L"0MX8+G7BU
M,>W*]W5>0T/U3+8@\*24JJ$&0U7YNE5 "U?4<#\*@J7?4":\-'9[.Y7&LC.<
M"=@IHKNFH>I] USVB1=ZQXTG5M7&;OAIW-(*,C"_VYW"R)]0"M: T$P*HJ!,
MO'6XVBQLODOXPZ#7)VMBE>RE?+'!]R+Q DL(..3&(E!\'6 +G%L@I/$Z8GI3
M2UMXNCZB/SCMJ&5/-6PE?V:%J1/OJT<**&G'S9/L'V'4<VOQ<LFU>Y)^R%UB
M<MYI(YNQ&!DT3 QO^C9^AY."<'FA(!H+(L=[:.18WE%#TUC)GBB;C6AVX:2Z
M:B3'A+V4S"@\95AGTI_WZ^P^(Y_NP%#&]>?8-XAJS_Q\1-@,"-$%A!^=F)%Y
M<$.B(%K\6^XCF8E1-#&*'-[B MXC6NNUH\J TD26)<N!Z);:9[?G@#=P0S*T
M5TTR*LB#HB)G.I<W9$LY0Y<*1L^)N-K46G_EFB0>>EN#.H"7?OP0+H-O5R3-
M)TESASZ_("D;B9-UI0#0TN8<P_E_8+B8&"ZN?O1GYUXH"#V PF'$>;,3S41%
M!N9X&\TYTM=APY T4IA:DY 4]/T<4?_$N_8W\(NJB@F-;4N$#&9?;CVBAM$:
M B-;9^>]-#@<;EFC94#9!#POI33'P$[(]']+_P)02P,$%     @ M( &66/_
M1D+] @  0 L  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULM59K;YLP
M%/TK%JNF5EH+ 4*R+$%J M4VM5+5M-UG!YQ@%>S,=A[[][,-80E0E&S9E^#'
M/>?ZG%S#'6XH>^,)0@)LLY3PD9$(L1R8)H\2E$%^0Y>(R)TY91D4<LH6)E\R
M!&,-RE+3MBS/S" FAC_4:X_,']*52#%!CPSP599!]FN,4KH9&1UCM_"$%XE0
M"Z8_7,(%FB+QLGQD<F:6+#'.$.&8$L#0?&3<=@9A3\7K@%>,-GQO#)22&:5O
M:O(M'AF6.A!*4204 Y2/-9J@-%5$\A@_"TZC3*F ^^,=^YW6+K7,($<3FO[
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MRKKIR9IA>;^63P1=ZH9D1H5L;_0PD2TN8BI [L\I%;N)2E VS?YO4$L#!!0
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MLIVY-M"B<GV^%=I,C5N6YIH":1/,>2&$/@1V=/J++_T#4$L#!!0    ( +2
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ M( &6978$>+\!   &B<
M  \   !X;"]W;W)K8F]O:RYX;6S%FEN/VC@4@/^*Q5,K+0OD,FU'I5(FA"%:
M2-@D,U+W9>4)!JSF@NQDIO37KY,,4Z?#'.W+*4\A%\R78WR^XSB?GTKQ[:$L
MOY'O>5;(Z6!?58?KT4BF>Y93^6=Y8(4ZLRU%3BNU*W8C>1",;N2>L2K/1L9X
M?#7**2\&7SZ?VEJ+D;Y35BRM>%FH@\V!>\Z>Y,_SS2YYY)(_\(Q7Q^F@_9RQ
M <EYP7/^@VVF@_& R'WYM"@%_U$6%<WB5)19-AU,NA/W3%0\?74X;B 3^B#;
M(Q5]B*@"F0ZNQJK!+1>R:J]HVZ>*\9&IB[N]NBKG/*N8F-&*W8JR/O!BUS2C
M[F*DW48;A].V"^*U^#]A++=;GK)9F=8Y*ZHNCH)E#6 A]_P@!Z2@.9L.9J%[
MM_*"A#C!C*BMGWPE?C /HY63^&'0W*GZ:7_3W76E<+48BFNN3@A_TX+C0;IA
M,/."V)N1&V?I!*Y'XH7G);%&9P!TQF7HR+LU%:S0($T TOQ=D''B)%[3Y3$)
MYR1<>Y'J:0W2 B"M"T+^:VB0-@!I7P;2#5?KR%MHD%< Y-5E(.,D=/]:A!KD
M!P#RPP4A>]W]$8#\>*'N=N(%F2\UR$\ Y"=<R#"Z=0+_GS9EMYD\OENMG.AK
M&TW_5L_B8RB-CW$Q R\ARS".B1K/*DDZD:>3@8)!-DSDW7O!G:<;90(I98+L
ME'@=!G$8J7]=Y,6>$[F+MEN7OMO\%XF."4EE@FP5/QAV2'YPVP(Z[M]W?NS_
M6CI 3ID@2Z7-)L,;IQG"38Y6M*]*&T@G$V2?A,E"C89>Z=!RAD&3:G1*R"<3
M;*&H=/='E_0\U<7WSK)-A&VN6821C@D998*LE+GC1T3!W?4R"Z2/";(_9MY-
MHK- EI@@:V+IJ5'0JYHA&QC(-EC3(WF49,U$^_4B963&99J5LA9,AX3$8""+
MP2\DWS!!$D$W:HY&'"%HL6/-MZ3.",X_D&4!VK]71QF0+ QD6;RV/WFG9L09
MD^]U1,@5!K(K3F7 63!($@:R)"#1*E@=$[*$@6R)MUS['$\=$[*$@6P)6+EZ
M=65 ZC"PIQZ0<_OC&K**@6R5G\X]-VQ,2#$FLF(:^9Z%@I1B(BNEL_!9+,@B
MYD4M8NJ8X'.L"UADQBK*LWXH(8V8OTLCPZ:BH;N=8#N%LGDFU3$AJ9C(4M$P
MG>;Y-*^.YV,)*<5$5HH&J2K%5%U,=XP\'(E;RZK,=4Q(*2:R4L )>R]7FY!2
M3&2E@'7$4#>?"2G%1%8*B-F+I@7IQ4+6R]OESJ_CW(*$8R$+YTW,(0D/50\3
M$I"%_<SK;4Q'REK'A 1D(0L(P%QG5%_NL<"E%&0'@35N?PA!#K(N^?2K5W58
MD(4L9 O!F):."5G(PEY1 6<,O6A"%K(N.K'I11.RD(5L(1C3UI<C(0O9R!;2
MYU]GJC<;4H^-K)YN A;7>4[%D91;LBQI(<F:'IO)3P\34H^-K)X.,Z!"T.8]
MC??G PE9QT:V3DLX)/.ZJ@4CJ^;EE3IOXM@^B=0+-QNRCHULG=/<]ESXP#5[
M9,T\<PW)DE')B/==M:6V)TX=$]*,C:R9%TR7RCV99^43\8NN)75IKY<AS=C(
MFGG!C&OUPTU =<IW.B:D&1M9,R^8SZ.FZ_NS8P;2C-UJ9G1Z%VO#MKQ@FT#]
MA%3'4YJE:T&:3;=J;-G-&L^VSC)7'0L+E?$VIU>[3J^E??D/4$L#!!0    (
M +2 !EE9=@'X]0$  #@C   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'/-VKM.ZT 4A>%7B?P 3/8MP!&AHJ%%O( 5)A>1Q)8]"'A[HE"$95&<!LVJ
MK+'E[;_Z9(U]]Y3W;=EUQW&[Z\?9QV%_')?-MI3^7TKC:IL/[7C5]?EXNK+N
MAD-;3LMAD_IV]=IN<M+Y?)&&GS.:^[N?,V?/GWW^GXG=>KU;Y8=N]7;(Q_++
MX/3>#:_C-N?2S)[;89/+LDD?^\OI,9T/<G6:W,P>7Y;-\/@B3:H=I!"D]8,,
M@JQ^D$.0UP\*"(KZ00L(6M0/NH:@Z_I!-Q!T4S_H%H)NZP?)'&6<$R1-L";0
M6I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R70
M6U%O)=!;)R_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$
M>AOJ;01Z&^IM!'H;ZFT$>MMDLX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-
M0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!OGVQV$^CMJ+<3Z.VHMQ/H[:BW
M$^CMJ+<3Z.VHMQ/H':AW$.@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!V3CY4$>@?J
M'01Z!^H=!'H'ZAT$>@?J'7^I]U@^]WF\]'RO\3OW7U)=3O?FR^//R^^3B//B
MC'."'V7NOP!02P,$%     @ M( &61?(S!O; 0  T2(  !,   !;0V]N=&5N
M=%]4>7!E<UTN>&ULS=I=3X,P% ;@O[)P:T;7K_D1YXUZJU[X!RJ<#3*@3=O-
M^>\M3$TT2EQFXGL#@;;G/;3)<\7EXXNC,-FU31<6616CNV L%!6U)N3649=&
MEM:W)J9'OV+.%&NS(B9FLSDK;!>IB]/8U\BN+F]H:39-G-SNTNM0VVZ1>6I"
M-KG>3^RS%IEQKJD+$],XVW;EEY3I6T*>5@YS0E6[<)(F9.S;A'[DYX"W=?=;
M\KXN:?)@?+PS;9K%=@T+\:6AD(^7^*9'NUS6!96VV+1I21Z<)U.&BBBV3;XO
M>C*>'-,.T_[*C\X?RHP%IID/WKJ03LS3X7'O1]*OGKI4B'RLQS_Q(S&5/OK[
MJ#_MDLI?9J?M?;9^/9Q'8,/M^#W^?,8?]0_L0X#T(4'Z4"!]:) ^YB!]G(+T
M<0;2QSE('WR&T@B*J!R%5(YB*D=!E:.HRE%8Y2BN<A18.8JL D56@2*K0)%5
MH,@J4&05*+(*%%D%BJP"15:!(JM$D56BR"I19)4HLDH4626*K!)%5HDBJT21
M5:+(JE!D52BR*A19%8JL"D56A2*K0I%5H<BJ4&15*+)J%%DUBJP:15:-(JM&
MD56CR*I19-4HLFH46?5_ROID[?JO?[+H[WEKZNX]GPU_LER] E!+ 0(4 Q0
M   ( +2 !ED'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ M( &6?U&KN#O    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ M( &69E<
MG",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " "T@ 999K&U /$%   ''P  &               @($.
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ M( &69,6
MGA!I!@  +AT  !@              ("!-0X  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( +2 !ED<2]]=]0$  !$$   8
M  " @=04  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "T
M@ 99Q J^QL$%  "J&P  &               @('_%@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ M( &62>6UC;^ 0  )00  !@
M         ("!]AP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( +2 !EG1PU*))@,  %H+   8              " @2H?  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "T@ 99L9CRL8P*  #O8P
M&               @(&&(@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ M( &605.J%H( @  .P0  !@              ("!2"T  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( +2 !EDGCZ/RH0<
M +\A   8              " @88O  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "T@ 99DJ%T$#</  #_)0  &0              @(%=
M-P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( +2 !ED2
MLCK3Y ,  .\*   9              " @<M&  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ M( &655\)ZS,!@  AQ<  !D
M     ("!YDH  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +2 !EFAG>)@<@8   @5   9              "
M@7&%  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ M( &
M6=#.LF2! P  QPH  !D              ("!&HP  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "T@ 99NAN:;(H'  !^%0  &0
M        @('2CP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( +2 !EE!^<T=X00  ($/   9              " @9.7  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ M( &69%D**Z# @  P <
M !D              ("!JYP  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "T@ 99RE!,V40"  "*!@  &0              @(%EGP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +2 !EE6!,G^
M& H   (;   9              " @>"A  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ M( &62+^/V1U @  M 8  !D
M ("!+ZP  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "T
M@ 99QF:8:RP%  "K$P  &0              @(';K@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +2 !EDS[6FQB@(   T&   9
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M970S,"YX;6Q02P$"% ,4    " "T@ 99<W8.;%,#  !""0  &0
M    @($&R   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M +2 !EFMU28I? ,  /T,   9              " @9#+  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ M( &67C&&0$/ P  &0D  !D
M             ("!0\\  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "T@ 99/(8UJ6,#  !'$   &0              @(&)T@  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +2 !EF")"+'[P0
M .@@   9              " @2/6  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ M( &60G!F0/,!0  82,  !D              ("!
M2=L  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "T@ 99
M_'[H+Y,#  "[$0  &0              @(%,X0  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( +2 !EF\IOL2P"<  )4I P 9
M      " @1;E  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ M( &6;KG)!!G#   CK<  !D              ("!#0T! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "T@ 99"4!>+EX"  !)!0
M&0              @(&K&0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( +2 !EG2A+6*A0,  (<0   9              " @4 < 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ M( &6?_([%#;
M!   &!0  !D              ("!_!\! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "T@ 99TSX%>T$#   _"P  &0
M@($.)0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( +2
M!EE84D-BY@0  +L=   9              " @88H 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ M( &6<BA\ZD/ P  I@D  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( +2 !EG!N8;;5P0  ,P2   9
M  " @2!! 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MM( &6:9%<48"!0  @2,  !D              ("!KD4! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "T@ 99@>CI!>D"  !W"0  &0
M            @('G2@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( +2 !EGCAN9&BP@  "1F   9              " @0=. 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ M( &69*@W;I& @
M>P4  !D              ("!R58! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "T@ 99DRW8!"4"  #K!   &0              @(%&
M60$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( +2 !EEC
M_T9"_0(  $ +   9              " @:); 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ M( &6?1 6]BF @  XP<  !D
M     ("!UEX! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M" "T@ 99GJRHHNH"  !L#   &0              @(&S80$ >&PO=V]R:W-H
M965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +2 !EF'ZD0:-0(   0%   9
M              " @=1D 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L!
M A0#%     @ M( &66825I%$ P  )A0   T              ( !0&<! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "T@ 99EXJ[',     3 @  "P
M        @ &O:@$ 7W)E;',O+G)E;'-02P$"% ,4    " "T@ 99E=@1XOP$
M   :)P  #P              @ &8:P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ M( &65EV ?CU 0  .",  !H              ( !P7 ! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ M( &61?(S!O; 0
MT2(  !,              ( ![G(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $, 0P!,$@  ^G0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>288</ContextCount>
  <ElementCount>274</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200205 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONDENSED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995200405 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitParenthetical</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995200500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract</Role>
      <ShortName>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - IN-LICENSING AND ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureInLicensingAndAcquisition</Role>
      <ShortName>IN-LICENSING AND ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - OTHER BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOtherBalanceSheetComponents</Role>
      <ShortName>OTHER BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureFairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99920102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureRevenues</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - IN-LICENSING AND ACQUISITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionTables</Role>
      <ShortName>IN-LICENSING AND ACQUISITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureInLicensingAndAcquisition</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - OTHER BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables</Role>
      <ShortName>OTHER BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureOtherBalanceSheetComponents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureFairValueTables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureFairValue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureDebt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - REVENUES - Disaggregated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails</Role>
      <ShortName>REVENUES - Disaggregated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - REVENUES - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesActivityDetails</Role>
      <ShortName>REVENUES - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940303 - Disclosure - REVENUES - Percentage by Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails</Role>
      <ShortName>REVENUES - Percentage by Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails</Role>
      <ShortName>SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - IN-LICENSING AND ACQUISITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails</Role>
      <ShortName>IN-LICENSING AND ACQUISITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940502 - Disclosure - IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails</Role>
      <ShortName>IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Options and RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940603 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940604 - Disclosure - STOCK-BASED COMPENSATION - Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails</Role>
      <ShortName>OTHER BALANCE SHEET COMPONENTS - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails</Role>
      <ShortName>OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940703 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails</Role>
      <ShortName>OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureFairValueDetails</Role>
      <ShortName>FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureFairValueTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - DEBT (Summary of Loans Payable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails</Role>
      <ShortName>DEBT (Summary of Loans Payable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureDebtTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - DEBT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebtNarrativeDetails</Role>
      <ShortName>DEBT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureDebtTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99941003 - Disclosure - DEBT - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails</Role>
      <ShortName>DEBT - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.rigel.com/role/DisclosureLeasesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - LEASES - Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails</Role>
      <ShortName>LEASES - Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941103 - Disclosure - LEASES - Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails</Role>
      <ShortName>LEASES - Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941104 - Disclosure - LEASES - Sublease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails</Role>
      <ShortName>LEASES - Sublease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rigl-20240630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99941105 - Disclosure - LEASES - Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails</Role>
      <ShortName>LEASES - Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rigl-20240630.xsd</File>
    <File>rigl-20240630_cal.xml</File>
    <File>rigl-20240630_def.xml</File>
    <File>rigl-20240630_lab.xml</File>
    <File>rigl-20240630_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="rigl-20240630x10q.htm">rigl-20240630x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rigl-20240630x10q006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="618">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rigl-20240630x10q.htm": {
   "nsprefix": "rigl",
   "nsuri": "http://www.rigel.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "rigl-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rigl-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rigl-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rigl-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rigl-20240630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "rigl-20240630x10q.htm"
     ]
    }
   },
   "keyStandard": 231,
   "keyCustom": 43,
   "axisStandard": 27,
   "axisCustom": 1,
   "memberStandard": 30,
   "memberCustom": 55,
   "hidden": {
    "total": 36,
    "http://fasb.org/us-gaap/2023": 16,
    "http://xbrl.sec.gov/dei/2023": 8,
    "http://www.rigel.com/20240630": 8,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "contextCount": 288,
   "entityCount": 1,
   "segmentCount": 90,
   "elementCount": 571,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 618,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://www.rigel.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - DOCUMENT AND ENTITY INFORMATION",
     "shortName": "DOCUMENT AND ENTITY INFORMATION",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.rigel.com/role/StatementCondensedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.rigel.com/role/StatementCondensedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
     "longName": "995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfOperationsParenthetical",
     "longName": "995200205 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss",
     "longName": "995200300 - Statement - CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONDENSED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit",
     "longName": "995200400 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M9P7eTJN40GnRu7yAa6KCw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gvz4si6MdkS4fdUVQlbKOA",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitParenthetical",
     "longName": "995200405 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)",
     "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows",
     "longName": "995200500 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995210101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.rigel.com/role/DisclosureNetLossPerShare",
     "longName": "995210201 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.rigel.com/role/DisclosureRevenues",
     "longName": "995210301 - Disclosure - REVENUES",
     "shortName": "REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract",
     "longName": "995210401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT",
     "shortName": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.rigel.com/role/DisclosureInLicensingAndAcquisition",
     "longName": "995210501 - Disclosure - IN-LICENSING AND ACQUISITION",
     "shortName": "IN-LICENSING AND ACQUISITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensation",
     "longName": "995210601 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponents",
     "longName": "995210701 - Disclosure - OTHER BALANCE SHEET COMPONENTS",
     "shortName": "OTHER BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments",
     "longName": "995210801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.rigel.com/role/DisclosureFairValue",
     "longName": "995210901 - Disclosure - FAIR VALUE",
     "shortName": "FAIR VALUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.rigel.com/role/DisclosureDebt",
     "longName": "995211001 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.rigel.com/role/DisclosureLeases",
     "longName": "995211101 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:StockholdersEquityReverseStockSplitPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:StockholdersEquityReverseStockSplitPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.rigel.com/role/DisclosureNetLossPerShareTables",
     "longName": "99930203 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.rigel.com/role/DisclosureRevenuesTables",
     "longName": "99930303 - Disclosure - REVENUES (Tables)",
     "shortName": "REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionTables",
     "longName": "99930503 - Disclosure - IN-LICENSING AND ACQUISITION (Tables)",
     "shortName": "IN-LICENSING AND ACQUISITION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99930603 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables",
     "longName": "99930703 - Disclosure - OTHER BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "OTHER BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables",
     "longName": "99930803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.rigel.com/role/DisclosureFairValueTables",
     "longName": "99930903 - Disclosure - FAIR VALUE (Tables)",
     "shortName": "FAIR VALUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.rigel.com/role/DisclosureDebtTables",
     "longName": "99931003 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.rigel.com/role/DisclosureLeasesTables",
     "longName": "99931103 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails",
     "longName": "99940101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.rigel.com/role/DisclosureNetLossPerShareDetails",
     "longName": "99940201 - Disclosure - NET LOSS PER SHARE (Details)",
     "shortName": "NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
     "longName": "99940301 - Disclosure - REVENUES - Disaggregated (Details)",
     "shortName": "REVENUES - Disaggregated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_66nF3F7T6EeO_T5ormWp2A",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.rigel.com/role/DisclosureRevenuesActivityDetails",
     "longName": "99940302 - Disclosure - REVENUES - Activity (Details)",
     "shortName": "REVENUES - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails",
     "longName": "99940303 - Disclosure - REVENUES - Percentage by Customer (Details)",
     "shortName": "REVENUES - Percentage by Customer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i1LjpfRajUeDxjso7nYoyA",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:DisaggregationOfRevenueByCustomerTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i1LjpfRajUeDxjso7nYoyA",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:DisaggregationOfRevenueByCustomerTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
     "longName": "99940401 - Disclosure - SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)",
     "shortName": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:ContingentPaymentsUnderAgreement",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:ContingentPaymentsUnderAgreement",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
     "longName": "99940501 - Disclosure - IN-LICENSING AND ACQUISITION - Narrative (Details)",
     "shortName": "IN-LICENSING AND ACQUISITION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_mlAixP0Kq0KRgxnPySwCUQ",
      "name": "rigl:CollaborativeArrangementUpfrontPayment",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails",
     "longName": "99940502 - Disclosure - IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)",
     "shortName": "IN-LICENSING AND ACQUISITION - Purchase Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails",
     "longName": "99940601 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
     "longName": "99940602 - Disclosure - STOCK-BASED COMPENSATION - Options and RSUs (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Options and RSUs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_mp0URjlEF0yvPpfS-o63hg",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_mp0URjlEF0yvPpfS-o63hg",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "longName": "99940603 - Disclosure - STOCK-BASED COMPENSATION - Assumptions (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails",
     "longName": "99940604 - Disclosure - STOCK-BASED COMPENSATION - Plans (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_5_1_2024_To_5_31_2024_DjxYIP5b9kafOLRsY1Sj5g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "unitRef": "Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_1_2024_To_5_31_2024_DjxYIP5b9kafOLRsY1Sj5g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "unitRef": "Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails",
     "longName": "99940701 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Inventories (Details)",
     "shortName": "OTHER BALANCE SHEET COMPONENTS - Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails",
     "longName": "99940702 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details)",
     "shortName": "OTHER BALANCE SHEET COMPONENTS - Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
     "longName": "99940703 - Disclosure - OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details)",
     "shortName": "OTHER BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense Of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
     "longName": "99940801 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_JbLXs-0VY0esSnNCYQq-kA",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
     "longName": "99940802 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Gross Unrealized Gains and Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
     "longName": "99940803 - Disclosure - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)",
     "shortName": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA",
      "name": "rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.rigel.com/role/DisclosureFairValueDetails",
     "longName": "99940901 - Disclosure - FAIR VALUE (Details)",
     "shortName": "FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BRYGoVu9R0e32mZYGbN33w",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails",
     "longName": "99941001 - Disclosure - DEBT (Summary of Loans Payable) (Details)",
     "shortName": "DEBT (Summary of Loans Payable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.rigel.com/role/DisclosureDebtNarrativeDetails",
     "longName": "99941002 - Disclosure - DEBT (Narrative) (Details)",
     "shortName": "DEBT (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:InterestExpense",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_Oloq2T-qkUSk0moW_WdUNg",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
      "unitRef": "Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails",
     "longName": "99941003 - Disclosure - DEBT - Future Minimum Payments (Details)",
     "shortName": "DEBT - Future Minimum Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.rigel.com/role/DisclosureLeasesDetails",
     "longName": "99941101 - Disclosure - LEASES (Details)",
     "shortName": "LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails",
     "longName": "99941102 - Disclosure - LEASES - Lease Expense (Details)",
     "shortName": "LEASES - Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails",
     "longName": "99941103 - Disclosure - LEASES - Cash Flow Information (Details)",
     "shortName": "LEASES - Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails",
     "longName": "99941104 - Disclosure - LEASES - Sublease Information (Details)",
     "shortName": "LEASES - Sublease Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA",
      "name": "rigl:FixedSubleaseExpense",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA",
      "name": "rigl:FixedSubleaseExpense",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails",
     "longName": "99941105 - Disclosure - LEASES - Future Lease Payments (Details)",
     "shortName": "LEASES - Future Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "rigl:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rigl-20240630x10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r606"
     ]
    },
    "rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts receivable and prepaid and other current assets.",
        "label": "Accounts receivable and prepaid and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Expense",
        "terseLabel": "Accretion expense",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r735"
     ]
    },
    "rigl_AccruedResearchAndDevelopmentLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AccruedResearchAndDevelopmentLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Liability Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Unrealized Gains",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r145",
      "r716",
      "r717"
     ]
    },
    "rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, before Tax",
        "terseLabel": "Gross Unrealized Gains (Losses)",
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r77",
      "r134",
      "r469",
      "r489",
      "r490"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r29",
      "r384",
      "r387",
      "r424",
      "r485",
      "r486",
      "r715",
      "r716",
      "r717",
      "r722",
      "r723",
      "r724"
     ]
    },
    "rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AchievementOfCertainNearTermRegulatoryMilestoneMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents achievement of a certain near-term regulatory milestone.",
        "label": "Achievement of certain near-term regulatory milestone"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_AchievementOfMilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AchievementOfMilestoneAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by categories of milestones achieved.",
        "label": "Achievement of Milestone [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_AchievementOfMilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AchievementOfMilestoneDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different categories of achievement of milestones.",
        "label": "Achievement Of Milestone [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Intangible assets, estimated useful life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r495",
      "r722",
      "r723",
      "r724",
      "r780",
      "r798"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r333"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvancesOnInventoryPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances on Inventory Purchases",
        "terseLabel": "Advance payments for raw materials",
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r649",
      "r674"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r677"
     ]
    },
    "rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option under agreement to buy back product rights within number of months from regulatory approval, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Agreement, Option To Buy Back Product Rights Within Number Of Months From Regulatory Approval",
        "terseLabel": "Option to buy back product rights within number of months from regulatory approval"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r643",
      "r653",
      "r670",
      "r678",
      "r682",
      "r690"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r370"
     ]
    },
    "rigl_AmendedLillyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AmendedLillyAgreementMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amended Lilly Agreement.",
        "label": "Amended Lilly Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense",
        "verboseLabel": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r43",
      "r46"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities excluded from the computation of diluted net loss per share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "totalLabel": "Total purchase consideration",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "terseLabel": "Acquisition-related liabilities",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Summary of total purchase consideration in connection with asset acquisition",
        "documentation": "Tabular disclosure of contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionPriceOfAcquisitionExpected",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Price of Acquisition, Expected",
        "terseLabel": "Asset acquisition, expected price",
        "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "rigl_AssetPurchaseAgreementDrugProductInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "AssetPurchaseAgreementDrugProductInventories",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of agreement for purchase of drug product inventories.",
        "label": "Asset Purchase Agreement Drug Product Inventories",
        "terseLabel": "Asset purchase agreement, drug product inventories"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r133",
      "r159",
      "r198",
      "r206",
      "r210",
      "r247",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r377",
      "r381",
      "r402",
      "r466",
      "r524",
      "r606",
      "r619",
      "r738",
      "r739",
      "r784"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r136",
      "r159",
      "r247",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r377",
      "r381",
      "r402",
      "r606",
      "r738",
      "r739",
      "r784"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r255",
      "r465"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]",
        "terseLabel": "Fair value and gross unrealized losses of investments in individual securities in unrealized loss position"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER BALANCE SHEET COMPONENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Biomedical Advanced Research and Development Authority [Member].",
        "label": "BARDA"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_BlueprintMedicinesCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "BlueprintMedicinesCorporationMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Blueprint Medicines Corporation.",
        "label": "Blueprint"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "IN-LICENSING AND ACQUISITION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "IN-LICENSING AND ACQUISITION",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r373"
     ]
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "rigl_CardinalHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CardinalHealthIncMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Cardinal Health Inc.",
        "label": "Cardinal Health Inc."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CashAndCashEquivalentsAndAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash and Cash Equivalents and Available For Sale Securities [Line Items]",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r130",
      "r575"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "totalLabel": "Cash, cash equivalents and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "verboseLabel": "CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS",
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r87",
      "r157"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Continuing Operations",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r87"
     ]
    },
    "rigl_CashEquivalentsAndAvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Available For Sale Securities [Abstract]",
        "terseLabel": "Cash equivalents and available-for-sale securities"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities.",
        "label": "Cash Equivalents and Available For Sale Securities, Weighted Average Maturity Period",
        "terseLabel": "Weighted-average time to maturity of cash equivalents and available-for-sale securities"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CashFlowInformationRelatedToOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CashFlowInformationRelatedToOperatingLeaseTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to operating lease.",
        "label": "Cash Flow Information Related To Operating Lease [Table Text Block]",
        "terseLabel": "Schedule of supplemental information related to operating lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "rigl_CencoraIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CencoraIncMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Cencora Inc.",
        "label": "Cencora Inc. (formerly ASD Healthcare)"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CentralNervousSystemPenetrantIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CentralNervousSystemPenetrantIntellectualPropertyMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents central nervous system penetrant intellectual property.",
        "label": "CNS penetrant IP"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "rigl_ChargebacksDiscountsAndFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ChargebacksDiscountsAndFeesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents chargebacks, discounts and fees.",
        "label": "Chargebacks, Discounts and Fees"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "rigl_CollaborationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CollaborationTerm",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time of collaboration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Term",
        "terseLabel": "Collaboration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContract"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r118",
      "r124"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative arrangement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "rigl_CollaborativeArrangementPotentialPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CollaborativeArrangementPotentialPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of contingent payments under collaborative arrangement.",
        "label": "Collaborative Arrangement Potential Payments",
        "terseLabel": "Potential payments"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CollaborativeArrangementRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CollaborativeArrangementRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the revenue recognized during the period under the terms of sponsored research and license agreements.",
        "label": "Collaborative Arrangement Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CollaborativeArrangementUpfrontFeeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CollaborativeArrangementUpfrontFeeReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.",
        "label": "Collaborative Arrangement Upfront Fee Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CollaborativeArrangementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CollaborativeArrangementUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of collaborative arrangement upfront payment.",
        "label": "Collaborative Arrangement Upfront Payment",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborations",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "rigl_CommercialAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CommercialAndLicenseAgreementMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents commercial and license agreements.",
        "label": "Commercial and license agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r63",
      "r467",
      "r511"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r610",
      "r611",
      "r613",
      "r614",
      "r615",
      "r616",
      "r722",
      "r723",
      "r780",
      "r796",
      "r798"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r468",
      "r606"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r142",
      "r144",
      "r149",
      "r461",
      "r476"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r57",
      "r58",
      "r214",
      "r571"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r57",
      "r58",
      "r214",
      "r491",
      "r571"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r57",
      "r58",
      "r214",
      "r571",
      "r698"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r57",
      "r58",
      "r214"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r57",
      "r58",
      "r214",
      "r571"
     ]
    },
    "rigl_ContingentPaymentsUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ContingentPaymentsUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additional contingent payments by entities.",
        "label": "Contingent Payments Under Agreement",
        "terseLabel": "Contingent payments"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_ContractRevenuesFromCollaborationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ContractRevenuesFromCollaborationsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents contract revenues from collaborations.",
        "label": "Revenues from collaborations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r319"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized associated with remaining performance obligation",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Refund Liability, Current",
        "verboseLabel": "Revenue reserves and refund liability",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "rigl_CorporateBondSecuritiesAndCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CorporateBondSecuritiesAndCommercialPaperMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Corporate bonds and commercial paper"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CorporateCollaborationsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CorporateCollaborationsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Collaborations",
        "label": "SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r458"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DOCUMENT AND ENTITY INFORMATION",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CreditAgreementTrancheFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CreditAgreementTrancheFiveMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche five representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 5"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CreditAgreementTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CreditAgreementTrancheFourMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche four representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 4"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CreditAgreementTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CreditAgreementTrancheOneMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 1"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CreditAgreementTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CreditAgreementTrancheThreeMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 3"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CreditAgreementTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CreditAgreementTrancheTwoMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two representing borrowing capacity under terms of the credit agreement.",
        "label": "Tranche 2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_CreditableAdvanceRoyaltyPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "CreditableAdvanceRoyaltyPaymentMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents creditable advance royalty payment.",
        "label": "Creditable advance royalty payment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r214"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r158",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r292",
      "r299",
      "r300",
      "r302"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r106",
      "r107",
      "r160",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r411",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r720"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails": {
       "parentTag": "rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal outstanding",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r107",
      "r303"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Rate adjustment",
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r60"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Floor rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r278"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r411",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r720"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r160",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r411",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r720"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Final payment fee, percentage of principal",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r47",
      "r48",
      "r59",
      "r60",
      "r62",
      "r64",
      "r98",
      "r99",
      "r160",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r411",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r720"
     ]
    },
    "rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized debt issuance costs.",
        "label": "Debt Principal Outstanding, Net Of Unamortized Debt Issuance Costs",
        "totalLabel": "Principal outstanding, net of unamortized debt issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of investments in continuous unrealized loss position for more than 12 months",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r257",
      "r581"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less than 12 Months Accumulated Loss",
        "negatedLabel": "Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r257"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of individual securities in unrealized loss position for 12 months or less",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of fair value and gross unrealized losses of investments in unrealized loss position",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r581",
      "r732"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails": {
       "parentTag": "rigl_DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r741"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r203"
     ]
    },
    "rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development and regulatory milestones by central nervous system disease products.",
        "label": "Development and regulatory milestones by CNS disease products"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development and regulatory milestones by non-central nervous system disease products.",
        "label": "Development and regulatory milestones by non-CNS disease products"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_DevelopmentAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development and regulatory milestones.",
        "label": "Development and regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_DevelopmentCostsCostSharingArrangementPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DevelopmentCostsCostSharingArrangementPercentage",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs in cost sharing arrangement.",
        "label": "Development Costs Cost Sharing Arrangement Percentage",
        "terseLabel": "Company's percentage of development costs"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_DisaggregationOfRevenueByCustomerTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DisaggregationOfRevenueByCustomerTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue by customer.",
        "label": "Disaggregation Of Revenue By Customer [Table Text Block]",
        "terseLabel": "Schedule of revenues from product sales disaggregated by customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of revenues disaggregated by category",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r335",
      "r363",
      "r364",
      "r366",
      "r601"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_DiscountsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DiscountsAndAllowancesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents discounts and allowances.",
        "label": "Discounts and allowances"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_DueToCollaborationPartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "DueToCollaborationPartner",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due to collaboration partner.",
        "label": "Due To Collaboration Partner",
        "terseLabel": "Development costs due to collaboration partner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r183",
      "r186",
      "r189",
      "r190",
      "r191",
      "r195",
      "r391",
      "r392",
      "r462",
      "r477",
      "r577"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r186",
      "r189",
      "r190",
      "r191",
      "r195",
      "r391",
      "r392",
      "r462",
      "r477",
      "r577"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r192",
      "r193",
      "r194"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "terseLabel": "Stock-based compensation expense related to stock-based awards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average recognition period of unrecognized compensation cost",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation cost related to purchase plan",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total unrecognized compensation cost related to performance-based stock options",
        "verboseLabel": "Total unrecognized compensation costs",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r126",
      "r145",
      "r146",
      "r147",
      "r168",
      "r169",
      "r170",
      "r172",
      "r178",
      "r180",
      "r197",
      "r248",
      "r249",
      "r306",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r424",
      "r485",
      "r486",
      "r487",
      "r495",
      "r551"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r649",
      "r674"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate Of Fair Value Fair Value Disclosure",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r401",
      "r585",
      "r586"
     ]
    },
    "rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents European Medicines Agency approval of fostamatinib for treatment of chronic immune thrombocytopenic purpura.",
        "label": "Upon EMA approval of fostamatinib for treatment of chronic ITP"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r398"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r398"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r104"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Hierarchy [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r395",
      "r429",
      "r430",
      "r431",
      "r585",
      "r586",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r56",
      "r290",
      "r585",
      "r586"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r397",
      "r399"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r323",
      "r328",
      "r395",
      "r429",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r323",
      "r328",
      "r395",
      "r430",
      "r585",
      "r586",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r429",
      "r430",
      "r431",
      "r585",
      "r586",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r399"
     ]
    },
    "rigl_FdaApprovalAndFirstCommercialSaleOfProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FdaApprovalAndFirstCommercialSaleOfProductMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents FDA approval and first commercial sale of the product.",
        "label": "FDA approval and first commercial sale of product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r258",
      "r259",
      "r301",
      "r305",
      "r389",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r475",
      "r581",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r727",
      "r728",
      "r729",
      "r730"
     ]
    },
    "rigl_FinancingLiabilityIncludingInterestExpenseAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FinancingLiabilityIncludingInterestExpenseAccretion",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financing liability including interest expense accretion.",
        "label": "Financing Liability Including Interest Expense Accretion",
        "terseLabel": "Financing liability with accreted interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_FinancingLiabilityInterestAccretionDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FinancingLiabilityInterestAccretionDiscountRate",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate applied to the undiscounted amount of financing liability.",
        "label": "Financing Liability Interest Accretion Discount Rate",
        "terseLabel": "Financing liability interest accretion discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r260"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Remainder of 2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible asset cost",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r460"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible asset, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r459"
     ]
    },
    "rigl_FirstAnniversaryOfClosingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FirstAnniversaryOfClosingDateMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first anniversary of the closing date.",
        "label": "First anniversary of the closing date"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_FirstCommercialSaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FirstCommercialSaleMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents first commercial sale.",
        "label": "First commercial sale"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_FixedSubleaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FixedSubleaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "parentTag": "rigl_NetSubleaseIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed sublease expense.",
        "label": "Fixed Sublease Expense",
        "terseLabel": "Fixed sublease expense"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_FollowingFourthAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FollowingFourthAmendmentMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time following fourth amendment of credit agreement.",
        "label": "Following Fourth Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_FollowingThirdAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FollowingThirdAmendmentMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time following third amendment of credit agreement.",
        "label": "Following Third Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r678"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r678"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r678"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r678"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r678"
     ]
    },
    "rigl_FormaTherapeuticsHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FormaTherapeuticsHoldingsIncMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Forma Therapeutics Holdings, Inc.",
        "label": "Forma"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_FostamatinibMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "FostamatinibMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents fostamatinib.",
        "label": "fostamatinib"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on sale and disposal of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "rigl_GavretoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "GavretoMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents GAVRETO (pralsetinib) product.",
        "label": "GAVRETO (pralsetinib)"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_GovernmentAndOtherRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "GovernmentAndOtherRebatesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents government and other rebates.",
        "label": "Government and Other Rebates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentContractMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government contracts",
        "documentation": "Formal agreement with government or its agency."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "rigl_GrifolsS.a.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "GrifolsS.a.Member",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Grifols, S.A.",
        "label": "Grifols"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_GrossProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "GrossProductMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents gross product.",
        "label": "Gross product sales"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Headquarters office space sublease in South San Francisco, California.",
        "label": "Headquarters office space sublease, South San Francisco, California"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r535"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r535"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "rigl_IncreaseDecreaseInAccruedResearchAndDevelopmentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Research and Development Liability",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r718"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r718"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other current and long-term liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current and non-current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_IncreaseDecreaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "IncreaseDecreaseRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase or decrease in right-of-use assets.",
        "label": "Increase Decrease Right Of Use Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r643",
      "r653",
      "r670",
      "r678",
      "r682",
      "r690"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r694"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r694"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r694"
     ]
    },
    "rigl_IntangibleAssetsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "IntangibleAssetsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of intangible assets that have occurred.",
        "label": "Intangible Assets Incurred But Not Yet Paid",
        "terseLabel": "Intangible assets included within acquisition-related liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible asset, net",
        "verboseLabel": "Intangible asset",
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r112",
      "r148",
      "r202",
      "r410",
      "r536",
      "r617",
      "r797"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r155",
      "r156"
     ]
    },
    "rigl_InventoryAndInventoryReportedAsOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "InventoryAndInventoryReportedAsOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureInventoriesAlternateCalculationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of inventory and inventory reported as other assets.",
        "label": "Inventory And Inventory Reported As Other Assets",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_InventoryAndInventoryReportedAsOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "InventoryAndInventoryReportedAsOtherAssetsAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory And Inventory Reported As Other Assets [Abstract]",
        "label": "Inventory And Inventory Reported As Other Assets Abstract",
        "terseLabel": "Reported as:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails": {
       "parentTag": "rigl_InventoryAndInventoryReportedAsOtherAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureInventoriesAlternateCalculationDetails": {
       "parentTag": "rigl_InventoryAndInventoryReportedAsOtherAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r576",
      "r606"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails": {
       "parentTag": "rigl_InventoryAndInventoryReportedAsOtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw Materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "rigl_InventoryReportedAsOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "InventoryReportedAsOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureInventoriesAlternateCalculationDetails": {
       "parentTag": "rigl_InventoryAndInventoryReportedAsOtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of inventory reported as other assets.",
        "label": "Inventory Reported As Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails": {
       "parentTag": "rigl_InventoryAndInventoryReportedAsOtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r201"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Net amortization of discount on short-term investments and term loans",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r554",
      "r556",
      "r558",
      "r561",
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r611"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type Categorization [Member]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r554",
      "r556",
      "r558",
      "r561",
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r611"
     ]
    },
    "rigl_InvestmentsCreditLossExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "InvestmentsCreditLossExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for expected credit loss on investments.",
        "label": "Investments Credit Loss Expense",
        "terseLabel": "Credit losses recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments at fair value",
        "verboseLabel": "Fair Value",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "rigl_KisseiPharmaceuticalCo.Ltd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "KisseiPharmaceuticalCo.Ltd.Member",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Kissei Pharmaceutical Co., Ltd.",
        "label": "Kissei"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_KnightTherapeuticsInternationalSaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "KnightTherapeuticsInternationalSaMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Knight Therapeutics International SA.",
        "label": "Knight"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r605"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of operating lease expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "rigl_LeaseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "LeaseDisclosureTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "verboseLabel": "LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum payments required",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r159",
      "r247",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r378",
      "r381",
      "r382",
      "r402",
      "r510",
      "r578",
      "r619",
      "r738",
      "r784",
      "r785"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r108",
      "r471",
      "r606",
      "r721",
      "r731",
      "r781"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' (deficit) equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r129",
      "r159",
      "r247",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r378",
      "r381",
      "r382",
      "r402",
      "r606",
      "r738",
      "r784",
      "r785"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_LicensedRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "LicensedRightsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents licensed rights.",
        "label": "Licensed Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Outstanding balance",
        "documentation": "Fair value of the amount outstanding under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Increase, Accrued Interest",
        "terseLabel": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility with MidCap",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_LiquidityAndCapitalResourcesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "LiquidityAndCapitalResourcesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity and capital resources.",
        "label": "Liquidity And Capital Resources Policy Policy Text Block",
        "terseLabel": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable",
        "totalLabel": "Total",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r107",
      "r793"
     ]
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails": {
       "parentTag": "us-gaap_LoansPayable",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Current",
        "terseLabel": "Loans payable, net, current portion",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt",
        "totalLabel": "Principal amount (Tranches 1, 2, 3 and 4)",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r107",
      "r289",
      "r304",
      "r585",
      "r586",
      "r793"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2025",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r160",
      "r294"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r160",
      "r294"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r160",
      "r294"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails": {
       "parentTag": "us-gaap_LoansPayable",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Long-term portion of loans payable, net",
        "verboseLabel": "Long-term portion of loans payable, net",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_LongtermLoansPayableByCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermLoansPayableByCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtSummaryOfLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Current and Noncurrent [Abstract]",
        "terseLabel": "Reported as:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r592",
      "r742",
      "r794",
      "r795"
     ]
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Future minimum payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r329",
      "r456",
      "r484",
      "r502",
      "r503",
      "r555",
      "r557",
      "r559",
      "r560",
      "r565",
      "r572",
      "r573",
      "r580",
      "r589",
      "r600",
      "r608",
      "r740",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "rigl_MckessonSpecialtyCareDistributionCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "MckessonSpecialtyCareDistributionCorporationMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents McKesson Specialty Care Distribution Corporation.",
        "label": "McKesson Specialty Care Distribution Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "rigl_MedisonPharmaLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "MedisonPharmaLtd.Member",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Medison Pharma Ltd.",
        "label": "Medison"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_MilestonePaymentsOnProductByProductBasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "MilestonePaymentsOnProductByProductBasisMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payments made on a product-by-product basis.",
        "label": "Milestone payments on a product-by-product basis"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r329",
      "r456",
      "r484",
      "r502",
      "r503",
      "r555",
      "r557",
      "r559",
      "r560",
      "r565",
      "r572",
      "r573",
      "r580",
      "r589",
      "r600",
      "r608",
      "r740",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r592",
      "r742",
      "r794",
      "r795"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash (used in) provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash (used in) provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r89",
      "r111",
      "r127",
      "r141",
      "r143",
      "r147",
      "r159",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r187",
      "r198",
      "r205",
      "r209",
      "r211",
      "r247",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r392",
      "r402",
      "r474",
      "r532",
      "r549",
      "r550",
      "r579",
      "r617",
      "r738"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net loss",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r173",
      "r174",
      "r175",
      "r176",
      "r183",
      "r184",
      "r188",
      "r191",
      "r198",
      "r205",
      "r209",
      "r211",
      "r579"
     ]
    },
    "rigl_NetSubleaseIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "NetSubleaseIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sublease income (expense).",
        "label": "Net Sublease Income Expense",
        "totalLabel": "Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "NonCentralNervousSystemPenetrantIntellectualPropertyMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents non-central nervous system penetrant intellectual property.",
        "label": "Non-CNS penetrant IP"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r670",
      "r678"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "rigl_NumberOfAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "NumberOfAgreements",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_OcadusertibMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "OcadusertibMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RIPK1 inhibitor for the treatment of non-central nervous system (non-CNS) diseases.",
        "label": "ocadusertib"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "OneTimeDeliveryOfDrugSupplyForCommercializationMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a one-time delivery of drug supply for commercialization.",
        "label": "Delivery of drug supply for commercialization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r205",
      "r209",
      "r211",
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r605"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Schedule of operating sublease information",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesFutureLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "verboseLabel": "Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash payments included in the measurement of operating lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r420"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r605"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment",
        "terseLabel": "Funding commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net unrealized (loss) gain on short-term investments",
        "verboseLabel": "Net change in unrealized gain (loss) on short-term investments",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r103"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive (loss) gain:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other long-term liabilities, current portion",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r606"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r676"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r654",
      "r679"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r644",
      "r654",
      "r679"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "rigl_PaymentOfCostShareToCollaborationPartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "PaymentOfCostShareToCollaborationPartner",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of cost share to collaboration partner.",
        "label": "Payment Of Cost Share To Collaboration Partner",
        "negatedLabel": "Cost share payments to a collaboration partner",
        "terseLabel": "Payment of cost share to collaboration partner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Acquisition payment",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r374"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Payments for acquisition of intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionPurchaseConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Closing purchase price",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "rigl_PotentialMilestonePaymentObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "PotentialMilestonePaymentObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of potential milestone payment obligations.",
        "label": "Potential Milestone Payment Obligations",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_PotentialTieredRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "PotentialTieredRoyaltyPercentage",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of potential tiered royalties.",
        "label": "Potential Tiered Royalty Percentage",
        "terseLabel": "Potential tiered royalties (as a percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Collaborators",
        "terseLabel": "Collaborative payment received",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Net proceeds from issuances of common stock upon exercise of options",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Net proceeds from term loan financing",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
        "terseLabel": "Maturities of short-term investments",
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r85"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ProductLiabilityAccrualComponentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductLiabilityAccrualComponentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Accrual, Component Amount",
        "terseLabel": "Financing component liability",
        "documentation": "Recorded amount of the accrual for a material component of a product liability contingency."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product sales, net",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r458",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r574",
      "r590",
      "r607",
      "r700",
      "r736",
      "r737",
      "r742",
      "r794"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r458",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r574",
      "r590",
      "r607",
      "r700",
      "r736",
      "r737",
      "r742",
      "r794"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r141",
      "r143",
      "r153",
      "r159",
      "r171",
      "r179",
      "r180",
      "r198",
      "r205",
      "r209",
      "r211",
      "r247",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r376",
      "r379",
      "r380",
      "r392",
      "r402",
      "r463",
      "r473",
      "r494",
      "r532",
      "r549",
      "r550",
      "r579",
      "r603",
      "r604",
      "r618",
      "r717",
      "r738"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r464",
      "r472",
      "r606"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r322",
      "r329",
      "r358",
      "r359",
      "r360",
      "r432",
      "r456",
      "r484",
      "r502",
      "r503",
      "r555",
      "r557",
      "r559",
      "r560",
      "r565",
      "r572",
      "r573",
      "r580",
      "r589",
      "r600",
      "r608",
      "r611",
      "r734",
      "r740",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r322",
      "r329",
      "r358",
      "r359",
      "r360",
      "r432",
      "r456",
      "r484",
      "r502",
      "r503",
      "r555",
      "r557",
      "r559",
      "r560",
      "r565",
      "r572",
      "r573",
      "r580",
      "r589",
      "r600",
      "r608",
      "r611",
      "r734",
      "r740",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "rigl_RegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "RegulatoryMilestonesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents regulatory milestones.",
        "label": "Regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r647",
      "r672"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r648",
      "r673"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r645",
      "r655",
      "r680"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r100",
      "r470",
      "r488",
      "r490",
      "r493",
      "r513",
      "r606"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r168",
      "r169",
      "r170",
      "r172",
      "r178",
      "r180",
      "r248",
      "r249",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r383",
      "r385",
      "r386",
      "r388",
      "r390",
      "r485",
      "r487",
      "r495",
      "r798"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "verboseLabel": "Total revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r204",
      "r207",
      "r208",
      "r212",
      "r213",
      "r214",
      "r317",
      "r318",
      "r458"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "REVENUES",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r321"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation",
        "terseLabel": "Revenue, remaining performance obligation",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "rigl_RevenueReservesAndRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "RevenueReservesAndRefundLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability.",
        "label": "Revenue Reserves And Refund Liability",
        "terseLabel": "Revenue reserves and refund liability"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_RezlidhiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "RezlidhiaMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents REZLIDHIA product.",
        "label": "REZLIDHIA"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_RightToOptBackInCoFundingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "RightToOptBackInCoFundingTerm",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of time of right to opt-back-in co-funding, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Right To Opt Back In Co Funding Term",
        "terseLabel": "Right to opt-back-in co-funding of R552 development, term"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_RightToOptOutOfAgreementNumberOfPeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "RightToOptOutOfAgreementNumberOfPeriods",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of periods with right to opt out of agreement.",
        "label": "Right To Opt Out Of Agreement Number Of Periods",
        "terseLabel": "Right to opt out of agreement, different specified times"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "RoyaltyDeliveryOfDrugSuppliesAndOthersMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesDisaggregatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalty, delivery of drug supplies and others.",
        "label": "Delivery of drug supplies, royalty and others"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "rigl_RoyaltyPaymentAsPercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "RoyaltyPaymentAsPercentageOfNetSales",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalty payment as a percentage of net sales.",
        "label": "Royalty Payment As Percentage Of Net Sales",
        "terseLabel": "Royalty payment as a percentage of net sales"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "rigl_SalesDiscountsAndAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "SalesDiscountsAndAllowances",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales discounts and allowances during the period.",
        "label": "Sales Discounts And Allowances",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesPercentageByCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales",
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesReturnsAndAllowancesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Returns",
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r330",
      "r696",
      "r725"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, cash equivalent and short term investments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ]
    },
    "rigl_ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ScheduleOfCashAndCashEquivalentsAndAvailableForSaleSecuritiesTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances, excluding any restricted cash balances, and available-for-sale securities.",
        "label": "Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and short-term investments",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of loans payable, net",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of weighted-average assumptions relating to options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "verboseLabel": "Schedule of product revenue allowance and reserve categories",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r167"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated future amortization expense of intangible asset",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOFR",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the offering period for awards under the equity-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Award Offering Period",
        "terseLabel": "Award offering period"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase period for awards under the equity-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Award Purchase Period",
        "terseLabel": "Award purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Grant-date weighted-average fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Outstanding (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions",
        "verboseLabel": "Weighted-average assumptions relating to Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as a percent)",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stock Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares approved",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purchase periods per award offering period under the equity-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods Per Award Offering Period",
        "terseLabel": "Number of purchase periods per award offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of common stock available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase price expressed as a percentage of the fair market value of common stock on the first day of the offering period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Purchase Price of Common Stock Percentage on First Day of Offering Period",
        "verboseLabel": "Purchase price expressed as a percentage of fair market value of common stock on the first day of the offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award",
        "terseLabel": "Shares purchased",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting upon achievement of corporate performance-based milestones",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_ShareBasedCompensationOptionsAndRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "ShareBasedCompensationOptionsAndRsusMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share based compensation options and RSUs.",
        "label": "Employee stock options and Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "positiveLabel": "Purchase price expressed as a percentage of fair market value of common stock on the purchase date",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r713"
     ]
    },
    "rigl_SpecifiedCommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "SpecifiedCommercialMilestonesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified commercial milestones.",
        "label": "Commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_SpecifiedDevelopmentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "SpecifiedDevelopmentEventsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified development events.",
        "label": "Specified Development Events"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_SpecifiedProductLaunchEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "SpecifiedProductLaunchEventsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified product launch events.",
        "label": "Specified Product Launch Events"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_SpecifiedRegulatoryEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "SpecifiedRegulatoryEventsMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents specified regulatory events.",
        "label": "Specified Regulatory Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r27",
      "r126",
      "r145",
      "r146",
      "r147",
      "r168",
      "r169",
      "r170",
      "r172",
      "r178",
      "r180",
      "r197",
      "r248",
      "r249",
      "r306",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r424",
      "r485",
      "r486",
      "r487",
      "r495",
      "r551"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r197",
      "r458",
      "r492",
      "r496",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r531",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r612"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails",
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r330",
      "r696",
      "r697",
      "r725"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r197",
      "r458",
      "r492",
      "r496",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r531",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r612"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r675"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Options exercised during the period (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r100",
      "r344"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (RSUs)",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon exercise of options",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r67",
      "r68",
      "r100"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r92",
      "r514",
      "r530",
      "r552",
      "r553",
      "r606",
      "r619",
      "r721",
      "r731",
      "r781",
      "r798"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails",
      "http://www.rigel.com/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperationsParenthetical",
      "http://www.rigel.com/role/StatementCondensedStatementsOfStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "rigl_StockholdersEquityReverseStockSplitPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "StockholdersEquityReverseStockSplitPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reverse stock split arrangement.",
        "label": "Stockholders Equity Reverse Stock Split Policy Policy Text Block",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_StrategicCollaborationAgreementWithConnectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "StrategicCollaborationAgreementWithConnectMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents strategic collaboration agreement with CONNECT, an international collaborative network of pediatric cancer centers.",
        "label": "Strategic collaboration agreement with CONNECT"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_StrategicCollaborationAgreementWithMdaccMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "StrategicCollaborationAgreementWithMdaccMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents strategic collaboration agreement with MDACC.",
        "label": "Strategic collaboration agreement with MDACC"
       }
      }
     },
     "auth_ref": []
    },
    "rigl_SubleaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "SubleaseAgreementAbstract",
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesDetails",
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Sublease Agreement Abstract",
        "terseLabel": "Sublease Agreement",
        "verboseLabel": "Operating sublease information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "parentTag": "rigl_NetSubleaseIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease income",
        "negatedLabel": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureInLicensingAndAcquisitionNarrativeDetails",
      "http://www.rigel.com/role/DisclosureStockBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r425"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOtherBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "OTHER BALANCE SHEET COMPONENTS",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.rigel.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r301",
      "r305",
      "r389",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r475",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r727",
      "r728",
      "r729",
      "r730"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureSponsoredResearchAndLicenseAgreementsAndGovernmentContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsUnrealizedLossPositionDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government-sponsored enterprise securities",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r792"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsDetails",
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAndLossesDetails",
      "http://www.rigel.com/role/DisclosureFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US treasury bills",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.rigel.com/role/DisclosureCashCashEquivalentsAndShortTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and short-term investments including securities with unrealized gains and losses",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.rigel.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r117",
      "r119",
      "r120",
      "r121"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowances and Reserves, Balance",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r166"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowances and Reserves, Additions for Charges to Cost and Expense",
        "terseLabel": "Provision related to current period sales",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowances and Reserves, Deductions",
        "negatedLabel": "Credit or payments made during the period",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r165",
      "r166"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r165",
      "r166"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.rigel.com/role/DisclosureRevenuesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable operating lease expense (net credit)",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r605"
     ]
    },
    "rigl_VariableLeaseExpenseNetCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "VariableLeaseExpenseNetCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease expense (net credit).",
        "label": "Variable Lease Expense Net Credit",
        "terseLabel": "Variable operating lease expense (net credit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "rigl_VariableSubleaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rigel.com/20240630",
     "localname": "VariableSubleaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails": {
       "parentTag": "rigl_NetSubleaseIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.rigel.com/role/DisclosureLeasesSubleaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable sublease expense.",
        "label": "Variable Sublease Expense",
        "terseLabel": "Variable sublease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.rigel.com/role/DisclosureStockBasedCompensationOptionsAndRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares outstanding and common stock equivalents",
        "terseLabel": "Weighted average shares used in computing net loss per share, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r191"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.rigel.com/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average common shares outstanding, Basic",
        "terseLabel": "Weighted average shares used in computing net loss per share, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r191"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481639/420-10-35-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001558370-24-011079-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-011079-xbrl.zip
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M(:97\-,R.KL.89NT=L1A?&(7FBMO7)L!&SS+GYJLE=R%IY##8^I#1K=I.<S
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M?9IRC!RT8RQ6LG/97[^2;!,;+%LV#A;.ULSTT" =Z3O?D8ZN1Y]^?5[9VB/
M!"+G<Z-STFYHP#'1 CH/GQN>:S6[C5^__.VG3W]O-O^XGHZT!3*]%7!<S<3
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M@\#5VF:5X=\M,; ^-S!\L)N,@/;'LS;+_H^92UEDYM%'S@(XE.QKPV8H9DL
M7-+0F.COTV$, !4#[!,3K5KLUU:F#*X_*5):I</9?$-T2U\#S.DHBDLD3!6
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M\_/CXS 34,#9!T4YFV"P-N BF,M0S\%7,63&/A(Y:\%P49P!\>?J^-,)1FN
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MIH-O]*?ACX$VTF?*KD<DK")F+,"FYCAL*X[-0WJ/!K39YO$<1=;&@^6V:X-
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MY G%]71!]53QZSP'LA$!\LP DXI;R)C.<^9/P'X$=\AQEP4FPA)"WZ'-2*E
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M0O<?1RS:N(XE.C[6<N!0*7*8[V[\14K^N? 2:*=]+G0WP2*H/_TYHB500 @
M@D=&-HH2GL&1SW[@]0Z9>DW!RH L<)YNW5).#9M-XO<!FB@PUCXHTY6?=LY+
M>6Q-I%PU*#ZID]64[-I[07'OSX)DE5!LHIG@9CZU?,*"/OC+_P!02P,$%
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MN;CS&C=V,]?D#)2#9MZ-K(=+^9# P\'NRB.@!V&44A4Q!7Z*"+H #[_Z41J
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M$0S?;6,[@H^?<UP2V@NB#FY8"3+!DW&E0VN@D)<)\$'X0D6%7KY"8.V%0:&
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MT? \H$X:0H\KF;C#/'%1[*V#B#/32N;*.9SZCS;B;N7$+\O08_]<_9;ZKTY
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MQ\.G-1OCQO&%JE^[XY<>Z(_X"R:N'_-/HX.U>H<2NPB<-8$^'91F"3\JUE'
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M1YQ";+LO'4]O*Y9(<4[LXN5VD1;[Y1;C?PPBQ\[EG_,;VD5:)#LJT9$[[44
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M#X< \WQAP.2]#J+/-^$N(GL^>G><Z%'O#1NP>UJA"LV*7>&"<%\%=*.ARD>
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M:85J!"MVA1O/?170]??'JY^O[C^=39&F">/)E!1\XA\!QG+7D-NC^ZRCN75
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MTUJATZHX;'K14.D4<9DR?#P%Q6FBN\N2,D/>^B&^2?!>=FK1"&'@\6S,=K5
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M-:HGO"?LK%3*'6C3#\=F LLOOFRV-2Y'V*@P@;5K3P*,QPXN7DRAM/;S A+
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M=I[Z?<0N]E]9RI<.$0\$'QS?RR= JY00-A_*GBN1S>SU2<%T9!/V*58"FG2
MKQ"&:J4;'@_$YZ]=E*_9Q*S@$I]5N\Y!O/+,RCP>G#AF.QQ.OL-!"DGY]/L@
M9*TL.EPA;O8\SK1K#UOF7&I:!]HNZJWDK( N#9BX-,@B?7=4;^$>*1BFAL6=
MU=L1SB$8VT/*9AY:.Q%E7YB1HV4!]6VDK".\2-$37S=".O>,%BAC-<;@>L#$
MC[RKT+NU;HC1M=PD#DF@Z@D R\0^B+>-V,,M].]7X@D5+6/):<T9ZSHLI(Y]
M$D)SQ<(N=4;$QJ7G\7=^8[2+"!*"Q.QQ"?X<$FM[U?@2D!&+==Z>MV.V!Q*]
M^O')8QOY6D1@H?8%HK'/Y&!VO8E]GWJ'.ZK=YXPTYW;H<3ZGZ#M7/&G08$0(
M*;D9Q8@_"RN$[&PU'C"_,FB,['5'"I1YS7NT=SR,O)0_6\R*9PAX,)<QY=MI
MS=>SFG(Z[<UA1K2JGD5VLZ4M\ RFBN3::35>%(&_'<6X2&\6GGOKM&G',6W
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M@_.,WZMF[NI=8 9?'WU;<ZN5]O!68+VD-I==7:"2OJ57;$;56*K=Q$_#KZ*
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MJX_'ZX)2QW]9AMXE?L5!=.#/+Z;)2T3\MEU ?5* 0WN@?8I0UZ0#//2':F4
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M<9%0&2@H"2'8?J)'Q4 QEX.7G71/)9FXDJ05,UWV,<@(6=52KQ)9%=*JK=T
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M_I#&[,AUC../)(JEQ>.ZN\&$M;YZUTK)=?2!N[Y2EES;S?-*#$F$,A:HY+%
MG(N=$G-CJU[-JF1S#COOP7+MO&L_]!-\RZK<G=YB_AMF576QMWS%A.+-IQCO
MTN#6WTGO_ XC"1L 3-BK_B:M/CVXP&%$JT&1Q<9,P?V"LS^OC+! N0@HDP$)
M(1"3PM+[N!;-=G-:6V"!Z)+(W_/')%)AF>#<,D,.SC$V#]2*+U2 HI35)4F?
ML]+B-R';'8F(WUP,LV=_F,"B;8GR=%R/SL 74EJJ#,__E \PL%K<AXP_^\2C
MK(OJ\G[)?.)3<).:A2=V<VYEF3O$^!6O%U0X6GB18'I[%$[AE(\[R)QC_+)Y
MGPX4/,(DFZ0VF4BY)V!4[*=]9[6\>C?@2-A3B>$8**V"AU+!,E^EP*B*9]@.
M\I)X&:,\*PZG'IYA"^1Z[K"5%P?/UML9DC.=VPKAJ?2#"7&]-6_-*9UV@KLV
M5!?=9%:I9&*S,-[XNF=7%\OYBNY>O/&C.JLHC'T/9T^H4!B+Q3NG_$?'%4WB
MT\G,<&JPHW^@E=I.]"B2@HL40Q4R>-:GQAI5>"]0A3MB[$$<_)G*5%7E74H0
M1$%*F?(#;?=FL&0(>,P?+2:%AU' ($J<P 08#(]^)DDYU7"K?*S<LW!?L)<&
M>+V[VA^"Z(CQ!I-7.O_9O#@$?Z R>JMHS^H%<Q&7 1>#E^XMGV463_DQ=(S;
M*MN.Q0LVQ(QJX=H]D3$8P06O<=75OJ>22<7R0[E<*!,,<<DN6$,/565;H%(Z
MUK&4#V6O9'();18)O@G=:(\WB9/P3,IM)FW+G=?V'K!C5D';:N2U-(<;/RI"
MZV^,,MJH((YRZA;OP4KT;;T+V]5GEEXLOQ/;VF%VGFSH;FR++]N\'XL#2N[Y
M(P[IY#%8AM[2V_NA'R<BZ7TEGGAHKF"E2P.VMVM9I#9_ZD, ;C3HJ:$]WQ'<
M%NA9\.-O:3LUCC;"XQ''F/K."U7_$K_B(#JPT,UT;PT*M9ZP0Z&']M4 4.@&
MU^W["*]?"DKPX$[NE5QL>+B91<]MQQ5V\UQ@1\Y(5JU&F6$6<"-R+$5UH]?\
M<OQ6>K-_FBT,:!;>))'[:V90MR)"_N(8(CC@9V.3",65MLYGAWAV]D&$<;#7
M;+ML^) EC54[P\:\?C:H[8 H]82+4#WEU][]R-E($0==C?<D7_=&Z#16$#L?
M<0=$F#L(VJS-^L#O0=-9XF.<MA1X[M4;9GQK6J$X%*K>%?C!4 U%#!2+C1E7
MU.#ID6#,%Q&/FT\3'XR?T!C%A(L'?5UO'"?$YY5/^*0!?0I].R<A?F8W=L+G
MEHV,>@N8L=ZB377 KGP,=U1N$E+7!3-:%K<=,@E:MQE.V\S"Q^3;"+4&X/W,
MT#9!X6DV-P6:%X!L=<7.L+@O>"TIIJ]' ;:?:EBCMAV@WAVNC^LH,30"T@.=
MY)R4RG>S=P5Y399=1/:4=[X0&O3 Q%@Q4UX:^7 LFV2'T;G]LBG3.DWBA$YI
MJ.:/41!<1X1]V._K&,YLEI%HR,8*03N0T^SBVY2^VHE 69ZC>DWLZ5C+A^0U
MU+AX"Y0)2'\H142_,"%1)N4H.==73)ZB]GP)4)O?IPS%&=AR[K,$TX^T81+?
MA"([W586:1Q.;QM&6ZQK$D,;V+Q= &U3%@)Z"OF0'V9;5S8+1$&T-:=)[?>.
M6HAG[&(KQ>%X$NPFCE/L7::$C@Q"1X'D_,/,!E=?V".FL?1FCA8AX+"G;9L:
MJO6F ABT]'6!@$FY5!58LH-'TYLQ(XAP3A%YG#-_V/0@#A?8AB)STULQ)1U_
M&EWP 0YD8UEVI!6P8 (8!D=3%0)*5J1;("'?+&=MYJV<@VA44IX54%[]EOK)
M\2:,$\(WKN,U17^R?7'R;=C[*'S%<<*J)(^64=05XHU"[*#OQ C^:DGP!L%Y
MF!TL(K<0'%4D1UQT.K=SPA+7"_%S5"]3=A/D-\>#>SO?VZRSGITFJV<\)O_&
MSMA_K>#?_#U, _MUWE\CX$LL !_J3Y.O;PS0#7\O4%*QH]GK9S[Z64/S,_9?
M*YHW?P_3H'F=]]>(YA(+P$=S(?B;17/#WTMFK3<+YL5J9IPDMP;_KQ7.)=_$
MQ$F9-YLLUS8!?$0_2\6\,4@W_<U4C^*]?6 _>3>(+T\NG01?.S[YV0E2#"([
MWU/*KWZ0T/E6)QY*^HCX50\X6H::U;!T]MX:UQ$Q)1'3$G$UT2_+)U9MR4W>
M[)[!I%]USNRBU>IO:]BK)_,ZS6TYV:@BW]<ZU&E^DS9V,SJ%^QJ'-UT3P1_8
MS@^CJXUO<[OH ^XKYB0O/&;5S_G8YF06WS$SO_)I!%O3>>SM+!*SPZAB?3>O
MY5U>R,+S>!U_)[CT8S>(XI3Z2#Y)&NF@6Q?/-SH>];&XR8.JK0S?X+C12VT(
M!UA+25%%U-FN52:Q?\5F7DE^C@AL>3WQ_Z\:3'XKXUT/_1I7 /.=YX.<R4]\
M[W3\+^IOIU/T9VY*/GT'.5M7JD-;I/*X:6->#K+Z.:M%>Q\E?\=)6:6V>@E/
M\N5.Q1OVN##I-]"[FO50QG#'@&G5'U9Z-0U)6<BZ5I&2/4-9K<U\7J.I5L'1
M4CKF[=C:RH1^-/.)8?$Z(MF?6+OW4W^',B&^4MAN_4XFP>]&";Y"(&^WPP1O
M&11"BTE\O*A/_IG,M$V"CCA!I=B+_*D#.A"@BNAPWSF \^6<S=])23TO\A#M
M.L:(6>5\^'^R^H_"IK(!P# +V/ ^ACV-I&(:Z,.%YE&TM)A$X?^@O%KJ'.\2
MC&'8W!Z')GO 1K\B\[.,XW1?5-*_P\E+Y$5!]'P<:^>Q%^<WBI7]K6\$0M79
MOD%DU5#>(N!6#DI6Y.7O4%0DGNW&Y(1?QMG,UBE9SNV0#A"SB;P;+P$7H0=J
MH!?:!3U03K,? Q_]^-=K@O%-2)V?#N^/3F)\G[<'WZ]H_&NS_&BC7Q/3KV3L
M:U4=W,BW0$Q>Q 1&N<2(B3S_<6^4+X(1O=@Q:_FYM?A3%N\<.HE@"Q:7BF3O
MF.13M^V>5&S''OIC+W)M,=FWIF_&8C@#@![5UF?(/ HWX) \KLX L3@7%#%)
M[2$P3+L7QJ%*[/F)ER-VR,RN'+>9Z=)_]3T<>E/-C25\9P"]4UA^M+EQ$U/@
M0#R)ZI#Q.!?XC4R-1_D>"AL=?1QX4&;$IDWV<\12-(&?'*>&Z3/.7R%0-UM_
M=*BNL_W*P%JB/&2X+D5^8X!M^+LH#/9:&LP^;A='?-A9S-8G:IM;PL;%%NT:
M#^.5S>#B3INPNKXY=/^#O7#/?.L/W__I]]]S_VIY\U[UH,-ZM\/EZT GUAB#
M/DQ?'LV2+ *,$[<;-U[D\HO_7(&Q/69X?AL?J)*87>ABSU!%&?7\J"([ >KP
M,Y4H#3U>U $CS$L<9$-U[?#B@4KQ[1BC;Q,8P3,FYX0^J$UULG:-!\1RN6R<
M$(-G5F&3$]<$,$+D(]8#\5V\WM'>^RCD0^*#F$TYSW@=7OLD3BZ=XWHWXF R
M6)2W..Z8^7Z&#U'#Y'BKHYDAJQ@:^ [Y[// Q$'X"_N4X7-U=<2.[T0[WI[?
MQ=T[Y%><9%=RZ0<NUR&_,!>*ADP!Y#G'O.<)CLUDN+3\;0T>62O'J_@73+\,
MH0/B2J"'RC<<(JX'NA1?V@2#<<M9MUE_;0\]HLI81 &8&8B:R^M=87XN6$S_
M&7M5V9?S6QSWM:P_?)COQ?:MCNIZ1C TB(?%@W#E<"[X\R(93M,ZXJVM:Z?]
M H:/R^4C?N4(G7UG]-_9KX>G_3KN-0( P'!9GZJ,E&H]H_\6A[X62QI*M=:)
MO]5AK$U5XRO.KR+5:MB8QE*M)Z/.C(:6,<PJ;'+BFK,ZW=ZYXC5]$%:%(<RA
M9CI;&SG=WLD-[G[Y!#I;/)[3GEI;Y+FU,:#U$,5^XK^.<\1]?../DA\KT-L[
M/PH%^QQFOE@J*R'S=O$R35XBPFKEF#Y[I<1Q!N@]KK6-G+?L9@<<OT=6VB*
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M)[&40C?8$:RJ=S6*N_K C61ER8=D0Q-\P3F@DD4VZ-I,_XZN>D5;/M?B9Q6
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MZFC<X ;[!#IKY[]8:47$WG-T OZ:(Y/)8*Y+IKK1(!Z7$\SHG<"Z18)M'#;
M\W C*VVB\F!:AFW PC@**ZM"]NY<-5%W1'N^+\0J%B9HY_@D2X[Q!)3[0L7!
MK$_ED\HCK_0#4::>O?9*\ L.8_^5M:>_8_3N_,C\-XLLE\C.W!^$F2CCTDXL
M:Q?6+%5DWZ;-?@']HL^0F<EC=!NB_XT"6?++!#W ,&O"4N5NQ0!BP"'3B&JZ
M\7(?4;C;L2M]'&ERCA-GTFU:8-#M'"8&XG*,\@)<^\M"ULUVEFV-RW3KA8%T
M:PL$JRK<]HJD)AW@D*MKF1K4]B4";Q4Y7)5!@-(31T9]1[(;1>S8Z!0W6F^0
M6LFGG1BB?I8FN^V.O544)Q^<6+J-HT$&)L8,M4LMH]63!CR$&:R);O P!A7T
M6)3@4@3. A5\T>K\P8YQ8<6:85IUGCH#SU\^6U77_3=\V<\6I!\P.]2S=;Z\
M[\Y]*M,!CAFZEI&DP=6( $8-;56THV.]ND%%:@9EN1FT/,DNU=,SZ*8XV_7$
M14%4%CMH,KG!FK/\Z)U(*7UC][)9?.WXY&>6<+ST8S>(6(Y28KG.3K"10TWG
MY@MF33W@8H*BW,,OEM$Y V. . =4LK 2V--I74_ACZ'L*R9/D55UR^\5PHJI
MG.ZMZ)CBAVF4QB6@,B!]B&*>>ZS ._NS)&\S)A_8*#B:9=L698.9P,7:\535
MGI^=IS^JB[Q2K-/M+91+9BN/!->FU^6V+,LP/?,9W<D&,'ND=U?-5+-M6S_T
M_%??2YV@>F6#?G"Z>WS(-+"3WOX;]I]?V#-]=.!QGO&=D_!-ZP=,_,@;FNWK
M(@X3,,>QH59VO)7R#'8ES>JI7_>(KO-B'ICL@M+GC-F%([BA V?#;RMEC(OJ
MA@H9YI-;6=-O?,(P<O]-BP7*)4*92"B7"0FA8.]EC&O/OYUZ*;]7ET1:/FIW
M%^0D;7MBT*Z1_?T/XI&W-;F-PF=,[E-VSF>]RS^7;9J,SQ7F\#6QU:NS_Y%9
MPET+3*7XJ!L^"NN#!7K_ Q+"LLN[0MP%$@(S0"I$MK)\@/XUE'8Z62RXI>EE
MRP-^OWK/\N?)BQ.R[V'/I9T?H-_B.-Y2'7)[3P/H*ES?,J K6]T<H'>R?*N
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M5N=W8G2HP445 SH-O4ESMOE0\"^A)G^\E,K IEA""EY/RDXE*7M6J]F!K5#
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M+#"!K1E(+?WE%IH0*Q4_01QJAF2[,E5N&(4*"-VLVQ[G>F2T8!I&!R;Q1 7
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M+&(@S:R]9N!@- -M>'!(VZ/MK>?>;F=@G["Y]).W40863_TFP"9&:$'QCX;
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M\'TH$/:]Y6D['!LW!<?&SG*0Y&]UOK\;K91'$/UR3M]S-TB8/\F/?\K[XOL
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MT72#Z'-UW[OKM$L_OHX;#5'X)I/A%!6.4_NZW>O>*CA08SK.,IZHHM7MK=-
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MK9EK$#M/R+"H;ZZO$_9TV&@K;+5UUBRK#8U%_MOG@+/AS_[Q_P%02P,$%
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MZG/QOU/TF]&7Z@-G-!HW"9J1^OR\/*<F?G%^8:%'B.>C[@%%'L-A4M"CYV4
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M];BE^KTYVAJT9KVJ%MH0Z )HB^*2UQ.YGN$UWA  ,P;@<$_P-H8V/1@MMH$
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MGC6 [P?P]9L5RZOI@^T\8C"_&+Q+\X.7SQ7XZL#D&'!L9N"-0 JN(@DC*$/
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M9\U@ICI8=9/A-2C5(,:, 7"=U;Y;#/][/2>Y30G'_F -WA,5%XA_KG;GYH
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M@A5430JC<\+2MKJJI=O.GX+)[04[/J#1-U#D:<9,.&7F,.<+] !( 9 B:5*
M-W1+[4J:ZNU>Q.% #.-]XGPGZ2*8*G.8ZV7$$V "P(2DL3W!AS7!*]:A2+=N
M6]^# ^+6X. 87;Z!!-$LF1?3  P &) T7B=%;CL+CM-S101%2?R;69GDK6'
M,;I\ P.>)@&BGU[1OZW7&3$)OH7G&I=[C0($\LH">:X.]<F\HKO!(B4O2J@+
MKB$:0;]\/?^:X1PW]'^ T*1!:();[#<OC4[;\_!3"_K\"9Q[40E9QJENZ'<Z
MPCPU/8I.^W$IS[V9PB]]T5P'11_BO75>3/MJ+DA63?.?]RN$G[([SV\K'J/X
M8\,>^+EA#YHD)GI5:/V\/9THY@'[34NG0_.ES(N?P^V IDZWT-3I!2D1)!+A
M'\]MGB:8A$Q0#!8)E&1$G$(HD6'"-D\(K4@37,4).<S5_]7FZ1,EHD_7 ^KW
MI_-N 7/VN3;W0^98!>H/&T UG^N?'S;]<9G;D^^9C*'6*Y9YPEK=BEK334Q;
M-EZ5MH"?!08CCY'LN\O[O.OG*4GUP,7O=HTZ6O!W<JI+]MWK(03QMX3^>FNQ
M@+E>- T[,,UOBJ@FHT-:GF\6N&:7*V0>EYF)UOFA9'03U&SLKXJ5\6:V'SXP
M<O_.O"&_2&H(PL 3551D"1-Q#&7$"0K#(D[*E(91FD3+U"MHZ\EBTRDU1-*N
MVX:N-_A)I=XLSS;ML.GHVY'>TFV89!5=<#4(&5!C83\H(:R(QD?*J@[YA;:K
M"3S+S\R^/1\QK6DPDG@[LM_,-7J;B4C":&G #(?-,C3R61&+SUEU\;%N4DN9
MXW/=_:JH35?DL"WB(OQVI-8<MG-KFA]R W8^@EQYZ>+UJ4C$1^8*RWJ58H6!
M,.#8G+K<FJ.FV!;)^$B='-I:/YA/T*M=0H9&V'+/A"-CZYSOE:$*X6*-TWMN
ML>"6K2%E3H.1L;U7.OTU-IKN20YUI^YDH8ESUMB(5/S;C;6NLF3>[G JM-H.
MD%6A.QNU13H^<L-V%V7=*DEPC88J972UF,F3C<C$1\*]R63+%#5<@# U.&Z#
MW$ J*R)P?*C7+3902FMCAE]A)_/R$&G[^XV((/&A#"<3@L:8.ZY4J[6697[G
MCQO!4#0^M+FBYJUA<V$(_D*F$%>SW18>+ "+#YT;?DT:.TN2RY>WG36.<4Z/
M#H8>.?Q!CK'7&*&-X5U_(716.F\@W6 !1TZ_,)]K&QG9.L9N5I+Q]JZF3FO!
MT"/'CW,K:%K59BJ\F,!21V_-\NL)&PZ-G;^E24T+W^QU02_FR;U11$BS'@V-
M,8#N%'HUI=8T.718($9J!\&\[51$CG! H,XX\-PW(&&PY@ELO^CD/2@8>HP%
MO,*H5-Z@#:[F%4L:-]^TEFBP@",\@,RMCHX6:-[P;;3M4@UTD:M&0V/;&J\&
M]&8ZZH^%KJ7)>%TMS*12.QP:V]8@-RHIR"2'PY"NS22KU\2]9B#]1SBK@ZTV
MLZ:SK, #2V;7%6>PWQG!T".<-2OY[0%-[VM<WMR2RXK,M2K01D2/<-:NMEL5
M=DW9%'@AIW>]6=&9;MOA4#+&VHZH5N:%%@+KIEV<-3E4@'+! HXQ8<F>S#;U
M;H5;60M^,YQQ^Z8;S'J$"7NC84=P/6D##ZJB)B-PK6BWI^%0+,:$<FFR;&\6
M:Z'+B>/YVMF-)V@PZQ%^1=4!4D)5N60LQ%IA5S:+8Y\/9CW"K\I@-MBTUK0A
MH+M]LT@4'&H8,"%ZA+,DKFRC>8)>P*O*=%:KJE!E&R &>H2S^-Q^6O>8*B7L
M:H-!TQFM?&;5#H?&M@7-Y U16!L0K+,"626ME5%H!PLXPH1MK"\U60M7X>ZF
MX.?Q^5*MS#9A=_C8T,:$ZI.M-;<2(),RNY0^JE!--AP:6X Q(0I5F=FV#57?
MPD*)'3=R9C#T"&>-.M.B3.:7#6ZU0]%!Q9UA\WFP@".<Y4!$9>97=R3G6\X.
M)Y4Y-[6"H4?89;FLCZ=*E=<-?YMCR-ZF"[$!9F-'#G8D04B/GM5;'%0ST4DM
MP$0\$$/LR&D1HSK'SJLE%ZZ1*%3FFC5T, T6<.2T:+V:TTC7[1@UL4]Y8F^!
MS)6IB!TY@N'45?K.@F@9_%C!))U <MZ&%?$C1V N:U!]U.<T@USNO0(^6XWU
M0+;P(W355SNDH \;0TZ?B!5F7>^8C!W,>H2NENXK J]*N*%7 P73FC/*KA_,
M>H2NRK2KBN*V)L,[INE#Y47#[@7W%GY$95A!2QONY[4>M^"7?5<);+VMM F'
M/F'6J3IW/AKSD5, "JSYP# D*>J-M^"%,S36T1.!L0<,.4%+3X)YH)ET]-M+
MI)_UV[TE$1)0_8)4G^F>"@43R*%1'I+K:9L/- X.(@D'03R0%#B)!)P$^L"
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M"Z3!L HLV7R?)MOECLY%@DJ&@HIA-^Y"**B:&M F#(9$$1+@+P F$O 7G!L
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MV^VZ/'<6ME'KY$?R "?6&W(CHO3AE2YYAB)EU]-'#IVLY'CA;> [2;QY]8'
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M\JC/?)21?,_.P!DX_%XI(K6(RY(JT9(F4@P*BSA!,Z*$2XI(:1JFT1(UH?"
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M&''5="N81X]<EY*G1M6[PK0QTU>"W^I6IJ-/5?-1=7<SK&7YP=B.&C9>RP2
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MS)_R25??_AF7 &R]MH PL?V^=^"',XS_&Y/]9U% /R4*2* ]IALR#VGC7T+
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MACV '@)J;H":&Y>&C@LY8SZ"#KFTK^[+.Q(2!F(U+]>I[A:=1GH(\^-?+,O
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M5J#RV;X;Z(KNWTE:F&])OA*HX,HI5W49'>=14#5%812:0$6"P# 11S5:9(A
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M@C:L=C4*1E>&EV<QNH/HE^I3BG>PY;B]6!)<C5SE25G R2[3#G$E+$\:]X*
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MJ>Y(GY%_EO%_Q/18X^:,I/<UQE%[:[.T:M!D]@/VE":A1D;2U E7PBMXAUG
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MFT($C\/M,XK(\D8<" 4,5L(=R"!0^[Z#HF=+-,V-"?^Q(;AI$(;06,A/>,D
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M;]DJTKFP,HLS(VS@JP@!*KEH$E YM>7%W1&:SF$)A$ )/)R9<=34,&KF= _
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MWDPA>L!;OD%=RT-R_M^;O#)**7@T86_4KRWRF.;HCVO'EM"'-7%(T4.&.J[
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MR%OC!=%'SMT-H&EHP=L 1%G(,)+"RZ8 ?Y8Q-74!@O@=V%(PT#:U&=A:_ZY
M,0B1/L/I1C!0536XVH0(91N']ZUIZKK$!7Y:MT+[E((+5I4UCI:B;2@<F"\
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M)[,C"&PKN$\V1[Q@)V-;AYISR2B>6P3MPHM7&,_A-'1;#<PY"7.&:F54>*N
M9ZO"8(#SKT]UNM?X[]W.*^RVQ&NT4H_5@+HP"-6T7<N$^S7>5F+/]_&PC4C]
MO);9L8=Z&&V%E\784-MFZ Z1IJE6)TE-WL?N;^?=%*K9(P8F=, C)EZKFJ #
MY8B#FVB/VFIM8=1,*.KW.UDUT5FIB76\;GW/N*2+;]D!,X_U6FH_ ZA^B(F5
MMML5BO4;:_5<R@F2* *<%W-@.0-#/O;)Z3ABHYNRL1=:4"9!RKA"OEBKQ[(*
M<@5<EF;'7I$W5[+,$FBEB)*&8ADVR1750*$>>'\$V::.@K$C2.9UT.4LOB 5
MEJ:D6;(4L0U^@#Y!H.?$1]YF(.>HS;F--#?G^V.T3VD^KL?TDYI/DYII/ZG9
M3VK^2Y.:[=QE)OSA1&3Z78G(S%>1RA7OL"(NCI5\:_,VH0]KXB?40W1]$ZEN
M^"*KPP(&;OO[=6]'5">]4HR<MXI@)]28<#7W?M^%4UY>0\I0:K\CG@;E0I_)
M,U8,ES*2; XULU6-#6)008Q<=%8X 3$K&D%9><KWR0;RCB?;V4 H_0O'+%&P
M<Q]"MJ1QHI4*1,C(D54%K*(R<6\N"=AAQANOYF)P.'T,+-RFSOY)OP,_N5]6
MA-/VNKER9)SH)K+M\.>.EKH T%!&OT$9\%!60BO-M+*'X2*@2?VS4/]EJ<\_
M1]??_?C.A;H33H(4Q%EM0(: 8.L?EI)B!;S5^4(&1V]WB":]6ISLI)<=]"];
MM=UO#78DP+-DYR#AM"*<IV(]17\]^T72]U3!-[&RWI"VQ$&52]>MPZXX&5#F
MW*(-?H+U8E#EAZ^L %$R+$7/]6!G_[## CEQU;6"<O7=$?(3,]=1\#%;R5LK
MZ<?RF5@97\YM4/:1">VS.^7)>9P,.R_HC&//M-(Q9 8KL>L0@W?TW+W'VTWQ
M8R\]5FNA[FOGMANV@UQ!V&8;3@+*USF@LZ/U>AN<7^.=_ /A.QHK]S;J=KTA
M"7)77U?UTKC8>!.^CTP67"3B'$\G&0\CZ-7DPB:6.U]1E%!V!/8_03Q1%9MC
MW"ELKOCV,7C;]IKMXW-^YB08B !8^2&:9)OB'NEC."/8:PUKG)!XR KCX/%W
MDMX0LL-W04[+!0(Z>+F5.XF\$"BO8X.SU^"Y>3:^'":VH#Q,B0P;*0V41F]*
M+U/Y]\<6';YS\LN=G4GPO 8%4LK9Q01.Z_!D1W[*I=>)R()D2TIBIC6JF0S-
M0+,]''TY[^2Y9T<+-;GO[]QCKG7N91W>W&\R+L<'NH$V&XM?U ,([7,3\IRW
M;Z^QRH$B"T+EV98UJ6UR:JS%#CK[+R$/YYY@WR^ 4NE> L[S F"SP/H#.AH<
M?KB578G3+P^G8Z]7H.MY*^]SCPY.6JF5(>DH8=+<5E-</X$/M'P<3IS@Y5JJ
M?S0$Y='6[#U$;^O5:C@U2!<R9INM-RKS5JV^O!3Q><4CYARN/7TSUKY['J/&
MMC';2-IDP$J+K)EK%4O5F-:XN@7<1U.H/KE56SJF,L5A+LWF%H-LHQ IYK+C
MK]XJP6@7-6.069-+,R)'LJ-JAIM]X5;="TJ^8*L2L<)R8E+4B@3-A)$2!+E?
M'WT]5WURJW1Y*X=EII)DNV'(4J%QD\Q5OYJKPBMBNQM(5(M-\8FDT5)SH[$V
M_O%O]=S[_($/L)V'P?<(=%U)Y]"^MC-*=6D3F,/=G>@HNQ]>=50:C"]!A_4>
MT4]OD\(*U1WJ)Y!A"PR/6HLO\\<P0\;. 'TO;_6:J_XP/"AJ,S,%\EJM%BV%
MF?>'\QW6:EHE!4T<OX*DK!\LVMK>H/7DMW*TE5HD6^PD \+S*C%>-7JU$!+E
M48_*QN.RN<L%*XZU;-EV(RSP76482.%]NYCE4,>T%_"HH2>DLLL"QRHR7,AK
MI39')3;>[H]"_2N8Y!2Z<:+PM3SS2L9@W5ESP>6QJ=L.&YNYA+6AR,7(8L?2
MM2'!YR6CJWR\&-,[ WG/<79ED7<",@#+TD+0R!5;*K9(0Q=R=,F P!\A/33%
MO5;NV$K6C:U2+JML"3N*; ?2OLS1DYQ[WY(+VZP@VM+D-,,*\5K)S%=RS<,X
MAJ+W+'-5&I-=?"/@**@[&^EU9OLHIU7#<S%6SRW93&Z^F8^$&:A$%A_.+?T,
MIQ'SUG9<U^@Y"[+AY9S2>G-CED F2?0CC+;W/!V*= 17 =F)%VOOE<:_0 6J
MR(T*Q2L45!@61ULG 4&QQ"BD)NU"-TE9F(?"3-0MS3*+OKNY_X9&E 8BT#14
M]X]WW=NP%W-+I<%,FV0I.0E->"*7KLS6-]<=K:W9'[4/V"! V()-58F2<Z*[
M#E>,A4+G/J$M7K,WZJ(4"QF 2<V6B7!(6:9-PUA#IE>N4!:A6#:PW,7!!_MA
MKG+??:NT4U[GSOO$8&4P#7B\$P'&BLHP-_,]7VK%[%FL>*$Q\X]_:TJ@!<^E
MM58Z9JTU>-8.""7"P/<5'">DU[&W_(A6I@9.;X7Z\MC*!++KER41WWB#//BH
MF=!9*@=V>E_(\)$4Y^%7):K;Q8-'^2-VMLB>E'8MM1/:_7"GZ?>>$*>3.FJM
M7A-="'_X46*.30V\SOTV.P?,(&?FULCSY#;:ILOE=K.2S([/CQ04^)=S@I(<
M/RLH*35K[68;:'/7F>KHU6JW!8&&-<4J)T[8:C^*\EPO,Q5#0OFP/0373WKZ
M7?RMN\F$TPG$(Z!U%CEY+<5HC&HF7\TQ.B1H6GT%+K,X+CMW'9>XZ[C8?"^X
M=*N3!"6'Y:RUNM*,E(MI1MA9A\0?#U5[NU^CO;$7-_+9O..?9'@^O:Q%)0Z4
MR)Q*#XA8:#:(3]_?]N8]09UB91P.]:4%R,PI?;+-,_FD"2V'?VGZY7QPZU4T
M>2MP7S@'2!OV#LCH1([=B6M.]@?ZVV(J^!.[J/LL3+1O#P!O)N.S<?1 B!HJ
MXD\W)*,&S_:U$,B5HV6'?P5=S'SAN?N5>R:F[K?D5'*&@[AO@'.\D$O;&P->
M[M@\W$/.6JM!3<A0IPS]3XU.64G1)FBK*7>==MWJ=^-YC@KS=K?<%X05&QEF
MVG0Q$X]EHJ@2A[ID]^*T8G<NYCE#20INQ"9X'Z=#LV*[U0L"4:M)T(*3!"_5
MS3)_W;K@(?*RUQBL-AYVQQ/4A@7G.LM0V2%0XO+^)TC6_-QWBG-JM:U__W)X
M&)TUJRT1/#/8.M(G +Q#K[1?SL*!/YGGO&)U=N]$)XAFNY+WKF5O;MP(-$L!
M;<0":D9'\NF^,<LV?OP;NEBY\Q7=R.YO9=UA>[-#8M,AS 8]2^WX9HB8YY/Y
M##SL(<9#:!Z*[%$A@N5:D+>X^^9)8D30E1QVG:J&J^O<FO\5BIE5 KL/CKK\
MMZ=%#D=95XK=">=$FB=D8X)AR3[TR-H =LLEC!?([V8]PCJ^"\[QC!R#GW2%
MAKC'0E?#(7C+$T0T7H6W/:K9C:7>!4Q?V6#B3\2@/AT1QH5VO)39EJ5Y51BH
M>2&<> N#4#LMU*S+;JGEY:E#S71,E$6 .C$I=F<OJ\N>98%?U>(,MS9ST@XM
MV8E;-.)G!)'J>'AZT%+K]BW0["9A5DK?#,C21+7:-L&S:.N93AF'6[5%*U>1
M<J:!N6K A[@;<AU=:#>"PJ.0[I/1%S^K5WBC 90]&>2L[].=>CV=KW??Z4EQ
M=?DY+QD\[_IT-$?EX!$*%#G%;N1$Q:V+O+H'O6O,2G"O(UUJ1'0Z ^-L"HN[
MFI$[*O?9MV^!#W72V)P6.5\?O:#B.'IAR7KX#P%(PS(8<W(&%?-N#PAFOU'K
MA7NQ$2R<7RV2M6U"(B4ZFIR72B%Q]U$$^V0/G5RTIRC9RJK%YEII*I1+-D/I
M5 -Y?"ZWT'%Z QZ:,B,&>-XM?U\GV-2>SP_%\4Y#96V9B3>[W(RL99?S*56G
MIZO=/=L@#!IZ-YZK9]HL($OC+9^?M58-Y,2(1ST:*KLKU:UNY]>T,GB]!9+C
MA=,-@)U75GDY@<O+SVO5]T%RNYC]4+AN^991<U8-1]F_.$7Q$YQS63W)NN#K
MRFSF"#F-<\-"(9WAB$U%VU8JXUAN_*%:YJ:UX3;W)/1#U7)-K (##P/USG$L
MYT*FS,N51<;L$R%IW-(VG20^]][URWO*X?8S!VE!DY8.:I790B#&+CA=1S3\
MF4G]VK>EXYQ)7UC#J> T!SP<RH0ZM>8(K)^5A-66[T@LK."O]CX!I.<?/1%R
M"'X8^\L9VH9K?TL!7)YG9U:CEG3FH004?KN/@6;85R:3P><I$A\HM.NXYYV
MO- +N"1@]<!5[4)Z$6T4.DXHIH%=!_O;H(-D(26JF[';J 9/.R>2Q]+LRT"4
MMN(<)#H*])".6__XRJ/0R^ZZ:GQ23V:62W6]BA:6^K+R\<1]^&PT-4'/0M*E
MW*/W/(&R5B&KR]&N,&;G8Z53%H;*4*PB+]5%G?RD)9\-94$KUQVCF0AY^7EI
M=)6@<\X.&G[&H^$?"2B$^&W"YM":Z*9E5M7:#D/7Q)1U*@KS.;08V_ ?\Y'*
M;PUX._AIW=0@0G,?99=R/<)'Q/1V-#,56AMRC2XO[>[9";\FMB.CM<YWV9+
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MV>U#CC_=B2?7X6ZKS-(Y@B]'N7Q7U,<(W,_]]Y\\_B^!VQ:*72K(?KL$^\H
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M&[M=E!CSJ 3N\C0K-&3UN&F$NZ'#>QM(6"TC< \)U$O"F$C:FQTD"&O>G_7
MLP&!N/6,I?/H 5V5][+W'#H_Z0$_Z21P-*QA[^ZQ(![=?._@=A;B<G*_/0C5
M0R"\]F(."@1$E# -WV"OF=AJ!((%W5U$Y8B.DU=Q.6N.;11/_XJ'M^2MSA:'
M"-VC>EP\2+MX+?7"UI/<J1<CR,)H8# DOJ;@-W5J_O0OR.:^+OKNI$5)"O)@
M$B-9Y6='[T_N4UOP3OS8.PFD5SP$7KHBVX*V/9JRZ'C*D2<#G9:?Z5KZUP-U
M0Q<M3GO,OK>[-G.'L<*G>8UO-@ \O)_#:K;((AO];:1>*.?8FK"A!Y-9ISJ/
M/:338Z^R7&Z%9%%FI2$57HW6^D0F[YXA^O&=9+/$4!DOM J;8\Q1LKB=J_)C
M>DO389755[/6CMSFB$V,I4&WD,<M<[TBTZ]I!4CH88\5TB'7<(N/# W\#3RT
M3CLE53..(AW'?9/056#%R2:*2."B.$X$AFWL.H&'U\9Q'876)JJ^P'""A-8$
MPBFA2?K,-7$5:<*I6J>0)M#LBOLJO!]GGEW$R"Y:W;[!@EJ]5*-685V?/&:<
M08Z=+87)2EEGEEUQ-BF:AL&%;^^&?\-9^?&M+.<6M4E8(A8SL[\4!RVC4E$Z
M'ZC'O\7 CJDF3:IS:3'+,?RNTVVW %5?7YEW?<,J>SM<!S5AK+'>LF[^F;2+
MI*3.[8)R>\2=$&@"'7 :B@#BN,)!N?R93#33B7OI',[^'"81HLIZ<VSJQF'
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MQ.? :LJ7^3 U$@&YC:8XMJQNPN'M46D@_6ZL:F,*-BT"UJW6#-SXT$B.H%U
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M\ EYT[1%P<-G;S'==3</'F^R:TC4"P3!=QDK[=1&RI8P6<9*T2'14IT,UF7
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M.C<!6DS!OIUQ^ETM?LZ 0T92)7,J"I&)I@EAQ.'*'LL#PVM!G*8WW:%'SE,
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M4(#JY']'#GZ&PSD3'5AK>+!\1[6$VZ\=EQ/N_OA!KOE6\BQ-_P=#8]2QX!'
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M"[7L> JKI!?.IAVE4LU6V6#E)K4:QMU3N,0+BF!A*.J:]M&CE>!FV<^/'EB
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MW^=,I6/QVX+M=^<B"\\IKP82X<*'"Q_$P=Y^=WS7[_N=^\!'3MCOG)6//**
MZ,JWR*_OY&,$>Z%O#HH/%O_O[Y'Q&/IN)/_AJL#,-3"@C2@\RS[Y]"(1>+/I
M->TQE(E0)D*9N.N&&EK9H94=6MDG5O8#*V#C9T;XN]:4&='&D8*MBA$<>8G
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M.!;O#VVF^JA!XQXPW]^2PI\SXG[6APR#2/Q%(_&OMX5U\VN"H$$0-/@T08,
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M10L[7:Z8R $.OD"8?T"79^HDZ^DD#*UD/?4$NRZFD A->T(6'C/#*^DR_L9
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MY_?H<2(N6I+%3%KC^;3?,A[C-:5Q69"F!NL"J@[T!3.5%+E8>1!6-?U#(.5
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M"$'WO'U=^ ]4X2,V'>:% ! !( ) ; #!$K870.)ZNN<YXN+226U--!5!+3-
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MX3VKQ';!XMU1QK$B]2\^DG"_ CF<_#<-HQI4YOTKRD>$S?>'BSE..Q/;5(Z
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M(9*'I^Q9VF Z[IH/)D(3\[!HS+&Y:$+QGJ7M-8;<0B/7*/KX+;UAK+H+'9Y
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MB%E8:J7B'34+QQIR\CZKS#Z,]K8+1DL6!AC%%MEREX4U!OQ]:76!LNXC3[=
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MS$.K+ZC4T2V$KJ,1II#/Y+1T#NJ<R=PC>2U>Q)#';V>VVZ@^,M-PQ70 38E
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M$K@;LK =09_5GLLJT1,#>" F*CY2/]Q2?OAXD8"_3B5>,V],^'U<H&W4&FA
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MW$YE#/%%UO5<GK#%EQG>3)?7Z4!_[8,9'UJCC7+YN+QP"*R[$-Q^+K&[57U
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MPFSNACA+H\EY04"K00J?1Q$9+V+)EY(E]6.1%3YA'1,8369=LAZ<2,&%YE=
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MLX%LII'$@231;76;+5$'032FJ29R -/4$#?701*-:6H$T0BB<$:LQ7AI!''
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MYC.:H3S>P#8GD3=*DS""8;Q)(S6&;368WJO>)U!U6T.M93!L-=XEA4.-.1#
M\BU\.()C<"V*\9.WK@M?@M5C R4EG6$S\RM^A3-5>/AKV([=XG9<:>@-'P2'
M-!8^_"&BQX^C]!Z.Z/G<]]"M,+"9^8T_P_*$/J%$@R@Z^5<:8UCS2N%$ 2I1
MN'#\9+&-0[*/!>YMM<#F=+N&?9,KW'OR=.F;*Q>\I5J2:N.LE,KCY\S$N 71
M/%D*:),+^@AF+YR)PL9/Y[CL[M2#]]";T6.$0,:!%\*:B#@) Z48^!#GT8G&
MUGWD!/+)::S,ZIL/;UK6[Z%I*9>FP</2;Q\_W7(=3Y996/2GL,175$L8M9.P
M-Y]"'""RG<0GH)^.1>' ED&)^ I[!.>>G1I9H,)>3.Z8Q_4/8"YE'P>)SASP
MAIP'K2<\G);U(8U*G ;\]&@YRAB+&44^^*X<*KV-@5)PS]/:PMO"UX&*S/B+
M,L+B+2IC+/,3%)_P\V*T'$[@FD_ KSG!(A=[E3]++01UY157XAVH.<32"5F5
M,HGA-[7(>$!QMA9:7OAF%H1A)<G5"!"_?_,NQP=([366DG84G*XWI"'+9_74
MH4.Z;Q[28S$1423&AA.#L$ZXH=A-R(_1N8<=1B][])*I.N0@;(+ $=[P" _.
M]J9%&Y4?2S8BAH?$$] 7^7)\?@0*XP7X0G#S\5*51!>.?.^>#P_I+3 BDP$T
MY?I@OC%#,GVMPDS**\@]IRDTZ!X7_BW!KKK=UN5<P>\K)"KCL;EG7;@0DKQ>
M>WU;&995(:N2[POM]I<,2.^J0O*%U6FM76"S\'__(P<*II7X0@8&LL_6$**2
M#V6L[L4%8XXY$UB%5X[_Z"QBN>17PY;&Q'BE6W5[=%2V6[W+[RWC9\HO%%4'
MV1P,\>78&N37\H0-ZI<;L,^DYB7A_!4$WX.\XO4[K:MES:NZ3H$49) Y#(X%
M9^+D'W_[^^?0+4U8XL^O MQW?JYO7_X*PC2BS8#=BJX>&C0M=J<TY&M?#GIN
MY[7JZEY6DO(]7)1)V5+OH:AC;:OU;1B3,_-1GGQW>/+IWNM]\(E<0/1_?75Y
M=77=+>BED<E=8A%1RK0SAPB7V?1;_8:GHIC+?T(J_\D8CJH J($P/>2JKR?0
M;@1Q=$$,P08V@JB!(+H-@U0]!,%,YXT@CBX(,$W#1A"-B_3"5WT]]VHCB*,+
M8M#J-7:HL4,O?=77V*%&$'40Q#7A$S>".+H@(%1K(H0Z"*(Q3341Q'5#6]>X
M2"]_U9M0K>:":$*U:@7Q5$"T3;>:AYOU<"ZA\?G2W4M@N.Z!:%5J @2RGR78
MGHAHI?O<;5V>-E_ P6B\OAEEVIECX*K5WR^>W7-UY>;^/A+W3B(:^3_'F+#E
M:+<&5R=M.9Y-:];HS;=M-QJ/K'Z;8;C%"JR=\SI6GGTH?Z?-4 >G:T<K96PZ
M!/'C;HQFNZ ;-.JQ$^%=8RK6G),GK JWU G5*$,5RC!L=8<GK0S5'AM[AJ(^
MM6/#:!4Z5>5H#HWFT%AU:,C(JW!_L&JGY1:R,]0KF9OI#TT\5\=XKB[)C<[5
MKAMPT&L-]GLZ/7>'G5&[=YC&3C".SZO(<1P=LEHV,.9:]W?3[3IC$!YZRZ_O
M(#NVT+^K8";<@E5K7,&M@-NZ]G7[JDI"D#H T:]VG*K0X./ +.]#@X<O08,[
M=OOJ\EE>26.YMZV6>@EZS^5&+T'OKWK=1N_WK_<U.-"JT'ON1#A]O>_;U[OH
M_?J4X+$%O%>/Y05I\.%)#_;B<[<O&\O=>"S?FL?2M:^NVTL"/C+B_6<"%2[)
M BF<PECB#O-'O. !GAI&&F@Y"2T$3_4((-6$#&8L^"6,P >A<0P1+['P-(4T
M/8=YA6,$2A:Q(!10A9JH!K P(9\=]W]3#T$*0X7$S\BP^#3&)?WIS8WES.%O
M#XZ/\Z"7\'09_7$<6D&(&*(3GS$W$=71]_7$&=PT/US;BCT$(R18?/P@+5I*
M<(GZ[;DW$Z8W3.K!"]/87Q#"9X! TS@$AK&D1<-I.Q&"[1/D[(/P0P)G5E\@
MJ$F"GG93WXDDPC."*Z;POP2MZ/):PS-GH(@I;3@8WCT,CH&L":#Q+Q&%/$=<
M>I15!F5O3-?.(!P5*&EHS9POPDICPGY3@@M ]:PN_K5G+6 *C#:)"Y1'@[;\
M$-9BI>;EE.!QBJN&,T3\]^H5@(;X*-1#C&=8LS ROTIZ6/+Z' PH(W]FGZ,Y
MRD^,')_@*^.I$ QM6KX"$B=SA2[R0(EZ00T5_T%JJ !;6U9I;I<02!T_SI!C
M-X.):MAR%/(\1$PZA(857UT1(Z4%X?^B]F#7B$A$7G$$Z.6,/C(B2'4& X[C
M=#9G[&<P#&FBD%(E/"S^?S!:7P3!^S*B:FQ2 .A)384_L1"2.=8X\W^:>N:
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M:E\,C9Y0W+-S8W&#SGC(55]S1=2@,]9!$,-6MY%##>30;>!*ZR&(!L"W)H(
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MZ>JIK'MF/JK?G _@XE1.]735^ I[;'JHJ4G>V")02V7M#H;VL+.LL"=XAVJ
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MR+7+P0*8"?TG<AM23CW"<I!'FX54K5QT_"=Z*D@9"F%O[,&727]B(;Z0!+W
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MQ]01[SW < C-!;M@]=O$5R^60!E9JV\4CE,788+TZ9Y_ K538O_C*)2=K#C
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M'NV&7MPT.>\P?<N#_G,&9A5HN,[ /2N30R7FF6;+)7;5KY!%RHBO>#/:E^=
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M:;_P#P]MY?^,-_H^B: ECNJS85M?-<U1NZWI;JCIGFQKNMN:[K:F^R5KNE%
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M*&XD]Y<@! UYFM*%PDK4##?6:C0.N*JKO>@AZ-IL(^A;27 J@X;UENJ_#W%
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ML$):M($]1@$)!KVCFGQ3M^T>NV@R9V4M@!EJ/9,FO(@5P 45 8?1!['M)U^
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MC!B#W*["-L/-2IB+R,M":E$D@&A(!XRKV8+E3Z'Q*((Z_]1D_RA*FT(Z93:
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MNL+^(PV=*#/.25Z*Y%@P+()%B3O7$&A6WD)1VM0J?%;RY#A>WO>I,C"WAY0
M0S@I>X6&)L$RS1PO(FT@-;F5#><6][=5[=&J]NFVJKVM:F^KVM^?]\+4M>^?
MEQ\.3T\.3QX>/3[\*B2VFUN-GR X'?U*ZR1[D[?P(-2VY:H/3\[?[-XSG*03
MXRM&CAR#'/X(YR$%-B8;9_ZW0/[A&0@Q"U-(_@TBTJM+3*N;HDQX=C!KB6VF
M.D5X]&:L1@UNMT5!HOEG0</J"K6)/*L.9_PMQ$LY^PY7O,K^@<UO\#;RI@'?
M S&7JQ5LB03KX]X#N9P(7F>P)& /Y >R2(.>C/TB%QHQV12E"R#:Z#V-#I^C
M1[R 1(9\D9UABRX7XX06'N+)5=U8.2&*C"S$LG"E=0,8ID;V=2SVDJ3-9!BY
MNA<41:S81.Z%X6Y-E]5[DN^0$=T:;%L:1JU,Z'%9W%JN:\):ZN2[2P9POR:U
M"U@OOK=C@X%9 %P'%G,-V6"51D_/+K'RT$A;RSKXMIC/< K9\?#DF0.>0C-+
MPU>ERW#9-1" ,%N3U#E"M[?ZRK3\[YF;29/H/=^2I9$V:F<)NC5DDJ^@+J-N
M19*K,L7#$0:76TH.[LV[%UO+6ULL2:4^:NB1L!MVH-O+342ES%>,-B+10N%3
M%(LIFS= JJ1/UIL'8]H#V ,[%JEB#.="TC9!BF-!T7QJR'F?Q <^XWC:P\S=
M+C&>OX K_%.E)GJ'^X/#H].O>+C?IP7?9;+!V#JR$$IRW@S4/S0K324!?/]G
M%]+(PDIY(B8[] A2MJ6/2VD5J_DSWF?0OJH:8STV?^ZQ(KP9W84;.%61E4P;
M@?&YA+UT,F*"X%>&)K6K@M*"K30[K/SA*.D7=GMX*Q;95$GRKD0+ I\)UP[#
MI:J>-K1Y-:HWPZQS+9>#L5^])CPA/!8L_)G'Y<]#!T3 \IS_8K42540Q1\98
MT'G",CI2G\( N17A6!PM82S/\P],T3<\LX/P\<K(0&2K",Q^](Y9[X;;*[B;
M%9ZSXI>X ^/GANM\M5?/]]Z)/V"'.WD.T@NA^E"XDJ4+A5,DXC),ZID43G@(
M 1\/AMJUN0DZRN>90C@"!)EA&&F#EXMYBV;O$4$[Y\^?OMVU ]S;Y@2%KK!,
MC9MK3JG2V*>,IS@9IR[19%._[XTS\=HHX=0-\Z V*_X4D_7#0'=3['/!-1&U
M#B&R4?9%^!",>W6#2\2?&'RE*:T'01))[D;Y,FA9Q!?B'E[,)*$+;_ESQ8!\
M=BZ$?ZDD,4ZZ\@,XGE=AVRE1%$8$0[G;D#T3]>;PY0@]#VRN^LI<GA+_'_X"
M&\.NMB?%U K\4:JTHI/V9]BPT!:494$7QR\5^7-*>\*MYR?LBO#US>,V[:$^
M,@HW(QMEI'Q!N4?Z)_7X%I..X='R>!P.A =,-\&;#"U(VW)1H;Y//@M_#W??
MP5=^=/!C5^$.LJ1\'/WJ\,<TD;]AIKG_.R%WLE]K_0K^1#JF'!3!GV@(5) ,
M-]BC8;D710<2R@%)HI,/)WJ[<F1UCGZ SERD)H%Q#2ZU$]?(X"_T57S9&9-9
M]<,I)UN%P2?.).S'61-)S60*>=OT5D/E4,T@]*77@0&"G3?QS,%.5GLL3T8Y
MW2#!8$>JXWVRE[X)_$# MD88O..5("3X_">1-*=38OQ*5]T"D_-4&+^\ D_[
M9W[=HR].9PE%P!B LY%N'Y5B^='%2$8OB+A#-_6>E+<_RX3S(E\7>RS%[8"1
MQ@W__%ES$7 S2E64;D^V9S^(X)R1[[3(9CU;"/Y>]'1ZT.%@\#D_%$9;$;.U
M"["&9VO4C </NCTSXF$^8?!F*1@:773M)G?9>:X6Y.8^;-QE$-YEDY%*CZB3
MZ2N-="OYA8[M WB-OW?8 :\2=K 4+GE%KX57%C>X!SBZXP>XY%=7K<OE$>)$
M$3PY<;#Y#*&W9WT,NN#1 2SKM<;-T>$$F^_+".X3G0-GTY6&G<[$W=/UH$8/
M_\AA^ :.$5J0L/0Q*51:9I1HC-311,VR5HMR\H'7C!V ?49;1T*^5%FH/)N9
M\A#! XQ]):8VFW)K").*L.SYA-SR%7JJ<)61H_6K4&N,@1S?78G64N#\R?1D
M;>OY"KT@/5HI'X204G8H C&0A?ZTTW008Y7$Y5,PHQ1NL'IQPN&4D8!H>/]D
M(0C5)M=,OJ&C((:FO"3S"&'H@G&COV+4G+S.EF@2SQG@G#H[EUX$[5<_EV9?
M@DT*">4)FP^^Z2$IE@-:4I,Y+$YIK!8CP4P1#/XGRIW7>K] 6_3U,&_&%K(8
M2K )G)$[S7&U]73GHD:I6 "I7<(_ZJ:U(Q#=(A*O]!^$  6N'TZ3=_YH=G'=
MRSHY/#AY_ -,_,%AFIR_.$M>8SO3.CDX.#GN_>+A@26KG^AXW^%XV]XE3X\?
M_'!T<'BB7MGJRH3$T :CCH#,9$7&:B-]R['#//^(F?[ %?H+MJ>4Y/R*)\A3
M[&:,0X>(D]S!#_#@9IE%C!O-,0SO85LH'RV4/]@6RK>%\FVA_'=,%EP3?0\J
M>-"&9H=!N^IFI%/:PT]'@9;I;@:LTODO>US)H8)>WH:N$BIC=!-LV,TJQPNL
M;:O<!0".K#EI< #,#7"EE68*LBTP?W%V!A=HVP(UP[E'%D8"?Q^"1/>35Q@*
MPEZV-J+HZ-*M:(1K2L#K=K+?"P[M O%0&9->C?-[6#Z .GJP'I@;.P\I]295
MUC3U3;G>U9+:BL.'J/,%9IZ"BR4^'279A<09(O>5M'_*)&HJBO+8CEVY:(B[
M<R.LUDG,2J0@LTI.-I)33J.+FM,E*>%9C0'XYW1KW&YQ>+3O;'7(_;1I)6/=
MHYA&*WE2ES/XQGEUE9'_%LC#!%6N*6Z3]"77D4S/<XOA;P()F22YB"-FB:W.
MV33ON#06P7MG=16H,Y?P3ZK]P4OEQ,^X5C.S RSJ&5;=A)DNR %S>W657V8L
MNCO*/V>=_6EHQ Y49YCOPV.=^PY-OQB3583S,[;6B,"(.\5S;.3^ROE:5+0O
MESI_K=!GZ]0("ER[\+/H#>R)%T:;TJ;IY[@%[]$& C=<JWD^6X?;*AWI6UU[
M. #TM;,E[99$?;Q:<^E*+\W-'530IAR^!+U8HN=D "?;U/H(_T!II36LVSX%
M%]% W6)OK2O!5=F"MTJLB75(IC6]PC"9\P,&W!1V,-XQ;K-0X45@[73^DI%3
M(+Q%X3Z#9DA%Y@\X+?P$^.(\/0/!%.@!HE5(M\I7*\7J4G(OP&+AE+Y$KDIA
MGZ[@@L+(0-1LN=)6W&$B2I*M#Q])OL[]&_ED6R,JDKUEMEYL_#O3A[E=A,I0
MF)TW;''%"2+J$<&J$&M<W7+7B.$#"<^>/W^;*E.RY'DN*J(HA,?3.%GKI;Q]
M"<56-I.^LGI95/92I//KDGP#3Z9,C@-\=$JK8C#"0'HP+XE7!#\?-FD+O'0H
M7GQ]'D]3F/ZZT5=X^[O83UZ"^]$@K4/$Y.LKP+<MM]2M-Y]"KBYK N@[TLK(
MV$-+2]^>X_RZ6Y)]DXRZ7JP2'O,1"^5AB&Y#E9Y>UPT&ZU)$Q3]Z--441EA&
M0Z,TGFN(V+!\![X+;:["Q.KS/DH6I(DZYE*ATRW4+_I-_A'S(HT(?K.4>><Y
M\#/T0[ $?WVFP[WUU7Y9S^;^-)>ONMNV9>-QL0-F!1?BTI'R6-K>EVXRR%2G
MRE[/M;X7;FXW(ID94KE36YQ1.W&B5\M]RE?C6</EW#2:5-4AQ..3J-8S]S[3
MWEM,(VI4M\@DMYIRQCAU"*G PM? %%2(4&-KQA@A[H0(_2FDVA O4?@UP52F
MF/U;*7J-S*A'Z"@X 1S%;0R\] !4\LU-+1'=?P.B9E-N/^E1606WSNB5 EV5
M(0.%?DC36H/7(+M\+R-8&7VFO* <I5XV4>Q^%][G/T?$<3'O0VN9$HNC5";]
MXJH@'(W2$VPO/[BU=2/>)&O4TB*S-R9XPC2>?ME8<>KSV1?PUG_/=A8:A9\]
M?7*6RK_.J)-)XG=*I;]\>B8D,+TIXGS_I,FH3VG6=)=&,4$E)ORB'%+5BIW6
M%59&V>4-^6ZT:>Q,S]&31P -E7[C-T296BR72P4([[:OSA&6 H, UIQSX?T4
M2FH/X\;4=A9=2(DZ9$<HV Y:\%940?]=C(!""HHE$&N6307W"L?X#/>5'61,
M4GQ\B@D2[(RF4@D5"&&F&%OG=D*DD<=T%:?9Z79XA$^*.H@;:69&IUY&0]Z^
MD[$X.'P<WJKCR>-/[QG4WE\;)M![C/,:#CG,IU3%!!,Q$ BS(DB)0%@CS8NG
M50(4PN_0_6DF<1#B4GQ4+Z'-<Y<N8M#-J)GYA?B]N /O9.4$&B/I&W4&MOGA
M0L$L6D#<+[D.PB5B</HU-3RC:=+62.I75:ZAC/*CI,40.+/JFXJ1"]YTZ*;B
M%40;:\B4_^E_S>D_6-!Z>F91P)FF^)[B)5Y'N^([BL3)F4O.G6F=PS\Z.0-W
M(,Q@@1!"@-((I-KY"DOG>?)377^0@N>N;)U&CB\28O*@BAUQ17W) 2A9,OS3
M9'(R*E.#2[.\XK5V\5<+R.%[OT#L0G#VJ3+A;/YT2G\F&#E/+VX()Z?\02K+
M(SR2@3WZP:B9%=,!./\:B#/Z:TK4?4WP1A2QCB\9891X05UTSKC4.HA AM\\
MPN=4,^3&4XO(W(DD@$N7\)!:SK)BHBZU0R+DE[/D^&"/, R833#=*V\@?F@!
M<8])4_\1A6:H-$&4V<,@K&4$&\X1$30K$B+>R5E"*[R8F<XV;#:T-L'WTY,G
M'OD2M5=FQ@*V9I:F.5<F90/#O0N/<ER3.0,M](0DS\DA3*+^"14,; <; 0Z?
M4N'3<,@6;<B;RYJ%&_/(=/U'438.24]%"EZQXNT^[-6B^@M>WX8Q>_H/2=8^
MW[8&CU<\'VXKGMN*Y[;B^07=K2$G]CO=]/5(QS@ED.CIGN?WM2)VA]"5(@XM
M=1>Z)=$U8(%I'FV<X:C"39GI>B718O[6/4[4&R$TJJ?3KAFDR+Q/*Z27@\"R
M6&E@V?8BRQO-PTAL^350:T,?F)2#P<-@HKL;[O\ANO%,72B(%%;$]:F4+GK<
M<9CE$,QXRL*Y=U;! LA2+4/35\;"P)$PX=W97\]^OGC[]IQA^?$(K&:=(1B,
M/;H$G3E/43+ZEE!@E;V)ES6\WH?IR<GC].3TT8_)H_3HP7%Z>'2$_WQP>I2>
M/*9_/GQXF#XX>43'\J/T\>EA>GIPDKJN5W'-M?D@.+QC(T<H>*/H8<G)B4U'
M<E)BFK,PB\$V-;4K5I9*[RW)*6O.$7\%;],[T;W+Q.,:<,7>.K/JRY).$T4W
MO3AE;#)>5?<(2Q@W>)H&,YP3H7>F!3=7+WRJ#C9+7(OV:O@U4C[!0ODSMDRO
M;<P\#<+W2%5/.)<S6I7/4="N3G[.)FWR\VJVSUZC_/:7MV<H#SG=3Q5"$5Q_
M"6MA3#H/)J1'<]&;^LTS2[,TD*^$B=@X:OA5>V,=%B35E#<$EF5<*)+8EUG#
MP$34]=8!(WM@GXQ'K2B4+Q,9-"R15/]]B /2WS\._X95$GI(X&=8)V$C_=7>
M9"5#)L!K/#%^^(2/[,E#'JD54_]U'HV7B>5ZSS3ETU;AEM8Q>'RHU[O7N#[E
M-O"Z7Q V!#L2L>G"97FE[I?*500?B@2&%*4I&AX+1/O:9_9K+M!8'-=U<5EC
M88TZ3:47DB H1">OJ7]2W6$I LP^$ZNS%<#<QAJR\-CVUV(B7C)5E';3%4<;
MT[)A2N$5<3@Q/G=EF</;-G .F)!\-Q 2E)1'(QL#0Z5\+.9;RI).7$M5(F9(
M7KA<@W>;T1#*Q5S2T7G[L J/1D]-%ST&J5+,:7TH+,:P8LX*G@D5L1]\8*@P
MN8XJ1;);J8BFH%B57]8V^;NS1=*8:^,B';*L9+Q_>%SS,H+&HNI7]K %-V86
M2\Q^3E&/ M].$'ZGD#?4CW@!V4D52D4AK3ATQ]H[O (?^8YD\"5;+^()'N(#
MS@'.@*NZNI%+P4.Y,\3CI%2-\:MR#<V5359YMA#FVKFSL?#]B# CY_J*5>AH
MX1!+<T/N%%FUO2"^%3YQ.-%-';/)2<&,=1++]5#^@9$?0W7$?YIZSB^5=+U7
M))VP$FY<-2Z8_^;22\3H!#E-C/CMLYZHK"%65&2FD( FQ"3E;);<9$W%[<JL
M>2*MI[+ZQ+-B;RJ\Z;""\2C24Q+%*Z]IT:M,!T&FM*!GY;RXA?X[*R*!WT3)
M1GJH;O!>8$[ C5RPK*IIQ<_K:=<R60<G9>5C*J$8ZIA.3B: /F'@\7L-6+PP
MYWUY=ZK:X*8I4 AX<1&V!*UEUF0W(5^I2;#08L!+[GNI/S 40+?--O#5N)T+
M"S$MG$7XQ"3"*70\L%=3<^QDW9M)E]O,RC_1DXYG61[SVN6\ F.>U$6G]- >
MB3XMV_Q/^H\?/T.:3%.+C\-O<# T<90U++-UW:W^-"\^YC.?[]&<%8]ZU<!_
M9\;S01^CR?[##_X/O^O5]E*7]%YAK#]Z5A$P?N04D7$^HOP;);]DH/_[?SU^
M\/#QC__GA]7,CRO^T'#__*U#OF=:RK4(>JR@Q\U25ER%?V ]E=DD)R9G@AX*
M::L5(,.FRK)2R  Q5?@7Z6-CF@8.OX;)A)97ZQ:;]07O)M@A&$-(>>&$_8"O
M^0>RBV]OHH^W)OI]F*AN] +JZU>IU&5V3?+B)#"K?N>:&["6@O[8W)T.#'@D
M\E:Y@S^XV)?@MDP*!5S$SRZ,0S'"A]LYZ>0A(RQ,*,)IP6:V1KXU<C1R46:<
MQ(3^SI>]X9*EV30&NP(UP>1/JMS'WF.(VU!Q2P[7LUV\[_&B=Q=T!)(W2&D0
M:OVTEEZ$E,9;!+KDE^MDY\WYB[>[6WO>VK.W9XZ#@D5Z.7:P'E'*!MM;U*)5
M2OOPUHRV9D1FM+HJFMD>Y@TQ>[C&I!&:%<?K%*PB"H\"]&(QZ9J6MRU-X6@L
MM+6GK3V1/459-XN4T:0T:Q<SP6X-9VLX/?_,]4HX>%NH^9-,!&>ZN(Q%5(W?
MD1T=;.WHV]E1W+/!U-,=,N3M;[:0>R3MMK"^/JSOT1;6MX7U;6%]7Q76M[D>
MIN"!KN4*3(8J1D0.C?I+65&MA-52$6',,BJR$QL*1' 2(RA;1%*CMC9IBB1N
M[%:^I*UN08"/^.[D8BRA2\=X/%2A@::$MZOR:E'7BKG?:VO+6U\JHK)R_1&E
MJ9GTOJVGW,H_J+"F7ER0,U":V8<IFF9=8 Z(NHEC -BF$FP_0DOE-4@+,=T/
M)=6J2ZIR8Z]>*!10BR=?5[CXC4P"_@0#P[)B.C2;U577<@D]Y'&3T9"@1Q"!
MHWUS_C\_7SQ]?A&ZZ_8L>4S)-"IX(,0,^X#JC[D5F%%V1.> J7N897U6$#4N
M&K!(:%8SL";KW1<9LGFVPEY;$O20IV1DIEZ/^N=X/Z$^F< ;$!5.>8(Y=)8>
M#IN#3I@WHER@7%-WJN_"FA$<% $%!"'0,@VO5@ (P\(..[5P.Z=]RK2N0V_=
M>?-22C4]NC1F#6"(+Z4C]HWTLN_VZ[["3;D!3!(:9JQ'E_80[GU&"F4CV)_D
MLFD)&R:CO-(>=@4FE@XA[MPFD8U9:VC'SK4R"]#+=105V'Q-XL'2C2ZX'S$(
M5"I:.W!9FY?7>;BV/*BU;MMBDXHT2O=QA_P-+V>%YH2-VZ:-* [>$+"X%%.$
MF2^H!D,;,L+91,,D'4XV%RQE2K:U[FWL->*K:8H'#_L%X:84EZBM=O!+Q/+E
M,8:?&2YR21,1U]<V+[2U*4E0(P9T([3)6=?6CK9VM-F.Z*A<:Y.*RQ!1,ZB+
M.PQ22#*XP8G86M+6DCA3'8$?S6,=I2(E/6%T_\K2$.SRIZT];>V)2V:>O8R2
M*1:)"+J=.TM"^+0UG:WIL.FX.&]15_D*"8$D/@W$K=L"V=9F@LV4-0?_DE_]
M?66Q+Y6OTOJ'VV3N2F&%TA0VW5FCWU5=SI+_.#S8/^ TVP*3GJR@,<Q06;;&
MH"^:*G39G6R6_[TCPKJ:/T9""B[-$L4AE)#!]J_^E;D[SC%L6R:*V@;]#47A
M5VB^AH.DSKX$KU2+CA_*/%$7"8H'=M0KYT;-8-FU-,SIP]>-3U?+2:29+1;(
M4/T2(L6DYNMA7\Y8_Q0GCC@)K&R*4FC(.JDHM*MZBISLV#)-!R#Z4OF72O(?
M[#\:-[.1GNF[=)_N:,!ZY6?#.OI<SQEU4@Y:!C%[N$2&F44Q';0Z2K;4FO^X
M"\@D1#GE'KI7AZCJ'*FHJ:^@(X&MZ1685NH$C=+@RWKZ=;Y:LZP1E1K_)2:'
MY?RX/7=X[:S&I^T.PF:@74S4Z5K6$^PCG-95O4"&\[*^F=4WU1=NYHHM G>Z
MT[%=YR[[>&VO+,J8PNK&#N.<].50=7!##0%)<4E]D]2%2*&'N)&6L+IG7--H
MJ?=QWTO]!+'J[$->24<7L@KG[ ;HD*+>.>]WJD8MUD+A%DT^U6YU_B'M=]9Y
ML\JIDA77[J1WF1[(OJ.>K#,5G"1B_(@MT<@@12);&XY#.[+*_XU;:7R#"1T(
ML'F6RK%,+0=$,OD%;6FCGM4037$/-CE?+G/\7$]>_?7BZ=[A8WO+5 NH)]*^
MSS9D];N]64U$V1%];2:-[4V.13]4&,#\1TOB6O,<^_41A:%<*Z(>2Z*O3I23
MCTE'L&K[F"M<\,:TG[P.I4:ZIA&O)BTJ8 5^UD#N-?*<1+.I/[(5><UZ%7@F
M%>6KVOD$5MOL54C15K040F69*6FVP5?+FJ0J<-/U'.9AW'B3O]4DC5<BDW%C
M^IF>VEJXJ.U[?+XZ9I"Q<>TG9X;O1O+.S$U!:,FT^9&4.^X\S67.:A@PI<A=
M3/X([[3A1-@;KDH1R,I:USM-E.+&;0SK!W8:W Y@7^J,^]V@!4@BR"3V9$G!
MA^KU7U"QC-HJX.?KHN&93QDLP(M5TB>T WC!*G[?K%G:.QJ'QK*?/+U]R>C9
M<N<ZS&E9D(."/,?$N=?!'MBR>TEJB@Q9Z:073[1EC!>9_<8@Z)U7EYET8/,U
M1E<86O75>M(4-D^R0>^Q DNTI-,-,RXK@_$7_;73]MP['DQR7P3-OR<*[O$6
M!;=%P6U1<-^;M_1KCYALS$M,^W[R9G=J5=<?G)-=NP:^)J?.*MR+;5\6O=&8
M,T$^J)H(3L6:9:Q,=X+\E;KYH$0+0CJD;/;8HF,$J1 NDW0K'A4&#/3"/XSE
M$9E>/ 7M216QAD8U^M"8CV@*(K6-M)P)1]/7W_2C$SKF)6%44L(-P1SS::X'
M.]*2ZU3D55.7I867&@^A9 JJHXKSB<I#*&))CH@^(7]5^'7"T<;<TAI)]CQ&
MYQEM<A?2T1/1,$\5"X^P'"9ZB<2!STN-B#J(9:M9[TW6>_)/_B-X @6+9*&N
M-]:O":HF;R3H1/FXAF<89Z*UQ!");I.;#+["-38\2WAVZWMA0D:DN>T,B39!
M[;HI(8\H^IZ.\OKAE)'>7GA5/X"GFN<5*0NA9!PZ*>I@649ISN-F+X=4*$P6
MAA%FI#5,VF^K_+*![] C>LO#Z)^YO;%4"RY L21OU1D-0K00@S9JFTAFG#,A
M#658[K![]JG&7GH8E%W*LB[SH;&-OY%H1R#9DV(A_V0775";$=XAN(HK.(Y7
M0^NGK %J>LDM^/><5VI;=,;=<@LY'RQ$KJ4OGV) SB^2/DB^$B;Z)00ULI5,
MIW#<!V5L_CI*@=1PZNPG7T]>;>1(B-,NG%6,.*,XCR"97TJIN'2#H64=9#.$
M7[_FO-:(/:QHG$QDG6)^%4'60D#/\%U'FL;P@JMBN>'R:8+L"IH,-/D5#I9Y
MA#:VOB6!/=)J_GO'<FBJ#4&WY.\*F5M=SU2RJ;FF>'4EVG0,F^P/SH>"8TM*
M,P8NF:MB.4A;BE6HL*<8&1.J7</YIH)W'/=(W(GS2U:%,FVH:Y6K?).LZNAU
M$2,?D5"RN!CUW5=YZ5=7#U_*9"G36$)- M>ROL2#92H@9E(+K1O!AV@$1MMV
MGJ\\MFT(@,:]<A&DD/.9$M,9V3JG/&3%QME7V6GFJ,P1#+95T,I@"GQ251:[
MIN_IG+6W,DR;J7WT4=EO,?"7/_HAB/Z49:G'::<$RI\'S#<?Z%1I:@,,-YHS
MGU9,QZC6TEOJ!^#YW5 "J:;#RB781TCX/F.L=KORXXB+'RJ+]XOEOH9 Y=U^
M=+RM\D2:N@3M&6693>HF0*E*V%ZJEITT$7U2VMAA%:+?>L)G*"6Y0FM$S\;@
MO7+;"OQ:-PL'N\'=+,CD_3H@6HRK#>W=4X +PJ\$(X/DIQ.T^=@([WY>6YXF
M2^!\ I+:C#QC.9GE2H.'E\UYDG-;CJ;5%&L?O2H=_E<41<5U0R>V_@,F]SFG
MNCP#$7KF>+BJ+?2=+YB\LB;B9O]6@GBPVQ_BQ*"5022S%674[Q<**O&V1C$%
M*T_:;I0[R1:XH\H<DHQ$O ?#O[1:''G[IGO,CO/0?H5$5=/:.>R.5YLGD7H"
M0AY[R=56IEM<Y-'XQ4T.LX3LBZ+-DN]!H$F\4/]PJDL;_&V-\GA.;4QP"A1@
M0_P^3+N[[2\OWK]]=30T+,7V/W+OKT+L?M^],V)\Q0)9GIOS.6);_2I=*!UF
MFSQ9F 2).L*IR7N);'VF(*6!2Q5CJ3E5KQNZ)S;*EEC0QG=Y]X/B58U^LRS^
MWA&/LS59,4VECZF&92)^F1E<!$=&JN&R=L:+S>2C94$"L7=&4&#.OB^,#%TY
M3/?4I*?95>3K26S,['I.,.GNQ[T9!6>0:\AP/=>KQ^+#.+HGN'YY&W^;3SN,
M=9,SE#"EY]F1/]MO=MD;?E',GF3+Y)F]WG<-N+3)#O]^U[G4HA,F3Q*,"89V
MCS?8\Y7\$7_WMS^?\Q9;"8L-"0\TU<^MP!/3O?X&#]0Z"YUBX>:XN\4WEE,4
M'1VCK?G2*-1JZ:GXJ!6HA6L E;.W%UOU819N[S2TAO2PC:R(FOKOJ-JF?@0>
M1KE.@?@8/M#%CD@$W9CYRVE!='S8-<>O85HTTV[!^JWW\)<D^09?O"HNK\"D
MNDK7<D A.E9T.=C@5=QCZ>$4PHN9(Q7@E'!/K,958,^:%BWQV?&,6= <=<XY
MI>JR9*9LB:0*R?! C!2CZ@833B322G$5"XZA@4L0%5 ]94W9K6CM.]EUPWIP
M-K!0@OJ0AX47IWVXNJTQEL/<(#%)C?TX%130(#*Q[VJ_6AQ^J+?"[XG12E%4
MQ3*.%+:',>-'.8>?2VMY4-43:$O1?N"KFQ&0RR/]NIC&*]N<\]\T7? N1=:.
M:/&>$:%C*[IVN R9%WI;C!PK1CXXV!8CM\7(;3'R,^"/-S)P_"8]9=38R8I2
MNA>7FNH4S!6<['J@++.U'.:EM'JH"XE[Z@M"%!4B(OHFG^#Y]EH$U4T1(DA@
M4Y:YF'KD3CB4-NJ3NRB@X5M@0(?,]1V5.\,)9Q+F08U<:$#X-!3GET9%PMX^
M(& 08M4KR_1AAK=YCV.B#/_Y?1'^_YJ+) L5K73R;WN/%"EZWEE,WSQY\9:=
MX..3@Y]40I9?[&U?PV](@N6-HI0D )$JP%FDI9PZ1T4E5LEK0AIR+ZU.^8S;
M3(MR$QPF]9[?69>[X*9KQ4!S^^NE*EGW2*>7A+B=:'\Y/<E-T1J*RLR8/NWO
MS\R7ID4A<"GE<4"0-?DM%(]65>ZJI%P^,Y\7G04DP1%T6Y7/$>>('M\/30[3
M4&A-8Q4]$M6OJ8@YS5H/P#.UT=N-A@-/?G(<A@FKZLPN<G1M0VL"[SLL*T'Z
MKH)#1Z\7# A^LEHU:?V%N;+<$C^SV9P2F\CSJ(%&+C'[F3C,'VQ' 3<*%8MD
M73>:Y?F88H)S+?6UJ& 08(A4]"#HPPHYP,,F1F XB"Q61C<2;8OTDH?9,G7)
M24ZX97&Y:/R#]^8*3BG>!4FD":@@:47.24HEG4A&<M3:H54UA?W,&*/G)-6#
MZ%0DZ<!$))>(#;;*6YY$9/2=5OM+ BL3-6VD[CEH)B7@H9\*J=]"H#>A3#,!
M,+FZCT9X7?-KF],4L4&Q,C0N(,KC9#">K FW::B5)3P 6!1=M\PHA]TM.8*^
MIOV$; USU*L;3(=1(98B=?@,'P]RZ+!XGF+&'49YFA=+R0,@*%<^I]FF.;PY
M#K06+#.<#PL(".V /V#+32M1(AG2=-IT>?3D3M0K6H/R^G&!&A)(^5[ F2EF
M'=<B"+/Q[JKC'$:3*^-05;,86%8I!O@FO!3-* 6)$O@]4]N[AIS0.&,K*:RN
M44<"Q<UP15$.A',KM&F*I+/.<,;"9GKN$I<"\2C%Q*TAE:*3B*(397U#:0+6
MQ;/=-HP,YN.)6"\V1<A76RU?=@M) P=NZ\_M(GPGKD&4'291Q>?/X>1\-9^+
ME/H%Y^9A'O^;CSMW.D>;F<C46=XH<X<ZRB/4U(A.DQE4A7AC,FVAY=AN/:\]
M.-YO=-V*TI]$=166!YPQ5_6LQFHZW% E<Z)Z.VUHLN'#NY7VM4ADCCO *+V"
MV"3^D3+"?O^B>H>ZSB,IU[N.3,J/L[8HK3>\0=XTY 6,<+:1_&JK"G<Z6P20
M\3PW^%I@<\973GO?P,783YY!(-"QTBUEJ<&9 "/&=8G+A?-(YHGX70 O)<MZ
MI$10EKFN<T=,%>9"_;EG60DKZ0ES.IU)EX]ST5WB$2_&$ESF$$'@")<TK^"7
MM_X)N:QD);3,_RT T83+-S):<:<T& F47'3"1&>48R?\,MM#+-17#%"%X(N;
M5+'J"N9R-)&!99K"3W&;UWFW-Q=$ J_!$LCV^"V9M884+7N?=;=2U)QHJ#31
M5V LK\%I2WX*9M@K,]NA0;T PN,^DXOP=[_-MCB,K['200" P ?M&R)=QEM.
M9_&2;HV.DAWZD_RTBQ[6E%R5-%E@HAA.\-XVQ;NE.]J7-7@3C/G2OCPBGFLU
MM0SC]H!<7F ;3T%V%?:NZJ[5#DV!)P5]IB!!*QL1/L1>#@<ZP80U*&$W%4\/
M&#56&1%=*=Z6^:O1TRED@86)6QXLHQ!5&U.?]KJH::>VZ46GIENINB-X!0;Z
MC">0S@YK3QVN]OWDQ7#"#2,UDV'K"!&A)PN)?//@XL(6Q-K$\*AGRV6.!6C%
MF[PCL-X3+%\4 5WAQ8N?U&6WF!29?8B&T72"J9QGUS5!GLU[]6.&1U#C85=/
MOBVVA7U 9+:TK]+4:K0Z.!()($CS*^%D[>J?(X91D>X?NK^P4T* 3TPS5?^Z
MW%M&)S6GG320IA$%[20W[?V)UJ9+R^M3>$H')U:))&@(<KPGZ9UOY1PW!IMP
M497'/YPU'["HV^+P<.^Z*B8%+6^!3WQ0N[(Z#?S-)LVM,_%;I&^J:P4.TY_&
M?5XT5-D@IDN$N>.14)(%L%M43V&Q-WD8/MU0_/_ -!F[7)@$P$6"O6%EIRA"
MZ8J#"6F*DB8+YHYTAKJ*TIZDUA**)S+!D:0M&Y=&P:Q?"R=_T99!\U:"Q-Z8
MY) =W3,UG&$&R8#L<S*:VWK+2+WE<%MOV=9;MO66[ZO><@Z^NNS6=1ODW!SU
M*!V,=/P1-_I:V)[S*"=H/,>P2ZX%ELTE'*969Y]HEJ.W3URZ UYUY.^P/O?4
MM5^,:"Y9%!8PH=(^CD"-KL+458@4)1KND4M3M*+$UFV>.)Q20,4,"=8IGA 6
M9WCF>4'[[E?$A0YS(\]B:/UG>'<5DF.!IX%'L+Y'#)-)&P1=7>S(N^L-@CTQ
M*LX=K77S&5XMN_"WV5(<T;D)2;U@^L P,LQ!]U ]OI5/LHK]IJ1YC8D\Y*A*
MMD3/6PZQ,<58/A+0K89-1,&ELX0K$?/(^=SR%6[MQI$Y]U0GJ.$!&5.LKS%9
MUDO)/W+/XYJ E[B%9DNCE]JH5R&I _OXUOBVQK?)^&(3"N*]*$0M95?"62XB
MLI^M16TMBBP*\V(.T*(X\#C='LB.>EB)8%F>JG5K6UO;VK!;:?S!)Z!%(^T:
M3&HA] [HQN>;@B?$QIO1U5QIWQK<UN!$O&4!YB >.X&8,#+.IHP+4T6HJM]R
MM[6?K?W8AH72?EEIT:!OM\&SLG5*>5N[V=J-V8U#Y]4$-1LYO#"W13*0&9<S
M<RQ_7^<,$-J:T]:<_#:$F+$; A0TEWF?JL59E:.WW-K-O[W=@/>35Y<(^=,<
MO"+.(K(AB?.VJAI;\XE/,4;T&?>=+P8%J09"Z(H6@X'Q#+P[EJ1RTKO8X0+O
M<J^>[RWK*1:)I*:435IE-*36D7O<[WM0_KA_3?!<NNB12A V<06E?=8*:UT)
M)R*V[03JL1%GA"N/C.:*:ZJ^S\K11 2]5Q*"':(THS@=X3M2TV.TM<"XM/1,
MJ%=YIR5"(KEO7,N%Z9VU7[VIBFR[ABT><*\<S(7#MFL1DX903&P.^JR8T4WO
M_=,! +]**P6Q=(YPFL0D$XB^LQHPMC5T0VX[:8\G8IYO6AC_5:CS& Z=1PKM
MIO2"K3[RJ$A33ICDEKL]A=&"T<I"-$3'VZAV@B\+HR)Y7]MN2%/:&AK^7GQ?
MQF?:YOD'^*IR)"A[!KIMC3"*Y3WU&;J+=?MLEBJY8P@#IK$ZOF!H]&)DQ3CY
MBS!GUI6[(74GFB(/]WTA/GN%8'UZ\DE>"I!$Y)T#@8B\O["=:'.0PRN0Y7+&
MF;D.0Y\8C/IOC)E&<^ZW2/3+_6H7]Y@N^'Q3=Y=7^!@E/!W#A2LPX.3P2)J[
MZ-D872JM)D4;.JUP(W%]/I8KI]U.) %NFAK;3&138K2_B,YSBY)!YX<3U=9U
MI7RQ-UX(B@ER]I.?<FF=XMIC!>NH01JU35P5_780AZ\H,_CH52I((,?%LGEG
M]ZHO=Z^_&^Y1Z2HU-)M&'HH,DPG>E#4GWMJ%-&;(@#/65QAX:ZYS1U-##D;8
M74(7D=%$=2NBFW2DE$@6_)$@K"ON:!GIJO%#\-R^HW2C]YVUK\(!-BHZ1FO4
MTP9M.H'4T>,Y)2".O #Y 'Z1)BH@=TA5I#0?1?P)XT&[QSXG-^U]DSIE*]$[
MH?G,0X>ML.FL&;[,^'#L!VC8O:D;WZQS"]-QKU#6?[^Q;K.)KC"#X8",NG>"
M* $6/@@SL$8\7_1D?+[P<\<4!_^?O7=M;MO*TD;_"FM.SUOV%*2VE'OG/5.E
MV$G'Z:2=L9Q)G?/E%$B"$F(28.,B6?/KW[V>==EK R E=QS;<P93-=4.10+[
MLO;:Z_H\TL\D6FW?+[<$W8PNM!LZ9Z0V8<UO &\MZ';+3GN'@/<;WBX&VNO@
MO2A$7_(:_7;L\C0=1B!^LN.HWZ;5R&:(F^F2Z_.YY'HNN9Y+KG_O8AWPKWP<
M)EC\)XC$_,N_4XFIJJO,6M7%Z(VJ#>TEJ<5[NGB1-M\W.>%QC._$(7*W^\EQ
M\+T$IN^?!N(SB+,$.-ISD,5FMMLZ_!6 9T.F0NLBC5 2TK"3HGGS97Q#K77*
M.\I&UBJ"1(X0/0=X<F$4V_4M794#1-4Q$X&.13[OZ+YFL(VRM9_1%U[V;5OF
M)[^\;LC+7]SFC?WV^WR7MR?/VR8OMO2'T\4OU5:AXX(14V[56%53U>(.N7=:
MHLD3 ?#KNWS+7!!!MH.%&PQXM5<3^E7*)BI98$2\#*_BM2JB%=5>XT(=7>S2
M5JV7N[O5-WK3MPS."?-[<-&#C>P(X'7>-%1 )CZ6\RMM%&Q%M7'%BS=DM;$W
MP@2H4I8A/:6$Y=-2D _QF* W*H9U 0:F 9B:%4@3#UO,$ S(P%X'B3^AH^CQ
M3D\7*4P@X<$<.)=H5 W^&NSYX0H-F3*,QI5(=]%9RJCQ4A*%3FZ'1NN#%^N2
M&^4&_=?*%9!"X,8"]G3-@AM"#^2VQ'2*XF/;WP>_C,V0TE:PC'NSCMA:[77>
M !"%N@4GYCN JM;P1)S<=_R)!>A6UW7-[?('-T!PF:4GP*D8RH=2N49QQ:H'
M%"RB&>GT4&? ;8PRZ%*ZP\C&K_6;BS<66PBC*Q>LPTJ4N>@H ;"^2W!JI?ZH
M==VK82!YY7O0M7MST*7//J R5J0GSQP$KU^,#=D'A1@1)VC6&S_ZP2@F1S I
M,%,'(_48:,BCF^FH7HB-[;XVD)$5;-T,+F"7LS/4 \@@^$WA)^&0 RH*9IJQ
M0W3%ZKI2\(UZ,OH0/KTB3%,-J:%IF"-3!F!%7@SZGG6=^[ T?P"WR[L-^ JZ
M"8E-L:ZDT99;68B/FOAYH 2W=7CVOF_:/N<(&GUGB+WL13I%L9Y$49U D8A@
M.L[R852G6&C<*FU/%$%3#WQTT]B/LG:[SG!3!9O)B60>5B@^:$V4,\2H+!8*
M\96L69]BR>1DO\=(MX50X/\AS@ $D6,[0[)[6>R[ G?!^1?9XOS)V5=$R,,\
MR[6UI7]%?SH_RQ;?%<NFIP:ZLS-\=)XM?NC#9O*/Z3]IW[@_6[[R*?=FC08B
M_>5"Q;;XT^=&,/\0@UI)Z*-,#K3JZ>("N_I#'VRA3YYDKK?>7V)AI!4%S;9Z
MZ^L>XIFWP?3 P!;R/IY?I1PUL/V@S0!H,@0D08WRX0'^8E^:%+N\&2HXREUJ
M%)$N-<0]##\LO()15HCCNMCD!&RCB00;153@0'21,VZKD%&:8E?V.^Z*J^ZR
MQ(R*GR*_!6B!'C]GJ!U&L>@8FQUYD_$ #H@#? >!9VY3MCP.!84[-[B6G8+:
M&(0!DCER.SD]>R\2]F51*%+RWXE6\.P)_O/L[.O%LZ $%3&9[P863/=U7!K!
MM5TS5&&$E[\D( O<//($_JG,C .  (QYGBV>AV_RG\\DV]TN_L/@ U\:P.!W
MI(+/GIS\!Y^5>).N"Z+D/JB]5/\(:$4, O.-I4P*PZU@D&IX<L*QB(AR#;4]
MP)&*8$*)3>#QY)OZ-L7*!G@1A4"AHQ(B K49S.12K!\#@MSJ;1UU_@O_\%'2
M%B;]9AL&P8'[$>&6&#Z#O! #?#(\')E2'J:>/A3D?;4?*6K^?.+*B;GCGKN*
M>2R'C)A\71,T7\7-N10=#HX=19>!2Q]!+;'8O5*AV"#)#H51!Z,IRHGX'99L
M2&P6&08E?2B+$YXAL/-L=-\4XQ!$H?XBQ[^=T3!HE67 $WZK>N%ZLT_>^AU/
MD1P=RVT.4H7,>@;,+D-5:0O/6 \!TR^-_UH1>GK9Q!A+:J)XVA#5HTI%* 8^
M+W9$!AS[7!&='T"^@O3Y\&BV"47-MHR/'LDO;!?9K$$C\IW:FV8'.3]FPO:?
M&M(AV00A(&V..>'Q4EH 2"XF36B!WF5QP\,3_"^&$FDXB'*/I"26=J3^,O=I
MSU5IXS V.-+Z+2GQA)X,,B0HR@?#ETKMP'4!KMZZ: %2.)=<SU(FG4-42*<*
M=*1-#YLP"M0,G$^)>&2,*FI4PH.:2GZ8!>3L813O[AL"Q)KE<I9+EDN%I]T0
M!O92,RV(95:"<9TQ:FF^$DRT[%!L1AS)=1\LU[NY\GN6LN2.34CUCABG UZ#
M_P8%V$\2T_1H/,Z%/X@@F;&8]C"Q8\@,>*GP)Z[ 52:_E<0<%5T3&K\PZ0$I
MD@*6S+ALH.:;(X$PKG>WI;?[!3G5(N:LAL&FQ%\3?FJ.\+MBPW#W "QKZ(C$
M#18 5:2Z#D;!TLC:7.DS6>GSR5SI,U?ZS)4^[Z[2![KZJ&JT2+A&P?^ #H_?
MD>1K"B&I0>;<U?TT6AA[6Z>=>HYE64/Y:"$>5K7C=K$"'_W*T2:=TS\@)_IV
M<:)DILZK.C[3QM?$AT4D1=R@ZKJ<6$!6T^VBOJVX#"I/>JLHVTQ%MD80TYPN
M+DS""%^]/CQ02<<PBS5=EEQ.?T]OU*#DQ!=N#6>CW-*_;SIA-$(,@6H#,AO(
ML.&VJ["K^57LWNL)Y[P0HF?])FIP*)Q[)(<<TP$I:S1 $R:YGV4=;#F'V5NM
M&ZGH*#-U:0[H(2H;H4HJLD]RCK)2Q/D&Y08:H=^4M+CY:@7Z">JMJV]!9$P3
MH; C,&< I4FAH"R6R+@E0)]%^!O/>UT('VT0B'R'UL2T)2V-&NCZ6:/1X<53
M*4FVFD%+B%F(J],L,&_-4/0\J2VD?KJ8J7!)SOL3<1:J7FVY,T-0Q!)N)KH"
M>'>8)4E!51P^1CCZU)ZCFS(,Q@VWL?65<5.4KO&<61Z-,SSA[92#15D2Y8QZ
MAH_GVR$>O0-Z-+/J=I$OI@M0U2G9*"Z<9#;;43GB(]<70,Z"9"S(%'=5DI';
MG,#Q]]J(S<!9>=5R*LO*"-O'">.;$\CPA7##<_.5K1YJ'PN?ZRBJF.I847G;
MRD$KN;X6&IOF,.CVK!MAQ8)P;<%W4_$QXU8O[;PHE?OC8;PE TT@"3O-\7C6
M.ZTR*][L-3FEF1X5Y$$5"[^P]ZS !!U,'3R:PI15$7+FC[33\[NP^,$IXPJU
MY/IN#W"A^)M$=]&.@50+V ]^*Y35$O3$RAN6I0=-<DU$*U X&BVN+V0D"B4R
M&2BO8OU'E]B<GS[Y[#XSPB9B<3$1KY;EB^W<C2PU_Q>*)%\722=?4USEC3CC
MHH_9;>=Z!VT_NW=;R@VW'/DF:$IY[LO.=>LE/7K*:Y$V[LFJQVXUSB.JL<AM
M4['5-%)&LDW S)5<*J&M2*[WSZ5DJ19+:K*N"FJ<VE_KK:7$D[TJ6)$A8S;"
MT:,BM9P+1"\.LJ_1Y=)P7RDSN%F/IWZ9UO8F*#9T,Z(0_S"R<U*?S*V/PC15
MLCZ+!-Z*$CWG&.?XYP'DBRFHN/L<J*0_4,F<;ERM,_<A)K2?$\Z ;P(%YZT[
MNG,F:)91R*@2]CG34^F"4('D;,5=C>OL<9:"I62NKSJ8N%Q^3U?B=@L/1_+C
M9*J%&X4*M4G%JH5W8^RW_)Z2 3O)UA*ZG5$#[RR[L^R:?FVX6XD+[)SWS^3:
M_39O1&=ZI;K94HE=K!84<VS"2IAE;98UUI,''/E8.>WN[*%C/TO1+$5<=Y%3
M9YT!E['QICA="[R\S!OK'0-Z2M-?S?(SR\^D_"A':I0A)?L@/71=4A#N;I:>
M67H2Z1E#XKC.W%GQS*(SP>?!P3<.(#M2#L:HB[FJK07E$(EC( (QM!GSC%!B
M]2FWUW7X5_BOIIT+!V=I,VF+T>J[A)97^R*5]_A.X3@3;,%8EN8%%;'V"6?1
M&N>:DG.J'UWMX72J(L%74\ /A4M,,>WXO$U&'=LQ--M2T0G1;,^-B@JN%]R=
MW_KUE67U\Y5%BI08G>L""):C:6A,]E/-,FJ%9*OP9<).&;,,/F."Y'3RC(EW
M*GJ"M'=IH;(T%%[UY9JQ7WWF"C@ Q0TY^\"CI*QIS!A(S>/KPKW;R+-;*R;A
ME35^[<Q"8%@<2B@ <(0;[>*3*(%CVM!54?;!7ML)A!S >:G7-E<BSW4$1R'$
MMQ+0, /N<\M-@[LR 5K1Z.^= F888B"]!$E5^C/G\-*Q<M\?JD*K<0J<EKLJ
MMF[4N_+-Z?WU 4#[39,Z:>?F#1A=%971R2"5CZY_ZQECLRV2/S$6J<_FTH^K
M8AK9EW!C &"C8:-P'.LU2QV%@A@O1K0,0=A55MWT+<Y<L9:#@'GH*U@NZ __
ML+;?!*K14EA7Q#I$B2L)214SOMV!JM=/YZK7N>IUKGI]=U6O,6 IRJ\*HP,B
M5B9=\:OK-%2^BK4YL<XLTHHXQ%6R\JG,(R.-2N#K6KF4@@A,55!,U$;$VA'7
M3$(X'=Q.4JVGL,D_TLJ<7PT1%06>@&/7O@J'P[K=^NH'9Q!MZK;+Z=.J7/KD
MK\!1N"*>0L&,T%_Q8XFJT[^5;5N4V>*O89HU)>A^*L(5(%6!?ZMHI']PZ<WY
MEZ=GQY;TG2^0)3"/I-DMO(\R-2XG29Z?+X/7-Q$Y ?Q79HP)_B<10B(;X/H"
MI^"*U[QX4ZQZ3H]*>0#;HF*[CZ"#TR]E";O[9I.78%VG1OZP3JX"@.J!JY[J
M51A:(BY,3JDNMFVH3. MY&0:D"[X$ALNF,FY-37"*0A\CH#LD_D$U)>!1_ V
M(WAUW0N,M],,KXMBSY5F!$JG"'2\-62O82N9U2;O>JBE!PN-U<9I"^7R3D#.
M05$/)Y4LT =,@MJZ>!X\XMZ/4?T'*36#CT%(+:R5O9AII2EP' %6\G;OIDIE
M6[5^M$X3P4(!"\55Q<K%+Y\@-?O5!5K(%!$!*@6B_**F#7FS[OHVOXL@01/[
MX'5;^,[.T"W@M?GN9^V@BZ"0A*3=)K@T[#"8G@&VW'6^9LB:H@KWR];JT:B6
MT548'RM:'Y3'?J17THL(D3]%BC#$?ME1&,%"-%H#]T'9/]YF!OU>YR CS_B_
M@K#QKL([+^YJK1@.@VIJ#\/+Q#,D+*H$NGHN 9PCF0=*5%9!.4JM;%2E11J%
M,P1C:,^(]CE@KDB,%V$.9?PI^5QC1>VD7A6,+RW4I2C%G.&9)=6Q0]97C5Y;
M0QZ-">813WWDJKY=+:$G1(H&:,$T@FQF4W_*P9)W*2]G.ZN?R[%F:8W0$F,@
M?.+(D<R$4W]!K#J.^L_B,XO/$?')';RS1+0:@#:UC._U_:L+ZNL)2I&LREF8
M9F%Z8&GH5+/G+#ZS^ Q<!.E\0]_%QM]@FW*+)"6B0F+,MVP1660\:=B;R;MG
MZ9HPZR%5!V@"C=ANE3<-=3I2\.^0B'D2Q%F1S:+&-8+5G<<(!%]T4^1K9HT_
MRJRKPC?+TBQ+D33> ?,*N[?!TXUZLD?JR665# V]:\JK*THG*(<,T*\=\6M"
M53,KN%DHCWF-^8JQ1B(1MQ63IGQ#U -;"S=2I',%\RI5J!+GSAR'G85L4L@8
M1LLQ4\R",@L*!$4ZZZDRWO3-2F!>I<+7F5CS+3;+S?%X@Q',9(N"ZAQ66B:T
M+C9%9?2S+L8NB U55VRWA15 [PNJ,6<&OKFK9Q8\$SQJ4@&U8MZV]:I$[9!A
MZSEP1(+3XX*QI*F^(N"K9=DY(DG'M[K:YI2W1)IGL<UOV[[L/KY6GJ,PXL^K
M$0$I][5X2+MU$40U6[0K@C!=HJ&S6114AU*!C8KZ%"AK02S4L1Q7$OY:N245
M4?>ZXQE#R*[[%3HCVMKZ/"*#J.XJOHL*-2'?Y%H_(YR.Q)J- -,J8R=:( 07
M, P[<G=.Y(,).+"BKHUM2:2S  \%4GE24T8B0/$NQ]:IM%@SJ/B!]HK/YO:*
MN;UB;J]X=^T55E5JT*O*:2U$VI.5HYXM8R\L\00%>U4S73.5758?<1VI5@UA
MT.2BT+U=.E1*1<>ER0I !6XJNU#"'=)*Q1"9JKX76%I88U'<)@QF^;XI><=+
M]9U6/)=OB%FSNVX7S+0[(*D%QN:JOJK".]:8Z(CX*4SQ3Y^??J:\M%2'$%Y;
M;@VUFC@<([V3F.A579U,7<D4PB1,S\VF+9#-&?9"QD;%-/:IG3?H@T5)-.\5
M75PHA :.[EHW:SB+(@]6Q5TXC6%) "I1,)$NVH+WM>&0T_H(4>I77WUN&*,Y
M.K,W)5DY_)CS)V=A%6D)2C+OFBO./VGQNT?+/FC58%G6)<E.FU"/2"B96S1O
M@G2CDI*XRZ<L$*I[0\A."!'="]B\RDQVV<T2.ZRN] R/[#'EF==R4*RZ]G37
M27<V5O[ LF=D'@4=V':QH^M-N+K.12AM8 U0C*F+H:J!5-N ]-.*X:E:V@A.
M\ZHBSRZ*%VWBKK!>73;;H=:%O&?Q5&'TN37# 1"'_UP5DHB4%G4JMT:SAG:I
M^Y7(%OT^S++R+&@'-YC7"20Y%N%'+5A]Q[W2^J&G.1_'_0>D]%;I7Q$FN94M
M4@EON1FGWJUY25(6JO8D;4%$\[JR=! =%@:]A_N9)R<RZ,-&IT<=Z]X!B>#D
M%&T=U$'.P[FB,4S4!*/>6.9!CQB-O^U;&C_V5\)*U(6U[[BE_C:A<E65O"T.
MT'3?<EL%]1&N5OVNYPZ2-2B  5J.<;U!-W?0,W\Z._V4]<.2]2&33 >I%HHB
MMP!R)KA)/UX,#J"M50)<NU,^THOTN<J5Z,I40%N?<7!I+B8HE@MXT]O6WA;6
MXT/M*U!L;_?H['CV5M782DF=X:3^\1C>][:$2 ?>G1R<EGL_1&OM7!Q!9=S(
M%'>$_;_?%L.DHE,-^.7$-@B DL?)KNI;8<GS'&>+7R/DMI 9^\?3I4#'JJX(
M'L XE<,NL!+E+A0P?-!7 >'4D95Y2YJE6$^_-<%3&347)CV"F;,.^.0S=*L@
M99I#3W>P1J U\!?.:0VB^-@7" \4USXJ+F_ L,JL&G[:6+XI\419TW5]2[_$
M4T514>>B0*.W4^+L>'T&?QSO5%06TC$$^LZ$0]S67TX7&:2#\,/AEKDA#+-U
M$\93.^BJ/*0'Z*8!!#H=M?%&*KIZ.8PI";LC&>=I2ZK$?#+JV]Z/_TP_68:M
MK\&>G=PUN&7&T:/3Q>4UPW!,%PZ94I+?#E>N$ >B1FMW[ ZPN[*D9KU6XT6P
MA?H(H\\ KCZ"&)<Q85D7IF@A; F&-S5%\K)ZL^T^[9<12@C1NN!*Q$-(.J4?
M)_%;S))!@[-O/O3?9JNEG(B7<LO/>&F,J ^IY;RJA2XERHQ3[\5 +Z W:*I'
MDYV#H42/[#2'-8-EXW?K V-$40!:)AG@A3.0,&4\H!-OI8OC&8/(J3"W\-6G
MCW&WW% 90 FQ"J(OO+NK+CVU;/S#:K?EXM"L+!L? 3)]Z"@!0"BHM;O#57E"
MV9 @\43 FG(5AAPFE+NH[_0%_V'(V]F&^Y:\PGIH,S.RA*XG;3!"V=99+1W
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M)1O1+C2%0?1WB*''R"ZC-MP6UJ*L1:3QB IL ]()X=X0$"16 WQ%6)M2^D:
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MG.]&I4-!^74 OGV %LKH(Y$V3*GM@!]%$8Q\5?2,\211CU("P* &!8!;PLY
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MAU@;NKMHM.%U<Q5&]%^Y4]JC9<4Z40)4JF2]D9!DY:\+-PGTZ=-:N\?V;2'
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M,&X 4_]6WWKH(I"0A89H,>#K<$@[,5HGKK?!Y6Z6RFT12[;RX'&22<NWMU:
M%PY[NVYP-R*LPM6(D]_)Q!C12R^]!-(E\7J>5@3^!_UANPVO0C"5<9FI-KX.
MM^2J;%;]K@56%<9/9@PM6+>U=!?9>SORH<@UE&7=UJVK@C\X<OOI*M8\ZCQN
M\G++AZ&)\B$A4++_L#MA/"4:U#]&-X#*EU%U3=>MKFC*>4->:%Z)A9NO@_JG
MY(;&K)6P4R(2E)U/3"CBWLD;RJ]0!:*#TB[( ?L@%GY<KU\)Z*)Y#0#,JN7
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ML8$N"4L-I#?YBG6#*;^#6^5[1-7@2VLK1$L.5CQ6#Q"NI$!D>LLR8O!:U^7
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M6B!:CJ6U$2ND\GMUFC9)*]7P/.F("Y+.53%JS4%A L!=S&US[;98T$&_L-3
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MSFX$<C0F 33*J^5VV&#^@;?N!5[ID!D%:YZ3I6PP<5;W7FI$=O(V0!&Z&#+
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M:":?"#DAE4K!M'88B"">R\O6RI\V=?.VP\JE.S$'TQ:;=UP3/QS)9YEF25%
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M]=7)$K<3Y*9M"1K37;VFJDJ^L+B5&KD3L:[;SBK0(1Y"#X/@C>5F\%W+R6"
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M6$U*^'TI?:&J AT,-F.^\Y<L%2 ;95E_J'6-2*3/(*Q42MB#>P<7EY2V4$F
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MA//04>E74,="]20@@I5&0TCBBM*0D(STA+FOD94EL4E7->^N@A(9I:FIE![
M0*.\J,H?3*UB@XR'S<34!]]E_%,RKU73,Z>YV"-3%X0\^?^T]ZW-;1M;MG\%
ME:FZY<Q LJBWDIE3I<A.HCFVXV/%<^Z=+RZ0;(J(08 '#\G,K[^]7]V[ 9"2
M$[T<XU1-C2.)(-#8O7L_UEZK52"S6Z->+47\![8]UA$]9:W[WC"D5;?<YYM\
MT*^O%6JN0(L/^T]41_/P1J?5JBX&SV-*Q*!9WPH]MRSC:4B,J.SBKJJ4R237
MW+-$C7##QN[@8F5,Y7 67"&7.2:$5BV(AJ@4%X863$2@?MX!:N)7V#HIQ%FR
MZ_F1*X_L)#8NQ<*8FC,417O4>Q+[-$/:GQN/9OC(?1W/,?NC#C+.O0)]9+1Z
M%2U17(ZJ9W D*_ 1VCG>JWU&E.9I:AB=Y?2!WI8K^@N8C>OU8C.=A:4=P3V-
M65+-$9$8@"^PN>T.*6Y^0957CE["/;H3J',^)TU%#1]\A.V((V2\&$09 ,ZB
M*Q'/D: 'V$GJ$:)D7%P9';;A7\CAABF,.MK#DZ5]7TZ]<(VGK>(;SGR2V>(3
MJK5H MXS:OY7HZ45VZG>#MU<NK-!@-K!M5:<(!/4T,.O7"*O.7I$BN=R*-E"
M'\IEVKQ4V*#TP1%W"U!R+D5?3=!K%;BY$3)VS!NC/^&?@K-:\%RMIBL';X)I
MS(S[$)^@FC^4HY//6#4$YP+N @U$$V#S8>:Z.?)@L%*4 80#8]18Q:8/?;)Q
MJ_F9]T0\O9+[([4?_B&[90QA0?B^;D<ZC@CP"A434T8C/E'=S1?>71-JPPUA
M]%#W8CN:!QW91^I=Y\=2.1FAV'<*#9VR60K*F@0I.>'1J!'.E."8!$J+RL6\
ML5)<X2Z^3X1BG-<$YF ,2)CWFODQ*$#B'4)0&FB+0+[ ,Y6":+,1K#6/2856
MEM:UT?U@X+\J00W2SVOR.8>P ^^JY;A6QV^8)891#3>\J'=-8(3VN4@^US5[
MZ22-NZB KF?O5 JPCT>D^*T&:NN#]D76Q03'2V;1OZ@5CWU'NPYFZKXW CKN
M!;?=<5WA+??IT0&%"<DV(-E:^-[9"?)X@W[+;L8BA_"P$R8!I B"S*JVA_EZ
MK!#B/CO+ZHD4"?%6PG:O!!;FB+P]QQJ<P0'8565WNJ;FC;V22*LWR, S7;="
MK_LC%)T]Q<KM.S17W#]\0SWCLKA6R4#+C :9^XT-TMVA03HT2(<&Z5WV];KE
M;&)TI$Q  0^A?(:1 ""BG'J&RAB0WL+])/1KG52B-6[)B1G_R)=X**FT7IZR
M3/QC2B@!#C71I"_$ \BE:DY*F2.?B/5SN1J=4_818'=R?3&I)!>J:$3H=Z:&
MH]%/ZN,EC7#:ZM$I.+9+,^<"JNNZ(.!(4955HB 4ZR>G^5 Y<!QZ*T'A\ZC$
M1B3"P& F$3&>[KB9&JQ:"4;>+Y \/&'FH$ZAND,\Y4:/5:E5L3FU#?B%RPR7
M]L;<OY/AA])0^N#E%R[3=7QIF\7D!1S^)K]*RP)GFA1"/XRI>OHLMPV9* O+
M9QDL+L5,U>:@J>J/FH)@L?6-&/K(!"+;3#<Z[A3I6Y-KZNF8Y0]KA(SY#"ZN
MX*/JE;HH*]P+K0(-5PPZ;U"55U7=R(9<T.#YW?&DSFWX AT]%58G(,..IM%3
M-TA")1+[33.<^KU*B\S@4* ?&]X2<EOK9F;FFK($C,A5 A#JN8L/0/)QV43R
M7@G&RMQ[5:'#Q):%X@0UY2Z3.4LU,UM)*T3F$0/50G* 6Y?9\Z"I(*+S]N:[
M\QR4PBC@KDMGJ[OLT+XEHB*[;#AXX[L7UB%\W"*226NY2>8$AS;TM<8F,%$.
MK^4%!PTF.2NNBNQ*6ON=JWJ;4&#9!YPFZR[P&VZ%]2R8S.[%/-!'F(8"* 0]
M&1+4#]L(!D298,HG\ -.7:C+-Q.<M",89U$^PJ,*.SF>WOQ!8I1:G^(H:]<%
M>Y_Y"*MA'^#"W6[LJX:])</'*<2<WFAT7$U9_QK0'?=^#$][M<KN77C5OS:N
M 2J]W.V5> M,)\69!]Y><.F<U&Z+4L]<<HG'8R/4.HN,3^R^  =-9U AGN!P
M89#9MTXT5#.U:0>E]^P@-[QJ8@$$RF6O,P[&+'M63!?< *\/%@/Q")P3T\F*
M.JY5:U!%VN^M$A?<I'<OR#FW]HUU%_T2U;9*J*A ^9(;C5A9@B,X=$VZ]8A
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M\7_?]U)O_8 D&]P]]\DY6D(I=1#XK]X[8->&=R]V,$NQT4*;%CO#8";;-[.
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M7?:>ZC9WWA3O?U@GKH= #I78^^*CFN0.%$)BKY"KCD4-TZBX<D() .T/51A
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M99 ZR3X5>OM ^Y0[#41"DSB:'GL):/%CT ?4XSF#>GMW*1\: +J'&A2<&##
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M&"-Q \WS5.*%5=*7U#5,Y(DN"A11/YJ5CJGP%XHXXNEHR?3RYD!@" PV=D7
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M7A7IM'](T4TA/A\7TY7]?_-ZD?WM_P-02P,$%     @ M( &654-+@(B( $
MIUD! !@   !R:6=L+3(P,C0P-C,P>#$P<3 P-BYJ<&?LNW=<4^VS+[J0*DCO
M'04$*:(4D2XB(" @4@)$0*6#=!"0$J3W*J!4Z1U$>HWT#M*ED] $!!)J@)!<
MWO?N<[>_XGE_=W_.OF?O^SDK67\\*UDS\YWYSCPS*=COV&6 0E5)10G N0(
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M<?&8X8<"RS3HJ8IHX:I@@QL&\8(7=T000Z:2;^AAP2K>*4ZW ^LK)TN;IA#
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MP59E=\[WXRA/_"TS\Y]T834>77%!)/,>2QG78A#VAK"-1>ZBS \3'I2?EOH
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M,L /.B:BZW_SG"$;1I2C6*84F$'1&C%*P[> $5&6>^*9B% X];D:0O0;A"Q
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MZT^:L"!T:<DNJF'\C *&=6;Y^3/B]]35).ZDA]Z8%'%-6YKR)$H,)I$Z=WB
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MP461EEO]7\.P8864R!\K4<5HZ03U?E6I6-JU9>*=*QH-W[+YS 9@2.%Z$_(
MBQ"T8$+8T(%0B(:,2?:N[N@VB23BE2J3N3_P<B$_LL(:N$_3A!MC\R^%0C/X
M 4U7G(,;96I$!JU<B(!LMG9H9>3;>$7D?0C;+2=B8(BQ:*K4FPK"1;+WFHB$
M]E-)AWL<L&N$C55,2U!S,$;*/35G>!A\^9G:V_HP26#L3KC_+Y1WDG-PEP4S
MXX3> DQJP;\]UTC/Z =N 6&M.7T=VJ];9MCK0R3T#47)G8:5>;-%RO72;P&]
MPCXY:'!]SO4-_RV &K)UR+&VOT"9^8Y[#7[\B64N?>^PX+PB^OD(?-&12Z><
ME25K82Q;5=YO O5,[X_C3-?*=PG\]"T T2J]EMZN?@N0AJK?H.]2_=B%$?#7
MEM6;>R-7E]FW@'.TWMT8S%?8!@DVRNE-SS==8G$65&1Y:XE512<B-QDWZGH4
M=1J/M(+\<6;J_"XB!!?= M8]P/](7WE)+^4!Y]>$7F6AP\9E0N %9QGY [UH
M=;DQ#U6[0!SD,JC"F3V%1?\3T=/?;TZ9,XFU;4W8.J8<QCKRE":@^>T&KFD&
MS/A--.OT KN2W%/_3//473@R!P-?HJ?!1Z==**?Z\,>NV-P<;[<J_0-.P8$1
MJ>[)XZBY_"/G7O.8Z$%^A_3XQ?I P7D0DF[%MR!.=DG_;6/(!C]D&'>S7QCH
M[6M_+E]35S>3WY1UB*7!G>+E0=AYL/^3E**[>V/!_I]0_0O6/:=N(ONB[8A,
M(OF:II?L(5_BSXM5YBM,QSI34?'B'0M$6_V59M/[/)J9$NWW#YC-<Y>9!33W
MFR<"$)J_TS>N\"Z(E@J=9I:&'+Z]4'JX5Y\8(M8#ZV!'4Y;WW0).;@IO :L[
M8.0R/7S,Y(]SFP?LZ%N RBU@8"_GQFCB<DX^+,G>GJ7RPL;QIN&36[/X5-V)
M-;[M.F4N?,.0!1H8>Q;CC>^6[YGPW M@[2:>:>9Q(39!,3%_-A+KM\5I33B0
MT%<MA\4= 8MU_ZBA_'R(/4F9)=DD^=_EV7WMD+$,6TW?%R1?N^C002YKGFD!
M3P/:*UQ=['6M^ J3[DG_,\&_[^S;#B&-NG/FTA=7IFA1HZ[=*N];P(M:=*>U
MXO^PN__(3,6K\JQ;P"1/%^0SV'D3?()F0H^:'FM+'PR;;C6<-?C@]JQ^\!OL
M7:4 V^V*BCP#W62M+=DSUVTDQE$"!ND:#O_F#H6OM[%^N8H%Z>R[NKBD/?,*
MK)=F@<7HX%E)0]<VBNC>5'5:_JM+6/AB\'O:?^:PQCC_JWR9O%#4>R/B009P
M+ F&4POXR5ZZ5Z*?/#K/WL+T$SDQCW\UCFO2,V/Y -%K.^2[.T'3UU_T++.K
M3@6(05;4+;]B52,,G]D>OWL^)(BM*(:9^'$7]]7>MRG]J,PD+UWG0SV!<E$U
MX)"I<]\5FE/+)TEIV2*VV])##(] EL!5#?))B!2QW:,41(C"A:\T%8MT>!8O
MKZPBDW4:DK;NO_MP^+3G\:G@DW$2R[2'N8C,QW1[Y_G(Z07%7EU3>)01LJ;=
MVW7M_I:]+]F$G4S*I[5H/-%1'W9 U3-C@9%MS2YKEH7E(FC7+PL$8=1%<M?>
MC^L0ZCW[Z,C<*!BG=?@]_<0>FY,9EUUIJNPN<3;D>P3QKYS86X#-!,G2;BM?
M$8R:.^OQBH>CV/2#K2^P&$'T!=?7F+TX-R4G@= ].L:;L@!_N+4N,K+(9YB7
MNN_"CSV, 4'Z :I3D1I!9Y!$S_;">$C'5V;E/@OG+^+WA<?0-).Q$O\@KCO'
MY_2RXDW0=-/I+>#[%3H*F3YR#D$6%=J*IHG'Q4O58 ^&'YZ1SBI^$,877%)N
MB\+YPIRX-3Q![ BE(6%9C_/-T+PI"^*TZ21 OG7^:KB3BF9!["J7RWL7V5P8
MINO;EI.H%>S7!)R\7K%2PB-5U/ZI>.[HOZ2^>[10<I9G:OC^/$NV:7["Z[S<
ME=B8*=Q&+F2W)(][EL />7F7P4? D5(C*LWP[AD4J Q93("_T[H%*5RV/7_6
MR_4L>J)N%/.0^K[ X8#ZRGJ6:8A7$%OU32.::0D)T9YIB-4!<ENB,XJA#15N
MBELAA7WCFQ1N LW;@(LR'\IO@BD**2D+V65!G9UR^A%#1:0M9[3C746+*[Q%
M T6VV$MF]UFR=,;] @JWT[M,<0(LD<(5*.>;<C0;TE^A%M[C&R!=5-':V$$2
M[U[,R7XQ#WJ"O@B=2Z#!2#],/@]!AOZZ"P90!DW-<;UZ</9>?#$J7RN"FZ+2
M5_/O\[10$+ZJ"48:S,FY$0R?_IF4Y63[^?GKI1IN0JO+U+2F;;3B@I#>B+C>
M 08"LSO]J+<%Z,D67O4;+5[=W!Y%^WCN5\[K) DPD,U0@3@/BV^?<>+YOD_&
M*M0:=H5BAYOVD[3#Z\7IHQI^")U.RL?$2Z:T)PMB;E_F*B'E$FM<,T^F\RS/
M+.;2ZQ97O:MR0M$5VGT]'N"YKM%KMRADN<)->1#G('P$1A\G_(CVWK;JC&?!
M6@<1Q;328A5TYQVQ$4T"DWPB+BZ/^W2K*2'* MD [X*Q5:Z!"7=7J!:(Z._M
MFK UMLZ<+O+^,'HA]<;#%K2!1R!V&7ZAQ!2>-J=:7KZWT)!Q716Z]]3NW'J>
M1&_ 3W%0.O:"ZN*;I,B>%CQ8FLC#W1\KLFA4X=,(B5LJ\SB=*T?WP27 BIF%
MP]Q4YZ8TB >$ B9KJ' #KL@CSR0Q^TP8:Z8V.T(6>1,-N4,=:L.5,L#COQK[
MM5P&-X5OLG1W.'D#;O2<=O("K6ASSFX!CP/+Y,U]^(W4B7VDY>;6.QIFDZZ&
MJ1-]+8K,,OQP5BG>*6EG!JN]V ,);];#H-9:WGH/.?(3OOV'2LG]YVL/]KO6
M=Z4K20S @[-@0PY,M_:3_AR\=DD8?T0K>?31?KHC6"9.__0Z\5EII*4&"S8&
M=!'@B4M;/KE;>.6FSBUFA75.JODI_XC\K5#V]I> 5TB)-=-HSF)Z0OTQWO$T
M@>R!\_%#D$JY-3.>>3J;GE'<?=STK8!GUUP!0O /5QY0DX]"1/IVV\9-5EW9
MLDUATCS?O<664_;=GHT_,UF]2::_@,;O?[X%=,Y5V,_%^#*+I-DG[/1T6C4
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M<YH(]":P?E3B&$=]!R=WQT1R'FCI:#6%#-=M"!L__CVZH4QB<+SP5D)!T!=
MO%)NF_, Q5NXBWXZFS<]=P@$U5W;J#.KT/[0'WW[2H +9X A&""VU?'H[YCZ
M*EEXW;G*6F-4L^^S\/X68#6!@1*9+Y@/D"X<(JNT=SJ?)]XE3R,O>TN-^>D]
M:T)$PC:V^5)B?\"VZ+X.#$R(#'U1WS4-%%ZKI%9;T-9K;I]L\+\(D5<6_=0X
M8\E+6B<MV[-$<P7K1/R=WO9*XB"J+9S&G1?HUL_#'\58*GQUL^#$W5#K]YZK
MN(IYA2LT\X?%[5VU+2F;1&.<V$L\?1"N^ST4S#%ZDOE!0Z;X'H^NE_8"N=#^
M2V-L@8_M,Y9-#K<4ZE)DVT&%B1$4%!37'34F!W]OE2%]NGKU*VV[MON_#@XK
M"9Z&_PH/_34;0!"0;AZ=@PVEYB5$S_!?"2D(QY115]\"N#A&-A#Z5$W[-? C
M_?J.Q@S5KA")Y5='NLW7;!!O)\OL34WKGUHR*9ZQ,NIM@VJJ_MY_\B7]A_*T
M]*.FO+7!X+.?M,\EI\66'\E5P\<CWQ;:>M4LVC8^86UHJ)=[1&*3IZ-8#7C8
M89CS%\OZ4SKZC4MM0C]&\AND_V8%"90>NB5_@ZZ!8TQ:]G><S6*DR=N!+09O
MS@O^U"G <NH?0+[XK^G_]Z;K42*T!\E-[G75A$RO4*<T1V;%+'YG6(^A6NM:
M\[?K.GU<=PL8O(M[@R5KHQ#22!,HY :SXBY'OOL5H,D;R^^2DSUI%!AE@[G$
M\4<"]/'@ZUW:(3YQ"Z#_XZGP_Z]AG!R%=1'Q!SC"U/>7RO5Y8<<FQO##Y<1X
M[2.3\C^U$"SXNU+]+YKX4PNY>*W<?W'6;^;&<W)MO0U3\[QX>1S-;:VRU5LC
M<)2%\-G9+5L,H\)[J;;"U[G](^NCSUM!OL O*04V*Z)0"AP]C5[&]S3NZ= _
M]:<L-#>E_:%L:,!NS/N?4!7+_'^TG%=_>4MO2&A;AA>U]B/!?8P$PZTEARQ
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M]5I+(37O(-F,-M]L?W\S(-N?487EN%?(,"F=I]O<QV:7SSI YSA_Y""];M'
MP#O2B[!3\T@*\ 0<_1.T<XU1-Q6V;A)S6RW03-I-EJ_#;_$Q1"-BU5-WS>2\
M+-#P%%#UN:;>)!B2W2-*86$N.B8=S>Z)^8HG.;B;JK2:CURF.(_H,="2Z//-
M1!-'W_\]IBOL](<B@LN?]%8C-6@'69ECZ%"=<Q5KH_DKG3&!89'!AB0(WS+D
M+^G@8G9!6Z?1B<22M(B[9$\> 37[6&C6SCO1,;]78U&R@NGMX.1RL=RY[$?=
M/+K1JPI1GE<!.R;&6A8Q%(Q!-9^&]./]S"3%QO>#+L4V4_++\E[N'/6+7.\Z
M>RXNRN4 /YHO+4K(=?8J4$!82'8]MVD\+8>J5)Q@AVZ.MF(]_'C9.(4"9 QI
M,4BS#FJTU;LU$/Z,V8]#Y!3D>YD 52\W[RS'_1U"U@@RUD3Z8[+[P+5N!0@3
MO#J@#&@L3N%O1FQ2*[K/M;G/;.,G0GOV-!$'Q+J2-F4<<Y[2L\2'<HQQ$UA!
MC<6^AH:\.KVRADB__-(<WV7?:1HZUK"\;I["MRFX!: VO*M!-:^)=Z=>0T8"
M9 G^Y+=?O_.MK6@>"N]$R1_O[BOTY;RH]L_,A"6(]<3%%QG1'97>'YKR?45P
M5%D7;%LQZS^@^7NJ\CO-+'/V",*?&@ZU$" ?RMSS$G[IMS71$3P-PGCSB^&4
M==4QU%.W&&#Q-CZ80MH1FB=M+H\<=:(1X+5#TOGSCIW1J^Y+B7C61ABJJ>.'
M;.994Z/ -G7T/8G]U,=.LY\*VP;5\6-7BH??EY5T?IN!7H<Q*<UD0,Q^AHB4
M[V9*]UZ^%??#=N;GOA+X%JZ6)3@=TI8<:JP_ +;]>0NX#Y$+,\W5FMPL.#!Q
MR)S;2H;KNW(FKCX];MI;*+VG&A@A'7_,$J43K-0<1J5!]6U6@PN*&]6F8>\A
MD4UPZO,AC#4@;9_9*9<[K=6/;L0C)Z\E)<9'SM4:]V?'XV;4_GYM<< J&8E<
MWJG#TD;RRJE^!JX&>Q:GC2.N_7N<Q%YW#\_W4M"&D_EJ3,?NQWR'](R43WPL
M3]%:F>U5N[[4W;H>I19@\-B'#PP(CO<@N?XYFD*+F6]+=..RVJLR27J(@YG>
MTTM]+?"(,[9:B#.M*J0Q2 <G=26@P%EG0";2_:Z!BS^+*MJWHFJI;Y58RX54
MPJHA8O$ &1\4E&"I=%+M(T%^/\*8[>D8MA1-7B:#MS]AG_AF4^?:C3'G*P;@
MHCSX8X?I!.>,C^F)]KWS_IE>8WGF&=$O:6!(FM=#6&L2:S*U721_:[>%.CBI
MN-0B[_=R$(F7%>M]&+5$W82VJU.(8YLLUCS+Z/GRGF?Q2PS)4JF/5.VS63=;
MAB_6EWY7X+I/!Z 7=3+0Y(YXGEIV]S]VY"HYVJ)I>([P;.:IY"BQS*]4YV\"
M4P;'KTM MP YM767D7\Q_\7\%_,OS!4%B %ZK,9I4WP!EZSP:J<M_O_EANM_
M50A*@O&S6=%+6Z#J4U/\,*JZ$@4(J'.K$I,4O/_W_PD5J3K_G<^"$%\^G@I5
MK1E79-9&LY^&GONA-0TLC8WK,V>,OQI-B;9F"W!E!!&1V!&<+MR5>04+I<<\
M0EEW:TD#M4EF!;+SHIM;<M0*5CVE:3*&' 9L\NY^-?93\9;5<M8WL%CFW?9S
M:^[3*2W?J:QUA".N-]SV&=PN=A38U4Z38)A?+&G5N%&X[\*EWUF%V*-GNA$#
M2;:H_A3.@]:@3=J*EDG^I2 9(T">IB0#)3JY@@#L^<PCZGU^;2#E(RB:]T4B
MXWO#Q<SOK7M^"O_^$BG_CFZAW<>2:.;8HUPQ2ZR9[]6;4_)Z$B(GBU^P<F9;
M<)_ SQ5/&:6PVGL+H,&(5+IDT4N<\C<%)EYZ/86Q;4K1LV'9I0+HO-+2!JB8
M$<R3<];Z51L?H)&75U%5EGQ-&8<^']L1+2[;9MO5/_T*_T/+1D[@%'[P7^4*
M).O+><K,7Q__8S<P.H,P>.0ZES6IXOD]6P=>=?V"3X;MA+69\94P&F^NNA(>
MA):M#9 4^D7]912N1W]X^"=\ $N4YM]4A(J=+\QI/FQ,]X+^KT(U_1C.JOF3
MP[V:E3^0A)XWD =0QW2^B+ZKC><_^16>)<_5BNJ(JBR[:&]N@,3[^:G$#+'(
M"J^X>DKB2#%/[QEVG^\BWS/+H!UCZGYAN7F5FB!<J+,R:0C-]XD\T\KE'HDS
M7COAY/\(Y1]!DE(=8-QGX)<<+37P3*L'4V"]::,%M@\%^^[1;(>;;(7\V$\<
MG6UR_<(@@I&EIK.+0'HCV,>N*G.&?/XE<ZY]#1C@\Y,J=HD"9%HF]YUAAC<9
M+Z%N\J0N!1RHVNR5P_O &!T4.+\WVCUY=5<']H2T1E\!5)'%NH&!WAS?*0E"
M*?=V"#9^AJ#5$K)GE!+SR7>U$DL_[INVY>Z&^P?8IKCL$=A2OT\[!A0QX2XS
M>><*@$09%EE,Z]&BQ\I,M3&B.M 1A'IKV\^F9X.VBBQ!- RR36.&BV"TN=F4
M=PKQ?%^I95-^U8Y94D$NZ6I_ T.8M+=:*A]VC2%Q*B$[J\,7.GER_VI#.!*=
M7+9*;(!NCXL7D#2M2:A0=A&__DB@?"R9=^A@^RV-6F$:LTC6;^"/D2M>ID6H
M0ZZ#M%H*O^MML-/PU)XS(I6IY;_^P+.4,(=WL/O#>N%FH75>R$6:GJRJ<M'3
MU"[.D?VQU/1!C0PF/3$*50!Q^K<!5@]3:W(?,N9@:13$R^ERCYECJA::RV=.
M"P6:K/ W:$!7,]7#]1A8\4VF:H7]C#6\5MJM>Y8$IGR6[VB]JM\E:=C)L2IN
M?Y7IDZ@*NS^8S;-!+OK2()JP8H,ULZK*G[W/ZF'RW*\1:ZUA^I'D,KR,C$;"
M_=4(R[T"6Z8)F<3@7A[:E<!PK[-"F@.,6BU&+$6Q<(] ?_H0,F*KV:(BK"0K
M#1I>=LR-&#1Z&M?0S.D>8+1YUG4=9C%]B)BQ1C]M.(\?G2)UZS%NTE&%PW#1
MG(W]E+F>?G@.QQ* 3N'/+^W0G5]SM2F#M5!G2:+7ST*(=>N!*4VYBE@MR_9R
M$,\C0O*!+=(:I0M5,J6$)18462P'.CJA]CQ+9]+U &).5//@R^<W:SE7PP];
M-!K<(^]7'<VX+PS[O<12I#=;[OT)Z:3KC-K#R(&!+0VF Z%KVLE8Y$_WV; G
M-/E=[MJRTPT-]KM[8&->3I1/\F]$:D\=B &KFSY;$KU2:==\JS/!'NV>4*_^
MJN]T)8+VP *Y;.:?+2_C<I;#;@K]_(._)&=>1\UD0SYD'(]3YUG#&8/)O<66
M:0']%9%=\4SZS$_>H*#>-!<OEZQ'.T;R#H52.6)Q2 -0'Y6>9'>GP(<NU@.V
M<&E2ZS7?+.0^NV[KM#?(I?NH.TB=:R*'<+WE%J#Q09FX(HN=O<IVVF(-UY:=
M2B38?@*RO&\W<[*OW4-#[Y-CW=Y1FB;SG;@S$TP7H4$5]VY]/G\^=BVM('1Y
M):]SSJ^^K"+ZA$A03$!^'R0J(,8:+;E?J_>*6;%XPQ>AJFYH!; J V.TSQ^0
M]9$"]7,N#R1KA$3%)HU$[J6E>[=J?BCC#3720=<:_.IB^HGC.[\:F/]DHD<'
MM03]N+2L>EC1$RP0,V]Y[TL<'9>]J7B$[Z ^*\7L6M2Y%WKG:*O[AB+2\H?/
MOG*OV5Y6PNNF'V:PO,_#5'GOWW.X?-J1D%]N7OQVL("*Z68O.:]X,5WVHXVI
MN"S1]<Y/Z:= L>&:WWZW*<[3DG=080W9)BS\@0AY2LMSO3!"#0&,2!+YC&Z$
M8JQ:CJN#!F7B"8*"0!X"<.ED.MF7Z6F!Q1:AMF+%M$FW$T2TJTV5<)YVLW5K
MQ4[R)V.I,D2 UJ2^<B6X)</I"\"?G!'&T6U*U0O.F4TS60YP/A_UU8+[HH[>
M[WBXG;MT,P<E<;U,SI:),-:VJ%T+%%<D>#O-"59O,3^W0_.YU=*T1_SH%4^S
M\7S;IPXE'#HC]H+(KV$D@L$/ E:=-]NBUZZL$/VXLV\ICP2HL5\$KE>QS_[
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M$\'*:R#I@565S5Q7BF<&T^1P)GG]_ GU:%:.=[3,+[<C^_Q_?3(XA550%\Q
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M#2YJVPW%2G&78"U>W%V*4XH7#>X!@A0+4K1 <2M2M+@[P:407(L%BA.L0)$
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MW^7JT1DH),Q"0@GV:DY72UXFZQ5F)#->8\!4 F*&-L1.S%#+T;76"[5_[(.
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MURTHZ^&$12GC(((8&YV=S[CBG%,UCZ^*$,@N%W/(*''@%-[?-UU,((B (U)
M4&XD+_QM31$Z$R+94^XCL"':[22M+=RZ[QUYI,#HSS\<2ON?Z[W+S,>)9XPI
MMSI"Z*UL@J9OJOJ6(&!V,QOV1<Y;JZOI=NS1B1 [T=O8!SO_^B,IA:569]]N
M"Y>/<IH#'B)BWE5-Y#5 #XF61C*,ENF]^E-XF?NQ/.D#KD.#:XYRE1/ONO&-
M9I7;Y8N_,Y1VF5:Y\MTDWWC@W#"O'T9]U2%,KH'X)X$)!?2]<Y9>TB[&9 HW
M!V[/X7\_G6Y$&<YX?Z? F&P8FB5;=]D=)/T'L.>(7=8-HD:\(Y,KA/'.;W=$
M3A,?4'KVZ>0.$*R-T8B=/O@C(<Y'=&Q?5GDS^V6RFM9=#$#CWHXA$W,EV45D
M)60'NHI?0Q3J\8*]YXZ[_#^U_@, +,Q#[8]N^^A@[1_50:L#]*GJU>5:O^2.
M6.TC"[P1'8DZHWVDD7"]G\=]@-ZVZ'EIR=\BX%.WO(DL<3P(4*G-,38DX+W8
MH3ZF$P5&^W^ZNBPCAAWU$&A_-_Q8G,AUBE7H5' ^12J5E[=-G:3U;8\/E;EB
MUGG*,O0DM"#:0 8^K0;[WP8FQ_:W^!RYNQVH\P!:DIP<&8-H<0:B8M\%?!SU
M)+[\=;):_2L2?C?UA+%\ZB9BG,KKT^U='DXQ#XEE_=XUXGGY*HKCT8Y,REBM
MRF63IN.B/X&__MJA8Z%U_#!+/_RTQ,Z+A[1&.$R;MJTZS"3R,BG[&Y'J(5(^
MH0PE]W6'VS692*D6MK]4AJ@2;9UU>S(GF:JC>.9@O>8 5[:78,X?(K+ZB-(<
M]AYU+?ZO(63)L=S[+GVYG0,%M)4J5$ZS>O9.*9]=4;A=-7^2YV_/VU"\&J3+
M>*S;VR3J:[UHB.8[=SOL%&MSTC&EJ1YG4647BM(7[I\\T_B.M>SJ[[U]>U'Q
MV2X7?C%>"C4+, ()@TDMCEY,39,=TM=VC*_-A)1B9L\]L4#/1\S:LLK *;_H
M&*9R/DXO;2P=,[S!2EG/%J0;\"PA4E47(J?%UD9R<PSV4XDFAH(Z0,]/?__A
M#0$]AVSIYH!/>;)76N=)J?YLW-)@*3$BW]@-B/X2D^.^F,DO<LG9+TA!'!5E
MS6=*![TG[YLO??/<8,S1_D4GK:V48:X%Q\!=3$2A7J128Y9*)RSI]!M5ZL,1
MG0.&OF"GPG?<(AID&/#B?$CJK"8 *2MNE?NVJV>>GVK%_$A01F^BCDP=GZ7[
MBT<NMC]]8,[VMYY>!(0G:J:LTJU_7C3^D&1+DQP7E)W#(R3 W6BC*AB>^B/O
MUHKP#R'SD>"LS8[Q!:2^V"YS4SH53-O+3VMM:)UQ.4#-*D:$VS3R?G4KZHFI
ME,X-)=;PZNN<8S1GWE#ZYC#PN_9.@@PJHB\V?0P0YDDEY==09?5KU;V0#U:I
MX;6]%O1]&@G,5O;7%R:6S![3]$X2\,3%A 7&1+/US3UX51_=)96Q(?\![,"W
M!AK"A5SNXCH4"6%YS*%<1'/A>06E<PW0$NT+CSB11W[MB\2;AAJ-LG'6T)^D
MJT71\]0J/[M,[;9%:CZ9WR*K?]U:XJ,H1_HKUT_,_&ISANMZ%V_$Y]6>$IWH
MU<<:@/35D?S9FAA3):MALE1Q0U9 M/<]J6AXPU'HRF\D6S]UZF->FR>%1K>[
M]XBPP2:Z0F7!-\CB];EQ(VR)+TSL1MB\6$=@G.D5>6<G[K??SICZ<3LR&JA"
M> A#CHAF\JE7Y*%<E@@Y_@>V.(%F8@$2C6S2@1V0Q#9#0-]+9X_2V<JC=L3=
M-8GYL"OG?+UM]LBE>B4FPS:!.U:$=Y@GWG=F!C;*Q'+H)/P.47P74E@/;K_]
M56!GMF8QREK=O_FZ-$7R1*,"N@!?[2MB2TSJ+;?<4CW@:&OO2=*@_,Y:I:N!
MA6V7;'>D 'QO+,X_)(LS<64:J=<?J6'QVJ<]9U<W1\+6$9JF!_O:";37]4[R
M_E.=54C1"@REA 8I1!Q(WT]_^'G.:]_6$3EY:>S..JF.'[TI]AF>ADEO3:[
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ME.G^#FH_<QYGIZU$?K$N))]Q^!"KKC700W:9%C0G6150%>.Z[&"K6P>LF5"
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MT#6]$?)"Q<%_;4^/3,V:8!KHK6XL75J)T:U=(Y2:SB/<C),/(30MWC>@CS1
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M4P2+5--/=6^[$9;@6C/X=1#=(!2#FC3B\P<[_,^LCOX7E];?E?\#4$L#!!0
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MZ%C7.4.X%+ =U;H%=E.BA ^)<2,5\E8RR<$F3WZ'<>V&PG261%?Q@3"G6ZV
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M!LM+D;J+PJGSUTN)/4Y^GFUZ-V_<5[-H(!<CD7%=NN>XKXYX\QS'/D6TX;2
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M^3"8(0TJW?@P/">X"L<'.(5O,>#][!#P_@,'O&^-_<[NTCHRF%()._PZ><-
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M.]LX_ GG1G900?&)=6MN@J;BEN:<=U[<FMI3U/KF;>&Z&938HC+(K 9(!#7
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MM-BF@:4B!(= CA&"*9BT+G)FD@&<DV3YP^$FTI_;Y\:Z>L&-TR%EC'UTG/%
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M/!GFHLJS;;DP3R=5=@7_6+3+XL__#U!+ P04    " "T@ 99"!=O:+5'  !
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MUR!CIZ+3"S$HC5 9?L[4HFG)[ "OH$1I Q_5-8A RU#%LT&"S'H@WA"]4;F
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M2>AP3L9L[PTMZ14R;V2]CQ3=#>XZIW7DB3/B")";A9P8TM>)4A.+4MKCB+4
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M:Z&V)OK@-%HKW00<E U!31:>Q:4^$O)+J&YX@1T.E[Y'TN%QLR_N9HCSNF3
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M39-9EK:5BCG;327YKN&O/0CZQ7,KJS&6K(]"@(LD^QD%*/D[X@R<.Q+0'?9
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M [TSE:8L_1U9J'_*:+P_$./]PVB\>YSP;)GLALD>QF9(GQTXR U,LQ /+6R
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MH<)BX!@UUJH/>IJB/GVLG:]0V(\;\&ML0&M ]7,HLHJO>W?5D$&D]\P&L&_
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M0!4"=(&B+@ >BD.V:N3S/('3DJ+_!']'HHRA34!J S)=0#G'$[8 H"%'('>
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M,S%D,BYH=&U02P$"% ,4    " "T@ 99)]2U@@('  #X(@  &
M    @ &LS 8 <FEG;"TR,#(T,#8S,'AE>#,R9#$N:'1M4$L%!@     ,  P
*,@,  .33!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>rigl-20240630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rigl="http://www.rigel.com/20240630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rigl-20240630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_cuHB688G_ked7r68OdX4FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_YseB19IaTUeq6LVKzfKj0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_tCX8H5e_0kK--61UsSImug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_XZhamrPP1kS0gkYOdPFL2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_uk1O_sp-Y0--KVAhhGNE-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_zCeB2BBtfU-Wb3oZ3EUjpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_YfpRiaWZxUqB5w9lvYJvVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pt2UPlNyCUWGebgWK5jSPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Ij2f4OxgUUCWtD_5lHA7pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_yxzYceuVAE2CBLGPEXWLcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_5kGrsJtJPUaXWHfMUTNnAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_6fGEzsR-EU2ukRaZfEQHTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_K66Fz-gvL0-4yU--dKixIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__q2T26iax0eiR5sdI86W6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_pvl3dQL-10KWQKcJlK7PhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_pwaobjInbUCU4wLXJWRgWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pxFiNodJ0UaXW8PVpDH_dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:GovernmentAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DeoG3uLWSE6eChBxTmVl_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">rigl:ChargebacksDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ieLLpNjElUSlKRg-RIcl7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0jRDeqtQJE6s6Jso2tDR_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5haw8gzz_kCqIrKMQPuu3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m6FKz0lCzEavyGq5m7-dVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6_5O45BUnkyJOAznzy2CsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k8Gu3743e0GwNZtJz5p2Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gsUfXJSf702qktCA38R1iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sIg7hAM9oUWSDXtYBBt_Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KlQgIhdaH0KRHwHHBqCVag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IA3yy1pN9UWx3KzvJPTixQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_rFOBOeyLMEiRCtDUqDQoow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rPjPB2Hmbk-fkqxrA8Qngw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_otHOXZ_Ey0WmO49o2jMv6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JKqbAPtAjkGccR66L8k_qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGqVrCjqIU2_N3yu6dMC8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tVwp1l-1kEuXU6ahtps2VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_izJ-lHsOY06-uJsEfZQQXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2hx_ymqnNEmbyAqqcCVWhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GnF2WrQG20ug_b0PbRql7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zBZ0CJwMEUaUNEdiy_40SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_RB2aD2voQkKnT5jqSouijg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P4KZWdg170yGNV_k_L91Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1lu-VK7_o0-Max8PseaIIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7oPrIr8cXkqlq5Yd3Q1yWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jynRgS2pl0CPMnlU_535aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ons628waiU-GMU91DELbBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBUO2o21ukOtCErji3SQCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c4Il3dY-Cka-Z7hPZIh3_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w10yELUyuUKFpRmpWRAlCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M9P7eTJN40GnRu7yAa6KCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkUV1BM-xU2eirtWLK871A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_5_1_2024_To_5_31_2024_DjxYIP5b9kafOLRsY1Sj5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_31_2024_ljnvk8kzm0a4q-SYLyQozA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_viFreQeDZ0G9JJCWlMU9Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_ProductOrServiceAxis_rigl_OcadusertibMember_XRvY_5ZJrkuCeHrOO7K53A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_L2X2ODMWN02W75JbcgBOuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_YUs53Q9t60y3XCZGyv6pTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_66nF3F7T6EeO_T5ormWp2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_kgj2lfO1x06p8zrIfFzVjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_jsAPdtswwUqlYhdOCwaqtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxQfYCTi-EmntNNb3PEHNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_X2QX2SMv0UeS4dY9h3vreQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_HU2T--c6-k2PWST4x-p1iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rnk0gbYth0SBm1kX1fW23A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_dRwb9LpMMUGY_8SiQzA0vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_qF77QLopJkm7QArlC1YAAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_KLumYMF9xEy2B9eFN1r15g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember__ugQCo2hvkaHA8jhmfIr6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_vkZ_1rGsnkW09QyZQM9DaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_crGh4Gmf10KG35aVQN5FmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_0CKs5sN0Y06oyeNfimQy-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ktlf9P2M7UaLAIc_BeIB8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RoyaltyDeliveryOfDrugSuppliesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_aYmi2v0mz0e4c5dQ7lldvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GrossProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_n6rbBTWKREaLGIeGb095og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:DiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_sXlfY9W4v0-bUvEUlAVg8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:ContractRevenuesFromCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mtfju_YpJkGk_bnLaNb2Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:AchievementOfCertainNearTermRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_hZmC_MKxK0ib0qKh4OuwDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FZKSbfgCCUOxIEsBo793zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember__kWatA4PfkmKIM4_lvUSqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:CreditableAdvanceRoyaltyPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_XFzWo9hPBEqqowv7IqsqMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d_VNrgzWz0a3BkPN9MKEVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MyObbAmPakSYdCOgOM9oXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dWSzM4PiYkqhpk6Pu6GX4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H4solk7YuEifDSX0Yinypw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zmuW7qmKekWpcj688rHkvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_srt_RangeAxis_srt_MaximumMember_wXz-NhXK80mSJezdO35NGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_cDqO7iaeK0Go2Z-84kZ9jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:AmendedLillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_1Qsy0om_TUCfBSYK6lE0DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rigl:HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R1A7IWBmT0KvJy9Tq1LCYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nR9Unjlvxk-pD68DK4-gZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a0Js5EGrGk62uZjqtY72Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gvz4si6MdkS4fdUVQlbKOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_hDix6efDJEqhQT4ixJzEQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_DJRbQsRz1EqcG6iJ-_88Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-28</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_W7cIc5yiHEas_ePcVbSr0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_Pa4eaLZ_bkuPdtNWU8Iy2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_eYkavSct0kShqm_SrY7OiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rigl:CreditAgreementTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_uZH0PMnJBEKSBgu31l8iYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_VuYcYAoXfUqSaPoOv41VZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_moMylpkG0EKqa1L_9E6qSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_2ZqFwePmoEW5EP2yf9fpUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_3NxUn5GogkWWrIfF-O4kPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SLvI2lqsxkmQG2QFPN79Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_N7Gpz1AcU0-D3M0pAjqqNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_bumoYf9sREKWHIIx5_Gz1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kR5PxZmiZEehJumbiChaaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6YzcAGW4m0ayhMSEkUdByA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BRYGoVu9R0e32mZYGbN33w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_LrJM0R9Q4EqCjEm9Lk2Smw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SCWsGh-x_EiHDPQEk17sgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_TowDf4q6oE-409UeTRDU9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_Ke66dznHTEab1HHdbbjp0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_tfFBS5hWFE6pF6skJ5FQLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_78B3hepUPkmvOj-N8djJNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_U7guuJSV4U6vqE5RJhmf9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_60P2wgsrD0awxLyja-p9nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zmcdanbJ0SDNc-vDFtkkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5l5sjSngpkO-FXuFuyQBGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bJS_m4Vp_0uGViKVve720w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_DMeCAgkRW0C78bbvGK_1ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lWODGT6XzEuM8DkFcLQ2LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_8_QPIix-oEu90IoZH6mxdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_RqBa2FWeTk6bS0CYoSM8OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_URKfF5ajyUiJLXquchdVgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FdaApprovalAndFirstCommercialSaleOfProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_E24Tg32FFUaoGudnG6SLlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_mp0URjlEF0yvPpfS-o63hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_QvpswMek70eb5QDV4za2tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rigl:ShareBasedCompensationOptionsAndRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aH2IYHCJPkuM5HXlyZvgaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_NSJW9_H2-Uyr8T7g60jFnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_eZ13M7o2S0y8eAY3w05FHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RgL4dFy2q0eUvIbUb8HPxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_YXCwufdL2kCunkEAIR-kOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_BiMbBxhh6Uq0yCW2lzj5vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_EBFPUJEfP0-IMk-f5UWHvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_Oloq2T-qkUSk0moW_WdUNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingFourthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_W4Ti807K5EGWOf1btN6_6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_w34DeP8NUkiGwpi5OQ3ysw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingFourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6ou1l9PZikOK2y-Wb2RGFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingThirdAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_xDqwa338u06zbkGihig_Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:FollowingFourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i1LjpfRajUeDxjso7nYoyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PbJR__bHUUymqE5jma_jhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Q7EkAAoHeUKJsjYoTZrhbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_zwK5QRRX6EqsKGahncDIOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jkelz1ePoUOQLw4bzruVCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eFVzoQltvEO4gINVqtxI-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7fwMtHOoHUm7LRR4eArbsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NhxdhXczxkO1of_nfPZIOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oLL4Ndsu6UyV_O0-24gTWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_9m5rS6MB3E-SUlgdlXlTSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:MckessonSpecialtyCareDistributionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LEnPZ15moEKAEm_18pTBow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CencoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_GgfOc-xLJ0CVzgWger3Arw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rigl:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_ykyILY5HlkKht7OKVYHIvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_1A5iQpFj_USrbxcLaNA6XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_JbLXs-0VY0esSnNCYQq-kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_aYSlG3CFDEO3az0cwNa1cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_XVD5BbqpPk-9fwQojvfB5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ckfW59j6Okm6xRNuxxkwMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_hTn2f1VUkUCR_wGtI1n8ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_p4HneMQsy0Sje5M5K7gO5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_89x-n-BkT02zjUtAjZbcGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_I_VPJB4u6EaCQYJB-1nRzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_YesGsLryt0qGsoVabogaQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_LwXt8QqnrUCTiqADnWfuhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_kZWlKhsNBU6_AklsH7sLKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_QPE9o_N_LkOoOgf3_7ge7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_Som_sdy7kEqstJssH42W1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstCommercialSaleMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_HquhUMFeGkasyQJBoBZ3wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FirstCommercialSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstAnniversaryOfClosingDateMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_0IVrFL5NR0Kuz75nULfm_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:FirstAnniversaryOfClosingDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_SZRu02N1XEGrAyfYF5SwyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JastdyjIyEGJursVulIfKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RaKuxSzhSUupPD2oOUXYKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_XpXugziTxk2FFISdmEQLwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_FZjvdGbKikurAAd8fQxjGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q7YoKf7gyU2XWicwj8JbrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bYo6kwZv60OcoBnM9_riJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_MiyxZQLaX0CaycIWWGMjpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_P5Ej5A9ePUSqZtXcVBF9vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_w7P1z0EI5EueFIgNkc89sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_3xxTQ5sXyEG51cWWfHtXmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fv5v2douMUSk7zWe57p0FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bSe8WAEXkUG7k9-Nd_2uvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ieBTYFxiqUCvCIZyspbbWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xJyvi82Gwk2Tr-43Oekyrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2LCsKqr1LEqrGC4lXCGiqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v32Ol4crf0K8DOnTPxOuGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9NUp0OtJ9ku2HiQECijrIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aqTJrxACT0OLl53X_CyKsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EYUKQoEsRUCEo0sMj1Wymg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QJLTwjYbzkmfnUQQu3xMaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_KnTLXRz0jkWgF6jXhPXEDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_KKP0C9QqkUiTkWevYxJzTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8oQqRK0A4Eeyfv827MVcYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_OVx2OrQCKEaSY3aBoBA0Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_XjdV-Jp880KnhPP0PN-3mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_LS7cZ0Bs8U-InZ3368zHAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_vAVgV6NViE6ez_AdrA5iUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_gG5MuB9lWk-MYGQsRJNXbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_sBMx05ZL3UeBF780dfwknA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_YF4pFiaiVkGskNRvWduW9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rigl:CorporateBondSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_uiwrXRdPDki6YFyL0CW_EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_N2zaSMxsLEqGccjjlPSgFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rigl:AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_slyl5l3MBUW5I6J4gR0GNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_y28o3J_GDUGpZFQI6JGFgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_TsNN5CZDIEuTUPQMmSOPqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_cM6viZkjnk2XQ_C6vVZS3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_1_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BqxcFSw3c0GKMZqu-UgZLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_rBLR8Q6qY0qEWXFfKO_L3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_nO2J61EcMEKdr-tpRvz54A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rigl:AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_60j9a_IIDEa-xMryMMg8Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_yt0kuytHc0y7T2LLTRMBFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:AmendedLillyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jcLc51bfe0y7CaULox55yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_4FtiCBTyVkqS_xmhg_p41w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_-mlrFhf7yU-O2VqahK8vIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_oSHvi732xUWC_qqhrIXIIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:GavretoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_E2TAw1ebLEyqMCfIkUc_jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithMdaccMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_yedyexNn70m-Ww5Mtpn2GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_gz1pnQN6FE2qge7r5TPFfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithConnectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_yUFONy52JkaEdNe2JBvS1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithMdaccMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:OcadusertibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_CpgL9jNlMUCw-IA9e3o4uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_BbXVI_lx-kK6eTLL9cByJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_7B-bKGDqJkynpyyI5LI52A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rigl:MilestonePaymentsOnProductByProductBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_I9tiGJJzSUW1uADT_0QYGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedRegulatoryEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_7aOcJ_X2Jka6LsC0YG-yLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedProductLaunchEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_VqV4K0jYxU-ud5heUgA7Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedDevelopmentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_4tLATJ2ucUu7Kj1hYljxvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_ErotTwxGbUGeaPCNLokv5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LP6c6fDybkun2r_aQWcizQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_VrqE9RWak0OFqmj1P2jvzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_mlAixP0Kq0KRgxnPySwCUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_1QwBIhoEuUGYpKJv6_D94Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KnightTherapeuticsInternationalSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_30_2021_pVVWDpbMUESUodMAWy20aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_6gKiuqunlUW1exXxbGX2YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_5HvpBOyAi0i27BmKK4fzHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_4TZ-_gslzUuCVFLIXWN05Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_DpExNDuvFEiRGecQztGf_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_82mZ1UCHkUeFIeF9NNLnDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_fiVixnDOc0CkJwTCK4-50w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_MfToFdRbjkuykAJfE2s1oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RFpgzqwWbUSTBMlmSIJ36w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_LGpOh5i-pkuYqfZStMMnVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LqSICzN8jECsv3g5VfvRtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_Ed6jJO0mDEC7vy2gXWKNvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_zrxVuGp9HUq29bG3-ZjB6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_Q7Q9_fXocUmGbwkegfzFlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_oyau3O4tJkKVZI8B-c9oEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_z6tFpSWYtUeOPKO1v5sshA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_r0ldwSj5VEOIFSa8XhrMcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_93VaWr0Vn0W3qhHJHD5l2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_maf7KtajvE6t_Jc1HPqseQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_SI850_iDiUWOa__58mOaXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AvQMdmjfrkKF0n7u_e-4ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:KisseiPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8YAIxGaCJ0WOl3D_P-ZFyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_AIuTRpIOpUS1-j2v1hsfzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:OneTimeDeliveryOfDrugSupplyForCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:GrifolsS.a.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_GWiAmU3NwEe-z4kehp2dcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_N5mf8PGqUEGmxmbdkeM6pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:CentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:LicensedRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_dwtnlJ6pzU2O_-cHitWnLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:NonCentralNervousSystemPenetrantIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_8_31_2023_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_5kULnBvdYEevZnx2IVnM6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_ZZ7iW4JQ8UGfKFajT3fUtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:SpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_4U40SB3W_kmm7wCJE8B4_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rigl:AchievementOfMilestoneAxis">rigl:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:FormaTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_Yi_QU2DWrk2zU3zLJ3F28w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithMdaccMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_6M9-yuHtNE6cG9tYWmjCqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:RezlidhiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:StrategicCollaborationAgreementWithConnectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_bk4CtdQf3EaimZs7lkGnMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_vUvPo1jezUiyVDGej1nLMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">rigl:BlueprintMedicinesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_Gnk6YUapu02MxjednNsESw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rigl:FostamatinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rigl:CommercialAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rigl:MedisonPharmaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_1_2024_ZkEoN3QwO0iUKn5isedLVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <instant>2024-08-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001034842</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_XCinVrYiMEykKvzVM-r2og">
        <measure>rigl:agreement</measure>
    </unit>
    <unit id="Unit_Standard_period_7S5qJ8_ryE2V-D21SVB1hA">
        <measure>rigl:period</measure>
    </unit>
    <unit id="Unit_Standard_item_lkAE3fTQ8kCadM7_hQ6xtA">
        <measure>rigl:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_position__77Wb-sxgEODSR6HmbQE7w">
        <measure>rigl:position</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      id="Hidden_yDGzFrfcrEOmNGA7I9jCyg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      id="Hidden_2AI0OC10Y06diHgXqAS-1w"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ"
      xsi:nil="true"/>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"
      id="Hidden_tLN0a4X5JU2Cq3R9ffzyHQ">P24M</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="2"
      id="Hidden_ctTfnEu_tkqhRm4vV9ngHQ"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="2"
      id="Hidden_5KELc9U4NUif45kVCZ-0dQ"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="2"
      id="Hidden_rflHIBSyUUetrL1tzhin1g"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="2"
      id="Hidden_nLgi9I2UlkyQbQfrdOSHrw"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Hidden_UoJdFgu_IkWu_Qxlk8o0YQ"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17549000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Hidden_5JdjzeEPu0Wh6kWkPeDgvQ"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17356000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Hidden_JO3IwUSKB0ip4_u39kEa-g"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17534000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Hidden_QosfsYYINEKeFnE4rrZZNw"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17365000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      id="Hidden__uvDi--VAUGqtC3eWeIntA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ"
      xsi:nil="true"/>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      id="Hidden_RyRJdE2X_E-Mg-mp9DscQQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ"
      xsi:nil="true"/>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_lQtRnSPQoE-Il8zeJ8WGew"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ"
      xsi:nil="true"/>
    <rigl:NetSubleaseIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      id="Hidden_mnAsvI_5pkqF9r4khAkUlQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ"
      xsi:nil="true"/>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_fH6LEQzMaEGXhp8V1oGx4A">RIGEL PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_XpVfPSs_-UGk-hUG348m0Q">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_h8wadImYIU22G70HrsnAow_1_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_wCIkaT3Ps0SxqNEqe6-_AQ_2_1">0001034842</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_RVsgnlekekKF2seTzMl_RQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_X6Zen7yAMkKWOaY61tE6Bg_4_1">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_R-HBsYc660KNGNpFbwbQkw_5_1">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_V62lT-Nc40uzkgz0WDXucA">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_QvpswMek70eb5QDV4za2tQ"
      id="Hidden_BSYq7x4JLEq-_Jg2cZgicA">P2Y1M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"
      id="Hidden_U2j5tAbzr0-MSQXB1Kv0GQ">P24M</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_10_1_2022_To_12_31_2022_GWiAmU3NwEe-z4kehp2dcw"
      decimals="-5"
      id="Hidden_HvqYF3vuKUK_Cbhmr3ItgA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">20000000</rigl:CollaborativeArrangementRevenueRecognized>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rigl_HeadquartersOfficeSpaceSubleaseSouthSanFranciscoCaliforniaMember_1Qsy0om_TUCfBSYK6lE0DQ"
      id="Hidden_xfW9usukwk2f_jXEjoY-Ag">P0Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_8fNFwOpvSkS3Ae-chWCEig">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_qBoUQQL0r0CNAQ63h7ll_w">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_tgDiYNPmjkeAMaI3ed0HFw">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Hidden_4jghMFuwh06SniMlhZ5R1A">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ"
      decimals="1"
      id="Hidden_cVzsh-nsgkmvDysnunKDMw"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ"
      decimals="1"
      id="Hidden_avsxiqC5EEGbi6wZ76xCjw"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ"
      decimals="1"
      id="Hidden_8Yk6g2alTk2siSqoGmM1-A"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_27_2024_To_6_27_2024_p5jHY0C4j0G5AQlIuBQmfQ"
      decimals="1"
      id="Hidden_nJcNMH1G4kyCDx--KfxI4A"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod
      contextRef="Duration_7_1_2024_To_7_1_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BqxcFSw3c0GKMZqu-UgZLg"
      id="Hidden_zN5HkjsdLkqRRzBvM8xfWQ">P24M</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardOfferingPeriod>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_lReETCNoU0aeBz39TL0spg">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_ZhR2QEOyHUS1HV3dTw8Mig_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_ZHOi2RWqQ0WOYY6QbFojJQ">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_S8XUA8iX5EOWxEuKoE2Vlg_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_XNXwtmMbR0iFD7RxIennEg">0-29889</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_DQ4ijrEdDEyyd12VlJ98jg_3_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_vqExNYZNiUmcfRrnL0S-Vw_3_2">94-3248524</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_JvU688dQN0KkRTmbyAgLIg_8_0">611 Gateway Boulevard, Suite 900,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_BipdUlPG2EWskiEJnNqRuQ">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_2mZo2rpPzEybPboSbE5kIw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_osqtv3txmUqovvIUre3Ggw_9_2">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_Tz0roqazekG_PFK9mxqP7Q">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_7J5HINKj7kq9XdGqDJmyYg">624-1100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_Y1K82NcZfkidhf9EdVDgkQ_3_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tc_37HSumNmjkaPAuzbKnB9aQ_3_2">RIGL</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_Bzz5UDdbYEq-MfCyBXscuw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_gu0lN9CMz0-fgUijH3IlFg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_etajvsjInUyxnZ9iaOBk9g">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_dT7w1JhmukyQt7oECXbHJQ">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_NwksFjm1yEujlUWuaew_aA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_1_2024_ZkEoN3QwO0iUKn5isedLVg"
      decimals="INF"
      id="Narr_eDgYLYC00EqpU4sVqz4Uvg"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17594977</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_tGxYN4fWJEaX6u5WwJIiJA_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">36053000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_9nNS5k0J20uLDszoekCW2w_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">32786000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_ZUBoBL2gnEK26lwXEscBvg_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13049000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_2z9NULN830OR0bmdMKobrw_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">24147000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_17wjKpuEGkakunyD7dcxiQ_8_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">28904000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_jbYWVC_GGEuSvyFwMQR1rA_8_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">30550000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_jKCQePuZYkilBj8dNlysXw_9_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8059000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_rbZ6M15pl0K_RjiOFzK1Zw_9_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5522000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_01WuhbTo6UmrpBCBxxoCzA_10_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8658000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_rgSpX4ir4kGEzYELUtHY8Q_10_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6261000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc__Q1jewbg7U6LjOo5TOF97A_11_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">94723000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_cvmo9F3KYkiTHrEAwmZgFQ_11_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">99266000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Rtr9epP6jkafozeogIUZqg_12_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">115000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_RYPkdAUd2Ua849R28Pk_Jw_12_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">165000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Oza0iW15n0mDff7dOrjEqA_13_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">28275000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_bMR8zTMZzEC9mauz4Biuzg_13_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13878000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_iWVnE1Ff1UWDx2k-Yb8ZSw_14_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">560000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_l0rShuRX5UyBHocv2i2pWw_14_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">861000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_2x73TY66D0-u6HjRQQpKKw_15_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4735000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_KBkBxVA6Q0G0FkONQrVkzw_15_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3055000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_jgPNltEmn0myFcKL2Uf89w_16_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">128408000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_FbVQzIRK7UeO8CC0DCiniQ_16_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">117225000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_GpIAy2BApEaU3vJy64rkRg_19_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6130000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_Hv_cGeGdIku9VnDKuicHcQ_19_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7142000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_GjAnJ8rYV0CMWORHgRgY0w_20_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6373000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_azaOguUxeEGmrD72FPcviA_20_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8676000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <rigl:AccruedResearchAndDevelopmentLiabilityCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_FyAyVFW7gU-nLaaCLq-Ceg_21_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4672000</rigl:AccruedResearchAndDevelopmentLiabilityCurrent>
    <rigl:AccruedResearchAndDevelopmentLiabilityCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_vS3FMfYLd0qxRhCaBtR9jg_21_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3513000</rigl:AccruedResearchAndDevelopmentLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_YD4Lxq8wDU6hD6lu-7Daow_22_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_GV3fqEjn3UyzBg5Z9lD53Q_23_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">18547000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_RyuKr1XEaE6jgqUB00CfgQ_23_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15684000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_DfW5dic6EkKlzQXzwd_gBA_24_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7229000</us-gaap:LoansPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_lGxF2seVJkeW2Toff_RsZg_25_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5933000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_hV-m1M9Ad0aoOV86QHRiEg_25_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5334000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_KKNnndZlWUWNyOpMLfvCkw_26_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1355000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_kDT1mGRVGEqEJQD6T8ANbQ_26_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1355000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_StsLO34EjEuxhnmoe7HpnQ_27_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">639000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_M-jyv_PNzkisIdyxC1kbhA_27_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">692000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_0oQLcjrmokKRCYcW45vw6w_28_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3642000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_9vmFhQ2JFkqQxcGd0PfT8g_29_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">58649000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_RE9Uc8jh5Eu0IHqxR0yB9w_29_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">53267000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_e-Q1ayWYekKGPKr2aLXR0w_30_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">285000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_QnMCa_gdBkadtZMjsl04dg_31_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59692000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_Pf0HHS-H_UOABQO381TX4Q_31_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">52373000</us-gaap:LongTermLoansPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_D-oxEfcgtE--2VlVaR7zTw_32_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">39981000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_hoz8SztUpUWBsPUi47GNXA_32_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">39944000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_NUY3jZv4VU-tXbzkc7ny7Q_33_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">158322000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_lp79YbrMTEm6t571pYuHsQ_33_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">145869000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_z-nzBVJH1k-wb43jIxM8sg_38_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_4f7W3UX8F0uA8Cf90hwqtw_38_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_bFleT3K4aE6ft581AxxLqA_39_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1386905000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_zUth746V6Uuo_Fno-OeflA_39_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1378881000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_476NNQZ-c02rVfwgCVsMmA_40_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_H7oC04_c30GlE3QIwwn3rw_40_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_H0OPGtKx6Uyfj-qhi2oiDA_41_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1416827000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_o8VypU4dh0uoG73Ps5WO4A_41_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1407550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_09HmkWSDmUSreHiVgYROwg_42_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-29914000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_IHL5Q_F1k0OujO1whVhV0A_42_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-28644000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_IWT4GVjORkuqyNSls-TRnQ_43_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">128408000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_K9xCI_HO6Eiacmp-AVRSLw_43_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">117225000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_L2X2ODMWN02W75JbcgBOuA"
      decimals="-3"
      id="Tc_QXV-qH1RYkOVk2mkSgw1Mw_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">33450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_qF77QLopJkm7QArlC1YAAQ"
      decimals="-3"
      id="Tc_TpWkpzWjv06uCUm7mqxwQw_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">23881000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxQfYCTi-EmntNNb3PEHNw"
      decimals="-3"
      id="Tc_iC-oCc0QCkOIjvekv-yjJg_4_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_0CKs5sN0Y06oyeNfimQy-w"
      decimals="-3"
      id="Tc_-07UZTKkbUqO9cr7-RFb_w_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">47626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_jsAPdtswwUqlYhdOCwaqtQ"
      decimals="-3"
      id="Tc_WbPTomUUKEe_Z3tbFVzEyA_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_crGh4Gmf10KG35aVQN5FmQ"
      decimals="-3"
      id="Tc_swRBfStK3kWhblgc8CLfjw_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_dRwb9LpMMUGY_8SiQzA0vQ"
      decimals="-3"
      id="Tc_10p2PDAeNkqjxz1cUbyARw_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_sXlfY9W4v0-bUvEUlAVg8w"
      decimals="-3"
      id="Tc_ziO8HN1aNES4X7jMWQUQ9Q_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg"
      decimals="-3"
      id="Tc_ZyYnBP85eEG-NrrAMg1mgA_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w"
      decimals="-3"
      id="Tc_AaF4k0P3CE6c54kRd7xnvw_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_iw81z4ADE0O6EwrgoP0rkg_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">36841000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_dEvZe28WtUupBcFNhi_OgA_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">26886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_fCcON0f2w0CCzcrU47ozwQ_7_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">66375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_UYPZmexhlUaYZPYnkXRigA_7_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">52956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_y2BbPXSoyUGtWUww68BpVQ_9_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2807000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_nYwbkjaTG0SpWflKnEeLIA_9_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1075000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_bdvgs5yMR0aaM8HDmn5StA_9_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4832000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_0Lm-DLAJSEqWPS_6Fi_Xsw_9_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2052000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_QsiBODQnTUiWzEtKWedjcg_10_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5540000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_-SQ_opl1vkeEGrOYdhKrmQ_10_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4772000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_KDAMM7-e-0mdHCkQ9iV5Ng_10_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">11566000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_hfFy35qQnUyxYab-OVHcBA_10_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">14861000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_XQp7k3VyDUGs6Q1jrL3IjQ_11_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">28047000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_hi3jHLalxkmrkb95e07Miw_11_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">26306000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_g8Cpjbo2PkyoPPqQdfS0NA_11_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">56496000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_mOZcD1X3_0C_SuxLntDGTQ_11_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">54035000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_4OqoZCReb0WHMaEqEb0Xzg_12_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">36394000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_rEp01StVIkirk3FPiy2zNQ_12_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">32153000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_91uKpCfZFUKQ2XGdm4lW7A_12_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">72894000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_qv9hbYoWlkigL9daFh-ujg_12_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">70948000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_nIk9fJU5M0eRPmCW1SBE7A_13_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">447000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_RxaUu1zOukuAceO9hRzr0g_13_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-5267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_JXCm98A0WEOTjXQy-L0FSw_13_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-6519000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_SYfEfg29Q0O8U9Bi9mIc9A_13_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-17992000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_EBOmj-XzdE2wbdsDk2Jg-Q_14_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">552000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_PCM6AK5HlUKT4VelYKvaHA_14_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">529000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_tZKg4SKyI0uV2B-3CfPURg_14_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1145000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_0Z4ZR4W59EqfmuT9zCvAYQ_14_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">922000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_JdrHIAmTqkSANOqvnWG0Fw_15_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2029000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_gaJG3BiZ5kmYVvhlz39TzQ_15_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1862000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_cGzJzHy6-UW_JCcL7Sx2gw_15_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3903000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_lXF9nfdGAkGAMm0kp9rRkg_15_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3066000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_b83wVSHgIkis8uSVi5M50A_16_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1030000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_nXcpwFl5dkiFwkW5MdLIkg_16_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-6600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_EtIWKdruz0OMWI--aVDbRg_16_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_GkdxtlFWpUORp87rFx0_5g_16_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-20136000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="2"
      id="Tc_ebN-OvkkdEClxKmtg-DaSg_18_3"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="2"
      id="Tc_h7-Jfx3ON0KM032sU8z5gg_18_6"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="2"
      id="Tc_3qToF9XoDUid-PCBACZWUw_18_9"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="2"
      id="Tc_t_DMaVrUxUWaW5m5McqvtQ_18_12"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">-1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_D24eGdMSlESXBBAPv3VIjQ_19_3"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17549000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_GbezLLUmJkKsWO2XcAItWQ_19_6"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17356000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_-GB7SjdAbUeJv4l4fRjA4Q_19_9"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17534000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_jnN1mue86UuPQVn0dEdUmQ_19_12"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17365000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_pr9GuL5_WUmiWImdkiDSjw_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1030000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_U1_SpzJp1k67gw-krsBtHg_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-6600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_EBHdD3ypYE-JpFdxwY7jEg_3_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9277000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_WacVSneLaUuP4N6egCiVdA_3_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-20136000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_c-48VIsBL0a0Z6BnpngCTA_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-4000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_Tr6L8TT5L0WthMZjJNJcvQ_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_qRcyRpivDk-Bxb4L_xzhcg_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-17000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_KSurRzD4zU2uxaaEPrMlAA_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">128000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_Ad6OVeEtzEyZawMVZvgSBQ_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1034000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_yqOmsUXfuE6dnHEBLZkJ6A_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-6598000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_-THL36yb7UKR9oNGib14ug_6_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9294000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_w-mWWkT4nkiRPmmsxSZZOg_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-20008000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBUO2o21ukOtCErji3SQCw"
      decimals="INF"
      id="Tc_a_GiI3j-ME6ISkT5-upGrA_5_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17482513</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBUO2o21ukOtCErji3SQCw"
      decimals="-3"
      id="Tc_a70VsEJNAUyfRnSZ55WUpw_5_5"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_otHOXZ_Ey0WmO49o2jMv6g"
      decimals="-3"
      id="Tc_WI0hd0nIHEWlJVT-9s2Rjw_5_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1378881000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JKqbAPtAjkGccR66L8k_qg"
      decimals="-3"
      id="Tc_xJlnnLmjvUWFGzvABO5b3A_5_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rPjPB2Hmbk-fkqxrA8Qngw"
      decimals="-3"
      id="Tc_-bEFTS_TBkaX4F7JUDs2NQ_5_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1407550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_emou6AapN0-zizu5QjoGNQ_5_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-28644000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nR9Unjlvxk-pD68DK4-gZg"
      decimals="-3"
      id="Tc_UjXzfcEnN0SuSFow71QEeg_6_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-8247000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q"
      decimals="-3"
      id="Tc_oaN1H2MbN0ah7jLBMSuznw_6_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-8247000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dWSzM4PiYkqhpk6Pu6GX4Q"
      decimals="-3"
      id="Tc_Zo6HUtwVlUqhuwwhqU74sw_7_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q"
      decimals="-3"
      id="Tc_3K0_YXOrLEWMOPr0KSvf7Q_7_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-13000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0jRDeqtQJE6s6Jso2tDR_w"
      decimals="INF"
      id="Tc_qof7egqtmk6J0Cd4b8nDVw_8_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">9066</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aqTJrxACT0OLl53X_CyKsA"
      decimals="-3"
      id="Tc_0_xzoqSWNU69LdSmq_pynA_8_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">89000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q"
      decimals="-3"
      id="Tc_qtCL_OV8FkuBEdyy9CE1Jg_8_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">89000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0jRDeqtQJE6s6Jso2tDR_w"
      decimals="INF"
      id="Tc_5KssmgWXakOPM7Hjxt0NPA_9_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">48658</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aqTJrxACT0OLl53X_CyKsA"
      decimals="-3"
      id="Tc_e50xNrYhPkq4076E9Q-WGQ_10_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_ELFg73jBAkCu4g2m_AHA1Q"
      decimals="-3"
      id="Tc_ihnrW_i9RkeUQihCk6ZmmQ_10_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5144000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ons628waiU-GMU91DELbBg"
      decimals="INF"
      id="Tc_qLiEOMtzz0uT0l3tRq8qfg_11_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17540237</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ons628waiU-GMU91DELbBg"
      decimals="-3"
      id="Tc_WIhivPvFxEGhSsgv3EeiaA_11_5"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KlQgIhdaH0KRHwHHBqCVag"
      decimals="-3"
      id="Tc_Y69tWUC6g0yndlMMckEzMw_11_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1384114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_IA3yy1pN9UWx3KzvJPTixQ"
      decimals="-3"
      id="Tc_THsgQmn_aUayeuqBNHUqNg_11_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sIg7hAM9oUWSDXtYBBt_Lw"
      decimals="-3"
      id="Tc_L7Oq_65EOkuEz5f3F4Khlw_11_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1415797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_rFOBOeyLMEiRCtDUqDQoow"
      decimals="-3"
      id="Tc_q0bfOg6UOUeeD_bih9_2Fg_11_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-31671000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R1A7IWBmT0KvJy9Tq1LCYQ"
      decimals="-3"
      id="Tc_6rbp_GUyQ0ysa7kA8iDlPQ_12_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1030000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_lWbOSePSVEK-3aFc-xoVOA_12_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1030000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MyObbAmPakSYdCOgOM9oXg"
      decimals="-3"
      id="Tc_KAAMGH2voEudRpT5xi5EFg_13_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-4000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_HVFh4Q_9PkqZWaoGZW-xLw_13_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-4000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ieLLpNjElUSlKRg-RIcl7g"
      decimals="INF"
      id="Tc_JFiNDd_iN0mT-z5GdNb-Ug_14_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">36130</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9NUp0OtJ9ku2HiQECijrIQ"
      decimals="-3"
      id="Tc_Tpr2dwF5oEWqwCiLswrNjA_14_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">252000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_MK-H87N3SEiQRTKmpjAIPg_14_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">252000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ieLLpNjElUSlKRg-RIcl7g"
      decimals="INF"
      id="Tc_75eqINDtl0G4NLe_zyjNwg_15_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9NUp0OtJ9ku2HiQECijrIQ"
      decimals="-3"
      id="Tc_s1VOifmWWEST5OHtIZoBEg_16_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_BZwl7Qvw00-uSBNUY3N6gg_16_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jynRgS2pl0CPMnlU_535aw"
      decimals="INF"
      id="Tc_NufGJptqLU-e1kULCaq3Tg_17_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17594117</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jynRgS2pl0CPMnlU_535aw"
      decimals="-3"
      id="Tc_2f-8VoypsUeYtXWaR5kyKg_17_5"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k8Gu3743e0GwNZtJz5p2Rw"
      decimals="-3"
      id="Tc_rYvrP688LEC0oRXaRFWFjw_17_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1386905000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gsUfXJSf702qktCA38R1iw"
      decimals="-3"
      id="Tc_4R3pZQmp5EK6qC6cU46S9Q_17_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6_5O45BUnkyJOAznzy2CsA"
      decimals="-3"
      id="Tc_iy7BuizdhU--HkICV0CFxw_17_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1416827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_9u3QDZ5OqUquRfm7qsHFPg_17_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-29914000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M9P7eTJN40GnRu7yAa6KCw"
      decimals="INF"
      id="Tc_lOPvEQ6xW0WrNVTYEUA41Q_5_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17339816</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M9P7eTJN40GnRu7yAa6KCw"
      decimals="-3"
      id="Tc_MlRgJa-zqUqGEYnBYWpckw_5_5"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1lu-VK7_o0-Max8PseaIIA"
      decimals="-3"
      id="Tc_1IOF5jwWpE2kcnleQlvu9Q_5_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1368979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7oPrIr8cXkqlq5Yd3Q1yWw"
      decimals="-3"
      id="Tc_m0xRg9r0JUK-16V3SkdDBw_5_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_P4KZWdg170yGNV_k_L91Hg"
      decimals="-3"
      id="Tc_awVoI3bb9kipyLyG6lAH4Q_5_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1382459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA"
      decimals="-3"
      id="Tc_RpnuVw-ewkGjar8zQJ76mw_5_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-13616000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Gvz4si6MdkS4fdUVQlbKOA"
      decimals="-3"
      id="Tc_tpMM9XFza0SEwP7L6SoMug_6_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-13536000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ"
      decimals="-3"
      id="Tc_BEBa5sGD00GXvgTV2G_L1A_6_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-13536000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zmuW7qmKekWpcj688rHkvg"
      decimals="-3"
      id="Tc_prrZgNyv00uaJH0I-wbEvQ_7_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">126000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ"
      decimals="-3"
      id="Tc_Vs6jzzaPwkafO972WEdsfQ_7_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">126000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m6FKz0lCzEavyGq5m7-dVg"
      decimals="INF"
      id="Tc_b07xPl5Ypkil5-sewoaw9g_8_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">95</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QJLTwjYbzkmfnUQQu3xMaA"
      decimals="-3"
      id="Tc_tGwHkAASuUawtxThJltURg_8_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ"
      decimals="-3"
      id="Tc_r7Cwx72vK0Su9oZeN8kBCQ_8_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m6FKz0lCzEavyGq5m7-dVg"
      decimals="INF"
      id="Tc_RZbQ4BYAiUCz4oBRNv7EvQ_9_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">26625</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QJLTwjYbzkmfnUQQu3xMaA"
      decimals="-3"
      id="Tc_L0Ag_n15-EewlVcuBdhrgw_10_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_HkP-KAMkNUCPfG2lNpzZLQ"
      decimals="-3"
      id="Tc_IzLO_hr1fEa0oUKyb0DX-A_10_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w10yELUyuUKFpRmpWRAlCw"
      decimals="INF"
      id="Tc_xoZQCFqgk0qZsIFuT3_I3A_11_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17366536</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w10yELUyuUKFpRmpWRAlCw"
      decimals="-3"
      id="Tc_b0yMSyK7O0CeJTSMb-MBYQ_11_5"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GnF2WrQG20ug_b0PbRql7g"
      decimals="-3"
      id="Tc_yxKnlw-Y8Em20ixLO_T0HA_11_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1371748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_zBZ0CJwMEUaUNEdiy_40SA"
      decimals="-3"
      id="Tc_MB0tF1dn4kqp78P7HTMtCg_11_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2hx_ymqnNEmbyAqqcCVWhg"
      decimals="-3"
      id="Tc_d5LER-xc9UaR1w_v4DAQLA_11_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1395995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_RB2aD2voQkKnT5jqSouijg"
      decimals="-3"
      id="Tc_cq2Wo5IaZUSlNtq_rUHOIw_11_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-24257000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a0Js5EGrGk62uZjqtY72Kw"
      decimals="-3"
      id="Tc_zBD1TjdRIE2_7UecBGIqrA_12_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-6600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_I8mMeXqF7EioeOKbJ3HhuA_12_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-6600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H4solk7YuEifDSX0Yinypw"
      decimals="-3"
      id="Tc_lG2CkAVxpkicNkBFQalLng_13_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_QC6kFWUdb0-DN_kiPvLoaA_13_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5haw8gzz_kCqIrKMQPuu3g"
      decimals="INF"
      id="Tc_bnesGKfdNEm7Rb7eOq1GdQ_14_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">52379</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EYUKQoEsRUCEo0sMj1Wymg"
      decimals="-3"
      id="Tc_VPjB5q6aT0CYE_T478pEmQ_14_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">554000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_rcs2wmMU2EaXNZytuPbIEg_14_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">554000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5haw8gzz_kCqIrKMQPuu3g"
      decimals="INF"
      id="Tc_9b-CtIDJfEa9P1EsCJ9c5A_15_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">16875</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EYUKQoEsRUCEo0sMj1Wymg"
      decimals="-3"
      id="Tc_fXE5bJVrnkSlJCr8va7Kyw_16_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2186000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_rs9bK5wMxUmKFyBxS981mg_16_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2186000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c4Il3dY-Cka-Z7hPZIh3_Q"
      decimals="INF"
      id="Tc_2y67zNPYPUiY4bPmh4wZRA_17_2"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">17435790</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c4Il3dY-Cka-Z7hPZIh3_Q"
      decimals="-3"
      id="Tc_BTEAdjckjUytf0U571afEQ_17_5"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tVwp1l-1kEuXU6ahtps2VQ"
      decimals="-3"
      id="Tc_YL1u_TVSqk2cKxDKy7aMBg_17_8"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1374488000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_izJ-lHsOY06-uJsEfZQQXg"
      decimals="-3"
      id="Tc_bUTXdnayK0qlMpm8dbs0jA_17_11"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGqVrCjqIU2_N3yu6dMC8w"
      decimals="-3"
      id="Tc_czVcxhHkIkq8Feck354TOw_17_14"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1402595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA"
      decimals="-3"
      id="Tc_p5HrI-IyUU2-OJ7pmUkvfQ_17_17"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-28115000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_Zv4EwjatikeOUiZp2Vb0hg_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9277000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_XyVFDQYQ5EihBNFes7fS-g_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-20136000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_r8gSHcqADUOQ_njv-llyjw_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7662000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_g10cepHtM0eTZloGRA3Ejg_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4930000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_S1OGwdrTsEq-_KnSMaAbkw_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-398000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_hNEBjS0BBEittBpf8vQQwQ_8_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1013000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_U-JEdsFXVEWd3DqkldkLCg_8_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">653000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_eMoyspbgKU2s7Hk4HK7awQ_9_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">364000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_2mU4Tw_s50-yKdrP836nUw_9_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">114000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_CKnFhIl-8EeXVccHFH4EAg_11_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1646000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_fPbFB6Mkt0aU-ZKNHmpLUQ_11_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-19501000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_GRTYxOSAF0-JyfTAktt2QQ_12_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4505000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_iIj8djfUGkK8zGuOyAXEGw_12_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1640000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_xDH5-E-9Y0-iTiSVzoRfQw_13_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2088000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_0XJs5nuYSkqIDTsqRHidkA_13_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-3391000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <rigl:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_kJsTu3f6lkCOVLuuK4U-_Q_14_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">301000</rigl:IncreaseDecreaseRightOfUseAssets>
    <rigl:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_fbFb3t5KwUKu7V2yr59E2A_14_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">933000</rigl:IncreaseDecreaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_HzPdgnopW0WcF-nN0EBRLQ_15_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1012000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_rSu2eeXVD0qX6u2Wvi4frA_15_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-2268000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_P1fyWwiL_kmtB-iJN2-W-Q_16_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-2303000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_12rTC7ScBEq2tYQpe-AHAg_16_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-2127000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_FlVl6Nb58kK61m-HfXZ6mA_17_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1159000</rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability>
    <rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_f-GCgNqPzEW6znH-zS2bbQ_17_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1882000</rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability>
    <rigl:RevenueReservesAndRefundLiability
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_99kq9O9Zq0eO8VnBETP8kQ_18_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2863000</rigl:RevenueReservesAndRefundLiability>
    <rigl:RevenueReservesAndRefundLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_HZYm2BCA6UCE_FZz6ZeMkw_18_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1539000</rigl:RevenueReservesAndRefundLiability>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_pixl_I5pJk-OsU1ucOT5rQ_19_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">532000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_o2CgZjEkQ0-jWW2nSonIMA_19_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1472000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_1mXVad-bekyPoxO8pM1pBA_20_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-338000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_LxnCU9iaW0iGaU8dEya5Kw_20_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-1011000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_4QJYG7E7r0qAfrtyGQAGxA_21_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-14000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_dbt0CR7m10alCQjVtMB_6Q_22_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1175000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_PLxsMaHRHk2zL00wXwTS5Q_23_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-4711000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_PZ6QOE6sckCkMIGsKTr3mA_23_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1856000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_Sm5RL0Vw0UGhXYtple4K9g_25_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">26950000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_3rkBCXfCWUSXytFMjTrYQg_25_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">27400000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_jGI4yjb_lUKPXEDkE_OpoA_26_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15348000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_Nfr-K0_if0yAn9B46NEtag_26_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8780000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_qMJ6CwSZDkKlZc13Lhlv4Q_27_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">360000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_WFLbCgYjW0CrHlUIn48RTg_27_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_UeVHxaKNgUiC3hEPvHBoZQ_28_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">127000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_siqbr8sWGEGY0bxKMXkIiQ_29_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">11242000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_-zZCTLyGOUW_16hQw6yekg_29_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3747000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_sicD5NHaPUiiatpu59VDcQ_31_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">19950000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_5_vr4KeSHkmgixkuRXMe6A_32_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">341000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_2jT9w4fE5ki671Kc5OnQGQ_32_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">554000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <rigl:PaymentOfCostShareToCollaborationPartner
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_tuQ6kci05EGE87oKFJOfWA_33_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3605000</rigl:PaymentOfCostShareToCollaborationPartner>
    <rigl:PaymentOfCostShareToCollaborationPartner
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_IxqZcN0Hd0Gw1pYH3ZUlYw_33_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1754000</rigl:PaymentOfCostShareToCollaborationPartner>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_RruNvL1WWE-FOFkBQoqCYQ_34_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-3264000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_K2DOyuBY5kynwvAzUoyI6g_34_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">18750000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_KmhyK6gbk0qeqM5vPsYCmA_35_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3267000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_P4B8jC6hK0KKYiCErfBHsA_35_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">24353000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_Q3dZlDQle0C092l0zLpqTg_36_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">32786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA"
      decimals="-3"
      id="Tc_9KYq44rq7UODUowFGdmcQg_36_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">24459000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_ZI1hz9d7_UGHMMEPnLr2yw_37_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">36053000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA"
      decimals="-3"
      id="Tc_W_42X6liF0qPG6Shh6m4EQ_37_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">48812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_AhIHkFVcqUyljkgryWioqw_39_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3457000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_T4uXNHVPSUWbBGKt9BjISA_39_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2485000</us-gaap:InterestPaidNet>
    <rigl:IntangibleAssetsIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_9xaj5hVYB0yDyhcMtXupxg_40_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000</rigl:IntangibleAssetsIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_I3Kxb_ycXE68YfawGg_VIQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Organization and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;TAVALISSE&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (fostamatinib disodium hexahydrate) is our first product approved by the US Food and Drug Administration (FDA). TAVALISSE is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Canada, Israel and Japan (as TAVALISSE) for the treatment of chronic ITP in adult patients. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;REZLIDHIA&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&#160;&lt;/sup&gt;&lt;span style="color:#222222;background:#ffffff;"&gt;(olutasidenib) is o&lt;/span&gt;ur second FDA-approved product. REZLIDHIA capsules are indicated &lt;span style="color:#222222;background:#ffffff;"&gt;for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. W&lt;/span&gt;e in-licensed REZLIDHIA&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;from Forma Therapeutics, Inc., now Novo Nordisk (Forma), with exclusive, worldwide rights for its development, manufacturing and commercialization. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;GAVRETO&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="font-size:10pt;"&gt; (pralsetinib) is our third FDA-approved product which we began commercializing on June 27, 2024. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild-type rearranged during transfection (RET) and oncogenic RET fusions. GAVRETO is approved by the FDA for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. GAVRETO is also approved under accelerated approval based on overall response rate and duration response rate, for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). We acquired the rights to research, develop, manufacture and commercialize GAVRETO in the US from Blueprint Medicines Corporation (Blueprint) pursuant to an Asset Purchase Agreement entered in February 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;We continue to advance the development of R289, our interleukin receptor-associated kinases 1 and 4 (IRAK 1/4) &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;inhibitor program, in an open-label, Phase 1b trial to determine the tolerability and preliminary efficacy of the drug in patients with lower-risk &lt;/span&gt;&lt;span style="color:#222222;font-size:10pt;background:#ffffff;"&gt;myelodysplastic syndrome (MDS)&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; who are relapsed, refractory or resistant to prior therapies. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;We have strategic development collaborations with the University of Texas MD Anderson Cancer Center (MDACC) to expand our evaluation of REZLIDHIA in AML and other hematologic cancers with IDH1 mutations, and with Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in combination with temozolomide in patients with high-grade glioma (HGG) harboring an IDH1 mutation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;We have a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with our partner Eli Lilly and Company (Lilly). We also have product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;We filed with the Secretary of State of the State of Delaware a certificate of amendment to our Amended and Restated Certificate of Incorporation, to effect a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_nJcNMH1G4kyCDx--KfxI4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; reverse stock split, effective June 27, 2024. As a result of the reverse stock split, every ten issued and outstanding shares of our common stock were automatically combined into one issued and outstanding share of common stock. Accordingly, an amount equal to the par value of the decreased shares &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;resulting from the reverse stock split was reclassified from common stock to additional paid-in capital on the condensed balance sheet and statement of changes in stockholders&#x2019; deficit. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock were entitled to receive the cash value &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the common stock as reported by Nasdaq on the last trading day prior to the effective date of the split. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;As a result of the reverse stock split, proportionate adjustments were made to the number of shares underlying (and as applicable, the exercise or conversion prices of) our outstanding equity awards and to the number of shares of common stock issuable under our equity incentive plans. The reverse stock split did not change the par value of our common stock, which remains &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.001&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, or the authorized number of shares of our common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2023 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Our significant accounting policies are described in &#x201c;Note 1 &#x2013; Description of Business and Summary of Significant Accounting Policies&#x201d; to our&#160;&#x201c;Notes to Financial Statements&#x201d;&#160;contained in Part II, Item&#160;8, &#x201c;Financial Statements and Supplementary Data&#x201d; of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to these accounting policies except for the accounting consideration related to the Asset Purchase Agreement with Blueprint as discussed below in &#x201c;Note 5 &#x2013; In-licensing and Acquisition.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;As of June 30, 2024, we had approximately $49.1 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In November 2023, FASB issued ASU 2023-07,&#160;&lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&#160;&lt;/i&gt;This update expands public entities&#x2019; segment disclosures, among others, requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss; an amount and description of its composition for other segment items; and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;background:#ffffff;margin:0pt;"&gt;interim disclosures of a reportable segment&#x2019;s profit or loss and assets. All disclosure requirements under this update are also required for public entities with a single reportable segment. This update is effective for our Annual Report on Form 10-K for the fiscal year ending December 31, 2024, and interim periods thereafter. Early adoption is permitted. The update should be applied retrospectively to all periods presented in the financial statements. We are currently evaluating the impact of adopting this update on our financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In December 2023, FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;, which enhance the annual disclosure requirements regarding the tax rate reconciliation and incomes taxes paid information. This update is effective for our fiscal year ending December 31, 2025, and maybe adopted on a prospective or retrospective basis. Early adoption is permitted. We are currently assessing the impact of adopting this guidance but does not expect to have a significant impact to our financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"&gt;Other recently issued accounting guidance not discussed in this Quarterly Report on Form 10-Q are either not applicable or did not have, or are not expected to have, a material impact on us.&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <rigl:StockholdersEquityReverseStockSplitPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_m7I2PcevGEqNtVQElJ7DcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;We filed with the Secretary of State of the State of Delaware a certificate of amendment to our Amended and Restated Certificate of Incorporation, to effect a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_nJcNMH1G4kyCDx--KfxI4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; reverse stock split, effective June 27, 2024. As a result of the reverse stock split, every ten issued and outstanding shares of our common stock were automatically combined into one issued and outstanding share of common stock. Accordingly, an amount equal to the par value of the decreased shares &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;resulting from the reverse stock split was reclassified from common stock to additional paid-in capital on the condensed balance sheet and statement of changes in stockholders&#x2019; deficit. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock were entitled to receive the cash value &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the common stock as reported by Nasdaq on the last trading day prior to the effective date of the split. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;As a result of the reverse stock split, proportionate adjustments were made to the number of shares underlying (and as applicable, the exercise or conversion prices of) our outstanding equity awards and to the number of shares of common stock issuable under our equity incentive plans. The reverse stock split did not change the par value of our common stock, which remains &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.001&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, or the authorized number of shares of our common stock. All share amounts and per share amounts disclosed in this Quarterly Report on Form 10-Q have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented.&lt;/span&gt;&lt;/p&gt;</rigl:StockholdersEquityReverseStockSplitPolicyPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="INF"
      id="Narr_4TL5BxVXXUqaOKRgB0MrZw"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_itGe_sr4E0yiHzjCjr0Daw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:9pt 0pt 9pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Our accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (US GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by US GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2023 has been derived from audited financial statements at that date but does not include all disclosures required by US GAAP for complete financial statements. Because certain disclosures required by US GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_S5ZHIq2vakCQRPgee9MM9Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <rigl:LiquidityAndCapitalResourcesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_iGx7YVHZc0aC8j6G2BYkBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;As of June 30, 2024, we had approximately $49.1 million in cash, cash equivalents and short-term investments. Since inception, we have financed our operations primarily through sales of equity securities, debt financing, contract payments under our collaboration agreements and from product sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.&lt;/p&gt;</rigl:LiquidityAndCapitalResourcesPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-5"
      id="Narr_Nfp2OpPoDUenIY5L8bqENw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">49100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_P-6AXP-Nt0eN9xEmm10IQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In November 2023, FASB issued ASU 2023-07,&#160;&lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&#160;&lt;/i&gt;This update expands public entities&#x2019; segment disclosures, among others, requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss; an amount and description of its composition for other segment items; and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;background:#ffffff;margin:0pt;"&gt;interim disclosures of a reportable segment&#x2019;s profit or loss and assets. All disclosure requirements under this update are also required for public entities with a single reportable segment. This update is effective for our Annual Report on Form 10-K for the fiscal year ending December 31, 2024, and interim periods thereafter. Early adoption is permitted. The update should be applied retrospectively to all periods presented in the financial statements. We are currently evaluating the impact of adopting this update on our financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In December 2023, FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;, which enhance the annual disclosure requirements regarding the tax rate reconciliation and incomes taxes paid information. This update is effective for our fiscal year ending December 31, 2025, and maybe adopted on a prospective or retrospective basis. Early adoption is permitted. We are currently assessing the impact of adopting this guidance but does not expect to have a significant impact to our financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"&gt;Other recently issued accounting guidance not discussed in this Quarterly Report on Form 10-Q are either not applicable or did not have, or are not expected to have, a material impact on us.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_XGGfe0N4J0K4ZPY7KOVR0A">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period and the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Potentially dilutive securities include stock options, RSUs and shares issuable under our Employee Stock Purchase Plan (Purchase Plan). The dilutive effect of these potentially dilutive securities is reflected in diluted earnings per share using the treasury stock method. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;The potential shares of common stock that were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,691 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,524 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,691 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,524 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;388 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;196 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;388 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;196 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,079 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,720 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,079 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,720 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_jxxHfO4tTUyJbMDnK5khww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:93.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,691 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,524 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,691 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,524 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;388 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;196 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;388 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;196 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,079 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,720 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,079 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,720 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RaKuxSzhSUupPD2oOUXYKw"
      decimals="-3"
      id="Tc_MDFdhnSrnkWSj_W4FdyHYA_3_3"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">3691000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bYo6kwZv60OcoBnM9_riJQ"
      decimals="-3"
      id="Tc__Vww80aIs0KnlN44wZK0hg_3_6"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">3524000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_FZjvdGbKikurAAd8fQxjGA"
      decimals="-3"
      id="Tc_3B15ro6zekuQq-AV_pyz-w_3_9"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">3691000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_P5Ej5A9ePUSqZtXcVBF9vw"
      decimals="-3"
      id="Tc_gMM2mhbvBUCyt2mdmQ0aqw_3_12"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">3524000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_JastdyjIyEGJursVulIfKQ"
      decimals="-3"
      id="Tc_Jbc49jFbHUis5Gt1n-PtyA_4_3"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">388000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q7YoKf7gyU2XWicwj8JbrA"
      decimals="-3"
      id="Tc_D80EAUNhE0erm73tKvWPuw_4_6"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">196000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_XpXugziTxk2FFISdmEQLwQ"
      decimals="-3"
      id="Tc_ndPdOL31ZUexiznwchKwtQ_4_9"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">388000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_MiyxZQLaX0CaycIWWGMjpg"
      decimals="-3"
      id="Tc_JP4awCPtfUOwnp4w-jtubg_4_12"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">196000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_d6d-X_sZ90-SH-XiCVdEfA_5_3"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">4079000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_A-nZ0YaiTE6OjK2MxLscoA_5_6"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">3720000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_MHeDWO1RUUGVLtHgyr3zBQ_5_9"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">4079000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_XJQya9-5FEOeSQvo_0JSSA_5_12"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">3720000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_qFLpX7h74UiBccn7L9DMEw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Revenues&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:7pt 0pt 9pt 0pt;"&gt;Revenues disaggregated by category were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;48,980 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;33,456 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;87,406 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;66,654 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Discounts and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(15,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(9,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(27,953)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(19,028)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total product sales, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,453&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from collaborations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Delivery of drug supplies, royalty and others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,391 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,005 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,922 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,330 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total revenues from collaborations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government contracts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,956&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;Revenue from product sales are related to sales of our commercial products to our specialty distributors. For detailed discussions of our revenues from collaborations and government contracts, see &#x201c;Note 4 &#x2013; Sponsored Research, License Agreements and Government Contracts.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;Our net product sales include gross product sales, net of chargebacks, discounts and fees, government and other rebates and returns. Of the total discounts and allowances from gross product sales for the six months ended June 30, 2024 and 2023, $27.6 million and $18.6 million, respectively, was accounted for as additions to revenue reserves and refund liability, and $0.4 million and $0.4 million, respectively, as reductions in accounts receivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the condensed balance sheet. The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,165)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,441)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,020)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;"&gt;The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;McKesson Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;49%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;44%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;46%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;45%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cardinal Health, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;26%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cencora Inc. (formerly ASD Healthcare)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;20%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;19%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_z97QIKY3d0yMovsAhm7WvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:7pt 0pt 9pt 0pt;"&gt;Revenues disaggregated by category were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;48,980 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;33,456 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;87,406 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;66,654 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Discounts and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(15,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(9,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(27,953)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(19,028)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total product sales, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,453&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from collaborations:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Delivery of drug supplies, royalty and others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,391 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,005 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,922 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,330 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total revenues from collaborations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government contracts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,956&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_66nF3F7T6EeO_T5ormWp2A"
      decimals="-3"
      id="Tc_ceegp5OiwkKebiF_zQhzLw_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">48980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember__ugQCo2hvkaHA8jhmfIr6w"
      decimals="-3"
      id="Tc_bxhVDCF9fE-HRAVezNIz4A_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">33456000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GrossProductMember_HU2T--c6-k2PWST4x-p1iw"
      decimals="-3"
      id="Tc_cZU4rvLPMUOqpgChcGkgUg_4_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">87406000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_GrossProductMember_aYmi2v0mz0e4c5dQ7lldvA"
      decimals="-3"
      id="Tc_RUUAgTF83UKTkHYs4T-8tg_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">66654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_kgj2lfO1x06p8zrIfFzVjQ"
      decimals="-3"
      id="Tc_URvR-VokzUmeGFBLcl6rcg_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-15530000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_vkZ_1rGsnkW09QyZQM9DaQ"
      decimals="-3"
      id="Tc_T7pAXu6sJkC4dLJbG7VA9A_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_rnk0gbYth0SBm1kX1fW23A"
      decimals="-3"
      id="Tc_lxXcqshTpE-VZ8PrwGgavg_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-27953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_DiscountsAndAllowancesMember_n6rbBTWKREaLGIeGb095og"
      decimals="-3"
      id="Tc_VDrP-2MAA06D3PYqZEnhLg_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-19028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_L2X2ODMWN02W75JbcgBOuA"
      decimals="-3"
      id="Tc_O1AOml0FwE2lEPCCwCVBow_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">33450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_qF77QLopJkm7QArlC1YAAQ"
      decimals="-3"
      id="Tc_i-5dhpszl0-o8vsHz-TDng_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">23881000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxQfYCTi-EmntNNb3PEHNw"
      decimals="-3"
      id="Tc_ppKj2VRRYEe8I-S3wS_3aw_6_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_0CKs5sN0Y06oyeNfimQy-w"
      decimals="-3"
      id="Tc_1HdY0ATzpkaYnWF9zlyQCA_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">47626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_YUs53Q9t60y3XCZGyv6pTw"
      decimals="-3"
      id="Tc_gLeIDjvSZEunbIgvi4i-jg_8_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_KLumYMF9xEy2B9eFN1r15g"
      decimals="-3"
      id="Tc_TGqM3XW7z0-IFBS152MuVg_8_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_X2QX2SMv0UeS4dY9h3vreQ"
      decimals="-3"
      id="Tc_ukfcsAfyMkSIKQEUc1UkBA_8_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_RoyaltyDeliveryOfDrugSuppliesAndOthersMember_ktlf9P2M7UaLAIc_BeIB8A"
      decimals="-3"
      id="Tc_IYpoACRM_06PsFMWHC4HQg_8_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_jsAPdtswwUqlYhdOCwaqtQ"
      decimals="-3"
      id="Tc_YcQq8MMvOU-tU0Sjbj_uDQ_9_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_crGh4Gmf10KG35aVQN5FmQ"
      decimals="-3"
      id="Tc_9iXouj5iB0W7fif5jPl3Zw_9_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_dRwb9LpMMUGY_8SiQzA0vQ"
      decimals="-3"
      id="Tc_ClJog9Xlfk219iaBmW1Q-A_9_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_ContractRevenuesFromCollaborationsMember_sXlfY9W4v0-bUvEUlAVg8w"
      decimals="-3"
      id="Tc_1KmFUVb0_0mtaGjafVItmQ_9_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg"
      decimals="-3"
      id="Tc_Ou8JuAZKykOrkUJEyjh3zA_10_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w"
      decimals="-3"
      id="Tc_JR3UXrW0kk2-tjCd_KhqxA_10_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_850WWTqa00CjxKb74RoWCA_11_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">36841000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_FeKjYtAbdUK7feKdW-oQVw_11_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">26886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_nHYn3W9hokikZw6HOik8-A_11_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">66375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_nw1Qo8Az40CgWJ5nywlqWw_11_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">52956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-5"
      id="Narr_2FYjcsSdsUilgbO-pL5zaA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">27600000</rigl:SalesDiscountsAndAllowances>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-5"
      id="Narr_cBS_waCBj0Wk5CbwtW4Kxg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">18600000</rigl:SalesDiscountsAndAllowances>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_rBLR8Q6qY0qEWXFfKO_L3A"
      decimals="-5"
      id="Narr_OAOb-tTKnUO75ZGY0SoiNg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">400000</rigl:SalesDiscountsAndAllowances>
    <rigl:SalesDiscountsAndAllowances
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_BalanceSheetLocationAxis_rigl_AccountsReceivableAndPrepaidAndOtherCurrentAssetsMember_nO2J61EcMEKdr-tpRvz54A"
      decimals="-5"
      id="Narr_gDpCcZgqhUehmp1KvlLK2A"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">400000</rigl:SalesDiscountsAndAllowances>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_Q_HQfOUnykeLlt-MEbCtxg">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,165)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,441)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Discounts&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Provision related to current period sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Credit or payments made during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,020)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_6fGEzsR-EU2ukRaZfEQHTQ"
      decimals="-3"
      id="Tc_EsWZNq8isk6FY1QIqK-wbg_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8236000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_5kGrsJtJPUaXWHfMUTNnAA"
      decimals="-3"
      id="Tc_ohOxl4fN4U6o8v0JNULhKA_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3517000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_yxzYceuVAE2CBLGPEXWLcg"
      decimals="-3"
      id="Tc_w_eHA3VyQE6sWGbcJVZxuQ_4_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3931000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_j9P8jZh0aEqOI7oxQemCZA_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15684000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_tCX8H5e_0kK--61UsSImug"
      decimals="-3"
      id="Tc_0bQhKm2MPUm7HKQbQniu0g_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">21770000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_YseB19IaTUeq6LVKzfKj0A"
      decimals="-3"
      id="Tc_NW5BNMuXGUGCSaEfnK1PBA_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5259000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_cuHB688G_ked7r68OdX4FQ"
      decimals="-3"
      id="Tc_lda1T5-QlEKxt5sYSj3wUw_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">522000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_WreKuXkGuEKpBbNTdQrRYA_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">27551000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_tCX8H5e_0kK--61UsSImug"
      decimals="-3"
      id="Tc_HdcuX-NVWECJRY74jeEDQQ_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">20165000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_YseB19IaTUeq6LVKzfKj0A"
      decimals="-3"
      id="Tc_r4g8qHKV-UmXzYBukEXQhw_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4441000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_cuHB688G_ked7r68OdX4FQ"
      decimals="-3"
      id="Tc_TS-eHADv9UWA3tvNS1dnAQ_6_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">82000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_dBx7qeuUzUGjNFhIBAUFVA_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">24688000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_Ij2f4OxgUUCWtD_5lHA7pA"
      decimals="-3"
      id="Tc_cfv20zagMUqdAJDY0wi61Q_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">9841000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pt2UPlNyCUWGebgWK5jSPw"
      decimals="-3"
      id="Tc_0l1t1Zcj4U-wZ8J9R7oa4g_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4335000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2024_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_YfpRiaWZxUqB5w9lvYJvVQ"
      decimals="-3"
      id="Tc_fUqFMUWYmkykjTfIP2oaJQ_7_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4371000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_k5hUo4eS2kGXJuUh7DPpig_7_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">18547000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_DeoG3uLWSE6eChBxTmVl_g"
      decimals="-3"
      id="Tc_qtPcQ-jfB0Ga-jnrWZTe3g_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6213000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_pxFiNodJ0UaXW8PVpDH_dg"
      decimals="-3"
      id="Tc_nnRtS7xlU0qSa3bUkOJZdg_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2636000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_pwaobjInbUCU4wLXJWRgWg"
      decimals="-3"
      id="Tc_z2mT251zgE-0FyswBW8boA_4_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3296000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_12_31_2022_HZLRCMmL3kugIo1ZnxzpvA"
      decimals="-3"
      id="Tc_nXN31m5QiUeBTBGPXEYUdg_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12145000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_zCeB2BBtfU-Wb3oZ3EUjpQ"
      decimals="-3"
      id="Tc_Gxe0RH6OgECZxny0s7y8Lw_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">14439000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_uk1O_sp-Y0--KVAhhGNE-A"
      decimals="-3"
      id="Tc_0q7JfMRYxUSVL2nrZx7ZeA_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3725000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_XZhamrPP1kS0gkYOdPFL2A"
      decimals="-3"
      id="Tc_ydCzcXyD0kWOnWjkhQt1ZQ_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">395000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_TlgZjzxeoU2gYT1TSps1EA_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">18559000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_zCeB2BBtfU-Wb3oZ3EUjpQ"
      decimals="-3"
      id="Tc_4wlaio2aZUaNvLzRNbNRZw_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13139000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember_uk1O_sp-Y0--KVAhhGNE-A"
      decimals="-3"
      id="Tc_vRlkjZAXSUCTXWqvQbvjAg_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3765000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_XZhamrPP1kS0gkYOdPFL2A"
      decimals="-3"
      id="Tc_AlfbZ2GQxEuFfTz-5G6rbQ_6_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">116000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_WgCsdxvvAEy-DQWYp1Cieg_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17020000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_ChargebacksDiscountsAndFeesMember_pvl3dQL-10KWQKcJlK7PhQ"
      decimals="-3"
      id="Tc_SLiW55mYakGtBORwfEQ4fA_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7513000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_rigl_GovernmentAndOtherRebatesMember__q2T26iax0eiR5sdI86W6g"
      decimals="-3"
      id="Tc_NKuZ4rcbTUCkYL3TKCwsfg_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2596000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember_K66Fz-gvL0-4yU--dKixIA"
      decimals="-3"
      id="Tc_QqQSaxqbxEmsC_I-2Y7DMA_7_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3575000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="As_Of_6_30_2023_L_G7y3rgWEq__MXFYVC3iA"
      decimals="-3"
      id="Tc_EE_eiI3xVU6QHBBZBgzhNw_7_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13684000</us-gaap:ValuationAllowancesAndReservesBalance>
    <rigl:DisaggregationOfRevenueByCustomerTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_ulTC8umCI0-roWxCHy-ISg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.98%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;McKesson Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;49%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;44%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;46%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;45%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cardinal Health, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;26%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cencora Inc. (formerly ASD Healthcare)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;20%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;19%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</rigl:DisaggregationOfRevenueByCustomerTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_zwK5QRRX6EqsKGahncDIOQ"
      decimals="2"
      id="Tc__g81dAm5vUaGJWts15ZugA_3_3"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_9m5rS6MB3E-SUlgdlXlTSQ"
      decimals="2"
      id="Tc_wN3kRZwmcUuwwba80X7I5Q_3_6"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i1LjpfRajUeDxjso7nYoyA"
      decimals="2"
      id="Tc_AFMCda_hnEKRHK0eIHmm1g_3_10"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_MckessonSpecialtyCareDistributionCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7fwMtHOoHUm7LRR4eArbsg"
      decimals="2"
      id="Tc_HSXO9BPd8062la_5yrUjBQ_3_13"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eFVzoQltvEO4gINVqtxI-A"
      decimals="2"
      id="Tc_NmC39FwQjkiZZRWVA-yBBA_4_3"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_GgfOc-xLJ0CVzgWger3Arw"
      decimals="2"
      id="Tc__h3dN0qftUWdcekMeh04jA_4_6"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Q7EkAAoHeUKJsjYoTZrhbg"
      decimals="2"
      id="Tc_PNAc00XASEa4Fr_foTDeWA_4_10"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CardinalHealthIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_oLL4Ndsu6UyV_O0-24gTWQ"
      decimals="2"
      id="Tc_IPxhsnTQbkKGlntg5J4TcA_4_13"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jkelz1ePoUOQLw4bzruVCA"
      decimals="2"
      id="Tc_GueRg9tY-EGxmfDd36rlIg_5_3"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_LEnPZ15moEKAEm_18pTBow"
      decimals="2"
      id="Tc_ixUcjAS5C0-0syv-8YMbQw_5_6"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_PbJR__bHUUymqE5jma_jhA"
      decimals="2"
      id="Tc_jnmQHs15HkmZAOlP9-CUmQ_5_10"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_rigl_CencoraIncMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NhxdhXczxkO1of_nfPZIOQ"
      decimals="2"
      id="Tc_v2CMrHZXe0e3aGVBLtbZxA_5_13"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_-2zpGxaN50-OxQpdarf6Zw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;4.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Sponsored Research, License Agreements and Government Contracts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Sponsored Research and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We conduct research and development programs independently and in connection with our corporate collaborators. As of June 30, 2024, we are a party to collaboration agreements with Lilly to develop and commercialize ocadusertib (previously R552), a RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases and collaboration aimed at developing additional RIPK1 inhibitors for the treatment of central nervous system (CNS) diseases; with Grifols S.A. (Grifols) to commercialize fostamatinib for human diseases in all indications in Grifols territory which includes Europe, the UK, Turkey, the Middle East, North Africa and Russia (including Commonwealth of Independent States); with Kissei Pharmaceutical Co., Ltd. (Kissei) to develop and commercialize fostamatinib in Kissei territory which includes Japan, China, Taiwan and the Republic of Korea; with Medison Pharma Trading AG (Medison Canada) and Medison Pharma Ltd. (Medison Israel and, together with Medison Canada, Medison) to commercialize fostamatinib in all indications, in Medison territory which includes Canada and Israel; and with Knight Therapeutics International SA (Knight) to commercialize fostamatinib in all indications, in Knight territory which includes Latin America, consisting of Mexico, Central and South America, and the Caribbean (Knight territory).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Further, we are also a party to collaboration agreements, but do not have ongoing performance obligations with BerGenBio for the development and commercialization of &lt;span style="background:#ffffff;"&gt;AXL receptor tyrosine kinase (&lt;/span&gt;AXL) inhibitors in oncology, and with Daiichi to pursue research related to &lt;span style="background:#ffffff;"&gt;murine double minute 2&#160;(&lt;/span&gt;MDM2) inhibitors, a novel class of drug targets called ligases. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the above existing agreements that we entered into in the ordinary course of business, we received or may be entitled to receive upfront cash payments, payments contingent upon specified events achieved by such partners and royalties on any net sales of products sold by such partners under the agreements. As of June 30, 2024, total future contingent payments to us under all of the above existing agreements, excluding terminated agreements, could exceed $1.3 billion if all potential product candidates achieved all of the payment triggering events under all of our current agreements. Of this amount, $279.5&#160;million relates to the achievement of development events, $263.1 million relates to the achievement of regulatory events and $796.0&#160;million relates to the achievement of certain commercial events. This estimated future contingent amount does not include any estimated royalties that could be due to us if the partners successfully commercialize any of the licensed products. Future events that may trigger payments to us under the agreements are based solely on our partners&#x2019; future efforts and achievements of specified development, regulatory and/or commercial events. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We account for the milestone payments when such milestones are considered probable of being achieved, and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, and recorded as part of contract revenues from collaborations during the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Global Exclusive License Agreement with Lilly &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;We have a global exclusive license agreement and strategic collaboration with Lilly (Lilly Agreement) entered in February 2021, which became effective in March 2021, upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, to develop and commercialize ocadusertib (previously R552) for the treatment of non-CNS diseases. In addition, the collaboration is aimed at developing additional RIPK1 inhibitors for the treatment of CNS diseases. Pursuant to the terms of the Lilly Agreement, we granted Lilly the exclusive rights to develop and commercialize ocadusertib and related RIPK1 inhibitors in all indications worldwide. The parties&#x2019; collaboration is governed through a joint governance committee and appropriate subcommittees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;Under the terms of the Lilly Agreement, we were entitled to receive a non-refundable and non-creditable upfront cash payment amounting to $125.0 million, which we received in April 2021. We are also entitled to additional milestone payments for non-CNS disease products consisting of up to $330.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $100.0 million in sales milestone payments on a product-by-product basis. In addition, depending on the extent of our co-funding of ocadusertib development activities, we would be entitled to receive tiered royalty payments on net sales of non-CNS disease products at percentages ranging from the mid-single digits to high-teens, subject to certain standard reductions and offsets. We are also eligible to receive milestone payments for CNS disease products consisting of up to $255.0 million in milestone payments upon the achievement of specified development, regulatory and commercial milestones, and up to $150.0 million in sales milestone payments on a product-by-product basis. We would be entitled to receive tiered royalty payments on net sales of CNS disease products up to low-double digits, subject to certain standard reductions and offsets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 0pt 0pt;"&gt;Under the Lilly Agreement, we were responsible for performing and funding initial discovery and identification of CNS disease development candidates. Following candidate selection, Lilly is responsible for performing and funding all future development and commercialization of the CNS disease development candidates. Under the Lilly Agreement, we are responsible for 20% of the development costs for ocadusertib in the US, Europe, and Japan, up to a specified cap, and Lilly is responsible for funding the remainder of all development activities for ocadusertib and other non-CNS disease development candidates. Pursuant to the terms of the Lilly Agreement, we have the right to opt-out of co-funding the ocadusertib development activities in the US, Europe and Japan at two different specified times and as a result receive lesser royalties from sales. Prior to us providing our first opt-out notice as discussed below, under the Lilly Agreement, we were required to fund our share of the ocadusertib development activities up to a maximum funding &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"&gt;commitment of $65.0 million through April 1, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;We accounted for this agreement under ASC 606 and identified the following distinct performance obligations at inception of the agreement: (a) granting of the license rights over the non-CNS penetrant intellectual property (IP), and (b) granting of the license rights over the CNS penetrant IP which will be delivered to Lilly upon completion of the additional research and development efforts specified in the agreement. We concluded that each of these performance obligations is distinct. We based our assessment on the assumption that Lilly can benefit from each of the licenses on its own by developing and commercializing the underlying product using its own resources. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;At the inception of the Lilly Agreement, given our rights to opt-out from the development of ocadusertib, we believed at the minimum, we had a commitment to fund the development costs up to $65.0 million as discussed above. We considered this commitment to fund the development costs as a significant financing component of the contract, which we accounted for as a reduction of the upfront fee to derive the transaction price. This financing component was recorded as a liability at its net present value of approximately $57.9 million using a 6.4% discount rate. Interest expense was accreted on such liability over the expected commitment period, adjusted for timing of expected cost share payments. No interest was accreted during the three and six months ended June 30, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;At the inception, we allocated the net transaction price of $67.1&#160;million to each performance obligation based on our best estimate of its relative standalone selling price using the adjusted market assessment approach. The transaction price allocated to the non-CNS penetrant IP of $60.4 million was recognized as revenue upon delivery of the non-CNS penetrant IP to Lilly during the first quarter of 2021. The transaction price allocated to the CNS penetrant IP of $6.7 million was recognized as revenue from the effective date of the Lilly Agreement through the eventual acceptance by Lilly in June 2022 using the input method. There was no outstanding deferred revenue related to Lilly Agreement as of June 30, 2024 and December 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On September 28, 2023, we entered into an amendment to the Lilly Agreement which provides, among others that if we exercise our first opt-out right, we have the right to opt-in to the co-funding of ocadusertib development, upon us providing notice to Lilly within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of certain events as specified in the Lilly Agreement, and as a result receive greater royalties from sales. Following the amendment to the Lilly Agreement, on September 29, 2023, we provided the first opt-out notice to Lilly, and our share on the ocadusertib development cost was capped to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$22.6&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million through April 1, 2024. If we exercise our opt-in right, we will be required to continue to share in global development costs, and if we later exercise our second opt-out right (no later than April 1, 2025), our share in global development costs will be up to a specified cap through December 31, 2025, as provided for in the Lilly Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:11pt 0pt 11pt 0pt;"&gt;Lilly billed us $21.4 million for our share of development costs incurred through April 1, 2024, and the amount was fully paid as of June 30, 2024. The outstanding liability to Lilly reported within other long-term liabilities (current and non-current) in the condensed balance sheet as of June 30, 2024 and December 31, 2023 amounted to $40.0 million and $43.6 million, respectively. As discussed above, following the amendment to the Lilly Agreement, and us providing the first opt-out notice to Lilly, our cost share obligation for ocadusertib development ended on April 1, 2024. Although currently we are no longer obligated to pay Lilly for our share in the ocadusertib development cost incurred subsequent to April 1, 2024, the outstanding liability reported in our condensed balance sheet as of June 30, 2024 amounting to $40.0 million has not been recognized as revenue because we cannot conclude that it is probable that a significant reversal of the amount of revenue, if recognized, will not occur until the likelihood of us exercising our opt-in right becomes remote, or when the opt-in right period lapses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Grifols License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;We have an exclusive commercialization license agreement with Grifols entered in January 2019 with exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop fostamatinib in Grifols territory. Under the agreement, we received an upfront payment of $30.0 million, with the potential for $297.5 million in total regulatory and commercial milestones. We are also entitled to receive stepped double-digit royalty payments based on tiered net sales which may reach 30% of net sales. In January 2020, the European Commission (EC) granted a centralized Marketing Authorization (MA) for fostamatinib valid throughout the European Union (EU) and in the UK after the departure of the UK from the EU for the treatment of chronic ITP in adult patients who are refractory to other treatments. With this approval, in February 2020, we received $20.0 million non-refundable payment, composed of a $17.5 million payment due upon Marketing Authorization Application (MAA) approval by the European Medicines &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"&gt;Agency (EMA) of fostamatinib for the first indication and a $2.5&#160;million creditable advance royalty payment, based on the terms of our collaboration agreement with Grifols. The above milestone payment was allocated to the distinct performance obligations in the collaboration agreement with Grifols. We accounted for this agreement under ASC 606 and identified distinct performance obligations at inception of the agreement. We allocated the transaction price to the distinct performance obligations in our collaboration agreement based on our best estimate of the relative standalone selling price, and recognized the corresponding revenue in the periods we satisfied the performance obligations. There was no outstanding deferred revenue related to the Grifols license agreement as of June 30, 2024 and December 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We entered into a Commercial Supply Agreement with Grifols in October 2020 to supply and sell our drug product priced at a certain markup specified in the agreement, in quantities Grifols order from us pursuant to and in accordance with the agreement. Prior to the Commercial Supply Agreement, we had a Drug Product Purchase Agreement with Grifols entered in December 2019. There was no revenue recognized related to the delivery of drug supply to Grifols for the three and six months ended June 30, 2024. For the three and six month ended June 30, 2023, we recognized revenue of $1.2 million and $2.8 million, respectively, from the delivery of drug supply to Grifols. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We recognize royalty revenue from Grifols included within contract revenues from collaboration. Royalty revenue recognized for the three months ended June 30, 2024 and 2023 was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.1&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.8&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, respectively, and for the six months ended June 30, 2024 and 2023 was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, respectively. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Kissei License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We have an exclusive license and supply agreement with Kissei entered in October 2018, to develop and commercialize fostamatinib in all current and potential indications in Kissei&#x2019;s territory. Kissei is responsible for performing and funding all development activities for fostamatinib in the above-mentioned territories. We received an upfront cash payment of $33.0&#160;million, with the potential for up to an additional $147.0&#160;million in development, regulatory and commercial milestone payments, and will receive mid- to upper twenty percent, tiered, escalated net sales-based payments for the supply of fostamatinib. Under the agreement, we granted Kissei the license rights to fostamatinib in Kissei&#x2019;s territory and are obligated to supply Kissei with drug product for use in clinical trials and pre-commercialization activities. We are also responsible for the manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement. We accounted for this agreement under ASC 606 and identified the distinct performance obligations at inception of the agreement. We concluded that each of these performance obligations is distinct. We determined that the upfront fee represented the transaction price and was allocated to the performance obligations based on our best estimate of the relative standalone selling price and recognized the corresponding revenue in the period we satisfied the performance obligations. As of June 30, 2024 and December 31, 2023, the remaining deferred revenue &lt;span style="background:#ffffff;"&gt;was related to the material right associated with discounted fostamatinib supply which amounted to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.4&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million&lt;/span&gt;. No revenue was recognized during the three and six months ended June 30, 2024 and 2023 associated with the remaining performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In April 2022, Kissei announced that an NDA was submitted to Japan&#x2019;s Pharmaceuticals and Medical Devices Agency (PMDA) for fostamatinib in chronic ITP. With this milestone event, we received&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$5.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, and such amount was recognized as revenue in the second quarter of 2022. In December 2022, Kissei announced that Japan&#x2019;s PMDA approved the NDA for fostamatinib in chronic ITP. With this milestone event, we were entitled to receive &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$20.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million non-refundable and non-creditable payment from Kissei pursuant to the terms of our collaboration agreement, which we recognized as revenue in the fourth quarter of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_HvqYF3vuKUK_Cbhmr3ItgA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;. The amount was subsequently collected in January 2023.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;For the three and six months ended June 30, 2024, we recognized $2.2 million and $4.5 million, respectively, of revenue related to the delivery of drug supply to Kissei mainly for commercial use.&#160;No such revenue was recognized during the three and six months ended June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Medison Commercial and License Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; exclusive commercial and license agreements with Medison entered in October 2019 for the commercialization of fostamatinib for chronic ITP in Medison territory, pursuant to which, we received a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$5.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million upfront payment with respect to the agreement in Canada. We accounted for this agreement under ASC 606 and identified the following combined performance obligations at inception of the agreement: (a) granting of the license and (b) obtaining regulatory approval in Canada of fostamatinib in ITP. However, under the agreement, we have the option to buy back all rights to the product in Canada within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; from obtaining regulatory approval for the treatment of &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;auto immune hemolytic anemia&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; in Canada. We determined that the non-refundable upfront fee represented the transaction price, however, due to the buyback provision, we accounted this upfront payment as financing arrangement under ASC 606. In 2022, management &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;concluded that the likelihood of exercising the buyback option right was remote considering the top-line results from our Phase 3 trial of fostamatinib in warm auto immune hemolytic anemia (wAIHA) which showed that the trial did not demonstrate statistical significance in the primary efficacy endpoint, and the guidance received from the FDA. As such, in accordance with ASC 606, we relieved the outstanding financing liability which included the upfront payment and accreted interest, and recognized such amount as revenue in 2022. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;There was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; outstanding deferred revenue related to Medison license agreement as of June 30, 2024 and December 31, 2023. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;For the three and six months ended June 30, 2024, we recognized revenue from Medison of $0.1 million and $0.2&lt;span style="white-space:pre-wrap;"&gt; million, respectively, related to the delivery of drug supply and earned royalties. There was no material revenue  recognized in the three and six months ended June 30, 2023 related to the delivery of drug supply and earned royalties. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Knight Commercial License and Supply Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We have commercial license and supply agreements with Knight entered in May 2022 for the commercialization of fostamatinib for approved indications in Knight territory. Pursuant to such commercial license agreement, we received a $2.0 million one-time, non-refundable, and non-creditable upfront payment, with potential for up to an additional $20.0 million in regulatory and sales-based commercial milestone payments, and will receive twenty- to mid-thirty percent, tiered, escalated net-sales based royalty payments for products sold in the Knight territory. We accounted for this agreement under ASC 606 and identified that the upfront payment was a consideration for granting Knight the license to commercialize fostamatinib for approved indication in the Knight territory, and no further material deliverables associated to such upfront payment. As such, we recognized the upfront payment as revenue in 2022. We are also responsible for the exclusive manufacture and supply of fostamatinib for all future development and commercialization activities under the agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Government Contracts &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;i style="font-size:10pt;font-style:italic;"&gt;US Department of Defense (DOD)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Government contract revenue for the three and six months ended June 30, 2023 of $1.0 million was from an award we received from DOD to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib for the treatment of hospitalized high-risk patients with COVID-19. No revenue was recognized during the three and six months ended June 30, 2024 from this grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:9pt 0pt 0pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;i style="font-size:10pt;font-style:italic;"&gt;Biomedical Advanced Research and Development (BARDA)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"&gt;In August 2023, we were awarded up to $0.8 million by BARDA, part of the Office of the Assistant Secretary for the Preparedness and Response at the US Department of Health and Human Services (DHHS), for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress. No revenue was recognized during the three and six months ended June 30, 2024 from this grant. Through June 30, 2024, we have received $0.1 million of the award.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Strategic Development Collaborations with MDACC and CONNECT&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;In December 2023, we entered into a Strategic Collaboration Agreement with MDACC, a comprehensive cancer research, treatment, and prevention center. The collaboration will expand our evaluation of REZLIDHIA (olutasidenib) in AML and other hematologic cancers. Under the collaboration, we will provide MDACC the study materials and $15.0 million in time-based milestone payments as compensation for services to be provided for the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;studies, over the &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;five-year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; collaboration term, unless terminated earlier as provided for in the agreement. Through June 30, 2024, we provided &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million funding to MDACC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In January 2024, we announced our collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA in glioma. Under the collaboration, we will provide funding up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and study material over the &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;four-year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; collaboration. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;We account for the funding we provide under the above research collaboration agreements as prepaid research and development in the balance sheet to the extent the payment is made in advance of services being rendered, and recognize such amount as research and development expense within the statements of operations as the collaborative partners render the services under the respective agreement.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-8"
      id="Narr_n68AZRO_8E2E015mHPm5zQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1300000000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedDevelopmentEventsMember_VqV4K0jYxU-ud5heUgA7Fw"
      decimals="-5"
      id="Narr_zUnO4fGZQkC8vt1Fo3nfXg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">279500000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedRegulatoryEventsMember_I9tiGJJzSUW1uADT_0QYGQ"
      decimals="-5"
      id="Narr_5RZtzcWSd0KJ29MmpiVCxQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">263100000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedProductLaunchEventsMember_7aOcJ_X2Jka6LsC0YG-yLA"
      decimals="-5"
      id="Narr_ipFLcWosdE68mbDiWZR4ww"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">796000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_4_1_2021_To_4_30_2021_pVVWDpbMUESUodMAWy20aA"
      decimals="-5"
      id="Narr_AAE5y4ZUC0ul9YC3N-D1IQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">125000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_4tLATJ2ucUu7Kj1hYljxvw"
      decimals="-5"
      id="Narr_y9sKHD-PAE6SH6VRSm6imw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">330000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_BbXVI_lx-kK6eTLL9cByJg"
      decimals="-5"
      id="Narr_qMl5hJOKzk6uLaVzcklDBQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">100000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_ErotTwxGbUGeaPCNLokv5w"
      decimals="-5"
      id="Narr_e2daQwMVWEaVOcqSU-Jheg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">255000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember_srt_StatementScenarioAxis_rigl_MilestonePaymentsOnProductByProductBasisMember_7B-bKGDqJkynpyyI5LI52A"
      decimals="-5"
      id="Narr_zYYxAnfsIECwx1qxxC5SRw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">150000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:DevelopmentCostsCostSharingArrangementPercentage
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw"
      decimals="2"
      id="Narr_ASjISeIAhkqj8ADrHo4sEw"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.20</rigl:DevelopmentCostsCostSharingArrangementPercentage>
    <rigl:RightToOptOutOfAgreementNumberOfPeriods
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="INF"
      id="Narr_UZ3m8XSoYEe1Y438KyyvxQ"
      unitRef="Unit_Standard_period_7S5qJ8_ryE2V-D21SVB1hA">2</rigl:RightToOptOutOfAgreementNumberOfPeriods>
    <us-gaap:OtherCommitment
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_srt_RangeAxis_srt_MaximumMember_wXz-NhXK80mSJezdO35NGw"
      decimals="-5"
      id="Narr_psklkUf5KEilu_ruSN8Z8w"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">65000000.0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_srt_RangeAxis_srt_MaximumMember_wXz-NhXK80mSJezdO35NGw"
      decimals="-5"
      id="Narr_78LXxoywx0-0zPwNsKgJQw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">65000000.0</us-gaap:OtherCommitment>
    <us-gaap:ProductLiabilityAccrualComponentAmount
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg"
      decimals="-5"
      id="Narr_cjaDwA6p0UKnAkrQNEE23Q"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">57900000</us-gaap:ProductLiabilityAccrualComponentAmount>
    <rigl:FinancingLiabilityInterestAccretionDiscountRate
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw"
      decimals="3"
      id="Narr_QvGeJUe4LkyUu1yBjtwfVw"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.064</rigl:FinancingLiabilityInterestAccretionDiscountRate>
    <us-gaap:AccretionExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_TsNN5CZDIEuTUPQMmSOPqA"
      decimals="-5"
      id="Narr_QyQkxirhZUipFuGSJKN8rQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_y28o3J_GDUGpZFQI6JGFgA"
      decimals="-5"
      id="Narr_dtTJrtZEw0qu6l6FbNEakQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_A1nr_YV1DE6sTNIKj6H0xw"
      decimals="-5"
      id="Narr_A8Iqhu11v0eRAtCddlYPbQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_slyl5l3MBUW5I6J4gR0GNA"
      decimals="-5"
      id="Narr_5v-yzZi1SUCcABtSoGbgrg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:AccretionExpense>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_3_31_2021_srt_ProductOrServiceAxis_rigl_OcadusertibMember_XRvY_5ZJrkuCeHrOO7K53A"
      decimals="-5"
      id="Narr_L7SCpBSUhEe5mN-gvQXO4w"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">67100000</us-gaap:RevenueRemainingPerformanceObligation>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember_dwtnlJ6pzU2O_-cHitWnLA"
      decimals="-5"
      id="Narr_eeqKpdr0vUKJS0tsdG2KtQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">60400000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_rigl_AchievementOfMilestoneAxis_rigl_LicensedRightsMember_srt_ProductOrServiceAxis_rigl_CentralNervousSystemPenetrantIntellectualPropertyMember_N5mf8PGqUEGmxmbdkeM6pg"
      decimals="-5"
      id="Narr_-mSygPr2mUeF5qm1rXmtkA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6700000</rigl:CollaborativeArrangementRevenueRecognized>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg"
      decimals="-5"
      id="Narr_cfGqnQ3jR0KBh4hc-GDMkw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_yedyexNn70m-Ww5Mtpn2GA"
      decimals="-5"
      id="Narr_opK84te3CkqA54nqDuttwA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:DeferredRevenue>
    <rigl:RightToOptBackInCoFundingTerm
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_yt0kuytHc0y7T2LLTRMBFg"
      id="Narr_VsNNWS4hcUufNafhUNY7Rw">P30D</rigl:RightToOptBackInCoFundingTerm>
    <us-gaap:OtherCommitment
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember_us-gaap_TypeOfArrangementAxis_rigl_AmendedLillyAgreementMember_cDqO7iaeK0Go2Z-84kZ9jQ"
      decimals="-5"
      id="Narr_JMg54YipeEm1shyH3HBuLA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">22600000</us-gaap:OtherCommitment>
    <rigl:DueToCollaborationPartner
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg"
      decimals="-5"
      id="Narr_ImTWLYddvU6_ET2JE98E7g"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">21400000</rigl:DueToCollaborationPartner>
    <rigl:FinancingLiabilityIncludingInterestExpenseAccretion
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg"
      decimals="-5"
      id="Narr_Ixd2U1erbUe1k26HDYtkFQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">40000000.0</rigl:FinancingLiabilityIncludingInterestExpenseAccretion>
    <rigl:FinancingLiabilityIncludingInterestExpenseAccretion
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_OcadusertibMember_yedyexNn70m-Ww5Mtpn2GA"
      decimals="-5"
      id="Narr_F_-xV-uQ2kCzcR4-mHBHEg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">43600000</rigl:FinancingLiabilityIncludingInterestExpenseAccretion>
    <rigl:FinancingLiabilityIncludingInterestExpenseAccretion
      contextRef="As_Of_6_30_2024_srt_ProductOrServiceAxis_rigl_OcadusertibMember__AyeL_Cf3U6KZnQXj2qCHg"
      decimals="-5"
      id="Narr_Y26dgIT9KEyLimNdZoHd5A"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">40000000.0</rigl:FinancingLiabilityIncludingInterestExpenseAccretion>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_5HvpBOyAi0i27BmKK4fzHg"
      decimals="-5"
      id="Narr_G7XnnFMvSUGSD14GBR4DCQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">30000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_VrqE9RWak0OFqmj1P2jvzw"
      decimals="-5"
      id="Narr_ZQsW9GPETUe0KgycHkSvQA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">297500000</rigl:ContingentPaymentsUnderAgreement>
    <rigl:RoyaltyPaymentAsPercentageOfNetSales
      contextRef="Duration_1_1_2019_To_1_31_2019_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_60j9a_IIDEa-xMryMMg8Gg"
      decimals="2"
      id="Narr_LG4ulclMpEuY-4igSrxVBQ"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.30</rigl:RoyaltyPaymentAsPercentageOfNetSales>
    <us-gaap:ProceedsFromCollaborators
      contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_XFzWo9hPBEqqowv7IqsqMw"
      decimals="-5"
      id="Narr_OM0NqbzIgUmgnVLd_n_fNg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">20000000.0</us-gaap:ProceedsFromCollaborators>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LP6c6fDybkun2r_aQWcizQ"
      decimals="-5"
      id="Narr_OfT6bwscWUKdUiSZy2NIVQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17500000</rigl:ContingentPaymentsUnderAgreement>
    <us-gaap:ProceedsFromCollaborators
      contextRef="Duration_2_1_2020_To_2_29_2020_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_CreditableAdvanceRoyaltyPaymentMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember__kWatA4PfkmKIM4_lvUSqA"
      decimals="-5"
      id="Narr_Oze_C38rlk2mHLgOxJJtNA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_eZ13M7o2S0y8eAY3w05FHw"
      decimals="-5"
      id="Narr_A9rTtbVF-k25GKXsSMbLJg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_BiMbBxhh6Uq0yCW2lzj5vw"
      decimals="-5"
      id="Narr_7nDGCWvwu0ekWxd1x9r56Q"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:DeferredRevenue>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_Q7Q9_fXocUmGbwkegfzFlw"
      decimals="-5"
      id="Narr_uT5QWxSFFUi1e2TVdvKSzg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_MfToFdRbjkuykAJfE2s1oA"
      decimals="-5"
      id="Narr_K0Ppt_Eq3UWfW1pg3fBtWQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_SI850_iDiUWOa__58mOaXw"
      decimals="-5"
      id="Narr_FTs7XRk1JES1DF_eC1Q_5A"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_rigl_AchievementOfMilestoneAxis_rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember_AIuTRpIOpUS1-j2v1hsfzg"
      decimals="-5"
      id="Narr_cb2YVTG-20mHgck3ftwsMg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2800000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_fiVixnDOc0CkJwTCK4-50w"
      decimals="-5"
      id="Narr_kRuGdseCaUeH5sBP8DmFiw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1100000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_maf7KtajvE6t_Jc1HPqseQ"
      decimals="-5"
      id="Narr_jPVmMZiI4ESa-kZIzItPhA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">800000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_zrxVuGp9HUq29bG3-ZjB6w"
      decimals="-5"
      id="Narr_NNIsK5dMOU2UN7VhIIe4NA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_GrifolsS.a.Member_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_8YAIxGaCJ0WOl3D_P-ZFyQ"
      decimals="-5"
      id="Narr_2V9Bw5WSLU2G-cL7aHWfsg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1500000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_4TZ-_gslzUuCVFLIXWN05Q"
      decimals="-5"
      id="Narr_zoqDKHVCIU6ljbcmRjcsiA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">33000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_10_1_2018_To_10_31_2018_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_4TZ-_gslzUuCVFLIXWN05Q"
      decimals="-5"
      id="Narr__AIPuY9W30eUZwD0gdUh1Q"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">147000000.0</rigl:ContingentPaymentsUnderAgreement>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_NSJW9_H2-Uyr8T7g60jFnw"
      decimals="-5"
      id="Narr_DT9sfAtF_U248eKMTMdu5g"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1400000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_YXCwufdL2kCunkEAIR-kOw"
      decimals="-5"
      id="Narr_wQ3ZfTq_0EOuBa8MnAzj9Q"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1400000</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AvQMdmjfrkKF0n7u_e-4ng"
      decimals="-5"
      id="Narr_NIKLVmgzPk-z8ehXcpxIuA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_93VaWr0Vn0W3qhHJHD5l2g"
      decimals="-5"
      id="Narr_l_xFpvKVnES8r4Sg9vU-OA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_Ed6jJO0mDEC7vy2gXWKNvA"
      decimals="-5"
      id="Narr_htqZzIXvqky0evyCT3L0PA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_82mZ1UCHkUeFIeF9NNLnDQ"
      decimals="-5"
      id="Narr_tw8HVWfrfE-m8Ed-tUZdDQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ProceedsFromCollaborators
      contextRef="Duration_4_1_2022_To_6_30_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_FZKSbfgCCUOxIEsBo793zQ"
      decimals="-5"
      id="Narr_VUeJGVYMo0iXLgpPvnVhow"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_cM6viZkjnk2XQ_C6vVZS3A"
      decimals="-5"
      id="Narr_w2ijIyAng06PPZ2WE_JWOw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">20000000.0</us-gaap:AccountsReceivableNetCurrent>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_82mZ1UCHkUeFIeF9NNLnDQ"
      decimals="-5"
      id="Narr_6PtGm__Hg0K3VGlDCrDDnA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_Ed6jJO0mDEC7vy2gXWKNvA"
      decimals="-5"
      id="Narr_6LWDS9ER8keXVMAX1JqdHg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4500000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_AvQMdmjfrkKF0n7u_e-4ng"
      decimals="-5"
      id="Narr_R-t3Lp05pEinAzZE1oDrmQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_dei_LegalEntityAxis_rigl_KisseiPharmaceuticalCo.Ltd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_93VaWr0Vn0W3qhHJHD5l2g"
      decimals="-5"
      id="Narr_d9Xha_o2qEuU0ZfVXmihlg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:NumberOfAgreements
      contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_6gKiuqunlUW1exXxbGX2YQ"
      decimals="INF"
      id="Narr_e2ejHqgqq02mgYNbMtoZhA"
      unitRef="Unit_Standard_agreement_XCinVrYiMEykKvzVM-r2og">2</rigl:NumberOfAgreements>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_10_1_2019_To_10_31_2019_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_6gKiuqunlUW1exXxbGX2YQ"
      decimals="-5"
      id="Narr_wAUyJcGC4EOtvSGXmd4gNw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_Gnk6YUapu02MxjednNsESw"
      id="Narr_bLrh8PBGG0qB9fIIMImQLg">P6M</rigl:AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_aH2IYHCJPkuM5HXlyZvgaw"
      decimals="-5"
      id="Narr_ipS2oobe60Co-2JVKksoTw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RgL4dFy2q0eUvIbUb8HPxw"
      decimals="-5"
      id="Narr_mEOIvxUYm0-I4Qj8uwCGbQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:DeferredRevenue>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_DpExNDuvFEiRGecQztGf_g"
      decimals="-5"
      id="Narr_TxH2-_ISpEeVM6Sh2Z7pNQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">100000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_MedisonPharmaLtd.Member_srt_ProductOrServiceAxis_rigl_FostamatinibMember_LqSICzN8jECsv3g5VfvRtQ"
      decimals="-5"
      id="Narr_Ye8M31hnukOJMuC_39P3eA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">200000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementUpfrontFeeReceived
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_1QwBIhoEuUGYpKJv6_D94Q"
      decimals="-5"
      id="Narr_9wa1uCs2IE6OP26_lusJuQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000000.0</rigl:CollaborativeArrangementUpfrontFeeReceived>
    <rigl:ContingentPaymentsUnderAgreement
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_KnightTherapeuticsInternationalSaMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_rigl_CommercialAndLicenseAgreementMember_CpgL9jNlMUCw-IA9e3o4uA"
      decimals="-5"
      id="Narr_sq4RX3W4fk-lYQzz7-gcOA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">20000000.0</rigl:ContingentPaymentsUnderAgreement>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_0QYy6PILGUOdx2ZhkVNm8w"
      decimals="-5"
      id="Narr_XMqqydBJlUi_15vbwshl0Q"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000000.0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_UF-_ngprMUG3ubBJymolzg"
      decimals="-5"
      id="Narr_25oUsvkSz0yG-x8U2eWIHw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000000.0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_z6tFpSWYtUeOPKO1v5sshA"
      decimals="-5"
      id="Narr_GUkqdhvnwEqWfkhJutta5w"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_GovernmentContractMember_LGpOh5i-pkuYqfZStMMnVQ"
      decimals="-5"
      id="Narr_ujrihNmipkG3czVWTSe1Pw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementPotentialPayments
      contextRef="Duration_8_1_2023_To_8_31_2023_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_srt_RangeAxis_srt_MaximumMember_5kULnBvdYEevZnx2IVnM6g"
      decimals="-5"
      id="Narr_K6-wILDY9U2X7bixgB4IoQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">800000</rigl:CollaborativeArrangementPotentialPayments>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_oyau3O4tJkKVZI8B-c9oEQ"
      decimals="-5"
      id="Narr_NqjyjO8I1kK_Nk41bXsJrw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_4_1_2024_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_RFpgzqwWbUSTBMlmSIJ36w"
      decimals="-5"
      id="Narr_zSvG0a8uzUSG2qJoMg6iJg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:CollaborativeArrangementRevenueRecognized
      contextRef="Duration_8_1_2023_To_6_30_2024_dei_LegalEntityAxis_rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srt_ProductOrServiceAxis_rigl_FostamatinibMember_r0ldwSj5VEOIFSa8XhrMcQ"
      decimals="-5"
      id="Narr_5-j0Lz19Okar8jnbPYUamA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">100000</rigl:CollaborativeArrangementRevenueRecognized>
    <rigl:DueToCollaborationPartner
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_yUFONy52JkaEdNe2JBvS1Q"
      decimals="-5"
      id="Narr_lSQ8sU8GF02gB6edEf-pUA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000.0</rigl:DueToCollaborationPartner>
    <rigl:CollaborationTerm
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_Yi_QU2DWrk2zU3zLJ3F28w"
      id="Narr_MuyvBoP3jEGA62zEDxNzYQ">P5Y</rigl:CollaborationTerm>
    <rigl:PaymentOfCostShareToCollaborationPartner
      contextRef="Duration_12_1_2023_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithMdaccMember_E2TAw1ebLEyqMCfIkUc_jg"
      decimals="-5"
      id="Narr_q32m_aa7fk6WCo4jOTOg7g"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000000.0</rigl:PaymentOfCostShareToCollaborationPartner>
    <rigl:DueToCollaborationPartner
      contextRef="As_Of_1_31_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_gz1pnQN6FE2qge7r5TPFfQ"
      decimals="-5"
      id="Narr_FxIeeF0ib0GMg_PWrNXnsA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3000000.0</rigl:DueToCollaborationPartner>
    <rigl:CollaborationTerm
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_us-gaap_TypeOfArrangementAxis_rigl_StrategicCollaborationAgreementWithConnectMember_6M9-yuHtNE6cG9tYWmjCqQ"
      id="Narr_NnRHUaYRAECRl_ZFjzPR-Q">P4Y</rigl:CollaborationTerm>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_0CN_KJ0XQU2haPBHqDzcFg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;5.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;In-licensing and Acquisition &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Asset Purchase Agreement with Blueprint&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On February 22, 2024, we acquired the US rights to research, develop, manufacture and commercialize GAVRETO (pralsetinib) from Blueprint pursuant to an Asset Purchase Agreement. The acquired assets &lt;span style="background:#ffffff;"&gt;include, among other things, applicable intellectual property related to pralsetinib in the US, including patents, copyrights and trademarks, as well as clinical regulatory and commercial data and records.&lt;/span&gt; Pursuant to the Asset Purchase Agreement, we agreed to pay a purchase price of $15.0 million, of which, $10.0 million was payable upon our first commercial sale of GAVRETO and an additional $5.0 million is payable on the first anniversary of the closing date of the agreement, subject to certain conditions. Blueprint is also eligible to receive up to $97.5 million in future commercial milestone payments and up to $5.0 million in future regulatory milestone payments. &lt;span style="background:#ffffff;"&gt;The potential regulatory milestones include full regulatory approval of pralsetinib (or related compounds) for the treatment of adult RET-fusion positive thyroid cancer, and maintenance of the current regulatory approval of pralsetinib for the treatment of adult RET-fusion positive thyroid cancer during the period beginning on February 22, 2024 and ending on the third anniversary of the first commercial sale of pralsetinib subject to certain conditions.&#160;&lt;/span&gt;Subject to the terms and conditions of the Asset Purchase Agreement, Blueprint would be entitled to tiered royalty payments on net sales of products containing pralsetinib (or related compounds) ranging from 10% to 30%, subject to certain reductions and offsets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In accordance with ASC 805 &lt;i style="font-style:italic;"&gt;Business Combinations &lt;/i&gt;(ASC 805)&lt;i style="font-style:italic;"&gt;, &lt;/i&gt;the transaction was accounted for as an asset acquisition, because substantially all of the fair value of the gross assets acquired is concentrated in a single asset, which is the GAVRETO product rights. The GAVRETO product rights comprised &lt;span style="background:#ffffff;"&gt;developed technology, customers, trademarks and trade name, and are considered a single asset as they are inextricably linked. ASC 805 provides for a screen test, wherein if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the assets acquired are not considered to be a business. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the total purchase consideration in connection with the asset acquisition (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.21%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Closing purchase price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;360 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total purchase consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15,360 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;The closing purchase price was recorded within acquisition-related liabilities in the condensed balance sheet and was outstanding as of June 30, 2024, of which, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$10.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million was paid in July 2024 following our first commercial sale of GAVRETO at the end of June 2024. The transaction costs have been paid in cash as of June 30, 2024. The contingent considerations relating to future commercial and regulatory milestones were not included in the total purchase price consideration, and will be accounted for when the contingency is resolved and the consideration becomes payable. Royalties will be recognized within cost of sales, as revenue from GAVRETO product sales is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In an asset acquisition, the acquiring entity should recognize the assets acquired at cost to the acquiring entity which includes transaction costs and consideration given, allocated based on a relative fair value of the assets acquired measured at acquisition date. The fair value of the developed technology, customers, trademarks and trade name was &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;estimated using a multi-period excess earnings income approach that discounts expected cash flows to present value by applying discount rate that represents the estimated rate that market participants would use to value such assets. The relative fair value are based on estimates that required judgement and certain assumptions, categorized as Level 3 in the fair value hierarchy. Since we acquired a single asset, the total purchase consideration was recorded as intangible assets. The related intangible &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;assets is being amortized on a straight-line basis over the estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12 years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, and the related &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;amortization is recorded within cost of sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Simultaneously and in connection with entering into the Asset Purchase Agreement, we also entered into certain supporting agreements, including a customary transition agreement, pursuant to which, during the transition period, Blueprint will transition regulatory and distribution responsibility for GAVRETO to us. We also agreed to purchase certain drug product inventories from Blueprint under a Material Transfer Agreement, and received such inventories amounting to approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$6.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million during the six months ended June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;License and Transition Services Agreement with Forma &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;We have a license and transition services agreement with Forma entered in July 2022, for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mutated IDH1 (mIDH1), for any uses worldwide, including for the treatment of AML and other malignancies. Forma became a wholly owned subsidiary of Novo Nordisk following the closing of its acquisition by Novo Nordisk in October 2022. Pursuant to the terms of the license and transition services agreement, we paid an upfront fee of $2.0 million, with the potential to pay up to $67.5 million of additional payments upon achievement of specified development and regulatory milestones and up to $165.5 million of additional payments upon achievement of certain commercial milestones. &lt;span style="background:#ffffff;"&gt;In addition, subject to the terms and conditions of the license and transition services agreement, Forma would be entitled to tiered royalty payments on net sales of licensed products at percentages ranging from low-teens to mid-thirties, as well as certain portion of our sublicensing revenue, subject to certain standard reductions and offsets. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The transaction was accounted for as an acquisition of asset under ASC 730, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;. In accordance with the guidance, in a transaction accounted for as an asset acquisition, any acquired IPR&amp;amp;D that does not have alternative future use is charged to expense at the acquisition date. &lt;span style="background:#ffffff;"&gt;At the acquisition date, the acquired license asset was accounted for as IPR&amp;amp;D, and we anticipated no other economic benefit to be derived from such acquired licensed asset other than the primary indications. As such, we accounted for the upfront fee of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million &lt;/span&gt;as IPR&amp;amp;D and recorded such cost within research and development expense in the statements of operations in 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Under the accounting guidance, we account for contingent &lt;span style="background:#ffffff;"&gt;payments when a &lt;/span&gt;contingency is resolved, and the consideration becomes payable.&lt;span style="background:#ffffff;"&gt;&#160;We account for m&lt;/span&gt;ilestone payment obligations incurred at development stage and prior to a regulatory approval of an indication associated with the acquired licensed asset as research and development expense when the event requiring payment of the milestone occurs. Milestone payment obligations incurred upon and after a regulatory approval of an indication associated with the acquired licensed asset, and at the commercial stage, are recorded as intangible assets when the event requiring payment of the milestones occurs. Prior to the FDA approval of REZLIDHIA in December 2022, a certain regulatory milestone was met which entitled Forma to receive a $2.5 million milestone payment. Because such milestone payment obligation was incurred prior to a regulatory approval of an indication associated with the acquired licensed asset, we recorded such amount as research and development expense in the fourth quarter of 2022. On December 1, 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with susceptible IDH1 mutations as detected by an FDA-approved test. Following the FDA approval, we launched REZLIDHIA and made first shipments of the product to our customers in December 2022. With this FDA approval and first commercial sale of the product, Forma was entitled to receive a total of $15.0 million milestone payments. Since such milestone payment obligations were incurred upon and after regulatory approval of the product, we recorded such amount as intangible assets on our condensed balance sheet in the fourth quarter of 2022. No new milestone was met in 2023 and during the six months ended June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The amount recorded as intangible asset is being amortized on a straight-line basis over the estimated useful life of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;14 years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, and the related &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;amortization is recorded within cost of sales&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. Royalties are recognized within cost of sales, as revenue from REZLIDHIA product sales is recognized. &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected
      contextRef="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_SZRu02N1XEGrAyfYF5SwyQ"
      decimals="-5"
      id="Narr_AOF9-9KpvUeB_RiaLGdArQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000.0</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected
      contextRef="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstCommercialSaleMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_HquhUMFeGkasyQJBoBZ3wQ"
      decimals="-5"
      id="Narr_r6opWJvqfEuyfZ_8-PeUzA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10000000.0</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected
      contextRef="Duration_2_22_2024_To_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_FirstAnniversaryOfClosingDateMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_0IVrFL5NR0Kuz75nULfm_w"
      decimals="-5"
      id="Narr_zUhqpYWYH0O6s2u0y_1iSw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5000000.0</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <rigl:PotentialMilestonePaymentObligations
      contextRef="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_-mlrFhf7yU-O2VqahK8vIQ"
      decimals="-5"
      id="Narr_sqYf3odI4kC4zuSX_6Bn7g"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">97500000</rigl:PotentialMilestonePaymentObligations>
    <rigl:PotentialMilestonePaymentObligations
      contextRef="As_Of_2_22_2024_rigl_AchievementOfMilestoneAxis_rigl_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_oSHvi732xUWC_qqhrIXIIw"
      decimals="-5"
      id="Narr_8HR-rYI0LEyxh_j307Wm3A"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5000000.0</rigl:PotentialMilestonePaymentObligations>
    <rigl:PotentialTieredRoyaltyPercentage
      contextRef="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jcLc51bfe0y7CaULox55yA"
      decimals="2"
      id="Narr_C97sYRKk-kyUryjUM_gaHQ"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.10</rigl:PotentialTieredRoyaltyPercentage>
    <rigl:PotentialTieredRoyaltyPercentage
      contextRef="Duration_2_22_2024_To_2_22_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_srt_RangeAxis_srt_MaximumMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_4FtiCBTyVkqS_xmhg_p41w"
      decimals="2"
      id="Narr_NVBZqqANuUGeNn6hgxNY2g"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.30</rigl:PotentialTieredRoyaltyPercentage>
    <us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_clWA1sNPe0Ks_fUyY7fdDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the total purchase consideration in connection with the asset acquisition (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.21%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Closing purchase price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;360 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total purchase consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15,360 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g"
      decimals="-3"
      id="Tc_pLmSwayRkkK-KwtU5jGxzw_1_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g"
      decimals="-3"
      id="Tc_eA7DM5JE9Eui4ydrZWucTQ_2_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">360000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_jpJynvScvkyxdyDgtpYF9g"
      decimals="-3"
      id="Tc_PEz4d1HerUuZO6B1p4qXtQ_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15360000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_7_1_2024_To_7_31_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_d_VNrgzWz0a3BkPN9MKEVA"
      decimals="-5"
      id="Narr_-3yaLOoZDkKDmljuQ9dF5w"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_GavretoMember_KKP0C9QqkUiTkWevYxJzTw"
      id="Narr_Ogl5chOF90y0zwABV2juQA">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <rigl:AssetPurchaseAgreementDrugProductInventories
      contextRef="As_Of_6_30_2024_us-gaap_AssetAcquisitionAxis_rigl_BlueprintMedicinesCorporationMember_vUvPo1jezUiyVDGej1nLMQ"
      decimals="-5"
      id="Narr_adcDg1WlOkmxJ7AX4qku0g"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6500000</rigl:AssetPurchaseAgreementDrugProductInventories>
    <rigl:CollaborativeArrangementUpfrontPayment
      contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_mlAixP0Kq0KRgxnPySwCUQ"
      decimals="-5"
      id="Narr_Z7uJjd4mtUKaUmw2U_n8Wg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000000.0</rigl:CollaborativeArrangementUpfrontPayment>
    <rigl:CollaborativeArrangementPotentialPayments
      contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_DevelopmentAndRegulatoryMilestonesMember_4U40SB3W_kmm7wCJE8B4_g"
      decimals="-5"
      id="Narr_ddFOadpFjEqJTwP17RdHXQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">67500000</rigl:CollaborativeArrangementPotentialPayments>
    <rigl:CollaborativeArrangementPotentialPayments
      contextRef="Duration_7_1_2022_To_7_27_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_SpecifiedCommercialMilestonesMember_ZZ7iW4JQ8UGfKFajT3fUtA"
      decimals="-5"
      id="Narr_Bbo5PSIox0uQp8wQpUubew"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">165500000</rigl:CollaborativeArrangementPotentialPayments>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_hZmC_MKxK0ib0qKh4OuwDw"
      decimals="-5"
      id="Narr_qfFegwUhEkKUgBDIMpbPug"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_10_1_2022_To_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember_mtfju_YpJkGk_bnLaNb2Gw"
      decimals="-5"
      id="Narr_8F6vy5sOK0O4aYbneIco9g"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_rigl_FormaTherapeuticsHoldingsIncMember_rigl_AchievementOfMilestoneAxis_rigl_FdaApprovalAndFirstCommercialSaleOfProductMember_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_URKfF5ajyUiJLXquchdVgg"
      decimals="-5"
      id="Narr_sj5i5LXKP0invWVg4zkhxQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000.0</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_rigl_RezlidhiaMember_KnTLXRz0jkWgF6jXhPXEDQ"
      id="Narr_qN5ohqce10qXFcdfFhL4oQ">P14Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_8prAQRojv0GwkvD5MPKGfg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;6.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation for the periods presented was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.34%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,531&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,930&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;During the six months ended June 30, 2024, we granted stock options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;599,772&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of common stock with weighted-average grant-date fair value of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$9.64&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;9,294&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; stock options were exercised. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;The stock options granted during the six months ended June 30, 2024 generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. As of June 30, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3,691,139&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;stock options outstanding, of which, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;132,250&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; are outstanding performance-based stock options wherein the achievement of the corresponding corporate-based milestones were assessed not probable as of June 30, 2024. Accordingly, none of the &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million grant date fair value for these awards has been recognized as stock-based compensation expense as of June 30, 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. The following table summarizes the weighted-average assumptions relating to options granted pursuant to our Equity Incentive Plans (our 2018 Equity Incentive Plan and Inducement Plan, as amended) for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;88.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;86.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;87.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;During the six months ended June 30, 2024, we granted &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;291,373&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;RSUs &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;with a grant-date weighted-average fair value of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$12.52&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;66,408&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; RSUs were released. The RSUs granted during the six months ended June 30, 2024 generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. As of June 30, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;387,729&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; RSUs outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As of June 30, 2024, there was approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$14.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;of unrecognized stock-based compensation cost which is expected to be recognized over a remaining weighted-average period of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_BSYq7x4JLEq-_Jg2cZgicA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2.15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years, related to time-based stock options, performance-based stock options wherein achievement of the corresponding corporate-based milestones was considered as probable, and RSUs. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In March 2024 and April 2024, our Board of Directors approved additional 78,232 shares of common stock reserved for issuance under our Inducement Plan. In May 2024, our stockholders approved an amendment to our 2018 Plan, to, among other items, add an additional&#160;650,000&#160;shares&#160;to the number of shares of common stock authorized for issuance under our 2018 Plan.&#160;As of June 30, 2024, there were 1,412,669 shares of common stock available for future grant under our Equity Incentive Plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our Purchase Plan provides for a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_tLN0a4X5JU2Cq3R9ffzyHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-month offering period comprises &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;six-month&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; purchase periods with a look-back option. A look-back option is a provision in our Purchase Plan under which eligible employees can purchase shares of our common stock at a price per share equal to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;85%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the fair market value on the first day of the offering period or &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;85%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the fair market value on the purchase date. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Our Purchase Plan also includes a feature that provides for a new offering period to begin when the fair market value of our common stock on any purchase date during an offering period falls below the fair market value of our common stock on the first day of such offering period. This feature is called a &#x201c;reset.&#x201d; Participants are automatically enrolled in the new offering period. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_U2j5tAbzr0-MSQXB1Kv0GQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-month offering period under our Purchase Plan ended on June 30, 2024, and a new &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_zN5HkjsdLkqRRzBvM8xfWQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-month offering period started on July 1, 2024. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;The fair value of awards under our Purchase Plan is estimated on the date of our new offering period using the Black-Scholes option pricing model, which is being amortized over the requisite service periods. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;As of June 30, 2024, there was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; unrecognized stock-based compensation cost related to our Purchase Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the six months ended June 30, 2024, there were 35,902 shares purchased under the Purchase Plan. As of June 30, 2024, there were 213,681 shares reserved for future issuance under the Purchase Plan.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_IGTqLXscC0y4B4GoHQs9FQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation for the periods presented was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.34%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,531&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.2%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,930&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_w7P1z0EI5EueFIgNkc89sg"
      decimals="-3"
      id="Tc_zH2GD5GgPECo5PjYc-_vFg_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2223000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ieBTYFxiqUCvCIZyspbbWQ"
      decimals="-3"
      id="Tc_tvjdC2pBzUGW5HdgBSytvA_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1796000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fv5v2douMUSk7zWe57p0FA"
      decimals="-3"
      id="Tc_qqbKxV37jUur0YS1xZ0HMQ_3_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6707000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2LCsKqr1LEqrGC4lXCGiqA"
      decimals="-3"
      id="Tc_ydpM9aXpzU2bNY13ptaHTQ_3_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3531000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_3xxTQ5sXyEG51cWWfHtXmA"
      decimals="-3"
      id="Tc_7OebIbZn00e6Fic0jby55w_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xJyvi82Gwk2Tr-43Oekyrw"
      decimals="-3"
      id="Tc_VFx0J2pbQ0OiGdXIRgFulQ_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bSe8WAEXkUG7k9-Nd_2uvQ"
      decimals="-3"
      id="Tc_lkp-1kr5VE2Xn-EpdqLDHw_4_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v32Ol4crf0K8DOnTPxOuGg"
      decimals="-3"
      id="Tc_6HrVRGGg6ECJ2dXbMU-EHg_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_pRSOLpt8YU2c1yx4upXlQw_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_gBag667zW0WY6yMvNP6vkw_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_bobHtZ88ZUG_18WeITVDMA_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7662000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_ZKstY3IkYUCBnDCm4_VfWg_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      decimals="INF"
      id="Narr_0JMUJOnWZ0WSEiCGnHclEw"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">599772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      decimals="2"
      id="Narr_gs_fuu9HA0evWQrpEmocpw"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">9.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      decimals="INF"
      id="Narr_NUCziGL2kk2L-_4TnyF2WA"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">9294</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      id="Narr_zDYPBy5gUEe3dXOsv151Yg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NkUV1BM-xU2eirtWLK871A"
      decimals="INF"
      id="Narr_rPB7eXJErkWr0PphEAldGw"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">3691139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_E24Tg32FFUaoGudnG6SLlg"
      decimals="INF"
      id="Narr_9RlkLyAEjUG1tyThQDQ9AQ"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">132250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_E24Tg32FFUaoGudnG6SLlg"
      decimals="-5"
      id="Narr_a7rWeEzW0kmhiqxphEVcJQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      id="Tb_z1-K2Xeg40myQKxN5H8Nlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.03%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;88.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;86.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;87.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw"
      decimals="3"
      id="Tc_jHOTsEJ0QUWnhCaHcaMBVA_3_2"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw"
      decimals="3"
      id="Tc__0NRjH7j_kKG8rm1ZGNeCw_3_4"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      decimals="3"
      id="Tc_5rczz7HuUkqsc7JN2EZ1Iw_3_7"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q"
      decimals="3"
      id="Tc_Y03zQy0_c0i_v7JBvwZHMg_3_9"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw"
      id="Tc_beVR6OzVp0u63m8CBrijsg_4_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw"
      id="Tc_Pt4IUjm7lkGWWiRhWEINTA_4_4">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      id="Tc_Nw3ogNKHvEmiREeqjfiExA_4_7">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q"
      id="Tc_nrn-QWBw2UmM6WBBy9KxkA_4_9">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw"
      decimals="3"
      id="Tc_DRc0R7C8-kmw_JSPSjgnmQ_5_2"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw"
      decimals="3"
      id="Tc_3rbpYVHTOUyQkjZsxXZptA_5_4"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      decimals="3"
      id="Tc_mBKWLhlQoUC6cSndIXSmLQ_5_7"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q"
      decimals="3"
      id="Tc_oFcTRovcbEOtragDpmzvjQ_5_9"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5VrMTTk2PkSAJYlr-PpHiw"
      decimals="3"
      id="Tc_YjSCG5wuEkWYmiRsRpYNmA_6_2"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5MXYFf6rBkicvaAFDKiHWw"
      decimals="3"
      id="Tc_8c6QW8ukYUOiPnYVaNRCzw_6_4"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4RkcT8R28kWZVeMSIMgFcg"
      decimals="3"
      id="Tc_5ie7iyTbCUCWWcPuyycnuw_6_7"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GaMLQ6iVUEyiMF2mUA-80Q"
      decimals="3"
      id="Tc_tFeSJr6T-kav4XFqnbLvMQ_6_9"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g"
      decimals="INF"
      id="Narr_dMLlmGfiXECoRPvqyx0y9w"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">291373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g"
      decimals="2"
      id="Narr_OPDyRZ4Xt0W0phP44uIW4g"
      unitRef="Unit_Divide_USD_shares_-3-rTtRsgEWZKPgvVortiQ">12.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g"
      decimals="INF"
      id="Narr_lRKL_42QMkCey2B8cjzsLQ"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">66408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_pWqmZcuMu0iFlluSKTUq9g"
      id="Narr_0MLM276bY0-jh-b5KruE3A">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_viFreQeDZ0G9JJCWlMU9Bw"
      decimals="INF"
      id="Narr_yYu-qbIXHky-B5Bfm-bo2g"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">387729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_rigl_ShareBasedCompensationOptionsAndRsusMember_mp0URjlEF0yvPpfS-o63hg"
      decimals="-5"
      id="Narr_by_aBDtwyE--3ljVHjDGCQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">14000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_3_1_2024_To_3_31_2024_ljnvk8kzm0a4q-SYLyQozA"
      decimals="INF"
      id="Narr_NoTP5HYLl02XfdI9ZxL3vA"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">78232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_5_1_2024_To_5_31_2024_DjxYIP5b9kafOLRsY1Sj5g"
      decimals="INF"
      id="Narr_TM6-3bKyh0S7Rl5kBrDvKw"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="INF"
      id="Narr_aXwepT8G2kO-MmJUjpEvLg"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">1412669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"
      decimals="INF"
      id="Narr_YsdJjCR7VEWtutf3fyLeNw"
      unitRef="Unit_Standard_item_lkAE3fTQ8kCadM7_hQ6xtA">4</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriodsPerAwardOfferingPeriod>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"
      id="Narr_mT_LhrFCy0e2-dIfb0crGw">P6M</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"
      decimals="2"
      id="Narr_Jpozo7Vv80yLixxotDcTLg"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"
      decimals="2"
      id="Narr_76zLH48mHUOCb6lwgCgJFQ"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.85</rigl:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOnFirstDayOfOfferingPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_ykyILY5HlkKht7OKVYHIvw"
      decimals="INF"
      id="Narr_31OA3umKLU2pWTaxcIs_6Q"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_QXUHWON4pkyWw0QYQvWLlw"
      decimals="INF"
      id="Narr_APpuJTFYh0m4ck7qb3dAPw"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">35902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_ykyILY5HlkKht7OKVYHIvw"
      decimals="INF"
      id="Narr_E1f_qj39zESk0y9vITAHdA"
      unitRef="Unit_Standard_shares_INYsbbhP3ESfXawJwAjyHw">213681</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_ILKO4zBphEC2f6NZHFp0lA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Other Balance Sheet Components&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Inventories for the periods presented consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.71%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,145 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,609 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,006 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,876 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,368 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,508 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,519 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,993 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,519 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,993 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Inventories as of June 30, 2024 and December 31, 2023 include inventories acquired from Forma pursuant to the license and transition services agreement.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; Inventories as of June 30, 2024 also include inventories acquired from Blueprint pursuant to a Material Transfer Agreement as discussed in Note 5 &#x2013; In-licensing and Acquisition. As of June 30, 2024, advance payments to the manufacturer of our raw materials were included within prepaid and other current assets in the condensed balance sheet&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; amounted to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.2&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;No&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; such advance payment was included within prepaid and other current assets as of December 31, 2023. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Non-current inventories consist primarily of active pharmaceutical ingredients classified as raw materials which have multi-year shelf life, as well as certain work in process and finished goods inventories that are not expected to be consumed beyond our normal operating cycle. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;background:#ffffff;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.62%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible asset cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;30,360 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(2,085)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible asset, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28,275 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,878&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;See &#x201c;Note 5 &#x2013; In-licensing and Acquisition&#x201d; for related discussions of capitalized intangible assets. Amortization expense recorded within cost of sales in the statements of operations for the three months ended June 30, 2024 and 2023 was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.6&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million, respectively, and for the six months ended June 30, 2024 and 2023 was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table presents the estimated future amortization expense of intangible assets as of June 30, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.69%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,176 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;17,695 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28,275 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_QF7B6dZBhkes-V1tsnKsPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Inventories for the periods presented consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.71%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,145 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,609 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,006 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,876 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,368 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,508 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,519 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,993 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12,519 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,993 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Vn6I9baq8kW6fZ74423dZg_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2145000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_oEuytnnzVEmIWop-vPig6A_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4609000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Z41efP7ly0KDPGsXBHg2kw_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6006000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_-EWVj5uT50qHUmsLnbz7Hg_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1876000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_KV6-OUJ6CUe5i9_RFSrJOA_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4368000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_LsKCRveSXU2jZkrTEr8JEA_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1508000</us-gaap:InventoryFinishedGoods>
    <rigl:InventoryAndInventoryReportedAsOtherAssets
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_UKUxlsnX1E2TeadLTj8Ahg_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12519000</rigl:InventoryAndInventoryReportedAsOtherAssets>
    <rigl:InventoryAndInventoryReportedAsOtherAssets
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_qBh1JTBHGkq1hLpQp9xXWg_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7993000</rigl:InventoryAndInventoryReportedAsOtherAssets>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_-i05lcq6V0aWO0IDP0LrnA_9_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8059000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_kk4PJQ-soUyGe2tTrwtXwg_9_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5522000</us-gaap:InventoryNet>
    <rigl:InventoryReportedAsOtherAssets
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_ALnqoNI3rk-XX4OMmT9Pyg_10_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4460000</rigl:InventoryReportedAsOtherAssets>
    <rigl:InventoryReportedAsOtherAssets
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_yFJkwR9NEE-ls8FFp473Wg_10_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2471000</rigl:InventoryReportedAsOtherAssets>
    <rigl:InventoryAndInventoryReportedAsOtherAssets
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_fhDVuPGaa0-3oC1NY0ityA_11_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12519000</rigl:InventoryAndInventoryReportedAsOtherAssets>
    <rigl:InventoryAndInventoryReportedAsOtherAssets
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_Ip6qw23WDUK_paGNTOU_qQ_11_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7993000</rigl:InventoryAndInventoryReportedAsOtherAssets>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-5"
      id="Narr_JshpjXm2l0W0icld9FRAQw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2200000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-5"
      id="Narr_4oM0Jxuc_kqVmvY1qGqkcg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_cfEJ3Y18-E2XTZFM3JLC8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.62%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible asset cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;30,360 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(2,085)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible asset, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28,275 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,878&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_cMxrJvDtYEqsJvWWtwmeeA_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">30360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_x2FTp8SerkiuumvjThOi6w_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_XFQKYqk65k-pxE3r6JqU0g_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2085000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_DVqNJQH9Ok29Uy8zAJKQBQ_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1122000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_BO2ays6JB0az3Fmzc9Q27w_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">28275000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_oMAYE-fyXUajnRdd9NyrtQ_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13878000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-5"
      id="Narr_LzEsL98YbEa0cr-ZZttuWA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-5"
      id="Narr_C4Lln4J32E6eAunvzJBKdg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-5"
      id="Narr_u2JHG7xJD0yVR5ivWKrq-g"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-5"
      id="Narr_Z47IQ2Nrm0iQpIfvSgQL6A"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_i-qFXqM_vkyKgu_heNCElg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table presents the estimated future amortization expense of intangible assets as of June 30, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.69%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,176 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,351 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;17,695 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28,275 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Ot4PevaIEE-5CmduNfiH5Q_1_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1176000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_aAD-yC4CY0CdQMuebNPTSg_2_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2351000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_F0jwugOFoUStkIAdYVYzjw_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2351000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_9fwcAPgOxkuPbn5vM1-ndw_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2351000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_CqmtRFV5ZEKKmeJRm2x3SQ_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2351000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_fed-Odh8ZU6V4PsxufV66w_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">17695000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_qOsMTkv0c0q66-Nhx21S-Q_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">28275000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_g9l5i5tC70Kddk7jTuo8Ag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Cash, Cash Equivalents and Short-Term Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;"&gt;Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,126 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13,805 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,444 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13,764 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;49,102 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,053 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13,049 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;49,102 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;56,933 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;As of June 30, 2024 and December 31, 2023, our cash equivalents and short-term investments had a weighted-average time to maturity of approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;68 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;82 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;Our short-term investments are classified as available-for-sale securities. Accordingly, we have classified these securities as short-term investments on our condensed balance sheets as they are available for use in the current operations. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;June 30, 2024, we had &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; investments that had been in a continuous unrealized loss position for more than 12 months. As of June 30, 2024, a total of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;26&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; individual securities had been in an unrealized loss position for 12 months or less, and the losses were determined to be temporary. No significant facts or circumstances have arisen to indicate that there has been any significant &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;deterioration in the creditworthiness of the issuers of the securities held by us. Based on our review of these securities, including the assessment of the duration and severity of the unrealized losses, we have &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;t recognized any credit losses on these securities as of June 30, 2024 and December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_Dh2y09qDFke-TBnnky-1cQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;"&gt;Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,126 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13,805 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,444 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13,764 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;49,102 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,053 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13,049 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;49,102 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;56,933 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_aYSlG3CFDEO3az0cwNa1cQ"
      decimals="-3"
      id="Tc_XkEZs3HKI0y7aQdK-d1w_A_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">6126000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_p4HneMQsy0Sje5M5K7gO5g"
      decimals="-3"
      id="Tc_cBmJlskmjECBfJmIXtE6vA_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">8247000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_JbLXs-0VY0esSnNCYQq-kA"
      decimals="-3"
      id="Tc_Z9MQAp-JVkyd4hKZP4xN0Q_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13805000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_hTn2f1VUkUCR_wGtI1n8ow"
      decimals="-3"
      id="Tc_7TrVlc_BFkKpw2lXqnTFmg_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">9685000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_1A5iQpFj_USrbxcLaNA6XA"
      decimals="-3"
      id="Tc_H2svNJmLtEaSrfIH7xWROA_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4963000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_XVD5BbqpPk-9fwQojvfB5w"
      decimals="-3"
      id="Tc_IYclSLp7VUKeggM434P-MA_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12594000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ"
      decimals="-3"
      id="Tc_2UPYQbxtFk22_tFpBpiQjg_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10444000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_ckfW59j6Okm6xRNuxxkwMA"
      decimals="-3"
      id="Tc_b1mQR6skyUS6gdkmWb0bJg_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">11233000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA"
      decimals="-3"
      id="Tc_YnVLc7JM60y_22qd_vwv6Q_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13764000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_89x-n-BkT02zjUtAjZbcGQ"
      decimals="-3"
      id="Tc_GkYtYwT7K0qdEYbG-DVmxQ_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15174000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_u8C2NDqyzU-6CSTMrEkS6w_8_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">49102000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_Owuy7GIlZ0SHegF88tmNEg_8_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">56933000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_AEH1TyVMlEubRoMx4TUaCQ_10_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">36053000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_WrJ1xG5oRkOT99507QnOAQ_10_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">32786000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_RALlmcp2lUaEvxr3SfMB3g_11_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13049000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_-l3ykg4XfkuZmbA9wpSrdw_11_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">24147000</us-gaap:ShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_pAgDGERU7EiRxvyO0PHSWA_12_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">49102000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_v9nJ2DDsw0aFfBCNtuNuNg_12_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">56933000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_7oG9BlP1lECEDqbnC5ekGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;"&gt;Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.7%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.34%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_I_VPJB4u6EaCQYJB-1nRzw"
      decimals="-3"
      id="Tc_KB33WYLeaUi803PFpfxhbA_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4963000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_I_VPJB4u6EaCQYJB-1nRzw"
      decimals="-3"
      id="Tc_yzA98qDHg0eAqPQiHRW1uA_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4963000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_YesGsLryt0qGsoVabogaQw"
      decimals="-3"
      id="Tc_s5wknm51FUSHfTfNB7fQCw_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10446000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_8oQqRK0A4Eeyfv827MVcYw"
      decimals="-3"
      id="Tc_TZTxk4w9D0eiVlTQe5Dh0g_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_YesGsLryt0qGsoVabogaQw"
      decimals="-3"
      id="Tc_n4QrQGJBTka6n3kgPghCjQ_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10444000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_LwXt8QqnrUCTiqADnWfuhg"
      decimals="-3"
      id="Tc_0KldBGacQUe-DoNX3Pir3A_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13771000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_OVx2OrQCKEaSY3aBoBA0Kg"
      decimals="-3"
      id="Tc_8fb8d55ty0SOMwpgPlEWaw_6_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_LwXt8QqnrUCTiqADnWfuhg"
      decimals="-3"
      id="Tc_iD43firJC0uXgbGPGm8uEQ_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13764000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_FICV7gW2dk-JlC3rHlKcSA_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">29180000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_XjdV-Jp880KnhPP0PN-3mg"
      decimals="-3"
      id="Tc_4ti6kQN890e7HUGsExqmWA_7_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-9000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_0FhVDO4OzU-eA8CEYtSHFQ_7_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">29171000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_kZWlKhsNBU6_AklsH7sLKg"
      decimals="-3"
      id="Tc_BERRkQyeOEaaoiSguv9Fng_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12591000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_LS7cZ0Bs8U-InZ3368zHAg"
      decimals="-3"
      id="Tc_7BV-m3jFfkGDeKnSQHLV6w_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_kZWlKhsNBU6_AklsH7sLKg"
      decimals="-3"
      id="Tc_qBzQxAMrtEKfw7GSpfSyuA_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12594000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_QPE9o_N_LkOoOgf3_7ge7w"
      decimals="-3"
      id="Tc_t4YhJTxOukGl77jmMO7b8Q_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">11230000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_vAVgV6NViE6ez_AdrA5iUg"
      decimals="-3"
      id="Tc_5MeQBquEdkGqln6jdhRFbQ_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_gG5MuB9lWk-MYGQsRJNXbQ"
      decimals="-3"
      id="Tc_IN0DOzZqo0O7dhqMy8t3hA_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_QPE9o_N_LkOoOgf3_7ge7w"
      decimals="-3"
      id="Tc_YU0W2L6PEUClyLQlmD2aZg_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">11233000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_Som_sdy7kEqstJssH42W1g"
      decimals="-3"
      id="Tc_we_pdXQSZUqobYaeNYwFAg_6_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15172000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_sBMx05ZL3UeBF780dfwknA"
      decimals="-3"
      id="Tc_cGMbGwqRJk2MTxnTEMN9WQ_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_YF4pFiaiVkGskNRvWduW9Q"
      decimals="-3"
      id="Tc__WPxP-E_3keshczDEGo3vQ_6_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_Som_sdy7kEqstJssH42W1g"
      decimals="-3"
      id="Tc_zTxAsL90EkatR18wMUTFew_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15174000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_waJThiiLvkGKTK0-NmgaHg_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">38993000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_uiwrXRdPDki6YFyL0CW_EQ"
      decimals="-3"
      id="Tc_IIgzGtnweECh0P7YoXlVAQ_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_rigl_AccumulatedNetInvestmentLossIncludingPortionAttributableToNoncontrollingInterestMember_N2zaSMxsLEqGccjjlPSgFw"
      decimals="-3"
      id="Tc_t05GpulPa06O56wQA6AqEw_7_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_Qkm-2T9jG0K6f0vebbdIRg_7_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">39001000</us-gaap:InvestmentsFairValueDisclosure>
    <rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Narr_P0ueg2K1n0-ozSZXbRIMEg">P68D</rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod>
    <rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_bk4CtdQf3EaimZs7lkGnMA"
      id="Narr_q4H1IqBHnUOPDAxsHzDpYA">P82D</rigl:CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="INF"
      id="Narr_vxl7xK5WsUSRUx7q8iGLMw"
      unitRef="Unit_Standard_position__77Wb-sxgEODSR6HmbQE7w">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="INF"
      id="Narr_0loDrtwho0O4ooYNAcytqQ"
      unitRef="Unit_Standard_position__77Wb-sxgEODSR6HmbQE7w">26</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <rigl:InvestmentsCreditLossExpense
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-5"
      id="Narr_6-uc10Qy_EewR3YC0QOYwQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:InvestmentsCreditLossExpense>
    <rigl:InvestmentsCreditLossExpense
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-5"
      id="Narr_5GK2zaDoVkmK4AQ7WrmFNA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</rigl:InvestmentsCreditLossExpense>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_sbo9isx2D0OBU3xo5USPXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table shows the fair value and gross unrealized losses of our investments in individual securities that are in an unrealized loss position, aggregated by investment category (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.47%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ"
      decimals="-3"
      id="Tc_vnypFXwYBUC67hu65AieMA_2_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">9694000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dg_hiSt2-UmDyOgdHuBcnQ"
      decimals="-3"
      id="Tc_WieO4erLOEed0Gj-b0i35Q_2_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA"
      decimals="-3"
      id="Tc_1YbkZCet7UW93J9W2Bwxpg_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13265000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_6_30_2024_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_XP_zF2y1wUe91WfzqRHodA"
      decimals="-3"
      id="Tc_E6b_dV7TPUGhO7UbNDKqPg_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_n047Sv6bvkeZMYghNLtrsA_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">22959000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_zRKkA63DYEuofmu5B3GDwg_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_rpfHin8oI06RiHMmwDqKcg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;9.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:12pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_6Cc7tnwpt0W12k76uAeu7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.74%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of&#160;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,171&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&#160;at&#160;Fair&#160;Value&#160;as&#160;of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Government-sponsored enterprise securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds and commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_2ZqFwePmoEW5EP2yf9fpUw"
      decimals="-3"
      id="Tc_4Aw_t8r5o0-32XG6y5AlXw_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13805000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_N7Gpz1AcU0-D3M0pAjqqNQ"
      decimals="-3"
      id="Tc_ITBXarSy-kmowiqHX2Ttqw_3_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13805000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_uZH0PMnJBEKSBgu31l8iYQ"
      decimals="-3"
      id="Tc_jeCGY9FKeE2ae3kCoI2p3g_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4963000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_3NxUn5GogkWWrIfF-O4kPA"
      decimals="-3"
      id="Tc_gtxqtTZT_k6h57_fu0NYnw_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">4963000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_VuYcYAoXfUqSaPoOv41VZg"
      decimals="-3"
      id="Tc_dq3WZ_iNZUmWSSgNzWHOSQ_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10444000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SLvI2lqsxkmQG2QFPN79Dg"
      decimals="-3"
      id="Tc_6huAMHWOe0KUkqKrC6Otlw_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10444000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_moMylpkG0EKqa1L_9E6qSA"
      decimals="-3"
      id="Tc_cv5qxwhSoUiC189uxSGihw_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13764000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_bumoYf9sREKWHIIx5_Gz1w"
      decimals="-3"
      id="Tc_0A6G0r8ur02cJzg-nLUd4A_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13764000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_6YzcAGW4m0ayhMSEkUdByA"
      decimals="-3"
      id="Tc_k8UMt1tj3Eiir0pRCkRFyQ_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">13805000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kR5PxZmiZEehJumbiChaaw"
      decimals="-3"
      id="Tc__QVKmJKIokW3WNKeRu5Rpw_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">29171000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BRYGoVu9R0e32mZYGbN33w"
      decimals="-3"
      id="Tc_nmNaRBcWhUyzxzBiNpybvQ_7_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">42976000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_Ke66dznHTEab1HHdbbjp0Q"
      decimals="-3"
      id="Tc_1cOqhgty_kuyhdBm0vlPsw_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">9685000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_U7guuJSV4U6vqE5RJhmf9g"
      decimals="-3"
      id="Tc_XVJOx-BeREWrNIazplvJ9g_3_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">9685000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_LrJM0R9Q4EqCjEm9Lk2Smw"
      decimals="-3"
      id="Tc_FzBQ-2akQkGkutDTK0YJkw_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12594000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryBillSecuritiesMember_tfFBS5hWFE6pF6skJ5FQLQ"
      decimals="-3"
      id="Tc_6NRYnEwc-UG4j5Y7kvSuhg_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">12594000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_SCWsGh-x_EiHDPQEk17sgQ"
      decimals="-3"
      id="Tc_psBTLQr63Uu6WQnxyZhMvA_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">11233000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_78B3hepUPkmvOj-N8djJNA"
      decimals="-3"
      id="Tc_mX2kwPkFkku2d2Nz3bHV4Q_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">11233000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_TowDf4q6oE-409UeTRDU9g"
      decimals="-3"
      id="Tc_WkLWtkgeX0yjQTKzZ0Gt3A_6_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15174000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_rigl_CorporateBondSecuritiesAndCommercialPaperMember_60P2wgsrD0awxLyja-p9nA"
      decimals="-3"
      id="Tc_5KRP0OWpBUevs4cchHH0Bg_6_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">15174000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_5l5sjSngpkO-FXuFuyQBGA"
      decimals="-3"
      id="Tc_nmAdIr0sUEykfxCJdT_IAg_7_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">9685000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zmcdanbJ0SDNc-vDFtkkg"
      decimals="-3"
      id="Tc_jVt0j_tc9EmVou-HP2RNGA_7_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">39001000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bJS_m4Vp_0uGViKVve720w"
      decimals="-3"
      id="Tc_aF_S5UfCCkKGD3CzpfZOqw_7_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">48686000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_Y051GmuqpUqt3LpguSY1pA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;"&gt;The following table summarizes loans payable, net (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (308)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (398)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal outstanding, net of unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Loans payable, net, current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long-term portion of loans payable, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The outstanding loans payable as of the periods presented was related to our Credit and Security Agreement (Credit Agreement) with MidCap Financial Trust (MidCap) entered into on September 27, 2019 (Closing Date) and amended on March 29, 2021 (First Amendment), February 11, 2022 (Second Amendment), July 27, 2022 (Third Amendment), and on April 11, 2024 (Fourth Amendment).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Credit Agreement provides for a $60.0&#160;million term loan credit facility. At the Closing Date, $10.0 million was funded (Tranche 1), in May 2020, an additional $10.0 million was funded (Tranche 2), at the Second Amendment, an additional $10.0 million was funded (Tranche 3), at the Third Amendment, an additional $10.0 million was funded (Tranche 4), and in March 2023, an additional $20.0 million was funded (Tranche 5). As of June 30, 2024, the outstanding principal balance of the loan was $60.0 million, and no remaining funds are available for draw under the term loan credit facility. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The First Amendment to the Credit Agreement extended the period through which Tranche 3 was available to us. The Second Amendment to the Credit Agreement, among other things, amended the applicable funding conditions, applicable commitments and certain other terms relating to available credit facilities (Tranches 3 and 4), added additional term loan credit facility (Tranche 5), and revised certain terms related to the financial covenants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Following the Third Amendment but prior to the Fourth Amendment to the Credit Agreement in April 2024 as discussed below, the term loans would mature on September 1, 2026, and the interest-only period was through October 1, 2024. The term loans bore interest equal to &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;the sum of one-month &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Secured Overnight Financing Rate (SOFR)&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;, plus an adjustment of &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;0.11448%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;, subject to &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;1.50%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; applicable floor, plus applicable margin of&#160;&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;5.65%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;, and a&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; final payment fee of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;2.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of principal due at maturity date. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;Following the Fourth Amendment to the Credit Agreement in April 2024, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;the term loans mature on September 1, 2027, and the interest-only period is through October 1, 2025. The term loans bear interest equal to the sum of one-month &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;SOFR&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; plus an adjustment of &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;0.11448%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;, subject to a &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;4.00%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; applicable floor, plus applicable margin of&#160;&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;6.50%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;. A final payment fee of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;4.25%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of principal is due at maturity date. The amendment was accounted for as debt modification in accordance with the standards. The unamortized debt issuance costs are continuously being amortized as interest expense through maturity using the effective interest rate method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We &lt;/span&gt;may make voluntary prepayments, in whole or in part, subject to certain prepayment premiums and additional interest payments. The Credit Agreement also contains certain provisions, such as event of default and change in control provisions, which, if triggered, would require us to make mandatory prepayments on the term loan, which are subject to certain prepayment premiums and additional interest payments. The obligations under the amended Credit Agreement are secured by a perfected security interest in all of our assets including our intellectual property.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Interest expense, including amortization of the debt discount and accretion of the final fees related to the Credit Agreement for the three months ended June 30, 2024 and 2023 was $2.0 million and $1.9 million, respectively, and for the six months ended June 30, 2024 and 2023 was $3.9 million and $3.1 million, respectively. Accrued interest of $1.8 million was included within other accrued liabilities in the condensed balance sheet as of June 30, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2024 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal amount (Tranches 1, 2, 3 and 4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The amended Credit Agreement contains certain covenants which, among others, require us to deliver financial reports at designated times of the year and maintain minimum unrestricted cash and trailing net revenues. As of June 30, 2024, we were not in violation of any covenants.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_paaG8otW_ke8roT1-Opwqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 6pt 0pt;"&gt;The following table summarizes loans payable, net (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (308)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (398)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal outstanding, net of unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reported as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Loans payable, net, current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long-term portion of loans payable, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Ya-hVISjGE6h9pV97LgwHw_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">60000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_y18AJy-b20KSkSdgsBjrIw_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">60000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_TTCloBQNAEmV6Ovp-_1xBw_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">308000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_0epb5ulc6kiwZS_5oa6gCw_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">398000</us-gaap:DeferredFinanceCostsNet>
    <rigl:DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Wd0UWaGGdEGmFFoF5c3qQg_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59692000</rigl:DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts>
    <rigl:DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_S9C1DZev8k62_kKHEJEUjA_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59602000</rigl:DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts>
    <us-gaap:LoansPayableCurrent
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_NjUsFkMpvEuQLJkDpUiXlw_8_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7229000</us-gaap:LoansPayableCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_sCZdYxACMk2-C8I1TEVsaA_9_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59692000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_knBL9UTxlUilGu7a4K8U6g_9_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">52373000</us-gaap:LongTermLoansPayable>
    <us-gaap:LoansPayable
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_2FhTPYJtVk2xx9Wmd-y7oQ_10_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59692000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="As_Of_12_31_2023_oWPpNd1FVk2fs8yfXNyj3A"
      decimals="-3"
      id="Tc_ZTJEXWJ86EG5Y1luU6mNIw_10_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">59602000</us-gaap:LoansPayable>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA"
      decimals="-5"
      id="Narr_XzmU_W-m3kOqduEhby64ug"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">60000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheOneMember_hDix6efDJEqhQT4ixJzEQA"
      decimals="-5"
      id="Narr_kY1Q0dNzxE2YBbL0zotk7w"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_5_31_2020_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheTwoMember_eYkavSct0kShqm_SrY7OiQ"
      decimals="-5"
      id="Narr_AbyGeNbov0mcidHKX6xOow"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheThreeMember_W7cIc5yiHEas_ePcVbSr0Q"
      decimals="-5"
      id="Narr_GAibrG3sx0mtUY4_kFmHYw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_5_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFourMember_Pa4eaLZ_bkuPdtNWU8Iy2A"
      decimals="-5"
      id="Narr_WOQzPSuopUO_HkvXWKlwvQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">10000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_3_28_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_rigl_CreditAgreementTrancheFiveMember_DJRbQsRz1EqcG6iJ-_88Iw"
      decimals="-5"
      id="Narr_hWmUOsemcEilZW1bswHQyQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">20000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA"
      decimals="-5"
      id="Narr_jQTVKbdiWE-OdKSySifHrQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">60000000.0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_mkXWY98GM0SOsOMd4ochKA"
      decimals="-5"
      id="Narr_h67u9mUyxkeHETN6d6hx8w"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6ou1l9PZikOK2y-Wb2RGFQ"
      id="Narr_0iAGwJxixky90Ukiui48DQ">0.11448%</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_W4Ti807K5EGWOf1btN6_6g"
      decimals="4"
      id="Narr_PsfLMf6hd0OSOWHu27-vqg"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_6ou1l9PZikOK2y-Wb2RGFQ"
      decimals="4"
      id="Narr_Dg2HAyARh0KL171MyUFsPQ"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.0565</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingThirdAmendmentMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_EBFPUJEfP0-IMk-f5UWHvg"
      decimals="3"
      id="Narr_qcFOv9XO0UuGxAHUBrCYyg"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.025</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_xDqwa338u06zbkGihig_Sw"
      id="Narr_qrbhsstCiUut6S01JfXARA">0.11448%</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_w34DeP8NUkiGwpi5OQ3ysw"
      decimals="4"
      id="Narr_uMpUWWSXF0-pXanT30-XKg"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_xDqwa338u06zbkGihig_Sw"
      decimals="4"
      id="Narr_jfGFOdwoGEqIqx9ruIzzlw"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.0650</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_rigl_FollowingFourthAmendmentMember_Oloq2T-qkUSk0moW_WdUNg"
      decimals="4"
      id="Narr_i4G7ZE9PykuXnXucIhf1GQ"
      unitRef="Unit_Standard_pure_4mJP3oHqJEe0U4qhqQ2QBA">0.0425</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_DMeCAgkRW0C78bbvGK_1ag"
      decimals="-5"
      id="Narr_CQdwNPifjEe5olVa9XvulQ"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">2000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_8_QPIix-oEu90IoZH6mxdA"
      decimals="-5"
      id="Narr_vzKU1zj5IUO-2vXdkTmVLA"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lWODGT6XzEuM8DkFcLQ2LQ"
      decimals="-5"
      id="Narr_qaR6LfUG8EGTAja_nDwbGw"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_RqBa2FWeTk6bS0CYoSM8OA"
      decimals="-5"
      id="Narr_bJd9WxENGUeY6d6PRNkg2A"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">3100000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_lWODGT6XzEuM8DkFcLQ2LQ"
      decimals="-5"
      id="Narr_cKmGaaiiA06eizGOQ24MAg"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1800000</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_5F0n5oBguk-8QCRtbsIpmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents the future minimum principal payments of the outstanding loan as of June 30, 2024 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:72.33%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal amount (Tranches 1, 2, 3 and 4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_Fb_eJsG-Ok-wqjNFyXo3Uw_2_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">7500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_gKU2pDnMdkCNmET4IPu5_Q_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">30000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_8LzeWMBrDUC-bCMWsl8UNQ_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">22500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_FXtayv4nKk6klUnOZMUKCA_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">60000000</us-gaap:LongTermDebt>
    <rigl:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_N0ZZK3-EzUOfNq4UOaKTpw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;We have a sublease agreement with Atara Biotherapeutics, Inc. (Atara) entered in October 2022 to sublease an office space located in South San Francisco, California. Subject to the terms of the sublease agreement, the lease term commenced in November 2022 and shall expire in May 2025. This leased facility is currently held as our new Headquarters following the expiration of our previously leased facility in January 2023. &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;The weighted average remaining term of our leases as of June 30, 2024 was &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_xfW9usukwk2f_jXEjoY-Ag;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.92&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;We previously leased our prior headquarter space located in South San Francisco, California with Healthpeak Properties, Inc. (formerly known as HCP BTC, LLC), and had a sublease agreement with an unrelated third-party to sublet a portion of the leased facility. Both leases expired in January 2023.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The components of our operating lease expense were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable operating lease expense (net credit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 388&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Supplemental information related to our operating lease were as follow (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash payments included in the measurement of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;Supplemental information related to our operating sublease was as follow (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__uvDi--VAUGqtC3eWeIntA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_RyRJdE2X_E-Mg-mp9DscQQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lQtRnSPQoE-Il8zeJ8WGew;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_mnAsvI_5pkqF9r4khAkUlQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents the future lease payments as of June 30, 2024 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:56.56%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum payments required&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</rigl:LeaseDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_6_qSUlxmSUqzxpGPMbjKfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.39%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable operating lease expense (net credit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 388&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_Q8vqJs6r_EGs_Ih0yigS2Q_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">166000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_jjREkWQDWUKkiqfkddLocQ_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">166000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_fF97NNVenUa_kht9YwEDbA_3_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">332000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_oy9HGxycVkK4QH_g2SBuCA_3_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">778000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_vTfzKIGAYkW8012U_iqBnw_4_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">28000</us-gaap:VariableLeaseCost>
    <rigl:VariableLeaseExpenseNetCredit
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_12ArSiH3jEKgwdRze4VqVg_4_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">-42000</rigl:VariableLeaseExpenseNetCredit>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_QWRWUEzjG0y79Uk8Maxk0Q_4_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">56000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_t6E8KUFbVUe8mkhyp_b3sQ_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">30000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_BKSzFawNh0avb95babhrSQ_5_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">194000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_sTTmKm75DkeZpcwC40b79g_5_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">124000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_r16oca1jmUCLuQALwWBTZQ_5_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">388000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_6bpCKAelykmgTEqfyjarjA_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">808000</us-gaap:LeaseCost>
    <rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_vEreIKCRy0CvVnpjO_MsIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash payments included in the measurement of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rigl:CashFlowInformationRelatedToOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_4_1_2024_To_6_30_2024_6zYqLVP5gEC6ofhcafTxxA"
      decimals="-3"
      id="Tc_0IHv00lX5EOovdtqduKsTw_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">184000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_4_1_2023_To_6_30_2023_Lx6pOyIpek6jl3FsbufdOw"
      decimals="-3"
      id="Tc_ZN7qey1nHkiltvaREqQ1VQ_3_6"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">178000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      decimals="-3"
      id="Tc_THpsoC5-FkKDjWsSzJP_Hw_3_9"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">368000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_p44CynB18UmOs_HyB0VWsw_3_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">1174000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_uYbo_N2fD0uXfeZgJ3Mjlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:27.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six&#160;Months&#160;Ended&#160;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable sublease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__uvDi--VAUGqtC3eWeIntA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_RyRJdE2X_E-Mg-mp9DscQQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lQtRnSPQoE-Il8zeJ8WGew;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_mnAsvI_5pkqF9r4khAkUlQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <rigl:FixedSubleaseExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc__qp-BV9kA0yqTDKx_i4g4g_3_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">365000</rigl:FixedSubleaseExpense>
    <rigl:VariableSubleaseExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_KnZ54_DsHE2hKWePy4lStw_4_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">77000</rigl:VariableSubleaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_pPX34xXt1UG7IjJDQnkfPA"
      decimals="-3"
      id="Tc_a6XBsAVXpEGLsVcXtjfIcA_5_12"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">442000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_WpVv2WHGCEKqcXxOM_1SiA"
      id="Tb_Oh3c96_lAkqgJPZYe1fNmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:56.56%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remainder of 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum payments required&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_9UgbUWy0mEeqNCHK7oAPeg_1_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">371000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_2ziV3OntX0S1k9AjrKt3eg_2_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">301000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2024_uL-r6Ay2_Eqo7Da9Oe9dTQ"
      decimals="-3"
      id="Tc_jbL8eIzMbUaji_DDTV1Sew_3_3"
      unitRef="Unit_Standard_USD_emPJMz0zBEizegFH79_XcQ">672000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
